PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Ayombil, F; Petrillo, T; Kim, H; Camire, RM				Ayombil, Francis; Petrillo, Teodolinda; Kim, Haein; Camire, Rodney M.			Regulation of factor V by the anticoagulant protease activated protein C: Influence of the B-domain and TFPI alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTOR VA; BOVINE FACTOR-V; FACTOR-XA; BLEEDING DISORDER; BINDING-SITE; INACTIVATION; RESISTANCE; COFACTOR; CLEAVAGE; MUTATION	Activated protein C (APC) is an important anticoagulant protein that regulates thrombin generation through inactiva-tion of factor V (FV) and activated factor V (FVa). The rate of APC inactivation of FV is slower compared to FVa, although proteolysis occurs at the same sites (Arg306, Arg506, and Arg679). The molecular basis for FV resistance to APC is unknown. Further, there is no information about how FV-short, a phys-iologically relevant isoform of FV with a shortened B-domain, is regulated by APC. Here, we identify the molecular determinants which differentially regulate APC recognition of FV versus FVa and uncover how FV-short can be protected from this anticoagulant pathway. Using recombinant FV derivatives and B-domain fragments, we show that the conserved basic region (BR; 963-1008) within the central portion of the B-domain plays a major role in limiting APC cleavage at Arg506. Derivatives of FV lacking the BR, including FV-short, were subject to rapid cleavage at Arg506 and were inactivated like FVa. The addition of a FV-BR fragment reversed this effect and delayed APC inactivation. We also found that anticoagulant glycoprotein TFPI alpha, which has a C-terminal BR homologous to FV-BR, protects FV-short from APC inactivation by delaying cleavage at Arg506. We conclude that the FV-BR plays a major role in protecting FV from APC inactivation. Using a similar mechanistic strategy, TFPI alpha also shields FV-short from APC. These findings clarify the resis-tance of FV to APC, advance our understanding of FV/FVa regulation, and establish a mechanistic framework for manip-ulating this reaction to alter coagulation.	[Ayombil, Francis; Petrillo, Teodolinda; Kim, Haein; Camire, Rodney M.] Childrens Hosp Philadelphia, Raymond G Perelman Ctr Cellular & Mol Therapeut, Div Hematol, Philadelphia, PA 19104 USA; [Camire, Rodney M.] Univ Penn, Perelman Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; [Petrillo, Teodolinda] Univ Maryland, Baltimore, MD 21201 USA; [Kim, Haein] JDRF T1D Fund, 50 Milk St, 16th floor, Boston, MA 02109 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; University System of Maryland; University of Maryland Baltimore	Camire, RM (corresponding author), Childrens Hosp Philadelphia, Raymond G Perelman Ctr Cellular & Mol Therapeut, Div Hematol, Philadelphia, PA 19104 USA.; Camire, RM (corresponding author), Univ Penn, Perelman Sch Med, Dept Pediat, Philadelphia, PA 19104 USA.	rcamire@pennmedicine.upenn.edu	Ayombil, Francis/AAE-2889-2020	Ayombil, Francis/0000-0001-6011-1931	US National Institutes of Health (NIH);  [P01 HL139420];  [T32 HL007971]	US National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; 	Funding and additional information - This work was supported by US National Institutes of Health (NIH) grant P01 HL139420, Project 2 (RM Camire) and T32 HL007971 (F Ayombil) . The con- tent of this manuscript is solely the responsibility of the authors and does not necessarily represent the of fi cial views of the NIH.	Aparicio C, 1996, BIOCHEM J, V313, P467, DOI 10.1042/bj3130467; BAKKER HM, 1992, EUR J BIOCHEM, V208, P171, DOI 10.1111/j.1432-1033.1992.tb17171.x; Barhoover MA, 2011, BLOOD COAGUL FIBRIN, V22, P317, DOI 10.1097/MBC.0b013e3283456c4e; Betz A, 1998, J BIOL CHEM, V273, P10709, DOI 10.1074/jbc.273.17.10709; Bos MHA, 2012, J BIOL CHEM, V287, P26342, DOI 10.1074/jbc.M112.377168; Bradford HN, 2019, J BIOL CHEM, V294, P2422, DOI 10.1074/jbc.RA118.006510; Bradford HN, 2013, J BIOL CHEM, V288, P27789, DOI 10.1074/jbc.M113.502005; BROZE GJ, 1994, BLOOD COAGUL FIBRIN, V5, P551; Bunce MW, 2013, J BIOL CHEM, V288, P30151, DOI 10.1074/jbc.M113.506840; Camire RM, 2009, J THROMB HAEMOST, V7, P1951, DOI 10.1111/j.1538-7836.2009.03622.x; CAMIRE RM, 1995, J BIOL CHEM, V270, P20794, DOI 10.1074/jbc.270.35.20794; Cunha MLR, 2015, BLOOD, V125, P1822, DOI 10.1182/blood-2014-08-592733; Dahlback B, 1997, HAEMATOLOGICA, V82, P91; Dahlback B, 1997, THROMB HAEMOSTASIS, V78, P483; DAHLBACK B, 1995, THROMB HAEMOSTASIS, V73, P739; DAHLBACK B, 1994, P NATL ACAD SCI USA, V91, P1396, DOI 10.1073/pnas.91.4.1396; Dahlback B, 2018, RES PRACT THROMB HAE, V2, P114, DOI 10.1002/rth2.12057; Eaton SL, 2014, JOVE-J VIS EXP, DOI 10.3791/52099; Esmon C, 2000, CRIT CARE MED, V28, pS44, DOI 10.1097/00003246-200009001-00010; ESMON CT, 1981, P NATL ACAD SCI-BIOL, V78, P2249, DOI 10.1073/pnas.78.4.2249; ESMON CT, 1982, J BIOL CHEM, V257, P7944; Gale AJ, 2002, J BIOL CHEM, V277, P28836, DOI 10.1074/jbc.M204363200; Gould WR, 2004, J BIOL CHEM, V279, P2383, DOI 10.1074/jbc.M308600200; Heeb MJ, 1996, PROTEIN SCI, V5, P1883, DOI 10.1002/pro.5560050914; HIGGINS DL, 1983, J BIOL CHEM, V258, P6503; Kalafatis M, 1996, BLOOD, V87, P4695, DOI 10.1182/blood.V87.11.4695.bloodjournal87114695; KALAFATIS M, 1993, METHOD ENZYMOL, V222, P224; KALAFATIS M, 1993, J BIOL CHEM, V268, P27246; KALAFATIS M, 1995, J BIOL CHEM, V270, P4053, DOI 10.1074/jbc.270.8.4053; KALAFATIS M, 1994, J BIOL CHEM, V269, P31869; Kalafatis M, 1997, CRIT REV EUKAR GENE, V7, P241, DOI 10.1615/CritRevEukarGeneExpr.v7.i3.40; KANE WH, 1990, BIOCHEMISTRY-US, V29, P6762, DOI 10.1021/bi00481a003; KATZMANN JA, 1981, P NATL ACAD SCI-BIOL, V78, P162, DOI 10.1073/pnas.78.1.162; Kuang SQ, 2001, BLOOD, V97, P1549, DOI 10.1182/blood.V97.6.1549; Kumar S., 2015, BLOOD, V126, P121; Kumar S., 2011, BLOOD, V118, P375; Kumar S, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.253.253; Mann KG, 2003, BLOOD, V101, P20, DOI 10.1182/blood-2002-01-0290; Mann KG, 1997, J BIOL CHEM, V272, P20678, DOI 10.1074/jbc.272.33.20678; MANN KG, 1990, BLOOD, V76, P1; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; NICOLAES GAF, 1995, J BIOL CHEM, V270, P21158, DOI 10.1074/jbc.270.36.21158; Norstrom EA, 2003, J BIOL CHEM, V278, P24904, DOI 10.1074/jbc.M303829200; ODEGAARD B, 1987, J BIOL CHEM, V262, P11233; Peterson JA, 2022, J THROMB HAEMOST, V20, P565, DOI 10.1111/jth.15612; Petrillo T, 2021, J BIOL CHEM, V296, DOI 10.1074/jbc.RA120.016341; Ruben EA, 2021, BLOOD, V137, P3137, DOI 10.1182/blood.2021010684; Segers K, 2008, J BIOL CHEM, V283, P22573, DOI 10.1074/jbc.M801724200; SHEN L, 1994, J BIOL CHEM, V269, P18735; Steen M, 2008, J BIOL CHEM, V283, P20805, DOI 10.1074/jbc.M802703200; Thorelli E, 1999, BLOOD, V93, P2552, DOI 10.1182/blood.V93.8.2552.408k15_2552_2558; Thorelli E, 1998, J BIOL CHEM, V273, P16140, DOI 10.1074/jbc.273.26.16140; Toso R, 2004, J BIOL CHEM, V279, P21643, DOI 10.1074/jbc.M402107200; TRACY PB, 1982, BLOOD, V60, P59; Vincent LM, 2013, J CLIN INVEST, V123, P3777, DOI 10.1172/JCI69091; Wood JP, 2013, P NATL ACAD SCI USA, V110, P17838, DOI 10.1073/pnas.1310444110; Yegneswaran S, 2007, J BIOL CHEM, V282, P28353, DOI 10.1074/jbc.M704316200; Zhu H, 2007, J BIOL CHEM, V282, P15033, DOI 10.1074/jbc.M701315200; Zimowski KL, 2021, J THROMB HAEMOST, V19, P1653, DOI 10.1111/jth.15314	59	0	0	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV	2022	28	11							102558	10.1016/j.jbc.2022.102558	http://dx.doi.org/10.1016/j.jbc.2022.102558			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	6I4GS	36183835	Green Published, gold			2022-12-28	WOS:000886086000008
J	Yu, V; Ronzone, E; Lord, D; Peti, W; Page, R				Yu, Victor; Ronzone, Erik; Lord, Dana; Peti, Wolfgang; Page, Rebecca			MqsR is a noncanonical microbial RNase toxin that is inhibited by antitoxin MqsA via steric blockage of substrate binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; TRANSCRIPTIONAL REPRESSION; CRYSTAL-STRUCTURE; CLEAVAGE; COMPLEX; RELE; MECHANISM; RIBONUCLEASE; DIVERSITY; MAZF	The MqsRA toxin-antitoxin system is a component of the Escherichia coli stress response. Free MqsR, a ribonuclease, cleaves mRNAs containing a 5'-GC-3' sequence causing a global shutdown of translation and the cell to enter a state of dormancy. Despite a general understanding of MqsR function, the molecular mechanism(s) by which MqsR binds and cleaves RNA and how one or more of these activities is inhibited by its cognate antitoxin MqsA is still poorly understood. Here, we used NMR spectroscopy coupled with mRNA cleavage assays to identify the molecular mechanism of MqsR substrate recogni-tion and the MqsR residues that are essential for its catalytic activity. We show that MqsR preferentially binds substrates that contain purines in the -2 and -1 position relative to the MqsR consensus cleavage sequence and that two residues of MqsR, Tyr81, and Lys56 are strictly required for mRNA cleavage. We also show that MqsA inhibits MqsR activity by sterically blocking mRNA substrates from binding while leav-ing the active site fully accessible to mononucleotides. Together, these data identify the residues of MqsR that mediate RNA cleavage and reveal a novel mechanism that regulates MqsR substrate specificity.	[Yu, Victor; Page, Rebecca] Univ Connecticut, Dept Cell Biol, Hlth Ctr, Farmington, CT 06030 USA; [Ronzone, Erik; Lord, Dana] Brown Univ, Dept Mol Biol Cell Biol & Biochem, Providence, RI USA; [Peti, Wolfgang] Univ Connecticut, Dept Mol Biol & Biophys, Hlth Ctr, Farmington, CT USA	University of Connecticut; Brown University; University of Connecticut	Page, R (corresponding author), Univ Connecticut, Dept Cell Biol, Hlth Ctr, Farmington, CT 06030 USA.	rpage@uchc.edu		Yu, Victor/0000-0001-8942-0084	NSF;  [MCB-1817621]	NSF(National Science Foundation (NSF)); 	Funding and additional information-This work was supported by grant from the NSF MCB-1817621 to R. P.	Afif H, 2001, MOL MICROBIOL, V41, P73, DOI 10.1046/j.1365-2958.2001.02492.x; Aldridge GM, 2008, J NEUROSCI METH, V172, P250, DOI 10.1016/j.jneumeth.2008.05.003; Amaya MF, 2004, STRUCTURE, V12, P775, DOI 10.1016/j.str.2004.02.036; Bauerova-Hlinkova V, 2009, FEBS J, V276, P4156, DOI 10.1111/j.1742-4658.2009.07125.x; BERNARD P, 1993, J MOL BIOL, V234, P534, DOI 10.1006/jmbi.1993.1609; Bertelsen MB, 2021, STRUCTURE, V29, P139, DOI 10.1016/j.str.2020.10.002; Brown BL, 2013, J BIOL CHEM, V288, P1286, DOI 10.1074/jbc.M112.421008; Brown BL, 2011, J BIOL CHEM, V286, P2285, DOI 10.1074/jbc.M110.172643; Brown BL, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000706; BUCKLE AM, 1994, BIOCHEMISTRY-US, V33, P1644, DOI 10.1021/bi00173a005; Castro-Roa D, 2013, NAT CHEM BIOL, V9, P811, DOI [10.1038/NCHEMBIO.1364, 10.1038/nchembio.1364]; Choi W, 2017, FEBS LETT, V591, P1853, DOI 10.1002/1873-3468.12705; Chowdhury N, 2016, MICROBIOLOGYOPEN, V5, P370, DOI 10.1002/mbo3.335; Christensen-Dalsgaard M, 2010, MOL MICROBIOL, V75, P333, DOI 10.1111/j.1365-2958.2009.06969.x; Culviner PH, 2021, MBIO, V12, DOI 10.1128/mBio.02012-21; De Bruyn P, 2021, PROTEIN SCI, V30, P1103, DOI 10.1002/pro.4071; Garcia-Pino A, 2010, CELL, V142, P101, DOI 10.1016/j.cell.2010.05.039; Gobl C, 2014, PROG NUCL MAG RES SP, V80, P26, DOI 10.1016/j.pnmrs.2014.05.003; Gottesman S, 2019, J BIOL CHEM, V294, P11685, DOI 10.1074/jbc.REV119.005593; Griffin MA, 2013, BIOCHEMISTRY-US, V52, P8633, DOI 10.1021/bi401325c; Gucinski GC, 2019, STRUCTURE, V27, P1660, DOI 10.1016/j.str.2019.08.010; Han Y, 2020, BMB REP, V53, P611, DOI 10.5483/BMBRep.2020.53.12.203; Hayes F, 2011, CRIT REV BIOCHEM MOL, V46, P386, DOI 10.3109/10409238.2011.600437; Hurley JM, 2009, J BIOL CHEM, V284, P18605, DOI 10.1074/jbc.M109.008763; Jurenas D, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00262; Kamada K, 2003, MOL CELL, V11, P875, DOI 10.1016/S1097-2765(03)00097-2; Keren I, 2004, J BACTERIOL, V186, P8172, DOI 10.1128/JB.186.24.8172-8180.2004; Loverix S, 2000, CHEM BIOL, V7, P651, DOI 10.1016/S1074-5521(00)00005-3; Marsh JA, 2006, PROTEIN SCI, V15, P2795, DOI 10.1110/ps.062465306; Matzov D, 2019, FEBS J, V286, P3558, DOI 10.1111/febs.14968; Mets T, 2019, BIOCHIMIE, V156, P79, DOI 10.1016/j.biochi.2018.10.004; Moritz CP, 2017, PROTEOMICS, V17, DOI 10.1002/pmic.201600189; Neubauer C, 2009, CELL, V139, P1084, DOI 10.1016/j.cell.2009.11.015; Page R, 2016, NAT CHEM BIOL, V12, P208, DOI [10.1038/NCHEMBIO.2044, 10.1038/nchembio.2044]; Pandey DP, 2005, NUCLEIC ACIDS RES, V33, P966, DOI 10.1093/nar/gki201; Pavelich IJ, 2019, NUCLEIC ACIDS RES, V47, P10400, DOI 10.1093/nar/gkz760; Pedersen K, 2003, CELL, V112, P131, DOI 10.1016/S0092-8674(02)01248-5; Ramage HR, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000767; Rivero-Gutierrez B, 2014, ANAL BIOCHEM, V467, P1, DOI 10.1016/j.ab.2014.08.027; Schumann FH, 2007, J BIOMOL NMR, V39, P275, DOI 10.1007/s10858-007-9197-z; SEVCIK J, 1993, EUR J BIOCHEM, V216, P301, DOI 10.1111/j.1432-1033.1993.tb18145.x; Takagi H, 2005, NAT STRUCT MOL BIOL, V12, P327, DOI 10.1038/nsmb911; Williamson MP, 2013, PROG NUCL MAG RES SP, V73, P1, DOI 10.1016/j.pnmrs.2013.02.001; Yamaguchi Y, 2009, J BIOL CHEM, V284, P28746, DOI 10.1074/jbc.M109.032904; Yang W, 2011, Q REV BIOPHYS, V44, P1, DOI 10.1017/S0033583510000181; Zegers I, 1998, NAT STRUCT BIOL, V5, P280, DOI 10.1038/nsb0498-280; Zhang YL, 2003, MOL CELL, V12, P913, DOI 10.1016/S1097-2765(03)00402-7	47	0	0	1	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV	2022	298	11							102535	10.1016/j.jbc.2022.102535	http://dx.doi.org/10.1016/j.jbc.2022.102535			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	6D3XI	36162504	Green Published, gold			2022-12-28	WOS:000882627400003
J	Zhao, SY; Carnevale, V; Gabrielle, M; Gianti, E; Rohacs, T				Zhao, Siyuan; Carnevale, Vincenzo; Gabrielle, Matthew; Gianti, Eleonora; Rohacs, Tibor			Computational and functional studies of the PI(4,5)P-2 binding site of the TRPM3 ion channel reveal interactions with other regulators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE REGULATION; MEDIATED INHIBITION; SIDE-CHAIN; PROTEIN; ACTIVATION; MODEL; TRPV1; GENERATION; DOCKING; GLIDE	Transient receptor potential melastatin 3 (TRPM3) is a heat-activated ion channel expressed in peripheral sensory neurons and the central nervous system. TRPM3 activity depends on the membrane phospholipid phosphatidylinositol 4,5-bisphosphate (PI(4,5)P-2), but the molecular mechanism of activation by PI(4,5)P-2 is not known. As no experimental structure of TRPM3 is available, we built a homology model of the channel in complex with PI(4,5)P-2 via molecular modeling. We identified putative contact residues for PI(4,5)P-2 in the pre-S1 segment, the S4-S5 linker, and the proximal C-terminal TRP domain. Mutating these residues increased sensitivity to inhibition of TRPM3 by decreasing PI(4,5)P-2 levels. Changes in ligand-binding affinities via molecular mechanics/generalized Born surface area (MM/GBSA) showed reduced PI(4,5)P-2 affinity for the mutants. Mutating PI(4,5)P-2-interacting residues also reduced sensitivity for activation by the endogenous ligand pregnenolone sulfate, pointing to an allosteric interaction between PI(4,5)P-2 and pregnenolone sulfate. Similarly, mutating residues in the PI(4,5)P-2 binding site in TRPM8 resulted in increased sensitivity to PI(4,5)P-2 depletion and reduced sensitivity to menthol. Mutations of most PI(4,5)P-2-interacting residues in TRPM3 also increased sensitivity to inhibition by G beta gamma, indicating allosteric interaction between G beta gamma and PI(4,5)P-2 regulation. Disease-associated gain-of-function TRPM3 mutations on the other hand resulted in no change of PI(4,5)P-2 sensitivity, indicating that mutations did not increase channel activity via increasing PI(4,5)P-2 interactions. Our data provide insight into the mechanism of regulation of TRPM3 by PI(4,5)P-2, its relationship to endogenous activators and inhibitors, as well as identify similarities and differences between PI(4,5)P-2 regulation of TRPM3 and TRPM8.	[Zhao, Siyuan; Gabrielle, Matthew; Rohacs, Tibor] Rutgers New Jersey Med Sch, Dept Pharmacol, Physiol & Neurosci, Newark, NJ 07101 USA; [Carnevale, Vincenzo; Gianti, Eleonora] Temple Univ, Inst Computat Mol Sci, Philadelphia, PA 19122 USA; [Carnevale, Vincenzo] Temple Univ, Dept Biol, Philadelphia, PA USA; [Carnevale, Vincenzo] Temple Univ, Inst Genom & Evolutionary Med, Philadelphia, PA USA; [Gianti, Eleonora] Temple Univ, Dept Chem, Philadelphia, PA 19122 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Rohacs, T (corresponding author), Rutgers New Jersey Med Sch, Dept Pharmacol, Physiol & Neurosci, Newark, NJ 07101 USA.; Gianti, E (corresponding author), Temple Univ, Inst Computat Mol Sci, Philadelphia, PA 19122 USA.; Gianti, E (corresponding author), Temple Univ, Dept Chem, Philadelphia, PA 19122 USA.	tibor.rohacs@rutgers.edu; egianti@temple.edu		Zhao, Siyuan/0000-0003-2005-9440; Gabrielle, Matthew/0000-0002-7869-7106; Rohacs, Tibor/0000-0003-3580-2575	 [NSNS055159];  [GM131048]	; 	Funding dditional information - This study was supported by grants NSNS055159 (to T. R.) and GM131048 (to V. C. and T. R.) . The content is solely the responsibility of the authors and does not necessarily represent the of fi cial views of the National Institutes of Health.	Alkhatib O, 2019, J NEUROSCI, V39, P7840, DOI 10.1523/JNEUROSCI.0882-19.2019; Badheka D, 2017, ELIFE, V6, DOI 10.7554/eLife.26147; Badheka D, 2015, J GEN PHYSIOL, V146, P65, DOI 10.1085/jgp.201411336; Beard H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082849; Behrendt M, 2020, P NATL ACAD SCI USA, V117, P29090, DOI 10.1073/pnas.2001177117; Chernov-Rogan T, 2019, P NATL ACAD SCI USA, V116, P26008, DOI 10.1073/pnas.1913929116; Dembla S, 2017, ELIFE, V6, DOI 10.7554/eLife.26280; Duan JJ, 2018, P NATL ACAD SCI USA, V115, pEB201, DOI 10.1073/pnas.1810719115; Dyment DA, 2019, EUR J HUM GENET, V27, P1611, DOI 10.1038/s41431-019-0462-x; Fathizadeh A, 2021, J PHYS CHEM B, V125, P9547, DOI 10.1021/acs.jpcb.1c04052; Fluck EC, 2022, CELL REP, V39, DOI 10.1016/j.celrep.2022.110737; Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430; Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o; Grimm C, 2003, J BIOL CHEM, V278, P21493, DOI 10.1074/jbc.M300945200; Guo JT, 2017, NATURE, V552, P205, DOI 10.1038/nature24997; Halgren TA, 2009, J CHEM INF MODEL, V49, P377, DOI 10.1021/ci800324m; Halgren T, 2007, CHEM BIOL DRUG DES, V69, P146, DOI 10.1111/j.1747-0285.2007.00483.x; Hammond GRV, 2012, SCIENCE, V337, P727, DOI 10.1126/science.1222483; Held K, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.635659; Held K, 2015, P NATL ACAD SCI USA, V112, pE1363, DOI 10.1073/pnas.1419845112; Huang YH, 2020, CELL CALCIUM, V85, DOI 10.1016/j.ceca.2019.102111; Huang YH, 2018, NATURE, V562, P145, DOI 10.1038/s41586-018-0558-4; Hughes TET, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06753-6; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Jacobson MP, 2002, J MOL BIOL, V320, P597, DOI 10.1016/S0022-2836(02)00470-9; Jorgensen WL, 1996, J AM CHEM SOC, V118, P11225, DOI 10.1021/ja9621760; Jumper J, 2021, NATURE, V596, P583, DOI 10.1038/s41586-021-03819-2; Krugel U, 2017, PAIN, V158, P856, DOI 10.1097/j.pain.0000000000000846; Li JN, 2011, PROTEINS, V79, P2794, DOI 10.1002/prot.23106; Logothetis DE, 2015, ANNU REV PHYSIOL, V77, P81, DOI 10.1146/annurev-physiol-021113-170358; Lukacs V, 2007, J NEUROSCI, V27, P7070, DOI 10.1523/JNEUROSCI.1866-07.2007; Madeira F, 2022, NUCLEIC ACIDS RES, V50, pW276, DOI 10.1093/nar/gkac240; Nilius B, 2006, EMBO J, V25, P467, DOI 10.1038/sj.emboj.7600963; Nilius B, 2008, EMBO J, V27, P2809, DOI 10.1038/emboj.2008.217; Ningoo M, 2021, J BIOL CHEM, V296, DOI 10.1016/j.jbc.2021.100726; Oberwinkler J, 2014, HANDB EXP PHARMACOL, V222, P427, DOI 10.1007/978-3-642-54215-2_17; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Quallo T, 2017, ELIFE, V6, DOI [10.7554/eLife.26186, 10.7554/eLife.26138]; Rohacs T, 2005, NAT NEUROSCI, V8, P626, DOI 10.1038/nn1451; Rohacs T, 2015, PFLUG ARCH EUR J PHY, V467, P1851, DOI 10.1007/s00424-015-1695-3; Rohacs T, 2014, HANDB EXP PHARMACOL, V223, P1143, DOI 10.1007/978-3-319-05161-1_18; Ruan Z, 2021, NAT STRUCT MOL BIOL, V28, P604, DOI 10.1038/s41594-021-00607-4; Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822-013-9644-8; Shen Y, 2012, P NATL ACAD SCI USA, V109, P8752, DOI 10.1073/pnas.1117433109; Straub I, 2013, MOL PHARMACOL, V84, P736, DOI 10.1124/mol.113.086843; Su SX, 2021, J NEUROSCI, V41, P2457, DOI 10.1523/JNEUROSCI.1551-20.2020; Suh BC, 2008, ANNU REV BIOPHYS, V37, P175, DOI 10.1146/annurev.biophys.37.032807.125859; Toth BI, 2015, J GEN PHYSIOL, V146, P51, DOI 10.1085/jgp.201411339; Trebak M, 2009, PFLUG ARCH EUR J PHY, V457, P757, DOI 10.1007/s00424-008-0550-1; Ufret-Vincenty CA, 2015, J GEN PHYSIOL, V145, P431, DOI 10.1085/jgp.201511354; Van Hoeymissen E, 2020, ELIFE, V9, DOI 10.7554/eLife.57190; Vandewauw I, 2018, NATURE, V555, P662, DOI 10.1038/nature26137; Varadi M, 2022, NUCLEIC ACIDS RES, V50, pD439, DOI 10.1093/nar/gkab1061; Vriens J, 2014, NAT CHEM BIOL, V10, P188, DOI [10.1038/NCHEMBIO.1428, 10.1038/nchembio.1428]; Vriens J, 2011, NEURON, V70, P482, DOI 10.1016/j.neuron.2011.02.051; Wagner TFJ, 2008, NAT CELL BIOL, V10, P1421, DOI 10.1038/ncb1801; Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427; Winkler PA, 2017, NATURE, V552, P200, DOI 10.1038/nature24674; Yazici AT, 2021, J BIOL CHEM, V296, DOI 10.1016/j.jbc.2021.100573; Yin Y, 2019, SCIENCE, V363, P945, DOI 10.1126/science.aav9334; Yin Y, 2018, SCIENCE, V359, P237, DOI 10.1126/science.aan4325; Yu ZY, 2006, J COMPUT CHEM, V27, P72, DOI 10.1002/jcc.20307; Yudin Y, 2021, METHOD ENZYMOL, V652, P49, DOI 10.1016/bs.mie.2021.01.025; Zhang HL, 1999, NAT CELL BIOL, V1, P183, DOI 10.1038/11103; Zhao S, 2020, ELIFE, V9, DOI 10.7554/eLife.55634; Zhu K, 2007, J CHEM THEORY COMPUT, V3, P2108, DOI 10.1021/ct700166f	66	0	0	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV	2022	298	11							102547	10.1016/j.jbc.2022.102547	http://dx.doi.org/10.1016/j.jbc.2022.102547			18	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	6W5WW	36181791	Green Published, gold			2022-12-28	WOS:000895801300007
J	GILARDIHEBENSTREIT, P; NIETO, MA; FRAIN, M; MATTEI, MG; CHESTIER, A; WILKINSON, DG; CHARNAY, P				GILARDIHEBENSTREIT, P; NIETO, MA; FRAIN, M; MATTEI, MG; CHESTIER, A; WILKINSON, DG; CHARNAY, P			AN EPH-RELATED RECEPTOR PROTEIN TYROSINE KINASE GENE SEGMENTALLY EXPRESSED IN THE DEVELOPING MOUSE HINDBRAIN	ONCOGENE			English	Article							HOMEOBOX-CONTAINING GENES; AUG INITIATOR CODON; CHICK HINDBRAIN; NERVOUS-SYSTEM; MESSENGER-RNA; CDNA CLONING; 2 FORMS; SEQUENCE; IDENTIFICATION; DROSOPHILA	In search of genes possibly involved in the regulation of hindbrain segmentation, we have isolated mouse cDNA clones corresponding to putative protein kinase genes by polymerase chain reaction amplification of cDNA from 9.5-day-old embryo hindbrains. In situ hybridization analysis revealed that one of these genes, Sek, was expressed in an alternating segment-restricted pattern in the developing hindbrain. Isolation and analysis of Sek cDNAs covering the entire coding sequence indicated that Sek encoded a putative receptor protein tyrosine kinase, belonging to the Eph family. These data are consistent with a role of the Sek gene product in a signal transduction process involved in pattern formation in the hindbrain.	ECOLE NORM SUPER,GENET MOLEC LAB,CNRS,URA 1302,46 RUE ULM,F-75230 PARIS 05,FRANCE; HOP ENFANTS LA TIMONE,CTR GENET MED,INSERM,U242,F-13385 MARSEILLE,FRANCE; NATL INST MED RES,MRC,EUKARYOT MOLEC GENET LAB,LONDON NW7 1AA,ENGLAND	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; MRC National Institute for Medical Research			Nieto, M. Angela/A-6531-2008	Nieto, M. Angela/0000-0002-3538-840X; Wilkinson, David/0000-0001-6757-7080; Charnay, Patrick/0000-0002-3847-6042				BOUROUIS M, 1990, EMBO J, V9, P2877, DOI 10.1002/j.1460-2075.1990.tb07477.x; BRENNER S, 1987, NATURE, V329, P21, DOI 10.1038/329021a0; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; DAVISSON MT, 1990, CYTOGENET CELL GENET, V55, P434, DOI 10.1159/000133026; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; FROHMAN MA, 1989, TECHNIQUE, V1, P165; GUTHRIE S, 1991, DEVELOPMENT, V112, P221; HANKS SK, 1988, SCIENCE, V241, P45; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HOGAN B, 1986, MANIPULATING MOUSE E, P126; HOLTON TA, 1991, NUCLEIC ACIDS RES, V19, P1156, DOI 10.1093/nar/19.5.1156; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; HUNTER T, 1990, PROTEIN DESIGN DEV N, P119; KEYNES R, 1990, NEURON, V2, P1; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LETWIN K, 1988, ONCOGENE, V3, P621; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; Maniatis T., 1982, MOL CLONING; MARU Y, 1990, ONCOGENE, V5, P445; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; MURPHY P, 1991, DEVELOPMENT, V111, P61; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; PREAT T, 1990, NATURE, V347, P87, DOI 10.1038/347087a0; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; SAJJADI FG, 1991, NEW BIOL, V3, P769; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHUTTLEWORTH J, 1990, EMBO J, V9, P3233, DOI 10.1002/j.1460-2075.1990.tb07522.x; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0; WILKINSON DG, 1990, SEMINARS DEV BIOL, V1, P127; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603	46	116	134	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1992	7	12					2499	2506						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1281307				2022-12-28	WOS:A1992KA85600015
J	MAA, MC; WILSON, LK; MOYERS, JS; VINES, RR; PARSONS, JT; PARSONS, SJ				MAA, MC; WILSON, LK; MOYERS, JS; VINES, RR; PARSONS, JT; PARSONS, SJ			IDENTIFICATION AND CHARACTERIZATION OF A CYTOSKELETON-ASSOCIATED, EPIDERMAL GROWTH-FACTOR SENSITIVE PP60C-SRC SUBSTRATE	ONCOGENE			English	Article							TYROSINE KINASE-ACTIVITY; OVEREXPRESSING C-SRC; MITOGENIC RESPONSIVENESS; CELLULAR PROTEINS; CELLS; PHOSPHORYLATION; GENE; CLONING; CYCLE; DOMAINS	In studies aimed at identifying and characterizing pp60c-src substrates that participate in the enhanced mitogenic response to epidermal growth factor (EGF) observed in murine C3H10T1/2 fibroblasts overexpressing c-src, we have identified a 75-kDa protein (p75) whose properties are consistent with those expected of such a substrate. We present evidence to show that p75 is immunologically related to a recently described, cytoskeleton-associated, pp60v-src substrate [Wu et al. (1991). Mol. Cell. Biol., 11, 5113-5124), and that its phosphotyrosine content is increased cooperatively by c-src overexpression and EGF stimulation. p75 is rapidly (within 2 min) phosphorylated on tyrosine upon EGF treatment and undergoes a second, prolonged phase of tyrosyl phosphorylation from 7 to 21 h after EGF addition, suggesting that tyrosyl phosphorylation of p75 is important for late as well as early events following EGF receptor activation. Enhanced tyrosyl phosphorylation of p75 is also seen when cells overexpressing c-src are treated with platelet-derived growth factor (PDGF), but significantly less phosphorylation is observed with insulin and fibroblast growth factor (FGF). Both basal and EGF-induced tyrosyl phosphorylation of p75 are reduced in cells overexpressing mutated forms of c-src (unmyristylated, or kinase deficient) as compared with wild-type c-src overexpressers, indicating the dependence of the enhanced tyrosyl phosphorylation on membrane-associated, enzymatically active pp60c-src. In cellular fractionation experiments p75 partitions with the cytosol, while immunofluorescence studies reveal a striking colocalization with pp60c-src at the plasma membrane and in the perinuclear region. Partial co-staining of p75 and actin occurs at the cell's periphery. These data provide evidence for p75 being a direct substrate of pp60c-src. The possible role of p75 in the enhanced response to EGF seen in c-src overexpressers is discussed.	UNIV VIRGINIA, HLTH SCI CTR, CTR CANC, DEPT MICROBIOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, HLTH SCI CTR, INST MOLEC BIOL, CHARLOTTESVILLE, VA 22908 USA	University of Virginia; University of Virginia					NCI NIH HHS [CA 40042, CA 29243, CA 39438] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA029243, R01CA039438, P01CA040042, R01CA029243] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS BJ, 1989, NATURE, V342, P830, DOI 10.1038/342830a0; AVES SJ, 1985, EMBO J, V4, P457, DOI 10.1002/j.1460-2075.1985.tb03651.x; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; COPPER JA, 1990, PEPTIDES PROTEIN PHO, P85; COURTNEIDGE SA, 1980, P NATL ACAD SCI-BIOL, V77, P3783, DOI 10.1073/pnas.77.7.3783; DAVIDPFEUTY T, 1990, J CELL BIOL, V111, P3097, DOI 10.1083/jcb.111.6.3097; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; GENTRY LE, 1986, MOL CELL BIOL, V6, P735, DOI 10.1128/MCB.6.2.735; GOULD KL, 1985, CELL, V42, P849, DOI 10.1016/0092-8674(85)90281-8; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HOOPER C, 1990, J NIH RES, V2, P67; KADOWAKI T, 1986, J BIOL CHEM, V261, P6141; KANNER SB, 1989, J IMMUNOL METHODS, V120, P115, DOI 10.1016/0022-1759(89)90296-2; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MCMAHON AP, 1987, DIFFERENTIATION, V34, P68, DOI 10.1111/j.1432-0436.1987.tb00052.x; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; ODDIE KM, 1989, J NEUROSCI RES, V24, P38, DOI 10.1002/jnr.490240107; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PAWSON T, 1988, ONCOGENE, V3, P491; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; TAMURA T, 1984, FEBS LETT, V177, P151, DOI 10.1016/0014-5793(84)81001-7; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WADA I, 1992, J CELL BIOL, V116, P321, DOI 10.1083/jcb.116.2.321; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WILSON LK, 1990, ONCOGENE, V5, P1471; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	43	81	83	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1992	7	12					2429	2438						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1281304				2022-12-28	WOS:A1992KA85600007
J	FUJITAYOSHIGAKI, J; YOKOYAMA, S; SHINDOOKADA, N; NISHIMURA, S				FUJITAYOSHIGAKI, J; YOKOYAMA, S; SHINDOOKADA, N; NISHIMURA, S			AZATYROSINE INHIBITS NEURITE OUTGROWTH OF PC12 CELLS INDUCED BY ONCOGENIC RAS	ONCOGENE			English	Article							NERVE GROWTH-FACTOR; PROTEIN-KINASE-C; H-RAS; DIFFERENTIATION; PHOSPHORYLATION; MICROINJECTION; EXPRESSION; MOUSE; P21; ANTIBODY	An antibiotic, azatyrosine [L-beta-(5-hydroxy-2-pyridyl) alanine], specifically converts ras-, raf- or c-erbB2 (neu)-transformed NIH3T3 cells to apparently normal phenotype. The reversion induced by azatyrosine is permanent, and the phenotype of the revertant cells does not change even after prolonged culture in the absence of azatyrosine [N. Shindo-Okada, O. Manabe, H. Nagahara & S. Nishimura (1989). Mol. Carcinogen., 2, 159-167]. In the present study, we found that neurite outgrowth of PC12 cells induced by expression of either the ras or raf oncogenes was inhibited by addition of azatyrosine to the medium. Azatyrosine also inhibited neurite outgrowth induced by microinjection of oncogenic Ras protein into PC12 cells. The dose dependency was much the same for the two systems, inhibition of neurite outgrowth of PC12 cells and reversion of the transformed NIH3T3 cells. Microinjection of azatyrosine into the cells was as effective as addition to the medium, indicating that the target of azatyrosine is intracellular. In contrast, neurite outgrowth induced by nerve growth factor, which has been shown to be mediated by normal Ras [N. Hagag, S. Halegouna & M. Viola (1986). Nature, 319, 680-682], was found to be resistant to azatyrosine. Azatyrosine also showed no effect on neurite outgrowth induced by a membrane-permeant cyclic AMP analog through another pathway. These findings suggest that azatyrosine sensitivity is the result of abnormal signal transduction by oncogenic Ras. It was shown that azatyrosine also inhibited differentiation-associated growth arrest of PC12 cells induced by oncogenic Ras. In Ras-induced neurite outgrowth, the azatyrosine-sensitive process was found to be completed in the first 6-9 h, and is probably essential for the commitment of PC12 cells to differentiation rather than to growth.	UNIV TOKYO,FAC SCI,DEPT BIOPHYS,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,FAC SCI,DEPT BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; NATL CANC CTR,RES INST,CHUO KU,TOKYO 104,JAPAN	University of Tokyo; University of Tokyo; National Cancer Center - Japan			Yoshigaki, Junko/AAE-6702-2020; Yokoyama, Shigeyuki/N-6911-2015	Yokoyama, Shigeyuki/0000-0003-3133-7338				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; DIAZLAVIADA I, 1990, EMBO J, V9, P3907, DOI 10.1002/j.1460-2075.1990.tb07611.x; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HAYNES JR, 1988, MOL CELL BIOL, V8, P2419, DOI 10.1128/MCB.8.6.2419; INOUYE S, 1975, CHEM PHARM BULL, V23, P2669; IZAWA M, 1992, IN PRESS CANCER RES; KAMATA T, 1984, NATURE, V310, P147, DOI 10.1038/310147a0; KANAI T, 1987, JPN J CANCER RES, V78, P1314; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KRZYZOSIAK WJ, 1992, P NATL ACAD SCI USA, V89, P4879, DOI 10.1073/pnas.89.11.4879; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; MIURA K, 1986, JPN J CANCER RES, V77, P45; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MUROYA K, 1992, ONCOGENE, V7, P277; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; QIU MS, 1991, NEURON, V7, P937, DOI 10.1016/0896-6273(91)90339-2; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RYDEL RE, 1988, P NATL ACAD SCI USA, V85, P1257, DOI 10.1073/pnas.85.4.1257; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SHINDOOKADA N, 1989, MOL CARCINOGEN, V2, P159, DOI 10.1002/mc.2940020309; SHIROUZU M, 1992, ONCOGENE, V7, P475; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J	33	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					2019	2024						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1328988				2022-12-28	WOS:A1992JP42400016
J	SAKODA, T; KAIBUCHI, K; KISHI, K; KISHIDA, S; DOI, K; HOSHINO, M; HATTORI, S; TAKAI, Y				SAKODA, T; KAIBUCHI, K; KISHI, K; KISHIDA, S; DOI, K; HOSHINO, M; HATTORI, S; TAKAI, Y			SMG/RAP-1/KREV-1 P21S INHIBIT THE SIGNAL PATHWAY TO THE C-FOS PROMOTER ENHANCER FROM C-KI-RAS P21 BUT NOT FROM C-RAF-1 KINASE IN NIH3T3-CELLS	ONCOGENE			English	Article							GTPASE-ACTIVATING PROTEIN; NUCLEOTIDE EXCHANGE-REACTION; PUTATIVE EFFECTOR DOMAIN; SERUM-RESPONSE ELEMENT; BOVINE BRAIN; MAMMALIAN-CELLS; GROWTH-FACTOR; SMG P21; CATALYZED PHOSPHORYLATION; TYROSINE PHOSPHORYLATION	smg/rap1A/Krev-1 p21 cDNA is known to inhibit v-Kiras p21-induced cell transformation in NIH3T3 cells, but the inhibitory mechanism is not clear at present. In the present study, we examined the effect of smg p21s on the c-fos promoter/enhancer linked to the luciferase reporter gene (c-fos-luciferase). After transfection of c-fos-luciferase into NIH3T3 cells constitutively expressing c-Ki-ras(val-12) p21 or activated c-raf-1 kinase, expression of c-fos-luciferase was much higher than after transfection into control NIH3T3 cells. Addition of platelet-derived growth factor (PDGF), 12-O-tetradecanoyl phorbol 13-acetate (TPA) or dibutyryl cyclic AMP (Bt2cAMP) to the control NIH3T3 cells stimulated c-fos-luciferase expression. Transfection of the smg p21 cDNAs inhibited the activated ras p21-, PDGF- or TPA-stimulated c-fos-luciferase expression, but did not inhibit the activated c-raf-1 kinase- or Bt2cAMP-stimulated reaction. These results indicate that smg p21s inhibit the signal pathways from the PDGF receptor, protein kinase C, and ras p21s to the c-fos promoter/enhancer, but not those from c-raf-1 kinase and cyclic AMP-dependent protein kinase to the c-fos promoter/enhancer.	KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN; UNIV TOKYO,COLL ARTS & SCI,DEPT PURE & APPL SCI,TOKYO 153,JAPAN	Kobe University; University of Tokyo				kishida, shosei/0000-0003-0405-851X				ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BOSCH HVD, 1980, BIOCHIM BIOPHYS ACTA, V604, P191; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSS JE, 1991, MOL CELL BIOL, V11, P1523, DOI 10.1128/MCB.11.3.1523; CAMPA MJ, 1991, BIOCHEM BIOPH RES CO, V174, P1, DOI 10.1016/0006-291X(91)90475-M; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; FUJIOKA H, 1992, J BIOL CHEM, V267, P926; FUKUMOTO Y, 1990, J BIOL CHEM, V265, P774; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HATA Y, 1991, J BIOL CHEM, V266, P6571; HATA Y, 1990, J BIOL CHEM, V265, P7104; HIROYOSHI M, 1991, J BIOL CHEM, V266, P2962; HUANG YK, 1990, P NATL ACAD SCI USA, V87, P8008, DOI 10.1073/pnas.87.20.8008; ITOH T, 1991, BIOCHEM BIOPH RES CO, V177, P1319, DOI 10.1016/0006-291X(91)90685-Z; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; KAIBUCHI K, 1989, J BIOL CHEM, V264, P20855; KAIBUCHI K, 1991, MOL CELL BIOL, V11, P2873, DOI 10.1128/MCB.11.5.2873; KAIBUCHI K, 1989, J BIOL CHEM, V264, P13489; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAWATA M, 1988, J BIOL CHEM, V263, P18965; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KIM S, 1990, MOL CELL BIOL, V10, P2645, DOI 10.1128/MCB.10.6.2645; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; MATSUI Y, 1990, BIOCHEM BIOPH RES CO, V166, P1010, DOI 10.1016/0006-291X(90)90911-6; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MCCOY MS, 1984, MOL CELL BIOL, V4, P1577, DOI 10.1128/MCB.4.8.1577; MITSUNOBU F, 1989, ONCOGENE, V4, P437; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MURAMATSU MA, 1989, MOL CELL BIOL, V9, P831, DOI 10.1128/MCB.9.2.831; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OKU N, 1990, FEBS LETT, V269, P148, DOI 10.1016/0014-5793(90)81141-A; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719; PIZON V, 1988, ONCOGENE, V3, P201; RAPP UR, 1991, ONCOGENE, V6, P495; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; Sambrook J, 1989, MOL CLONING LABORATO; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; WEST M, 1990, FEBS LETT, V259, P245, DOI 10.1016/0014-5793(90)80019-F; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626; ZIPSER D, 1981, P NATL ACAD SCI-BIOL, V78, P6276, DOI 10.1073/pnas.78.10.6276	67	63	63	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1705	1711						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1323817				2022-12-28	WOS:A1992JJ37600005
J	LUDLOW, JW				LUDLOW, JW			SELECTIVE ABILITY OF S-PHASE CELL-EXTRACTS TO DEPHOSPHORYLATE SV40 LARGE T-ANTIGEN INVITRO	ONCOGENE			English	Note							SIMIAN-VIRUS 40; RETINOBLASTOMA SUSCEPTIBILITY GENE; DNA-REPLICATION INVITRO; LARGE TUMOR-ANTIGEN; PROTEIN PHOSPHATASE-2A; BINDING; PRODUCT; TRANSFORMATION; PHOSPHORYLATION; COMPLEX	Simian virus 40 (SV40) large tumor antigen (T) is an oncoprotein whose biological and biochemical functions appear to be modulated by phosphorylation. Recently, SV40 DNA replication in vitro has been shown to be activated by dephosphorylation involving the activity of a serine/threonine phosphoprotein phosphatase belonging to the type 2A class (PP2A) [Virshup, D.M., Kauffman, M.G. & Kelly, T.J. (1989) EMBO J., 8, 3891-3898]. To address the question of how specificity of PP2A activity towards T is regulated, an in vitro assay to study the process of T dephosphorylation was developed. Unlabeled extracts from cells enriched for various stages of the cell cycle were incubated with P-32-labeled, immunocomplexed T. Extracts from a population of cells enriched for S phase demonstrated a selective ability to dephosphorylate this labeled protein when compared with extracts prepared from G1- and M-phase cells. The time course of release from growth arrest demonstrated that this T-specific phosphatase activity occurred at the onset of host-cell DNA synthesis. In contrast, when using P-32-labeled phosphorylase a as the substrate, phosphatase activity appeared to be present throughout the cell cycle. The data presented here are consistent with the notion that PP2A activity towards T is regulated in a cell cycle-dependent manner.			LUDLOW, JW (corresponding author), UNIV ROCHESTER, CTR CANC, DIV TUMOR BIOL, BOX 704, 601 ELMWOOD AVE, ROCHESTER, NY 14642 USA.							BIKEL I, 1987, CELL, V48, P321, DOI 10.1016/0092-8674(87)90435-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADLEY MK, 1982, CELL, V28, P125, DOI 10.1016/0092-8674(82)90382-8; BRAUTIGAN DL, 1988, METHOD ENZYMOL, V159, P339; BRUGGE JS, 1975, J VIROL, V15, P619, DOI 10.1128/JVI.15.3.619-635.1975; CHOI YW, 1988, MOL CELL BIOL, V8, P3382, DOI 10.1128/MCB.8.8.3382; CHOU JY, 1975, J VIROL, V15, P145, DOI 10.1128/JVI.15.1.145-150.1975; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1988, METHOD ENZYMOL, V159, P390; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FANNING E, 1981, J VIROL, V37, P92, DOI 10.1128/JVI.37.1.92-102.1981; GREENSPAN DS, 1981, P NATL ACAD SCI-BIOL, V78, P105, DOI 10.1073/pnas.78.1.105; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON R, 1990, J VIROL, V64, P2380, DOI 10.1128/JVI.64.5.2380-2383.1990; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MAY P, 1976, EXP CELL RES, V100, P433, DOI 10.1016/0014-4827(76)90175-0; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; RUNDELL K, 1987, J VIROL, V61, P1240, DOI 10.1128/JVI.61.4.1240-1243.1987; SCHEIDTMANN KH, 1991, MOL CELL BIOL, V11, P1996, DOI 10.1128/MCB.11.4.1996; SCHEIDTMANN KH, 1982, J VIROL, V44, P116, DOI 10.1128/JVI.44.1.116-133.1982; SCHEIDTMANN KH, 1991, J VIROL, V65, P2098, DOI 10.1128/JVI.65.4.2098-2101.1991; SIMMONS DT, 1984, J BIOL CHEM, V259, P8633; TEGTMEYER P, 1972, J VIROL, V10, P591, DOI 10.1128/JVI.10.4.591-598.1972; TEGTMEYER P, 1975, J VIROL, V15, P613, DOI 10.1128/JVI.15.3.613-618.1975; TIJAN R, 1978, P NATL ACAD SCI USA, V75, P1279; VANROY F, 1983, J VIROL, V45, P315, DOI 10.1128/JVI.45.1.315-331.1983; VIRSHUP DM, 1989, EMBO J, V8, P3891, DOI 10.1002/j.1460-2075.1989.tb08568.x; VIRSHUP DM, 1989, P NATL ACAD SCI USA, V86, P3584, DOI 10.1073/pnas.86.10.3584; WALTER G, 1988, J VIROL, V62, P4760, DOI 10.1128/JVI.62.12.4760-4762.1988; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988	38	14	14	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1992	7	5					1011	1014						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1315015				2022-12-28	WOS:A1992HP64200023
J	HEIDARAN, MA; MOLLOY, CJ; PANGELINAN, M; CHOUDHURY, GG; WANG, LM; FLEMING, TP; SAKAGUCHI, AY; PIERCE, JH				HEIDARAN, MA; MOLLOY, CJ; PANGELINAN, M; CHOUDHURY, GG; WANG, LM; FLEMING, TP; SAKAGUCHI, AY; PIERCE, JH			ACTIVATION OF THE COLONY-STIMULATING FACTOR-I RECEPTOR LEADS TO THE RAPID TYROSINE PHOSPHORYLATION OF GTPASE-ACTIVATING PROTEIN AND ACTIVATION OF CELLULAR P21RAS	ONCOGENE			English	Article							FACTOR-I RECEPTOR; GAP-ASSOCIATED PROTEINS; GROWTH-FACTOR RECEPTORS; PHOSPHOLIPASE-C-GAMMA; PDGF BETA-RECEPTOR; KINASE-ACTIVITY; PHOSPHATIDYLINOSITOL 3-KINASE; CSF-1; TRANSFORMATION; PRODUCT	We have previously reported that platelet-derived growth factor (PDGF) induced tyrosine phosphorylation of GTPase-activating protein (GAP) in intact quiescent fibroblasts under conditions in which insulin and basic fibroblast growth factor (bFGF) were ineffective (Molloy et al., 1988). In the present study, we have provided evidence that colony-stimulating factor 1 (CSF-1) is capable of inducing tyrosine phosphorylation of GAP and its associated cellular proteins, p62 and p190, in NIH3T3 cells overexpressing the human CSF-1 receptor (CSF-1R). However, the extent of GAP tyrosine phosphorylation induced by CSF-1 was approximately 10% of that induced by PDGF-BB in the NIH3T3 fibroblasts. Despite this significant difference, both PDGF-BB and CSF-1 increased the activation of p21ras, the extent of which correlated well with the mitogenic response induced by each growth factor in these cells. Taken together, our findings provide evidence for a possible role of tyrosine phosphorylation of GAP and GAP-associated phosphoproteins in regulating transduction of CSF-1-induced mitogenic signals through p21ras activation.	NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892; UNIV TEXAS,HLTH SCI CTR,DEPT CELLULAR & STRUCT BIOL,SAN ANTONIO,TX 78284	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Texas System; University of Texas Health San Antonio			Molloy, Christopher/A-6821-2013	Molloy, Christopher/0000-0003-2964-6166				BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CHOUDHURY GG, 1991, J BIOL CHEM, V266, P8068; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; DEVENDITTIS E, 1986, EMBO J, V5, P3657, DOI 10.1002/j.1460-2075.1986.tb04696.x; DOWNING JR, 1989, EMBO J, V8, P3345, DOI 10.1002/j.1460-2075.1989.tb08496.x; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FLEMING TP, 1989, P NATL ACAD SCI USA, V86, P8063, DOI 10.1073/pnas.86.20.8063; GIBBS JB, 1987, J BIOL CHEM, V262, P10426; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARSHALL MS, 1987, MOL CELL BIOL, V7, P2309, DOI 10.1128/MCB.7.7.2309; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; STACEY DW, 1987, EXP CELL RES, V171, P232, DOI 10.1016/0014-4827(87)90266-7; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; TAPLEY P, 1990, MOL CELL BIOL, V10, P2528, DOI 10.1128/MCB.10.6.2528; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VANDERGEER P, 1990, MOL CELL BIOL, V10, P2991, DOI 10.1128/MCB.10.6.2991; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; VOGEL US, 1989, PROTEIN STRUCT FUNCT, V6, P306; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WANG LM, 1989, BIOTECHNIQUES, V7, P1000; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	40	34	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1992	7	1					147	152						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1311060				2022-12-28	WOS:A1992HC22700020
J	Ishikura, S; Yoshida, K; Tsunoda, T; Shirasawa, S				Ishikura, Shuhei; Yoshida, Kazumasa; Tsunoda, Toshiyuki; Shirasawa, Senji			Death domain-associated protein DAXX regulates noncoding RNA transcription at the centromere through the transcription regulator ZFAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN; SUSCEPTIBILITY; ACTIVATION; DISEASE; PROFILE; MITOSIS; HDAXX; LEADS	The centromere is an essential chromosomal structure for faithful chromosome segregation during cell division. No protein-coding genes exist at the centromeres, but centromeric DNA is actively transcribed into noncoding RNA (ncRNA). This centromeric transcription and its ncRNA products play important roles in centromere functions. We previously re-ported that the transcriptional regulator ZFAT (zinc -finger protein with AT hook) plays a pivotal role in ncRNA tran-scription at the centromere; however, it was unclear how ZFAT involvement was regulated. Here, we show that the death domain-associated protein (DAXX) promotes centromeric localization of ZFAT to regulate ncRNA transcription at the centromere. Coimmunoprecipitation analysis of endogenous proteins clearly reveals that DAXX interacts with ZFAT. In addition, we show that ectopic coexpression of ZFAT with DAXX increases the centromeric levels of both ZFAT and ncRNA, compared with ectopic expression of ZFAT alone. On the other hand, we found that siRNA-mediated depletion of DAXX decreases the centromeric levels of both ZFAT and ncRNA in cells ectopically expressing ZFAT. These results suggest that DAXX promotes the centromeric localization of ZFAT and ZFAT-regulated centromeric ncRNA transcription. Furthermore, we demonstrate that depletion of endogenous DAXX protein is sufficient to cause a decrease in the ncRNA levels at the centromeres of chromosomes 17 and X in which ZFAT regulates the transcription, indicating a physiological significance of DAXX in ZFAT-regulated centromeric ncRNA transcription. Taken together, these results demonstrate that DAXX regulates centromeric ncRNA transcription through ZFAT.	[Ishikura, Shuhei; Yoshida, Kazumasa; Tsunoda, Toshiyuki; Shirasawa, Senji] Fukuoka Univ, Fac Med, Dept Cell Biol, Fukuoka, Japan; [Ishikura, Shuhei; Yoshida, Kazumasa; Tsunoda, Toshiyuki; Shirasawa, Senji] Fukuoka Univ, Res Inst Adv Mol Med, Fukuoka, Japan	Fukuoka University; Fukuoka University	Shirasawa, S (corresponding author), Fukuoka Univ, Fac Med, Dept Cell Biol, Fukuoka, Japan.; Shirasawa, S (corresponding author), Fukuoka Univ, Res Inst Adv Mol Med, Fukuoka, Japan.	sshirasa@fukuoka-u.ac.jp		Yoshida, Kazumasa/0000-0002-0181-9857; Shirasawa, Senji/0000-0003-3076-3474	Japan Society for the Promotion of Science KAKENHI [20K07317, 22K07221]; Fukuoka University [925, K22009]	Japan Society for the Promotion of Science KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Fukuoka University	This work was supported by Japan Society for the Promotion of Science KAKENHI grant (grant nos.: 20K07317 [to S. I.] and 22K07221 [to K. Y.]) and by funding from Fukuoka University (Grantgrant nos. 925 and K22009).	Bouzinba-Segard H, 2006, P NATL ACAD SCI USA, V103, P8709, DOI 10.1073/pnas.0508006103; Catalano C, 2021, BLOOD CANCER J, V11, DOI 10.1038/s41408-021-00422-6; Chan FL, 2012, P NATL ACAD SCI USA, V109, P1979, DOI 10.1073/pnas.1108705109; Chen YJ, 2022, BIOESSAYS, V44, DOI 10.1002/bies.202100201; Drane P, 2010, GENE DEV, V24, P1253, DOI 10.1101/gad.566910; Emelyanov AV, 2002, J BIOL CHEM, V277, P11156, DOI 10.1074/jbc.M111763200; Erdogan OS, 2020, ONCOL LETT, V20, DOI 10.3892/ol.2020.12221; Eymery A, 2009, NUCLEIC ACIDS RES, V37, P6340, DOI 10.1093/nar/gkp639; Giovinazzi S, 2013, CELL DEATH DIFFER, V20, P721, DOI 10.1038/cdd.2012.169; Giovinazzi S, 2012, ONCOGENE, V31, P13, DOI 10.1038/onc.2011.211; Gostissa M, 2004, J BIOL CHEM, V279, P48013, DOI 10.1074/jbc.M310801200; Gunnarsson R, 2021, LEUKEMIA, V35, P1485, DOI 10.1038/s41375-021-01242-0; Hollenbach AD, 2002, J CELL SCI, V115, P3319; Hoyt SJ, 2022, SCIENCE, V376, P57, DOI 10.1126/science.abk3112; Inoue N, 2012, J CLIN IMMUNOL, V32, P1243, DOI 10.1007/s10875-012-9721-0; Ishikura S, 2021, J BIOL CHEM, V297, DOI 10.1016/j.jbc.2021.101213; Ishikura S, 2021, J CELL BIOCHEM, V122, P626, DOI 10.1002/jcb.29890; Ishikura S, 2020, NUCLEIC ACIDS RES, V48, P10848, DOI 10.1093/nar/gkaa815; Ishikura S, 2016, BBA-GENE REGUL MECH, V1859, P1398, DOI 10.1016/j.bbagrm.2016.08.010; Ishikura S, 2016, J BIOL CHEM, V291, P15282, DOI 10.1074/jbc.M116.723734; Ishikura S, 2015, J CELL BIOCHEM, V116, P149, DOI 10.1002/jcb.24954; Iwaihara Y, 2015, ANTICANCER RES, V35, P4419; Kuo HY, 2005, P NATL ACAD SCI USA, V102, P16973, DOI 10.1073/pnas.0504460102; Leclerc S, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.642732; Lin CW, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14502; Liu Q, 2021, GENES GENOM, V43, P217, DOI 10.1007/s13258-021-01041-y; Mahmud I, 2019, NUCLEIC ACIDS RES, V47, P7734, DOI 10.1093/nar/gkz634; McKinley KL, 2016, NAT REV MOL CELL BIO, V17, DOI 10.1038/nrm.2015.5; Mihic Pia, 2021, Prog Mol Subcell Biol, V60, P169, DOI 10.1007/978-3-030-74889-0_7; Morozov VM, 2017, EPIGENET CHROMATIN, V10, DOI 10.1186/s13072-017-0164-y; Morozov VM, 2012, NUCLEUS-AUSTIN, V3, P276, DOI 10.4161/nucl.20180; Nishi K, 2017, CELL DEATH DIS, V8, DOI 10.1038/s41419-017-0006-7; Ogawa M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076254; Pan WW, 2013, J BIOL CHEM, V288, P13620, DOI 10.1074/jbc.M112.446369; Pluta AF, 1998, J CELL SCI, V111, P2029; Quenet D., 2014, ELIFE, V3, pe03254, DOI [10.7554/eLife.03254, DOI 10.7554/ELIFE.03254]; Ramakrishna M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009983; Reddy A, 2017, CELL, V171, P481, DOI 10.1016/j.cell.2017.09.027; Sabatino G, 2013, J BIOL REG HOMEOS AG, V27, P729; Shirasawa S, 2004, HUM MOL GENET, V13, P2221, DOI 10.1093/hmg/ddh245; Slavin TP, 2011, HUM GENET, V130, P725, DOI 10.1007/s00439-011-1009-6; de Araujo ESS, 2014, EXP MOL PATHOL, V97, P425, DOI 10.1016/j.yexmp.2014.09.009; Ting DT, 2011, SCIENCE, V331, P593, DOI 10.1126/science.1200801; Tochio Naoya, 2015, Journal of Structural and Functional Genomics, V16, P55, DOI 10.1007/s10969-015-9196-3; Topp CN, 2004, P NATL ACAD SCI USA, V101, P15986, DOI 10.1073/pnas.0407154101; Tsunoda T, 2018, INT J MOL MED, V42, P2595, DOI 10.3892/ijmm.2018.3806; Woo HJ, 2018, BMC MED GENOMICS, V11, DOI 10.1186/s12920-018-0373-7; Zhang FF, 2020, MOL THER, V28, P613, DOI 10.1016/j.ymthe.2019.11.015	48	0	0	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV	2022	298	11							102528	10.1016/j.jbc.2022.102528	http://dx.doi.org/10.1016/j.jbc.2022.102528			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	6C1SV	36162510	Green Published, gold			2022-12-28	WOS:000881802600011
J	Bommisetti, P; Young, A; Bandarian, V				Bommisetti, Praneeth; Young, Anthony; Bandarian, Vahe			Elucidation of the substrate of tRNA-modifying enzymes MnmEG leads to in vitro reconstitution of an evolutionarily conserved uridine hypermodification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL TRANSFER-RNAS; MODIFIED NUCLEOSIDE; BINDING PROTEIN; BIOSYNTHESIS; GIDA; GENE; METHYLTRANSFERASE; IDENTIFICATION; INSIGHTS; FLAVIN	The evolutionarily conserved bacterial proteins MnmE and MnmG collectively install a carboxymethylaminomethyl (cmnm) group at the fifth position of wobble uridines of several tRNA species. While the reaction catalyzed by MnmEG is one of the central steps in the biosynthesis of the methyl-aminomethyl (mnm) posttranscriptional tRNA modification, details of the reaction remain elusive. Glycine is known to be the source of the carboxy methylamino moiety of cmnm, and a tetrahydrofolate (THF) analog is thought to supply the one carbon that is appended to the fifth position of U. However, the nature of the folate analog remains unknown. This article reports the in vitro biochemical reconstitution of the MnmEG reaction. Using isotopically labeled methyl and methylene THF analogs, we demonstrate that methylene THF is the true substrate. We also show that reduced FAD is required for the reaction and that DTT can replace the NADH in its role as a reductant. We discuss the implications of these methylene-THF and reductant requirements on the mechanism of this key tRNA modification catalyzed by MnmEG.	[Bommisetti, Praneeth; Bandarian, Vahe] Univ Utah, Dept Chem, Salt Lake City, UT 84112 USA; [Young, Anthony] Soliome Inc, San Francisco, CA USA	Utah System of Higher Education; University of Utah	Bandarian, V (corresponding author), Univ Utah, Dept Chem, Salt Lake City, UT 84112 USA.	vahe@chem.utah.edu		Young, Anthony/0000-0003-2273-346X	National Institutes of General Medical Sciences of the National Institutes of Health (NIH);  [R35 GM126956]	National Institutes of General Medical Sciences of the National Institutes of Health (NIH); 	Funding and additional information-The research reported in this publication was supported by the National Institutes of General Medical Sciences of the National Institutes of Health (NIH) under the award number R35 GM126956. The content is solely the re-sponsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Armengod ME, 2012, BIOCHIMIE, V94, P1510, DOI 10.1016/j.biochi.2012.02.019; Baba T, 2006, MOL SYST BIOL, V2, DOI 10.1038/msb4100050; Benitez-Paez A, 2010, RNA, V16, P2131, DOI 10.1261/rna.2245910; Bjork G. R., 2014, ECOSAL PLUS, V6, DOI [10.1128/ecosalplus.esp-0007-2013, DOI 10.1128/ECOSALPLUS.ESP-0007-2013]; Boccaletto P, 2018, NUCLEIC ACIDS RES, V46, pD303, DOI 10.1093/nar/gkx1030; Bommisetti P, 2022, ACS OMEGA, V7, P4011, DOI 10.1021/acsomega.1c05071; Bou-Nader C., 2017, ANGEW CHEM INT EDIT, V129, P12697; Bregeon D, 2001, GENE DEV, V15, P2295, DOI 10.1101/gad.207701; Bujnicki JM, 2004, RNA, V10, P1236, DOI 10.1261/rna.7470904; CARBON J, 1968, SCIENCE, V161, P1146, DOI 10.1126/science.161.3846.1146; ELSEVIERS D, 1984, NUCLEIC ACIDS RES, V12, P3521, DOI 10.1093/nar/12.8.3521; Esberg B, 1999, J BACTERIOL, V181, P7256, DOI 10.1128/JB.181.23.7256-7265.1999; Armengod ME, 2014, RNA BIOL, V11, P1495, DOI 10.4161/15476286.2014.992269; Fislage M, 2014, NUCLEIC ACIDS RES, V42, P5978, DOI 10.1093/nar/gku213; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; Green Jacalyn M, 2007, EcoSal Plus, V2, DOI 10.1128/ecosalplus.3.6.3.6; Grosjean H, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004363; HAGERVALL TG, 1984, MOL GEN GENET, V196, P201, DOI 10.1007/BF00328051; Hamdane D, 2013, BIOCHEMISTRY-US, V52, P8949, DOI 10.1021/bi4013879; Hamdane D, 2012, J AM CHEM SOC, V134, P19739, DOI 10.1021/ja308145p; Hamdane D, 2011, J BIOL CHEM, V286, P36268, DOI 10.1074/jbc.M111.256966; Jager G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153488; Kambampati R, 2003, BIOCHEMISTRY-US, V42, P1109, DOI 10.1021/bi026536+; Kirino Y, 2004, P NATL ACAD SCI USA, V101, P15070, DOI 10.1073/pnas.0405173101; Kirino Yohei, 2005, RNA Biol, V2, P41, DOI 10.4161/rna.2.2.1610; KOBAYASHI Y, 1991, AM J HUM GENET, V49, P590; Lee YJ, 2022, NUCLEIC ACIDS RES, V50, P3001, DOI 10.1093/nar/gkab781; McCarty RM, 2009, BIOCHEMISTRY-US, V48, P3847, DOI 10.1021/bi900400e; McCutcheon JP, 2012, NAT REV MICROBIOL, V10, P13, DOI 10.1038/nrmicro2670; Meyer S, 2008, J MOL BIOL, V380, P532, DOI 10.1016/j.jmb.2008.04.072; Meyer S, 2009, J MOL BIOL, V392, P910, DOI 10.1016/j.jmb.2009.07.004; Miles ZD, 2011, P NATL ACAD SCI USA, V108, P7368, DOI 10.1073/pnas.1018636108; Monleon D, 2007, PROTEINS, V66, P726, DOI 10.1002/prot.21186; Morscher RJ, 2018, NATURE, V554, P128, DOI 10.1038/nature25460; Moukadiri I, 2009, NUCLEIC ACIDS RES, V37, P7177, DOI 10.1093/nar/gkp762; Nasvall SJ, 2004, RNA, V10, P1662, DOI 10.1261/rna.7106404; Noma A, 2006, EMBO J, V25, P2142, DOI 10.1038/sj.emboj.7601105; OKADA N, 1979, J BIOL CHEM, V254, P3061; Osawa T, 2009, STRUCTURE, V17, P713, DOI 10.1016/j.str.2009.03.013; Scrima A, 2005, EMBO J, V24, P23, DOI 10.1038/sj.emboj.7600507; Shi R, 2009, J BACTERIOL, V191, P7614, DOI 10.1128/JB.00650-09; Shippy DC, 2013, MICROB PATHOGENESIS, V57, P1, DOI 10.1016/j.micpath.2013.01.004; Shippy DC, 2011, MICROB PATHOGENESIS, V50, P303, DOI 10.1016/j.micpath.2011.02.004; SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N; SLANY RK, 1993, BIOCHEMISTRY-US, V32, P7811, DOI 10.1021/bi00081a028; Suzuki T, 2002, EMBO J, V21, P6581, DOI 10.1093/emboj/cdf656; Suzuki T, 2011, ANNU REV GENET, V45, P299, DOI 10.1146/annurev-genet-110410-132531; Szczupak P, 2022, CELLS-BASEL, V11, DOI 10.3390/cells11091522; Thoden JB, 2005, J BIOL CHEM, V280, P32784, DOI 10.1074/jbc.M505730200; Urbonavicius J, 2005, NUCLEIC ACIDS RES, V33, P3955, DOI 10.1093/nar/gki703; Urbonavicius J, 2007, METHOD ENZYMOL, V425, P103; VONMEYENBURG K, 1982, MOL GEN GENET, V188, P240, DOI 10.1007/BF00332682; Waller JC, 2010, P NATL ACAD SCI USA, V107, P10412, DOI 10.1073/pnas.0911586107; WANG BY, 1989, BIOCHEMISTRY-US, V28, P1148, DOI 10.1021/bi00429a032; Wang XJ, 2010, J MOL BIOL, V395, P1038, DOI 10.1016/j.jmb.2009.12.002; Weixlbaumer A, 2007, NAT STRUCT MOL BIOL, V14, P498, DOI 10.1038/nsmb1242; White DJ, 2001, MOL MICROBIOL, V42, P503, DOI 10.1046/j.1365-2958.2001.02659.x; WITTWER AJ, 1986, ARCH BIOCHEM BIOPHYS, V248, P540, DOI 10.1016/0003-9861(86)90507-2; YAMADA Y, 1981, NUCLEIC ACIDS RES, V9, P1933, DOI 10.1093/nar/9.8.1933; Young AP, 2018, METHOD ENZYMOL, V606, P119, DOI 10.1016/bs.mie.2018.04.024; Young AP, 2013, CURR OPIN CHEM BIOL, V17, P613, DOI 10.1016/j.cbpa.2013.05.035	61	0	0	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV	2022	298	11							102548	10.1016/j.jbc.2022.102548	http://dx.doi.org/10.1016/j.jbc.2022.102548			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	6D3XI	36181794	Green Published, gold			2022-12-28	WOS:000882627400005
J	Embree, CM; Abu-Alhasan, R; Singh, G				Embree, Caleb M.; Abu-Alhasan, Rabab; Singh, Guramrit			Features and factors that dictate if terminating ribosomes cause or counteract nonsense-mediated mRNA decay	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							STOP CODON RECOGNITION; SHORT UPSTREAM ORFS; TRANSLATION TERMINATION; FRAMESHIFT SIGNAL; RELEASE FACTORS; UPF PROTEINS; POLY(A)-BINDING PROTEIN; SURVEILLANCE COMPLEX; NMD; MUTATIONS	Nonsense-mediated mRNA decay (NMD) is a quality control pathway in eukaryotes that continuously monitors mRNA transcripts to ensure truncated polypeptides are not produced. The expression of many normal mRNAs that encode full-length polypeptides is also regulated by this pathway. Such transcript surveillance by NMD is intimately linked to translation termination. When a ribosome terminates translation at a normal termination codon, NMD is not activated, and mRNA can undergo repeated rounds of translation. On the other hand, when translation termination is deemed abnormal, such as that on a premature termination codon, it leads to a series of poorly understood events involving the NMD pathway, which destabilizes the transcript. In this review, we summarize our current understanding of how the NMD machinery interfaces with the translation termination factors to initiate NMD. We also discuss a variety of cis-acting sequence contexts and transacting factors that can cause readthrough, ribosome reinitiation, or ribosome frameshifting at stop codons predicted to induce NMD. These alternative outcomes can lead to the ribosome translating downstream of such stop codons and hence the transcript escaping NMD. NMD escape via these mechanisms can have wide-ranging implications on human health, from being exploited by viruses to hijack host cell systems to being harnessed as potential therapeutic possibilities to treat genetic diseases.	[Embree, Caleb M.; Abu-Alhasan, Rabab; Singh, Guramrit] Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA; [Embree, Caleb M.; Abu-Alhasan, Rabab; Singh, Guramrit] Ohio State Univ, Ctr RNA Biol, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Singh, G (corresponding author), Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA.; Singh, G (corresponding author), Ohio State Univ, Ctr RNA Biol, Columbus, OH 43210 USA.	singh.734@osu.edu		Embree, Caleb/0000-0002-7437-4510	National Institutes of Health;  [R01- GM120209]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); 	Acknowledgments Funding and additional information - This work was supported by a grant from the National Institutes of Health (grant no.: R01- GM120209) to G. S. C. M. E. was partially supported by a Na- tional Institutes of Health T32 training grant. The content is solely the responsibility of the authors and does not necessarily represent the of fi cial views of the National Institutes of Health.	Burghes AHM, 2022, bioRxiv, DOI 10.1101/2022.01.10.475702; Alcazar-Roman AR, 2010, J BIOL CHEM, V285, P16683, DOI 10.1074/jbc.M109.082370; Alrahbeni T, 2015, MOL BRAIN, V8, DOI 10.1186/s13041-015-0122-1; Amrani N, 2004, NATURE, V432, P112, DOI 10.1038/nature03060; Annibaldis G, 2020, NUCLEIC ACIDS RES, V48, P10259, DOI 10.1093/nar/gkaa758; Arthur LL, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500154; Atkin AL, 1997, J BIOL CHEM, V272, P22163, DOI 10.1074/jbc.272.35.22163; ATKIN AL, 1995, MOL BIOL CELL, V6, P611; Aznarez I, 2018, CELL REP, V23, P2186, DOI 10.1016/j.celrep.2018.04.039; Baker SL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173980; Baradaran-Heravi A., 2021, NUCLEIC ACIDS RES, V49, P3692; Beissel C, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21031085; Beissel C, 2019, NUCLEIC ACIDS RES, V47, P4798, DOI 10.1093/nar/gkz177; Belew AT, 2011, NUCLEIC ACIDS RES, V39, P2799, DOI 10.1093/nar/gkq1220; Belew AT, 2014, NATURE, V512, P265, DOI 10.1038/nature13429; Beznoskova P, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003962; Bicknell AA, 2012, BIOESSAYS, V34, P1025, DOI 10.1002/bies.201200073; Bohlen J, 2020, MOL CELL, V79, P561, DOI 10.1016/j.molcel.2020.06.005; Bordeira-Carrico R, 2012, TRENDS MOL MED, V18, P667, DOI 10.1016/j.molmed.2012.09.004; Brown A, 2015, NATURE, V524, P493, DOI 10.1038/nature14896; BROWN CM, 1990, NUCLEIC ACIDS RES, V18, P6339, DOI 10.1093/nar/18.21.6339; Carnes J, 2003, RNA, V9, P648, DOI 10.1261/rna.5280103; Celik A, 2017, CURR GENET, V63, P1007, DOI 10.1007/s00294-017-0709-4; Celik A, 2017, RNA, V23, P735, DOI 10.1261/rna.060541.116; Celik A, 2015, BIOCHIMIE, V114, P2, DOI 10.1016/j.biochi.2014.10.027; Chan WK, 2009, NAT STRUCT MOL BIOL, V16, P747, DOI 10.1038/nsmb.1612; CHANG JC, 1979, P NATL ACAD SCI USA, V76, P2886, DOI 10.1073/pnas.76.6.2886; Chang KC, 2021, COMPUT STRUCT BIOTEC, V19, P3580, DOI 10.1016/j.csbj.2021.06.015; Chauvin C, 2005, MOL CELL BIOL, V25, P5801, DOI 10.1128/MCB.25.14.5801-5811.2005; Clark MB, 2007, J BIOL CHEM, V282, P37359, DOI 10.1074/jbc.M705676200; Cohen S, 2019, NUCLEIC ACIDS RES, V47, P6330, DOI 10.1093/nar/gkz319; Czaplinski K, 1998, GENE DEV, V12, P1665, DOI 10.1101/gad.12.11.1665; Dabrowski M, 2018, MOL MED, V24, DOI 10.1186/s10020-018-0024-7; Dabrowski M, 2015, RNA BIOL, V12, P950, DOI 10.1080/15476286.2015.1068497; De S, 2022, RNA BIOL, V19, P609, DOI 10.1080/15476286.2022.2065116; des Georges A, 2014, NUCLEIC ACIDS RES, V42, P3409, DOI 10.1093/nar/gkt1279; Dever TE, 2020, ANNU REV GENET, V54, P237, DOI 10.1146/annurev-genet-112618-043822; Dever TE, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a032649; Dinman JD, 2012, WIRES RNA, V3, P661, DOI 10.1002/wrna.1126; Doma MK, 2006, NATURE, V440, P561, DOI 10.1038/nature04530; DOrazio K. N., 2021, BIORXIV, DOI [10.1101/2021.08.03.454884, DOI 10.1101/2021.08.03.454884]; Dostie J, 2002, CURR BIOL, V12, P1060, DOI 10.1016/S0960-9822(02)00902-8; Enomoto S, 2004, MOL CELL BIOL, V24, P837, DOI 10.1128/MCB.24.2.837-845.2004; Fatscher T, 2014, RNA, V20, P1579, DOI 10.1261/rna.044933.114; Firth AE, 2012, J GEN VIROL, V93, P1385, DOI 10.1099/vir.0.042499-0; Fritz SE, 2022, EMBO J, V41, DOI 10.15252/embj.2021108898; Fritz SE, 2020, J BIOL CHEM, V295, P11613, DOI 10.1074/jbc.RA120.013824; Ganesan R, 2019, METHODS, V155, P58, DOI 10.1016/j.ymeth.2018.12.008; Gangras P, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1008830; Garzia A, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms16056; Gehring NH, 2005, MOL CELL, V20, P65, DOI 10.1016/j.molcel.2005.08.012; Gehring NH, 2003, MOL CELL, V11, P939, DOI 10.1016/S1097-2765(03)00142-4; Gehring NH, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000120; Ghosh S, 2010, RNA, V16, P1832, DOI 10.1261/rna.1987710; Giorgi C, 2007, CELL, V130, P179, DOI 10.1016/j.cell.2007.05.028; Gross T, 2007, SCIENCE, V315, P646, DOI 10.1126/science.1134641; Gurvich OL, 2009, HUM MUTAT, V30, P633, DOI 10.1002/humu.20913; Hammell AB, 1999, GENOME RES, V9, P417; Han Px, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107610; Harger JW, 2004, RNA, V10, P1721, DOI 10.1261/rna.7120504; Harries LW, 2005, HUM GENET, V118, P214, DOI 10.1007/s00439-005-0023-y; Hauryliuk V, 2006, BIOCHIMIE, V88, P747, DOI 10.1016/j.biochi.2006.06.001; Hoek TA, 2019, MOL CELL, V75, P324, DOI 10.1016/j.molcel.2019.05.008; Hogg JR, 2016, J VIROL, V90, P7010, DOI 10.1128/JVI.00607-16; Hogg JR, 2010, CELL, V143, P379, DOI 10.1016/j.cell.2010.10.005; Howard MT, 2004, J MED GENET, V41, P951, DOI 10.1136/jmg.2004.020248; Hronova V, 2017, RNA BIOL, V14, P1660, DOI 10.1080/15476286.2017.1353863; Hu WQ, 2010, NAT STRUCT MOL BIOL, V17, P244, DOI 10.1038/nsmb.1734; Huang X, 2012, NEUROBIOL DIS, V48, P115, DOI 10.1016/j.nbd.2012.06.013; Hurt JA, 2013, GENOME RES, V23, P1636, DOI 10.1101/gr.157354.113; Inacio A, 2004, J BIOL CHEM, V279, P32170, DOI 10.1074/jbc.M405024200; Isken O, 2008, CELL, V133, P314, DOI 10.1016/j.cell.2008.02.030; Ivanov A, 2016, NUCLEIC ACIDS RES, V44, P7766, DOI 10.1093/nar/gkw635; Ivanov PV, 2008, EMBO J, V27, P736, DOI 10.1038/emboj.2008.17; Jagannathan S, 2016, GENOME RES, V26, P1639, DOI 10.1101/gr.205070.116; Jakobsen CG, 2001, MOL BIOL+, V35, P575, DOI 10.1023/A:1010527127440; Joazeiro CAP, 2019, NAT REV MOL CELL BIO, V20, P368, DOI 10.1038/s41580-019-0118-2; Johansson MJO, 2010, GENE DEV, V24, P1491, DOI 10.1101/gad.1930710; Joncourt R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104391; Juszkiewicz S, 2020, ELIFE, V9, DOI 10.7554/eLife.60038; Juszkiewicz S, 2018, MOL CELL, V72, P469, DOI 10.1016/j.molcel.2018.08.037; Karousis ED, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17974-z; Kashima I, 2006, GENE DEV, V20, P355, DOI 10.1101/gad.1389006; Keeling KM, 2004, RNA, V10, P691, DOI 10.1261/rna.5147804; Khan YA, 2022, NATURE, V604, pE16, DOI 10.1038/s41586-022-04627-y; Konigs V, 2020, NAT STRUCT MOL BIOL, V27, P260, DOI 10.1038/s41594-020-0385-9; Korniy N, 2019, FEBS LETT, V593, P1468, DOI 10.1002/1873-3468.13478; Koutmou KS, 2015, ELIFE, V4, DOI 10.7554/eLife.05534; Kryuchkova P, 2013, NUCLEIC ACIDS RES, V41, P4573, DOI 10.1093/nar/gkt113; Kunz JB, 2006, RNA, V12, P1015, DOI 10.1261/rna.12506; Lawson MR, 2021, SCIENCE, V373, P876, DOI 10.1126/science.abi7801; Lee JH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61154-4; Lejeune F, 2022, BIOMEDICINES, V10, DOI 10.3390/biomedicines10010141; Letzring DP, 2010, RNA, V16, P2516, DOI 10.1261/rna.2411710; Lindeboom RGH, 2019, NAT GENET, V51, P1645, DOI 10.1038/s41588-019-0517-5; Lindeboom RGH, 2016, NAT GENET, V48, P1112, DOI 10.1038/ng.3664; Litchfield K, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17526-5; Lopez-Perrote A, 2016, NUCLEIC ACIDS RES, V44, P1909, DOI 10.1093/nar/gkv1527; Loughran G, 2014, NUCLEIC ACIDS RES, V42, P8928, DOI 10.1093/nar/gku608; Lykke-Andersen S, 2015, NAT REV MOL CELL BIO, V16, P665, DOI 10.1038/nrm4063; Mabin JW, 2018, CELL REP, V25, P2431, DOI 10.1016/j.celrep.2018.11.046; Maderazo AB, 2003, MOL CELL BIOL, V23, P842, DOI 10.1128/MCB.23.3.842-851.2003; Maderazo AB, 2000, MOL CELL BIOL, V20, P4591, DOI 10.1128/MCB.20.13.4591-4603.2000; Malik V, 2010, ANN NEUROL, V67, P771, DOI 10.1002/ana.22024; Mangkalaphiban K, 2021, PLOS GENET, V17, DOI 10.1371/journal.pgen.1009538; Manktelow E, 2005, NUCLEIC ACIDS RES, V33, P1553, DOI 10.1093/nar/gki299; Matheisl S, 2015, NUCLEIC ACIDS RES, V43, P8615, DOI 10.1093/nar/gkv909; May JP, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007459; MCCAUGHAN KK, 1995, P NATL ACAD SCI USA, V92, P5431, DOI 10.1073/pnas.92.12.5431; Mikhailova T, 2017, NUCLEIC ACIDS RES, V45, P1307, DOI 10.1093/nar/gkw1239; Min EE, 2013, RNA, V19, P1105, DOI 10.1261/rna.039396.113; Mitkevich VA, 2006, NUCLEIC ACIDS RES, V34, P3947, DOI 10.1093/nar/gkl549; Mohammad MP, 2017, NUCLEIC ACIDS RES, V45, P2658, DOI 10.1093/nar/gkx049; Moriarty PM, 1998, MOL CELL BIOL, V18, P2932, DOI 10.1128/MCB.18.5.2932; Mottagui-Tabar S, 1998, EUR J BIOCHEM, V257, P249, DOI 10.1046/j.1432-1327.1998.2570249.x; Nakano K, 2013, MICROBES INFECT, V15, P491, DOI 10.1016/j.micinf.2013.03.006; Namy O, 2001, EMBO REP, V2, P787, DOI 10.1093/embo-reports/kve176; Neu-Yilik G, 2017, EMBO J, V36, P2968, DOI 10.15252/embj.201797079; Neu-Yilik G, 2011, RNA, V17, P843, DOI 10.1261/rna.2401811; Pacho F, 2011, J MED GENET, V48, P640, DOI 10.1136/jmg.2011.089615; Peixeiro I, 2012, NUCLEIC ACIDS RES, V40, P1160, DOI 10.1093/nar/gkr820; Pelechano V, 2017, NUCLEIC ACIDS RES, V45, P7326, DOI 10.1093/nar/gkx479; Pereira FJC, 2015, NUCLEIC ACIDS RES, V43, P6528, DOI 10.1093/nar/gkv588; Pinotti M, 2012, HUM MUTAT, V33, P1373, DOI 10.1002/humu.22120; Pisarev AV, 2010, MOL CELL, V37, P196, DOI 10.1016/j.molcel.2009.12.034; Plant EP, 2004, NUCLEIC ACIDS RES, V32, P784, DOI 10.1093/nar/gkh256; Preis A, 2014, CELL REP, V8, P59, DOI 10.1016/j.celrep.2014.04.058; Ganesan R, 2021, bioRxiv, DOI 10.1101/2021.12.03.471156; Rahman MA, 2020, GENE DEV, V34, P413, DOI 10.1101/gad.332270.119; Raimondeau E, 2018, BIOCHEM SOC T, V46, P503, DOI 10.1042/BST20170427; Rajkowitsch L, 2004, J MOL BIOL, V335, P71, DOI 10.1016/j.jmb.2003.10.049; Reichert VL, 2002, GENE DEV, V16, P2778, DOI 10.1101/gad.1030602; Romao L, 2000, BLOOD, V96, P2895; Sato H, 2008, MOL CELL, V29, P255, DOI 10.1016/j.molcel.2007.12.009; Sauliere J, 2012, NAT STRUCT MOL BIOL, V19, P1124, DOI 10.1038/nsmb.2420; Schuller AP, 2018, NUCLEIC ACIDS RES, V46, P2060, DOI 10.1093/nar/gkx1263; Schuller AP, 2017, MOL CELL, V66, P194, DOI 10.1016/j.molcel.2017.03.003; Serdar LD, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms14021; Serin G, 2001, MOL CELL BIOL, V21, P209, DOI 10.1128/MCB.21.1.209-223.2001; Shao SC, 2016, CELL, V167, P1229, DOI 10.1016/j.cell.2016.10.046; Shum EY, 2016, CELL, V165, P382, DOI 10.1016/j.cell.2016.02.046; Silva AL, 2008, RNA, V14, P563, DOI 10.1261/rna.815108; Singh G, 2008, PLOS BIOL, V6, P860, DOI 10.1371/journal.pbio.0060111; Singh G, 2012, CELL, V151, P750, DOI 10.1016/j.cell.2012.10.007; Sinha NK, 2020, ELIFE, V9, DOI 10.7554/eLife.58828; Skabkin MA, 2010, GENE DEV, V24, P1787, DOI 10.1101/gad.1957510; Sliskovic I, 2022, BIOCHEM SOC T, V50, P187, DOI 10.1042/BST20210325; Smits AH, 2019, NAT METHODS, V16, P1087, DOI 10.1038/s41592-019-0614-5; STANSFIELD I, 1995, EMBO J, V14, P4365, DOI 10.1002/j.1460-2075.1995.tb00111.x; Stansfield I, 1996, MOL MICROBIOL, V20, P1135, DOI 10.1111/j.1365-2958.1996.tb02634.x; Stump MR, 2013, AM J PHYSIOL-HEART C, V305, pH1397, DOI 10.1152/ajpheart.00304.2013; Supek F, 2021, TRENDS GENET, V37, P657, DOI 10.1016/j.tig.2020.11.002; Tate WP, 1996, BIOCHIMIE, V78, P945, DOI 10.1016/S0300-9084(97)86716-8; Taylor D, 2012, P NATL ACAD SCI USA, V109, P18413, DOI 10.1073/pnas.1216730109; Wallmeroth D, 2022, EMBO J, V41, DOI 10.15252/embj.2021109191; Wang WR, 2001, EMBO J, V20, P880, DOI 10.1093/emboj/20.4.880; Wang XQ, 2004, NUCLEIC ACIDS RES, V32, P1382, DOI 10.1093/nar/gkh305; Wangen JR, 2020, ELIFE, V9, DOI 10.7554/eLife.52611; Welch EM, 2007, NATURE, V447, P87, DOI 10.1038/nature05756; Weng YM, 1996, MOL CELL BIOL, V16, P5491, DOI 10.1128/mcb.16.10.5491; Weng YM, 1996, MOL CELL BIOL, V16, P5477; Wills NM, 2006, J BIOL CHEM, V281, P7082, DOI 10.1074/jbc.M511629200; Woodward LA, 2017, WIRES RNA, V8, DOI 10.1002/wrna.1411; Wu C, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108399; Yamashita A, 2009, GENE DEV, V23, P1091, DOI 10.1101/gad.1767209; Yi ZX, 2022, EMBO J, V41, DOI 10.15252/embj.2021109202; Yi ZX, 2021, TRENDS GENET, V37, P143, DOI 10.1016/j.tig.2020.08.010; Young DJ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23223-8; Young DJ, 2019, CELL REP, V28, P39, DOI 10.1016/j.celrep.2019.05.111; Young DJ, 2018, MOL CELL, V71, P761, DOI 10.1016/j.molcel.2018.07.028; Young DJ, 2015, CELL, V162, P872, DOI 10.1016/j.cell.2015.07.041; Zhang J, 1997, EMBO J, V16, P826, DOI 10.1093/emboj/16.4.826; Zhang Z, 2004, MOL CELL, V16, P597, DOI 10.1016/j.molcel.2004.10.031; Zhao T, 2021, GENOME BIOL, V22, DOI 10.1186/s13059-020-02256-0; ZHOURAVLEVA G, 1995, EMBO J, V14, P4065, DOI 10.1002/j.1460-2075.1995.tb00078.x; Zhu XQ, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107895; Zinshteyn B, 2021, PLOS GENET, V17, DOI 10.1371/journal.pgen.1009813; Zund D, 2013, NAT STRUCT MOL BIOL, V20, P936, DOI 10.1038/nsmb.2635	178	0	0	2	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV	2022	298	11							102592	10.1016/j.jbc.2022.102592	http://dx.doi.org/10.1016/j.jbc.2022.102592			18	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	6W5WW	36244451	Green Published, gold			2022-12-28	WOS:000895801300010
J	Guo, Q; Qiu, YQ; Liu, YW; He, YQ; Zhang, GL; Du, Y; Yang, CX; Gao, F				Guo, Qian; Qiu, Yaqi; Liu, Yiwen; He, Yiqing; Zhang, Guoliang; Du, Yan; Yang, Cuixia; Gao, Feng			Cell adhesion molecule CD44v10 promotes stem-like properties in triple-negative breast cancer cells via glucose transporter GLUT1-mediated glycolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; MARKER; METABOLISM; RESISTANCE; HALLMARKS; ISOFORMS; HEAD; V10	Cell adhesion molecule CD44v8-10 is associated with tumor ste0mness and malignancy; however, whether CD44v10 alone confers these properties is unknown. Here, we demonstrated that CD44v10 promotes stemness and chemoresistance of triple-negative breast cancers (TNBCs) individually. Next, we identified that genes differentially expressed in response to ectopic expression of CD44v10 are mostly related to glycol-ysis. Further, we showed that CD44v10 upregulates glucose transporter 1 to facilitate glycolysis by activating the MAPK/ ERK and PI3K/AKT signaling pathways. This glycolytic reprogramming induced by CD44v10 contributes to the stem -like properties of TNBC cells and confers resistance to paclitaxel treatment. Notably, we determined that the knockdown of glucose transporter 1 could attenuate the enhanced effects of CD44v10 on glycolysis, stemness, and paclitaxel resistance. Collectively, our findings provide novel insights into the function of CD44v10 in TNBCs and suggest that targeting CD44v10 may contribute to future clinical therapy.	[Guo, Qian; Qiu, Yaqi; Liu, Yiwen; He, Yiqing; Zhang, Guoliang; Du, Yan; Yang, Cuixia; Gao, Feng] Shanghai Jiao Tong Univ Affiliated Peoples Hosp 6, Dept Mol Biol, Shanghai, Peoples R China; [Guo, Qian; Qiu, Yaqi; Yang, Cuixia; Gao, Feng] Shanghai Jiao Tong Univ Affiliated Peoples Hosp 6, Dept Clin Lab, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University	Gao, F (corresponding author), Shanghai Jiao Tong Univ Affiliated Peoples Hosp 6, Dept Mol Biol, Shanghai, Peoples R China.; Gao, F (corresponding author), Shanghai Jiao Tong Univ Affiliated Peoples Hosp 6, Dept Clin Lab, Shanghai, Peoples R China.	gaofengly@sjtu.edu.cn			National Natural Science Foundation of China, China [82073199, 81974445, 81974446, 81872357, 81702852]; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support, China [20171924]; Shanghai Pujiang Program [2019PJD037]; China and Shanghai "Rising Stars of Medical Talent" Youth Development Program Clinical Laboratory Practitioners Program, China [2020_087, 2021_099]	National Natural Science Foundation of China, China(National Natural Science Foundation of China (NSFC)); Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support, China; Shanghai Pujiang Program(Shanghai Pujiang Program); China and Shanghai "Rising Stars of Medical Talent" Youth Development Program Clinical Laboratory Practitioners Program, China	This work was supported by the National Natural Science Foundation of China, China (82073199, 81974445, 81974446, 81872357 and 81702852) , Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support, China (20171924) , Shanghai Pujiang Program (2019PJD037) , China and Shanghai "Rising Stars of Medical Talent" Youth Development Program Clinical Laboratory Practitioners Program, China (2020_087, 2021_099) .	Beham-Schmid C, 1998, J PATHOL, V186, P383; Bourguignon LYW, 2012, J BIOL CHEM, V287, P32800, DOI 10.1074/jbc.M111.308528; Bourguignon LYW, 1998, J CELL PHYSIOL, V176, P206, DOI 10.1002/(SICI)1097-4652(199807)176:1<206::AID-JCP22>3.0.CO;2-3; Dong CF, 2013, CANCER CELL, V23, P316, DOI 10.1016/j.ccr.2013.01.022; Feng WG, 2014, STEM CELLS, V32, P1734, DOI 10.1002/stem.1662; Gao RF, 2018, THERANOSTICS, V8, P6248, DOI 10.7150/thno.28721; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Guo Q, 2021, ONCOL REP, V45, DOI 10.3892/or.2021.7958; Hagiwara M, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-3988-3; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hussein YR, 2011, TRANSL ONCOL, V4, P321, DOI 10.1593/tlo.11256; Iida J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088712; Ishimoto T, 2011, CANCER CELL, V19, P387, DOI 10.1016/j.ccr.2011.01.038; Jogo T, 2021, GASTRIC CANCER, V24, P1089, DOI 10.1007/s10120-021-01194-5; Lau WM, 2014, CANCER RES, V74, P2630, DOI 10.1158/0008-5472.CAN-13-2309; Li C, 2020, FASEB J, V34, P13333, DOI 10.1096/fj.202000555R; Li N, 2000, BJU INT, V85, P514, DOI 10.1046/j.1464-410x.2000.00483.x; Li W, 2016, MOL CANCER RES, V14, P344, DOI 10.1158/1541-7786.MCR-15-0466; Liu PP, 2014, CELL DEATH DIFFER, V21, P124, DOI 10.1038/cdd.2013.131; Lobo S, 2020, CANCERS, V12, DOI 10.3390/cancers12092378; Megaptche AP, 2014, IMMUNOL CELL BIOL, V92, P709, DOI 10.1038/icb.2014.47; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Sancho P, 2016, BRIT J CANCER, V114, P1305, DOI 10.1038/bjc.2016.152; Tamada M, 2012, CANCER RES, V72, P1438, DOI 10.1158/0008-5472.CAN-11-3024; Todaro M, 2014, CELL STEM CELL, V14, P342, DOI 10.1016/j.stem.2014.01.009; Toden S, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.125294; Wang SJ, 2009, LARYNGOSCOPE, V119, P1518, DOI 10.1002/lary.20506; Wu HB, 2017, FASEB J, V31, P1731, DOI [10.1096/fj.201601085R, 10.1096/fj.201601085r]; Yae T, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1892; Yang CX, 2019, ONCOGENE, V38, P7113, DOI 10.1038/s41388-019-0899-y; Yang LQ, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0110-5; Zeilstra J, 2014, ONCOGENE, V33, P665, DOI 10.1038/onc.2012.611; Zhang HH, 2019, GENE DEV, V33, P166, DOI 10.1101/gad.319889.118; Zhou MY, 2021, WORLD J GASTROENTERO, V27, P6908, DOI 10.3748/wjg.v27.i40.6908; Zoller M, 2011, NAT REV CANCER, V11, P254, DOI 10.1038/nrc3023	35	0	0	1	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV	2022	298	11							102588	10.1016/j.jbc.2022.102588	http://dx.doi.org/10.1016/j.jbc.2022.102588			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	6W5WW	36243113	Green Published, gold			2022-12-28	WOS:000895801300009
J	Irwin, S; Karr, C; Furman, C; Tsai, JNF; Gee, P; Banka, D; Wibowo, AS; Dementiev, AA; O'Shea, M; Yang, JY; Lowe, J; Mitchell, L; Ruppel, S; Fekkes, P; Zhu, P; Korpal, M; Larsen, NA				Irwin, Sean; Karr, Craig; Furman, Craig; Tsai, Jennifer; Gee, Patricia; Banka, Deepti; Wibowo, Ardian S.; Dementiev, Alexey A.; O'Shea, Morgan; Yang, Joyce; Lowe, Jason; Mitchell, Lorna; Ruppel, Sabine; Fekkes, Peter; Zhu, Ping; Korpal, Manav; Larsen, Nicholas A.			Biochemical and structural basis for the pharmacological inhibition of nuclear hormone receptor PPAR? by inverse agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA; CANCER; ANTAGONIST; LIGAND; RECRUITMENT; ACTIVATION; REVEALS; POTENT	Recent studies have reported that the peroxisome proliferator- activated receptor gamma (PPAR gamma) pathway is activated in approximately 40% of patients with muscle-invasive bladder can-cer. This led us to investigate pharmacological repression of PPAR gamma as a possible intervention strategy. Here, we characterize PPAR gamma antagonists and inverse agonists and find that the former behave as silent ligands, whereas inverse agonists (T0070907 and SR10221) repress downstream PPAR gamma target genes leading to growth inhibition in bladder cancer cell lines. To understand the mechanism, we determined the ternary crystal structure of PPAR gamma bound to T0070907 and the corepressor (co-R) peptide NCOR1. The structure shows that the AF-2 helix 12 (H12) rearranges to bind inside the ligand-binding domain, where it forms stabilizing interactions with the compound. This dramatic movement in H12 unveils a large interface for co-R binding. In contrast, the crystal structure of PPAR gamma bound to a SR10221 analog shows more subtle structural differences, where the compound binds and pushes H12 away from the ligand-binding domain to allow co-R binding. Interestingly, we found that both classes of compound promote recruitment of co-R proteins in biochemical assays but with distinct conformational changes in H12. We validate our structural models using both site-directed mutagenesis and chemical probes. Our findings offer new mechanistic insights into pharmacological modulation of PPAR gamma signaling.	[Irwin, Sean; Karr, Craig; Furman, Craig; Tsai, Jennifer; Gee, Patricia; Banka, Deepti; O'Shea, Morgan; Yang, Joyce; Lowe, Jason; Mitchell, Lorna; Ruppel, Sabine; Fekkes, Peter; Zhu, Ping; Korpal, Manav; Larsen, Nicholas A.] H3 Biomed, Dept Drug Discovery, Cambridge, MA 02139 USA; [Wibowo, Ardian S.; Dementiev, Alexey A.] Shamrock Struct LLC, Chicago, IL USA; [Tsai, Jennifer] Monta Rosa Therapeut, Boston, MA USA; [Wibowo, Ardian S.] Helix Biostruct, Indianapolis, IN USA; [Dementiev, Alexey A.] Schrodinger Inc, Natick, MA USA; [O'Shea, Morgan] C4 Therapeut, Watertown, MA USA; [Yang, Joyce] Blueprint Med, Cambridge, MA USA; [Lowe, Jason] Foghorn Therapeut, Cambridge, MA USA; [Mitchell, Lorna] Certa Therapeut, Melbourne, Vic, Australia; [Ruppel, Sabine] Ikena Oncol, Boston, MA USA; [Fekkes, Peter] 54 Gene, Washington, DC USA		Larsen, NA (corresponding author), H3 Biomed, Dept Drug Discovery, Cambridge, MA 02139 USA.	nick.a.larsen@gmail.com						Audenet F, 2018, UROL ONCOL-SEMIN ORI, V36, P313, DOI 10.1016/j.urolonc.2018.02.017; Brust R, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07133-w; Choi JH, 2011, NATURE, V477, P477, DOI 10.1038/nature10383; Davidson MA, 2018, CRIT REV TOXICOL, V48, P52, DOI 10.1080/10408444.2017.1351420; Felsenstein KM, 2018, NAT REV UROL, V15, P92, DOI 10.1038/nrurol.2017.179; Gampe RT, 2000, MOL CELL, V5, P545, DOI 10.1016/S1097-2765(00)80448-7; Goldstein JT, 2017, CANCER RES, V77, P6987, DOI 10.1158/0008-5472.CAN-17-1701; Halstead AM, 2017, ELIFE, V6, DOI 10.7554/eLife.30862; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Itoh T, 2008, NAT STRUCT MOL BIOL, V15, P924, DOI 10.1038/nsmb.1474; Korpal M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00147-w; Lamotte Y, 2010, BIOORG MED CHEM LETT, V20, P1399, DOI 10.1016/j.bmcl.2009.12.107; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Lee G, 2002, J BIOL CHEM, V277, P19649, DOI 10.1074/jbc.M200743200; Marciano DP, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8443; Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349; Mohanty P, 2004, J CLIN ENDOCR METAB, V89, P2728, DOI 10.1210/jc.2003-032103; Nishiu J, 2006, DIABETES OBES METAB, V8, P508, DOI 10.1111/j.1463-1326.2005.00536.x; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Robertson AG, 2017, CELL, V171, P540, DOI 10.1016/j.cell.2017.09.007; Rochel N, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08157-y; Rodriguez-Vida Alejo, 2018, Cancer Treat Res, V175, P259, DOI 10.1007/978-3-319-93339-9_12; Rosenberg JE, 2016, LANCET, V387, P1909, DOI 10.1016/S0140-6736(16)00561-4; Shang JS, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14750-x; Sweis RF, 2016, CANCER IMMUNOL RES, V4, P563, DOI 10.1158/2326-6066.CIR-15-0274; von der Maase H, 2005, J CLIN ONCOL, V23, P4602, DOI 10.1200/JCO.2005.07.757; Warrick JI, 2016, SCI REP-UK, V6, DOI 10.1038/srep38531; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Witjes JA, 2014, EUR UROL, V65, P778, DOI 10.1016/j.eururo.2013.11.046; Xu HE, 2002, NATURE, V415, P813, DOI 10.1038/415813a	30	0	0	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV	2022	28	11							102539	10.1016/j.jbc.2022.102539	http://dx.doi.org/10.1016/j.jbc.2022.102539			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	6I4GS	36179791	gold, Green Published			2022-12-28	WOS:000886086000005
J	Marques, C; Pocas, J; Gomes, C; Faria-Ramos, I; Reis, CA; Vives, RR; Magalhaes, A				Marques, Catarina; Pocas, Juliana; Gomes, Catarina; Faria-Ramos, Isabel; Reis, Celso A.; Vives, Romain R.; Magalhaes, Ana			Glycosyltransferases EXTL2 and EXTL3 cellular balance dictates heparan sulfate biosynthesis and shapes gastric cancer cell motility and invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN LINKAGE REGION; SYNDECAN-1 EXPRESSION; CHONDROITIN SULFATE; N-ACETYLGLUCOSAMINE; REDUCED EXPRESSION; TUMOR SUPPRESSORS; BREAST-CARCINOMA; FAMILY; XYLOSE; ROLES	Heparan sulfate (HS) proteoglycans (HSPGs) are abundant glycoconjugates in cells' glycocalyx and extracellular matrix. By acting as scaffolds for protein-protein interactions, HSPGs modulate extracellular ligand gradients, cell signaling networks, and cell-extracellular matrix crosstalk. Aberrant expression of HSPGs and enzymes involved in HSPG biosynthesis and processing has been reported in tumors, with impact in cancer cell behavior and tumor microenvironment properties. However, the roles of specific glycosyltransferases in the deregulated biosynthesis of HSPGs are not fully understood. In this study, we established glycoengineered gastric cancer cell models lacking either exostosin-like glycosyltransferase 2 (EXTL2) or EXTL3 and revealed their regulatory roles in both HS and chondroitin sulfate (CS) biosynthesis and structural features. We showed that EXTL3 is key for initiating the synthesis of HS chains in detriment of CS biosynthesis, intervening in the fine-tuned balance of the HS/CS ratio in cells, while EXTL2 functions as a negative regulator of HS biosynthesis, with impact over the glycoproteome of gastric cancer cells. We demonstrated that KO of EXTL2 enhanced HS levels along with concomitant upregulation of Syndecan-4, which is a major cell surface carrier of HS. This aberrant HS expression profile promoted a more aggressive phenotype, characterized by higher cellular motility and invasion, and impaired activation of Ephrin type-A 4 cell surface receptor tyrosine kinase. Our findings uncover the biosynthetic roles of EXTL2 and EXTL3 in rant HS/CS balance in cellular malignant features.	[Marques, Catarina; Pocas, Juliana; Gomes, Catarina; Faria-Ramos, Isabel; Reis, Celso A.; Magalhaes, Ana] Univ Porto, i3S Inst Invest & Inovacao Saude, Porto, Portugal; [Marques, Catarina; Pocas, Juliana; Gomes, Catarina; Faria-Ramos, Isabel; Reis, Celso A.; Magalhaes, Ana] Univ Porto, IPATIMUP Inst Patol & Imunol Mol, Porto, Portugal; [Pocas, Juliana] Inst Ciencias Biomed Abel Salazar ICBAS, Programa Doutoral Biol Mol & Celular MCbiol, Porto, Portugal; [Pocas, Juliana; Reis, Celso A.; Magalhaes, Ana] Univ Porto, ICBAS Inst Ciencias Biomed Abel Salazar, Porto, Portugal; [Reis, Celso A.] FMUP Fac Med Univ Porto, Porto, Portugal; [Vives, Romain R.] Univ Grenoble Alpes, CNRS, CEA, IBS, Grenoble, France	Universidade do Porto; i3S - Instituto de Investigacao e Inovacao em Saude, Universidade do Porto; Universidade do Porto; Universidade do Porto; Universidade do Porto; Universidade do Porto; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Magalhaes, A (corresponding author), Univ Porto, i3S Inst Invest & Inovacao Saude, Porto, Portugal.; Magalhaes, A (corresponding author), Univ Porto, IPATIMUP Inst Patol & Imunol Mol, Porto, Portugal.; Magalhaes, A (corresponding author), Univ Porto, ICBAS Inst Ciencias Biomed Abel Salazar, Porto, Portugal.	amagalhaes@ipatimup.pt	; Reis, Celso/B-9969-2008	Gomes, Catarina/0000-0002-0352-6783; Pocas Almeida, Juliana/0000-0003-2877-473X; Reis, Celso/0000-0002-0286-6639; Magalhaes, Ana/0000-0003-4863-6668	FEDER funds through the Operational Programme for Competitiveness Factors-COMPETE [POCI-01-0145-FEDER-007274, POCI-01-0145-FEDER-028489, POCI-01-0145-FEDER-029780]; Foundation for Science and Technology (FCT) [PTDC/MED-ONC/28489/2017, PTDC/MED-QUI/29780/2017, UID/BIM/4293, 2020.06412.BD, SFRH/BD/137319/2018]; Norte Portugal Operational Regional Programme (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF) [NORTE-01-0145-FEDER-000051]; COST Action [CA18103, CA18103-45514]; CNRS; GDR GAG [GDR 3739]; "Investissements d'avenir" program Glyco@Alps [ANR-15-IDEX-02]; Agence Nationale de la Recherche [ANR-17-CE11-0040]	FEDER funds through the Operational Programme for Competitiveness Factors-COMPETE; Foundation for Science and Technology (FCT)(Portuguese Foundation for Science and TechnologyEuropean Commission); Norte Portugal Operational Regional Programme (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF); COST Action(European Cooperation in Science and Technology (COST)); CNRS(Centre National de la Recherche Scientifique (CNRS)); GDR GAG; "Investissements d'avenir" program Glyco@Alps(French National Research Agency (ANR)); Agence Nationale de la Recherche(French National Research Agency (ANR))	This work was funded by FEDER funds through the Operational Programme for Competitiveness Factors-COMPETE (POCI-01-0145-FEDER-007274, POCI-01-0145-FEDER-028489 and POCI-01-0145-FEDER-029780) and National Funds through the Foundation for Science and Technology (FCT), under the projects: PTDC/MED-ONC/28489/2017 (to A. M.), PTDC/MED-QUI/29780/2017 (to C. G.), UID/BIM/4293 and the project NORTE-01-0145-FEDER-000051, supported by Norte Portugal Operational Regional Programme (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF). COST Action CA18103 INNOGLY: INNOvation with Glycans new frontiers from synthesis to new biological targets (ECOST-STSM-Request-CA18103-45514). C. M. and J. P. acknowledge FCT PhD scholarships 2020.06412.BD and SFRH/BD/137319/2018, respectively. This work was also supported by the CNRS and the GDR GAG (GDR 3739), the "Investissements d'avenir" program Glyco@Alps (ANR-15-IDEX-02), by a grant from the Agence Nationale de la Recherche (ANR-17-CE11-0040). IBS acknowledges integration into the Interdisciplinary Research Institute of Grenoble (IRIG, CEA).	Afratis N, 2012, FEBS J, V279, P1177, DOI 10.1111/j.1742-4658.2012.08529.x; Annaval T, 2020, MOLECULES, V25, DOI 10.3390/molecules25184215; Arai T, 1999, INT J ONCOL, V15, P915; Barbareschi M, 2003, CANCER-AM CANCER SOC, V98, P474, DOI 10.1002/cncr.11515; Bernal C, 2008, CLIN CANCER RES, V14, P6264, DOI 10.1158/1078-0432.CCR-07-4522; Brinkman EK, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku936; Busse M, 2007, J BIOL CHEM, V282, P32802, DOI 10.1074/jbc.M703560200; Busse-Wicher M, 2014, MATRIX BIOL, V35, P25, DOI 10.1016/j.matbio.2013.10.001; Chen YH, 2018, NAT METHODS, V15, P881, DOI 10.1038/s41592-018-0086-z; Corti F, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09605-z; Crespo A, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4597-x; DAVID G, 1992, J CELL BIOL, V118, P961, DOI 10.1083/jcb.118.4.961; Depau L, 2020, J MED CHEM, V63, P15997, DOI 10.1021/acs.jmedchem.0c01848; El Masri R, 2017, GLYCOCONJUGATE J, V34, P285, DOI 10.1007/s10719-016-9736-5; Faria-Ramos I, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11020136; Fernandez-Vega I, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1724-9; Fukai J, 2008, MOL CANCER THER, V7, P2768, DOI 10.1158/1535-7163.MCT-07-2263; Furuhashi S, 2021, ANTICANCER RES, V41, P1733, DOI 10.21873/anticanres.14938; Gao W, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137664; Gingis-Velitski S, 2004, J BIOL CHEM, V279, P44084, DOI 10.1074/jbc.M402131200; Gopal S, 2010, J BIOL CHEM, V285, P14247, DOI 10.1074/jbc.M109.056945; Grobe K, 2002, BBA-GEN SUBJECTS, V1573, P209, DOI 10.1016/S0304-4165(02)00386-0; Hagner-McWhirter A, 2000, BIOCHEM J, V347, P69, DOI 10.1042/0264-6021:3470069; Hassan N, 2021, CELL SIGNAL, V77, DOI 10.1016/j.cellsig.2020.109822; Henriet E, 2017, BBA-GEN SUBJECTS, V1861, P2250, DOI 10.1016/j.bbagen.2017.06.006; Holmborn K, 2012, J BIOL CHEM, V287, P33905, DOI 10.1074/jbc.M112.401646; Hwang JA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079634; Inokuchi M, 2018, ANTICANCER RES, V38, P1685, DOI 10.21873/anticanres.12402; Irie F, 2008, P NATL ACAD SCI USA, V105, P12307, DOI 10.1073/pnas.0801302105; Izumikawa T, 2015, J BIOL CHEM, V290, P5438, DOI 10.1074/jbc.M114.603266; Jin Y, 2017, ONCOL LETT, V14, P6191, DOI 10.3892/ol.2017.6944; Kania A, 2016, NAT REV MOL CELL BIO, V17, P240, DOI 10.1038/nrm.2015.16; Karibe T, 2008, J PATHOL, V216, P32, DOI 10.1002/path.2377; Katta K, 2015, J BIOL CHEM, V290, P13168, DOI 10.1074/jbc.M114.631754; Kim BT, 2003, J BIOL CHEM, V278, P41618, DOI 10.1074/jbc.M304831200; Kim BT, 2001, P NATL ACAD SCI USA, V98, P7176, DOI 10.1073/pnas.131188498; Kim SY, 2015, INT J MED SCI, V12, P92, DOI 10.7150/ijms.10497; Kitagawa H, 1999, J BIOL CHEM, V274, P13933, DOI 10.1074/jbc.274.20.13933; Koike T, 2014, J BIOL CHEM, V289, P6695, DOI 10.1074/jbc.M113.520536; Koike T, 2009, BIOCHEM J, V421, P157, DOI 10.1042/BJ20090474; Lanzi C, 2020, BIOCHEM PHARMACOL, V178, DOI 10.1016/j.bcp.2020.114084; Le Jan S, 2012, ARTERIOSCL THROM VAS, V32, P1255, DOI 10.1161/ATVBAHA.111.240622; Lee JS, 2004, NEURON, V44, P947, DOI 10.1016/j.neuron.2004.11.029; Li JP, 2016, INT REV CEL MOL BIO, V325, P215, DOI 10.1016/bs.ircmb.2016.02.009; Li N, 2020, J HISTOCHEM CYTOCHEM, V68, P841, DOI 10.1369/0022155420933709; Li N, 2018, TRENDS CANCER, V4, P741, DOI 10.1016/j.trecan.2018.09.004; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; Lim HC, 2014, BBA-GEN SUBJECTS, V1840, P2482, DOI 10.1016/j.bbagen.2014.01.018; Lonowski LA, 2017, NAT PROTOC, V12, P581, DOI 10.1038/nprot.2016.165; Magalhaes A, 2009, FEMS IMMUNOL MED MIC, V56, P223, DOI 10.1111/j.1574-695X.2009.00569.x; Marques C, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.778752; Matsumoto A, 1997, INT J CANCER, V74, P482, DOI 10.1002/(SICI)1097-0215(19971021)74:5<482::AID-IJC2>3.0.CO;2-#; McCormick C, 2000, P NATL ACAD SCI USA, V97, P668, DOI 10.1073/pnas.97.2.668; Mereiter S, 2019, CANCER CELL, V36, P6, DOI 10.1016/j.ccell.2019.06.006; Merry C. L. R., 2022, PROTEOGLYCANS SULFAT; Miyazaki K, 2013, BMC CLIN PATHOL, V13, DOI 10.1186/1472-6890-13-19; Nadanaka S, 2020, FASEB J, V34, P8385, DOI 10.1096/fj.201902076R; Nadanaka S, 2013, J BIOL CHEM, V288, P9321, DOI 10.1074/jbc.M112.416909; Narimatsu Y, 2018, GLYCOBIOLOGY, V28, P295, DOI 10.1093/glycob/cwx101; Neelamegham S, 2019, GLYCOBIOLOGY, V29, P620, DOI 10.1093/glycob/cwz045; Nikitovic D, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00069; Ohkawa Y, 2021, MOL CANCER RES, V19, P150, DOI 10.1158/1541-7786.MCR-20-0420; Okada M, 2010, BIOCHEM J, V428, P463, DOI 10.1042/BJ20100101; Oki M, 2008, WORLD J GASTROENTERO, V14, P5650, DOI 10.3748/wjg.14.5650; Ponighaus C, 2007, J BIOL CHEM, V282, P5201, DOI 10.1074/jbc.M611665200; Purnomo E, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000405; Sarrazin S, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004952; Sembajwe LF, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20180770; Shi XJ, 2011, ACTA BIOCH BIOPH SIN, V43, P849, DOI 10.1093/abbs/gmr084; Shintani Y, 2006, EMBO J, V25, P3045, DOI 10.1038/sj.emboj.7601188; Takahashi I, 2009, BIOCHEM BIOPH RES CO, V383, P113, DOI 10.1016/j.bbrc.2009.03.140; Thacker BE, 2014, MATRIX BIOL, V35, P60, DOI 10.1016/j.matbio.2013.12.001; Theocharis AD, 2003, INT J BIOCHEM CELL B, V35, P376, DOI 10.1016/S1357-2725(02)00264-9; Wen JZ, 2014, P NATL ACAD SCI USA, V111, P15723, DOI 10.1073/pnas.1417993111; Weyers A, 2013, GLYCOCONJUGATE J, V30, P701, DOI 10.1007/s10719-013-9476-8; Wilson LFL, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-31048-2; Xu D, 2014, ANNU REV BIOCHEM, V83, P129, DOI 10.1146/annurev-biochem-060713-035314	77	0	0	2	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV	2022	298	11							102546	10.1016/j.jbc.2022.102546	http://dx.doi.org/10.1016/j.jbc.2022.102546			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	6D3XI	36181793	Green Published, gold			2022-12-28	WOS:000882627400004
J	Miyata, Y; Yamada, K; Nagata, S; Segawa, K				Miyata, Yugo; Yamada, Kyoko; Nagata, Shigekazu; Segawa, Katsumori			Two types of type IV P-type ATPases independently re-establish the asymmetrical distribution of phosphatidylserine in plasma membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID FLIPPASES; AMINOPHOSPHOLIPID TRANSLOCASE; TRANSPORT; EXPRESSION; EXPOSURE; SCRAMBLASE; P4-ATPASE; CASPASE; COMPLEX; LIPIDS	Phospholipids are asymmetrically distributed between the lipid bilayer of plasma membranes in which phosphatidylserine (PtdSer) is confined to the inner leaflet. ATP11A and ATP11C, type IV P-Type ATPases in plasma membranes, flip PtdSer from the outer to the inner leaflet, but involvement of other P4-ATPases is unclear. We herein demonstrated that once PtdSer was exposed on the cell surface of ATP11A(-/-)ATP11C(-/-) mouse T cell line (W3), its internalization to the inner leaflet of plasma membranes was negligible at 15 degrees C. However, ATP11A(-/-)ATP11C(-/-) cells internalized the exposed PtdSer at 37 degrees C, a temperature at which trafficking of intracellular membranes was active. In addition to ATP11A and 11C, W3 cells expressed ATP8A1, 8B2, 8B4, 9A, 9B, and 11B, with ATP8A1 and ATP11B being present at recycling endosomes. Cells deficient in four P4-ATPases (ATP8A1, 11A, 11B, and 11C) (QKO) did not constitutively expose PtdSer on the cell surface but lost the ability to re-establish PtdSer asymmetry within 1 hour, even at 37 degrees C. The expression of ATP11A or ATP11C conferred QKO cells with the ability to rapidly re-establish PtdSer asymmetry at 15 degrees C and 37 degrees C, while cells expressing ATP8A1 or ATP11B required a temperature of 37 degrees C to achieve this function, and a dynamin inhibitor blocked this process. These results revealed that mammalian cells are equipped with two independent mechanisms to re-establish its asymmetry: the first is a rapid process involving plasma membrane flippases, ATP11A and ATP11C, while the other is mediated by ATP8A1 and ATP11B, which require an endocytosis process.	[Miyata, Yugo; Segawa, Katsumori] Tokyo Med & Dent Univ, Med Res Inst, Dept Med Chem, Bunkyo Ku, Tokyo, Japan; [Yamada, Kyoko; Nagata, Shigekazu; Segawa, Katsumori] Osaka Univ, World Premier Int Res Ctr, Immunol Frontier Res Ctr, Lab Biochem & Immunol, Suita, Osaka, Japan	Tokyo Medical & Dental University (TMDU); Osaka University	Segawa, K (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Med Chem, Bunkyo Ku, Tokyo, Japan.; Nagata, S; Segawa, K (corresponding author), Osaka Univ, World Premier Int Res Ctr, Immunol Frontier Res Ctr, Lab Biochem & Immunol, Suita, Osaka, Japan.	segawa.mche@tmd.ac.jp; snagata@ifrec.osaka-u.ac.jp	Nagata, Shigekazu/AAG-3203-2019	Nagata, Shigekazu/0000-0001-9758-8426; Segawa, Katsumori/0000-0003-2408-7668; Miyata, Yugo/0000-0002-3245-4600	Japan Society for the Promotion of Science [21H02682, 15H05785, 21H04770, 18H02615]; Ichiro Kanehara foundation; Kobayashi Foundation; SENSHIN Medical Research Foundation; Daiichi Sankyo Foundation of Life Science; Toray Science Foundation; Chugai Foundation for Innovative Drug Discovery Science; Nanken-Kyoten TMDU; Ohsumi Frontier Science Foundation	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Ichiro Kanehara foundation; Kobayashi Foundation; SENSHIN Medical Research Foundation(SENSHIN Medical Research Foundation); Daiichi Sankyo Foundation of Life Science; Toray Science Foundation(Toray Industries, Inc.); Chugai Foundation for Innovative Drug Discovery Science; Nanken-Kyoten TMDU; Ohsumi Frontier Science Foundation	This work was supported in part by Grants -in -Aid from the Japan Society for the Promotion of Science (18H02615 and 21H02682 to K. S., 15H05785 and 21H04770 to S. N.) , Ichiro Kanehara foundation (K. S.) , Kobayashi Foundation (K. S.) , SENSHIN Medical Research Foundation (K. S.) , Ohsumi Frontier Science Foundation (K. S.) , Daiichi Sankyo Foundation of Life Science (K. S.) , Toray Science Foundation (K. S.) , Chugai Foundation for Innovative Drug Discovery Science (K. S.) , and Nanken-Kyoten TMDU (2021-2-01, to K. S. and S. N.) .	Alder-Baerens N, 2006, MOL BIOL CELL, V17, P1632, DOI 10.1091/mbc.E05-10-0912; Andersen JP, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00275; Arashiki N, 2019, BIOCHEM BIOPH RES CO, V516, P705, DOI 10.1016/j.bbrc.2019.06.092; Atilla-Gokcumen GE, 2014, CELL, V156, P428, DOI 10.1016/j.cell.2013.12.015; Bevers EM, 2016, PHYSIOL REV, V96, P605, DOI 10.1152/physrev.00020.2015; BEVERS EM, 1989, BIOCHEMISTRY-US, V28, P2382, DOI 10.1021/bi00432a007; Cheng MT, 2022, P NATL ACAD SCI USA, V119, DOI 10.1073/pnas.2118656119; Chung J, 2015, SCIENCE, V349, P428, DOI 10.1126/science.aab1370; Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143; Das M, 2004, PLACENTA, V25, P396, DOI 10.1016/j.placenta.2003.11.004; Dieudonne T, 2022, ELIFE, V11, DOI 10.7554/eLife.75272; Gadella BM, 2002, BIOL REPROD, V67, P340, DOI 10.1095/biolreprod67.1.340; GHOSH RN, 1994, J CELL SCI, V107, P2177; Grifell-Junyent M, 2022, J CELL SCI, V135, DOI 10.1242/jcs.258649; Harayama T, 2018, NAT REV MOL CELL BIO, V19, P281, DOI 10.1038/nrm.2017.138; Hiraizumi M, 2019, SCIENCE, V365, P1149, DOI 10.1126/science.aay3353; Hsu VW, 2012, NAT REV MOL CELL BIO, V13, P1, DOI 10.1038/nrm3332; Kitamura T, 2003, EXP HEMATOL, V31, P1007, DOI 10.1016/j.exphem.2003.07.005; KUISMANEN E, 1989, METHOD CELL BIOL, V32, P257; Lee S, 2015, EMBO J, V34, P669, DOI 10.15252/embj.201489703; Lenoir G, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.737907; M.Ishiyama, 2020, bioRxiv, DOI 10.1101/2020.11.16.379206; McCluskey A, 2013, TRAFFIC, V14, P1272, DOI 10.1111/tra.12119; McCusker D, 2012, CURR OPIN CELL BIOL, V24, P845, DOI 10.1016/j.ceb.2012.10.008; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Montigny C, 2016, BBA-MOL CELL BIOL L, V1861, P767, DOI 10.1016/j.bbalip.2015.12.020; Murate M, 2015, J CELL SCI, V128, P1627, DOI 10.1242/jcs.163105; Nagata S, 2021, CURR OPIN IMMUNOL, V68, P1, DOI 10.1016/j.coi.2020.07.007; Nagata S, 2020, CURR OPIN IMMUNOL, V62, P31, DOI 10.1016/j.coi.2019.11.009; Nakanishi H, 2020, J BIOL CHEM, V295, P10180, DOI 10.1074/jbc.RA120.014144; Ochiai Y, 2022, P NATL ACAD SCI USA, V119, DOI 10.1073/pnas.2200582119; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Okamoto S, 2020, MOL BIOL CELL, V31, P2115, DOI 10.1091/mbc.E20-04-0225; Park J, 2021, EMBO J, V40, DOI 10.15252/embj.2020107121; Raymond C, 2011, METHODS, V55, P44, DOI 10.1016/j.ymeth.2011.04.002; Ryoden Y, 2020, J IMMUNOL, V204, P559, DOI 10.4049/jimmunol.1900448; Sartorel E, 2018, MOL BIOL CELL, V29, P1299, DOI 10.1091/mbc.E18-01-0051; Sebastian TT, 2012, BBA-MOL CELL BIOL L, V1821, P1068, DOI 10.1016/j.bbalip.2011.12.007; Segawa K, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI148005; Segawa K, 2018, P NATL ACAD SCI USA, V115, P12212, DOI 10.1073/pnas.1814323115; Segawa K, 2018, J BIOL CHEM, V293, P2172, DOI 10.1074/jbc.RA117.000289; Segawa K, 2016, J BIOL CHEM, V291, P762, DOI 10.1074/jbc.M115.690727; Segawa K, 2015, TRENDS CELL BIOL, V25, P639, DOI 10.1016/j.tcb.2015.08.003; Segawa K, 2014, SCIENCE, V344, P1164, DOI 10.1126/science.1252809; Siggs OM, 2011, P NATL ACAD SCI USA, V108, P7890, DOI 10.1073/pnas.1104631108; Siggs OM, 2011, NAT IMMUNOL, V12, P434, DOI 10.1038/ni.2012; Stevens HC, 2008, J BIOL CHEM, V283, P35060, DOI 10.1074/jbc.M802379200; SULLIVAN PC, 1987, J CELL PHYSIOL, V131, P58, DOI 10.1002/jcp.1041310110; Suzuki J, 2016, P NATL ACAD SCI USA, V113, P9509, DOI 10.1073/pnas.1610403113; Suzuki J, 2013, SCIENCE, V341, P403, DOI 10.1126/science.1236758; Suzuki J, 2010, NATURE, V468, P834, DOI 10.1038/nature09583; Takatsu H, 2014, J BIOL CHEM, V289, P33543, DOI 10.1074/jbc.M114.593012; Takatsu H, 2011, J BIOL CHEM, V286, P38159, DOI 10.1074/jbc.M111.281006; Tanaka K, 2011, J BIOCHEM, V149, P131, DOI 10.1093/jb/mvq140; Tsuchiya M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04436-w; van den Eijnde SM, 2001, J CELL SCI, V114, P3631; van Meer G, 2008, NAT REV MOL CELL BIO, V9, P112, DOI 10.1038/nrm2330; Vance JE, 2015, TRAFFIC, V16, P1, DOI 10.1111/tra.12230; Wang J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29108-z; Yang YB, 2018, J BIOL CHEM, V293, P6230, DOI 10.1074/jbc.R117.000582; Zhou Y, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11101439	61	0	0	2	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV	2022	298	11								10.1016/j.jbc.2022.102527	http://dx.doi.org/10.1016/j.jbc.2022.102527			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	6D3XI	36162506	Green Published, gold			2022-12-28	WOS:000882627400012
J	Shoop, WK; Gorsuch, CL; Bacman, SR; Moraes, CT				Shoop, Wendy K.; Gorsuch, Cassandra L.; Bacman, Sandra R.; Moraes, Carlos T.			Precise and simultaneous quantification of mitochondrial DNA heteroplasmy and copy number by digital PCR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MELAS; MUTATION; MTDNA; MANIFESTATIONS	Mitochondrial DNA (mtDNA) is present in multiple copies and phenotypic consequences of mtDNA mutations depend on the mutant load surpassing a specific threshold. Additionally, changes in mtDNA copy number can impact mitochondrial ATP production, resulting in disease. Therefore, the precise determination of mtDNA heteroplasmy and copy number is crucial to the study of mitochondrial diseases. However, cur-rent methods can be imprecise, and quantifying small changes in either heteroplasmy or copy number is challenging. We developed a new approach to measure mtDNA heteroplasmy using a single digital PCR (dPCR) probe. This method is based on the observation that fluorescent-labeled probes in dPCR exhibit different intensities depending on the presence of a single nucleotide change in the sequence bound by the probe. This finding allowed us to precisely and simultaneously determine mtDNA copy number and heteroplasmy levels using duplex dPCR. We tested this approach in two different models (human and mouse), which proved faster and more internally controlled when compared to other published methods routinely used in the mitochondrial genetics field. We believe this approach could be broadly applicable to the detection and quantification of other mixed genetic variations.	[Shoop, Wendy K.; Gorsuch, Cassandra L.] Precis Biosci, Durham, NC 27701 USA; [Shoop, Wendy K.; Bacman, Sandra R.; Moraes, Carlos T.] Univ Miami, Miller Sch Med, Miami, FL 33136 USA	University of Miami	Shoop, WK (corresponding author), Precis Biosci, Durham, NC 27701 USA.; Shoop, WK; Moraes, CT (corresponding author), Univ Miami, Miller Sch Med, Miami, FL 33136 USA.	wendy.shoop@precisionbiosciences.com; cmoraes@med.miami.edu			National Institute of Health [5R01EY010804, 1R01NS079965]; Florida Biomedical Foundation [21K05]; Muscular Dystrophy Association [MDA 964119]; Army Research Office [W911NF-21-1-0248]	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Florida Biomedical Foundation; Muscular Dystrophy Association(Muscular Dystrophy Association); Army Research Office	The authors would like to thank Armin Hekele, Adam Mischler, Emma Sevigny, and Alison Gatherum for their contributions to this work. The work in the Moraes Lab was funded by National Institute of Health Grants 5R01EY010804 and 1R01NS079965, The Florida Biomedical Foundation (21K05) , The Muscular Dystrophy Association (MDA 964119) , and the Army Research Office (W911NF-21-1-0248) .	Bacman SR, 2010, GENE THER, V17, P713, DOI 10.1038/gt.2010.25; Bacman SR, 2018, NAT MED, V24, P1696, DOI 10.1038/s41591-018-0166-8; Ballantyne KN, 2008, GENOMICS, V91, P301, DOI 10.1016/j.ygeno.2007.10.016; Barrera-Paez JD, 2022, TRENDS GENET, V38, P869, DOI 10.1016/j.tig.2022.04.011; Basel D, 2020, CLIN PERINATOL, V47, P123, DOI 10.1016/j.clp.2019.10.008; Bio-Rad, 2018, DROPL DIG PCR APPL G, P1; BioRad, 2015, RAR MUT DET BEST PRA; Bubner B, 2004, BMC BIOTECHNOL, V4, DOI 10.1186/1472-6750-4-14; Carr IM, 2009, BIOINFORMATICS, V25, P3244, DOI 10.1093/bioinformatics/btp583; Castellani CA, 2020, MITOCHONDRION, V53, P214, DOI 10.1016/j.mito.2020.06.004; Duan MQ, 2018, MOLECULES, V23, DOI 10.3390/molecules23020323; El-Hattab AW, 2015, MOL GENET METAB, V116, P4, DOI 10.1016/j.ymgme.2015.06.004; El-Hattab A, 2013, NEUROTHERAPEUTICS, V10, P186, DOI 10.1007/s13311-013-0177-6; Gorman GS, 2016, NAT REV DIS PRIMERS, V2, P1, DOI 10.1038/nrdp.2016.80; Kauppila JHK, 2016, CELL REP, V16, P2980, DOI 10.1016/j.celrep.2016.08.037; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Kutyavin IV, 2000, NUCLEIC ACIDS RES, V28, P655, DOI 10.1093/nar/28.2.655; Madic J, 2016, Biomol Detect Quantif, V10, P34; McStay B, 2008, ANNU REV CELL DEV BI, V24, P131, DOI 10.1146/annurev.cellbio.24.110707.175259; Montier LLC, 2009, J GENET GENOMICS, V36, P125, DOI 10.1016/S1673-8527(08)60099-5; MORAES CT, 1992, AM J HUM GENET, V50, P934; Moraes CT, 2003, J MOL DIAGN, V5, P197, DOI 10.1016/S1525-1578(10)60474-6; MORAES CT, 1993, NEUROMUSCULAR DISORD, V3, P43, DOI 10.1016/0960-8966(93)90040-Q; PETRUZZELLA V, 1994, HUM MOL GENET, V3, P449, DOI 10.1093/hmg/3.3.449; Pinheiro LB, 2012, ANAL CHEM, V84, P1003, DOI 10.1021/ac202578x; Rebolledo-Jaramillo B, 2014, P NATL ACAD SCI USA, V111, P15474, DOI 10.1073/pnas.1409328111; Rong E., 2018, BIOMED RES INT, P1; Seroussi E, 2021, GENES-BASEL, V12, DOI 10.3390/genes12020283; Shepherd RK, 2006, J INHERIT METAB DIS, V29, P86, DOI 10.1007/s10545-006-0148-8; Taylor SD, 2014, AGING CELL, V13, P29, DOI 10.1111/acel.12146; Tong Y, 2017, CELL PHYSIOL BIOCHEM, V43, P1718, DOI 10.1159/000484035; Woischnik M, 2002, GENOME RES, V12, P885, DOI 10.1101/gr.227202; Yang Y, 2018, PROTEIN CELL, V9, P283, DOI 10.1007/s13238-017-0499-y; Yarham JW, 2010, WIRES RNA, V1, P304, DOI 10.1002/wrna.27; Young M. J., 2022, LIFE, V12, P1; Yuan Y, 2020, NAT GENET, V52, P342, DOI 10.1038/s41588-019-0557-x; Zekonyte U, 2020, J INTERN MED, V287, P685, DOI 10.1111/joim.13055; Zekonyte U, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23561-7	38	0	0	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV	2022	298	11							102574	10.1016/j.jbc.2022.102574	http://dx.doi.org/10.1016/j.jbc.2022.102574			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	6W5WW	36209825	Green Published, gold			2022-12-28	WOS:000895801300005
J	JOOSS, K; MULLER, R				JOOSS, K; MULLER, R			ANALYSIS OF TEMPERATURE-SENSITIVE FUNCTIONS OF FOS - LACK OF A CORRELATION BETWEEN TRANSFORMATION AND TRE-DEPENDENT TRANSACTIVATION	ONCOGENE			English	Article							INDUCE CELLULAR-TRANSFORMATION; ROUS-SARCOMA VIRUS; PROTO-ONCOGENE FOS; C-FOS; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; AUTO-REGULATION; BINDING DOMAIN; JUN; CELLS	We have identified and characterized a mutant v-Fos protein (DN16G) that is temperature sensitive for transformation. This protein contains an asparagine to glycine substitution at position 156 in the basic region encompassing the DNA contact site. This point mutation also strongly decreases trans-activation in a transient expression assay, using the collagenase 12-O-tetradecanoyl phorbol 13-acetate (TPA)-responsive element (TRE) as the target element. However, the apparent correlation between trans-activation and transformation does not hold in view of the observation that under certain temperature conditions (DN16G at 39.5-degrees-C and E300 at 37-degrees-C) both proteins showed similarly poor transactivation properties, but dramatically differed in their transforming potential. These findings clearly suggest that the activation of transcription via TREs as analysed in this study is not a crucial mechanism in Fos-induced transformation.	UNIV MARBURG,INST MOLEK BIOL & TUMORFORSCH,EMIL MANNKOPFF STR 2,W-3550 MARBURG,GERMANY	Philipps University Marburg			Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ADAMS SL, 1982, CELL, V30, P373, DOI 10.1016/0092-8674(82)90235-5; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4784; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KAMATA N, 1992, MOL CELL BIOL, V12, P876, DOI 10.1128/MCB.12.2.876; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LUCIBELLO F C, 1991, Critical Reviews in Oncogenesis, V2, P259; LUCIBELLO FC, 1988, ONCOGENE, V3, P43; LUCIBELLO FC, 1991, NEW BIOL, V3, P671; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; LUCIBELLO FC, 1990, EMBO J, V9, P2828; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; MILLER AD, 1984, CELL, V36, P51; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; Muller R, 1986, Biochim Biophys Acta, V823, P207, DOI 10.1016/0304-419X(86)90003-X; NEUBERG M, 1991, ONCOGENE, V6, P1325; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SCHUERMANN M, 1991, ONCOGENE, V6, P567; SETOYAMA C, 1986, P NATL ACAD SCI USA, V83, P3213, DOI 10.1073/pnas.83.10.3213; SUPERTIFURGA G, 1991, P NATL ACAD SCI USA, V88, P5114, DOI 10.1073/pnas.88.12.5114; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VELCICH A, 1990, MOL CELL BIOL, V10, P6273, DOI 10.1128/MCB.10.12.6273; VERMA IM, 1986, TRENDS GENET, V2, P93, DOI 10.1016/0168-9525(86)90191-5; VERRIER B, 1986, EMBO J, V5, P913, DOI 10.1002/j.1460-2075.1986.tb04303.x	48	10	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					1933	1939						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408134				2022-12-28	WOS:A1992JP42400005
J	VANDENBARK, GR; DECASTRO, CM; TAYLOR, H; DEWKNIGHT, S; KAUFMAN, RE				VANDENBARK, GR; DECASTRO, CM; TAYLOR, H; DEWKNIGHT, S; KAUFMAN, RE			CLONING AND STRUCTURAL-ANALYSIS OF THE HUMAN C-KIT GENE	ONCOGENE			English	Article								The recent identification of the mouse White spotting and Steel loci as genes encoding the c-kit receptor and its ligand, respectively, has shed light on the importance of this ligand and receptor in embryogenesis, melanogenesis and hematopoiesis. In order to determine if the c-kit proto-oncogene is involved in human disease, we isolated seven overlapping lambda recombinants, using a fetal brain cDNA, and characterized the normal human gene (KIT). The longest mapped transcript is 5230 bp, is alternatively spliced and includes 21 exons that span more than 70 kb of DNA. From the exon-intron structure, we have localized an alternative splice site to the 3' end of exon 9. The overall c-kit gene structure closely resembles that found in the CSF-1R gene (c-fms). This similarity includes a large first intron, the same number of exons containing translated sequence and very similar exon-intron boundaries. Using pulsed-field gel electrophoresis, we have linked KIT to the platelet-derived growth factor receptor A gene, with both residing on a 700-kb BssHI fragment. These data will allow investigation into the control of KIT expression and the potential to identify mutations or altered expression of this gene in human disease.	DUKE UNIV, MED CTR, DEPT NEUROSCI, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Duke University; Duke University	VANDENBARK, GR (corresponding author), DUKE UNIV, MED CTR, DEPT MED, DIV HEMATOL ONCOL, BOX 3167, DURHAM, NC 27710 USA.			Kaufman, Russell/0000-0003-4612-4861	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038699] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38699] Funding Source: Medline; PHS HHS [H102643] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; ANDRE C, 1989, ONCOGENE, V4, P1047; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHU G, 1986, SCIENCE, V232, P65; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DENHARDT DT, 1966, BIOCHEM BIOPH RES CO, V23, P641, DOI 10.1016/0006-291X(66)90447-5; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOLCI S, 1991, NATURE, V352, P809, DOI 10.1038/352809a0; DOUGHERTY GJ, 1991, J EXP MED, V174, P1, DOI 10.1084/jem.174.1.1; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FLEISCHMAN RA, 1991, P NATL ACAD SCI USA, V88, P10885, DOI 10.1073/pnas.88.23.10885; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GODIN I, 1991, NATURE, V352, P807, DOI 10.1038/352807a0; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HAMPE A, 1989, ONCOGENE RES, V4, P9; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; MAJUMDER S, 1988, MOL CELL BIOL, V8, P4896, DOI 10.1128/MCB.8.11.4896; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATSUI Y, 1990, NATURE, V347, P667, DOI 10.1038/347667a0; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; METCALF D, 1991, P NATL ACAD SCI USA, V88, P6239, DOI 10.1073/pnas.88.14.6239; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; OGURA M, 1985, BLOOD, V66, P1384; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; ROBERTS WM, 1988, CELL, V55, P655, DOI 10.1016/0092-8674(88)90224-3; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SARVELLA PATRICIA A., 1956, JOUR HEREDITY, V47, P123; SEKIDO Y, 1991, CANCER RES, V51, P2416; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SHERR CJ, 1990, BLOOD, V75, P1; SHIBUYA M, 1990, ONCOGENE, V5, P519; SMITH EA, 1991, P NATL ACAD SCI USA, V88, P4811, DOI 10.1073/pnas.88.11.4811; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STROHMEYER T, 1991, CANCER RES, V51, P1811; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; ULICH TR, 1991, BLOOD, V78, P645; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WANG C, 1989, LEUKEMIA, V3, P699; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4; [No title captured]; [No title captured]	55	99	111	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1992	7	7					1259	1266						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1377810				2022-12-28	WOS:A1992HZ97100002
J	BENVENISTY, N; ORNITZ, DM; BENNETT, GL; SAHAGAN, BG; KUO, A; CARDIFF, RD; LEDER, P				BENVENISTY, N; ORNITZ, DM; BENNETT, GL; SAHAGAN, BG; KUO, A; CARDIFF, RD; LEDER, P			BRAIN-TUMORS AND LYMPHOMAS IN TRANSGENIC MICE THAT CARRY HTLV-I LTR/C-MYC AND IG/TAX GENES	ONCOGENE			English	Article							CELL LEUKEMIA-VIRUS; E-MU-MYC; T-CELL; B-CELL; TAX GENE; EXPRESSION; TUMORS; HYBRIDIZATION; RNA; TRANSFORMATION	The human T-cell leukemia virus type 1 (HTLV-I) is associated with adult CD4+ T-cell leukemia (ATL) and tropical spastic paraparesis (TSP). In as much as only a small percentage of individuals infected with HTLV-I develop either disease, we set out to model a genetic partner for this virus in an effort to understand and possibly reproduce its pathophysiology. To this end we have developed a binary set of transgenic mice, one bearing the relatively inactive HTLV-I long terminal repeat (LTR) positioned to drive the c-myc oncogene and another bearing a fusion transgene consisting of the immunoglobulin promoter/enhancer driving the gene for the HTLV-I transcription activator, tax. Alone, the tax construct, though expressed in the thymus, spleen, lung and brain, has no deleterious effect. Alone, the HTLV-I LTR/c-myc construct is expressed at very low levels in lymphoid cells and occasionally induces lymphomas in older animals. When these two transgenic lines are mated, bigenic offspring harboring both transgenes exhibit dramatic tumor formation. As in the human, these animals develop CD4+ T-cell lymphomas, but they also develop central nervous system tumors by 25-90 days of age. The syndrome, which is 100% penetrant and lethal, provides an animal model for adult T-cell lymphoma and a source of cultured cells of neurogenic origin.	UNIV CALIF DAVIS, SCH MED, DEPT PATHOL, DAVIS, CA 95616 USA	University of California System; University of California Davis	BENVENISTY, N (corresponding author), HARVARD UNIV, SCH MED, HOWARD HUGHES MED INST, 25 SHATTUCK ST, BOSTON, MA 02115 USA.			Ornitz, David/0000-0003-1592-7629				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; BRINSTER RL, 1984, CELL, V37, P367, DOI 10.1016/0092-8674(84)90367-2; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DURNAM DM, 1983, ANAL BIOCHEM, V131, P385, DOI 10.1016/0003-2697(83)90188-4; FURUTA Y, 1989, J VIROL, V63, P3185, DOI 10.1128/JVI.63.7.3185-3189.1989; GESSAIN A, 1985, LANCET, V2, P407; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN JE, 1989, NATURE, V341, P72, DOI 10.1038/341072a0; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HINRICHS SH, 1987, SCIENCE, V237, P1340, DOI 10.1126/science.2888191; ITO Y, 1985, CURR TOP MICROBIOL, V115, P99; IWAKURA Y, 1991, SCIENCE, V253, P1026, DOI 10.1126/science.1887217; JULIEN JP, 1986, MOL BRAIN RES, V1, P243, DOI 10.1016/0169-328X(86)90030-6; KOIZUMI T, 1989, INT J CANCER, V44, P701, DOI 10.1002/ijc.2910440425; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MENGLEGAW L, 1987, EMBO J, V6, P1959, DOI 10.1002/j.1460-2075.1987.tb02458.x; NAKAHIRA K, 1990, J BIOL CHEM, V265, P19786; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; NERENBERG MI, 1991, J VIROL, V65, P3349, DOI 10.1128/JVI.65.6.3349-3353.1991; PIGOTT T J D, 1990, British Journal of Neurosurgery, V4, P287, DOI 10.3109/02688699008992738; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; TEPPER RI, 1990, CELL, V62, P457, DOI 10.1016/0092-8674(90)90011-3; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; WILKINSON DG, 1987, DEVELOPMENT, V99, P493; XU YL, 1990, J BIOL CHEM, V265, P20285; ZELLER R, 1987, GENE DEV, V1, P693, DOI 10.1101/gad.1.7.693	36	58	59	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1992	7	12					2399	2405						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1461648				2022-12-28	WOS:A1992KA85600004
J	DUTHU, A; DEBUIRE, B; ROMANO, J; EHRHART, JC; FISCELLA, M; MAY, E; APPELLA, E; MAY, P				DUTHU, A; DEBUIRE, B; ROMANO, J; EHRHART, JC; FISCELLA, M; MAY, E; APPELLA, E; MAY, P			P53 MUTATIONS IN RAJI CELLS - CHARACTERIZATION AND LOCALIZATION RELATIVE TO OTHER BURKITTS LYMPHOMAS	ONCOGENE			English	Article							CELLULAR TUMOR-ANTIGEN; CDNA CLONE; SUPPRESSOR GENE; ONCOGENE; TRANSFORMATION; EXPRESSION; PROTEIN; LINES; DNA; IMMORTALIZATION	The nuclear phosphoprotein p53 is an important regulator of cell proliferation in normal cells. Interestingly, the gene encoding p53 has usually undergone mutations in a wide range of tumor types. Recent studies of the p53 gene in Burkitt's lymphomas have demonstrated that mutations are extremely common, and in fact it is rare that both alleles of the p53 gene in these tumors are not inactivated by mutation or deletion. We present here genetic data regarding the status of the p53 gene in the Burkitt lymphoma cell line, Raji. As is typical for this type of tumor, both alleles have undergone point mutations. Further, statistical analysis of available data from a large number of Burkitt's lymphomas indicates an apparent tumor-specific distribution of p53 mutations. The possibility that specific mutations of the p53 gene may be important for different tumor types is discussed.	CNRS,UPR 275,BP 8,F-94801 VILLEJUIF,FRANCE; NCI,CELL BIOL LAB,BETHESDA,MD 20892	Centre National de la Recherche Scientifique (CNRS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARTEK J, 1990, ONCOGENE, V5, P893; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DEPPERT W, 1990, ONCOGENE, V5, P1701; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; EPSTEIN MA, 1986, EPSTEIN BARR VIRUS; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HATFULL G, 1988, VIROLOGY, V164, P334, DOI 10.1016/0042-6822(88)90546-6; HIROSE M, 1983, JPN J CANCER RES, V74, P106; HOLLSTEIN MC, 1991, CANCER RES, V51, P402; ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KASTAN MB, 1991, CANCER RES, V51, P6304; KLEIN G, 1985, IMMUNOL TODAY, V6, P208, DOI 10.1016/0167-5699(85)90036-2; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3892; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MATLASHEWSKI G, 1984, EMBO J, V3, P3257, DOI 10.1002/j.1460-2075.1984.tb02287.x; MCBRIDE OW, 1986, P NATL ACAD SCI USA, V83, P130, DOI 10.1073/pnas.83.1.130; MERCER WE, 1982, P NATL ACAD SCI USA, V79, P309; MUNROE DG, 1990, MOL CELL BIOL, V10, P3307, DOI 10.1128/MCB.10.7.3307; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; POLACK A, 1984, VIROLOGY, V133, P146, DOI 10.1016/0042-6822(84)90433-1; PULVERTA.RJ, 1965, J CLIN PATHOL, V18, P261, DOI 10.1136/jcp.18.3.261; ROMANO JW, 1989, ONCOGENE, V4, P1483; ROVINSKI B, 1988, ONCOGENE, V2, P445; Sambrook J, 1989, MOL CLONING LABORATO; SHOHAT O, 1987, ONCOGENE, V1, P277; SOUSSI T, 1987, ONCOGENE, V1, P71; SOUSSI T, 1990, ONCOGENE, V5, P945; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; WIMAN KG, 1991, ONCOGENE, V6, P1633; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x	43	57	59	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2161	2167						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437144				2022-12-28	WOS:A1992JW66500008
J	GOLUBIC, M; ROUDEBUSH, M; DOBROWOLSKI, S; WOLFMAN, A; STACEY, DW				GOLUBIC, M; ROUDEBUSH, M; DOBROWOLSKI, S; WOLFMAN, A; STACEY, DW			CATALYTIC PROPERTIES, TISSUE AND INTRACELLULAR-DISTRIBUTION OF NEUROFIBROMIN	ONCOGENE			English	Article							GTPASE-ACTIVATING PROTEIN; TYPE-1 GENE-PRODUCT; RAS GTPASE; IDENTIFICATION; SEQUENCE; DOMAIN; LIPIDS; GAP; MUTANTS; LOCUS	The neurofibromatosis type 1 (NF1) gene encodes a protein, neurofibromin, that shows homology with members of the GTPase-activating protein (GAP) family. To study neurofibromin, rabbit polyclonal antisera were raised against two synthetic peptides. These antisera immunoprecipitated a specific protein of about 240 kDa in lysates of adult murine and rat tissues both in the soluble (S100) and to a lesser degree in the particulate (P100) fractions. The neurofibromin immunoprecipitated from the lysates of several murine organs stimulated the intrinsic GTPase activity of p21 c-Ha-ras protein. Based on immunoblotting, immunoprecipitation and GTPase assays, neurofibromin appears to be at least 10-fold more abundant in the brain than in the other murine organs. The GTPase-stimulatory activity of full-length neurofibromin, like the catalytic GAP-related domain, is inhibited by arachidonic acid and the detergent dodecyl maltoside, while phosphatidic acid, containing arachidonic and stearic acid, is non-inhibitory. Immunofluorescence analysis with anti-neurofibromin sera in NIH3T3 cells suggests that at least some of the cellular protein associates with cytoplasmic structures that are distinct from actin or tubulin filaments.	CLEVELAND CLIN FDN,DEPT VASC CELL BIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation	GOLUBIC, M (corresponding author), CLEVELAND CLIN FDN,DEPT MOLEC BIOL,9500 EUCLID AVE,NC1 150,CLEVELAND,OH 44195, USA.			Roudebush, Margaret/0000-0001-9005-3672	NATIONAL CANCER INSTITUTE [R01CA048662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM041220] Funding Source: NIH RePORTER; NCI NIH HHS [CA48662, CA53436] Funding Source: Medline; NIGMS NIH HHS [GM41220] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BUCHBERG AM, 1990, NATURE, V347, P291, DOI 10.1038/347291a0; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; Cohen B H, 1989, Oncology (Williston Park), V3, P23; DASTON MM, 1992, NEURON, V8, P415, DOI 10.1016/0896-6273(92)90270-N; DECLUE JE, 1991, P NATL ACAD SCI USA, V88, P9914, DOI 10.1073/pnas.88.22.9914; GOLUBIC M, 1991, EMBO J, V10, P2897, DOI 10.1002/j.1460-2075.1991.tb07839.x; GUTMANN DH, 1991, P NATL ACAD SCI USA, V88, P9658, DOI 10.1073/pnas.88.21.9658; HAN JW, 1991, SCIENCE, V252, P576, DOI 10.1126/science.1902323; HARLOW E, 1988, ANTIBODIES LABORATOR, P309; HATTORI S, 1992, ONCOGENE, V7, P481; HATTORI S, 1991, BIOCHEM BIOPH RES CO, V177, P83, DOI 10.1016/0006-291X(91)91951-8; LOWY DR, 1991, TRENDS GENET, V7, P346, DOI 10.1016/0168-9525(91)90253-M; MARCHUK DA, 1991, GENOMICS, V11, P931, DOI 10.1016/0888-7543(91)90017-9; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; NISHI T, 1991, ONCOGENE, V6, P1555; OSBORN M, 1977, CELL, V12, P561, DOI 10.1016/0092-8674(77)90257-4; RICCARDI VM, 1981, NEW ENGL J MED, V305, P1617, DOI 10.1056/NEJM198112313052704; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SERTH J, 1991, EMBO J, V10, P1325, DOI 10.1002/j.1460-2075.1991.tb07651.x; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TSAI MH, 1991, MOL CELL BIOL, V11, P2785, DOI 10.1128/MCB.11.5.2785; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; VANREGENMORTEL MHV, 1988, SYNTHETIC POLYPEPTID, P104; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WALLACE MR, 1991, NATURE, V353, P864, DOI 10.1038/353864a0; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; YU CL, 1990, MOL CELL BIOL, V10, P6683, DOI 10.1128/MCB.10.12.6683; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4	33	59	59	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2151	2159						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437143				2022-12-28	WOS:A1992JW66500007
J	SUNDARESAN, V; GANLY, P; HASLETON, P; RUDD, R; SINHA, G; BLEEHEN, NM; RABBITTS, P				SUNDARESAN, V; GANLY, P; HASLETON, P; RUDD, R; SINHA, G; BLEEHEN, NM; RABBITTS, P			P53 AND CHROMOSOME-3 ABNORMALITIES, CHARACTERISTIC OF MALIGNANT LUNG-TUMORS, ARE DETECTABLE IN PREINVASIVE LESIONS OF THE BRONCHUS	ONCOGENE			English	Article							POLYMERASE CHAIN-REACTION; REACTION PCR; THRB GENE; BAMHI POLYMORPHISM; RSAI POLYMORPHISM; SUPPRESSOR GENE; D3S32 LOCUS; REGION 3P21; CELL-LINES; CANCER	Bronchial epithelial dysplasia is believed to precede invasive squamous cell carcinoma of the lung. Six paired dysplasia and tumour samples were distinguished histologically in sections of formalin-fixed paraffin-embedded lung tissue from patients with lung cancer. Additionally, samples of dysplastic bronchial epithelium were obtained from patients without lung tumours. Microdissection of the unstained sections provided dysplastic and tumour samples from which DNA was prepared for comparison with the patients' constitutional genotype, using polymerase chain reaction-based restriction fragment length polymorphism analysis. All six samples of tumour and the paired adjacent samples of bronchial dysplasia showed loss of heterozygosity (LOH) at loci on the short arm of chromosome 3. Five of the six cases showed involvement of the p53 gene as assessed by LOH at the AccII site within the gene, and by immunoreactivity to CM-1, an antibody which recognizes the mutated form of the p53 protein in paraffin-embedded material. Of the dysplastic samples, obtained from patients without invasive tumours, all three showed LOH at 3p; one sample showed LOH at the AccII polymorphic locus within the p53 gene, and another sample, uninformative at this locus, stained positively with this antibody. These results indicate that somatic genetic changes are present in preinvasive lesions in the bronchus.	MRC,CLIN ONCOL & RADIOTHERAPEUT UNIT,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND; ADDENBROOKES HOSP,DEPT HISTOPATHOL,CAMBRIDGE CB2 2QQ,ENGLAND; LONDON CHEST HOSP,DEPT RESP MED,LONDON E2 9JX,ENGLAND; WYTHENSHAWE HOSP,REG CARDIOTHORAC CTR,DEPT PATHOL,MANCHESTER M23 9LT,LANCS,ENGLAND; LONDON CHEST HOSP,DEPT PATHOL,LONDON E2 9JX,ENGLAND	University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of London; Queen Mary University London; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; University of London; Queen Mary University London				Ganly, Peter/0000-0003-0335-2063				AUERBACH O, 1962, NEW ENGL J MED, V267, P111, DOI 10.1056/NEJM196207192670301; AUERBACH O, 1957, NEW ENGL J MED, V256, P97, DOI 10.1056/NEJM195701172560301; AUERBACH O, 1979, NEW ENGL J MED, V300, P381, DOI 10.1056/NEJM197902223000801; BARTEK J, 1991, ONCOGENE, V6, P1699; BUYS C, 1991, EUR J CANCER S2, V27, P82; CHIBA I, 1990, ONCOGENE, V5, P1603; DELACALLEMARTIN O, 1990, NUCLEIC ACIDS RES, V18, P4963, DOI 10.1093/nar/18.16.4963; DONTI E, 1990, HUM GENET, V84, P391; ERLANDSSON R, 1990, ONCOGENE, V5, P1207; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GANLY PS, 1992, GENOMICS, V12, P221, DOI 10.1016/0888-7543(92)90369-4; GANLY PS, 1991, NUCLEIC ACIDS RES, V19, P3761, DOI 10.1093/nar/19.13.3761; GANLY PS, 1991, NUCLEIC ACIDS RES, V19, P3760; GANLY PS, 1991, NUCLEIC ACIDS RES, V19, P3757, DOI 10.1093/nar/19.13.3757-a; GANLY PS, 1991, NUCLEIC ACIDS RES, V19, P3758, DOI 10.1093/nar/19.13.3758; GEBERT JF, 1991, ONCOGENE, V6, P1859; GORADIA TM, 1991, GENOMICS, V10, P748, DOI 10.1016/0888-7543(91)90459-R; GREENWALD BD, 1992, CANCER RES, V52, P741; GUSTERSON BA, 1991, ONCOGENE, V6, P1785; HOULE B, 1991, GENE CHROMOSOME CANC, V3, P358, DOI 10.1002/gcc.2870030506; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; HUNG J, 1991, LASER SURG MED, V11, P99, DOI 10.1002/lsm.1900110203; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; KIM JH, 1991, J NATL CANCER I, V83, P938, DOI 10.1093/jnci/83.13.938; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; LAFORGIA S, 1991, P NATL ACAD SCI USA, V88, P5036, DOI 10.1073/pnas.88.11.5036; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MELTZER SJ, 1991, P NATL ACAD SCI USA, V88, P4976, DOI 10.1073/pnas.88.11.4976; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MITSUDOMI T, 1992, ONCOGENE, V7, P171; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; OKA K, 1991, MOL CARCINOGEN, V4, P10, DOI 10.1002/mc.2940040104; PAABO S, 1989, J BIOL CHEM, V264, P9709; PAL N, 1990, ONCOGENE, V5, P1665; PONDER B, 1988, NATURE, V335, P400, DOI 10.1038/335400a0; RABBITTS P, 1989, GENE CHROMOSOME CANC, V1, P95, DOI 10.1002/gcc.2870010115; RABBITTS PH, 1991, DIAGN ONCOL, V1, P298; SHIBATA D, 1988, CANCER RES, V48, P4564; SOZZI G, 1991, CANCER RES, V51, P400; STRETCH JR, 1991, CANCER RES, V51, P5976; TOKUDA Y, 1990, J CLIN PATHOL, V43, P748, DOI 10.1136/jcp.43.9.748; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023; WILKINS RJ, 1988, LANCET, V1, P329; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153; YAMADA Y, 1991, CANCER RES, V51, P5800	47	288	291	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					1989	1997						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408139				2022-12-28	WOS:A1992JP42400012
J	ESPINO, PC; CHOU, WY; SMITH, AE; CHENG, SH				ESPINO, PC; CHOU, WY; SMITH, AE; CHENG, SH			THE AMINO-TERMINAL HALF OF PP59C-FYN CONTAINS SEQUENCES NECESSARY FOR FORMATION OF A 75KDA FORM AND ALSO REPRESSIVE ELEMENTS ABSENT IN PP60C-SRC	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASES; MIDDLE-T-ANTIGEN; SIGNAL TRANSDUCTION; REGULATORY DOMAIN; COMPLEX-FORMATION; CARBOXY TERMINUS; PHOSPHOLIPASE-C; GENE-PRODUCT; SRC; PHOSPHORYLATION	Members of the src family of tyrosine kinases are composed of amino acid sequences which can be divided into three regions: the unique amino-terminal 80 residues; the next 180 residues of conserved but non-catalytic sequence; and the catalytic carboxy-terminal half of the molecule. To characterize the elements that regulate the catalytic and transforming activities of two members of this family, pp59c-fyn and pp60c-src, we generated six chimeric proteins by interchanging the three regions of the 531F mutant of pp59c-fyn and of the 527F mutant of pp60c-src. Our data indicate that substituting all or part of the amino-terminal 263 residues of pp59c-fyn for those of 527F inhibited the kinase and transforming activities of 527F. Conversely, substituting the amino-terminal half of pp60c-src for that of 531F resulted in an increase in the transforming potential of 531F. These results suggest that the amino-terminal half of pp59c-fyn contains elements which act to suppress the catalytic and transforming activities of the enzyme and that these suppressive elements are either absent or inactive in pp60c-src. These differences argue that the src family of tyrosine kinases are regulated differently in the cell. In vitro translation of some of the chimeras in rabbit reticulocyte lysates generated a 75kDa protein in addition to the expected 59kDa product. This 75kDa species is analogous to the p75 protein previously detected in wild-type pp59c-fyn translation products. Interestingly, formation of p75 required the presence of DNA sequences encoding the unique amino-terminal residues of pp59c-fyn.			ESPINO, PC (corresponding author), GENZYME CORP,CELLULAR REGULAT LAB,1 MT RD,FRAMINGHAM,MA 01701, USA.		Cheng, Seng H/AAC-6564-2022		NATIONAL CANCER INSTITUTE [P01CA050661, R01CA043186] Funding Source: NIH RePORTER; NCI NIH HHS [CA43186, CA50661] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; CHENG SH, 1988, MOL CELL BIOL, V8, P1736, DOI 10.1128/MCB.8.4.1736; CHENG SH, 1991, J VIROL, V65, P170, DOI 10.1128/JVI.65.1.170-179.1991; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; ESPINO PC, 1990, ONCOGENE, V5, P283; HARVEY R, 1989, MOL CELL BIOL, V9, P3647, DOI 10.1128/MCB.9.9.3647; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PARSONS SJ, 1986, J VIROL, V59, P755, DOI 10.1128/JVI.59.3.755-758.1986; PAWSON T, 1988, ONCOGENE, V3, P491; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; POTTER H, 1991, ALZHEIMERS DISEASE B, P276; RUDD CE, 1990, IMMUNOL TODAY, V11, P400, DOI 10.1016/0167-5699(90)90159-7; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SAMUELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0	33	3	3	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1992	7	2					317	322						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1372400				2022-12-28	WOS:A1992HG98200017
J	SAXENA, A; ALI, IU				SAXENA, A; ALI, IU			INCREASED EXPRESSION OF GENES FROM GROWTH-FACTOR SIGNALING PATHWAYS IN GLIOBLASTOMA CELL-LINES	ONCOGENE			English	Article							MESSENGER RIBONUCLEIC-ACID; FACTOR-ALPHA; TRANSFORMED-CELLS; FACTOR RECEPTOR; BREAST-CANCER; DNA-SEQUENCE; FACTOR-BETA; FACTOR CDNA; AMPLIFICATION; RNAS	The concept of autocrine stimulation of cell proliferation postulates growth autonomy by acquisition of the ability to produce and respond to growth factors. Overproduction of several growth factors in a variety of human tumors and cell lines derived from these tumors has been reported. We have screened several cell lines derived from glioblastomas for anomalies in the expression of genes encoding transforming growth factor alpha (TGF-alpha), TGF-beta, basic fibroblast growth factor (bFGF) and its high-affinity receptor, flg. Compared with normal human brain tissue, we observed a generalized elevation in the levels of expression of these genes in glioblastoma cell lines and an SV40-transformed human astroglial cell line. Overexpression of these genes does not appear to be merely a reflection of the proliferative state of transformed cells since some other human tumor cell lines, when analysed for the expression of TGF-beta and bFGF, did not show a significant increase in these transcripts. The specificity of the elevated transcription of TGF-alpha, TGF-beta, bFGF and flg in glioblastoma cell lines is further suggested by the fact that the transcription of the proto-oncogene c-erbB2, which is overproduced in breast tumor cell lines, was not elevated in glioblastoma cell lines. Increased expression of growth factors, which are potent mitogens and angiogens, and/or their receptors may have critical roles in autonomous proliferation as well as neovascularization of glioblastomas.	NINCDS,SURG NEUROL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)								ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; ALI IU, 1989, ONCOGENE, V4, P89; ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; BATES SE, 1988, MOL ENDOCRINOL, V2, P543, DOI 10.1210/mend-2-6-543; BIARD A, 1987, BIOCHEM BIOPH RES CO, V142, P428; BLAM SB, 1988, ONCOGENE, V3, P129; BREM S, 1972, J NATL CANCER I, V48, P347; CLARK GM, 1991, CANCER RES, V51, P944; DERYNCK R, 1987, CANCER RES, V47, P707; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1988, AM J PATHOL, V130, P393; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; KERBEL RS, 1991, BIOESSAYS, V13, P31, DOI 10.1002/bies.950130106; KERNOHAN JW, 1952, ATLAS TUMOR PATHOLOG; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KINZLER KW, 1986, P NATL ACAD SCI USA, V83, P1031, DOI 10.1073/pnas.83.4.1031; KRAUS MH, 1989, CANCER CEL, V7, P303; KUROKAWA T, 1987, FEBS LETT, V213, P189, DOI 10.1016/0014-5793(87)81489-8; MAJOR EO, 1985, P NATL ACAD SCI USA, V82, P1257, DOI 10.1073/pnas.82.4.1257; MAXWELL M, 1991, CANCER RES, V51, P1345; MURPHY PR, 1988, MOL ENDOCRINOL, V2, P591, DOI 10.1210/mend-2-7-591; MYELLO JH, 1988, PROSTATE, V13, P241; NEUFELD G, 1988, J CELL BIOL, V106, P1385, DOI 10.1083/jcb.106.4.1385; NISTER M, 1988, CANCER RES, V48, P3910; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; RUSHDI A, 1983, SCIENCE, V222, P390; Russell D., 1989, PATHOLOGY TUMORS NER; SANETO RP, 1985, DEV NEUROSCI-BASEL, V7, P340, DOI 10.1159/000112301; SASADA R, 1988, MOL CELL BIOL, V8, P588, DOI 10.1128/MCB.8.2.588; SCHIMKE RT, 1984, CELL, V37, P705, DOI 10.1016/0092-8674(84)90406-9; SCHLEGEL U, 1990, ONCOGENE, V5, P1839; Sporn M B, 1987, Important Adv Oncol, P75; STERNFELD MD, 1988, J CELL PHYSIOL, V136, P297, DOI 10.1002/jcp.1041360212; TAKAHASHI JA, 1991, BIOCHEM BIOPH RES CO, V177, P1, DOI 10.1016/0006-291X(91)91939-A; TAKAHASHI JA, 1990, P NATL ACAD SCI USA, V87, P5710, DOI 10.1073/pnas.87.15.5710; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; WEIBEL M, 1985, INT J DEV NEUROSCI, V3, P617, DOI 10.1016/0736-5748(85)90052-8; WESTERMARK B, 1973, INT J CANCER, V12, P438, DOI 10.1002/ijc.2910120215; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; ZAGZAG D, 1990, CANCER RES, V50, P7393	47	46	47	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1992	7	2					243	247						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1347915				2022-12-28	WOS:A1992HG98200006
J	Cobo, NL; Sibinelli-Sousa, S; Biboy, J; Vollmer, W; Bayer-Santos, E; Prehna, G				Cobo, Neil Lorente; Sibinelli-Sousa, Stephanie; Biboy, Jacob; Vollmer, Waldemar; Bayer-Santos, Ethel; Prehna, Gerd			Molecular characterization of the type VI secretion system effector Tlde1a reveals a structurally altered fold	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDOGLYCAN STRUCTURE; PROTEIN; BIOSYNTHESIS; FEATURES	The type VI secretion system (T6SS) is a molecular machine that Gram-negative bacteria have adapted for multiple func-tions, including interbacterial competition. Bacteria use the T6SS to deliver protein effectors into adjacent cells to kill rivals and establish niche dominance. Central to T6SS-mediated bacterial competition is an arms race to acquire diverse effec-tors to attack and neutralize target cells. The peptidoglycan has a central role in bacterial cell physiology, and effectors that biochemically modify peptidoglycan structure effectively induce cell death. One such T6SS effector is Tlde1a from Salmonella Typhimurium. Tlde1a functions as an LD-carboxypeptidase to cleave tetrapeptide stems and as an LD-transpeptidase to exchange the terminal D-alanine of a tetrapeptide stem with a noncanonical D-amino acid. To un-derstand how Tlde1a exhibits toxicity at the molecular level, we determined the X-ray crystal structure of Tlde1a alone and in complex with D-amino acids. Our structural data revealed that Tlde1a possesses a unique LD-transpeptidase fold consisting of a dual pocket active site with a capping subdomain. This in-cludes an exchange pocket to bind a D-amino acid for exchange and a catalytic pocket to position the D-alanine of a tetrapeptide stem for cleavage. Our toxicity assays in Escherichia coli and in vitro peptidoglycan biochemical assays with Tlde1a variants correlate Tlde1a molecular features directly to its biochemical functions. We observe that the LD-carboxypeptidase and LD-transpeptidase activities of Tlde1a are both structurally and functionally linked. Overall, our data highlight how an LD-transpeptidase fold has been structurally altered to create a toxic effector in the T6SS arms race.	[Cobo, Neil Lorente; Prehna, Gerd] Univ Manitoba, Dept Microbiol, Winnipeg, MB, Canada; [Sibinelli-Sousa, Stephanie; Bayer-Santos, Ethel] Univ Sao Paulo, Biomed Sci Inst, Dept Microbiol, Sao Paulo, Brazil; [Biboy, Jacob; Vollmer, Waldemar] Newcastle Univ, Biosci Inst, Ctr Bacterial Cell Biol, Newcastle Upon Tyne, England	University of Manitoba; Universidade de Sao Paulo; Newcastle University - UK	Prehna, G (corresponding author), Univ Manitoba, Dept Microbiol, Winnipeg, MB, Canada.	gerd.prehna@umanitoba.ca		Sibinelli de Sousa, Stephanie/0000-0003-4875-8737; Prehna, Gerd/0000-0001-5539-7533; Lorente Cobo, Neil/0000-0001-5783-8988; Bayer-Santos, Ethel/0000-0003-3832-3449	Natural Sciences and Engineering Research Council of Canada (NSERC) [RGPIN-2018-04968]; Canadian Foundation for Innovation award (CFI) [37841]; UKRI Strategic Priorities Fund [EP/T002778/1]; Sao Paulo Research Foundation [2017/02178-2]; FAPESP Fellowship [2021/09162-0]	Natural Sciences and Engineering Research Council of Canada (NSERC)(Natural Sciences and Engineering Research Council of Canada (NSERC)); Canadian Foundation for Innovation award (CFI); UKRI Strategic Priorities Fund(UK Research & Innovation (UKRI)); Sao Paulo Research Foundation(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); FAPESP Fellowship(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	This work was supported by the Natural Sciences and Engineering Research Council of Canada (NSERC) grants RGPIN-2018-04968 to G. P. and a Canadian Foundation for Innovation award (CFI) 37841 to G. P. This research was also funded by the UKRI Strategic Priorities Fund (https:// www.ukri.org) EP/T002778/1 to W. V. and a Sao Paulo Research Foundation grant 2017/02178-2 to E. B-S. Additionally, S.S.S. was funded by a FAPESP Fellowship (2021/09162-0) .	Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; Ahmad S, 2020, ELIFE, V9, DOI 10.7554/eLife.62816; Aliashkevich A, 2022, FEBS J, V289, P4718, DOI 10.1111/febs.16066; Allsopp LP, 2020, CELL MICROBIOL, V22, DOI 10.1111/cmi.13153; Ashkenazy H, 2016, NUCLEIC ACIDS RES, V44, pW344, DOI 10.1093/nar/gkw408; Basler M, 2013, CELL, V152, P884, DOI 10.1016/j.cell.2013.01.042; Bayer-Santos E, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007651; Blondel CJ, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-354; Boyer F, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-104; Bui NK, 2009, J BACTERIOL, V191, P494, DOI 10.1128/JB.00608-08; Catherwood AC, 2020, J AM CHEM SOC, V142, P5034, DOI 10.1021/jacs.9b08822; Caveney NA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09507-0; Chou S, 2012, CELL REP, V1, P656, DOI 10.1016/j.celrep.2012.05.016; Chow J, 2010, CELL HOST MICROBE, V7, P265, DOI 10.1016/j.chom.2010.03.004; Cianfanelli FR, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005735; DeShazer D, 2019, MICROBIOL RES, V226, P48, DOI 10.1016/j.micres.2019.05.007; Durand E, 2015, NATURE, V523, P555, DOI 10.1038/nature14667; Egan AJF, 2018, MOL MICROBIOL, V110, P335, DOI 10.1111/mmi.14082; Egan AJF, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2015.0031; Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493; English G, 2012, MOL MICROBIOL, V86, P921, DOI 10.1111/mmi.12028; Flaugnatti N, 2020, EMBO J, V39, DOI 10.15252/embj.2019104129; GLAUNER B, 1988, ANAL BIOCHEM, V172, P451, DOI 10.1016/0003-2697(88)90468-X; Grosdidier A, 2011, NUCLEIC ACIDS RES, V39, pW270, DOI 10.1093/nar/gkr366; Grosdidier A, 2011, J COMPUT CHEM, V32, P2149, DOI 10.1002/jcc.21797; Hachani A, 2016, CURR OPIN MICROBIOL, V29, P81, DOI 10.1016/j.mib.2015.11.006; Han YY, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1008198; Hanwell MD, 2012, J CHEMINFORMATICS, V4, DOI 10.1186/1758-2946-4-17; Hernandez SB, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107578; Holm L, 2020, METHODS MOL BIOL, V2112, P29, DOI 10.1007/978-1-0716-0270-6_3; Jana B, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11546-6; Jiang F, 2014, CELL HOST MICROBE, V15, P600, DOI 10.1016/j.chom.2014.04.010; Jurenas D, 2021, NUCLEIC ACIDS RES, V49, P8384, DOI 10.1093/nar/gkab608; Jurenas D, 2021, MOL MICROBIOL, V115, P383, DOI 10.1111/mmi.14648; Jurrus E, 2018, PROTEIN SCI, V27, P112, DOI 10.1002/pro.3280; Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337; Kim HS, 2015, J BIOL CHEM, V290, P25103, DOI 10.1074/jbc.M115.658781; Kim HS, 2013, ACTA CRYSTALLOGR D, V69, P420, DOI 10.1107/S0907444912048998; Kudryashev M, 2015, CELL, V160, P952, DOI 10.1016/j.cell.2015.01.037; Kuru E, 2019, ACS CHEM BIOL, V14, P2745, DOI 10.1021/acschembio.9b00664; Kuru E, 2017, NAT MICROBIOL, V2, P1648, DOI 10.1038/s41564-017-0029-y; Lovering AL, 2012, ANNU REV BIOCHEM, V81, P451, DOI 10.1146/annurev-biochem-061809-112742; Ma AT, 2010, P NATL ACAD SCI USA, V107, P4365, DOI 10.1073/pnas.0915156107; Feria JM, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.584751; Mulder DT, 2012, INFECT IMMUN, V80, P1996, DOI 10.1128/IAI.06205-11; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Painter J, 2006, J APPL CRYSTALLOGR, V39, P109, DOI 10.1107/S0021889805038987; Park YJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07796-5; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Pettersen EF, 2021, PROTEIN SCI, V30, P70, DOI 10.1002/pro.3943; Pissaridou P, 2018, P NATL ACAD SCI USA, V115, P12519, DOI 10.1073/pnas.1814181115; Quentin D, 2018, NAT MICROBIOL, V3, P1142, DOI 10.1038/s41564-018-0238-z; Renault MG, 2018, J MOL BIOL, V430, P3143, DOI 10.1016/j.jmb.2018.07.018; Russe AB, 2012, CELL HOST MICROBE, V11, P538, DOI 10.1016/j.chom.2012.04.007; Russell AB, 2014, NAT REV MICROBIOL, V12, P137, DOI 10.1038/nrmicro3185; Russell AB, 2011, NATURE, V475, P343, DOI 10.1038/nature10244; Santin YG, 2018, NAT MICROBIOL, V3, P1304, DOI 10.1038/s41564-018-0234-3; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Si MR, 2017, P NATL ACAD SCI USA, V114, pE2233, DOI 10.1073/pnas.1614902114; Sibinelli-Sousa S, 2022, FEBS J, V289, P4192, DOI 10.1111/febs.16211; Sibinelli-Sousa S, 2021, J BACTERIOL, V203, DOI 10.1128/JB.00478-20; Sibinelli-Sousa S, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107813; Souza DP, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7453; Sycuro LK, 2013, MOL MICROBIOL, V90, P869, DOI 10.1111/mmi.12405; Tipping MJ, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007885; Typas A, 2012, NAT REV MICROBIOL, V10, P123, DOI 10.1038/nrmicro2677; Nguyen VS, 2018, CURR OPIN STRUC BIOL, V49, P77, DOI 10.1016/j.sbi.2018.01.007; Verster AJ, 2017, CELL HOST MICROBE, V22, P411, DOI 10.1016/j.chom.2017.08.010; Vollmer W, 2008, BBA-BIOMEMBRANES, V1778, P1714, DOI 10.1016/j.bbamem.2007.06.007; Vollmer W, 2008, FEMS MICROBIOL REV, V32, P149, DOI 10.1111/j.1574-6976.2007.00094.x; Wang TT, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005020; Wenren LM, 2013, MBIO, V4, DOI 10.1128/mBio.00374-13; Whitney JC, 2015, CELL, V163, P607, DOI 10.1016/j.cell.2015.09.027; Whitney JC, 2013, J BIOL CHEM, V288, P26616, DOI 10.1074/jbc.M113.488320; Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749; Wood TE, 2019, CELL REP, V29, P187, DOI 10.1016/j.celrep.2019.08.094	77	0	0	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV	2022	28	11							102556	10.1016/j.jbc.2022.102556	http://dx.doi.org/10.1016/j.jbc.2022.102556			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	6I4GS	36183829	Green Published, gold, Green Submitted			2022-12-28	WOS:000886086000011
J	Ki, N; Kim, J; Jo, I; Hyun, Y; Ryu, S; Ha, NC				Ki, Nayeon; Kim, Jinshil; Jo, Inseong; Hyun, Yongseong; Ryu, Sangryeol; Ha, Nam-Chul			Isocitrate binds to the itaconic acid-responsive LysR-type transcriptional regulator RipR in Salmonella pathogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; PATHWAY; GENE; CATABOLISM	Macrophages produce itaconic acid in phagosomes in response to bacterial cell wall component lipopolysaccharide to eliminate invading pathogenic bacteria. Itaconic acid compet-itively inhibits the first enzyme of the bacterial glyoxylate cycle. To overcome itaconic acid stress, bacteria employ the bacterial LysR-type transcriptional regulator RipR. However, it remains unknown which molecule activates RipR in bacterial patho-genesis. In this study, we determined the crystal structure of the regulatory domain of RipR from the intracellular pathogen Salmonella. The RipR regulatory domain structure exhibited the typical dimeric arrangement with the putative ligand-binding site between the two subdomains. Our isothermal titration calorimetry experiments identified isocitrate as the physiological ligand of RipR, whose intracellular level is increased in response to itaconic acid stress. We further found that 3-phenylpropionic acid significantly decreased the resis-tance of the bacteria to an itaconic acid challenge. Consistently, the complex structure revealed that the compound is antago-nistically bound to the RipR ligand-binding site. This study provides the molecular basis of bacterial survival in itaconic acid stress from our immune systems. Further studies are required to reveal biochemical activity, which would elucidate how Salmonella survives in macrophage phagosomes by defending against itaconic acid inhibition of bacterial metabolism.	[Ki, Nayeon; Kim, Jinshil; Jo, Inseong; Hyun, Yongseong; Ryu, Sangryeol; Ha, Nam-Chul] Seoul Natl Univ, Dept Food & Anim Biotechnol, Dept Agr Biotechnol, Seoul, South Korea; [Ki, Nayeon; Kim, Jinshil; Jo, Inseong; Hyun, Yongseong; Ryu, Sangryeol; Ha, Nam-Chul] Seoul Natl Univ, Res Inst Agr & Life Sci, Seoul, South Korea; [Ki, Nayeon; Kim, Jinshil; Jo, Inseong; Hyun, Yongseong; Ryu, Sangryeol; Ha, Nam-Chul] Sejong Univ, Ctr Food & Bioconvergence, Seoul 05006, South Korea; [Kim, Jinshil] Sejong Univ, Dept Food Sci & Biotechnol, Seoul 05006, South Korea; [Kim, Jinshil] Sejong Univ, Carbohydrate Bioprod Res Ctr, Seoul 05006, South Korea	Seoul National University (SNU); Seoul National University (SNU); Sejong University; Sejong University; Sejong University	Ryu, S; Ha, NC (corresponding author), Seoul Natl Univ, Dept Food & Anim Biotechnol, Dept Agr Biotechnol, Seoul, South Korea.; Ryu, S; Ha, NC (corresponding author), Seoul Natl Univ, Res Inst Agr & Life Sci, Seoul, South Korea.; Ryu, S; Ha, NC (corresponding author), Sejong Univ, Ctr Food & Bioconvergence, Seoul 05006, South Korea.	sangryu@snu.ac.kr; hanc210@snu.ac.kr		Hyun, Yongseong/0000-0002-4731-8492	Korea Institute of Planning and Evaluation for Technology in Food, Agriculture and Forestry (IPET) through the High Value-added Food Technology Development Program - Ministry of Agriculture, Food and Rural Affairs (MAFRA) [321036052HD020]; Bio & Medical Technology Development Program of the National Research Foundation (NRF) - Ministry of Science ICT [2019M3E5D6063871]; Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education [2022R1A6A1A03055869]; Ministry of Food and Drug Safety [20162MFDS142]	Korea Institute of Planning and Evaluation for Technology in Food, Agriculture and Forestry (IPET) through the High Value-added Food Technology Development Program - Ministry of Agriculture, Food and Rural Affairs (MAFRA)(Ministry of Agriculture, Food & Rural Affairs (MAFRA), Republic of KoreaInstitute of Planning & Evaluation for Technology in Food, Agriculture, Forestry, & Fisheries (iPET), Republic of Korea); Bio & Medical Technology Development Program of the National Research Foundation (NRF) - Ministry of Science ICT(National Research Foundation of KoreaMinistry of Science, ICT & Future Planning, Republic of Korea); Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education(National Research Foundation of KoreaMinistry of Education (MOE), Republic of KoreaNational Research Council for Economics, Humanities & Social Sciences, Republic of Korea); Ministry of Food and Drug Safety(Ministry of Food & Drug Safety (MFDS), Republic of Korea)	These works were supported by the Korea Institute of Planning and Evaluation for Technology in Food, Agriculture and Forestry (IPET) through the High Value-added Food Technology Development Program funded by the Ministry of Agriculture, Food and Rural Affairs (MAFRA) (No. 321036052HD020 to N.-C. H.) . This research was supported by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) , which is funded by the Ministry of Science & ICT (2019M3E5D6063871 to N.-C. H.) . This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2022R1A6A1A03055869 to J. K.) . This research was supported by a grant (20162MFDS142 to S. R.) from Ministry of Food and Drug Safety in 2022.	Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; Api A. M., 2019, FOOD CHEM TOXICOL, V134; Barnes MR, 1997, J BACTERIOL, V179, P6145, DOI 10.1128/jb.179.19.6145-6153.1997; Basler T, 2006, J LEUKOCYTE BIOL, V79, P628, DOI 10.1189/jlb.0905520; Bintsis T, 2017, AIMS MICROBIOL, V3, P529, DOI 10.3934/microbiol.2017.3.529; BURLINGAME R, 1983, J BACTERIOL, V155, P113, DOI 10.1128/JB.155.1.113-121.1983; C. L. M. Gilchrist, 2022, bioRxiv, DOI 10.1101/2022.02.07.479398; Chew S. Y., 2021, ENCY MYCOLOGY, P220; Chew SY, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929-019-0546-5; Choi HJ, 2001, CELL, V105, P103, DOI 10.1016/S0092-8674(01)00300-2; Coelho C, 2022, PLOS PATHOG, V18, DOI 10.1371/journal.ppat.1010361; Cordes T, 2015, ANNU REV NUTR, V35, P451, DOI 10.1146/annurev-nutr-071714-034243; Craven SH, 2009, MOL MICROBIOL, V72, P881, DOI 10.1111/j.1365-2958.2009.06686.x; Cronan John E Jr, 2005, EcoSal Plus, V1, DOI 10.1128/ecosalplus.3.5.2; Dallakyan S, 2015, METHODS MOL BIOL, V1263, P243, DOI 10.1007/978-1-4939-2269-7_19; David S, 2011, NAT REV NEUROSCI, V12, P388, DOI 10.1038/nrn3053; Degrandi D, 2009, J INTERF CYTOK RES, V29, P55, DOI 10.1089/jir.2008.0013; Diaz E, 1998, J BACTERIOL, V180, P2915; Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493; Gautam A, 2011, INFECT IMMUN, V79, P4876, DOI 10.1128/IAI.05451-11; HASSETT DJ, 1989, FASEB J, V3, P2574, DOI 10.1096/fasebj.3.14.2556311; Hersch SJ, 2020, INFECT IMMUN, V88, DOI 10.1128/IAI.00303-20; Hess B, 2008, J CHEM THEORY COMPUT, V4, P435, DOI 10.1021/ct700301q; Huang J, 2017, NAT METHODS, V14, P71, DOI [10.1038/NMETH.4067, 10.1038/nmeth.4067]; Jo I, 2019, P NATL ACAD SCI USA, V116, P3740, DOI 10.1073/pnas.1811509116; Jo I, 2017, J BIOL CHEM, V292, P7223, DOI 10.1074/jbc.M116.743765; Jo I, 2015, P NATL ACAD SCI USA, V112, P6443, DOI 10.1073/pnas.1424495112; Jo S, 2008, J COMPUT CHEM, V29, P1859, DOI 10.1002/jcc.20945; Jumper J, 2021, NATURE, V596, P583, DOI 10.1038/s41586-021-03819-2; Lahiri A, 2009, INT J BIOCHEM CELL B, V41, P2129, DOI 10.1016/j.biocel.2009.05.006; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; Lorenz MC, 2001, NATURE, V412, P83, DOI 10.1038/35083594; M. Mirdita, 2021, bioRxiv, DOI 10.1101/2021.08.15.456425; Maddocks SE, 2008, MICROBIOL-SGM, V154, P3609, DOI 10.1099/mic.0.2008/022772-0; Mahounga DM, 2018, ACTA CRYSTALLOGR F, V74, P506, DOI 10.1107/S2053230X18008841; Manso I, 2009, J BIOL CHEM, V284, P21218, DOI 10.1074/jbc.M109.008243; MCFADDEN BA, 1977, J BACTERIOL, V131, P136, DOI 10.1128/JB.131.1.136-144.1977; Menage S, 2014, NAT CHEM BIOL, V10, P326, DOI 10.1038/nchembio.1505; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pronk S, 2013, BIOINFORMATICS, V29, P845, DOI 10.1093/bioinformatics/btt055; Ren J, 2015, APPL ENVIRON MICROB, V81, P5675, DOI 10.1128/AEM.01009-15; Sasikaran J, 2014, NAT CHEM BIOL, V10, P371, DOI 10.1038/nchembio.1482; Tangsudjai S, 2010, MICROBIOL IMMUNOL, V54, P282, DOI 10.1111/j.1348-0421.2010.00205.x; Taylor JL, 2012, MOL MICROBIOL, V83, P457, DOI 10.1111/j.1365-2958.2011.07919.x; Thomas DM, 2005, FASEB J, V19, P515, DOI 10.1096/fj.05-4873fje; Uzzau S, 2000, EPIDEMIOL INFECT, V125, P229, DOI 10.1017/S0950268899004379; Vagin A, 2010, ACTA CRYSTALLOGR D, V66, P22, DOI 10.1107/S0907444909042589; Varadi M, 2022, NUCLEIC ACIDS RES, V50, pD439, DOI 10.1093/nar/gkab1061; Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749	49	0	0	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV	2022	298	11							102562	10.1016/j.jbc.2022.102562	http://dx.doi.org/10.1016/j.jbc.2022.102562			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	6C7OU	36198361	Green Published, gold			2022-12-28	WOS:000882199400006
J	STEUER, B; STOPPLER, H; BREUER, B; ALONSO, A				STEUER, B; STOPPLER, H; BREUER, B; ALONSO, A			TRANSCRIPTION OF BPV-1 GENES IN TRANSFECTED F9 CELLS	ONCOGENE			English	Article							BOVINE PAPILLOMAVIRUS TYPE-1; MURINE TERATOCARCINOMA CELLS; EMBRYONAL CARCINOMA-CELLS; STEM-CELLS; DNA; DIFFERENTIATION; EXPRESSION; KERATINOCYTES; ANTIGEN; INVITRO	In F9 cells transformed with bovine papillomavirus type 1 (BPV-1) sequences two different phenotypes can be recognized. One cell type shows the characteristics of the parental stem cell line, whereas the other comprises cells with spindle-like morphology that do not adhere to each other, similar to retinoic acid-treated F9 embryonal carcinoma cells. The phenotypically altered cells plate more efficiently than the stem cells, grow well in soft agar and show an extended lifespan in the differentiated stage. Both types of cells contain BPV-1 DNA sequences as episomes, but only the non-stem-like cells have RNA transcripts for the unspliced E5 reading frame as well as for the spliced E6/E4.	GERMAN CANC RES CTR,NEUENHEIMER FELD 280,W-6900 HEIDELBERG 1,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ)								BREUER B, 1989, GENE, V81, P307, DOI 10.1016/0378-1119(89)90191-1; DURST M, 1987, ONCOGENE, V1, P251; Hogan B. L. M, 1983, CANCER SURV, V2, P115; LAMBERT PF, 1988, ANNU REV GENET, V22, P235, DOI 10.1146/annurev.ge.22.120188.001315; LAW MF, 1981, P NATL ACAD SCI-BIOL, V78, P2727, DOI 10.1073/pnas.78.5.2727; LEVINE RA, 1984, MOL CELL BIOL, V4, P2142, DOI 10.1128/MCB.4.10.2142; LINNENBACH A, 1980, P NATL ACAD SCI-BIOL, V77, P4875, DOI 10.1073/pnas.77.8.4875; MCCANCE DJ, 1988, P NATL ACAD SCI USA, V85, P7169, DOI 10.1073/pnas.85.19.7169; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; ROSENSTRAUS MJ, 1982, DEV BIOL, V89, P516, DOI 10.1016/0012-1606(82)90340-2; SCHILLER JT, 1984, P NATL ACAD SCI-BIOL, V81, P7880, DOI 10.1073/pnas.81.24.7880; SCHILLER JT, 1986, J VIROL, V57, P1; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; STEWART CL, 1982, P NATL ACAD SCI-BIOL, V79, P4098, DOI 10.1073/pnas.79.13.4098; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; SWARTZENDRUBER DE, 1975, J CELL PHYSIOL, V85, P179, DOI 10.1002/jcp.1040850204; TIENARI J, 1987, DEV BIOL, V123, P566, DOI 10.1016/0012-1606(87)90415-5; YANG YC, 1985, P NATL ACAD SCI USA, V82, P1030, DOI 10.1073/pnas.82.4.1030	18	1	1	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1875	1878						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1323821				2022-12-28	WOS:A1992JJ37600025
J	OTTILIE, S; RAULF, F; BARNEKOW, A; HANNIG, G; SCHARTL, M				OTTILIE, S; RAULF, F; BARNEKOW, A; HANNIG, G; SCHARTL, M			MULTIPLE SRC-RELATED KINASE GENES, SRK1-4, IN THE FRESH-WATER SPONGE SPONGILLA-LACUSTRIS	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASE; AMINO-ACID SEQUENCE; ONCOGENE C-SRC; NUCLEOTIDE-SEQUENCE; MESSENGER-RNA; EXPRESSION; PP60C-SRC; CELLS; PRODUCT; DNA	In one of the simplest metazoan organisms, the sponge Spongilla lacustris, at least four different src-related kinase genes (srk1-4) are expressed, all of which show a high degree of similarity to the c-src genes of vertebrates. Whereas srk2 and srk3 are clearly unrelated at the nucleic acid level, srk1 and srk4 share identical sequences in the 5' parts of their cDNAs. The cloning of several primer extension clones and genomic polymerase chain reaction experiments confirmed the hypothesis of an alternative splicing of tandemly arranged carboxy-terminal parts of srk1 and srk4. The genomic sequence encoding both proteins was found to be interrupted at the splice point by an intron which is located in the same position as one of the introns in the chicken src gene, which is the only gene conserved in invertebrates and vertebrates. All four srk genes are expressed in adult sponges as mRNA transcripts of about 2.2 kb. Tyrosine kinase activity of a src-related kinase could be detected in adult sponges but not in their resting form (gemmulae), and may reflect the activity of the srk protein products. Spongilla lacustris is the simplest organism from which a protein tyrosine kinase gene has been isolated. The presence of at least four such genes in the evolutionary ancient and primitive phylum Porifera suggests that tyrosine kinase genes arose concomitantly with or shortly after the appearance of multicellular organisms and that their activity may be involved in aggregation and cell-cell recognition.	MAX PLANCK INST BIOCHEM, GENECTR, KLOPFERSPITZ 18A, W-8033 MARTINSRIED, GERMANY; UNIV MUNSTER, DEPT EXPTL TUMORBIOL, W-4400 MUNSTER, GERMANY	Max Planck Society; University of Munster				Schartl, Manfred/0000-0001-9882-5948				ANDERSON SK, 1985, MOL CELL BIOL, V5, P1122, DOI 10.1128/MCB.5.5.1122; BARNEKOW A, 1984, MOL CELL BIOL, V4, P1179, DOI 10.1128/MCB.4.6.1179; BARNEKOW A, 1990, ONCOGENE, V5, P1019; BARNEKOW A, 1989, Critical Reviews in Oncogenesis, V1, P277; BOSCH TCG, 1989, MOL CELL BIOL, V9, P4141, DOI 10.1128/MCB.9.10.4141; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; DAVIS LG, 1986, BASIC METHODS MOL BI, P133; DELORBE WJ, 1980, J VIROL, V36, P50, DOI 10.1128/JVI.36.1.50-61.1980; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; GREGORY RJ, 1987, MOL CELL BIOL, V7, P2119, DOI 10.1128/MCB.7.6.2119; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANNIG G, 1991, ONCOGENE, V6, P361; HIRSCHBEHNAM A, 1988, COMP BIOCHEM PHYS B, V91, P125, DOI 10.1016/0305-0491(88)90123-X; HOFFMANN FM, 1983, CELL, V35, P393, DOI 10.1016/0092-8674(83)90172-1; KATAMINE S, 1988, MOL CELL BIOL, V8, P259, DOI 10.1128/MCB.8.1.259; KAWAKAMI T, 1986, MOL CELL BIOL, V6, P4195, DOI 10.1128/MCB.6.12.4195; KOCHER TD, 1989, P NATL ACAD SCI USA, V86, P6196, DOI 10.1073/pnas.86.16.6196; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; MANESS PF, 1986, J NEUROSCI RES, V16, P127, DOI 10.1002/jnr.490160113; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MULLER WEG, 1976, EXP CELL RES, V98, P31, DOI 10.1016/0014-4827(76)90459-6; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; PARKER RC, 1985, MOL CELL BIOL, V5, P831, DOI 10.1128/MCB.5.4.831; PYPER JM, 1989, J NEUROSCI RES, V24, P89, DOI 10.1002/jnr.490240113; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; Rasmont R., 1975, Transactions Congr int Un Game Biol, V10, P141; RAULF F, 1989, ONCOGENE RES, V5, P39; RAULF F, 1989, J NEUROSCI RES, V24, P81, DOI 10.1002/jnr.490240112; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHARTL M, 1982, DIFFERENTIATION, V23, P109, DOI 10.1111/j.1432-0436.1982.tb01273.x; SCHARTL M, 1989, ONCOGENE, V4, P1185; SCHARTL M, 1984, DEV BIOL, V105, P415, DOI 10.1016/0012-1606(84)90298-7; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; STEELE RE, 1989, J BIOL CHEM, V264, P10649; STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987; SUKEGAWA J, 1987, MOL CELL BIOL, V7, P41, DOI 10.1128/MCB.7.1.41; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; WANG LH, 1987, ONCOGENE RES, V1, P43; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	48	43	50	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1992	7	8					1625	1630						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1378585				2022-12-28	WOS:A1992JE81300019
J	LICHTENBERG, U; QUINTRELL, N; BISHOP, JM				LICHTENBERG, U; QUINTRELL, N; BISHOP, JM			HUMAN PROTEIN-TYROSINE KINASE GENE HCK - EXPRESSION AND STRUCTURAL-ANALYSIS OF THE PROMOTER REGION	ONCOGENE			English	Article							PROMYELOCYTIC LEUKEMIA-CELLS; SV40 T-ANTIGEN; HEMATOPOIETIC-CELLS; FGR PROTOONCOGENE; MAMMALIAN-CELLS; LCK GENE; DIFFERENTIATION; LINE; SEQUENCE; HL-60	The vertebrate gene HCK encodes a protein-tyrosine kinase that is closely related to the product of the proto-oncogene SRC. HCK is expressed principally in monocytic and granulocytic hematopoietic cells, in coordination with differentiation of these cells. Here we report an initial description of the mechanisms by which expression of human HCK is controlled. Induction of the gene during differentiation was manifested by an increase in the steady-state levels of HCK RNA and protein product. The accumulation of RNA apparently resulted from modulation of transcription itself, since no change occurred in the stability of the transcripts. Transcription initiated at multiple sites, clustered c. 145 nucleotides upstream of the first intron of HCK. The sequence of 660 bp upstream of the major initiation site was determined, revealing candidate binding sites for Sp1 and AP-2 transcription factors, but neither TATA nor CAAT elements. Comparison to the same region of the mouse hck locus showed five small regions of similarity, only two of which were topographically analogous between the two sequences. It appears that expression of HCK is regulated primarily through control of transcription, but the mechanisms by which tissue-specific expression and increase of transcription during differentiation are achieved remain to be explored.	UNIV CALIF SAN FRANCISCO, GEORGE WILLIAMS HOOPER FDN, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	LICHTENBERG, U (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA.				NATIONAL CANCER INSTITUTE [R35CA044338] Funding Source: NIH RePORTER; NCI NIH HHS [CA 44338] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM KM, 1991, J EXP MED, V173, P1421, DOI 10.1084/jem.173.6.1421; ADLER HT, 1988, J VIROL, V62, P4113, DOI 10.1128/JVI.62.11.4113-4122.1988; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; BARNEKOW A, 1986, EMBO J, V5, P701, DOI 10.1002/j.1460-2075.1986.tb04270.x; BERNARDS A, 1990, EMBO J, V9, P2279, DOI 10.1002/j.1460-2075.1990.tb07399.x; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BOLEN JB, 1989, TRENDS BIOCHEM SCI, V14, P404, DOI 10.1016/0968-0004(89)90288-0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; COLLINS SJ, 1980, INT J CANCER, V25, P213, DOI 10.1002/ijc.2910250208; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; COLLINS SJ, 1987, BLOOD, V70, P1233; COOKE M P, 1989, New Biologist, V1, P66; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; DALTON WT, 1988, BLOOD, V71, P242; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; GALLAGHER R, 1979, BLOOD, V54, P713; GARVIN AM, 1990, INT IMMUNOL, V2, P173, DOI 10.1093/intimm/2.2.173; GARVIN AM, 1988, MOL CELL BIOL, V8, P3058, DOI 10.1128/MCB.8.8.3058; GEE CE, 1986, P NATL ACAD SCI USA, V83, P5131, DOI 10.1073/pnas.83.14.5131; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HOLTZMAN DA, 1987, P NATL ACAD SCI USA, V84, P8325, DOI 10.1073/pnas.84.23.8325; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; LEY TJ, 1989, MOL CELL BIOL, V9, P92, DOI 10.1128/MCB.9.1.92; LOCK P, 1991, MOL CELL BIOL, V11, P4363, DOI 10.1128/MCB.11.9.4363; LOCK P, 1990, MOL CELL BIOL, V10, P4603, DOI 10.1128/MCB.10.9.4603; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MIKKO J, 1979, NATURE, V279, P605; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NOTARIO V, 1989, J CELL BIOL, V109, P3129, DOI 10.1083/jcb.109.6.3129; PATEL M, 1990, ONCOGENE, V5, P201; PERLMUTTER R M, 1988, Biochimica et Biophysica Acta, V948, P245; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SORGE LK, 1984, CELL, V36, P249, DOI 10.1016/0092-8674(84)90218-6; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; TAKADERA T, 1989, MOL CELL BIOL, V9, P2173, DOI 10.1128/MCB.9.5.2173; TARELLA C, 1982, CANCER RES, V42, P445; WILDIN RS, 1991, J EXP MED, V173, P383, DOI 10.1084/jem.173.2.383; WILLMAN CL, 1987, P NATL ACAD SCI USA, V84, P4480, DOI 10.1073/pnas.84.13.4480; WILLMAN CL, 1991, BLOOD, V77, P726; ZIEGLER SF, 1991, ONCOGENE, V6, P283; ZIEGLER SF, 1988, J EXP MED, V168, P1801, DOI 10.1084/jem.168.5.1801; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276; ZIEGLER SF, 1989, MOL CELL BIOL, V9, P2724, DOI 10.1128/MCB.9.6.2724; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	62	32	33	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1992	7	5					849	858						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1373873				2022-12-28	WOS:A1992HP64200003
J	METZ, T; GRAF, T				METZ, T; GRAF, T			THE NUCLEAR ONCOGENES V-ERBA AND V-ETS COOPERATE IN THE INDUCTION OF AVIAN ERYTHROLEUKEMIA	ONCOGENE			English	Article							THYROID-HORMONE RECEPTOR; CHICKEN ERYTHROID-CELLS; MONOCLONAL-ANTIBODIES; LEUKEMIA VIRUSES; MYELOID CELLS; GROWTH-FACTOR; PROTEIN; DIFFERENTIATION; TRANSFORMATION; GENE	The nuclear oncogenes v-erbA and v-ets are known to cooperate with other viral oncogenes in the induction of avian erythroleukemia. Thus, in the case of avian erythroblastosis virus (AEV), v-erbA enhances the effect of the tyrosine kinase-encoding v-erbB oncogene by blocking the terminal differentiation of erythroid cells. In the case of E26 virus a fusion of the product from v-ets to that of the nuclear oncogene v-myb is a prerequisite for leukemogenicity. Here we show that an artificial virus carrying both v-erbA and v-ets induces a rapid, acute erythroleukemia phenotypically similar to that induced by AEV. In contrast, virus constructs containing either v-erbA or v-ets alone are non-leukemogenic, although they are capable of transforming erythroid cells in vitro. Analysis of in vitro-transformed cells showed that v-erbA induces a block of differentiation without abrogating dependence on anemic serum, while v-ets predominantly causes anemic serum independence. As expected, cells transformed by both oncogenes exhibit an increased proliferative potential, are blocked in differentiation and are anemic serum independent. These data demonstrate that two separately expressed nuclear oncoproteins can complement each other in vitro and in vivo. They also show that the v-Ets protein on its own can contribute to leukemogenesis.			METZ, T (corresponding author), EUROPEAN MOLEC BIOL LAB, DIFFERENTIAT PROGRAMME, POSTFACH 102209, W-6900 HEIDELBERG, GERMANY.		Graf, Thomas/B-4252-2015	Graf, Thomas/0000-0003-2774-4117				BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BEUG H, 1982, J CELL PHYSIOL, P195; BEUG H, 1989, EUR J CLIN INVEST, V19, P491, DOI 10.1111/j.1365-2362.1989.tb00265.x; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BIGLER J, 1988, MOL CELL BIOL, V8, P4155, DOI 10.1128/MCB.8.10.4155; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; Frykberg L, 1988, Oncogene Res, V3, P313; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GOLDBERG Y, 1988, EMBO J, V7, P2425, DOI 10.1002/j.1460-2075.1988.tb03088.x; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GRAF T, 1986, CELL, V45, P357, DOI 10.1016/0092-8674(86)90321-1; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HENTZEN D, 1987, MOL CELL BIOL, V7, P2416, DOI 10.1128/MCB.7.7.2416; JANSSON M, 1987, ONCOGENE, V1, P167; KAHN P, 1984, P NATL ACAD SCI-BIOL, V81, P7122, DOI 10.1073/pnas.81.22.7122; KAHN P, 1986, CELL, V45, P349, DOI 10.1016/0092-8674(86)90320-X; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KORNFELD S, 1983, EXP CELL RES, V143, P383, DOI 10.1016/0014-4827(83)90065-4; KRIS RM, 1985, CELL, V40, P619, DOI 10.1016/0092-8674(85)90210-7; LAI MMC, 1980, VIROLOGY, V100, P475, DOI 10.1016/0042-6822(80)90537-1; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; METZ T, 1991, EMBO J, V10, P837, DOI 10.1002/j.1460-2075.1991.tb08016.x; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; NESS SA, 1987, CELL, V51, P41, DOI 10.1016/0092-8674(87)90008-0; ORKIN SH, 1975, P NATL ACAD SCI USA, V72, P98, DOI 10.1073/pnas.72.1.98; PAIN B, 1991, CELL, V65, P37, DOI 10.1016/0092-8674(91)90405-N; PAPAS TS, 1986, CANCER INVEST, V4, P555, DOI 10.3109/07357908609039835; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHMIDT JA, 1986, LEUKEMIA RES, V10, P257, DOI 10.1016/0145-2126(86)90023-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0	42	21	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1992	7	3					597	605						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1347919				2022-12-28	WOS:A1992HK00500030
J	SAMESHIMA, Y; MATSUNO, Y; HIROHASHI, S; SHIMOSATO, Y; MIZOGUCHI, H; SUGIMURA, T; TERADA, M; YOKOTA, J				SAMESHIMA, Y; MATSUNO, Y; HIROHASHI, S; SHIMOSATO, Y; MIZOGUCHI, H; SUGIMURA, T; TERADA, M; YOKOTA, J			ALTERATIONS OF THE P53 GENE ARE COMMON AND CRITICAL EVENTS FOR THE MAINTENANCE OF MALIGNANT PHENOTYPES IN SMALL-CELL LUNG-CARCINOMA	ONCOGENE			English	Article							CHROMOSOME-17; HETEROZYGOSITY; MUTATIONS; CANCER; EXPRESSION; PROTEIN	To clarify the incidence, timing and pathogenetic significance of p53 gene alterations in the progression of small-cell lung carcinoma (SCLC), 17 primary tumors, 13 metastases and nine cell lines from 27 patients were analysed by a polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) analysis. Allelic losses and mutations of the p53 gene were detected in 24 out of 25 informative cases (96%) and 23 out of 27 cases (85%) respectively. Simultaneous losses and mutations were detected in all 16 stage III-IV tumors, while these alterations were detected only in 3 of 6 stage I-II tumors. When allelic losses and/or mutations were detected in the primary tumors, the same alterations were always maintained in the process of metastasis. In three cases, identical p53 alterations were detected among different organ metastases. The mutations detected in five cell lines were also detected in the corresponding original tumors. These results suggest that the alterations of the p53 gene are common and early events, but probably not the first events, in the development of SCLC, and that these alterations are essential for the maintenance of malignant phenotypes in the progression of SCLC.	TOKYO WOMENS MED COLL,DEPT MED,SHINJUKU KU,TOKYO 162,JAPAN; NATL CANC CTR,CHUO KU,TOKYO 104,JAPAN	Tokyo Women's Medical University; National Cancer Center - Japan	SAMESHIMA, Y (corresponding author), NATL CANC CTR,RES INST,STUDIES METASTASIS SECT,1-1 TSUKIJI 5-CHOME,CHUO KU,TOKYO 104,JAPAN.							BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; CROPP CS, 1990, P NATL ACAD SCI USA, V87, P7737, DOI 10.1073/pnas.87.19.7737; ECCLES DM, 1990, ONCOGENE, V5, P1599; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; LEONE A, 1991, CANCER RES, V51, P2490; MASHIYAMA S, 1991, ONCOGENE, V6, P1313; MORI N, 1990, ONCOGENE, V5, P1713; MORI N, 1989, CANCER RES, V49, P5130; MURAKAMI Y, 1991, CANCER RES, V51, P3356; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OKAMOTO A, 1991, CANCER RES, V51, P5632; OKAMOTO A, 1991, CANCER RES, V51, P5171; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; RUSSELL SEH, 1990, ONCOGENE, V5, P1581; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SAMESHIMA Y, 1990, BIOCHEM BIOPH RES CO, V173, P697, DOI 10.1016/S0006-291X(05)80091-9; SOUSSI T, 1990, ONCOGENE, V5, P945; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; 1981, INT HISTOLOGICAL TYP; 1987, TNM CLASSIFICATION M	24	152	155	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1992	7	3					451	457						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1312700				2022-12-28	WOS:A1992HK00500008
J	DIRENZO, MF; OLIVERO, M; FERRO, S; PRAT, M; BONGARZONE, I; PILOTTI, S; BELFIORE, A; COSTANTINO, A; VIGNERI, R; PIEROTTI, MA; COMOGLIO, PM				DIRENZO, MF; OLIVERO, M; FERRO, S; PRAT, M; BONGARZONE, I; PILOTTI, S; BELFIORE, A; COSTANTINO, A; VIGNERI, R; PIEROTTI, MA; COMOGLIO, PM			OVEREXPRESSION OF THE C-MET HGF RECEPTOR GENE IN HUMAN THYROID CARCINOMAS	ONCOGENE			English	Note							HEPATOCYTE GROWTH-FACTOR; POORLY DIFFERENTIATED CARCINOMA; CHRONIC MYELOGENOUS LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; TYROSINE KINASE ONCOGENES; ACTIVATED RAS ONCOGENES; PROTO-ONCOGENE; SCATTER FACTOR; HUMAN-BREAST; CELL-LINE	The receptor for Hepatocyte Growth Factor is a transmembrane tyrosine kinase encoded by the c-MET oncogene. We have previously shown that the Met protein is expressed in several human epithelial tissues. The receptor is barely detectable, however, in normal thyroids and in specimens from patients affected by nonneoplastic thyroid diseases. Now we report that the expression of the Met/HGF receptor is increased a hundred fold in 22 out of 41 human carcinomas derived from the thyroid follicular epithelium. A comprehensive analysis of 15 cases showed that the overexpressing carcinomas belong to histotype variants correlated with negative prognosis and in all but one case there were evidences of locally advanced disease and/or distant metastases. The 11 benign adenomas and the 5 medullary carcinomas tested were negative. Western blot analysis with monoclonal antibodies directed against either the intracellular or the extracellular receptor domains failed to reveal major structural alterations. Southern blot analysis also demonstrated that the c-MET gene was not amplified nor rearranged. These data suggest a role for the overexpression of c-MET oncogene in the pathogenesis and progression of thyroid tumors derived from the follicular epithelium.	NATL CANC INST,DEPT EXPTL ONCOL A,MILAN,ITALY; NATL CANC INST,DEPT PATHOL,MILAN,ITALY; UNIV CATANIA,SCH MED,DEPT ENDOCRINOL,I-95124 CATANIA,ITALY	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Catania	DIRENZO, MF (corresponding author), UNIV TURIN,SCH MED,DEPT BIOMED SCI & ONCOL,I-10124 TURIN,ITALY.		DI RENZO, Maria Flavia/B-6091-2012; Belfiore, Antonino/B-4652-2011; olivero, martina/J-4811-2018; Bongarzone, Italia/B-9544-2017; Vigneri, Riccardo/M-3968-2017	DI RENZO, Maria Flavia/0000-0002-5093-3373; Belfiore, Antonino/0000-0002-6181-4193; olivero, martina/0000-0002-6815-3498; Bongarzone, Italia/0000-0003-2530-9170; Comoglio, Paolo/0000-0002-7056-5328; Vigneri, Riccardo/0000-0002-4401-3140; Pierotti, Marco Alessandro/0000-0002-7431-8332				ADNANE J, 1991, ONCOGENE, V6, P659; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; BERCHUCK A, 1990, CANCER RES, V50, P4087; BONGARZONE I, 1989, ONCOGENE, V4, P1457; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; COHEN JA, 1989, ONCOGENE, V4, P81; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; CROCE CM, 1987, P NATL ACAD SCI USA, V84, P7174, DOI 10.1073/pnas.84.20.7174; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; DIRENZO MF, 1991, ONCOGENE, V6, P1997; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; GIORDANO S, 1988, MOL CELL BIOL, V8, P3510, DOI 10.1128/MCB.8.8.3510; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GRECO A, 1992, ONCOGENE, V7, P237; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HEDIGAR C, 1988, HISTOLOGICAL TYPING; HENDLER FJ, 1984, J CLIN INVEST, V74, P647, DOI 10.1172/JCI111463; Hermanek P, 1987, TNM CLASSIFICATION M; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; JOHNSON TL, 1988, AM J SURG PATHOL, V12, P22, DOI 10.1097/00000478-198801000-00003; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMOINE NR, 1989, ONCOGENE, V4, P159; LEMOINE NR, 1990, ONCOGENE, V5, P1833; LEMOINE NR, 1988, CANCER RES, V48, P4459; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LU SH, 1988, INT J CANCER, V42, P502, DOI 10.1002/ijc.2910420406; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; NAKAMURA T, 1989, NATURE, V342, P442; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK JB, 1989, CANCER RES, V49, P6605; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PONZETTO C, 1991, ONCOGENE, V6, P553; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; SAKAMOTO A, 1983, CANCER, V52, P1849, DOI 10.1002/1097-0142(19831115)52:10<1849::AID-CNCR2820521015>3.0.CO;2-X; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOBRINHOSIMOES M, 1988, AM J CLIN PATHOL, V89, P264, DOI 10.1093/ajcp/89.2.264; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; SUAREZ HG, 1991, ONCOGENE, V6, P677; SUAREZ HG, 1988, ONCOGENE, V2, P403; SUAREZ HG, 1990, ONCOGENE, V5, P565; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; WEIDNER KM, 1990, J CELL BIOL, V111, P2907; WEIDNER U, 1990, CANCER RES, V50, P4504; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; YAMAMOTO T, 1986, CANCER RES, V46, P414; YONEMURA Y, 1991, CANCER RES, V51, P1034; ZARNEGAR R, 1989, BIOCHEM BIOPH RES CO, V163, P1370, DOI 10.1016/0006-291X(89)91130-3; ZARNEGAR R, 1990, P NATL ACAD SCI USA, V87, P1252, DOI 10.1073/pnas.87.3.1252	54	333	353	0	14	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1992	7	12					2549	2553						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1334253				2022-12-28	WOS:A1992KA85600024
J	LANDESMAN, Y; PAGANO, M; DRAETTA, G; ROTTER, V; FUSENIG, NE; KIMCHI, A				LANDESMAN, Y; PAGANO, M; DRAETTA, G; ROTTER, V; FUSENIG, NE; KIMCHI, A			MODIFICATIONS OF CELL-CYCLE CONTROLLING NUCLEAR PROTEINS BY TRANSFORMING GROWTH-FACTOR-BETA IN THE HACAT KERATINOCYTE CELL-LINE	ONCOGENE			English	Note							RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR; INHIBITION; PROLIFERATION; EXPRESSION; SUPPRESSION; KINASE		WEIZMANN INST SCI,DEPT MOLEC GENET & VIROL,IL-76100 REHOVOT,ISRAEL; GERMAN CANC RES CTR,EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAM,W-6900 HEIDELBERG,GERMANY; GERMAN CANC RES CTR,INST BIOCHEM,DIV DIFFERENTIAT & CARCINOGENESIS INVITRO,W-6900 HEIDELBERG,GERMANY; WEIZMANN INST SCI,DEPT CELL BIOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science; European Molecular Biology Laboratory (EMBL); Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Weizmann Institute of Science				pagano, michele/0000-0003-3210-2442				BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BOYD FT, 1989, J BIOL CHEM, V264, P2272; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; COFFEY RJ, 1988, MOL CELL BIOL, V8, P3088, DOI 10.1128/MCB.8.8.3088; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LIKE B, 1986, J BIOL CHEM, V261, P3426; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; NIELSENHAMILTON M, 1990, CURR TOP DEV BIOL, V24, P95; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; RESNITZKY D, 1991, CELL GROWTH DIFFER, V2, P33; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHIPLEY GD, 1986, CANCER RES, V46, P2068; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; TIEFENBRUN N, 1991, ONCOGENE, V6, P1001; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; YARDEN A, 1986, SCIENCE, V234, P1419, DOI 10.1126/science.3097823; ZENTELLA A, 1991, MOL CELL BIOL, V11, P4952, DOI 10.1128/MCB.11.10.4952	33	31	31	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1661	1665						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1385861				2022-12-28	WOS:A1992JE81300026
J	BRENNER, B; WILDHARDT, G; SCHNEIDER, S; ROYERPOKORA, B				BRENNER, B; WILDHARDT, G; SCHNEIDER, S; ROYERPOKORA, B			RNA-POLYMERASE CHAIN-REACTION DETECTS DIFFERENT LEVELS OF 4 ALTERNATIVELY SPLICED WT1 TRANSCRIPTS IN WILMS-TUMORS	ONCOGENE			English	Note							ENZYMATIC AMPLIFICATION; HUMAN CHROMOSOME-11; PHYSICAL MAP; PROTEIN; LOCUS; GENE	A Wilms' tumor susceptibility gene (WT1) localized to 11p13 was recently isolated and shown to be altered in some sporadic Wilms' tumors. This gene encodes a DNA-binding protein with four zinc fingers (ZFs) in the carboxy-terminal region and a glutamine/proline (Gln/Pro)-rich domain near the 5' end. Two alternative splice sites were described, splice I in the Gln/Pro-rich domain (51 bp) and splice II between ZFs 3 and 4 (9 bp). Using RNA polymerase chain reaction (PCR) we show that Wilms' tumors contain all four possible transcripts, which are also identified in normal adult and embryonic kidney cells. The transcripts containing the 9-bp ZF insert were always predominant in tumors and normal cells. The presence of all four WT1 transcripts in tumors and expressing tissues suggests that each encoded protein isoform has an important role for the function of the WT1 gene.	UNIV HEIDELBERG,INST HUMAN GENET & ANTHROPOL,NEUENHEIMER FELD 328,W-6900 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg								BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COMPTON DA, 1988, CELL, V55, P827, DOI 10.1016/0092-8674(88)90138-9; GESSLER M, 1989, GENOMICS, V5, P43, DOI 10.1016/0888-7543(89)90084-0; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MATSUNAGA E, 1981, HUM GENET, V57, P231; NOONAN KE, 1988, NUCLEIC ACIDS RES, V16, P10366, DOI 10.1093/nar/16.21.10366; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980	14	43	47	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1431	1433						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1320246				2022-12-28	WOS:A1992HZ97100023
J	SHARIF, M; PRIVALSKY, ML				SHARIF, M; PRIVALSKY, ML			V-ERBA AND C-ERBA PROTEINS ENHANCE TRANSCRIPTIONAL ACTIVATION BY C-JUN	ONCOGENE			English	Article							RETINOIC ACID RECEPTOR; THYROID-HORMONE RECEPTORS; GLUCOCORTICOID RECEPTOR; RESPONSE ELEMENT; NEGATIVE REGULATION; ONCOGENE PROTEIN; OSTEOCALCIN GENE; BINDING DOMAIN; BETA-GENE; TATA BOX	The ability of different transcription factors to interact with one another is an important means by which the eucaryotic cell can integrate separate growth and differentiation signals into a coherent response. We report here an analysis of the interactions of transcription factors that are also the products of oncogenes: the erbA, jun and fos proteins. We demonstrate that the c-jun polypeptide can functionally interact with the c-erbA protein (thyroid hormone receptor) to yield an enhanced activity greater than that of either factor individually. Although the avian erythroblastosis v-erbA allele is generally thought to act as a transcriptional repressor in vertebrate cells, we also report the existence of promoter contexts where v-erbA, as well as c-erbA, can serve as 'co-activators' of c-jun function. V-erbA appears to augment retinoic acid receptor function in the same context. Our results suggest that v-erbA may have unanticipated positive effect on transcription in the neoplastic cell in addition to the repressor functions previously characterized.	UNIV CALIF DAVIS, DEPT MICROBIOL, DAVIS, CA 95616 USA	University of California System; University of California Davis					NCI NIH HHS [CA53394, CA38823] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA053394, R01CA053394, R01CA038823] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BOUCHER P, 1990, ONCOGENE, V5, P1303; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; CHATTERJEE VKK, 1989, P NATL ACAD SCI USA, V86, P9114, DOI 10.1073/pnas.86.23.9114; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; CRONE DE, 1990, J BIOL CHEM, V265, P10851; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DARLING DS, 1989, MOL ENDOCRINOL, V3, P1359, DOI 10.1210/mend-3-9-1359; DAYTON AI, 1984, P NATL ACAD SCI-BIOL, V81, P4495, DOI 10.1073/pnas.81.14.4495; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN B M, 1990, New Biologist, V2, P587; FORREST D, 1990, ONCOGENE, V5, P309; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GLASS CK, 1990, BIOCHIM BIOPHYS ACTA, V1032, P157, DOI 10.1016/0304-419X(90)90002-I; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARTINEZ E, 1991, MOL CELL BIOL, V11, P2937, DOI 10.1128/MCB.11.6.2937; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; OWEN TA, 1990, P NATL ACAD SCI USA, V87, P9990, DOI 10.1073/pnas.87.24.9990; PATHAK BG, 1990, GENOMICS, V8, P641, DOI 10.1016/0888-7543(90)90250-X; PRIVALSKY ML, 1990, CELL, V63, P1277, DOI 10.1016/0092-8674(90)90423-C; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; STEIN GS, 1989, CONNECT TISSUE RES, V20, P3, DOI 10.3109/03008208909049996; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P	42	31	31	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1992	7	5					953	960						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1349165				2022-12-28	WOS:A1992HP64200015
J	BOULET, I; RALPH, S; STANLEY, E; LOCK, P; DUNN, AR; GREEN, SP; PHILLIPS, WA				BOULET, I; RALPH, S; STANLEY, E; LOCK, P; DUNN, AR; GREEN, SP; PHILLIPS, WA			LIPOPOLYSACCHARIDE-GAMMA-INDUCED AND INTERFERON-GAMMA-INDUCED EXPRESSION OF HCK AND LYN TYROSINE KINASES IN MURINE BONE MARROW-DERIVED MACROPHAGES	ONCOGENE			English	Article							RESPIRATORY BURST; GENE HCK; HUMAN NEUTROPHIL; CELLS; PHOSPHORYLATION; ACTIVATION; PHAGOCYTES; RECEPTOR; OXIDASE; CD4	We have examined the role of tyrosine phosphorylation during the course of macrophage activation. Initial experiments indicated that vanadate, a known phosphotyrosine phosphatase inhibitor, enhanced the phorbol 12-myristate 13-acetate (PMA)-triggered respiratory burst and potentiated the priming effects of bacterial lipopolysaccharide (LPS) and interferon-gamma (IFN-gamma), suggesting that tyrosine phosphorylation may be important in these end cell functions. As src-related kinases have been implicated in the activation of cells of other haemopoietic lineages, we examined the relationship between the activity of two such kinases, hck and lyn, and priming of the respiratory burst. We found that the level of hck and lyn is increased following exposure of bone marrow-derived macrophages (BMM) to LPS or IFN-gamma. The induction of both of these kinases follows similar kinetics with maximal activity occurring at 24-48 h. Interestingly, the kinetics of induction of hck and lyn kinase activity in BMM demonstrated a close temporal relationship with the priming effects of LPS and IFN-gamma on the macrophage respiratory burst. Collectively, these observations raise the possibility that modulation of expression of hck and lyn is involved in the regulation of the respiratory burst.	LUDWIG INST CANC RES,MELBOURNE TUMOUR BIOL BRANCH,PO ROYAL MELBOURNE HOSP,MELBOURNE,VIC 3050,AUSTRALIA; UNIV MELBOURNE,ROYAL MELBOURNE HOSP,DEPT MED,MELBOURNE,VIC 3050,AUSTRALIA	Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Royal Melbourne Hospital; University of Melbourne			Stanley, Ed G/A-2985-2013; Phillips, Wayne A/H-8070-2013	Stanley, Ed G/0000-0002-6389-3665; Phillips, Wayne A/0000-0002-7961-638X; Lock, Peter/0000-0003-4421-3609; Ralph, Stephen/0000-0002-4335-092X				CHEAH MSC, 1986, NATURE, V319, P238, DOI 10.1038/319238a0; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; GOMEZCAMBRONERO J, 1989, BIOCHEM BIOPH RES CO, V162, P1478, DOI 10.1016/0006-291X(89)90841-3; GRINSTEIN S, 1990, J BIOL CHEM, V265, P318; HOLTZMAN DA, 1987, P NATL ACAD SCI USA, V84, P8325, DOI 10.1073/pnas.84.23.8325; HUANG CK, 1988, BIOCHEM BIOPH RES CO, V151, P794, DOI 10.1016/S0006-291X(88)80351-6; JOHNSTON RB, 1990, PEDIATRIC RES S, V27, P544; LOCK P, 1991, MOL CELL BIOL, V11, P4363, DOI 10.1128/MCB.11.9.4363; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; NASMITH PE, 1989, BIOCHEM J, V257, P893, DOI 10.1042/bj2570893; PHILLIPS WA, 1990, J CELL PHYSIOL, V144, P190, DOI 10.1002/jcp.1041440203; PHILLIPS WA, 1989, J IMMUNOL, V142, P2445; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; ROSSI F, 1986, BIOCHIM BIOPHYS ACTA, V853, P65, DOI 10.1016/0304-4173(86)90005-4; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; STANLEY E, 1991, MOL CELL BIOL, V11, P3399, DOI 10.1128/MCB.11.7.3399; TUSHINSKI RJ, 1982, CELL, V28, P71, DOI 10.1016/0092-8674(82)90376-2; VAIRO G, 1985, BIOCHEM BIOPH RES CO, V132, P430, DOI 10.1016/0006-291X(85)91040-X; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WILLMAN CL, 1987, P NATL ACAD SCI USA, V84, P4480, DOI 10.1073/pnas.84.13.4480; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YI TL, 1991, MOL CELL BIOL, V11, P2391, DOI 10.1128/MCB.11.5.2391; ZIEGLER SF, 1988, J EXP MED, V168, P1801, DOI 10.1084/jem.168.5.1801; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	26	116	116	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					703	710						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1373483				2022-12-28	WOS:A1992HQ68200012
J	Fallon, CM; Smyth, JS; Quach, A; Lajczak-McGinley, N; O'Toole, A; Barrett, KE; Sheridan, H; Keely, SJ				Fallon, Ciara M.; Smyth, Jessica S.; Quach, Andrew; Lajczak-McGinley, Natalia; O'Toole, Aoibhlinn; Barrett, Kim E.; Sheridan, Helen; Keely, Stephen J.			Pentacyclic triterpenes modulate farnesoid X receptor expression in colonic epithelial cells: Implications for colonic secretory function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILE-ACIDS; CHLORIDE SECRETION; OBETICHOLIC ACID; NUCLEAR RECEPTOR; HEDERACOSIDE C; ALPHA-HEDERIN; STEM-CELLS; IN-VITRO; IDENTIFICATION; HEDERAGENIN	The nuclear bile acid receptor, farnesoid X receptor (FXR), is an important regulator of intestinal and metabolic function. Previous studies suggest that pentacyclic triterpenes (PCTs), a class of plant-derived bioactive phytochemical, can modulate FXR activity and may therefore offer therapeutic benefits. Here, we investigated the effects of a prototypical PCT, hederagenin (HG), on FXR expression, activity, and antisecretory actions in colonic epithelial cells. T84 cells and murine enteroid-derived monolayers were employed to assess HG effects on FXR expression and activity in colonic epithelia. We measured mRNA levels by qRT-PCR and protein by ELISA and immu-noblotting. Transepithelial Cl-secretion was assessed as changes in short circuit current in Ussing chambers. We determined HG treatment (5-10 mu M) alone did not induce FXR activation but significantly increased expression of the recep-tor, both in T84 cells and murine enteroid-derived monolayers. This effect was accompanied by enhanced FXR activity, as assessed by FGF-15/19 induction in response to the synthetic, GW4064, or natural FXR agonist, chenodeoxycholic acid. Effects of HG on FXR expression and activity were mimicked by another PCT, oleanolic acid. Furthermore, we found FXR-induced downregulation of cystic fibrosis transmembrane conductance regulator Cl- channels and inhibition of trans -epithelial Cl- secretion were enhanced in HG-treated cells. These data demonstrate that dietary PCTs have the capacity to modulate FXR expression, activity, and antisecretory actions in colonic epithelial cells. Based on these data, we propose that plants rich in PCTs, or extracts thereof, have excellent poten-tial for development as a new class of "FXR-targeted nutraceuticals".	[Fallon, Ciara M.; Smyth, Jessica S.; Lajczak-McGinley, Natalia; Keely, Stephen J.] Beaumont Hosp, Sch Pharm & Biomol Sci, RCSI, Dublin, Ireland; [Quach, Andrew; Barrett, Kim E.] Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA USA; [O'Toole, Aoibhlinn] Beaumont Hosp, Dept Gastroenterol, Dublin, Ireland; [Barrett, Kim E.] Univ Calif Davis, Sch Med, Dept Physiol & Membrane Biol, Davis, CA USA; [Sheridan, Helen] Trinity Coll Dublin, Ctr Nat Prod Res, Sch Pharm & Pharmaceut Sci, NatPro, Dublin, Ireland	Royal College of Surgeons - Ireland; University of California System; University of California San Diego; University of California System; University of California Davis; Trinity College Dublin	Fallon, CM (corresponding author), Beaumont Hosp, Sch Pharm & Biomol Sci, RCSI, Dublin, Ireland.	cfallon@rcsi.com		Quach, Andrew/0000-0003-3253-3971	Science Foundation Ireland [17/TIDA/5050, 16-IA-445]; Royal College of Surgeons in Ireland; Ciaran Barry Research Scholarship from the Central Remedial Clinic; Estratest Settlement Fund	Science Foundation Ireland(Science Foundation IrelandEuropean Commission); Royal College of Surgeons in Ireland; Ciaran Barry Research Scholarship from the Central Remedial Clinic; Estratest Settlement Fund	This study was supported by an Investigator Program Award from Science Foundation Ireland (Grant #16-IA-445 to S. J. K.), a Technology Innovation Development Award from Science Foundation Ireland (Grant #17/TIDA/5050 to S. J. K.), a StAR PhD Program award from the Royal College of Surgeons in Ireland (to C. M. F.), the Ciaran Barry Research Scholarship from the Central Remedial Clinic (to C. M. F.), and an unrestricted gift from the Estratest Settlement Fund (to K. E. B.).	Ahmad TR, 2020, J BIOL CHEM, V295, P12545, DOI 10.1074/jbc.RA120.012792; Cao WY, 2015, MOLECULES, V20, P20569, DOI 10.3390/molecules201119719; CARTWRIGHT CA, 1985, J CLIN INVEST, V76, P1837, DOI 10.1172/JCI112176; Ceulemans LJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169331; Chandra S, 2015, INTEGR MED RES, V4, P123, DOI 10.1016/j.imr.2015.06.004; Chen JC, 2007, J ETHNOPHARMACOL, V113, P233, DOI 10.1016/j.jep.2007.05.031; Chiang JYL, 2019, ANNU REV NUTR, V39, P175, DOI 10.1146/annurev-nutr-082018-124344; Dabek M, 2008, FEMS MICROBIOL ECOL, V66, P487, DOI 10.1111/j.1574-6941.2008.00520.x; DHARMSATHAPHORN K, 1985, J CLIN INVEST, V75, P462, DOI 10.1172/JCI111721; Fang Liwen, 2019, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V35, P140; Fiorucci S, 2011, BRIT J PHARMACOL, V164, P1929, DOI 10.1111/j.1476-5381.2011.01481.x; FOTI ME, 1986, J CLIN PSYCHOPHARM, V6, P325; Furtado NAJC, 2017, MOLECULES, V22, DOI 10.3390/molecules22030400; Gadaleta RM, 2011, GUT, V60, P463, DOI 10.1136/gut.2010.212159; Gadaleta RM, 2017, MOL ASPECTS MED, V56, P66, DOI 10.1016/j.mam.2017.04.002; Gu M, 2019, BRIT J PHARMACOL, V176, P847, DOI 10.1111/bph.14570; Hegyi P, 2018, PHYSIOL REV, V98, P1983, DOI 10.1152/physrev.00054.2017; Inagaki T, 2005, CELL METAB, V2, P217, DOI 10.1016/j.cmet.2005.09.001; Inagaki T, 2006, P NATL ACAD SCI USA, V103, P3920, DOI 10.1073/pnas.0509592103; Jager S, 2009, MOLECULES, V14, P2016, DOI 10.3390/molecules14062016; Kliewer SA, 2015, DIGEST DIS, V33, P327, DOI 10.1159/000371670; Lee CW, 2015, INT IMMUNOPHARMACOL, V29, P528, DOI 10.1016/j.intimp.2015.10.002; Li QQ, 2021, SCI CHINA LIFE SCI, V64, P117, DOI 10.1007/s11427-019-1647-6; Liu BXZ, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-412; Liu HM, 2017, BIOCHEM BIOPH RES CO, V490, P841, DOI 10.1016/j.bbrc.2017.06.129; Liu WM, 2010, PHYTOTHER RES, V24, P369, DOI 10.1002/ptr.2948; Lu Y, 2018, MOL PHARMACOL, V93, P63, DOI 10.1124/mol.117.109900; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Maloney PR, 2000, J MED CHEM, V43, P2971, DOI 10.1021/jm0002127; MANDEL KG, 1986, AM J PHYSIOL, V250, pC486, DOI 10.1152/ajpcell.1986.250.3.C486; Miyoshi H, 2013, NAT PROTOC, V8, P2471, DOI 10.1038/nprot.2013.153; Modica S, 2008, CANCER RES, V68, P9589, DOI 10.1158/0008-5472.CAN-08-1791; Moses T, 2014, CRIT REV BIOCHEM MOL, V49, P439, DOI 10.3109/10409238.2014.953628; Mroz MS, 2014, GUT, V63, P808, DOI 10.1136/gutjnl-2013-305088; Nevens F, 2016, NEW ENGL J MED, V375, P631, DOI 10.1056/NEJMoa1509840; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Sieben A, 2009, BIOCHEMISTRY-US, V48, P3477, DOI 10.1021/bi802036b; Song M, 2019, J AGR FOOD CHEM, V67, P8868, DOI 10.1021/acs.jafc.9b03173; Sonne DP, 2021, EUR J ENDOCRINOL, V184, pR193, DOI 10.1530/EJE-20-1410; Sorribas M, 2019, J HEPATOL, V71, P1126, DOI 10.1016/j.jhep.2019.06.017; Stojancevic M, 2012, CAN J GASTROENTEROL, V26, P631, DOI 10.1155/2012/538452; Verbeke L, 2015, AM J PATHOL, V185, P409, DOI 10.1016/j.ajpath.2014.10.009; Walters JRF, 2015, ALIMENT PHARM THER, V41, P54, DOI 10.1111/apt.12999; Wang K, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02880-5; WEYMER A, 1985, J CLIN INVEST, V76, P1828, DOI 10.1172/JCI112175; Yang F, 2016, ONCOTARGET, V7, P75165, DOI 10.18632/oncotarget.12614; Yu K, 2012, CURR DRUG METAB, V13, P577, DOI 10.2174/1389200211209050577; Yu M, 2016, J SEP SCI, V39, P3292, DOI 10.1002/jssc.201600523; Zeng J, 2018, RSC ADV, V8, P24188, DOI 10.1039/c8ra03666g; Zhao J, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/827230; Zhou D, 2010, PHARMACOL BIOCHEM BE, V94, P488, DOI 10.1016/j.pbb.2009.11.003	53	0	0	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV	2022	298	11							102569	10.1016/j.jbc.2022.102569	http://dx.doi.org/10.1016/j.jbc.2022.102569			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	6W5WW	36209824	Green Published, gold			2022-12-28	WOS:000895801300006
J	SUDO, T; MIYAZAWA, H; HANAOKA, F; ISHII, S				SUDO, T; MIYAZAWA, H; HANAOKA, F; ISHII, S			THE C-MYB PROTOONCOGENE PRODUCT BINDS TO BUT DOES NOT ACTIVATE THE PROMOTER OF THE DNA POLYMERASE-ALPHA GENE	ONCOGENE			English	Article							TEMPERATURE-SENSITIVE MUTANT; V-MYB; CELL-PROLIFERATION; NUCLEOTIDE-SEQUENCE; EXPRESSION; REPLICATION; PROGENITOR; REGION	The myb proto oncogene product (c-Myb) is a transcriptional reglator and its expression and function are tightly linked to the cellular entry into S phase and DNA synthesis. It has been shown [Venturelli, D., Travali, S. & Calabretta, B. (1990). Proc. Natl. Acad. Sci. USA, 87, 5963-59671 that inhibition of T-cell proliferation by a myb antisense oligomer is accompanied by down-regulation of DNA polymerase-alpha-expression. To examine whether the transcription of the DNA polymerase-alpha-gene is directly regulated by c-Myb, we have identified and characterized the 5' regulatory region of the human DNA polymerase-alpha-gene. Two major and several minor transcription start sites were identified by nuclease S1 mapping. DNA sequence analysis showed that the promoter region contains no TATA box, one CCAAT box and putative Ap-1, AP-2 and E2F binding sites. In DNAase I footprinting, the bacterially expressed c-Myb protected six sites in the 5' flanking region of the human DNA polymerase-alpha-gene. However, c-Myb did not activate the DNA polymerase-alpha-gene promoter in a cotransfection assay. Our results suggest that an unknown factor(s) is required for the c-Myb-induced activation of the DNA polymerase-alpha-gene promoter, or c-Myb does not directly activate this promoter.	INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC GENET LAB,TSUKUBA,IBARAKI 305,JAPAN; INST PHYS & CHEM RES,CELLULAR PHYSIOL LAB,SAITAMA 35101,JAPAN; UNIV TOKYO,INST MED SCI,MINATO KU,TOKYO 108,JAPAN	RIKEN; RIKEN; University of Tokyo			Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478				ARAKI E, 1988, NUCLEIC ACIDS RES, V16, P1627, DOI 10.1093/nar/16.4.1627; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; CAMPBELL JL, 1986, ANNU REV BIOCHEM, V55, P733, DOI 10.1146/annurev.bi.55.070186.003505; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HU YL, 1991, ONCOGENE, V6, P1549; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; Maniatis T., 1982, MOL CLONING; MIYAZAWA H, 1986, BIOCHEM BIOPH RES CO, V139, P135; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; MIZUSAWA S, 1986, NUCLEIC ACIDS RES, V14, P1319, DOI 10.1093/nar/14.3.1319; MURAKAMI Y, 1985, P NATL ACAD SCI USA, V82, P1761, DOI 10.1073/pnas.82.6.1761; NAGASE T, 1990, J BIOL CHEM, V265, P17300; NAKAGOSHI H, 1989, NUCLEIC ACIDS RES, V17, P7315, DOI 10.1093/nar/17.18.7315; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NAKAGOSHI H, 1992, IN PRESS ONCOGENE; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; RUSHLOW KE, 1982, SCIENCE, V216, P1421, DOI 10.1126/science.6283631; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; STERN JB, 1986, SCIENCE, V233, P203, DOI 10.1126/science.3523754; TAKADATAKAYAMA R, 1991, J BIOL CHEM, V266, P15716; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; VENTURELLI D, 1990, P NATL ACAD SCI USA, V87, P5963, DOI 10.1073/pnas.87.15.5963; WAHL AF, 1988, MOL CELL BIOL, V8, P5016, DOI 10.1128/MCB.8.11.5016; WATSON RJ, 1987, EMBO J, V6, P1643, DOI 10.1002/j.1460-2075.1987.tb02413.x; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x; [No title captured]	36	10	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					1999	2006						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408140				2022-12-28	WOS:A1992JP42400013
J	CHAZIN, VR; KALEKO, M; MILLER, AD; SLAMON, DJ				CHAZIN, VR; KALEKO, M; MILLER, AD; SLAMON, DJ			TRANSFORMATION MEDIATED BY THE HUMAN HER-2 GENE INDEPENDENT OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR	ONCOGENE			English	Article							TYROSINE KINASE-ACTIVITY; HUMAN-BREAST-CANCER; NEU ONCOGENE; EGF RECEPTOR; MONOCLONAL-ANTIBODIES; C-ERBB-2 PROTEIN; POINT MUTATION; OVARIAN-CANCER; CELL-GROWTH; 3T3 CELLS	Amplification of the HER-2 (c-erbB-2) gene and overexpression of the p185HER-2 gene product is found in approximately one-third of primary human breast and ovarian cancers and is associated with a poor clinical outcome of early relapse and death. The HER-2 gene encodes a cell-surface growth factor receptor with intrinsic tyrosine kinase activity. Wild-type human HER-2 has been shown to act as a potent oncogene when overexpressed in mouse fibroblasts. Recent data suggest that the mechanism by which HER-2 mediates transformation requires the interaction of the epidermal growth factor (EGF) receptor. To test whether overexpression of normal human HER-2 can transform cells independently of the EGF receptor, we have introduced multiple copies of HER-2 into the EGF receptor-negative cell line, NR6, and have performed assays for both transformation and tumorigenicity. Engineered NR6 cells that overexpress the HER-2 gene product display a highly transformed and tumorigenic phenotype as compared with control cells. Additionally, a monoclonal antibody to the extracellular domain of the HER-2 receptor is able to inhibit the proliferation of the overexpressing cells in vitro as well as tumor growth in vivo. This study provides clear evidence that HER-2-mediated transformation can be achieved independently of the EGF receptor.	UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT MICROBIOL & IMMUNOL,LOS ANGELES,CA 90024; FRED HUTCHINSON CANC RES CTR,DEPT MOLEC MED,SEATTLE,WA 98104	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Fred Hutchinson Cancer Center				Miller, Dusty/0000-0002-3736-3660	NATIONAL CANCER INSTITUTE [R01CA036827] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007185] Funding Source: NIH RePORTER; NCI NIH HHS [CA 36827] Funding Source: Medline; NIGMS NIH HHS [GM-07185] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BERCHUCK A, 1990, CANCER RES, V50, P4087; Chen E, 1986, Biochem Soc Symp, V52, P65; CONNELLY PA, 1990, P NATL ACAD SCI USA, V87, P6054, DOI 10.1073/pnas.87.16.6054; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GULLICK WJ, 1991, BRIT J CANCER, V63, P434, DOI 10.1038/bjc.1991.100; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KOKAI Y, 1988, P NATL ACAD SCI USA, V85, P5389, DOI 10.1073/pnas.85.15.5389; KUMAR R, 1991, MOL CELL BIOL, V11, P976; LEMOINE NR, 1990, ONCOGENE, V5, P237; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MILLER AD, 1986, SOMAT CELL MOLEC GEN, V12, P175, DOI 10.1007/BF01560664; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; OREILLY SM, 1991, BRIT J CANCER, V63, P444, DOI 10.1038/bjc.1991.102; OSBORNE WRA, 1988, P NATL ACAD SCI USA, V85, P6851, DOI 10.1073/pnas.85.18.6851; PRESS MF, 1984, LAB INVEST, V50, P480; PRESS MF, 1988, ENDOCRINOLOGY, V122, P1165, DOI 10.1210/endo-122-3-1165; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; SARUP JC, 1991, GROWTH REGULAT, V1, P72; SAYA H, 1990, MOL CARCINOGEN, V3, P198, DOI 10.1002/mc.2940030406; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SLAMON DJ, 1989, CANCER CEL, V7, P371; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; WEINER DB, 1989, ONCOGENE, V4, P1175; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; YARDEN Y, 1991, BIOCHEMISTRY-US, V30, P3543, DOI 10.1021/bi00228a027; YARDEN Y, 1989, P NATL ACAD SCI USA, V86, P3179, DOI 10.1073/pnas.86.9.3179	47	164	179	2	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1859	1866						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1354348				2022-12-28	WOS:A1992JJ37600023
J	SAINTRUF, C; VIEGASPEQUIGNOT, E; ALFANI, E; CLEMENTI, M; DUTRILLAUX, B; CARLONI, G				SAINTRUF, C; VIEGASPEQUIGNOT, E; ALFANI, E; CLEMENTI, M; DUTRILLAUX, B; CARLONI, G			COAMPLIFICATION OF TRANSCRIPTIONALLY ACTIVE EPIDERMAL GROWTH-FACTOR RECEPTOR AND RIBOSOMAL GENES IN THE HUMAN HEPATOMA-CELL LINE LI7A	ONCOGENE			English	Article							HOMOGENEOUSLY STAINING REGIONS; BREAST-CANCER; SQUAMOUS-CELL; INVERTED DUPLICATION; ENHANCED EXPRESSION; ORGANIZER REGIONS; MAMMARY-CARCINOMA; HIGH-AFFINITY; SINGLE-COPY; A431 CELLS	A high level of expression of the functional product of the epidermal growth factor receptor (EGFR) gene was detected in the human hepatocarcinoma cell line Li7A and it was found to correlate with gene amplification. The karyotype was paratriploid, with 15 rearranged chromosomes, several of which contained abnormally banded regions (ABRs). The search for DNA sequences co-amplified with the EGFR gene, using the in-gel renaturation technique, allowed us to detect an amplified DNA band (La1) of about 30 kb. This DNA was used as a probe for in situ hybridization on chromosomes, to locate the amplified segment. In normal lymphocytes, the DNA of band La1 hybridized to chromosome regions in which repetitive DNAs are located, i.e. on juxtacentromeric regions, the site of alphoid and CCATT satellite DNA, and on the short arms of acrocentrics, the site of ribosomal RNA (RNR) genes. In Li7A cells, it hybridized to the same regions and, in addition, to several chromosome arms corresponding to ABRs. The same ABRs hybridized to EGFR and RNR probes, but neither Alu sequences nor various probes for other repetitive sequences were recognized. They also exhibited nucleolus organizer region staining characterizing functionally active (RNR) genes. It was concluded that transcriptionally active genes were co-amplified in the same ABRs, although they originated from different chromosomes, i.e. chromosome 7 for EGFR and acrocentrics for RNR genes.	INST CURIE,BIOL SECT,CNRS,URA 620,26 RUE ULM,F-75231 PARIS 05,FRANCE; CNR,IST MED SPERIMENTALE,ROME,ITALY; IST SUPER SANITA,BIOL CELLULAIRE LAB,I-00161 ROME,ITALY; UNIV ANCONA,IST MICROBIOL,I-60100 ANCONA,ITALY	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Consiglio Nazionale delle Ricerche (CNR); Istituto Superiore di Sanita (ISS); Marche Polytechnic University			Clementi, Massimo/F-6646-2013	Clementi, Massimo/0000-0002-7461-5898				ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; BERTICS PJ, 1985, J BIOL CHEM, V260, P14643; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CARLIN CR, 1988, MOL CELL BIOL, V8, P25, DOI 10.1128/MCB.8.1.25; CARLONI G, 1988, VIRAL HEPATITIS HEPA, P501; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CLEMENTI M, 1989, FEBS LETT, V249, P297, DOI 10.1016/0014-5793(89)80645-3; CORNEO G, 1970, J MOL BIOL, V48, P319, DOI 10.1016/0022-2836(70)90163-4; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; DUTRILLAUX B, 1990, CANCER GENET CYTOGEN, V49, P203, DOI 10.1016/0165-4608(90)90143-X; DUTRILLAUX B, 1981, PRATIQUE ANAL CHROMO, P7; FORD M, 1986, CELL, V45, P425, DOI 10.1016/0092-8674(86)90328-4; FORD M, 1985, P NATL ACAD SCI USA, V82, P3370, DOI 10.1073/pnas.82.10.3370; FUKUMOTO M, 1988, P NATL ACAD SCI USA, V85, P6846, DOI 10.1073/pnas.85.18.6846; GIL GN, 1981, NATURE, V293, P305; GONZALEZ IL, 1985, P NATL ACAD SCI USA, V82, P7666, DOI 10.1073/pnas.82.22.7666; HOLDEN JJA, 1985, CANCER GENET CYTOGEN, V14, P131, DOI 10.1016/0165-4608(85)90224-9; HUNTS J, 1985, JPN J CANCER RES, V76, P663; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KING CR, 1985, NUCLEIC ACIDS RES, V13, P8477, DOI 10.1093/nar/13.23.8477; KNOWLES AF, 1985, BIOCHEM BIOPH RES CO, V126, P8, DOI 10.1016/0006-291X(85)90564-9; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KORENBERG JR, 1988, CELL, V53, P391, DOI 10.1016/0092-8674(88)90159-6; LAFAGE M, 1990, GENE CHROMOSOME CANC, V2, P171, DOI 10.1002/gcc.2870020302; LAMMIE GA, 1991, ONCOGENE, V6, P439; LAVOLPE A, 1985, J MOL BIOL, V183, P213, DOI 10.1016/0022-2836(85)90214-1; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LIN CR, 1984, SCIENCE, V224, P843, DOI 10.1126/science.6326261; LOONEY JE, 1987, MOL CELL BIOL, V7, P569, DOI 10.1128/MCB.7.2.569; MADEN BEH, 1987, BIOCHEM J, V246, P519, DOI 10.1042/bj2460519; MERLINO GT, 1984, SCIENCE, V224, P417, DOI 10.1126/science.6200934; MILLER OJ, 1979, CHROMOSOMA, V71, P183, DOI 10.1007/BF00292822; MILLER OJ, 1981, GENES CHROMOSOMES NE, P253; MULERIS M, 1988, CANCER GENET CYTOGEN, V32, P43, DOI 10.1016/0165-4608(88)90310-X; PASSANANTI C, 1987, EMBO J, V6, P1697, DOI 10.1002/j.1460-2075.1987.tb02420.x; PONTE P, 1983, MOL CELL BIOL, V3, P1783, DOI 10.1128/MCB.3.10.1783; RIEHMAN RA, 1976, P NATL ACAD SCI USA, V73, P3589; Roninson I B, 1987, Methods Enzymol, V151, P332, DOI 10.1016/S0076-6879(87)51028-X; SAINTRUF C, 1990, GENE CHROMOSOME CANC, V2, P18, DOI 10.1002/gcc.2870020105; SAINTRUF C, 1991, CANCER GENET CYTOGEN, V52, P27, DOI 10.1016/0165-4608(91)90050-5; Sambrook J, 1989, MOL CLONING LABORATO; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P666; SCHIMKE RT, 1984, CELL, V37, P705, DOI 10.1016/0092-8674(84)90406-9; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWARZACHER HG, 1983, HUM GENET, V63, P89, DOI 10.1007/BF00291525; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; STARK GR, 1989, CELL, V57, P901, DOI 10.1016/0092-8674(89)90328-0; STURANI E, 1988, MOL CELL BIOL, V8, P1345, DOI 10.1128/MCB.8.3.1345; THEILLET C, 1990, ONCOGENE, V5, P147; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VIEGASPEQUIGNOT E, 1989, P NATL ACAD SCI USA, V86, P582, DOI 10.1073/pnas.86.2.582; VIEGASPEQUIGNOT E, 1990, CANCER GENET CYTOGEN, V49, P37, DOI 10.1016/0165-4608(90)90162-4; WAYE JS, 1987, MOL CELL BIOL, V7, P349, DOI 10.1128/MCB.7.1.349	56	14	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1557	1565						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1321403				2022-12-28	WOS:A1992JE81300012
J	KUMAR, G; SHARMA, AK; JAYARAMAN, K				KUMAR, G; SHARMA, AK; JAYARAMAN, K			INCORPORATION OF BRDU IN A DNA FRAGMENT MAY AFFECT PROTEIN DNA INTERACTIONS IN A SITE-DEPENDENT MANNER	ONCOGENE			English	Article							BINDING	DNA in which BrdU has been randomly incorporated is used to identify specific DNA-binding proteins. We show here that the location of BrdU incorporation in a DNA fragment can significantly affect specific protein-DNA interactions and thereby identification of DNA-binding proteins. We suggest that a radioactive labeled unmodified DNA, rather than BrdU-incorporated DNA, be used for identifying DNA-binding proteins by UV cross-linking.	WAYNE STATE UNIV,SCH MED,CTR MOLEC BIOL,DETROIT,MI 48201; EASTMAN KODAK CO,RES LABS,NEW YORK,NY 14601	Wayne State University; Eastman Kodak	KUMAR, G (corresponding author), WAYNE STATE UNIV,SCH MED,DEPT MOLEC BIOL & GENET,540 E CANFIELD,DETROIT,MI 48201, USA.			Sharma, Arun/0000-0002-2777-8731	NIGMS NIH HHS [GM 38228, GM 08167] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038228] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN JK, 1989, J VIROL, V63, P5425, DOI 10.1128/JVI.63.12.5425-5439.1989; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GALLINARI P, 1989, MOL CELL BIOL, V9, P1566, DOI 10.1128/MCB.9.4.1566; KUMAR G, 1984, J ORG CHEM, V49, P4905, DOI 10.1021/jo00199a032; SHARMA AK, 1991, FEBS LETT, V281, P272, DOI 10.1016/0014-5793(91)80409-V	7	6	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1453	1455						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1320247				2022-12-28	WOS:A1992HZ97100027
J	KUMABE, T; SOHMA, Y; KAYAMA, T; YOSHIMOTO, T; YAMAMOTO, T				KUMABE, T; SOHMA, Y; KAYAMA, T; YOSHIMOTO, T; YAMAMOTO, T			AMPLIFICATION OF ALPHA-PLATELET-DERIVED GROWTH-FACTOR RECEPTOR GENE LACKING AN EXON CODING FOR A PORTION OF THE EXTRACELLULAR REGION IN A PRIMARY BRAIN-TUMOR OF GLIAL ORIGIN	ONCOGENE			English	Article							TYROSINE KINASE-ACTIVITY; SIMIAN SARCOMA-VIRUS; FMS PROTO-ONCOGENE; PDGF RECEPTOR; GLIOBLASTOMA-MULTIFORME; NUCLEOTIDE-SEQUENCE; SIGNAL TRANSDUCTION; CDNA CLONING; EXPRESSION; FAMILY	In a primary brain tumor of glial origin, we found overexpression of the alpha-platelet-derived growth factor (alpha-PDGF) receptor mRNA. Southern blot analysis of the gene revealed amplification of the rearranged alpha-PDGF receptor gene in the glioma. A cDNA coding for an aberrant transcript from the amplified receptor gene was obtained and characterized. Partial nucleotide sequence analysis of the cDNA revealed a deletion of 243 nucleotides coding for 81 amino acids in a portion of the immunoglobulin-like domains of the extracellular region of the receptor. cDNA polymerase chain reaction (PCR) of the total cellular RNA in the glioma indicated that more than 80% of the transcripts have a deletion of 243 nucleotides. Analysis of a PCR-amplified DNA fragment derived from the amplified alpha-PDGF receptor gene in the glioma revealed that an exon coding for the 81 amino acids was removed by a 2.1 kb gene deletion. We also found amplification of the alpha-PDGF receptor gene in macroscopically normal cortex adjacent to the glioma from the same patient. The amplified gene in the macroscopically normal cortex has no major gene deletion, suggesting that gene amplification is not sufficient for the development of malignant gliomas.	TOHOKU UNIV,GENE RES CTR,1-1 TSUTSUMIDORI AMAMIYA,AOBA KU,SENDAI 981,JAPAN; TOHOKU UNIV,SCH MED,INST BRAIN DIS,DIV NEUROSURG,AOBA KU,SENDAI,MIYAGI 980,JAPAN	Tohoku University; Tohoku University								BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BURGER PC, 1985, CANCER, V56, P1106, DOI 10.1002/1097-0142(19850901)56:5<1106::AID-CNCR2820560525>3.0.CO;2-2; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FELDMAN RA, 1982, J VIROL, V42, P228, DOI 10.1128/JVI.42.1.228-236.1982; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HELDIN CH, 1985, MOL CELL ENDOCRINOL, V39, P169, DOI 10.1016/0303-7207(85)90061-9; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN CH, 1989, TRENDS GENET, V5, P108, DOI 10.1016/0168-9525(89)90040-1; LEE KH, 1990, MOL CELL BIOL, V10, P2237, DOI 10.1128/MCB.10.5.2237; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; MALDEN LT, 1988, CANCER RES, V48, P2711; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATSUSHIME H, 1986, MOL CELL BIOL, V6, P3000, DOI 10.1128/MCB.6.8.3000; NECKAMEYER WS, 1985, J VIROL, V53, P879, DOI 10.1128/JVI.53.3.879-884.1985; NECKAMEYER WS, 1986, MOL CELL BIOL, V6, P1478, DOI 10.1128/MCB.6.5.1478; NISTER M, 1988, CELL, V52, P791, DOI 10.1016/0092-8674(88)90421-7; RETTENMIER CW, 1985, SCIENCE, V228, P320, DOI 10.1126/science.2580348; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMID CW, 1982, SCIENCE, V216, P1065, DOI 10.1126/science.6281889; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHIBUYA M, 1990, ONCOGENE, V5, P519; STECK PA, 1988, CANCER RES, V48, P5433; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAHLS WP, 1990, MOL CELL BIOL, V10, P785, DOI 10.1128/MCB.10.2.785; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WESTERMARK B, 1983, GROWTH MATURATION FA, P73; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YAMAMOTO T, 1983, CELL, V35, P71, DOI 10.1016/0092-8674(83)90209-X; YAMAZAKI H, 1988, MOL CELL BIOL, V8, P1816, DOI 10.1128/MCB.8.4.1816; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; ZULCH KJ, 1979, INT HISTOLOGICAL CLA, V21	42	70	91	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					627	633						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1314366				2022-12-28	WOS:A1992HQ68200003
J	KREIDER, BL; ROVERA, G				KREIDER, BL; ROVERA, G			THE IMMEDIATE EARLY GENE RESPONSE TO A DIFFERENTIATIVE STIMULUS IS DISRUPTED BY THE V-ABL AND V-RAS ONCOGENES	ONCOGENE			English	Article							SERUM GROWTH-FACTORS; PROGENITOR-CELL LINE; C-FOS; PROTO-ONCOGENE; GRANULOCYTIC DIFFERENTIATION; FACTORS ENCODES; 3T3 CELLS; JUN; INDUCTION; TRANSCRIPTION	The immediate early gene activation in response to a differentiative stimulus was investigated in the hematopoietic progenitor cell line 32DC13(G). A transient and coordinated increase in mRNA levels for c-fos, c-jun, jun-B, TIS-7/PC-4, TIS-8/egr-1, and TIS-11 occurred during the first 2 h of treatment with granulocyte colony stimulating factor (G-CSF), which ultimately induces the 32DC13(G) cells to terminally differentiate into neutrophilic granulocytes. This pattern of mRNA induction was disrupted by v-abl and v-ras, two oncogenes known to interfere with G-CSF-induced differentiation of 32DC13(G) cells. Induction of the mRNAs for c-jun and TIS-7/PC-4 was blocked by the presence of v-abl, whereas v-ras caused constitutive expression of c-fos mRNA and blocked the c-jun, jun-B and TIS-7/PC-4 mRNA response. Release of the differentiation block in the ras-transformed 32DC13(G) cells by co-treatment with retinoic acid and G-CSF partially restored the normal c-fos and c-jun mRNA induction pattern, suggesting that the proper activation of these genes may be important for myeloid differentiation.	WISTAR INST,36TH & SPRUCE ST,PHILADELPHIA,PA 19104	The Wistar Institute					NCI NIH HHS [CA 52009, CA 10815, CA 09171] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009171, P30CA010815, P01CA052009] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURRAN T, 1988, ONCOGENE HDB; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; KHALILI K, 1984, J MOL BIOL, V180, P1007, DOI 10.1016/0022-2836(84)90268-7; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEDWITH BJ, 1990, MOL CELL BIOL, V10, P1545, DOI 10.1128/MCB.10.4.1545; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LIM RW, 1989, MOL CELL BIOL, V9, P1790, DOI 10.1128/MCB.9.4.1790; MAVILIO F, 1989, ONCOGENE, V4, P301; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; OHTA M, 1989, PATHOL IMMUNOPATH R, V8, P1, DOI 10.1159/000157134; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; ROVERA G, 1987, ONCOGENE, V1, P29; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TIRONE F, 1989, P NATL ACAD SCI USA, V86, P2088, DOI 10.1073/pnas.86.6.2088; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VARNUM BC, 1989, MOL CELL BIOL, V9, P3580, DOI 10.1128/MCB.9.8.3580; WATSON MA, 1989, MOL CELL BIOL, V9, P4213, DOI 10.1128/MCB.9.10.4213	34	20	20	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1992	7	1					135	140						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1371335				2022-12-28	WOS:A1992HC22700018
J	Bao, LT; Karpenko, VV; Forster, AC				Bao, Letian; Karpenko, Victoriia V.; Forster, Anthony C.			Rate-limiting hydrolysis in ribosomal release reactions revealed by ester activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA; GGQ MOTIF; PEPTIDYL; SITE; TRANSLATION		[Bao, Letian; Karpenko, Victoriia V.; Forster, Anthony C.] Uppsala Univ, Dept Cell & Mol Biol, Uppsala, Sweden	Uppsala University	Forster, AC (corresponding author), Uppsala Univ, Dept Cell & Mol Biol, Uppsala, Sweden.	a.forster@icm.uu.se			Swedish Research Council;  [2017-04148]	Swedish Research Council(Swedish Research CouncilEuropean Commission); 	Funding and additional information - This work was supported by the Swedish Research Council (NT project grant 2017-04148 to A. C. F.) .	Amort M, 2007, NUCLEIC ACIDS RES, V35, P5130, DOI 10.1093/nar/gkm539; CASKEY CT, 1971, P NATL ACAD SCI USA, V68, P3163, DOI 10.1073/pnas.68.12.3163; Doerfel LK, 2015, J AM CHEM SOC, V137, P12997, DOI 10.1021/jacs.5b07427; Freistroffer DV, 1997, EMBO J, V16, P4126, DOI 10.1093/emboj/16.13.4126; Fu ZA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10608-z; Indrisiunaite G, 2015, J MOL BIOL, V427, P1848, DOI 10.1016/j.jmb.2015.01.007; Jin H, 2010, P NATL ACAD SCI USA, V107, P8593, DOI 10.1073/pnas.1003995107; Johansson M, 2011, P NATL ACAD SCI USA, V108, P79, DOI 10.1073/pnas.1012612107; Kazemi M, 2016, ACS CATAL, V6, P8432, DOI 10.1021/acscatal.6b02842; Kuhlenkoetter S, 2011, NATURE, V476, P351, DOI 10.1038/nature10247; Kwiatkowski M, 2014, BIOCONJUGATE CHEM, V25, P2086, DOI 10.1021/bc500441b; Liljeruhm J, 2019, ACS CHEM BIOL, V14, P204, DOI 10.1021/acschembio.8b00952; Loh PG, 2010, CURR OPIN STRUC BIOL, V20, P98, DOI 10.1016/j.sbi.2009.12.005; Mora L, 2003, MOL MICROBIOL, V47, P267, DOI 10.1046/j.1365-2958.2003.03301.x; Pundir S, 2021, J BIOL CHEM, V296, DOI 10.1016/j.jbc.2021.100681; Schmeing TM, 2002, NAT STRUCT BIOL, V9, P225, DOI 10.1038/nsb758; Shaw JJ, 2007, MOL CELL, V28, P458, DOI 10.1016/j.molcel.2007.09.007; Simonovic M, 2008, RNA, V14, P2372, DOI 10.1261/rna.1118908; Vogel C, 2020, ENG REP, V2, DOI 10.1002/eng2.12126; Wang JF, 2016, J AM CHEM SOC, V138, P15587, DOI 10.1021/jacs.6b06936; Welch EM, 2007, NATURE, V447, P87, DOI 10.1038/nature05756; Zaher HS, 2011, EMBO J, V30, P2445, DOI 10.1038/emboj.2011.142; Zavialov AV, 2002, MOL CELL, V10, P789, DOI 10.1016/S1097-2765(02)00691-3; Zhang BL, 2007, J AM CHEM SOC, V129, P11316, DOI 10.1021/ja073487l	24	0	0	1	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV	2022	28	11								10.1016/j.jbc.2022.102509	http://dx.doi.org/10.1016/j.jbc.2022.102509			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	6I4GS	36300356	Green Published, gold			2022-12-28	WOS:000886086000012
J	Zhang, YY; Liang, RH; Wang, SJ; Ye, ZW; Wang, TY; Chen, M; Liu, JB; Na, L; Yang, YL; Yang, YB; Yuan, SF; Yin, X; Cai, XH; Tang, YD				Zhang, Yu-Yuan; Liang, Ronghui; Wang, Shu-Jie; Ye, Zi-Wei; Wang, Tong-Yun; Chen, Meng; Liu, Jianbo; Na, Lei; Yang, Yue-Lin; Yang, Yong-Bo; Yuan, Shuofeng; Yin, Xin; Cai, Xue-Hui; Tang, Yan-Dong			SARS-CoV-2 hijacks macropinocytosis to facilitate its entry and promote viral spike-mediated cell-to-cell fusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS ENTRY; RECEPTOR; REPLICATION; MECHANISMS; PATHWAY; TMPRSS2; GROWTH	Revealing the mechanisms of severe acute respiratory syn-drome coronavirus 2 (SARS-CoV-2) entry and cell-to-cell spread might provide insights for understanding the underly-ing mechanisms of viral pathogenesis, tropism, and virulence. The signaling pathways involved in SARS-CoV-2 entry and viral spike-mediated cell-to-cell fusion remain elusive. In the current study, we found that macropinocytosis inhibitors significantly suppressed SARS-CoV-2 infection at both the entry and viral spike-mediated cell-to-cell fusion steps. We demonstrated that SARS-CoV-2 entry required the small GTPase Rac1 and its effector kinase p21-activated kinase 1 by dominant-negative and RNAi assays in human embryonic kidney 293T-angiotensin-converting enzyme 2 cells and that the serine protease transmembrane serine protease 2 reversed the decrease in SARS-CoV-2 entry caused by the macro-pinocytosis inhibitors. Moreover, in the cell-to-cell fusion assay, we confirmed that macropinocytosis inhibitors signifi- cantly decreased viral spike-mediated cell-to-cell fusion. Overall, we provided evidence that SARS-CoV-2 utilizes a macropinocytosis pathway to enter target cells and to effi- ciently promote viral spike-mediated cell-to-cell fusion.	[Zhang, Yu-Yuan; Wang, Shu-Jie; Wang, Tong-Yun; Chen, Meng; Liu, Jianbo; Na, Lei; Yang, Yue-Lin; Yang, Yong-Bo; Yin, Xin; Cai, Xue-Hui; Tang, Yan-Dong] Chinese Acad Agr Sci, State Key Lab Vet Biotechnol, Harbin Vet Res Inst, Harbin, Peoples R China; [Liang, Ronghui; Ye, Zi-Wei; Yuan, Shuofeng] Univ Hong Kong, Dept Microbiol, Hong Kong, Peoples R China; [Yuan, Shuofeng] Univ Hong Kong, Li Ka Shing Fac Med, State Key Lab Emerging Infect Dis, Hong Kong, Peoples R China	Chinese Academy of Agricultural Sciences; Harbin Veterinary Research Institute, CAAS; University of Hong Kong; University of Hong Kong	Yin, X; Tang, YD (corresponding author), Chinese Acad Agr Sci, State Key Lab Vet Biotechnol, Harbin Vet Res Inst, Harbin, Peoples R China.; Yuan, SF (corresponding author), Univ Hong Kong, Dept Microbiol, Hong Kong, Peoples R China.; Yuan, SF (corresponding author), Univ Hong Kong, Li Ka Shing Fac Med, State Key Lab Emerging Infect Dis, Hong Kong, Peoples R China.	yuansf@hku.hk; yinxin@caas.cn; tangyandong2008@163.com			Health and Medical Research Fund [CIDHKU1-11, 20190732]; Food and Health Bureau; Government of the Hong Kong Special Administrative Region; HKU Seed Fund for Basic Research [202011159023]	Health and Medical Research Fund; Food and Health Bureau; Government of the Hong Kong Special Administrative Region; HKU Seed Fund for Basic Research	This study was partially funded by grants from the Health and Medical Research Fund (grant numbers: CIDHKU1-11 and 20190732), the Food and Health Bureau, and The Government of the Hong Kong Special Administrative Region, and HKU Seed Fund for Basic Research (grant number: 202011159023).	Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249; Bayati A, 2021, J BIOL CHEM, V296, DOI 10.1016/j.jbc.2021.100306; Braga L, 2021, NATURE, V594, P88, DOI 10.1038/s41586-021-03491-6; Chan JFW, 2020, J CLIN MICROBIOL, V58, DOI [10.1128/JCM.00310-20, 10.1128/JCM.00310-20.]; Doherty GJ, 2009, ANNU REV BIOCHEM, V78, P857, DOI 10.1146/annurev.biochem.78.081307.110540; Freeman MC, 2014, MBIO, V5, DOI 10.1128/mBio.01340-14; HAIGLER HT, 1979, J CELL BIOL, V83, P82, DOI 10.1083/jcb.83.1.82; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Hunt CL, 2011, J VIROL, V85, P334, DOI 10.1128/JVI.01278-09; Kerr MC, 2009, TRAFFIC, V10, P364, DOI 10.1111/j.1600-0854.2009.00878.x; Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301; Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145; Li XW, 2021, COMPUT STRUCT BIOTEC, V19, P1933, DOI 10.1016/j.csbj.2021.04.001; MATLIN KS, 1982, J MOL BIOL, V156, P609, DOI 10.1016/0022-2836(82)90269-8; Meng B, 2022, NATURE, V603, P706, DOI 10.1038/s41586-022-04474-x; Mercer J, 2012, CURR OPIN MICROBIOL, V15, P490, DOI 10.1016/j.mib.2012.05.016; Mercer J, 2010, ANNU REV BIOCHEM, V79, P803, DOI 10.1146/annurev-biochem-060208-104626; Mercer J, 2009, NAT CELL BIOL, V11, P510, DOI 10.1038/ncb0509-510; Moasser MM, 2001, CANCER RES, V61, P7184; Mugisha CS, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00658-20; Nanbo A, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001121; Ou TL, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009212; Perlman S, 2009, NAT REV MICROBIOL, V7, P439, DOI 10.1038/nrmicro2147; Pernet O, 2009, VIROLOGY, V395, P298, DOI 10.1016/j.virol.2009.09.016; Peterson JR, 2002, CHEM BIOL, V9, P1275, DOI 10.1016/S1074-5521(02)00284-3; Pommerenke C, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0255622; Raghu H, 2009, J VIROL, V83, P4895, DOI 10.1128/JVI.02498-08; Rajah MM, 2022, J MOL BIOL, V434, DOI 10.1016/j.jmb.2021.167280; Schmidt FI, 2011, EMBO J, V30, P3647, DOI 10.1038/emboj.2011.245; Shang J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/pnas.2003138117; Tang YD, 2014, J VIROL, V88, P12296, DOI 10.1128/JVI.01379-14; Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19; Wang XN, 2020, VIRULENCE, V11, P669, DOI 10.1080/21505594.2020.1770491; Whitt MA, 2010, J VIROL METHODS, V169, P365, DOI 10.1016/j.jviromet.2010.08.006; Wu F, 2020, NATURE, V580, pE7, DOI 10.1038/s41586-020-2202-3; Yang YL, 2021, J VIROL, V95, DOI 10.1128/JVI.00944-21; Yang YL, 2020, EMERG MICROBES INFEC, V9, P457, DOI 10.1080/22221751.2020.1730245; Yuan SF, 2021, NATURE, V593, P418, DOI 10.1038/s41586-021-03431-4; Yuan SF, 2020, NAT MICROBIOL, V5, P1439, DOI 10.1038/s41564-020-00802-x; Zeng C, 2022, P NATL ACAD SCI USA, V119, DOI [10.1073/pnas.2111400119, 10.1101/2021.06.01.446579]; Zhang HL, 2021, J BIOL CHEM, V296, DOI 10.1016/j.jbc.2021.100435; Zhao MM, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00558-8; Zhou P, 2020, NATURE, V588, pE6, DOI [10.1038/s41586-020-2951-z, 10.1038/s41586-020-2012-7]	43	0	0	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV	2022	298	11							102511	10.1016/j.jbc.2022.102511	http://dx.doi.org/10.1016/j.jbc.2022.102511			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	6G4BI	36259516	gold, Green Published			2022-12-28	WOS:000884698500004
J	FISCH, P; BOEHM, T; LAVENIR, I; LARSON, T; ARNO, J; FORSTER, A; RABBITTS, TH				FISCH, P; BOEHM, T; LAVENIR, I; LARSON, T; ARNO, J; FORSTER, A; RABBITTS, TH			T-CELL ACUTE LYMPHOBLASTIC LYMPHOMA INDUCED IN TRANSGENIC MICE BY THE RBTN1 AND RBTN2 LIM-DOMAIN GENES	ONCOGENE			English	Article							TISSUE-SPECIFIC EXPRESSION; DNA-BINDING MOTIF; HUMAN CD2 GENE; C-MYC GENE; CHROMOSOMAL TRANSLOCATION; MESSENGER-RNAS; CHAIN GENE; LEUKEMIA; PROTEIN; ONCOGENE	Two members of the RBTN gene family, RBTN1/Ttg-1 and RBTN2/Ttg-2, were found by their association with T-cell tumour-specific chromosomal translocations and are thought to be involved in the aetiology of such T-cell tumours. Here a transgenic mouse model is described in which T-cell tumours are induced by the presence of RBTN1 and RBTN2 transgenes that direct expression in thymus-derived cells. The latency period for lymphoid tumour appearance is variable, and tumours occur in a small proportion of transgenic animals that develop T-cell acute lymphoblastic malignancies. No significant increase in the rate of tumour development was observed in RBTN1 transgenic mice infected with Moloney murine leukaemia virus, nor did tumours arise in mice bearing a construct in which RBTN1 was expressed from the insulin transcriptional promoter. These data, which provide formal proof of the oncogenic activity of these genes, suggest that aberrant expression of transcription factor genes, such as RBTN1 and RBTN2, functions in tumour aetiology by disturbing some aspect of T-cell differentiation.	MRC, MOLEC BIOL LAB, HILLS RD, CAMBRIDGE CB2 2QH, ENGLAND; ADDENBROOKES HOSP, DEPT HISTOPATHOL, CAMBRIDGE CB2 2QQ, ENGLAND	MRC Laboratory Molecular Biology; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge			Rabbitts, Terence/D-6262-2016	Rabbitts, Terence/0000-0002-4982-2609				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ALLEN ND, 1988, NATURE, V333, P852, DOI 10.1038/333852a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BERNARD O, 1990, GENE CHROMOSOME CANC, V1, P194, DOI 10.1002/gcc.2870010303; BLUESTONE JA, 1987, NATURE, V326, P82, DOI 10.1038/326082a0; BOEHM T, 1990, EMBO J, V9, P857, DOI 10.1002/j.1460-2075.1990.tb08183.x; BOEHM T, 1990, ONCOGENE, V5, P1103; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BOEHM T, 1991, ONCOGENE, V6, P695; BOEHM T, 1988, EMBO J, V7, P2011, DOI 10.1002/j.1460-2075.1988.tb03040.x; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; BRUGGEMANN M, 1991, EUR J IMMUNOL, V21, P1323, DOI 10.1002/eji.1830210535; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; DUBE ID, 1991, BLOOD, V78, P2996; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GREENBERG JM, 1990, NATURE, V344, P158, DOI 10.1038/344158a0; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HEIM S, 1991, REC ADV PATH, V3, P37; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; KRIMPENFORT P, 1988, EMBO J, V7, P745, DOI 10.1002/j.1460-2075.1988.tb02871.x; LAKE RA, 1990, EMBO J, V9, P3129, DOI 10.1002/j.1460-2075.1990.tb07510.x; LANG G, 1988, EMBO J, V7, P1675, DOI 10.1002/j.1460-2075.1988.tb02995.x; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; LU M, 1991, EMBO J, V10, P2905, DOI 10.1002/j.1460-2075.1991.tb07840.x; MALISSEN M, 1984, CELL, V37, P1101, DOI 10.1016/0092-8674(84)90444-6; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; MCGUIRE EA, 1991, BLOOD, V77, P599; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; RABBITTS TH, 1985, EMBO J, V4, P2217, DOI 10.1002/j.1460-2075.1985.tb03917.x; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; RABBITTS TH, 1991, ADV IMMUNOL, V50, P119; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; SANCHEZGARCIA I, 1991, ONCOGENE, V6, P577; THICK J, 1992, IN PRESS GENES CHROM, V5; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416	51	113	118	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1992	7	12					2389	2397						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1461647				2022-12-28	WOS:A1992KA85600003
J	RAO, VN; REDDY, ESP				RAO, VN; REDDY, ESP			ELK-1 DOMAINS RESPONSIBLE FOR AUTONOMOUS DNA-BINDING, SRE-SRF INTERACTION AND NEGATIVE REGULATION OF DNA-BINDING	ONCOGENE			English	Article							PUTATIVE ONCOGENE SPI-1; MURINE LEUKEMIA-VIRUS; LONG TERMINAL REPEAT; ETS PROTO-ONCOGENE; C-ETS; V-ETS; TRANSCRIPTIONAL ACTIVATION; C-ETS-1 PROTOONCOGENE; GENE; SEQUENCE	The ets oncogene superfamily consists of a family of sequence-specific DNA-binding transcriptional activator proteins. We have previously identified, cloned and characterized one of the divergent ets-related members elk-1 and shown that it codes for a sequence-specific DNA-binding transcriptional activator. We have also shown that elk-1 forms SRF (Serum Response Factor) dependent ternary complex with SRE (Serum Response Element), similar to p62TCF. In this report, we have mapped the DNA-binding domain of the elk-1 protein (EDB, elk-1 DNA Binding domain) to the 76 amino acid ets homology region. We have also mapped the SRF interaction domain of the elk-1 protein (ESI, elk-1 SRF Interaction domain) to the carboxy-terminal region of the EDB domain. Ternary complex formation by elk-1 requires both EDB and ESI domains of the elk-1 protein. Our results also show that the EDB domain of the elk-1 protein (residues1-89) binds SRE autonomously, unlike full-length elk-1 protein, suggesting the presence of a potential Negative Regulatory DNA binding domain (NRD) which prevents the binding of elk-1 protein to SRE. Interaction of SRF with the ESI domain allows the elk-1 protein to bind to SRE. Thus elk-1 belongs to a class of transcriptional factors that are involved in gene regulation not only by autonomous DNA binding but also by indirect DNA binding through recruitment by cellular factors.			RAO, VN (corresponding author), JEFFERSON CANC INST,BLUMLE LIFE SCI BLDG,233 S 10TH ST,PHILADELPHIA,PA 19107, USA.							ANTON IA, 1988, NATURE, V336, P719, DOI 10.1038/336719a0; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BEUG H, 1984, CELL, V39, P579, DOI 10.1016/0092-8674(84)90465-3; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHEN JH, 1988, ONCOGENE RES, V2, P371; CLARK SP, 1983, P NATL ACAD SCI-BIOL, V80, P5037, DOI 10.1073/pnas.80.16.5037; COQUILLAND M, 1988, ONCOGENE RES, V2, P335; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DIAZ MO, 1986, SCIENCE, V231, P265, DOI 10.1126/science.3455787; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; FUJIWARA S, 1988, ONCOGENE, V2, P99; FUJIWARA S, 1988, MOL CELL BIOL, V8, P4700, DOI 10.1128/MCB.8.11.4700; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; HOLLAND CA, 1987, P NATL ACAD SCI USA, V84, P8662, DOI 10.1073/pnas.84.23.8662; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; POGNONEC P, 1989, ONCOGENE, V4, P691; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAO VN, 1992, ONCOGENE, V7, P65; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1988, ONCOGENE, V3, P497; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; REDDY ESP, 1988, ONCOGENE RES, V3, P239; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY ESP, 1991, ONCOGENE, V6, P2285; REDDY ESP, 1992, GUIDE BOOK ONCOGENES; REDDY ESP, 1990, CANCER RES, V50, P5013; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SETH A, 1990, ONCOGENE, V5, P1761; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TREISMAN R, 1990, CANCER BIOL, V1, P47; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	53	40	40	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2335	2340						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437156				2022-12-28	WOS:A1992JW66500028
J	REDDY, CD; DASGUPTA, P; SAIKUMAR, P; DUDEK, H; RAUSCHER, FJ; REDDY, EP				REDDY, CD; DASGUPTA, P; SAIKUMAR, P; DUDEK, H; RAUSCHER, FJ; REDDY, EP			MUTATIONAL ANALYSIS OF MAX - ROLE OF BASIC, HELIX LOOP HELIX LEUCINE ZIPPER DOMAINS IN DNA-BINDING, DIMERIZATION AND REGULATION OF MYC-MEDIATED TRANSCRIPTIONAL ACTIVATION	ONCOGENE			English	Article							ESCHERICHIA-COLI; PROTO-ONCOGENE; GROWTH-FACTOR; PROTEINS; EXPRESSION; CELLS; OLIGOMERIZATION; PURIFICATION; SPECIFICITY; ENHANCER	The Max protein forms a heterodimeric complex with the Myc family of proteins and binds to DNA in a sequence-specific manner. We investigated the role of the helix-loop-helix (HLH), leucine zipper (LZ) and basic domains of Max in protein complex formation, DNA-binding activity and transcriptional regulation. We mutagenized the basic, HLH and LZ domains of Max and studied the ability of the normal and mutant proteins to bind to DNA as both homo- and heterodimers and their ability to heterodimerize with Myc. Helix-1 and helix-2 regions of Max were found to be critical for homodimer formation and subsequent DNA binding, while the LZ was essential for heterodimer formation. In transient transfection assays the Myc protein functioned as a transcriptional activator while Max protein repressed the trans-activation observed with Myc.	FELS INST CANC RES & MOLEC BIOL,3420 N BROAD ST,PHILADELPHIA,PA 19140; WISTAR INST,PHILADELPHIA,PA 19104	The Wistar Institute			Reddy, E. Premkumar/F-6233-2011		NATIONAL CANCER INSTITUTE [P01CA052009, P01CA021124] Funding Source: NIH RePORTER; NCI NIH HHS [CA10817, CA52009, CA21124] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; BECKMANN H, 1991, GENE DEV, V5, P1057, DOI 10.1101/gad.5.6.1057; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENNEROT CD, 1987, P NATL ACAD SCI USA, V84, P6796; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BEREBERICH S, 1992, ONCOGENE, V7, P775; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COLLUM RG, 1990, CANCER CELL-MON REV, V2, P69; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI L, 1992, ADV CANCER RES, V58, P95, DOI 10.1016/S0065-230X(08)60292-4; MIKSICEK R, 1986, CELL, V46, P283, DOI 10.1016/0092-8674(86)90745-2; MIYAMOTO C, 1985, P NATL ACAD SCI USA, V82, P7232, DOI 10.1073/pnas.82.21.7232; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; SETH A, 1986, GENE, V42, P49, DOI 10.1016/0378-1119(86)90149-6; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; WAGNER AJ, 1992, P NATL ACAD SCI USA, V89, P3111, DOI 10.1073/pnas.89.7.3111; WIEGLER M, 1978, CELL, V14, P725; ZIMMERMAN K, 1990, Critical Reviews in Oncogenesis, V2, P75	37	62	62	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					2085	2092						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408152				2022-12-28	WOS:A1992JP42400027
J	FLEMING, TP; MATSUI, T; HEIDARAN, MA; MOLLOY, CJ; ARTRIP, J; AARONSON, SA				FLEMING, TP; MATSUI, T; HEIDARAN, MA; MOLLOY, CJ; ARTRIP, J; AARONSON, SA			DEMONSTRATION OF AN ACTIVATED PLATELET-DERIVED GROWTH-FACTOR AUTOCRINE PATHWAY AND ITS ROLE IN HUMAN TUMOR-CELL PROLIFERATION INVITRO	ONCOGENE			English	Article							SIMIAN SARCOMA-VIRUS; SIS-TRANSFORMED-CELLS; V-SIS; FACTOR RECEPTORS; GENE; EXPRESSION; CDNA; STIMULATION; SURAMIN; CLONING	In tumor cells expressing platelet-derived growth factor (PDGF) ligand(s) and receptor(s), immunoblot analysis established tyrosine phosphorylation of PDGF receptors (PDGFRs) in the absence of any exogenous ligand, implying chronic receptor activation. Exposure to suramin resulted in diminished receptor autophosphorylation and/or up-regulation of receptor protein. In a subset of such tumor lines, there was a marked reduction in DNA synthesis in response to suramin or PDGF-neutralizing antiserum. These findings demonstrate that autocrine PDGF stimulation contributes to proliferation of some human tumors and that agents which interfere with ligand-receptor interactions at the cell surface can significantly interfere in this process.	NCI,CELLULAR & MOLEC BIOL LAB,BLDG 37,ROOM 1E24,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Molloy, Christopher/A-6821-2013; Matsui, Toshimitsu/E-8065-2010	Molloy, Christopher/0000-0003-2964-6166; Matsui, Toshimitsu/0000-0002-2536-7584				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BECKMANN MP, 1988, SCIENCE, V241, P1346, DOI 10.1126/science.2842868; BETSHOLTZ C, 1986, P NATL ACAD SCI USA, V83, P6440, DOI 10.1073/pnas.83.17.6440; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; FLEMING TP, 1989, P NATL ACAD SCI USA, V86, P8063, DOI 10.1073/pnas.86.20.8063; GARRETT JS, 1984, P NATL ACAD SCI-BIOL, V81, P7466, DOI 10.1073/pnas.81.23.7466; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; HANNINK M, 1988, J CELL BIOL, V107, P287, DOI 10.1083/jcb.107.1.287; HELDIN CH, 1990, GROWTH FACTORS DIFFE, P267; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HUANG JS, 1984, CELL, V39, P79, DOI 10.1016/0092-8674(84)90193-4; HUANG SS, 1988, J BIOL CHEM, V263, P12608; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; JOHNSSON A, 1985, NATURE, V317, P438, DOI 10.1038/317438a0; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; LAROCCA RV, 1990, CANCER CELL-MON REV, V2, P106; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NISTER M, 1991, J BIOL CHEM, V266, P16755; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; ROBBINS KC, 1983, NATURE, V305, P605, DOI 10.1038/305605a0; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; STACEY DW, 1987, EXP CELL RES, V171, P232, DOI 10.1016/0014-4827(87)90266-7; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	31	52	53	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1355	1359						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1320245				2022-12-28	WOS:A1992HZ97100014
J	Suphakhong, K; Terashima, M; Wanna-udom, S; Takatsuka, R; Ishimura, A; Takino, T; Suzuki, T				Suphakhong, Kusuma; Terashima, Minoru; Wanna-udom, Sasithorn; Takatsuka, Risa; Ishimura, Akihiko; Takino, Takahisa; Suzuki, Takeshi			m6A RNA methylation regulates the transcription factors JUN and JUNB in TGF-beta-induced epithelial-mesenchymal transition of lung cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							M(6)A MODIFICATION; EXPRESSION; TRANSLATION; CONTRIBUTES; DECREASES; MIGRATION; EMT	N6-methyladenosine (m6A) is the most common internal chemical modification of mRNAs involved in many patholog-ical processes including various cancers. In this study, we investigated the m6A-dependent regulation of JUN and JUNB transcription factors (TFs) during transforming growth factor-beta-induced epithelial-mesenchymal transition (EMT) of A549 and LC2/ad lung cancer cell lines, as the function and regulation of these TFs within this process remains to be clarified. We found that JUN and JUNB played an important and nonredundant role in the EMT-inducing gene expression program by regulating different mesenchymal genes and that their expressions were controlled by methyltransferase-like 3 (METTL3) m6A methyltransferase. METTL3-mediated regu-lation of JUN expression is associated with the translation process of JUN protein but not with the stability of JUN protein or mRNA, which is in contrast with the result of m6A-mediated regulation of JUNB mRNA stability. We identified the specific m6A motifs responsible for the regulation of JUN and JUNB in EMT within 30UTR of JUN and JUNB. Furthermore, we discovered that different m6A reader proteins interacted with JUN and JUNB mRNA and controlled m6A-dependent expression of JUN protein and JUNB mRNA. These results demonstrate that the different modes of m6A-mediated regu-lation of JUN and JUNB TFs provide critical input in the gene regulatory network during transforming growth factor-beta- induced EMT of lung cancer cells.	[Suphakhong, Kusuma; Terashima, Minoru; Wanna-udom, Sasithorn; Takatsuka, Risa; Ishimura, Akihiko; Suzuki, Takeshi] Kanazawa Univ, Canc Res Inst, Div Funct Genom, Kanazawa, Ishikawa, Japan; [Takino, Takahisa] Kanazawa Univ, Inst Liberal Arts & Sci, Div Educ Global Stand, Kanazawa, Ishikawa, Japan; [Suzuki, Takeshi] Naresuan Univ, Fac Med Sci, Dept Anat, Phitsanulok, Thailand	Kanazawa University; Kanazawa University; Naresuan University	Suzuki, T (corresponding author), Naresuan Univ, Fac Med Sci, Dept Anat, Phitsanulok, Thailand.	suzuki-t@staff.kanazawa-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan;  [22K06880];  [22K07147];  [22K07146]	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); ; ; 	Funding and additional information-This work was supported in part by Grants-in-Aid for Scientific Research C (grant numbers: 22K06880 to T. S., 22K07147 to M. T., and 22K07146 to A. I.) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Chang GQ, 2020, CANCER CELL, V38, P857, DOI 10.1016/j.ccell.2020.10.004; Chen HM, 2009, CANCER RES, V69, P9228, DOI 10.1158/0008-5472.CAN-09-1950; Cheng C, 2021, MOL THER-NUCL ACIDS, V23, P487, DOI 10.1016/j.omtn.2020.12.001; Cheng MS, 2019, ONCOGENE, V38, P3667, DOI 10.1038/s41388-019-0683-z; Dai XY, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.635329; Dongre A, 2019, NAT REV MOL CELL BIO, V20, P69, DOI 10.1038/s41580-018-0080-4; Enkhbaatar Z, 2013, CELL CYCLE, V12, P2100, DOI 10.4161/cc.25142; Gervasi M, 2012, J CELL BIOL, V196, P589, DOI 10.1083/jcb.201109045; Ghosh Subarna, 2021, Oncotarget, V12, P1520, DOI 10.18632/oncotarget.28026; He PC, 2021, EMBO J, V40, DOI 10.15252/embj.2020105977; Hua WF, 2018, GYNECOL ONCOL, V151, P356, DOI 10.1016/j.ygyno.2018.09.015; Huang HL, 2020, CANCER CELL, V37, P270, DOI 10.1016/j.ccell.2020.02.004; Huang HL, 2018, NAT CELL BIOL, V20, P285, DOI 10.1038/s41556-018-0045-z; Huang XW, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0628-y; Huo FC, 2021, ONCOGENE, V40, P2968, DOI 10.1038/s41388-021-01753-1; Ishimura A, 2016, CELL TISSUE RES, V363, P723, DOI 10.1007/s00441-015-2276-7; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lan Q, 2019, CANCER RES, V79, P1285, DOI 10.1158/0008-5472.CAN-18-2965; Li A, 2017, CELL RES, V27, P444, DOI 10.1038/cr.2017.10; Li T, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1038-7; Lin GX, 2018, ONCOTARGETS THER, V11, P3805, DOI 10.2147/OTT.S162700; Lin XY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09865-9; Lin YX, 2022, ANN TRANSL MED, V10, DOI 10.21037/atm-21-6857; Liu T, 2020, J CELL PHYSIOL, V235, P548, DOI 10.1002/jcp.28994; Miao WJ, 2019, BIOCHEM BIOPH RES CO, V516, P719, DOI 10.1016/j.bbrc.2019.06.128; Muller S, 2019, NUCLEIC ACIDS RES, V47, P375, DOI 10.1093/nar/gky1012; Oktyabri D, 2014, BIOCHEM BIOPH RES CO, V453, P124, DOI 10.1016/j.bbrc.2014.09.082; Pastushenko I, 2019, TRENDS CELL BIOL, V29, P212, DOI 10.1016/j.tcb.2018.12.001; Serrano-Gomez SJ, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0502-x; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Shi HL, 2019, MOL CELL, V74, P640, DOI 10.1016/j.molcel.2019.04.025; Shi HL, 2017, CELL RES, V27, P315, DOI 10.1038/cr.2017.15; Song BW, 2021, BRIEF BIOINFORM, V22, DOI 10.1093/bib/bbab088; Stemmler MP, 2019, NAT CELL BIOL, V21, P102, DOI 10.1038/s41556-018-0196-y; Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336; Tange S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115684; Terashima M, 2018, J BIOL CHEM, V293, P18016, DOI 10.1074/jbc.RA118.004006; Terashima M, 2017, J BIOL CHEM, V292, P82, DOI 10.1074/jbc.M116.750950; Visvanathan A, 2018, ONCOGENE, V37, P522, DOI 10.1038/onc.2017.351; Wanna-Udom S, 2021, J BIOL CHEM, V296, DOI 10.1074/jbc.RA120.015502; Wanna-udom S, 2020, BIOCHEM BIOPH RES CO, V524, P150, DOI 10.1016/j.bbrc.2020.01.042; Xu YF, 2022, ONCOGENE, V41, P1281, DOI 10.1038/s41388-021-02146-0; Yoshida M, 2011, BIOCHEM J, V437, P555, DOI 10.1042/BJ20110343; Yue B, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1065-4; Zaccara S, 2019, NAT REV MOL CELL BIO, V20, P608, DOI 10.1038/s41580-019-0168-5; Zirkel A, 2013, NUCLEIC ACIDS RES, V41, P6618, DOI 10.1093/nar/gkt410	46	0	0	1	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV	2022	298	11							102554	10.1016/j.jbc.2022.102554	http://dx.doi.org/10.1016/j.jbc.2022.102554			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	6D3XI	36183833	gold, Green Published			2022-12-28	WOS:000882627400006
J	Wang, XX; Xie, C; Libby, AE; Ranjit, S; Levi, J; Myakala, K; Bhasin, K; Jones, BA; Orlicky, DJ; Takahashi, S; Dvornikov, A; Kleiner, DE; Hewitt, SM; Adorini, L; Kopp, JB; Krausz, KW; Rosenberg, A; McManaman, JL; Robertson, CE; Ir, D; Frank, DN; Luo, YH; Gonzalez, FJ; Gratton, E; Levi, M				Wang, Xiaoxin X.; Xie, Cen; Libby, Andrew E.; Ranjit, Suman; Levi, Jonathan; Myakala, Komuraiah; Bhasin, Kanchan; Jones, Bryce A.; Orlicky, David J.; Takahashi, Shogo; Dvornikov, Alexander; Kleiner, David E.; Hewitt, Stephen M.; Adorini, Luciano; Kopp, Jeffrey B.; Krausz, Kristopher W.; Rosenberg, Avi; McManaman, James L.; Robertson, Charles E.; Ir, Diana; Frank, Daniel N.; Luo, Yuhuan; Gonzalez, Frank J.; Gratton, Enrico; Levi, Moshe			The role of FXR and TGR5 in reversing and preventing progression of Western diet-induced hepatic steatosis, inflammation, and fibrosis in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FARNESOID-X RECEPTOR; FATTY LIVER-DISEASE; RENAL LIPID-METABOLISM; BILE-ACID METABOLISM; NONALCOHOLIC STEATOHEPATITIS; FUNCTIONAL-CHARACTERIZATION; OBETICHOLIC ACID; WEIGHT-LOSS; ACTIVATION; INT-767	Nonalcoholic steatohepatitis (NASH) is the most common chronic liver disease in the US, partly due to the increasing incidence of metabolic syndrome, obesity, and type 2 diabetes. The roles of bile acids and their receptors, such as the nuclear receptor farnesoid X receptor (FXR) and the G protein-coupled receptor TGR5, on the development of NASH are not fully clear. C57BL/6J male mice fed a Western diet (WD) develop characteristics of NASH, allowing determination of the effects of FXR and TGR5 agonists on this disease. Here we show that the FXR-TGR5 dual agonist INT-767 prevents progression of WD-induced hepatic steatosis, inflammation, and fibrosis, as determined by histological and biochemical assays and novel label-free microscopy imaging techniques, including third harmonic generation, second harmonic generation, and fluo-rescence lifetime imaging microscopy. Furthermore, we show INT-767 decreases liver fatty acid synthesis and fatty acid and cholesterol uptake, as well as liver inflammation. INT-767 markedly changed bile acid composition in the liver and in-testine, leading to notable decreases in the hydrophobicity in-dex of bile acids, known to limit cholesterol and lipid absorption. In addition, INT-767 upregulated expression of liver p-AMPK, SIRT1, PGC-1 alpha, and SIRT3, which are master regulators of mitochondrial function. Finally, we found INT-767 treatment reduced WD-induced dysbiosis of gut micro -biota. Interestingly, the effects of INT-767 in attenuating NASH were absent in FXR-null mice, but still present in TGR5-null mice. Our findings support treatment and prevention protocols with the dual FXR-TGR5 agonist INT-767 arrest progression of WD-induced NASH in mice mediated by FXR-dependent, TGR5-independent mechanisms.	[Wang, Xiaoxin X.; Libby, Andrew E.; Ranjit, Suman; Myakala, Komuraiah; Bhasin, Kanchan; Takahashi, Shogo; Levi, Moshe] Georgetown Univ, Dept Biochem & Mol & Cellular Biol, Washington, DC 20057 USA; [Xie, Cen; Krausz, Kristopher W.; Gonzalez, Frank J.] NCI, NIH, Bethesda, MD USA; [Levi, Jonathan; Kleiner, David E.; Hewitt, Stephen M.; Kopp, Jeffrey B.] Natl Inst Diabet & Digest & Kidney Dis, NIH, Bethesda, MD USA; [Jones, Bryce A.] Georgetown Univ, Dept Pharmacol & Physiol, Washington, DC USA; [Orlicky, David J.] Univ Colorado AMC, Dept Pathol, Aurora, CO USA; [Dvornikov, Alexander; Gratton, Enrico] Univ Calif Irvine, Dept Biomed Engn, Lab Fluorescence Dynam, Irvine, CA USA; [Adorini, Luciano] Intercept Pharmaceut, New York, NY USA; [Rosenberg, Avi] Johns Hopkins Univ, Dept Pathol, Baltimore, MD USA; [McManaman, James L.] Univ Colorado AMC, Integrated Physiol Programx, Aurora, CO USA; [Robertson, Charles E.; Ir, Diana; Frank, Daniel N.; Luo, Yuhuan] Univ Colorado AMC, Dept Med, Aurora, CO USA	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Georgetown University; AMC Cancer Research Center; University of California System; University of California Irvine; Intercept Pharmaceuticals; Johns Hopkins University; AMC Cancer Research Center; AMC Cancer Research Center	Wang, XX; Levi, M (corresponding author), Georgetown Univ, Dept Biochem & Mol & Cellular Biol, Washington, DC 20057 USA.	Xiaoxin.Wang@georgetown.edu; Moshe.Levi@georgetown.edu		MYAKALA, KOMURAIAH/0000-0003-3233-047X; Orlicky, David/0000-0002-0417-1400	National Institutes of Health (NIH) [R01 AG049493, DK116567]; NIH NIGMS [P41-GM103540]; Medical School Grant by Intercept; NIH [TL1 TR001431, F30 DK129003]; AHA Fellowship Grants; Intramural Program of NIDDK; NCI	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Medical School Grant by Intercept; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); AHA Fellowship Grants; Intramural Program of NIDDK; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	These studies were supported by grant support from National Institutes of Health (NIH) R01 AG049493 and DK116567 (M. L.), NIH NIGMS P41-GM103540 (E. G. and S. R.), Medical School Grant by Intercept (M. L., X. X. W. and S. R.), NIH TL1 TR001431 and F30 DK129003 (B. A. J.), AHA Fellowship Grants (A. E. L. and K. M.), Intramural Program of NIDDK (J. B. K., A. R., and J. L.), and NCI (F. J. G., K. W. K., S. M. H., and D. E. K.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Arab JP, 2017, HEPATOLOGY, V65, P350, DOI 10.1002/hep.28709; Brodosi L, 2016, ANN HEPATOL, V15, P673, DOI 10.5604/16652681.1212318; Brunt EM, 1999, AM J GASTROENTEROL, V94, P2467, DOI 10.1111/j.1572-0241.1999.01377.x; Chiang John Y. L., 2018, Gene Expression, V18, P71, DOI 10.3727/105221618X15156018385515; Chiang JYL, 2013, COMPR PHYSIOL, V3, P1191, DOI 10.1002/cphy.c120023; Comeglio P, 2018, J ENDOCRINOL, V238, P107, DOI 10.1530/JOE-17-0557; Corey KE, 2016, DIGEST DIS SCI, V61, P1387, DOI 10.1007/s10620-016-4083-8; Ding LL, 2016, HEPATOLOGY, V64, P760, DOI 10.1002/hep.28689; Ding ZM, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00410; Donepudi AC, 2017, HEPATOLOGY, V65, P813, DOI 10.1002/hep.28707; Dvornikov A, 2016, BIOMED OPT EXPRESS, V7, P3747, DOI 10.1364/BOE.7.003747; Edgar RC, 2011, BIOINFORMATICS, V27, P2194, DOI 10.1093/bioinformatics/btr381; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Frank DN, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-362; Ganz M, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0552-7; Gariani K, 2017, J HEPATOL, V66, P132, DOI 10.1016/j.jhep.2016.08.024; Gariani K, 2016, HEPATOLOGY, V63, P1190, DOI 10.1002/hep.28245; Hu YB, 2018, DRUG DES DEV THER, V12, P2213, DOI 10.2147/DDDT.S170518; Iracheta-Vellve A, 2018, HEPATOL COMMUN, V2, P1379, DOI 10.1002/hep4.1256; Itagaki H, 2013, INT J CLIN EXP PATHO, V6, P2683; Jadhav K, 2018, MOL METAB, V9, P131, DOI 10.1016/j.molmet.2018.01.005; Jiang CT, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10166; Jiang CT, 2015, J CLIN INVEST, V125, P386, DOI 10.1172/JCI76738; Jiang T, 2007, DIABETES, V56, P2485, DOI 10.2337/db06-1642; Jobira B, 2020, J CLIN ENDOCR METAB, V105, pE2134, DOI 10.1210/clinem/dgz263; Kawamata Y, 2003, J BIOL CHEM, V278, P9435, DOI 10.1074/jbc.M209706200; Kisseleva T, 2017, HEPATOLOGY, V65, P1039, DOI 10.1002/hep.28948; Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701; Kohli R, 2015, DIGEST DIS, V33, P440, DOI 10.1159/000371699; Kristiansen MNB, 2019, BMC GASTROENTEROL, V19, DOI 10.1186/s12876-019-1149-z; Lanaspa MA, 2018, J CLIN INVEST, V128, P2226, DOI 10.1172/JCI94427; LANE DJ, 1985, P NATL ACAD SCI USA, V82, P6955, DOI 10.1073/pnas.82.20.6955; Levene AP, 2012, HISTOPATHOLOGY, V61, P141, DOI 10.1111/j.1365-2559.2011.04145.x; Libby AE, 2016, J BIOL CHEM, V291, P24231, DOI 10.1074/jbc.M116.759795; MacLaren R, 2019, NEUROSCIENCE, V398, P206, DOI 10.1016/j.neuroscience.2018.11.048; Marchesini G, 2016, HEPATOLOGY, V63, P2032, DOI 10.1002/hep.28392; Maruyama T, 2002, BIOCHEM BIOPH RES CO, V298, P714, DOI 10.1016/S0006-291X(02)02550-0; McMahan RH, 2013, J BIOL CHEM, V288, P11761, DOI 10.1074/jbc.M112.446575; Mintziori G, 2016, EXPERT OPIN PHARMACO, V17, P1937, DOI 10.1080/14656566.2016.1225727; Morrison MC, 2018, HEPATOL COMMUN, V2, P1513, DOI 10.1002/hep4.1270; Mudaliar S, 2013, GASTROENTEROLOGY, V145, P574, DOI 10.1053/j.gastro.2013.05.042; Mukhopadhyay P, 2017, J HEPATOL, V66, P589, DOI 10.1016/j.jhep.2016.10.023; Myronovych A, 2014, OBESITY, V22, P390, DOI 10.1002/oby.20548; Orlicky DJ, 2019, J PHYSIOL-LONDON, V597, P1565, DOI 10.1113/JP277140; Pathak P, 2017, J BIOL CHEM, V292, P11055, DOI 10.1074/jbc.M117.784322; Pols TWH, 2011, J HEPATOL, V54, P1263, DOI 10.1016/j.jhep.2010.12.004; Pruesse E, 2012, BIOINFORMATICS, V28, P1823, DOI 10.1093/bioinformatics/bts252; Quast C, 2013, NUCLEIC ACIDS RES, V41, pD590, DOI 10.1093/nar/gks1219; R Development Core Team, 2009, R LANG ENV STAT COMP; Ranjit S, 2017, BIOMED OPT EXPRESS, V8, P3143, DOI 10.1364/BOE.8.003143; Ranjit S, 2016, KIDNEY INT, V90, P1123, DOI 10.1016/j.kint.2016.06.030; Rizzo G, 2010, MOL PHARMACOL, V78, P617, DOI 10.1124/mol.110.064501; Robertson CE, 2013, BIOINFORMATICS, V29, P3100, DOI 10.1093/bioinformatics/btt526; Roth JD, 2018, WORLD J GASTROENTERO, V24, P195, DOI 10.3748/wjg.v24.i2.195; Russell TD, 2007, J LIPID RES, V48, P1463, DOI 10.1194/jlr.M600474-JLR200; Ryan KK, 2014, NATURE, V509, P183, DOI 10.1038/nature13135; Ryu D, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf5504; Schloss PD, 2011, APPL ENVIRON MICROB, V77, P3219, DOI 10.1128/AEM.02810-10; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Spengler EK, 2015, MAYO CLIN PROC, V90, P1233, DOI 10.1016/j.mayocp.2015.06.013; Stal P, 2015, WORLD J GASTROENTERO, V21, P11077, DOI 10.3748/wjg.v21.i39.11077; Stephenson Kristen, 2018, Gene Expression, V18, P5, DOI 10.3727/105221617X15093707969658; Thomas C, 2009, CELL METAB, V10, P167, DOI 10.1016/j.cmet.2009.08.001; Trauner M, 2017, HEPATOLOGY, V65, P1393, DOI 10.1002/hep.28991; Vassileva G, 2010, J ENDOCRINOL, V205, P225, DOI 10.1677/JOE-10-0009; Verbeke L, 2016, SCI REP-UK, V6, DOI 10.1038/srep33453; Wang XXX, 2016, J AM SOC NEPHROL, V27, P1362, DOI 10.1681/ASN.2014121271; Wang XXX, 2010, DIABETES, V59, P2916, DOI 10.2337/db10-0019; Wang XX, 2009, AM J PHYSIOL-RENAL, V297, pF1587, DOI 10.1152/ajprenal.00404.2009; WEISBURG WG, 1991, J BACTERIOL, V173, P697, DOI 10.1128/JB.173.2.697-703.1991; Wree A, 2013, NAT REV GASTRO HEPAT, V10, P627, DOI 10.1038/nrgastro.2013.149; Xie C, 2017, DIABETES, V66, P613, DOI 10.2337/db16-0663; Xu Y, 2016, HEPATOLOGY, V64, P1072, DOI 10.1002/hep.28712; Younossi ZM, 2019, LANCET, V394, P2184, DOI 10.1016/S0140-6736(19)33041-7	74	1	1	2	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV	2022	298	11							102530	10.1016/j.jbc.2022.102530	http://dx.doi.org/10.1016/j.jbc.2022.102530			23	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	6G4BI	36209823	gold, Green Published			2022-12-28	WOS:000884698500001
J	MARCELLE, C; EICHMANN, A				MARCELLE, C; EICHMANN, A			MOLECULAR-CLONING OF A FAMILY OF PROTEIN-KINASE GENES EXPRESSED IN THE AVIAN EMBRYO	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; POLYMERASE CHAIN-REACTION; TYROSINE KINASE; C-KIT; W-LOCUS; DEVELOPMENTAL EXPRESSION; PHOSPHOTYROSINE ANTIBODY; SIGNAL TRANSDUCTION; MOUSE DEVELOPMENT; EYE DEVELOPMENT	We have used the polymerase chain reaction (PCR) technique to clone kinase-related sequences from avian blastula, neural crest and neural tube mRNA. Twenty-three distinct protein kinase (PK) sequences were amplified, of which eight are identical to previously described PK genes. The cloned molecules fall into three classes: growth factor receptor tyrosine kinases (RTKs), cytosolic tyrosine kinases and serine/threonine kinases. Among the cloned RTKs were the insulin-like growth factor type I receptor, platelet-derived growth factor receptor alpha, the CEK1 fibroblast growth factor (FGF) receptor as well as the avian homolog of a recently cloned PCR fragment related to the eph/elk/eck family, tyro-5. Furthermore, we cloned a novel FGF receptor-like molecule as well as two novel putative RTKs related to the vascular endothelial growth factor (VEGF) receptor. The pattern of expression of the PCR clones was examined by Northern blot analysis of adult tissues: each molecule recognized one or more transcripts of various sizes, suggesting that PK genes may play regulatory roles both in early development and in adult regulation of tissue function. Together with recent studies, this survey confirms the hypothesis that PKs may play important roles in early vertebrate development.			MARCELLE, C (corresponding author), INST EMBRYOL, CNRS, 49BIS, AVE BELLE GABRIELLE, F-94736 NOGENT SUR MARNE, FRANCE.							ADAMSON ED, 1987, DEVELOPMENT, V99, P449; BAKER NE, 1989, NATURE, V340, P150, DOI 10.1038/340150a0; BASLER K, 1988, TRENDS GENET, V4, P74, DOI 10.1016/0168-9525(88)90044-3; BELYAVSKY A, 1989, NUCLEIC ACIDS RES, V17, P2919, DOI 10.1093/nar/17.8.2919; BERNARDS A, 1991, ONCOGENE, V6, P1185; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU YH, 1991, P NATL ACAD SCI USA, V88, P4897, DOI 10.1073/pnas.88.11.4897; DESSEN P, 1990, CABIOS, V6, P335; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; ERLICH H, 1989, PCR TECHNOLOGY PRINC, P3; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GREGORY RJ, 1987, MOL CELL BIOL, V7, P2119, DOI 10.1128/MCB.7.6.2119; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HAO QL, 1989, MOL CELL BIOL, V9, P1587, DOI 10.1128/MCB.9.4.1587; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HOLTZMAN DA, 1987, P NATL ACAD SCI USA, V84, P8325, DOI 10.1073/pnas.84.23.8325; HOUSSAINT E, 1990, P NATL ACAD SCI USA, V87, P8180, DOI 10.1073/pnas.87.20.8180; IRIE K, 1991, CELL, V65, P785, DOI 10.1016/0092-8674(91)90386-D; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KATAMINE S, 1988, MOL CELL BIOL, V8, P259, DOI 10.1128/MCB.8.1.259; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KLEIN R, 1990, DEVELOPMENT, V109, P845; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; KROLEWSKI JJ, 1990, ONCOGENE, V5, P277; KRUH GD, 1986, SCIENCE, V234, P1545, DOI 10.1126/science.3787260; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LEHNER CF, 1990, EMBO J, V9, P3573, DOI 10.1002/j.1460-2075.1990.tb07568.x; LETWIN K, 1988, ONCOGENE, V3, P621; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; LORINCZ AT, 1984, NATURE, V307, P183, DOI 10.1038/307183a0; MAHLER PA, 1988, J BIOL CHEM, V106, P1747; Maniatis T, 1989, MOL CLONING; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MITRANI E, 1990, CELL, V63, P495, DOI 10.1016/0092-8674(90)90446-L; MULLER R, 1984, CURR TOP MICROBIOL, V112, P73; ORRURTREGER A, 1990, DEVELOPMENT, V109, P911; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PASQUALE EB, 1990, P NATL ACAD SCI USA, V87, P5812, DOI 10.1073/pnas.87.15.5812; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; RAZ V, 1991, ONCOGENE, V6, P753; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; RUBIN GM, 1989, CELL, V57, P519, DOI 10.1016/0092-8674(89)90120-7; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SMITH EA, 1991, P NATL ACAD SCI USA, V88, P4811, DOI 10.1073/pnas.88.11.4811; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STEPHENSON DA, 1991, P NATL ACAD SCI USA, V88, P6, DOI 10.1073/pnas.88.1.6; SUDOL M, 1988, NUCLEIC ACIDS RES, V16, P9876, DOI 10.1093/nar/16.20.9876; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TERMAN BI, 1991, ONCOGENE, V6, P1677; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; WILKS AF, 1989, GENE, V85, P67, DOI 10.1016/0378-1119(89)90465-4; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603	78	31	37	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1992	7	12					2479	2487						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1281306				2022-12-28	WOS:A1992KA85600013
J	AUWERX, J; SASSONECORSI, P				AUWERX, J; SASSONECORSI, P			AP-1 (FOS-JUN) REGULATION BY IP-1 - EFFECT OF SIGNAL TRANSDUCTION PATHWAYS AND CELL-GROWTH	ONCOGENE			English	Article							NF-KAPPA-B; DNA-BINDING PROTEINS; TRANSCRIPTION FACTOR AP-1; C-JUN; PROTO-ONCOGENE; GENE-EXPRESSION; KINASE-C; V-JUN; RAPIDLY DISSOCIATE; LEUCINE ZIPPERS	Transcription factor AP-1 is constituted by the various products of the fos and jun proto-oncogene family members, which associate as dimers to bind with variable efficiency to 12-O-tetradecanoyl phorbol 13-acetate (TPA)-responsive promoter elements (TREs). We have recently shown that DNA binding of AP-1 is regulated by an inhibitory protein, IP-1, whose activity is modulated by phosphorylation. Here it is shown that although AP-1 has a very high affinity for its recognition sequence, its binding to the TRE can be quickly inhibited by the addition of IP-1. IP-1 is more active on AP-1 complexes formed during a shorter period of time. IP-1 activity is blocked by stimulation of the protein kinase C (PKC) signal transducation pathway, achieved by treating HeLa cells with phorbol esters or with a diacylglycerol analog. We observed an increase in AP-1-DNA, binding after treatment of the cells with either the calcium ionophore A-23187 or dibutyryl cAMP; this could be ascribed to inhibition of IP-1 activity. A decreased IP-1 activity also correlates with the increase in AP-1-DNA binding after stimulating cells with serum. This suggests that IP-1 is an important target of the various signal transduction pathways. No effect on AP-1 and IP-1 was detected in cells transformed by Ki-ras or v-raf; nor could an effect of inhibition of protein synthesis be observed. We also analysed IP-1 regulation upon differentiation of P19 embryonal carcinoma cells by retinoic acid. We conclude that IP-1 regulation has a pivotal role in the final modulation of Fos-Jun by signal transduction pathways.	CATHOLIC UNIV LEUVEN,DEPT DEV BIOL,EXPTL MED & ENDOCRINOL LAB,B-3000 LOUVAIN,BELGIUM; CNRS,UMR 134,CTR BIOCHEM,F-06108 NICE,FRANCE; FAC MED STRASBOURG,GENET MOLEC EUCARYOTES LAB,CNRS,U184,INSERM,F-67085 STRASBOURG,FRANCE	KU Leuven; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg				Auwerx, Johan/0000-0002-5065-5393				ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; AUWERX J, 1990, NUCLEIC ACIDS RES, V18, P221, DOI 10.1093/nar/18.2.221; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; AUWERX JH, 1989, P NATL ACAD SCI USA, V86, P1133, DOI 10.1073/pnas.86.4.1133; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAICHWAL VR, 1991, NATURE, V352, P165, DOI 10.1038/352165a0; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CAMBIER JC, 1987, NATURE, V327, P619; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DEGROOT RP, 1990, EMBO J, V9, P1831, DOI 10.1002/j.1460-2075.1990.tb08308.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; FRIED MG, 1983, NUCLEIC ACIDS RES, V11, P141, DOI 10.1093/nar/11.1.141; GAUTHIERROUVIERE C, 1990, EMBO J, V9, P171, DOI 10.1002/j.1460-2075.1990.tb08093.x; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HIRAI SI, 1990, ONCOGENE, V5, P39; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MITCHELL RL, 1985, CELL, V40, P209, DOI 10.1016/0092-8674(85)90324-1; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; MURAKAMI Y, 1990, ONCOGENE, V5, P5; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NARANJO JR, 1991, NEURON, V6, P307; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SASSONECORSI P, 1986, TRENDS GENET, V2, P215, DOI 10.1016/0168-9525(86)90233-7; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SISTONEN L, 1989, EMBO J, V8, P815, DOI 10.1002/j.1460-2075.1989.tb03442.x; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; VOGT PK, 1989, TRENDS BIOCHEM SCI, V14, P172, DOI 10.1016/0968-0004(89)90268-5; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YANG-YEN H-F, 1990, New Biologist, V2, P351; YOSHIMASA T, 1987, NATURE, V327, P67, DOI 10.1038/327067a0; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	74	45	45	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2271	2280						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437149				2022-12-28	WOS:A1992JW66500020
J	DOMENGET, C; LEPRINCE, D; PAIN, B; PEYROL, S; LI, RP; STEHELIN, D; SAMARUT, J; JURDIC, P				DOMENGET, C; LEPRINCE, D; PAIN, B; PEYROL, S; LI, RP; STEHELIN, D; SAMARUT, J; JURDIC, P			THE VARIOUS DOMAINS OF V-MYB AND V-ETS ONCOGENES OF E26 RETROVIRUS CONTRIBUTE DIFFERENTLY, BUT COOPERATIVELY, IN TRANSFORMATION OF HEMATOPOIETIC LINEAGES	ONCOGENE			English	Article							AVIAN LEUKEMIA-VIRUS; LONG TERMINAL REPEAT; DNA-BINDING ACTIVITY; C-MYB; NUCLEOTIDE-SEQUENCE; TRANSCRIPTIONAL ACTIVATION; MITOGENIC STIMULATION; MYELOBLASTOSIS VIRUS; CELLULAR PROGENITOR; PROTO-ONCOGENE	The genome of the avian leukemia virus E26 is a unique example of association between two transcription factors which appear as a fused composite nuclear oncoprotein, P135gag-myb-ets. Previous studies with E26 have shown that v-myb and v-ets must cooperate to fully transform both erythrocytic and myelomonocytic precursor cells in vivo and in vitro. To analyse further the contribution of the individual domains involved in the transformation of various hematopoietic lineages, we have constructed several mutant viruses expressing a fusion protein with deletions in either v-myb or v-ets. We show here that integrity of the v-ets oncogene is necessary for transformation of the erythrocytic cells but that neither the DNA-binding domain nor the trans-activating domain of v-myb is required for this transformation. The DNA-binding domain of v-ets is necessary to transform myelomonocytic cells. Furthermore, we show that E26 oncoprotein also transforms granulocytic cells. The v-ets DNA-binding domain is not necessary to transform them, whereas deleting the v-myb DNA-binding domain strongly reduces transformation of these cells. These data show that the v-myb and v-ets DNA-binding domains provide quite different contributions to the transformation of various hematopoietic lineages by E26.	ECOLE NORMALE SUPER LYON,BIOL MOLEC & CELLULAIRE LAB,CNRS,UMR 13,46 ALLEE ITALIE,F-69364 LYON 07,FRANCE; INST PASTEUR,F-69007 LYON,FRANCE; INST PASTEUR,ONCOL MOLEC LAB,CNRS,U1160,INSERM,UNITE 186,F-59019 LILLE,FRANCE	Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille			Samarut, Jacques/AAD-2587-2019; Pain, Bertrand/A-7686-2015	Pain, Bertrand/0000-0002-1210-8444; Leprince, Dominique/0000-0002-1999-0775				AURIGEMMA RE, 1992, J VIROL, V66, P3056, DOI 10.1128/JVI.66.5.3056-3061.1992; BENCHAIBI M, 1989, VIROLOGY, V169, P15, DOI 10.1016/0042-6822(89)90036-6; BENDAVID Y, 1991, CELL, V66, P381; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BOULUKOS KE, 1990, GENE DEV, V4, P401, DOI 10.1101/gad.4.3.401; BOYLE WJ, 1985, MOL CELL BIOL, V5, P3017, DOI 10.1128/MCB.5.11.3017; CHEN JH, 1985, MOL CELL BIOL, V5, P2933; ENERBACK L, 1986, MAST CELL DIFFERENTI; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; Frykberg L, 1988, Oncogene Res, V3, P313; FUJIWARA S, 1988, MOL CELL BIOL, V8, P4700, DOI 10.1128/MCB.8.11.4700; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GAZZOLO L, 1979, CELL, V16, P627, DOI 10.1016/0092-8674(79)90036-9; GEGONNE A, 1992, IN PRESS NEW BIOL; GHYSDAEL J, 1986, EMBO J, V5, P2251, DOI 10.1002/j.1460-2075.1986.tb04492.x; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GONDA TJ, 1983, J VIROL, V46, P212, DOI 10.1128/JVI.46.1.212-220.1983; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; JURDIC P, 1987, J VIROL, V61, P3058, DOI 10.1128/JVI.61.10.3058-3065.1987; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1990, ONCOGENE RES, V5, P255; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; LI RP, 1989, ONCOGENE RES, V5, P137; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; MOELLING K, 1985, CELL, V40, P983, DOI 10.1016/0092-8674(85)90358-7; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOSCOVICI C, 1981, VIROLOGY, V113, P765, DOI 10.1016/0042-6822(81)90205-1; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; MOSCOVICI MG, 1989, J VIROL, V63, P2335, DOI 10.1128/JVI.63.5.2335-2339.1989; MUSCENSKI ML, 1991, CELL, V65, P677; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; PAUL R, 1991, J VIROL, V65, P464, DOI 10.1128/JVI.65.1.464-467.1991; POGNONEC P, 1989, ONCOGENE, V4, P691; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAVELCHAPUIS P, 1991, J VIROL, V65, P3928, DOI 10.1128/JVI.65.7.3928-3931.1991; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; SAMARUT J, 1980, J CELL PHYSIOL, V105, P553, DOI 10.1002/jcp.1041050320; SCHNEIKERT J, 1992, IN PRESS ONCOGENE; SCHWARTZ DE, 1983, CELL, V32, P853, DOI 10.1016/0092-8674(83)90071-5; SENECA S, 1991, ONCOGENE, V6, P357; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; VANDENBUNDER B, 1989, DEVELOPMENT, V106, P265; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; YUAN CC, 1989, J VIROL, V63, P205, DOI 10.1128/JVI.63.1.205-215.1989; ZOBEL A, 1991, ONCOGENE, V6, P1397	65	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2231	2241						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1331935				2022-12-28	WOS:A1992JW66500015
J	WONG, WY; HAVARSTEIN, LS; MORGAN, IM; VOGT, PK				WONG, WY; HAVARSTEIN, LS; MORGAN, IM; VOGT, PK			C-JUN CAUSES FOCUS FORMATION AND ANCHORAGE-INDEPENDENT GROWTH IN CULTURE BUT IS NONTUMORIGENIC	ONCOGENE			English	Note							CHICKEN-EMBRYO FIBROBLASTS; DNA-BINDING ACTIVITY; ONCOGENE JUN; AP-1; FOS; TRANSFORMATION; ENCODES; PROTEIN; MEMBER; FAMILY	The RCAS retroviral vector was used to express chicken and mouse cellular Jun proteins in chicken embryo fibroblasts. Both mouse and chicken proteins induced foci of transformed cells with low to moderate efficiency compared with viral Jun, but were as effective as the viral protein in promoting anchorage-independent growth. Viral Jun and a recombinant between viral and cellular Jun induced tumors in 1-day-old chicks; the cellular Jun proteins were uniformly non-tumorigenic.	NORRIS CANC CTR,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT MICROBIOL,LOS ANGELES,CA 90033; UNIV SO CALIF,LOS ANGELES CTY MED CTR,DEPT PEDIAT,1129 N STATE ST,LOS ANGELES,CA 90033	University of Southern California; University of Southern California			Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500; Havarstein, Leiv Sigve/0000-0001-8250-4322	NCI NIH HHS [CA 42564] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042564] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BALL AR, 1988, COLD SPRING HARB SYM, V53, P687, DOI 10.1101/SQB.1988.053.01.078; BERGER I, 1991, ONCOGENE, V6, P561; BISTER K, 1977, VIROLOGY, V82, P431, DOI 10.1016/0042-6822(77)90017-4; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CASTELLAZZI M, 1990, ONCOGENE, V5, P1285; CAVALIERI F, 1985, VIROLOGY, V143, P680, DOI 10.1016/0042-6822(85)90412-X; CHENG YC, 1987, J BIOL CHEM, V262, P2187; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; NISHIMURA T, 1988, ONCOGENE, V3, P659; RANSONE LJ, 1990, P NATL ACAD SCI USA, V87, P3806, DOI 10.1073/pnas.87.10.3806; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SUZUKI T, 1991, JPN J CANCER RES, V82, P58, DOI 10.1111/j.1349-7006.1991.tb01746.x; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2	22	31	31	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					2077	2080						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408150				2022-12-28	WOS:A1992JP42400025
J	THOMPSON, PA; GUTKIND, JS; ROBBINS, KC; LEDBETTER, JA; BOLEN, JB				THOMPSON, PA; GUTKIND, JS; ROBBINS, KC; LEDBETTER, JA; BOLEN, JB			IDENTIFICATION OF DISTINCT POPULATIONS OF PI-3 KINASE-ACTIVITY FOLLOWING T-CELL ACTIVATION	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASE; FACTOR-I RECEPTOR; PHOSPHATIDYLINOSITOL KINASE; SIGNAL TRANSDUCTION; HUMAN PLATELETS; ANTIGEN RECEPTOR; CD4 RECEPTOR; PDGF RECEPTOR; RAT-LIVER; ASSOCIATION	Activation of mature CD4+ T lymphocytes by antigen-presenting cells involves engagement of the CD3/T-cell antigen receptor complex along with the CD4 surface glycoprotein and the phosphorylation of cellular proteins on tyrosine residues leading to stimulation of a variety of cellular second-messenger systems. Several recent studies have implicated non-receptor protein tyrosine kinases of the src family, especially p56lck and p59fyn, in mediating at least a portion of these tyrosine phosphorylation events. In the present study we have examined the involvement of one type of second-messenger system, phosphatidylinositol-3 kinase (PI-3 kinase), in signal transduction during antibody-induced activation of normal resting human CD4+ T cells. We demonstrate that PI-3 kinase activity is increased following co-approximation of CD4 with the T-cell receptor and that PI-3 kinase activity co-precipitates with the CD4-p56lck complex. We also show that following T-cell activation a complex containing PI-3 kinase activity can be demonstrated in CD3-epsilon-immunoprecipitates which is distinct from that which interacts with p56lck.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,POB 4000,PRINCETON,NJ 08543; NCI,TUMOR VIRUS BIOL LAB,BETHESDA,MD 20892; NIDR,CELLULAR DEV & ONCOL LAB,BETHESDA,MD 20892; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121	Bristol-Myers Squibb; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Bristol-Myers Squibb			Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009	Gutkind, J. Silvio/0000-0002-5150-4482; 				ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BERRIDGE MJ, 1984, NATURE, V312, P312; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; BOLEN JB, 1991, CELL GROWTH DIFFER, V2, P409; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHAN TO, 1990, MOL CELL BIOL, V10, P3280, DOI 10.1128/MCB.10.6.3280; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; CUNNINGHAM TW, 1990, J BIOL CHEM, V265, P21676; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FUKUI Y, 1991, ONCOGENE, V6, P407; FUKUI Y, 1991, MOL CELL BIOL, V11, P1972, DOI 10.1128/MCB.11.4.1972; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; FUKUI Y, 1989, ONCOGENE RES, V4, P283; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; HEIDARAN MA, 1991, MOL CELL BIOL, V11, P134, DOI 10.1128/MCB.11.1.134; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; HORAK ID, 1990, ONCOGENE, V5, P597; HORAK ID, 1990, NATURE, V348, P557, DOI 10.1038/348557a0; JUNE CH, 1987, MOL CELL BIOL, V7, P4472, DOI 10.1128/MCB.7.12.4472; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LEDBETTER JA, 1988, EUR J IMMUNOL, V18, P525, DOI 10.1002/eji.1830180406; MITCHELL CA, 1990, P NATL ACAD SCI USA, V87, P9396, DOI 10.1073/pnas.87.23.9396; MITTLER RS, 1989, P NATL ACAD SCI USA, V86, P8531, DOI 10.1073/pnas.86.21.8531; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PATEL MD, 1987, J BIOL CHEM, V262, P5831; PERLMUTTER R M, 1988, Biochimica et Biophysica Acta, V948, P245; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; RUDD CE, 1990, IMMUNOL TODAY, V11, P400, DOI 10.1016/0167-5699(90)90159-7; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SERUNIAN LA, 1990, J VIROL, V64, P4718, DOI 10.1128/JVI.64.10.4718-4725.1990; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; VEILLETTE A, 1988, MOL CELL BIOL, V8, P4353, DOI 10.1128/MCB.8.10.4353; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1989, MOL CELL BIOL, V9, P4441, DOI 10.1128/MCB.9.10.4441; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0	59	61	83	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					719	725						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1373484				2022-12-28	WOS:A1992HQ68200014
J	WOODWORTH, CD; CHENG, ST; SIMPSON, S; HAMACHER, L; CHOW, LT; BROKER, TR; DIPAOLO, JA				WOODWORTH, CD; CHENG, ST; SIMPSON, S; HAMACHER, L; CHOW, LT; BROKER, TR; DIPAOLO, JA			RECOMBINANT RETROVIRUSES ENCODING HUMAN PAPILLOMAVIRUS TYPE-18 E6 AND E7 GENES STIMULATE PROLIFERATION AND DELAY DIFFERENTIATION OF HUMAN KERATINOCYTES EARLY AFTER INFECTION	ONCOGENE			English	Article							HUMAN EPIDERMAL-KERATINOCYTES; HUMAN FORESKIN KERATINOCYTES; SERUM-FREE MEDIUM; EPITHELIAL-CELLS; TERMINAL DIFFERENTIATION; CERVICAL-CARCINOMA; GENITAL CANCER; GROWTH; DNA; TRANSFORMATION	Human papillomavirus (HPV) DNAs are detected in most genital dysplasias and cancers, suggesting that these viruses perturb epithelial growth and differentiation. The E6 and E7 genes of HPV type 18 induce immortality in keratinocytes cultured from genital tract epithelia, and the immortal cell lines display aberrant squamous differentiation. To examine whether the E6 and E7 proteins directly alter keratinocyte growth and differentiation, high-titer recombinant retroviruses were constructed for efficient transfer and expression of HPV-18 genes E6, E6* and E7 in cultures of normal human keratinocytes. Infection with retroviruses encoding E6 and E7 stimulated cell proliferation, reduced the requirement for bovine pituitary extract and induced immortality. E6 and E7 also delayed but did not prevent the onset of terminal squamous differentiation. The magnitude of effects on growth and differentiation of cultured cells was directly related to levels of E7 protein expression. Thus, expression of the HPV-18 E6 and E7 genes stimulates cell proliferation and delays differentiation of keratinocytes in vitro.	UNIV ROCHESTER, SCH MED, DEPT BIOCHEM, ROCHESTER, NY 14642 USA	University of Rochester	WOODWORTH, CD (corresponding author), NCI, BIOL LAB, BETHESDA, MD 20892 USA.				NATIONAL CANCER INSTITUTE [R01CA036200] Funding Source: NIH RePORTER; NCI NIH HHS [CA36200] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASSELINEAU D, 1984, BRIT J DERMATOL, V111, P219, DOI 10.1111/j.1365-2133.1984.tb15608.x; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; BANKS L, 1990, ONCOGENE, V5, P833; BARBOSA MS, 1989, ONCOGENE, V4, P1529; BLANTON RA, 1991, AM J PATHOL, V138, P673; BOSHART M, 1984, EMBO J, V3, P1151, DOI 10.1002/j.1460-2075.1984.tb01944.x; BOYCE ST, 1983, J INVEST DERMATOL, V81, pS33, DOI 10.1111/1523-1747.ep12540422; BRAUN L, 1990, CANCER RES, V50, P7324; BROWN KW, 1985, INT J CANCER, V35, P799, DOI 10.1002/ijc.2910350617; CHERINGTON V, 1986, P NATL ACAD SCI USA, V83, P4307, DOI 10.1073/pnas.83.12.4307; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DURST M, 1987, ONCOGENE, V1, P251; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; ESTERVIG DN, 1990, J CELL PHYSIOL, V142, P552, DOI 10.1002/jcp.1041420314; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; GALLOWAY DA, 1989, ADV VIRUS RES, V37, P125; GROSS G, 1987, PAPILLOMAVIRUSES HUM, P197; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HAUSEN HZ, 1989, CANCER RES, V49, P4677; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HUDSON JB, 1990, J VIROL, V64, P519, DOI 10.1128/JVI.64.2.519-526.1990; HURLIN PJ, 1991, P NATL ACAD SCI USA, V88, P570, DOI 10.1073/pnas.88.2.570; KAUR P, 1988, J VIROL, V62, P1917, DOI 10.1128/JVI.62.6.1917-1924.1988; KOPAN R, 1987, J CELL BIOL, V105, P427, DOI 10.1083/jcb.105.1.427; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; LORINCZ AT, 1987, J NATL CANCER I, V79, P671; MCCANCE DJ, 1988, P NATL ACAD SCI USA, V85, P7169, DOI 10.1073/pnas.85.19.7169; MCINDOE WA, 1984, OBSTET GYNECOL, V64, P451; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P3489, DOI 10.1073/pnas.88.8.3489; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGER K, 1989, J VIROL, V63, P4417; PECORARO G, 1989, P NATL ACAD SCI USA, V86, P563, DOI 10.1073/pnas.86.2.563; PECORARO G, 1991, AM J PATHOL, V138, P1; PFISTER H, 1987, ADV CANCER RES, V48, P113, DOI 10.1016/S0065-230X(08)60691-0; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; REEVES WC, 1989, REV INFECT DIS, V11, P426; Reiss M, 1989, Cancer Commun, V1, P75; RHEINWALD JG, 1980, CELL, V22, P629, DOI 10.1016/0092-8674(80)90373-6; ROTENBERG MO, 1989, VIROLOGY, V172, P468, DOI 10.1016/0042-6822(89)90189-X; SATO H, 1989, VIROLOGY, V168, P195, DOI 10.1016/0042-6822(89)90423-6; SCHLEGEL R, 1988, EMBO J, V7, P3181, DOI 10.1002/j.1460-2075.1988.tb03185.x; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SCHNEIDERGADICKE A, 1988, CANCER RES, V48, P2969; SHIPLEY GD, 1986, CANCER RES, V46, P2068; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; WATT FM, 1988, P NATL ACAD SCI USA, V85, P5576, DOI 10.1073/pnas.85.15.5576; WILLE JJ, 1984, J CELL PHYSIOL, V121, P31, DOI 10.1002/jcp.1041210106; WOODWORTH CD, 1989, J VIROL, V63, P159, DOI 10.1128/JVI.63.1.159-164.1989; WOODWORTH CD, 1988, CANCER RES, V48, P4620; WOODWORTH CD, 1990, J VIROL, V64, P4767, DOI 10.1128/JVI.64.10.4767-4775.1990; WOODWORTH CD, 1990, CANCER RES, V50, P3709; YUSPA SH, 1989, J VIROL, V63, P159	57	83	86	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1992	7	4					619	626						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1314365				2022-12-28	WOS:A1992HQ68200002
J	KORNILOVA, ES; TAVERNA, D; HOECK, W; HYNES, NE				KORNILOVA, ES; TAVERNA, D; HOECK, W; HYNES, NE			SURFACE EXPRESSION OF ERBB-2 PROTEIN IS POSTTRANSCRIPTIONALLY REGULATED IN MAMMARY EPITHELIAL-CELLS BY EPIDERMAL GROWTH-FACTOR AND BY THE CULTURE DENSITY	ONCOGENE			English	Article							HUMAN-BREAST-CANCER; BETA-CASEIN GENE; FACTOR-RECEPTOR; EGF RECEPTOR; TYROSINE PHOSPHORYLATION; POLYACRYLAMIDE GELS; C-ERBB-2 PROTEIN; KINASE-ACTIVITY; NEU ONCOGENE; A431 CELLS	The control of expression of the erbB-2 protein was examined in two mammary epithelial cells lines, HC11 and 31E. The erbB-2 protein content varied dramatically depending upon cell density and upon the presence of epidermal growth factor (EGF) in the culture medium. The changes in protein content were not due to variation in the erbB-2 mRNA level. Analysis of the metabolic turnover of the erbB-2 protein showed that its rate of degradation was two- to threefold higher in cells growing at low density than in cells confluent for 2 days. The addition of EGF to the culture medium caused an increase in the phosphoamino acid content and an increase in the turnover of the erbB-2 protein. Cell fractionation experiments were performed, and a shift in the cellular localization of the erbB-2 protein towards the lysosomal compartment in EGF-treated HC11 cells was found. This is reflected by an increase in the degradation rate of the erbB-2 protein. These findings suggest that in mammary epithelial cells the stability of the erbB-2 protein is an important regulatory control point in determining the level of the protein. The degradation rate is sensitive to cell confluency and is controlled by EGF receptor activity.	FRIEDRICH MIESCHER INST,POB 2543,CH-4002 BASEL,SWITZERLAND; ACAD SCI USSR,INST CYTOL,LENINGRAD,USSR	Friedrich Miescher Institute for Biomedical Research; Russian Academy of Sciences			taverna, daniela/J-8358-2016; Kornilova, Elena Sergeevna/AAB-5559-2021	taverna, daniela/0000-0002-6365-527X; Kornilova, Elena/0000-0002-2951-6292; Hoeck, Wolfgang/0000-0001-9142-7103				AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; BACUS SS, 1990, MOL CARCINOGEN, V3, P350, DOI 10.1002/mc.2940030607; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BERGER MS, 1988, CANCER RES, V48, P1238; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLEMAN S, 1988, DEV BIOL, V127, P304, DOI 10.1016/0012-1606(88)90317-X; DANIELSON KG, 1984, P NATL ACAD SCI-BIOL, V81, P3756, DOI 10.1073/pnas.81.12.3756; DATI C, 1990, ONCOGENE, V5, P1001; EPSTEIN RJ, 1990, J BIOL CHEM, V265, P10746; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; GAMOU S, 1987, J BIOL CHEM, V262, P6708; GORMAN RM, 1987, J CELL PHYSIOL, V131, P158, DOI 10.1002/jcp.1041310204; GULLICK WJ, 1987, INT J CANCER, V40, P246, DOI 10.1002/ijc.2910400221; GULTEKIN H, 1988, ANAL BIOCHEM, V172, P320, DOI 10.1016/0003-2697(88)90451-4; HUDSON LG, 1990, J BIOL CHEM, V265, P4389; HYNES NE, 1990, MOL CELL BIOL, V10, P4027, DOI 10.1128/MCB.10.8.4027; HYNES NE, 1989, J CELL BIOCHEM, V39, P167, DOI 10.1002/jcb.240390208; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KORNILOVA ES, 1987, TSITOLOGIYA+, V29, P904; LACROIX H, 1989, ONCOGENE, V4, P145; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MUNSON PJ, 1990, CANCER RES, V50, P3947; REDMOND SMS, 1988, ONCOGENE, V2, P259; REICHMANN E, 1989, J CELL BIOL, V108, P1127, DOI 10.1083/jcb.108.3.1127; RICHARDS J, 1982, EXP CELL RES, V141, P433, DOI 10.1016/0014-4827(82)90231-2; RICHNER J, 1990, ANN ONCOL, V1, P263, DOI 10.1093/oxfordjournals.annonc.a057745; RIZZINO A, 1988, CANCER RES, V48, P4266; SAINSBURY JRC, 1987, LANCET, V1, P1398; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SNEDEKER SM, 1991, P NATL ACAD SCI USA, V88, P276, DOI 10.1073/pnas.88.1.276; SORKIN A, 1989, BIOCHIM BIOPHYS ACTA, V1011, P88, DOI 10.1016/0167-4889(89)90083-9; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; SUEN TC, 1991, MOL CELL BIOL, V11, P354, DOI 10.1128/MCB.11.1.354; TAKETANI Y, 1983, FEBS LETT, V152, P256, DOI 10.1016/0014-5793(83)80391-3; TAVERNA D, 1991, CELL GROWTH DIFFER, V2, P145; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Vonderhaar B K, 1988, Cancer Treat Res, V40, P251; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; YARDEN Y, 1991, BIOCHEMISTRY-US, V30, P3543, DOI 10.1021/bi00228a027; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499	46	62	64	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1992	7	3					511	519						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1347917				2022-12-28	WOS:A1992HK00500017
J	SAKSELA, K; MAKELA, TP; HUGHES, K; WOODGETT, JR; ALITALO, K				SAKSELA, K; MAKELA, TP; HUGHES, K; WOODGETT, JR; ALITALO, K			ACTIVATION OF PROTEIN-KINASE-C INCREASES PHOSPHORYLATION OF THE L-MYC TRANSACTIVATOR DOMAIN AT A GSK-3 TARGET SITE	ONCOGENE			English	Article							AVIAN MYELOCYTOMATOSIS VIRUS; DNA-BINDING PROTEINS; HUMAN SMALL CELL; NUCLEOTIDE-SEQUENCE; OKADAIC ACID; GENE; ONCOGENE; TUMOR; EXPRESSION; LINES	The L-myc protein migrates as three distinct differentially phosphorylated bands in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). This phosphorylation can be rapidly increased either by treatment with the protein kinase C (PKC) activator phorbol ester 12-O-tetradecanoyl-phorbol-13-acetate (TPA) or by inhibition of serine/threonine protein phosphatases with okadaic acid. In vitro mutagenesis and phosphoamino acid analyses define the N-terminal serine residues 38 and 42 of L-myc as critical targets for the PKC-dependent phosphorylation. These are the exclusive sites of phosphorylation in the N-terminal third of the L-myc protein, and can be phosphorylated in vitro by glycogen synthase kinase 3-beta (GSK-3-beta). A mutant L-myc protein in which these serines have been replaced by alanine residues does not show heterogeneous electrophoretic migration or hyperphosphorylation in response to PKC activation, and is not a substrate for GSK-3-beta in vitro. Similar potential phosphorylation sites are present in c-myc and N-myc in a highly conserved region thought to represent a transcriptional activation domain. We suggest that N-terminal phosphorylation of the L-myc protein is a means of rapid regulation of this oncoprotein, possibly mediated in vivo by the action of GSK-3.	UNIV HELSINKI, DEPT VIROL, CANC BIOL LAB, HAARTMANINKATU 3, SF-00290 HELSINKI 29, FINLAND; LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND; UNIV HELSINKI, DEPT PATHOL, CANC BIOL LAB, SF-00290 HELSINKI 29, FINLAND	University of Helsinki; Ludwig Institute for Cancer Research; University of Helsinki			Woodgett, Jim/F-1087-2010; Alitalo, Kari K/J-5013-2014; makela, tomi/B-3734-2009	Woodgett, Jim/0000-0003-3731-5797; Alitalo, Kari K/0000-0002-7331-0902; makela, tomi/0000-0002-4869-8044; Saksela, Kalle/0000-0003-0827-122X				ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P100, DOI 10.1073/pnas.80.1.100; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BERGH J, 1985, ACTA PATH MICRO IM A, V93, P133; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOHMANN D, 1990, CANCER CELL-MON REV, V2, P337; BOUROUIS M, 1990, EMBO J, V9, P2877, DOI 10.1002/j.1460-2075.1990.tb07477.x; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; COLBY WW, 1983, NATURE, V301, P722, DOI 10.1038/301722a0; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DEGREVE J, 1988, MOL CELL BIOL, V8, P4381, DOI 10.1128/MCB.8.10.4381; GLINEUR C, 1990, GENE DEV, V4, P1663, DOI 10.1101/gad.4.10.1663; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HEMMINGS BA, 1981, EUR J BIOCHEM, V119, P443, DOI 10.1111/j.1432-1033.1981.tb05628.x; HUGHES K, 1991, ADV PROTEIN PHOSPHAT, V6, P483; IKEGAKI N, 1989, EMBO J, V8, P1793, DOI 10.1002/j.1460-2075.1989.tb03573.x; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEACH KL, 1989, J CELL BIOL, V109, P685, DOI 10.1083/jcb.109.2.685; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MAKELA TP, 1989, MOL CELL BIOL, V9, P1545; MAKELA TP, 1991, MOL CELL BIOL, V11, P4015; MAKELA TP, 1991, EMBO J, V10, P1331, DOI 10.1002/j.1460-2075.1991.tb07652.x; MCCLUTCHAN JH, 1968, J NATL CANCER I, V41, P351; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOORE JP, 1987, ONCOGENE RES, V2, P65; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x; RAMSAY G, 1984, P NATL ACAD SCI-BIOL, V81, P7742, DOI 10.1073/pnas.81.24.7742; ROSENBAUM H, 1989, EMBO J, V8, P749, DOI 10.1002/j.1460-2075.1989.tb03435.x; SAKSELA K, 1989, EMBO J, V8, P149, DOI 10.1002/j.1460-2075.1989.tb03359.x; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SHEINESS D, 1979, J VIROL, V31, P514, DOI 10.1128/JVI.31.2.514-521.1979; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; SLAMON DJ, 1986, SCIENCE, V232, P768, DOI 10.1126/science.3008339; WOODGETT JR, 1991, TRENDS BIOCHEM SCI, V16, P177, DOI 10.1016/0968-0004(91)90071-3	48	58	58	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1992	7	2					347	353						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1312697				2022-12-28	WOS:A1992HG98200021
J	SCHROEDER, C; GIBSON, L; ZENKE, M; BEUG, H				SCHROEDER, C; GIBSON, L; ZENKE, M; BEUG, H			MODULATION OF NORMAL ERYTHROID-DIFFERENTIATION BY THE ENDOGENOUS THYROID-HORMONE AND RETINOIC ACID RECEPTORS - A POSSIBLE TARGET FOR V-ERBA ONCOGENE ACTION	ONCOGENE			English	Article							AVIAN ERYTHROBLASTOSIS VIRUS; CELLS-INVITRO; C-ERBA; GENE-EXPRESSION; GROWTH; TRANSFORMATION; PHENOTYPE; PROTEIN; PROLIFERATION; FIBROBLASTS	The v-erbA oncogene, a mutated version of the thyroid hormone receptor alpha (c-erbA/TR-alpha), inhibits erythroid differentiation and constitutively represses transcription of certain erythrocyte genes, suggesting a normal function of the proto-oncogene c-erbA in erythropoiesis. Here we demonstrate that the endogenous thyroid hormone receptor alpha (c-erbA/TR-alpha) and the closely related retinoic acid receptor alpha (RAR-alpha) play a role in the regulation of normal erythroid differentiation. Retinoic acid (RA) distinctly modulated the erythroid differentiation program of normal erythroid progenitors and erythroblasts reversibly transformed by a conditional tyrosine kinase oncogene. When added pulsewise to immature cells, differentiation was accelerated while more mature cells underwent premature cell death. Thyroid hormone (T3) alone caused similar but weaker effects. Interestingly, T3 strongly enhanced the action of RA, suggesting cooperative action of the two receptors in modulating erythroid differentiation. Expression of the human RAR-alpha in receptor-negative erythroblasts conferred RA-induced regulation of differentiation to the otherwise unresponsive cells, thus showing that the RAR-alpha is essential for the RA effect. Likewise, enhanced expression of exogenous c-erbA/TR-alpha in erythroblasts rendered them susceptible to modulation of differentiation by T3, suggesting a similar function of both receptors.	INST MOLEC PATHOL, DR BOHR GASSE 7, A-1030 VIENNA, AUSTRIA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)			Gibson, Leonie/AAM-5917-2021	Gibson, Leonie/0000-0002-0904-8145				BEUG H, 1982, J CELL PHYSIOL, P195; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BEUG H, 1986, J VIROL, V57, P1127, DOI 10.1128/JVI.57.3.1127-1138.1986; BEUG H, 1985, VIROLOGY, V145, P141, DOI 10.1016/0042-6822(85)90209-0; BEUG H, 1991, NUCLEAR HORMONE RECE, P355; BIGLER J, 1988, MOL CELL BIOL, V8, P4155, DOI 10.1128/MCB.8.10.4155; BLOMHOFF R, 1990, SCIENCE, V250, P399, DOI 10.1126/science.2218545; CAMPBELL A, 1985, J CLIN INVEST, V75, P2085, DOI 10.1172/JCI111928; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAINIAK N, 1986, BLOOD, V68, P1289; DAINIAK N, 1978, NATURE, V272, P260, DOI 10.1038/272260a0; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; DOUER D, 1982, J CLIN INVEST, V69, P1039, DOI 10.1172/JCI110507; FEIN HG, 1975, MED CLIN N AM, V59, P1133, DOI 10.1016/S0025-7125(16)31963-0; FORREST D, 1990, EMBO J, V9, P1519, DOI 10.1002/j.1460-2075.1990.tb08270.x; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; FUERSTENBERG S, 1990, J VIROL, V64, P5891, DOI 10.1128/JVI.64.12.5891-5902.1990; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GARG LC, 1983, DIFFERENTIATION, V25, P79; GLINEUR C, 1990, GENE DEV, V4, P1663, DOI 10.1101/gad.4.10.1663; GRAF T, 1973, VIROLOGY, V54, P398, DOI 10.1016/0042-6822(73)90152-9; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HENTZEN D, 1987, MOL CELL BIOL, V7, P2416, DOI 10.1128/MCB.7.7.2416; HORTON L, 1976, Q J MED, V45, P101; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; KNIGHT J, 1988, GENE DEV, V2, P247, DOI 10.1101/gad.2.2.247; KOEFFLER HP, 1985, CIBA F SYMP, V113, P252; KOWENZ E, 1987, MODERN TRENDS HUMA 7, V31, P199; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; MAIHLE NJ, 1989, BIOCHIM BIOPHYS ACTA, V948, P287, DOI 10.1016/0304-419X(89)90003-6; Maniatis T., 1982, MOL CLONING; MULDOWNEY FP, 1957, CLIN SCI, V16, P309; NAGLER A, 1986, EXP HEMATOL, V14, P60; PAIN B, 1990, New Biologist, V2, P284; PAIN B, 1991, CELL, V65, P37, DOI 10.1016/0092-8674(91)90405-N; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; REIMANN J, 1979, EXP HEMATOL, V7, P45; ROBERTS RA, 1987, J CELL PHYSIOL, V132, P203, DOI 10.1002/jcp.1041320204; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHMIDT JA, 1986, LEUKEMIA RES, V10, P257, DOI 10.1016/0145-2126(86)90023-8; SCHMIDT JA, 1986, CELL, V46, P41, DOI 10.1016/0092-8674(86)90858-5; SCHROEDER C, 1992, ONCOGENE, V7, P203; SCHROEDER C, 1990, ONCOGENE, V5, P1445; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P	52	90	91	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1992	7	2					217	227						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1347914				2022-12-28	WOS:A1992HG98200003
J	Miyazaki, R; Ai, MT; Tanaka, N; Suzuki, T; Dhomae, N; Tsukazaki, T; Akiyama, Y; Mori, H				Miyazaki, Ryoji; Ai, Mengting; Tanaka, Natsuko; Suzuki, Takehiro; Dhomae, Naoshi; Tsukazaki, Tomoya; Akiyama, Yoshinori; Mori, Hiroyuki			Inner membrane YfgM-PpiD heterodimer acts as a functional unit that associates with the SecY/E/G translocon and promotes protein translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTO-CROSS-LINKING; ESCHERICHIA-COLI; TRANSLATION ARREST; TPR DOMAIN; CHAPERONE; SECYEG; SECA; COMPONENT; INSERTION; COMPLEX	PpiD and YfgM are inner membrane proteins that are both composed of an N-terminal transmembrane segment and a C-terminal periplasmic domain. Escherichia coli YfgM and PpiD form a stable complex that interacts with the SecY/E/G (Sec) translocon, a channel that allows protein translocation across the cytoplasmic membrane. Although PpiD is known to function in protein translocation, the functional significance of PpiD-YfgM complex formation as well as the molecular mechanisms of PpiD-YfgM and PpiD/YfgM-Sec translocon interactions remain unclear. Here, we conducted genetic and biochemical studies using yfgM and ppiD mutants and demonstrated that a lack of YfgM caused partial PpiD degra-dation at its C-terminal region and hindered the membrane translocation of Vibrio protein export monitoring polypeptide (VemP), a Vibrio secretory protein, in both E. coli and Vibrio alginolyticus. While ppiD disruption also impaired VemP translocation, we found that the yfgM and ppiD double dele-tion exhibited no additive or synergistic effects. Together, these results strongly suggest that both PpiD and YfgM are required for efficient VemP translocation. Furthermore, our site-directed in vivo photocrosslinking analysis revealed that the tetratricopeptide repeat domain of YfgM and a conserved structural domain (NC domain) in PpiD interact with each other and that YfgM, like PpiD, directly interacts with the SecG translocon subunit. Crosslinking analysis also suggested that PpiD-YfgM complex formation is required for these proteins to interact with SecG. In summary, we propose that PpiD and YfgM form a functional unit that stimulates protein trans-location by facilitating their proper interactions with the Sec translocon.	[Miyazaki, Ryoji; Tsukazaki, Tomoya] Nara Inst Sci & Technol, Grad Sch Sci & Technol, Div Biol Sci, Ikoma, Japan; [Ai, Mengting; Tanaka, Natsuko; Akiyama, Yoshinori; Mori, Hiroyuki] Kyoto Univ, Inst Life & Med Sci, Kyoto, Japan; [Suzuki, Takehiro; Dhomae, Naoshi] RIKEN Ctr Sustainable Resource Sci, Biomol Characterizat Unit, Saitama, Japan	Nara Institute of Science & Technology; Kyoto University; RIKEN	Mori, H (corresponding author), Kyoto Univ, Inst Life & Med Sci, Kyoto, Japan.	hiromori@infront.kyoto-u.ac.jp			Japan Society for the Promotion of Science KAKENHI [19K21179, 20K15715, 21KK0126, 22K15061, 22H05567, 21H05155, 22H02586, 22H02571, 20K06556]; Institute for Fermentation, Osaka [Y-2020-02-027]	Japan Society for the Promotion of Science KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Institute for Fermentation, Osaka(Institute for Fermentation (IFO))	This work was supported by the Japan Society for the Promotion of Science KAKENHI grant numbers 19K21179, 20K15715, 21KK0126, 22K15061, 22H05567 (to R. M.), 21H05155, 22H02586 (to T. T.), 22H02571 (to Y. A.), and 20K06556 (to H. M.) and by the Institute for Fermentation, Osaka (Y-2020-02-027) (to R. M.).	AKIYAMA Y, 1990, BIOCHEM BIOPH RES CO, V167, P711, DOI 10.1016/0006-291X(90)92083-C; AKIYAMA Y, 1987, EMBO J, V6, P3465, DOI 10.1002/j.1460-2075.1987.tb02670.x; Antonoaea R, 2008, BIOCHEMISTRY-US, V47, P5649, DOI 10.1021/bi800233w; BABA T, 1990, J BACTERIOL, V172, P7005, DOI 10.1128/jb.172.12.7005-7010.1990; Baba T, 2006, MOL SYST BIOL, V2, DOI 10.1038/msb4100050; Bitto E, 2002, STRUCTURE, V10, P1489, DOI 10.1016/S0969-2126(02)00877-8; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; BlondeletRouault MH, 1997, GENE, V190, P315, DOI 10.1016/S0378-1119(97)00014-0; Carlson ML, 2019, ELIFE, V8, DOI 10.7554/eLife.46615; Chin JW, 2002, CHEMBIOCHEM, V3, P1135, DOI 10.1002/1439-7633(20021104)3:11<1135::AID-CBIC1135>3.0.CO;2-M; Daimon Y, 2017, MOL MICROBIOL, V106, P760, DOI 10.1111/mmi.13844; Dartigalongue C, 1998, EMBO J, V17, P3968, DOI 10.1093/emboj/17.14.3968; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; E. M. Germany, 2022, bioRxiv, DOI 10.1101/2021.10.29.466387; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; Evans R., 2022, BIORXIV, DOI [10.1101/2021.10.04.463034, DOI 10.1101/2021.10.04.463034]; Furst M, 2018, BBA-MOL CELL RES, V1865, P273, DOI 10.1016/j.bbamcr.2017.10.012; Gotzke H, 2014, J BIOL CHEM, V289, P19089, DOI 10.1074/jbc.M113.541672; Graham JB, 2019, CRIT REV BIOCHEM MOL, V54, P103, DOI 10.1080/10409238.2019.1590305; Gunasinghe SD, 2018, CELL REP, V23, P2782, DOI 10.1016/j.celrep.2018.04.093; Han D, 2008, PROTEINS, V70, P900, DOI 10.1002/prot.21597; Harris CR, 1999, J BACTERIOL, V181, P3438, DOI 10.1128/JB.181.11.3438-3444.1999; Ishii E, 2015, P NATL ACAD SCI USA, V112, pE5513, DOI 10.1073/pnas.1513001112; Jakob RP, 2015, J BIOL CHEM, V290, P3278, DOI 10.1074/jbc.M114.622910; Jauss B, 2019, J BIOL CHEM, V294, P19167, DOI 10.1074/jbc.RA119.010686; Jumper J, 2021, NATURE, V596, P583, DOI 10.1038/s41586-021-03819-2; Justice SS, 2005, J BACTERIOL, V187, P7680, DOI 10.1128/JB.187.22.7680-7686.2005; Kater L, 2019, EMBO REP, V20, DOI 10.15252/embr.201948191; KIHARA A, 1995, P NATL ACAD SCI USA, V92, P4532, DOI 10.1073/pnas.92.10.4532; Kumazaki K, 2014, SCI REP-UK, V4, DOI 10.1038/srep07299; Kumazaki K, 2014, NATURE, V509, P516, DOI 10.1038/nature13167; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; Ludlam AV, 2004, P NATL ACAD SCI USA, V101, P13436, DOI 10.1073/pnas.0405868101; Maddalo G, 2011, J PROTEOME RES, V10, P1848, DOI 10.1021/pr101105c; Matern Y, 2010, BMC MICROBIOL, V10, DOI 10.1186/1471-2180-10-251; Miller J. H, 1972, EXPT MOL GENETICS; Mirdita Milot, 2021, Zenodo, DOI [10.5281/ZENODO.5123297, 10.1038/s41592-022-01488-1]; Miyazaki R, 2020, ELIFE, V9, DOI 10.7554/eLife.62623; Miyazaki R, 2020, BBA-GEN SUBJECTS, V1864, DOI 10.1016/j.bbagen.2019.03.003; Miyazaki R, 2018, J BIOL CHEM, V293, P677, DOI 10.1074/jbc.M117.817270; Mori H, 2001, TRENDS MICROBIOL, V9, P494, DOI 10.1016/S0966-842X(01)02174-6; Mori H, 2006, P NATL ACAD SCI USA, V103, P16159, DOI 10.1073/pnas.0606390103; Mori H, 2018, J BIOL CHEM, V293, P2915, DOI 10.1074/jbc.M117.816561; Nakatogawa H, 2001, MOL CELL, V7, P185, DOI 10.1016/S1097-2765(01)00166-6; NISHIYAMA K, 1993, EMBO J, V12, P3409, DOI 10.1002/j.1460-2075.1993.tb06015.x; Okunishi I, 1996, J BACTERIOL, V178, P2409, DOI 10.1128/jb.178.8.2409-2415.1996; Rapoport TA, 2017, ANNU REV CELL DEV BI, V33, P369, DOI 10.1146/annurev-cellbio-100616-060439; Rhodius VA, 2006, PLOS BIOL, V4, P43, DOI 10.1371/journal.pbio.0040002; Sachelaru I, 2014, J BIOL CHEM, V289, P21706, DOI 10.1074/jbc.M114.577916; Samuelson JC, 2000, NATURE, V406, P637, DOI 10.1038/35020586; Satoh Y, 2003, BIOCHEMISTRY-US, V42, P7434, DOI 10.1021/bi034331a; SCHAFER A, 1994, GENE, V145, P69, DOI 10.1016/0378-1119(94)90324-7; Silhavy T. J., 1984, EXPT GENE FUSIONS; Sklar JG, 2007, GENE DEV, V21, P2473, DOI 10.1101/gad.1581007; Stull Frederick, 2018, EcoSal Plus, V8, DOI 10.1128/ecosalplus.ESP-0005-2018; Tanaka Y, 2018, BIOCHEM BIOPH RES CO, V505, P141, DOI 10.1016/j.bbrc.2018.09.043; Tanaka Y, 2015, CELL REP, V13, P1561, DOI 10.1016/j.celrep.2015.10.025; Terashima H, 2010, J BACTERIOL, V192, P5609, DOI 10.1128/JB.00720-10; Tsukazaki T, 2018, FEMS MICROBIOL LETT, V365, DOI 10.1093/femsle/fny112; Tsukazaki T, 2011, NATURE, V474, P235, DOI 10.1038/nature09980; Val ME, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002472; van den Berg B, 2004, NATURE, V427, P36, DOI 10.1038/nature02218; Varadi M, 2022, NUCLEIC ACIDS RES, V50, pD439, DOI 10.1093/nar/gkab1061; Wang X, 2021, MBIO, V12, DOI 10.1128/mBio.00597-21; Weininger U, 2010, PROTEIN SCI, V19, P6, DOI 10.1002/pro.277; Young TS, 2010, J MOL BIOL, V395, P361, DOI 10.1016/j.jmb.2009.10.030; Zeytuni N, 2012, STRUCTURE, V20, P397, DOI 10.1016/j.str.2012.01.006; Zimmer J, 2008, NATURE, V455, P936, DOI 10.1038/nature07335	68	0	0	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV	2022	298	11							102572	10.1016/j.jbc.2022.102572	http://dx.doi.org/10.1016/j.jbc.2022.102572			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	6W5WW	36209828	Green Published, gold			2022-12-28	WOS:000895801300001
J	WEISSKER, SN; MULLER, BF; HOMFELD, A; DEPPERT, W				WEISSKER, SN; MULLER, BF; HOMFELD, A; DEPPERT, W			SPECIFIC AND COMPLEX INTERACTIONS OF MURINE P53 WITH DNA	ONCOGENE			English	Article							LARGE-T-ANTIGEN; TRANSFORMATION-RELATED PROTEIN; CELL-CYCLE CONTROL; A MOUSE CELLS; WILD-TYPE P53; MONOCLONAL-ANTIBODY; MUTANT P53; TRANSCRIPTIONAL ACTIVATION; NUCLEAR-LOCALIZATION; BINDING-PROTEIN	Biologically active mutant p53 from Balb/c mouse tumor cells (Meth A) was analysed for its specific interaction with DNA. Restricted phage lambda-DNA, representing DNA of high complexity with regard to sequence and secondary structure, was used to probe for such an activity in a target-bound DNA-binding assay, using doubly immunopurified p53. A single lambda-DNA fragment was specifically retained with very high affinity (K(D) = 10(-10) M). Specific DNA binding was shown to be an intrinsic property of p53, as it could be blocked with p53-specific monoclonal antibodies PAb122 and PAb421. The characteristics of the DNA binding of p53 to this lambda-DNA fragment, as well as the structural properties of this fragment, suggested the possibility that p53 might be able to interact with nuclear matrix attachment region (MAR) DNA. Indeed, established genomic MAR elements were specifically bound by Meth A p53, whereas no binding was observed to an AT-rich control DNA. The interaction of p53 with MAR elements in vitro is compatible with the idea that p53 in vivo is involved in the regulation of replication and/or expression of cellular DNA. Complex DNA interactions were not restricted to mutant p53 from Meth A cells. Mutant p53 of a different conformational phenotype (PAb246+ 'wild-type' as opposed to PAb246- 'mutant' for p53 from Meth A cells) from minimally transformed T3T3 cells, as well as genotypic wild-type p53 expressed by a recombinant baculovirus in insect cells, exhibited similar DNA-binding properties.	UNIV HAMBURG,HEINRICH PETTE INST EXPTL VIROL & IMMUNOL,MARTINISTR 52,W-2000 HAMBURG 20,GERMANY	Heinrich Pette Institute; University of Hamburg								AMATI B, 1990, MOL CELL BIOL, V10, P5442, DOI 10.1128/MCB.10.10.5442; ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BADING H, 1987, ONCOGENE, V1, P395; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BARTEK J, 1990, ONCOGENE, V5, P893; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BRUN C, 1990, MOL CELL BIOL, V10, P5453; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P159; CASEY G, 1991, ONCOGENE, V6, P1791; COCKERILL PN, 1987, J BIOL CHEM, V262, P5394; DEFROMENTEL CC, 1986, EXP CELL RES, V164, P35, DOI 10.1016/0014-4827(86)90452-0; DELEO AB, 1977, J EXP MED, V146, P720, DOI 10.1084/jem.146.3.720; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; DEPPERT W, 1990, ONCOGENE, V5, P1701; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GASSER SM, 1987, TRENDS GENET, V3, P16, DOI 10.1016/0168-9525(87)90156-9; GETZENBERG RH, 1991, J CELL BIOCHEM, V47, P289, DOI 10.1002/jcb.240470402; GILLESPIE PG, 1991, P NATL ACAD SCI USA, V88, P2563, DOI 10.1073/pnas.88.6.2563; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HERBOMEL P, 1990, New Biologist, V2, P937; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HINZPETER M, 1986, VIROLOGY, V148, P159, DOI 10.1016/0042-6822(86)90411-3; HINZPETER M, 1987, ONCOGENE, V1, P119; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LANE DP, 1983, CELL BIOL INT REP, V7, P513, DOI 10.1016/0309-1651(83)90154-6; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MCKAY RDG, 1981, J MOL BIOL, V145, P471, DOI 10.1016/0022-2836(81)90540-4; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MERCER WE, 1990, ONCOGENE, V5, P973; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OROURKE RW, 1990, ONCOGENE, V5, P1829; PHIVAN L, 1988, EMBO J, V7, P655, DOI 10.1002/j.1460-2075.1988.tb02860.x; PHIVAN L, 1990, PROG MOL SUBCELL BIO, V11, P1; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROTTER V, 1983, EMBO J, V2, P1041, DOI 10.1002/j.1460-2075.1983.tb01543.x; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHIRMBECK R, 1988, VIROLOGY, V165, P527, DOI 10.1016/0042-6822(88)90597-1; SCHIRMBECK R, 1989, J VIROL, V63, P2308, DOI 10.1128/JVI.63.5.2308-2316.1989; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SHOHATFOORD O, 1991, NUCLEIC ACIDS RES, V19, P5191; STEINMEYER K, 1990, ONCOGENE, V5, P1691; STEINMEYER K, 1988, ONCOGENE, V3, P501; Summers MD, 1987, TEXAS AGR EXPT STATI; VONKRIES JP, 1991, CELL, V64, P123, DOI 10.1016/0092-8674(91)90214-J; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; YOUISHROUACH E, 1991, NATURE, V352, P345; ZERRAHN J, 1992, IN PRESS ONCOGENE	62	24	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					1921	1932						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408133				2022-12-28	WOS:A1992JP42400004
J	HIBI, K; TAKAHASHI, T; YAMAKAWA, K; UEDA, R; SEKIDO, Y; ARIYOSHI, Y; SUYAMA, M; TAKAGI, H; NAKAMURA, Y; TAKAHASHI, T				HIBI, K; TAKAHASHI, T; YAMAKAWA, K; UEDA, R; SEKIDO, Y; ARIYOSHI, Y; SUYAMA, M; TAKAGI, H; NAKAMURA, Y; TAKAHASHI, T			3 DISTINCT REGIONS INVOLVED IN 3P DELETION IN HUMAN LUNG-CANCER	ONCOGENE			English	Article							RENAL-CELL CARCINOMA; SHORT ARM; DNA-SEQUENCE; CHROMOSOME-3; HETEROZYGOSITY; GENE; ADENOCARCINOMA; EXPRESSION; MYC; ABNORMALITIES	The 3p deletion was first noted by cytogenetic analysis and was later confirmed by several independent studies using restriction fragment length polymorphism (RFLP) probes. As an initial step towards positional cloning (reverse genetics) of the tumor-suppressor gene(s) on 3p, a detailed analysis of the minimum deleted region(s) on 3p was performed with 13 RFLP probes and 48 paired human lung cancer samples. All nine small-cell lung cancer cases (100%) and 31 of 39 non-small-cell lung cancer cases (79%) showed allelic loss at one or more loci mapped on 3p. We show here that three distinct regions on 3p appear to be frequently deleted in lung cancer. These regions include 3p25, 3p21.3 and 3p14-cen. The present study should warrant future work focusing on these chromosomal regions on 3p, and may ultimately lead to the isolation of tumor-suppressor genes involved in the pathogenesis of lung cancer.	AICHI CANC CTR,RES INST,CHEMOTHERAPY LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; NAGOYA UNIV,SCH MED,DEPT SURG 2,SHOWA KU,NAGOYA,AICHI 466,JAPAN; NAGOYA UNIV,SCH MED,DEPT INTERNAL MED 1,SHOWA KU,NAGOYA,AICHI 466,JAPAN; JAPANESE FDN CANC RES,INST CANC,BIOCHEM LAB,TOSHIMA KU,TOKYO 170,JAPAN; AICHI CANC CTR,DEPT SURG,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR,IMMUNOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN	Aichi Cancer Center; Nagoya University; Nagoya University; Japanese Foundation for Cancer Research; Aichi Cancer Center; Aichi Cancer Center			Takahashi, Takashi/I-7262-2014; Yamakawa, Kazuhiro/N-5050-2015	Takahashi, Takashi/0000-0003-0615-7001; Yamakawa, Kazuhiro/0000-0002-1478-4390; Sekido, Yoshitaka/0000-0002-2428-3848				BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; BRAUCH H, 1990, GENE CHROMOSOME CANC, V1, P240, DOI 10.1002/gcc.2870010309; DALY MC, 1991, GENOMICS, V9, P113, DOI 10.1016/0888-7543(91)90227-6; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; EHLEN T, 1990, ONCOGENE, V5, P219; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HIBI K, 1991, ONCOGENE, V6, P2291; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOSOE S, 1990, GENOMICS, V8, P634, DOI 10.1016/0888-7543(90)90249-T; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOVACS G, 1988, P NATL ACAD SCI USA, V85, P1571, DOI 10.1073/pnas.85.5.1571; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; LOTHE RA, 1989, GENOMICS, V5, P134, DOI 10.1016/0888-7543(89)90097-9; NAU M, 1985, P NATL ACAD SCI USA, V83, P1092; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; PONDER B, 1988, NATURE, V335, P400, DOI 10.1038/335400a0; RABBITTS P, 1989, GENE CHROMOSOME CANC, V1, P95, DOI 10.1002/gcc.2870010115; RABBITTS P, 1990, GENE CHROMOSOME CANC, V2, P231, DOI 10.1002/gcc.2870020312; RODENHUIS S, 1987, NEW ENGL J MED, V317, P929, DOI 10.1056/NEJM198710083171504; SEIZINGER BR, 1988, NATURE, V332, P268, DOI 10.1038/332268a0; SEKIDO Y, 1991, CANCER RES, V51, P2416; TAKAHASHI T, 1989, CANCER RES, V49, P2683; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKAHASHI T, 1990, J CLIN INVEST, V86, P363, DOI 10.1172/JCI114710; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; WHANGPENG J, 1991, GENE CHROMOSOME CANC, V3, P168, DOI 10.1002/gcc.2870030303; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023; YAMAKAWA K, 1991, GENOMICS, V9, P536, DOI 10.1016/0888-7543(91)90421-A; YAMAKAWA K, 1991, CANCER RES, V51, P4707; YAMAKAWA K, 1991, GENOMICS, V11, P565, DOI 10.1016/0888-7543(91)90063-K; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOTA J, 1989, CANCER RES, V49, P3598; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0	34	278	283	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1992	7	3					445	449						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1347916				2022-12-28	WOS:A1992HK00500007
J	Quaas, CE; Lin, BC; Long, DT				Quaas, Colleen E.; Lin, Baicheng; Long, David T.			Transcription suppression is mediated by the HDAC1-Sin3 complex in Xenopus nucleoplasmic extract	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE INHIBITOR; DNA-REPLICATION; CELL-CYCLE; HDAC 1; CHROMATIN; NUCLEOSOME; BRD4; ACETYLATION; ROMIDEPSIN; BIOLOGY	Modification of histones provides a dynamic mechanism to regulate chromatin structure and access to DNA. Histone acetylation, in particular, plays a prominent role in controlling the interaction between DNA, histones, and other chromatin -associated proteins. Defects in histone acetylation patterns interfere with normal gene expression and underlie a wide range of human diseases. Here, we utilize Xenopus egg extracts to investigate how changes in histone acetylation influence transcription of a defined gene construct. We show that inhi-bition of histone deacetylase 1 and 2 (HDAC1/2) specifically counteracts transcription suppression by preventing chromatin compaction and deacetylation of histone residues H4K5 and H4K8. Acetylation of these sites supports binding of the chromatin reader and transcription regulator BRD4. We also identify HDAC1 as the primary driver of transcription sup-pression and show that this activity is mediated through the Sin3 histone deacetylase complex. These findings highlight functional differences between HDAC1 and HDAC2, which are often considered to be functionally redundant, and provide additional molecular context for their activity.	[Quaas, Colleen E.; Lin, Baicheng; Long, David T.] Med Univ South Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Long, DT (corresponding author), Med Univ South Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.	longdt@musc.edu		Quaas, Colleen/0000-0002-7853-3128	NIH; Hollings Cancer Center Abney Fellowship;  [R35GM119512]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Hollings Cancer Center Abney Fellowship; 	Funding and additional information-This work was supported by NIH grant R35GM119512 to D. T. L. and a Hollings Cancer Center Abney Fellowship to B. L. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Allis CD, 2016, NAT REV GENET, V17, P487, DOI 10.1038/nrg.2016.59; Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22; Barrows JK, 2021, NUCLEIC ACIDS RES, V49, P3263, DOI 10.1093/nar/gkab111; Barrows JK, 2019, J BIOL CHEM, V294, P19645, DOI 10.1074/jbc.RA119.011350; Baud MGJ, 2014, SCIENCE, V346, P638, DOI 10.1126/science.1249830; Boyson SP, 2021, CANCERS, V13, DOI 10.3390/cancers13143606; Cappellacci L, 2020, CURR MED CHEM, V27, P2449, DOI 10.2174/0929867325666181016163110; Chaidos A, 2014, BLOOD, V123, P697, DOI 10.1182/blood-2013-01-478420; Chen Hong Ping, 2015, Critical Reviews in Oncogenesis, V20, P35; Chen IC, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.576391; Constanze B., 2013, CHROMATIN MECH REGUL; Corujo D, 2018, CANCERS, V10, DOI 10.3390/cancers10030059; Cosgrove MS, 2004, NAT STRUCT MOL BIOL, V11, P1037, DOI 10.1038/nsmb851; Cosgrove MS, 2005, BIOCHEM CELL BIOL, V83, P468, DOI 10.1139/O05-137; Dewar JM, 2017, GENE DEV, V31, P275, DOI 10.1101/gad.291799.116; Dey A, 2003, P NATL ACAD SCI USA, V100, P8758, DOI 10.1073/pnas.1433065100; Drogaris P, 2012, SCI REP-UK, V2, DOI 10.1038/srep00220; Eberharter A, 2002, EMBO REP, V3, P224, DOI 10.1093/embo-reports/kvf053; Esteve PO, 2020, J MOL BIOL, V432, P5304, DOI 10.1016/j.jmb.2020.07.023; Filippakopoulos P, 2012, CELL, V149, P214, DOI 10.1016/j.cell.2012.02.013; Fullbright G, 2016, MOL CELL BIOL, V36, P2983, DOI 10.1128/MCB.00434-16; Gallinari P, 2007, CELL RES, V17, P195, DOI 10.1038/sj.cr.7310149; Gates LA, 2017, J BIOL CHEM, V292, P14456, DOI 10.1074/jbc.M117.802074; Gonneaud A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41842-6; Gruszka DT, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abc0330; Grzenda A, 2009, BBA-GENE REGUL MECH, V1789, P443, DOI 10.1016/j.bbagrm.2009.05.007; Hartman HB, 2005, EMBO REP, V6, P445, DOI 10.1038/sj.embor.7400391; Hauer MH, 2017, GENE DEV, V31, P2204, DOI 10.1101/gad.307702.117; Heijo H, 2020, MOL BIOL CELL, V31, P2703, DOI 10.1091/mbc.E20-02-0113; Hergeth SP, 2015, EMBO REP, V16, P1439, DOI 10.15252/embr.201540749; Hiraoka N, 2013, BLOOD CANCER J, V3, DOI 10.1038/bcj.2013.66; HUTCHISON CJ, 1989, J CELL SCI, P197; Imesch P, 2010, FERTIL STERIL, V94, P2838, DOI 10.1016/j.fertnstert.2010.04.052; Jamaladdin S, 2014, P NATL ACAD SCI USA, V111, P9840, DOI 10.1073/pnas.1321330111; Johnson CA, 2002, J BIOL CHEM, V277, P9590, DOI 10.1074/jbc.M107942200; Jung M, 2014, J BIOL CHEM, V289, P9304, DOI 10.1074/jbc.M113.523019; Jurkin J, 2011, CELL CYCLE, V10, P406, DOI 10.4161/cc.10.3.14712; Kelly RDW, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32927-9; Kelly RDW, 2013, BIOCHEM SOC T, V41, P741, DOI 10.1042/BST20130010; Kim MY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228460; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Lazarchuk P, 2020, MOL CELL BIOL, V40, DOI 10.1128/MCB.00421-19; Lebofsky Ronald, 2009, V521, P229, DOI [10.1007/978-1-60327-817-5_13, 10.1007/978-1-60327-815-7_13]; Li YX, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026831; Low E, 2020, GENE DEV, V34, P1534, DOI 10.1101/gad.339739.120; Luo Y, 2009, J BIOL CHEM, V284, P34901, DOI 10.1074/jbc.M109.038356; Ma YQ, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00019; Madamba EV, 2017, CELL REP, V21, P1361, DOI 10.1016/j.celrep.2017.10.033; Mann BS, 2007, ONCOLOGIST, V12, P1247, DOI 10.1634/theoncologist.12-10-1247; Marino-Ramirez L, 2005, EXPERT REV PROTEOMIC, V2, P719, DOI 10.1586/14789450.2.5.719; Marmorstein R, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a018762; Marques JG, 2020, ELIFE, V9, DOI 10.7554/eLife.54993; MARTINEZBALBAS MA, 1995, CELL, V83, P29, DOI 10.1016/0092-8674(95)90231-7; Milazzo G, 2020, GENES-BASEL, V11, DOI 10.3390/genes11050556; Millard CJ, 2017, TRENDS PHARMACOL SCI, V38, P363, DOI 10.1016/j.tips.2016.12.006; Musselman CA, 2012, NAT STRUCT MOL BIOL, V19, P1218, DOI 10.1038/nsmb.2436; Odenike OM, 2008, CLIN CANCER RES, V14, P7095, DOI 10.1158/1078-0432.CCR-08-1007; Parbin S, 2014, J HISTOCHEM CYTOCHEM, V62, P11, DOI 10.1369/0022155413506582; Pavlik CM, 2013, J NAT PROD, V76, P2026, DOI 10.1021/np400198r; PHILPOTT A, 1992, CELL, V69, P759, DOI 10.1016/0092-8674(92)90288-N; Prakash K, 2018, BIOSYSTEMS, V164, P49, DOI 10.1016/j.biosystems.2017.11.005; Quenet D, 2018, INT REV CEL MOL BIO, V335, P1, DOI 10.1016/bs.ircmb.2017.07.006; Rando OJ, 2012, GENETICS, V190, P351, DOI 10.1534/genetics.111.132266; Sanchez R, 2009, CURR OPIN DRUG DISC, V12, P659; Sato Y, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.179127; Seto E, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a018713; Shechter D, 2009, J BIOL CHEM, V284, P1064, DOI 10.1074/jbc.M807273200; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Terui R, 2018, GENE DEV, V32, P806, DOI 10.1101/gad.310995.117; Thompson LL, 2013, CANCER METAST REV, V32, P363, DOI 10.1007/s10555-013-9434-8; VanderMolen KM, 2011, J ANTIBIOT, V64, P525, DOI 10.1038/ja.2011.35; Vinodhkumar R, 2008, BIOMED PHARMACOTHER, V62, P85, DOI 10.1016/j.biopha.2007.06.002; Vrtis KB, 2021, MOL CELL, V81, DOI 10.1016/j.molcel.2020.12.039; Wang WL, 2016, INT J DEV BIOL, V60, P315, DOI 10.1387/ijdb.160161ds; WOODLAND HR, 1979, DEV BIOL, V68, P360, DOI 10.1016/0012-1606(79)90210-0; Workman JL, 2006, GENE DEV, V20, P2009, DOI 10.1101/gad.1435706; Wu RA, 2019, NATURE, V567, P267, DOI 10.1038/s41586-019-1002-0; Wu SY, 2007, J BIOL CHEM, V282, P13141, DOI 10.1074/jbc.R700001200; Xie F, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26496-0; Yang H, 2021, MOL THER-ONCOLYTICS, V21, P1, DOI 10.1016/j.omto.2021.03.005; Yu XY, 2020, DRUG DES DEV THER, V14, P121, DOI 10.2147/DDDT.S234871; Zaware N, 2019, NAT STRUCT MOL BIOL, V26, P870, DOI 10.1038/s41594-019-0309-8; Zhang H, 2017, HEPATOL RES, V47, P149, DOI 10.1111/hepr.12757	83	0	0	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV	2022	298	11							102578	10.1016/j.jbc.2022.102578	http://dx.doi.org/10.1016/j.jbc.2022.102578			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	6W5WW	36220390	gold, Green Published			2022-12-28	WOS:000895801300004
J	Quinlan, RA; Clark, JI				Quinlan, Roy A.; Clark, John I.			Insights into the biochemical and biophysical mechanisms mediating the longevity of the transparent optics of the lens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							ALPHA-A-CRYSTALLIN; AGE-RELATED-CHANGES; GAMMA-S-CRYSTALLIN; PROTEIN-PROTEIN INTERACTIONS; CHOLESTEROL BILAYER DOMAIN; ASPARTIC-ACID RACEMIZATION; WATER-INSOLUBLE PROTEIN; HEAT-SHOCK-PROTEIN; EYE LENS; POSTTRANSLATIONAL MODIFICATIONS	In the human eye, a transparent cornea and lens combine to form the "refracton" to focus images on the retina. This re-quires the refracton to have a high refractive index "n," mediated largely by extracellular collagen fibrils in the corneal stroma and the highly concentrated crystallin proteins in the cytoplasm of the lens fiber cells. Transparency is a result of short-range order in the spatial arrangement of corneal collagen fibrils and lens crystallins, generated in part by post -translational modifications (PTMs). However, while corneal collagen is remodeled continuously and replaced, lens crystal-lins are very long-lived and are not replaced and so accumulate PTMs over a lifetime. Eventually, a tipping point is reached when protein aggregation results in increased light scatter, inevitably leading to the iconic protein condensation-based disease, age-related cataract (ARC). Cataracts account for 50% of vision impairment worldwide, affecting far more people than other well-known protein aggregation-based diseases. However, because accumulation of crystallin PTMs begins before birth and long before ARC presents, we postulate that the lens protein PTMs contribute to a "cataractogenic load" that not only increases with age but also has protective effects on optical function by stabilizing lens crystallins until a tipping point is reached. In this review, we highlight decades of experimental findings that support the potential for PTMs to be protective during normal development. We hypothesize that ARC is preventable by protecting the biochemical and bio-physical properties of lens proteins needed to maintain trans-parency, refraction, and optical function.	[Quinlan, Roy A.] Univ Durham, Dept Biosci, South Rd Sci Site, Durham, England; [Quinlan, Roy A.; Clark, John I.] Univ Washington, Dept Biol Struct, Seattle 98195, WA USA	Durham University; University of Washington; University of Washington Seattle	Quinlan, RA (corresponding author), Univ Durham, Dept Biosci, South Rd Sci Site, Durham, England.; Quinlan, RA; Clark, JI (corresponding author), Univ Washington, Dept Biol Struct, Seattle 98195, WA USA.	r.a.quinlan@durham.ac.uk; clarkji@uw.edu	quinlan, roy/A-1348-2012	quinlan, roy/0000-0003-0644-4123	University of Washington (Seattle, WA, USA); University of Durham (Durham, UK)	University of Washington (Seattle, WA, USA)(University of Washington); University of Durham (Durham, UK)	We thank Drs Judy Clark and Alexia Kalligeraki for helpful discussions and the referees who helped in the refinement of this review through their helpful and insightful comments.The academic support of the University of Washington (Seattle, WA, USA) and the University of Durham (Durham, UK) is greatly appreciated.	Ahmadi M, 2022, RADIAT RES, V197, P78, DOI 10.1667/RADE-20-00284.1; Ainsbury EA, 2022, RADIAT RES, V197, P1, DOI 10.1667/RADE-21-00188.1; Ainsbury EA, 2021, EXP EYE RES, V212, DOI 10.1016/j.exer.2021.108772; Ainsbury EA, 2016, MUTAT RES-REV MUTAT, V770, P238, DOI 10.1016/j.mrrev.2016.07.010; ALBERTINI DF, 1975, P NATL ACAD SCI USA, V72, P4976, DOI 10.1073/pnas.72.12.4976; AlGhoul KJ, 1996, CURR EYE RES, V15, P533, DOI 10.3109/02713689609000764; Anderson DM, 2020, J MASS SPECTROM, V55, DOI 10.1002/jms.4473; ARNOLD JM, 1966, J ULTRA MOL STRUCT R, V14, P534, DOI 10.1016/S0022-5320(66)80080-1; Asbell PA, 2005, LANCET, V365, P599; Audette DS, 2017, EXP EYE RES, V156, P41, DOI 10.1016/j.exer.2016.03.016; Augusteyn RC, 2014, MOL VIS, V20, P410; B. Norton-Baker, 2021, bioRxiv, DOI 10.1101/2021.06.21.449298; Bahrami M, 2015, EXP EYE RES, V140, P19, DOI 10.1016/j.exer.2015.08.011; Bahrami M, 2014, EXP EYE RES, V124, P93, DOI 10.1016/j.exer.2014.05.009; Barnard S, 2022, RADIAT RES, V197, P92, DOI 10.1667/RADE-20-00294.1; Bassnett S, 2005, EXP EYE RES, V81, P716, DOI 10.1016/j.exer.2005.04.009; Bassnett S, 2017, PROG RETIN EYE RES, V60, P181, DOI 10.1016/j.preteyeres.2017.04.001; Bassnett S, 2017, EXP EYE RES, V156, P50, DOI 10.1016/j.exer.2016.03.009; Bassnett S, 2011, PHILOS T R SOC B, V366, P1250, DOI 10.1098/rstb.2010.0302; Bassnett S, 2010, MOL VIS, V16, P2294; BEAULIEU CF, 1990, INVEST OPHTH VIS SCI, V31, P1339; BEEBE DC, 1979, SCIENCE, V206, P836, DOI 10.1126/science.493982; Benedek GB, 1997, INVEST OPHTH VIS SCI, V38, P1911; Benedek GB, 1999, PROG RETIN EYE RES, V18, P391, DOI 10.1016/S1350-9462(98)00023-8; BENEDEK GB, 1971, APPL OPTICS, V10, P459, DOI 10.1364/AO.10.000459; BENEDEK GB, 1979, PHILOS T R SOC A, V293, P329, DOI 10.1098/rsta.1979.0100; Berry V, 2022, OPHTHALMIC GENET, V43, P218, DOI 10.1080/13816810.2021.1998556; Berry V, 2020, BRIT J OPHTHALMOL, V104, P1331, DOI 10.1136/bjophthalmol-2019-315282; Berthoud VM, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165822; Bettelheim F. A., 1985, OCULAR LENS STRUCTUR, P265; BETTELHEIM FA, 1979, EXP EYE RES, V28, P189, DOI 10.1016/0014-4835(79)90130-1; BETTELHEIM FA, 1983, BIOPHYS J, V41, P29, DOI 10.1016/S0006-3495(83)84402-6; BETTELHEIM FA, 1979, BIOPHYS J, V26, P85, DOI 10.1016/S0006-3495(79)85237-6; Bhat SP, 2019, J BIOL CHEM, V294, P13530, DOI 10.1074/jbc.RA119.008853; Biswas S, 2016, EXP EYE RES, V145, P130, DOI 10.1016/j.exer.2015.11.017; Biswas SK, 2014, EXP EYE RES, V127, P132, DOI 10.1016/j.exer.2014.07.020; Blakely E A, 2010, Radiat Res, V173, P709, DOI 10.1667/RRXX19.1; Bloemendal H, 2004, PROG BIOPHYS MOL BIO, V86, P407, DOI 10.1016/j.pbiomolbio.2003.11.012; Boob M, 2019, J PHYS CHEM B, V123, P8341, DOI 10.1021/acs.jpcb.9b05467; Borchman D, 1996, EXP EYE RES, V63, P407, DOI 10.1006/exer.1996.0130; Borchman D, 2021, J LIPID RES, V62, DOI 10.1194/jlr.TR120000874; Borchman D, 2017, J LIPID RES, V58, P2289, DOI 10.1194/jlr.M079368; Borchman D, 2010, J LIPID RES, V51, P2473, DOI 10.1194/jlr.R004119; Braakhuis AJ, 2019, NUTRIENTS, V11, DOI 10.3390/nu11051186; BREWITT B, 1988, SCIENCE, V242, P777, DOI 10.1126/science.3187521; BREWITT B, 1992, J CELL PHYSIOL, V150, P586, DOI 10.1002/jcp.1041500320; BREWITT B, 1992, DEV BIOL, V152, P315, DOI 10.1016/0012-1606(92)90138-7; Brink PR, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186943; Brooks-Wilson AR, 2013, HUM GENET, V132, P1323, DOI 10.1007/s00439-013-1342-z; Brown N. P., 1996, LENS DISORDERS CLIN, V3rd; Budnar P, 2022, BIOCHEMISTRY-MOSCOW+, V87, P225, DOI [10.1134/S000629792203004X, 10.31857/S0320972522030071]; BYERS B, 1964, P NATL ACAD SCI USA, V52, P1091, DOI 10.1073/pnas.52.4.1091; Cagan A, 2022, NATURE, V604, P517, DOI 10.1038/s41586-022-04618-z; Cai J, 2017, SCIENCE, V357, P564, DOI 10.1126/science.aal2674; Cantrell LS, 2021, J AM SOC MASS SPECTR, V32, P2755, DOI 10.1021/jasms.1c00193; Cao L, 2018, J CELL PHYSIOL, V233, P2202, DOI 10.1002/jcp.26074; CARTER JM, 1995, EXP EYE RES, V60, P181, DOI 10.1016/S0014-4835(95)80009-3; CENEDELLA RJ, 1992, CURR EYE RES, V11, P801, DOI 10.3109/02713689209000753; Chaturvedi SK, 2019, J AM CHEM SOC, V141, P2990, DOI 10.1021/jacs.8b11371; Chaturvedi SK, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06902-x; Chen YD, 2022, AM J PHYSIOL-REG I, V322, pR263, DOI 10.1152/ajpregu.00309.2021; Cheng CTRE, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.772276; Cheng C, 2017, EXP EYE RES, V156, P58, DOI 10.1016/j.exer.2016.03.005; Cheng X, 2013, J R SOC INTERFACE, V10, DOI 10.1098/rsif.2013.0512; CHERIAN M, 1995, BIOCHEM BIOPH RES CO, V208, P675, DOI 10.1006/bbrc.1995.1391; Chitra PS, 2020, EXP EYE RES, V200, DOI 10.1016/j.exer.2020.108230; Choquet H, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23873-8; CHYLACK LT, 1984, OPHTHALMOLOGY, V91, P596; CHYLACK LT, 1990, EXP EYE RES, V50, P575, DOI 10.1016/0014-4835(90)90097-E; Clark AR, 2012, INT J BIOCHEM CELL B, V44, P1687, DOI 10.1016/j.biocel.2012.02.015; Clark J. I., 2021, ALBERT JAKOBIECS PRI; CLARK JI, 1980, OPHTHALMIC RES, V12, P16, DOI 10.1159/000265057; Clark JI, 1999, EYE, V13, P417, DOI 10.1038/eye.1999.116; Clark JI, 2004, EXP EYE RES, V78, P427, DOI 10.1016/j.exer.2003.10.008; CLARK JI, 1982, INVEST OPHTH VIS SCI, V22, P186; Clark JK, 2021, AGR HUM VALUES, V38, P175, DOI 10.1007/s10460-020-10146-1; Clark JI, 2016, BBA-GEN SUBJECTS, V1860, P240, DOI 10.1016/j.bbagen.2015.08.014; Collins TN, 2018, ELIFE, V7, DOI 10.7554/eLife.32586; Cvekl A, 2021, EXP EYE RES, V207, DOI 10.1016/j.exer.2021.108564; Cvekl A, 2017, TRENDS GENET, V33, P677, DOI 10.1016/j.tig.2017.08.001; Cvekl A, 2015, PROG MOL BIOL TRANSL, V134, P129, DOI 10.1016/bs.pmbts.2015.05.001; Cvekl A, 2014, DEVELOPMENT, V141, P4432, DOI 10.1242/dev.107953; Dai E., 2008, OPHTHALMOLOGY, V3rd, P1528; Dasari S, 2007, J PROTEOME RES, V6, P3819, DOI 10.1021/pr070182x; de Jong W.W., 1988, Advances in Experimental Medicine and Biology, V231, P95; DELAMERE NA, 1980, J PHYSIOL-LONDON, V308, P49, DOI 10.1113/jphysiol.1980.sp013461; Delamere NA, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.6.58; DELAYE M, 1983, NATURE, V302, P415, DOI 10.1038/302415a0; DELAYE M, 1982, BIOPHYS J, V37, P647; Derham BK, 2002, BIOCHEM J, V364, P711, DOI 10.1042/BJ20011512; Derham BK, 1997, BIOCHEM J, V328, P763; DICKEY JB, 1993, AM J OPHTHALMOL, V115, P234, DOI 10.1016/S0002-9394(14)73929-7; Disatham J, 2022, EPIGENET CHROMATIN, V15, DOI 10.1186/s13072-022-00440-z; DISCHE Z, 1951, AM J OPHTHALMOL, V34, P104, DOI 10.1016/0002-9394(51)90013-X; DISCHE Z, 1956, ARCH OPHTHALMOL-CHIC, V55, P471; Donaldson Paul J, 2017, Prog Retin Eye Res, V56, pe1, DOI 10.1016/j.preteyeres.2016.09.002; EISENBERG RS, 1976, J PHYSIOL-LONDON, V262, P285, DOI 10.1113/jphysiol.1976.sp011596; Ellis RJ, 2006, BIOL CHEM, V387, P485, DOI 10.1515/BC.2006.064; Ellis RJ, 2001, CURR OPIN STRUC BIOL, V11, P114, DOI 10.1016/S0959-440X(00)00172-X; Evert J, 2003, J GERONTOL A-BIOL, V58, P232; Fan XJ, 2021, EXP EYE RES, V210, DOI 10.1016/j.exer.2021.108705; Fan XJ, 2015, MOL CELL PROTEOMICS, V14, P3211, DOI 10.1074/mcp.M115.050948; Faranda AP, 2021, EXP EYE RES, V209, DOI 10.1016/j.exer.2021.108663; Farnsworth DR, 2021, EXP EYE RES, V206, DOI 10.1016/j.exer.2021.108535; Farrell R. A., 2000, CORNEAL TRANSPARENCY, V2nd; Feig M, 2021, J PHYS CHEM B, V125, P10649, DOI 10.1021/acs.jpcb.1c07093; Feneck EM, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.6.5; Fischer RS, 2003, FEBS LETT, V547, P228, DOI 10.1016/S0014-5793(03)00711-7; FitzGerald P, 2016, MOL VIS, V22, P970; FITZGERALD PG, 1989, CURR EYE RES, V8, P801, DOI 10.3109/02713688909000870; FITZGERALD PG, 1988, CURR EYE RES, V7, P1243, DOI 10.3109/02713688809033228; FLORY PJ, 1975, FARADAY DISCUSS, V57, P7; Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102; FRANKE WW, 1987, EUR J CELL BIOL, V43, P301; Frederikse P, 2017, NEUROCHEM RES, V42, P933, DOI 10.1007/s11064-016-2156-x; Friedrich MG, 2019, BIOCHEM J, V476, P3817, DOI 10.1042/BCJ20190743; Fudge DS, 2011, INVEST OPHTH VIS SCI, V52, P3860, DOI 10.1167/iovs.10-6231; Fujii N, 1999, BIOCHEM BIOPH RES CO, V265, P746, DOI 10.1006/bbrc.1999.1748; Fujii N, 2001, BBA-PROTEIN STRUCT M, V1549, P179, DOI 10.1016/S0167-4838(01)00258-8; Fujii N, 2020, BBA-PROTEINS PROTEOM, V1868, DOI 10.1016/j.bbapap.2020.140446; Gao JY, 2015, BIOPHYS J, V109, P1830, DOI 10.1016/j.bpj.2015.09.018; Garner WH, 2016, INVEST OPHTH VIS SCI, V57, P2851, DOI 10.1167/iovs.15-18413; Gavrilova NS, 2022, J GERONTOL A-BIOL, V77, P736, DOI 10.1093/gerona/glab380; Gelineau-Morel R, 2016, GENES-BASEL, V7, DOI 10.3390/genes7100085; Giannone AA, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.818649; Giegling I, 2020, TRANSL PSYCHIAT, V10, DOI 10.1038/s41398-020-0791-0; GISSELBERG M, 1991, AM J ANAT, V191, P408, DOI 10.1002/aja.1001910408; GOLDMAN JEROME N., 1967, INVEST OPHTHALMOL, V6, P574; GOLDMAN JN, 1968, INVEST OPHTH VISUAL, V7, P501; Goodenough D.A., 1992, Seminars in Cell Biology, V3, P49; Graw J, 2003, NAT REV GENET, V4, P876, DOI 10.1038/nrg1202; Graw J, 2017, EXP EYE RES, V156, P5, DOI 10.1016/j.exer.2015.11.006; Graw J, 2010, CURR TOP DEV BIOL, V90, P343, DOI 10.1016/S0070-2153(10)90010-0; GREINER JV, 1981, INVEST OPHTH VIS SCI, V21, P700; Grey AC, 2003, EXP EYE RES, V77, P567, DOI 10.1016/S0014-4835(03)00192-1; Grey AC, 2009, INVEST OPHTH VIS SCI, V50, P4319, DOI 10.1167/iovs.09-3522; Griep AE, 2006, SEMIN CELL DEV BIOL, V17, P686, DOI 10.1016/j.semcdb.2006.10.004; Griesser E, 2021, REDOX BIOL, V44, DOI 10.1016/j.redox.2021.102014; GROENEN PJTA, 1990, FEBS LETT, V269, P109, DOI 10.1016/0014-5793(90)81131-7; Grosas A. B., 2021, LONG LIVED PROTEINS; Grosas A. B., 2021, LONG LIVED PROTEINS, P59; Grosas AB, 2021, EXP EYE RES, V208, DOI 10.1016/j.exer.2021.108619; Grosas AB, 2020, J MOL BIOL, V432, P5593, DOI 10.1016/j.jmb.2020.08.011; Gu SM, 2019, INVEST OPHTH VIS SCI, V60, P4021, DOI 10.1167/iovs.18-26270; GULIKKRZYWICKI T, 1984, BIOCHIM BIOPHYS ACTA, V800, P28, DOI 10.1016/0304-4165(84)90090-4; Gunhaga L, 2011, PHILOS T R SOC B, V366, P1193, DOI 10.1098/rstb.2010.0175; Guo G, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23461-w; Gupta A, 2020, BIOMED OPT EXPRESS, V11, P5388, DOI 10.1364/BOE.401254; Gupta R, 2004, J BIOL CHEM, V279, P44258, DOI 10.1074/jbc.M405648200; Gupta R, 2011, J BIOL CHEM, V286, P11579, DOI 10.1074/jbc.M110.148627; Guseman AJ, 2021, STRUCTURE, V29, P284, DOI 10.1016/j.str.2020.11.006; Hahnel C, 2000, CORNEA, V19, P185, DOI 10.1097/00003226-200003000-00012; Hains PG, 2007, J PROTEOME RES, V6, P3935, DOI 10.1021/pr070138h; Hains PG, 2010, INVEST OPHTH VIS SCI, V51, P3107, DOI 10.1167/iovs.09-4308; Hains PG, 2008, PROTEOM CLIN APPL, V2, P1611, DOI 10.1002/prca.200800085; Hammond CJ, 2001, INVEST OPHTH VIS SCI, V42, P601; Hanson SRA, 1998, EXP EYE RES, V67, P301, DOI 10.1006/exer.1998.0530; Hanson SRA, 2000, EXP EYE RES, V71, P195, DOI 10.1006/exer.2000.0868; Harding J., 1991, CATARACT BIOCH EPIDE; HARDING JJ, 1976, EXP EYE RES, V22, P1, DOI 10.1016/0014-4835(76)90033-6; Harrington V, 2007, MOL VIS, V13, P1680; Harrington V, 2004, MOL VIS, V10, P476; Harvey SR, 2022, ANAL CHEM, V94, P1515, DOI 10.1021/acs.analchem.1c04322; Hassell JR, 2010, EXP EYE RES, V91, P326, DOI 10.1016/j.exer.2010.06.021; Heys KR, 2007, AGING CELL, V6, P807, DOI 10.1111/j.1474-9726.2007.00342.x; Hogan MJ, 1971, HISTOLOGY HUMAN EYE; Hong T, 2013, OPHTHALMOLOGY, V120, P2091, DOI 10.1016/j.ophtha.2013.03.032; Hooi MYS, 2013, PROTEIN SCI, V22, P93, DOI 10.1002/pro.2191; Hooi MYS, 2012, PROTEIN SCI, V21, P1074, DOI 10.1002/pro.2095; Hooi MYS, 2012, INVEST OPHTH VIS SCI, V53, P3554, DOI 10.1167/iovs.11-9085; Hooi MYS, 2011, AGE, V33, P131, DOI 10.1007/s11357-010-9171-7; HORWITZ J, 1992, CURR EYE RES, V11, P817, DOI 10.3109/02713689209000754; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; HORWITZ J, 1993, INVEST OPHTH VIS SCI, V34, P10; Horwitz M, 2015, BRIT J HAEMATOL, V168, P518, DOI 10.1111/bjh.13148; Huang YF, 1999, BIOPHYS J, V77, P1655, DOI 10.1016/S0006-3495(99)77013-X; Inaba Y, 2020, ELIFE, V9, DOI 10.7554/eLife.58149; Islam S., 2022, J BIOL CHEM, V298; Ismail VS, 2016, BBA-BIOMEMBRANES, V1858, P2763, DOI 10.1016/j.bbamem.2016.06.026; Jara O, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10101418; JEDZINIAK JA, 1973, EXP EYE RES, V15, P185, DOI 10.1016/0014-4835(73)90118-8; JEDZINIAK JA, 1978, INVEST OPHTH VIS SCI, V171, P51; Jester JV, 2008, SEMIN CELL DEV BIOL, V19, P82, DOI 10.1016/j.semcdb.2007.09.015; Jiang J, 2018, INVEST OPHTH VIS SCI, V59, P4986, DOI 10.1167/iovs.18-25067; Johnston IG, 2022, P NATL ACAD SCI USA, V119, DOI 10.1073/pnas.2113883119; Kador PF, 2016, PROG RETIN EYE RES, V54, P1, DOI 10.1016/j.preteyeres.2016.04.006; KADOR PF, 1980, EXP EYE RES, V30, P59, DOI 10.1016/0014-4835(80)90124-4; Kalligeraki A., 2021, ENCY BIOL CHEM, V3, P639; Kalligeraki AA, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-73625-9; Khago D, 2018, J PHYS-CONDENS MAT, V30, DOI 10.1088/1361-648X/aae000; Kilpelainen TO, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08008-w; KINOSHITA JIN H., 1965, INVEST OPHTHALMOL, V4, P619; Kirkwood TBL, 2002, MECH AGEING DEV, V123, P737, DOI 10.1016/S0047-6374(01)00419-5; Kleiman N. J., 2012, Annals of the ICRP, V41, P80, DOI 10.1016/j.icrp.2012.06.018; Klevit RE, 2020, CELL STRESS CHAPERON, V25, P573, DOI 10.1007/s12192-020-01092-2; Koppers M, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.618733; KORETZ JF, 1988, SCI AM, V259, P92, DOI 10.1038/scientificamerican0788-92; Krishnan K, 2007, J BIOL CHEM, V282, P18953, DOI 10.1074/jbc.M609275200; Kumari SS, 2015, BIOCHEM BIOPH RES CO, V462, P339, DOI 10.1016/j.bbrc.2015.04.138; Kumari S, 2017, INVEST OPHTH VIS SCI, V58, P6006, DOI 10.1167/iovs.17-22153; KUPFER C, 1985, T OPHTHAL SOC UK, V104, P1; Kuszak J. R., 2008, BIOL LENS LENS TRANS; Kuszak J. R., 2004, STRUCTURE VERTEBRATE; Kuszak JR, 2006, MOL VIS, V12, P251; Kuszak JR, 2004, INT J DEV BIOL, V48, P889, DOI 10.1387/ijdb.041880jk; Kuszak JR, 2004, EXP EYE RES, V78, P673, DOI 10.1016/j.exer.2003.09.016; KUSZAK JR, 1994, EXP EYE RES, V59, P521, DOI 10.1006/exer.1994.1138; Lachke SA, 2022, EXP EYE RES, V214, DOI 10.1016/j.exer.2021.108889; Lampi KJ, 2014, PROG BIOPHYS MOL BIO, V115, P21, DOI 10.1016/j.pbiomolbio.2014.02.004; Lampi KJ, 1998, EXP EYE RES, V67, P31, DOI 10.1006/exer.1998.0481; Lapko VN, 2003, EXP EYE RES, V77, P383, DOI 10.1016/S0014-4835(03)00156-8; Lapko VN, 2002, BIOCHEMISTRY-US, V41, P8638, DOI 10.1021/bi015924t; LASSER A, 1972, EXP EYE RES, V13, P292, DOI 10.1016/0014-4835(72)90111-X; LATINA M, 1987, INVEST OPHTH VIS SCI, V28, P175; Lauf U, 2002, P NATL ACAD SCI USA, V99, P10446, DOI 10.1073/pnas.162055899; Leonard M, 2011, DEV BIOL, V349, P363, DOI 10.1016/j.ydbio.2010.10.009; Lewis PN, 2010, STRUCTURE, V18, P239, DOI 10.1016/j.str.2009.11.013; Li YX, 2020, MOL VIS, V26, P603; LIANG JN, 1991, EXP EYE RES, V53, P61, DOI 10.1016/0014-4835(91)90145-5; LIOU W, 1988, CELL MOTIL CYTOSKEL, V9, P17, DOI 10.1002/cm.970090104; Liu BF, 2007, FEBS LETT, V581, P3936, DOI 10.1016/j.febslet.2007.07.022; Liu P, 2019, ELIFE, V8, DOI 10.7554/eLife.50170; Lo WK, 2003, EXP EYE RES, V77, P615, DOI 10.1016/S0014-4835(03)00176-3; Lo WK, 2014, INVEST OPHTH VIS SCI, V55, P1202, DOI 10.1167/iovs.13-13379; Logan CM, 2019, EXP BIOL MED, V244, P1240, DOI 10.1177/1535370219867296; Lopes MC, 2009, INVEST OPHTH VIS SCI, V50, P126, DOI 10.1167/iovs.08-2385; Lovicu FJ, 2005, DEV BIOL, V280, P1, DOI 10.1016/j.ydbio.2005.01.020; Lund AL, 1996, EXP EYE RES, V63, P661, DOI 10.1006/exer.1996.0160; Lyon YA, 2017, J PROTEOME RES, V16, P1797, DOI 10.1021/acs.jproteome.7b00073; Ma ZX, 1998, EXP EYE RES, V67, P21, DOI 10.1006/exer.1998.0482; MacCoss MJ, 2002, P NATL ACAD SCI USA, V99, P7900, DOI 10.1073/pnas.122231399; Maddala R, 2016, AM J PHYSIOL-CELL PH, V310, pC115, DOI 10.1152/ajpcell.00111.2015; Maddala R, 2011, DEV BIOL, V357, P179, DOI 10.1016/j.ydbio.2011.06.036; Mahendiran K, 2014, SCI REP-UK, V4, DOI 10.1038/srep05195; Mainali L, 2021, CURR EYE RES, V46, P185, DOI 10.1080/02713683.2020.1786131; Mainali L, 2012, EXP EYE RES, V97, P117, DOI 10.1016/j.exer.2012.01.012; MAISEL H, 1972, EXP EYE RES, V14, P7, DOI 10.1016/0014-4835(72)90136-4; Maisel H., 1985, OCULAR LENS; Maisel H. C., 1981, MORPHOLOGY LENS MOL; Makrides N, 2022, OPEN BIOL, V12, DOI 10.1098/rsob.210265; MARAINI G, 1990, OPHTHALMOLOGY, V97, P752; Markiewicz E, 2015, OPEN BIOL, V5, DOI 10.1098/rsob.150011; MASTERS PM, 1978, P NATL ACAD SCI USA, V75, P1204, DOI 10.1073/pnas.75.3.1204; MASTERS PM, 1977, NATURE, V268, P71, DOI 10.1038/268071a0; Mathias RT, 2007, J MEMBRANE BIOL, V216, P1, DOI 10.1007/s00232-007-9019-y; MATHIAS RT, 1979, BIOPHYS J, V25, P181, DOI 10.1016/S0006-3495(79)85284-4; Matsushima H, 1997, EXP EYE RES, V64, P387, DOI 10.1006/exer.1996.0220; Matsuura T, 1999, EUR BIOPHYS J BIOPHY, V28, P357, DOI 10.1007/s002490050220; MAURICE DM, 1957, J PHYSIOL-LONDON, V136, P263, DOI 10.1113/jphysiol.1957.sp005758; MCAVOY JW, 1980, DIFFERENTIATION, V17, P137, DOI 10.1111/j.1432-0436.1980.tb01091.x; McCally R. L., 1990, NONINVASIVE DIAGNOST, P189; MCFALLNGAI MJ, 1985, EXP EYE RES, V41, P745, DOI 10.1016/0014-4835(85)90183-6; Meek K. M., 2008, P359, DOI 10.1007/978-0-387-73906-9_13; Meek KM, 2015, PROG RETIN EYE RES, V49, P1, DOI 10.1016/j.preteyeres.2015.07.001; Meek KM, 2003, EYE, V17, P927, DOI 10.1038/sj.eye.6700574; Meek KM, 2003, BIOPHYS J, V85, P2205, DOI 10.1016/S0006-3495(03)74646-3; Merriam G. R., 1973, T AM OPHTHAL SOC, V71, P108; Merriam G R Jr, 1973, Trans Am Ophthalmol Soc, V71, P88; MERRIAM GR, 1983, B NEW YORK ACAD MED, V59, P372; Metlapally S, 2008, EXP EYE RES, V86, P434, DOI 10.1016/j.exer.2007.11.018; MICHON J, 1968, ARCH OPHTHALMOL-CHIC, V79, P611, DOI 10.1001/archopht.1968.03850040613022; MIESBAUER LR, 1994, J BIOL CHEM, V269, P12494; Millar A., 1997, NOVA ACTA LEOPOLDIAN, V299, P169; Minton AP, 2005, J PHARM SCI-US, V94, P1668, DOI 10.1002/jps.20417; Moncaster JA, 2022, EXP EYE RES, V221, DOI 10.1016/j.exer.2022.108974; Moreau KL, 2009, J BIOL CHEM, V284, P33285, DOI 10.1074/jbc.M109.031344; MORGAN CF, 1989, BIOCHEMISTRY-US, V28, P5065, DOI 10.1021/bi00438a025; Morner C., 1894, HOPPE SEYL, V18, P61; Nagaraj RH, 2012, BBA-MOL BASIS DIS, V1822, P120, DOI 10.1016/j.bbadis.2011.11.011; Nandi SK, 2019, BIOCHEMISTRY-US, V58, P1260, DOI 10.1021/acs.biochem.8b01053; Neumayer T, 2017, CURR EYE RES, V42, P1604, DOI 10.1080/02713683.2017.1343852; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; Niederkorn JY, 2002, CRIT REV IMMUNOL, V22, P13; Nielsen J, 2016, SCIENCE, V353, P702, DOI 10.1126/science.aaf1703; NISHIO I, 1984, EXP EYE RES, V39, P61, DOI 10.1016/0014-4835(84)90115-5; Norton-Baker B, 2022, STRUCTURE, V30, P763, DOI 10.1016/j.str.2022.03.002; Omholt SW, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2102088118; Pan XZ, 2019, BIOMED OPT EXPRESS, V10, P4462, DOI 10.1364/BOE.10.004462; Pande A, 2015, BIOCHEMISTRY-US, V54, P4890, DOI 10.1021/acs.biochem.5b00185; PANDE J, 1993, EXP EYE RES, V57, P257, DOI 10.1006/exer.1993.1123; PATTERSON JW, 1988, OPHTHALMIC RES, V20, P139, DOI 10.1159/000266570; Pendergrass W, 2010, MOL VIS, V16, P1496; Pendergrass WR, 2001, EXP EYE RES, V73, P221, DOI 10.1006/exer.2001.1033; Perng MD, 2005, EXP CELL RES, V305, P1, DOI 10.1016/j.yexcr.2004.11.021; PIATIGORSKY J, 1972, J CELL BIOL, V55, P82, DOI 10.1083/jcb.55.1.82; PIATIGORSKY J, 1991, SCIENCE, V252, P1078, DOI 10.1126/science.252.5009.1078; Piatigorsky J, 1998, ANN NY ACAD SCI, V842, P7, DOI 10.1111/j.1749-6632.1998.tb09626.x; PIATIGORSKY J, 1981, DIFFERENTIATION, V19, P134, DOI 10.1111/j.1432-0436.1981.tb01141.x; Piatigorsky J, 2001, CORNEA, V20, P853, DOI 10.1097/00003226-200111000-00015; Pierscionek B, 2015, ONCOTARGET, V6, P30532, DOI 10.18632/oncotarget.5762; Pierscionek BK, 2012, PROG RETIN EYE RES, V31, P332, DOI 10.1016/j.preteyeres.2012.03.001; PIRIE A, 1968, INVEST OPHTH VISUAL, V7, P634; PIRIE A, 1967, NATURE, V216, P503, DOI 10.1038/216503a0; Plesnar E, 2018, BBA-BIOMEMBRANES, V1860, P434, DOI 10.1016/j.bbamem.2017.10.020; Ponce A, 2006, MOL VIS, V12, P879; Porter K. R., 1966, PRINCIPLES BIOMOLECU; Puri S, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00731; Quinlan R. A., 2002, CYTOSKELETAL COMPETE; Quinlan RA, 2018, J BIOL CHEM, V293, P18010, DOI 10.1074/jbc.H118.006240; Quinlan RA, 2017, J CELL SCI, V130, P3437, DOI 10.1242/jcs.202168; RAFFERTY NS, 1981, J CELL PHYSIOL, V107, P309, DOI 10.1002/jcp.1041070302; RAMAEKERS FCS, 1980, EXP CELL RES, V127, P309, DOI 10.1016/0014-4827(80)90437-1; Regnault F., 1980, P S AG LENS, P29; Reneker LW, 1996, DEV BIOL, V180, P554, DOI 10.1006/dbio.1996.0328; Richardson RB, 2020, INT J RADIAT BIOL, V96, P1339, DOI 10.1080/09553002.2020.1812759; Richardson RB, 2009, AGING-US, V1, P887, DOI 10.18632/aging.100081; Robinson M. L., 2004, EARLY LENS DEV; Robinson NE, 2001, P NATL ACAD SCI USA, V98, P12409, DOI 10.1073/pnas.221463198; Rocha MA, 2021, CHEMBIOCHEM, V22, P1329, DOI 10.1002/cbic.202000739; Rose KML, 2006, INVEST OPHTH VIS SCI, V47, P1562, DOI 10.1167/iovs.05-1313; ROY D, 1976, P NATL ACAD SCI USA, V73, P3484, DOI 10.1073/pnas.73.10.3484; ROY D, 1978, EXP EYE RES, V26, P445, DOI 10.1016/0014-4835(78)90131-8; Sagar V, 2017, STRUCTURE, V25, P1068, DOI 10.1016/j.str.2017.05.015; Sandilands A, 2003, EXP EYE RES, V76, P385, DOI 10.1016/S0014-4835(02)00330-5; SCHATTEMAN GC, 1992, DEVELOPMENT, V115, P123; Schey KL, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100802; Schlussler R, 2022, ELIFE, V11, DOI [10.7554/eLife.68490, 10.7554/eLife.68490.sa0, 10.7554/eLife.68490.sa1, 10.7554/eLife.68490.sa2]; Schmid PWN, 2021, NAT STRUCT MOL BIOL, V28, P143, DOI 10.1038/s41594-020-00543-9; Schurmann M, 2016, J BIOPHOTONICS, V9, P1068, DOI 10.1002/jbio.201500273; Schuster AK, 2020, GRAEF ARCH CLIN EXP, V258, P2223, DOI 10.1007/s00417-020-04770-0; Seal S, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.608812; Sen P, 2016, CELL, V166, P822, DOI 10.1016/j.cell.2016.07.050; Serebryany E, 2022, ELIFE, V11, DOI 10.7554/eLife.76923; Serebryany E, 2021, EXP EYE RES, V211, DOI 10.1016/j.exer.2021.108707; Serebryany E, 2018, J BIOL CHEM, V293, P17997, DOI 10.1074/jbc.RA118.004551; Sharma KK, 2009, BBA-GEN SUBJECTS, V1790, P1095, DOI 10.1016/j.bbagen.2009.05.008; Shi YR, 2015, INVEST OPHTH VIS SCI, V56, P799, DOI 10.1167/iovs.14-16028; Shi YR, 2009, J CELL SCI, V122, P1607, DOI 10.1242/jcs.045203; Shiels A, 2021, EXP EYE RES, V209, DOI 10.1016/j.exer.2021.108662; Shiels A, 2017, EXP EYE RES, V156, P95, DOI 10.1016/j.exer.2016.06.011; Shparberg R, 2021, DATA BRIEF, V34, DOI 10.1016/j.dib.2020.106657; SHUNSHIN GA, 1989, BRIT J OPHTHALMOL, V73, P522, DOI 10.1136/bjo.73.7.522; SIPPEL THEODORE O., 1965, INVEST OPHTHALMOL, V4, P502; Slingsby C, 2013, PROTEIN SCI, V22, P367, DOI 10.1002/pro.2229; Snider NT, 2014, NAT REV MOL CELL BIO, V15, P163, DOI 10.1038/nrm3753; Song SH, 2009, J CLIN INVEST, V119, P1837, DOI 10.1172/JCI38277; SPECTOR A, 1984, INVEST OPHTH VIS SCI, V25, P130; Srikanthan D, 2004, EXP EYE RES, V79, P823, DOI 10.1016/j.exer.2004.05.009; Srivastava O P, 2017, Biochem Biophys Rep, V10, P94, DOI 10.1016/j.bbrep.2017.01.011; Srivastava OP, 2003, MOL VIS, V9, P110; Stein N, 2021, EXP EYE RES, V206, DOI 10.1016/j.exer.2021.108536; Stein-Streilein J, 2008, TRENDS IMMUNOL, V29, P548, DOI 10.1016/j.it.2008.08.002; Stepp MA, 2021, TRANSL RES, V236, P52, DOI 10.1016/j.trsl.2021.05.005; Stewart DN, 2013, MOL VIS, V19, P463; Straub BK, 2003, J CELL SCI, V116, P4985, DOI 10.1242/jcs.00815; Streilein JW, 1996, INVEST OPHTH VIS SCI, V37, P1940; Subczynski WK, 2012, J MEMBRANE BIOL, V245, P51, DOI 10.1007/s00232-011-9412-4; Subczynski WK, 2017, ADV EXP MED BIOL, V977, P27, DOI 10.1007/978-3-319-55231-6_5; Svitkina TM, 2020, TRENDS CELL BIOL, V30, P556, DOI 10.1016/j.tcb.2020.03.005; Szenker-Ravi E, 2022, NAT GENET, V54, P62, DOI 10.1038/s41588-021-00970-4; Takata T, 2018, BBA-PROTEINS PROTEOM, V1866, P767, DOI 10.1016/j.bbapap.2018.04.002; Takemoto L, 2000, MOL VIS, V6, P164; Takemoto L, 1996, EXP EYE RES, V63, P585, DOI 10.1006/exer.1996.0149; Takemoto L, 2008, EXP EYE RES, V87, P496, DOI 10.1016/j.exer.2008.08.018; Takemoto LJ, 1998, CURR EYE RES, V17, P247, DOI 10.1076/ceyr.17.3.247.5218; Talens RP, 2012, AGING CELL, V11, P694, DOI 10.1111/j.1474-9726.2012.00835.x; TANAKA T, 1977, INVEST OPHTH VIS SCI, V16, P135; TANAKA T, 1975, INVEST OPHTH VISUAL, V14, P449; TANAKA T, 1981, SCI AM, V244, P124, DOI 10.1038/scientificamerican0181-124; Tapodi A, 2019, EXP EYE RES, V185, DOI 10.1016/j.exer.2019.02.001; TAYLOR A, 1993, J AM COLL NUTR, V12, P138; Taylor A., 1999, CRC MOD NUT, V1st, P53; Taylor HR, 1999, EYE, V13, P445, DOI 10.1038/eye.1999.119; Taylor VL, 1996, INVEST OPHTH VIS SCI, V37, P1396; Tholozan FMD, 2007, MOL BIOL CELL, V18, P4222, DOI 10.1091/mbc.E06-05-0416; Thompson D. W., 1917, GROWTH FORM; Thornell E, 2015, CELL MOL LIFE SCI, V72, P4127, DOI 10.1007/s00018-015-1996-x; Timmers PRHJ, 2019, ELIFE, V8, DOI 10.7554/eLife.39856; Tkatchenko TV, 2021, GENOMICS, V113, P2780, DOI 10.1016/j.ygeno.2021.06.021; Tkatchenko TV, 2019, BMC MED GENOMICS, V12, DOI 10.1186/s12920-019-0560-1; TROKEL S, 1962, INVEST OPHTH VISUAL, V1, P493; Truscott RJW, 2000, OPHTHALMIC RES, V32, P185, DOI 10.1159/000055612; Truscott RJW, 2005, EXP EYE RES, V80, P709, DOI 10.1016/j.exer.2004.12.007; TRUSCOTT RJW, 1977, BIOCHIM BIOPHYS ACTA, V492, P43, DOI 10.1016/0005-2795(77)90212-4; Truscott RJW, 2019, INVEST OPHTH VIS SCI, V60, P5007, DOI 10.1167/iovs.19-27535; Truscott RJW, 2016, TRENDS BIOCHEM SCI, V41, P654, DOI 10.1016/j.tibs.2016.06.004; Upadhya D, 2013, DEVELOPMENT, V140, P1573, DOI 10.1242/dev.081042; Uwineza A, 2019, MUTAT RES-REV MUTAT, V779, P68, DOI 10.1016/j.mrrev.2019.02.004; Vaghefi E, 2018, AM J PHYSIOL-REG I, V315, pR994, DOI 10.1152/ajpregu.00180.2018; Valiunas V, 2019, INVEST OPHTH VIS SCI, V60, P3821, DOI 10.1167/iovs.19-27302; van Beek JHGM, 2016, INTERFACE FOCUS, V6, DOI 10.1098/rsfs.2015.0079; van den Berg TJTP, 2018, OPHTHAL PHYSL OPT, V38, P6, DOI 10.1111/opo.12426; van Dongen J, 2014, GENES-BASEL, V5, P347, DOI 10.3390/genes5020347; Van Heyningen R., 1962, VEGETATIVE PHYSL BIO, P213; van Loon AP, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.201904144; VANHEYNINGEN R, 1954, BIOCHEM J, V56, P372, DOI 10.1042/bj0560372; VANKLEEF FSM, 1975, NATURE, V258, P264, DOI 10.1038/258264a0; Varadaraj K, 2021, EXP EYE RES, V209, DOI 10.1016/j.exer.2021.108645; Vermeij WP, 2016, NATURE, V537, P427, DOI 10.1038/nature19329; Vetter CJ, 2020, PROTEIN SCI, V29, P1945, DOI 10.1002/pro.3915; von Sallmann L, 1966, Invest Ophthalmol, V5, P560; VONSALLMANN L, 1962, EXP EYE RES, V1, P449, DOI 10.1016/S0014-4835(62)80037-2; VOORTER CEM, 1988, J BIOL CHEM, V263, P19020; VOORTER CEM, 1987, FEBS LETT, V221, P249, DOI 10.1016/0014-5793(87)80935-3; WALEY SG, 1965, EXP EYE RES, V4, P293, DOI 10.1016/S0014-4835(65)80043-4; Walker RF, 2022, CELLS-BASEL, V11, DOI 10.3390/cells11050917; Walls G. L., 1942, P1; Wang ET, 2003, EXP EYE RES, V76, P29, DOI 10.1016/S0014-4835(02)00257-9; Wang KH, 2016, SCI REP-UK, V6, DOI 10.1038/srep31171; Wang Z, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.12.25; Wang Z, 2017, EXP EYE RES, V159, P23, DOI 10.1016/j.exer.2017.02.012; Wang Z, 2015, INVEST OPHTH VIS SCI, V56, P8349, DOI 10.1167/iovs.15-18273; Wang Z, 2014, AGING CELL, V13, P226, DOI 10.1111/acel.12164; Wang Z, 2013, INVEST OPHTH VIS SCI, V54, P1135, DOI 10.1167/iovs.12-11168; Warmack RA, 2019, J BIOL CHEM, V294, P12203, DOI 10.1074/jbc.RA119.009052; Weber GF, 2006, DEV BIOL, V295, P714, DOI 10.1016/j.ydbio.2006.03.056; Wenke JL, 2015, INVEST OPHTH VIS SCI, V56, P7398, DOI 10.1167/iovs.15-18117; Wiegand T, 2020, EMERG TOP LIFE SCI, V4, P247, DOI 10.1042/ETLS20190174; Willcox DC, 2008, J GERONTOL A-BIOL, V63, P1201, DOI 10.1093/gerona/63.11.1201; WILLIAMS WF, 1988, EXP EYE RES, V47, P97, DOI 10.1016/0014-4835(88)90027-9; WILLIS JA, 1986, EXP EYE RES, V43, P329, DOI 10.1016/S0014-4835(86)80070-7; Wilmarth PA, 2006, J PROTEOME RES, V5, P2554, DOI 10.1021/pr050473a; Wishart TFL, 2021, EXP EYE RES, V210, DOI 10.1016/j.exer.2021.108709; Wolf LV, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004159; Wu JJ, 2015, J R SOC INTERFACE, V12, DOI 10.1098/rsif.2015.0391; Wu WJ, 2021, EXP EYE RES, V213, DOI 10.1016/j.exer.2021.108808; Wu WJ, 2014, EXP EYE RES, V120, P10, DOI 10.1016/j.exer.2013.12.004; Xie Q, 2011, J BIOL CHEM, V286, P43259, DOI 10.1074/jbc.M111.264580; Yonova-Doing E, 2016, OPHTHALMOLOGY, V123, P1237, DOI 10.1016/j.ophtha.2016.01.036; Young R. W., 1991, AGE RELATED CATARACT; Zhang P, 2012, EXP EYE RES, V101, P36, DOI 10.1016/j.exer.2012.05.007; Zhang ZL, 2003, EXP EYE RES, V77, P259, DOI 10.1016/S0014-4835(03)00159-3; Zhao ZF, 2021, BIOORG CHEM, V108, DOI 10.1016/j.bioorg.2020.104557; Zheng MY, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.864191; Zhou YF, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10102606; Zhu Y, 2019, BIOPHYS J, V116, P1171, DOI 10.1016/j.bpj.2019.02.007	426	1	1	7	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV	2022	298	11							102537	10.1016/j.jbc.2022.102537	http://dx.doi.org/10.1016/j.jbc.2022.102537			22	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	6C1SV	36174677	gold, Green Published			2022-12-28	WOS:000881802600005
J	DEGROOT, RP; SASSONECORSI, P				DEGROOT, RP; SASSONECORSI, P			ACTIVATION OF JUN/AP-1 BY PROTEIN KINASE-A	ONCOGENE			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; CLONED PLACENTAL CDNA; DNA-BINDING PROTEINS; C-FOS GENE; CYCLIC-AMP; RESPONSE ELEMENT; TRANSCRIPTIONAL ACTIVATION; POSITIVE REGULATION; ENHANCER ELEMENTS; MAMMALIAN-CELLS	The product of the c-jun proto-oncogene is the major component of the 12-O-tetradecanoyl phorbol 13-acetate (TPA)-inducible transcription factor AP-1. Jun binds to the TPA-responsive elements (TREs) present in a large number of TPA-inducible genes, thereby regulating their expression in response to activation of protein kinase C. Previously we have shown that Jun/AP-1 can also activate cAMP-responsive elements (CREs), indicating the existence of cross-talk in signal transduction at the transcriptional level. Here we show that Jun/AP-1 is activated by the cAMP-dependent protein kinase A (PKA). In transient transfection experiments, TRE activation by Jun is strongly enhanced by co-transfection of the catalytic subunit of PKA or forskolin treatment, although not in all cell types studied. Jun activity can be significantly inhibited by co-transfection of the regulatory subunit of PKA. Furthermore, we show a cell-specific increase in AP-1 binding in response to forkolin treatment. However, since direct phosphorylation of Jun by PKA does not occur, we suggest an indirect activation mechanism.	FAC MED STRASBOURG, GENET MOLEC EUCARYOTES LAB,CNRS,U184,INSERM, 11 RUE HUMANN, F-67085 STRASBOURG, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg								ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; AUWERX J, 1992, IN PRESS ONCOGENE; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BENBROOK DM, 1990, ONCOGENE, V5, P295; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BORRELLI E, 1992, IN PRESS CRC REV ONC; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; DEGROOT R, 1991, MOL CELL BIOL, V11, P192, DOI 10.1128/MCB.11.1.192; DEGROOT RP, 1990, EMBO J, V9, P1831, DOI 10.1002/j.1460-2075.1990.tb08308.x; DEGROOT RP, 1992, IN PRESS ONCOGENE; DEUTSCH PJ, 1988, P NATL ACAD SCI USA, V85, P7922, DOI 10.1073/pnas.85.21.7922; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HOEFFLER JP, 1989, MOL ENDOCRINOL, V3, P868, DOI 10.1210/mend-3-5-868; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MCKNIGHT GS, 1988, RECENT PROG HORM RES, V44, P307; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; TRATNER I, 1992, MOL CELL BIOL, V12, P998, DOI 10.1128/MCB.12.3.998; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; VOGT PK, 1989, TRENDS BIOCHEM SCI, V14, P172, DOI 10.1016/0968-0004(89)90268-5; Woodgett J R, 1990, Semin Cancer Biol, V1, P389; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	52	68	69	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1992	7	11					2281	2286						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1331936				2022-12-28	WOS:A1992JW66500021
J	SZEBERENYI, J; ERHARDT, P; CAI, H; COOPER, GM				SZEBERENYI, J; ERHARDT, P; CAI, H; COOPER, GM			ROLE OF RAS IN SIGNAL TRANSDUCTION FROM THE NERVE GROWTH-FACTOR RECEPTOR - RELATIONSHIP TO PROTEIN-KINASE-C, CALCIUM AND CYCLIC-AMP	ONCOGENE			English	Article							PC12 CELLS; TRK PROTOONCOGENE; ADENYLATE-CYCLASE; ONCOGENE PRODUCT; PHOSPHOLIPASE-C; 3T3 CELLS; DIFFERENTIATION; TRANSCRIPTION; ACTIVATION; INHIBITION	A dominant inhibitory ras mutant (Ha-ras Asn-17) has been used to investigate the role of Ras in nerve growth factor (NGF)-mediated signal transduction in PC12 cells. Expression of Ha-Ras Asn-17 blocks neuronal differentiation of these cells in response to NGF treatment. The Ha-Ras Asn-17 block was bypassed by treatment with NGF plus dibutyryl cAMP or NGF plus the Ca2+ ionophore ionomycin, but not by NGF plus 12-tetradecanoyl phorbol acetate (TPA). Direct stimulation of the cAMP or Ca2+ pathways thus appeared to act synergistically with a Ras-independent NGF signaling pathway. This Ras-independent pathway was also distinct from protein kinase C, since its activity was not affected by protein kinase C down-regulation. It thus appears that NGF stimulation generates a Ras-independent intracellular signal that contributes to neuronal differentiation independently of the cAMP, Ca2+ or protein kinase C second messenger systems Since TPA did not bypass the Ha-Ras Asn-17 block to differentiation, protein kinase C also did not appear to be sufficient for Ras-dependent pathways mediating NGF-induced differentiation. Down-regulation experiments further indicated that protein kinase C was not required for NGF induction of early response genes via either Ras-dependent or Ras-independent pathways. Moreover, the formation of inositol phosphates and mobilization of intracellular calcium in response to NGF was not inhibited in PC12 cells expressing the Ha-Ras Asn-17 protein. Therefore, although calcium was able to bypass the Ha-Ras Asn-17 block to PC12 differentiation, Ras activity was not required for activation of phospholipase C in response to NGF. It thus appears that both Ras-dependent and Ras-independent signaling pathways contribute to NGF-induced PC12 cell differentiation independently of the cAMP, calcium and protein kinase C second messenger systems.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School					NATIONAL CANCER INSTITUTE [R01CA018689] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA18689] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BALLESTER R, 1985, J BIOL CHEM, V260, P5194; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BECKNER SK, 1985, NATURE, V317, P71, DOI 10.1038/317071a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRADY MJ, 1990, J NEUROCHEM, V54, P1034, DOI 10.1111/j.1471-4159.1990.tb02354.x; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHARLES CH, 1990, MOL CELL BIOL, V10, P6769, DOI 10.1128/MCB.10.12.6769; COLLIN C, 1990, SCIENCE, V250, P1743, DOI 10.1126/science.2176747; CONTRERAS ML, 1987, J NEUROCHEM, V48, P1466, DOI 10.1111/j.1471-4159.1987.tb05687.x; COPELAND NG, 1979, CELL, V16, P347, DOI 10.1016/0092-8674(79)90011-4; CREMINS J, 1986, J CELL BIOL, V103, P887, DOI 10.1083/jcb.103.3.887; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1984, TRENDS NEUROSCI, V7, P91, DOI 10.1016/S0166-2236(84)80164-2; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HAMA T, 1986, P NATL ACAD SCI USA, V83, P2353, DOI 10.1073/pnas.83.8.2353; HEASLEY LE, 1989, J BIOL CHEM, V264, P8646; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HORWITZ J, 1987, METHOD ENZYMOL, V141, P169; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KIM UH, 1991, J BIOL CHEM, V266, P1359; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAZAROVICI P, 1989, J NEUROSCI RES, V23, P1, DOI 10.1002/jnr.490230102; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OHMICHI M, 1991, J BIOL CHEM, V266, P14858; PANDIELLAALONSO A, 1986, FEBS LETT, V208, P48, DOI 10.1016/0014-5793(86)81529-0; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SMITH MR, 1990, SCIENCE, V247, P1074, DOI 10.1126/science.2408147; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; SUGIMOTO Y, 1988, J BIOL CHEM, V263, P12102; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; VICENTINI LM, 1986, BIOCHEM J, V234, P555, DOI 10.1042/bj2340555; WAKELAM MJO, 1986, NATURE, V323, P173, DOI 10.1038/323173a0; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	51	50	50	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2105	2113						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1331931				2022-12-28	WOS:A1992JW66500002
J	DO, MS; FITZERATTAS, C; GUBBAY, J; GREENFELD, L; FELDMAN, M; EISENBACH, L				DO, MS; FITZERATTAS, C; GUBBAY, J; GREENFELD, L; FELDMAN, M; EISENBACH, L			MOUSE PLATELET-DERIVED GROWTH FACTOR-ALPHA RECEPTOR - SEQUENCE, TISSUE-SPECIFIC EXPRESSION AND CORRELATION WITH METASTATIC PHENOTYPE	ONCOGENE			English	Article							TUMOR-CELL LINES; PDGF-RECEPTOR; TYROSINE KINASE; SARCOMA-VIRUS; STRUCTURAL SIMILARITY; SIGNAL TRANSDUCTION; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; TRANSFORMING GENE; PROTEIN-KINASE	High- and low-metastatic cells derived from metastatic murine tumors were screened for the differential expression of proto-oncogenes which may code for cell-surface receptors to growth factors. We found that metastatic clones of 3LL carcinoma and T10 sarcoma but not non-metastatic clones of these tumors express a 6.5-kb mRNA that is recognized by a v-fms probe containing a tyrosine kinase domain. The cloning and sequence analysis of a full-length cDNA clone corresponding to the v-fms-related 6.5-kb transcript showed that this transcript is the murine homolog of platelet-derived growth factor alpha (PDGF-alpha) receptor. The cDNA contains an open reading frame that predicts a 1089 amino acid protein. Comparison with the human and rat PDGF-alpha receptor reveals an overall amino acid sequence identity of 91% and 94% respectively. Northern blot analysis shows that this gene is preferentially expressed in the high-metastatic clones and is also selectively expressed in normal mouse tissues. Immunoprecipitation using anti-PDGF-alpha receptor serum shows that 185-kDa and 170-kDa proteins were specifically precipitated from cells of the high-metastatic D122 but not from the low-metastatic A9 cells. The possibility that overexpression of PDGF-alpha receptor in high-metastatic clones may contribute to an increase in the capacity of tumor cells to generate metastases in the lung is discussed.	WEIZMANN INST SCI, DEPT CELL BIOL, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science				Eisenbach, Lea R/0000-0002-4816-1968; Fitzer-Attas, Cheryl/0000-0002-8709-1384	NCI NIH HHS [CA28139] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028139] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BESNER G, 1990, CELL REGUL, V1, P811, DOI 10.1091/mbc.1.11.811; BEVEREN CV, 1981, NATURE, V289, P258; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; DEBAETSELIER P, 1980, NATURE, V288, P179; DELORBE WJ, 1980, J VIROL, V36, P50, DOI 10.1128/JVI.36.1.50-61.1980; EISENBACH L, 1986, NATO ASI SER, V121, P57; EISENBACH L, 1983, J CANCER, V32, P3293; ESCOBEDO JA, 1988, MOL CELL BIOL, V8, P5126, DOI 10.1128/MCB.8.12.5126; FRANCHINI G, 1982, MOL CELL BIOL, V2, P1014, DOI 10.1128/MCB.2.8.1014; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; HAMPE A, 1984, P NATL ACAD SCI-BIOL, V81, P85, DOI 10.1073/pnas.81.1.85; HARSH GR, 1990, J NEURO-ONCOL, V8, P1; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; Hart I R, 1982, Cancer Metastasis Rev, V1, P5, DOI 10.1007/BF00049477; HEIDARAN MA, 1990, J BIOL CHEM, V265, P18741; HEIDARAN MA, 1991, MOL CELL BIOL, V11, P134, DOI 10.1128/MCB.11.1.134; HELDIN CH, 1981, P NATL ACAD SCI-BIOL, V78, P3664, DOI 10.1073/pnas.78.6.3664; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN NE, 1988, P NATL ACAD SCI USA, V85, P9302, DOI 10.1073/pnas.85.23.9302; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; IIDA H, 1991, P NATL ACAD SCI USA, V88, P6560, DOI 10.1073/pnas.88.15.6560; KITAMURA N, 1982, NATURE, V297, P205, DOI 10.1038/297205a0; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEE KH, 1990, MOL CELL BIOL, V10, P2237, DOI 10.1128/MCB.10.5.2237; LEVEEN P, 1990, INT J CANCER, V46, P1066, DOI 10.1002/ijc.2910460620; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; MALIK R, 1991, CANCER RES, V51, P5626; Maniatis T., 1982, MOL CLONING; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MAXWELL M, 1990, J CLIN INVEST, V86, P131, DOI 10.1172/JCI114675; MAXWELL M, 1990, INT J CANCER, V46, P16, DOI 10.1002/ijc.2910460106; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MORI S, 1991, J BIOL CHEM, V266, P21158; MOSHIER JA, 1987, GENE, V58, P19, DOI 10.1016/0378-1119(87)90025-4; NAHARRO G, 1984, SCIENCE, V223, P63, DOI 10.1126/science.6318314; NISTER M, 1991, MOL BASIS HUMAN CANC, P62; Paget S, 1989, LANCET, V8, P98, DOI [DOI 10.1016/S0140-6736(00)49915-0, 10.1016/S0140-6736(00)49915-0]; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; ROBBINS KC, 1983, NATURE, V305, P605, DOI 10.1038/305605a0; ROTHWELL VM, 1987, ONCOGENE RES, V1, P311; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHIBUYA M, 1982, CELL, V30, P787, DOI 10.1016/0092-8674(82)90283-5; Sjolund M, 1990, GROWTH FACTORS, V3, P191, DOI 10.3109/08977199009043904; SRINIVASAN A, 1981, P NATL ACAD SCI-BIOL, V78, P2077, DOI 10.1073/pnas.78.4.2077; SUGIURA K, 1955, CANCER RES, V15, P38; TARIN D, 1984, CANCER RES, V44, P3584; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VENNSTROM B, 1982, CELL, V28, P135, DOI 10.1016/0092-8674(82)90383-X; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WANG CY, 1990, MOL CELL BIOL, V10, P6781, DOI 10.1128/MCB.10.12.6781; WANG JL, 1990, INT J CANCER, V46, P772, DOI 10.1002/ijc.2910460504; WANG LH, 1982, J VIROL, V41, P833, DOI 10.1128/JVI.41.3.833-841.1982; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YU JC, 1991, MOL CELL BIOL, V11, P3780, DOI 10.1128/MCB.11.7.3780	64	19	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1992	7	8					1567	1575						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1321404				2022-12-28	WOS:A1992JE81300013
J	HASLAM, SZ; WIRTH, JJ; COUNTERMAN, LJ; FLUCK, MM				HASLAM, SZ; WIRTH, JJ; COUNTERMAN, LJ; FLUCK, MM			CHARACTERIZATION OF THE MAMMARY HYPERPLASIA, DYSPLASIA AND NEOPLASIA INDUCED IN ATHYMIC FEMALE-ADULT MICE BY POLYOMAVIRUS	ONCOGENE			English	Article							PHOSPHATIDYLINOSITOL KINASE-ACTIVITY; HUMAN-BREAST CARCINOMAS; MIDDLE T-ANTIGEN; TRANSGENIC MICE; C-MYC; GROWTH-FACTOR; VIRUS ONCOGENICITY; C-ERBB-2 ONCOGENE; PROTO-ONCOGENE; NEU ONCOGENE	We have characterized mammary oncogenesis induced after polyomavirus infection of adult female nude mice regarding histopathogenesis, viral replication and viral and cellular oncogene expression. A unique transient generalized epithelial hyperplasia was observed (starting at 2 weeks post infection), preceding the development of dysplasias (onset 6 weeks post infection) and multiple neoplasias (onset 6 weeks post infection) in all glands. The ductal epithelium was the target for neoplastic transformation, and the occurrence of numerous ductal dysplasias coincided with the appearance of frank tumors. Stromal abnormalities were also seen. Tumor growth was not dependent upon ovarian hormones, and new tumors continued to develop in ovariectomized mice. Viral replication, high although variable, preceded but did not correlate with oncogenesis. Most but not all tumors contained high levels of unintegrated viral DNA. Tumors produced very low levels of live virus. Viral gene expression was markedly increased in the tumors compared with the infected but morphologically normal glands. The expression of c-myc was moderately increased (fourfold); changes in c-int-2 and c-Ha-ras expression were slight and inconsistent, while expression of c-neu and c-int-1 was unchanged.	MICHIGAN STATE UNIV,DEPT MICROBIOL,INTERDEPT PROGRAM CELLULAR & MOLEC BIOL,E LANSING,MI 48824; MICHIGAN STATE UNIV,DEPT PHYSIOL,INTERDEPT PROGRAM CELLULAR & MOLEC BIOL,E LANSING,MI 48824	Michigan State University; Michigan State University								ALI IU, 1988, SCIENCE, V240, P1795, DOI 10.1126/science.3289120; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BEREBBI M, 1988, ONCOGENE, V2, P149; BEREBBI M, 1990, ONCOGENE, V5, P505; BERGER MS, 1988, CANCER RES, V48, P1238; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; BROWN FH, 1982, CANCER RES, V42, P1909; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; CLINE MJ, 1987, J CLIN ONCOL, V5, P999, DOI 10.1200/JCO.1987.5.7.999; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; DAWE CJ, 1987, AM J PATHOL, V127, P243; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; GARCIA I, 1989, CANCER RES, V49, P6675; Harper J S 3rd, 1983, Prog Clin Biol Res, V105, P359; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; LIDEREAU R, 1988, ONCOGENE RES, V2, P285; MARIANICOSTANTINI R, 1988, CANCER RES, V48, P199; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; NUSSE R, 1988, TRENDS GENET, V4, P291, DOI 10.1016/0168-9525(88)90172-2; RAPTIS L, 1985, MOL CELL BIOL, V5, P2476, DOI 10.1128/MCB.5.9.2476; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TREMBLAY PJ, 1989, MOL CELL BIOL, V9, P854, DOI 10.1128/MCB.9.2.854; TSUDA H, 1989, CANCER RES, V49, P3104; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902; VARLEY JM, 1987, ONCOGENE, V1, P423; VENTER DJ, 1987, LANCET, V2, P69, DOI 10.1016/S0140-6736(87)92736-X; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WIRTH JJ, 1992, IN PRESS J VIROL, V6; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0; ZHOU DJ, 1987, CANCER RES, V47, P6123	43	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1295	1303						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1320244				2022-12-28	WOS:A1992HZ97100007
J	VOLINIA, S; PATRACCHINI, P; OTSU, M; HILES, I; GOUT, I; CALZOLARI, E; BERNARDI, F; ROOKE, L; WATERFIELD, MD				VOLINIA, S; PATRACCHINI, P; OTSU, M; HILES, I; GOUT, I; CALZOLARI, E; BERNARDI, F; ROOKE, L; WATERFIELD, MD			CHROMOSOMAL LOCALIZATION OF HUMAN P85-ALPHA, A SUBUNIT OF PHOSPHATIDYLINOSITOL 3-KINASE, AND ITS HOMOLOG P85-BETA	ONCOGENE			English	Note							SOMATIC-CELL HYBRIDS; HUMAN-MOUSE HYBRIDS; MONOCLONAL-ANTIBODY; GENE; TRANSLOCATION; EXPRESSION; ANTIGEN; SUBLOCALIZATION; HYBRIDIZATION; KINASE	The human phosphatidylinositol (PI) 3-kinase p85-alpha subunit gene and its homologue p85-beta were assigned to human chromosomes by analysis of their segregation in a panel of somatic cell hybrids using human-specific polymerase chain reaction primers. The p85-alpha locus was only present in hybrids retaining the human chromosome 5q. The presence of the p85-beta locus coincided with the presence of chromosome 19. The precise chromosomal sublocalization of these two genes was then determined by in situ hybridization. We confirmed the localization of the p85-alpha gene at 5q12-q13, as recently described (Cannizzaro, L.A., Skolnik, E.Y., Margolis, B., Croce, C.M., Schlesinger, J. & Huebner, K. (1991). Cancer Res., 51, 3818-3820) and positioned the p85-beta locus at 19q13.2-q13.4.	LUDWIG INST CANC RES,91 RIDING HOUSE ST,LONDON W1P 8BT,ENGLAND; UNIV FERRARA,IST GENET MED,I-44100 FERRARA,ITALY; UNIV FERRARA,IST CHIM BIOL,I-44100 FERRARA,ITALY; IMPERIAL CANC RES FUND,S MIMMS EN6 3LD,ENGLAND	Ludwig Institute for Cancer Research; University of Ferrara; University of Ferrara			Volinia, Stefano/A-3029-2010; Volinia, Stefano/AAA-9264-2019; bernardi, francesco/F-5443-2013	Volinia, Stefano/0000-0003-0910-3893; Volinia, Stefano/0000-0003-0910-3893; 				BAI Y, 1982, ANN HUM GENET, V46, P337, DOI 10.1111/j.1469-1809.1982.tb01584.x; BISHOP DP, 1990, CYTOGENET CELL GENET, V55, P218; CALZOLARI E, 1987, HUM GENET, V77, P51; CANNIZZARO LA, 1991, CANCER RES, V51, P3818; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CARRITT B, 1980, TISSUE CULTURE MED R, V2, P169; CHANDLER ME, 1978, CYTOGENET CELL GENET, V22, P352, DOI 10.1159/000130970; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; CROCE CM, 1974, J EXP MED, V140, P1221, DOI 10.1084/jem.140.5.1221; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; EDWARDS YH, 1985, ANN HUM GENET, V49, P101, DOI 10.1111/j.1469-1809.1985.tb01681.x; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FISHER JH, 1987, AM J HUM GENET, V40, P503; GOODFELLOW P, 1980, SOMAT CELL GENET, V6, P777, DOI 10.1007/BF01538976; GOODFELLOW PN, 1982, P NATL ACAD SCI-BIOL, V79, P1190, DOI 10.1073/pnas.79.4.1190; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HEISTERKAMP N, 1982, NATURE, V299, P747, DOI 10.1038/299747a0; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; IKEMURA T, 1991, NUCLEIC ACIDS RES, V19, P4333, DOI 10.1093/nar/19.16.4333; JONES EA, 1976, SOMAT CELL GENET, V2, P483, DOI 10.1007/BF01542686; KIELTY CM, 1982, ANN HUM GENET, V46, P307, DOI 10.1111/j.1469-1809.1982.tb01582.x; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MULLEY JC, 1986, HUM GENET, V74, P423, DOI 10.1007/BF00280498; NABHOLZ M, 1969, NATURE, V223, P358, DOI 10.1038/223358a0; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PATRACCHINI P, 1989, HUM GENET, V81, P191, DOI 10.1007/BF00293902; PATRACCHINI P, 1989, HUM GENET, V83, P264, DOI 10.1007/BF00285168; PHILLIPS IR, 1985, ANN HUM GENET, V49, P267, DOI 10.1111/j.1469-1809.1985.tb01702.x; POVEY S, 1980, ANN HUM GENET, V43, P241, DOI 10.1111/j.1469-1809.1980.tb01557.x; ROOPERS HH, 1990, CYTOGENET CELL GENET, V55, P111; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SMITH B, 1988, AM J HUM GENET, V42, P335; SWALLOW DM, 1977, CYTOGENET CELL GENET, V18, P136, DOI 10.1159/000130758; VARESCO L, 1989, P NATL ACAD SCI USA, V86, P10118, DOI 10.1073/pnas.86.24.10118; WHITEHEAD AS, 1982, P NATL ACAD SCI USA, V79, P5012	38	15	18	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					789	793						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1314371				2022-12-28	WOS:A1992HQ68200025
J	REDNER, RL; LEE, AWM; OSAWA, GA; NIENHUIS, AW				REDNER, RL; LEE, AWM; OSAWA, GA; NIENHUIS, AW			VARIABLE PATTERN OF JUN AND FOS GENE-EXPRESSION IN DIFFERENT HEMATOPOIETIC-CELL LINES DURING INTERLEUKIN 3-INDUCED ENTRY INTO THE CELL-CYCLE	ONCOGENE			English	Article								Jun (c-jun, jun-B and jun-D) and fos (c-fos, fos-B and fra) proteins dimerize to form the family of AP-1 transcriptional activators. If each dimer exhibits unique transactivating properties, then any phenotypic change should show a characteristic pattern of jun and fos expression. To test this hypothesis we have assessed jun and fos RNA expression after stimulation of the factor-dependent cell lines 32D and FDCP1. These hematopoietic progenitor lines become quiescent in G0/G1 after interleukin 3 (IL-3) deprivation, and upon stimulation synchronously enter the cell cycle. 32D cells respond to IL-3 with rapid induction of jun-B and c-fos, followed by induction of jun-D and fra-1, but no rise in c-jun expression. FDCP1 cells show a very different pattern, with induction of c-jun, jun-D and fra-1. To investigate the response of a single cell line to different physiological stimuli we used a 32D subclone engineered to respond to colony stimulating factor 1 (CSF-1). This subclone showed identical induction of jun and fos after stimulation with either CSF-1 or IL-3. The conservation of response of a single cell line, but the disparate patterns demonstrated by different cells, suggest a fundamental difference in both the regulation and function of the fos/jun complexes in these cells.	NHLBI, CLIN HEMATOL BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUWERX J, 1990, NUCLEIC ACIDS RES, V18, P221, DOI 10.1093/nar/18.2.221; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; COOK N, 1989, EMBO J, V8, P2967, DOI 10.1002/j.1460-2075.1989.tb08446.x; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DEAN M, 1987, ONCOGENE RES, V1, P279; DEGROOT RP, 1990, NUCLEIC ACIDS RES, V18, P3195, DOI 10.1093/nar/18.11.3195; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERGER JS, 1983, FED PROC, V42, P2762; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HASTHORPE S, 1988, INT J CELL CLONING, V6, P30, DOI 10.1002/stem.5530060105; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; IHLE JN, 1989, INT J CELL CLONING, V7, P68, DOI 10.1002/stem.5530070202; IHLE JN, 1982, J IMMUNOL, V129, P2431; IHLE JN, 1982, J IMMUNOL, V129, P1377; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KATO JY, 1990, BLOOD, V75, P1780; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEE AW, 1990, P NATL ACAD SCI USA, V87, P7270, DOI 10.1073/pnas.87.18.7270; LONDON L, 1987, J EXP MED, V166, P1419, DOI 10.1084/jem.166.5.1419; MATSUI M, 1990, ONCOGENE, V5, P249; MITCHELL RL, 1985, CELL, V40, P209, DOI 10.1016/0092-8674(85)90324-1; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; PIERCE JH, 1990, P NATL ACAD SCI USA, V87, P5613, DOI 10.1073/pnas.87.15.5613; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; ROHRSCHNEIDER LR, 1989, MOL CELL BIOL, V9, P5081, DOI 10.1128/MCB.9.11.5081; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; RYSECK RP, 1991, ONCOGENE, V6, P533; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHERMAN ML, 1990, J BIOL CHEM, V265, P3320; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; YOKOTA T, 1984, P NATL ACAD SCI-BIOL, V81, P1070, DOI 10.1073/pnas.81.4.1070; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	58	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1992	7	1					43	50						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1371337				2022-12-28	WOS:A1992HC22700006
J	Carlson, CR; Adly, AN; Bi, M; Howard, CJ; Frost, A; Cheng, YF; Morgan, DO				Carlson, Christopher R.; Adly, Armin N.; Bi, Maxine; Howard, Conor J.; Frost, Adam; Cheng, Yifan; Morgan, David O.			Reconstitution of the SARS-CoV-2 ribonucleosome provides insights into genomic RNA packaging and regulation by phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORONAVIRUS NUCLEOCAPSID PROTEIN; N-TERMINAL DOMAIN; SARS CORONAVIRUS; DIMERIZATION DOMAIN; RICH MOTIF; MEMBRANE; VIRUS; RIBONUCLEOPROTEIN; MULTIMERIZATION; REPLICATION	The nucleocapsid (N) protein of severe acute respiratory syndrome coronavirus 2 is responsible for compaction of the X30-kb RNA genome in the X90-nm virion. Previous studies suggest that each virion contains 35 to 40 viral ribonucleoprotein (vRNP) complexes, or ribonucleosomes, arrayed along the genome. There is, however, little mechanistic understanding of the vRNP complex. Here, we show that N protein, when combined in vitro with short fragments of the viral genome, forms 15-nm particles similar to the vRNP structures observed within virions. These vRNPs depend on regions of N protein that promote protein-RNA and protein-protein interactions. Phosphorylation of N protein in its disordered serine/arginine region weakens these interactions to generate less compact vRNPs. We propose that unmodified N protein binds structurally diverse regions in genomic RNA to form compact vRNPs within the nucleocapsid, while phosphorylation alters vRNP structure to support other N protein functions in viral transcription.	[Carlson, Christopher R.; Adly, Armin N.; Morgan, David O.] Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94118 USA; [Bi, Maxine; Howard, Conor J.; Frost, Adam; Cheng, Yifan] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Morgan, DO (corresponding author), Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94118 USA.	David.Morgan@ucsf.edu		Carlson, Christopher/0000-0003-3599-4044; Morgan, David/0000-0001-8753-4416	ARCS; National Institute of General Medical Sciences [R35-GM118053]; UCSF Program for Breakthrough Biomedical Research; QBI Coronavirus Research Group at UCSF; Sandler Foundation; Chan Zuckerberg Biohub	ARCS; National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); UCSF Program for Breakthrough Biomedical Research; QBI Coronavirus Research Group at UCSF; Sandler Foundation; Chan Zuckerberg Biohub	This work was supported a graduate research fellowship from ARCS (C. R. C.), and grants (to D. O. M.) from the National Institute of General Medical Sciences (R35-GM118053) and the UCSF Program for Breakthrough Biomedical Research, which is funded in part by the Sandler Foundation. A. F. is supported by the Chan Zuckerberg Biohub and the QBI Coronavirus Research Group at UCSF. Y. C. is an investigator of the Howard Hughes Medical Institute.	A. T.Harding, 2020, bioRxiv, DOI 10.1101/2020.08.14.251207; Almazan F, 2004, J VIROL, V78, P12683, DOI 10.1128/JVI.78.22.12683-12688.2004; Barcena M, 2009, P NATL ACAD SCI USA, V106, P582, DOI 10.1073/pnas.0805270106; Bessa LM, 2022, SCI ADV, V8, DOI 10.1126/sciadv.abm4034; Bost AG, 2000, J VIROL, V74, P3379, DOI 10.1128/JVI.74.7.3379-3387.2000; Bouhaddou M, 2020, CELL, V182, P685, DOI 10.1016/j.cell.2020.06.034; Cao CC, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22785-x; Carlson CR, 2020, MOL CELL, V80, P1092, DOI 10.1016/j.molcel.2020.11.025; Chang CK, 2014, ANTIVIR RES, V103, P39, DOI 10.1016/j.antiviral.2013.12.009; Chang CK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065045; Chang CK, 2009, J VIROL, V83, P2255, DOI 10.1128/JVI.02001-08; Chen CY, 2007, J MOL BIOL, V368, P1075, DOI 10.1016/j.jmb.2007.02.069; Cong YY, 2020, J VIROL, V94, DOI 10.1128/JVI.01925-19; Cong YY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06062-w; DAVIES HA, 1981, J GEN VIROL, V53, P67, DOI 10.1099/0022-1317-53-1-67; Dolan K. A., 2022, BIORXIV, DOI [10.1101/2022.06.12.495841, DOI 10.1101/2022.06.12.495841]; Fan H, 2005, STRUCTURE, V13, P1859, DOI 10.1016/j.str.2005.08.021; Franklin R., 2021, BIORXIV, DOI [10.1101/2021.10.22.465468, DOI 10.1101/2021.10.22.465468]; Fung TS, 2019, ANNU REV MICROBIOL, V73, P529, DOI 10.1146/annurev-micro-020518-115759; Grossoehme NE, 2009, J MOL BIOL, V394, P544, DOI 10.1016/j.jmb.2009.09.040; He RT, 2004, BIOCHEM BIOPH RES CO, V316, P476, DOI 10.1016/j.bbrc.2004.02.074; Hurst KR, 2009, J VIROL, V83, P7221, DOI 10.1128/JVI.00440-09; Hurst KR, 2005, J VIROL, V79, P13285, DOI 10.1128/JVI.79.21.13285-13297.2005; Huston NC, 2021, MOL CELL, V81, DOI 10.1016/j.molcel.2020.12.041; Iserman C, 2020, MOL CELL, V80, P1078, DOI 10.1016/j.molcel.2020.11.041; Jayaram H, 2006, J VIROL, V80, P6612, DOI 10.1128/JVI.00157-06; Kang SS, 2020, ACTA PHARM SIN B, V10, P1228, DOI 10.1016/j.apsb.2020.04.009; Kastner B, 2008, NAT METHODS, V5, P53, DOI 10.1038/NMETH1139; Kim D, 2020, CELL, V181, P914, DOI 10.1016/j.cell.2020.04.011; Klein S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19619-7; Koetzner CA, 2022, VIROLOGY, V567, DOI 10.1016/j.virol.2021.12.004; Kuo L, 2002, J VIROL, V76, P4987, DOI 10.1128/JVI.76.10.4987-4999.2002; Kuo LL, 2016, VIROLOGY, V494, P100, DOI 10.1016/j.virol.2016.04.009; Kuo L, 2014, J VIROL, V88, P4451, DOI 10.1128/JVI.03866-13; Kuo LL, 2013, J VIROL, V87, P5182, DOI 10.1128/JVI.00100-13; Liu XL, 2021, P NATL ACAD SCI USA, V118, DOI [10.1073/pnas.2113401118, 10.1101/2021.02.17.21251933]; Lu S, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20768-y; Luo HB, 2006, BIOCHEMISTRY-US, V45, P11827, DOI 10.1021/bi0609319; Luo HB, 2005, FEBS LETT, V579, P2623, DOI 10.1016/j.febslet.2005.03.080; Luo HB, 2005, BIOCHEMISTRY-US, V44, P15351, DOI 10.1021/bi051122c; Luo HB, 2004, BIOPHYS CHEM, V112, P15, DOI 10.1016/j.bpc.2004.06.008; MACNAUGHTON MR, 1978, J GEN VIROL, V39, P545, DOI 10.1099/0022-1317-39-3-545; Masters PS, 2006, ADV VIRUS RES, V66, P193, DOI 10.1016/S0065-3527(06)66005-3; Masters PS, 2019, VIROLOGY, V537, P198, DOI 10.1016/j.virol.2019.08.031; McBride R, 2014, VIRUSES-BASEL, V6, P2991, DOI 10.3390/v6082991; Narayanan K, 2000, J VIROL, V74, P8127, DOI 10.1128/JVI.74.17.8127-8134.2000; Neuman BW, 2011, J STRUCT BIOL, V174, P11, DOI 10.1016/j.jsb.2010.11.021; Nikolakaki E, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.00219; Peng TY, 2008, FEBS J, V275, P4152, DOI 10.1111/j.1742-4658.2008.06564.x; Perdikari TM, 2020, EMBO J, V39, DOI 10.15252/embj.2020106478; Sawicki SG, 2007, J VIROL, V81, P20, DOI 10.1128/JVI.01358-06; Scherer KM, 2022, SCI ADV, V8, DOI 10.1126/sciadv.abl4895; Snijder EJ, 2006, J VIROL, V80, P5927, DOI 10.1128/JVI.02501-05; Snijder EJ, 2020, PLOS BIOL, V18, DOI 10.1371/journal.pbio.3000715; Sola I, 2015, ANNU REV VIROL, V2, P265, DOI 10.1146/annurev-virology-100114-055218; Stertz S, 2007, VIROLOGY, V361, P304, DOI 10.1016/j.virol.2006.11.027; Takeda M, 2008, J MOL BIOL, V380, P608, DOI 10.1016/j.jmb.2007.11.093; V'kovski P, 2021, NAT REV MICROBIOL, V19, P155, DOI 10.1038/s41579-020-00468-6; V'kovski P, 2019, ELIFE, V8, DOI 10.7554/eLife.42037; Verheije MH, 2010, J VIROL, V84, P11575, DOI 10.1128/JVI.00569-10; Verma S, 2006, J VIROL, V80, P4344, DOI 10.1128/JVI.80.9.4344-4355.2006; Wolff G, 2020, SCIENCE, V369, P1395, DOI 10.1126/science.abd3629; Wu CH, 2014, CELL HOST MICROBE, V16, P462, DOI 10.1016/j.chom.2014.09.009; Wu CH, 2009, J BIOL CHEM, V284, P5229, DOI 10.1074/jbc.M805747200; X. Wang, 2022, bioRxiv, DOI 10.1101/2022.06.28.497981; Yang D, 2015, VIRUS RES, V206, P120, DOI 10.1016/j.virusres.2015.02.025; Yao HP, 2020, CELL, V183, P730, DOI 10.1016/j.cell.2020.09.018; Ye QZ, 2020, PROTEIN SCI, V29, P1890, DOI [10.1002/pro.3909, 10.1101/2020.05.17.100685]; Zhang ZK, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-32019-3; Zhou CY, 2016, METHOD ENZYMOL, V573, P119, DOI 10.1016/bs.mie.2016.01.015; Zhou P, 2020, NATURE, V588, pE6, DOI [10.1038/s41586-020-2951-z, 10.1038/s41586-020-2012-7]; Zuniga S, 2010, J VIROL, V84, P2169, DOI 10.1128/JVI.02011-09	72	0	0	3	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV	2022	298	11							102560	10.1016/j.jbc.2022.102560	http://dx.doi.org/10.1016/j.jbc.2022.102560			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	6C7OU	36202211	Green Submitted, Green Published, gold			2022-12-28	WOS:000882199400004
J	Martinez, CA; Jiramongkol, Y; Bal, N; Alwis, I; Nedoboy, PE; Farnham, MMJ; White, MD; Cistulli, PA; Cook, KM				Martinez, Chloe -Anne; Jiramongkol, Yannasittha; Bal, Neha; Alwis, Imala; Nedoboy, Polina E.; Farnham, Melissa M. J.; White, Mark D.; Cistulli, Peter A.; Cook, Kristina M.			Intermittent hypoxia enhances the expression of hypoxia inducible factor HIF1A through histone demethylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYOCARDIAL-INFARCTION; OBSTRUCTIVE SLEEP-APNEA; OXYGEN; CHROMATIN; METHYLATION; SURVIVAL; ANIMALS; TARGETS	The cellular response to hypoxia is regulated through enzymatic oxygen sensors, including the prolyl hydroxylases, which control degradation of the well-known hypoxia induc-ible factors (HIFs). Other enzymatic oxygen sensors have been recently identified, including members of the KDM histone demethylase family. Little is known about how different oxygen-sensing pathways interact and if this varies depending on the form of hypoxia, such as chronic or intermittent. In this study, we investigated how two proposed cellular oxygen -sensing systems, HIF-1 and KDM4A, KDM4B, and KDM4C, respond in cells exposed to rapid forms of intermittent hypoxia (minutes) and compared to chronic hypoxia (hours). We found that intermittent hypoxia increases HIF-1 alpha protein through a pathway distinct from chronic hypoxia, involving the KDM4A, KDM4B, and KDM4C histone lysine demethylases. Intermit-tent hypoxia increases the quantity and activity of KDM4A, KDM4B, and KDM4C, resulting in a decrease in histone 3 lysine 9 (H3K9) trimethylation near the HIF1A locus. We demonstrate that this contrasts with chronic hypoxia, which decreases KDM4A, KDM4B, and KDM4C activity, leading to hypertrimethylation of H3K9 globally and at the HIF1A locus. Altogether, we found that demethylation of histones bound to the HIF1A gene in intermittent hypoxia increases HIF1A mRNA expression, which has the downstream effect of increasing overall HIF-1 activity and expression of HIF target genes. This study highlights how multiple oxygen-sensing pathways can interact to regulate and fine tune the cellular hypoxic response depending on the period and length of hypoxia.	[Martinez, Chloe -Anne; Bal, Neha; Farnham, Melissa M. J.; Cistulli, Peter A.; Cook, Kristina M.] Univ Sydney, Fac Med & Hlth, Sydney, NSW, Australia; [Jiramongkol, Yannasittha] Univ Sydney, Fac Sci, Charles Perkins Ctr, Sydney, NSW, Australia; [Jiramongkol, Yannasittha] Univ Sydney, Sch Chem, Sydney, NSW, Australia; [Alwis, Imala; Nedoboy, Polina E.; Farnham, Melissa M. J.] Univ Sydney, Heart Res Inst, Sydney, NSW, Australia	University of Sydney; University of Sydney; University of Sydney; University of Sydney; Heart Research Institute	Cook, KM (corresponding author), Univ Sydney, Fac Med & Hlth, Sydney, NSW, Australia.	kristina.cook@sydney.edu.au		Jiramongkol, Yannasittha/0000-0003-1824-4313; Farnham, Melissa/0000-0002-7612-1015; White, Mark/0000-0002-1431-0339	Cancer Institute NSW Early Career; University of Sydney; NSW Health grant - A. E. and F. A. Q. Stephens PhD Scholarship from the University of Sydney; RTP (International) Scholarship - Australian Government	Cancer Institute NSW Early Career; University of Sydney(University of Sydney); NSW Health grant - A. E. and F. A. Q. Stephens PhD Scholarship from the University of Sydney; RTP (International) Scholarship - Australian Government	Funding and additional information - This study was funded by a Cancer Institute NSW Early Career Fellowship, a University of Sydney Fellowship and an NSW Health grant to K. M. C. C. A. M. is funded by an A. E. and F. A. Q. Stephens PhD Scholarship from the University of Sydney. Y. J. is funded by an RTP (International) Scholarship provided by the Australian Government.	Almendros I, 2013, RESP PHYSIOL NEUROBI, V186, P303, DOI 10.1016/j.resp.2013.03.001; Ardaseva A, 2020, B MATH BIOL, V82, DOI 10.1007/s11538-020-00754-7; Batie M, 2019, SCIENCE, V363, P1222, DOI 10.1126/science.aau5870; Beyer S, 2008, J BIOL CHEM, V283, P36542, DOI 10.1074/jbc.M804578200; Cardenas-Navia LI, 2008, CANCER RES, V68, P5812, DOI 10.1158/0008-5472.CAN-07-6387; Cascella B, 2012, BIOCHEMISTRY-US, V51, P8699, DOI 10.1021/bi3012466; Cavadas MAS, 2015, SCI REP-UK, V5, DOI 10.1038/srep17851; Chakraborty AA, 2019, SCIENCE, V363, P1217, DOI 10.1126/science.aaw1026; Chopra S, 2016, AM J RESP CELL MOL, V54, P299, DOI 10.1165/rcmb.2015-0218TR; Choudhry H, 2018, CELL METAB, V27, P281, DOI 10.1016/j.cmet.2017.10.005; Dobrynin G, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11658-3; Friedrich J, 2009, NAT PROTOC, V4, P309, DOI 10.1038/nprot.2008.226; Gillies RJ, 2018, NAT REV CANCER, V18, P576, DOI 10.1038/s41568-018-0030-7; Gupta V., 2017, CIRCULATION, V136; Haase VH, 2013, BLOOD REV, V27, P41, DOI 10.1016/j.blre.2012.12.003; Hancock RL, 2017, ACS CHEM BIOL, V12, P1011, DOI 10.1021/acschembio.6b00958; Hancock RL, 2015, EPIGENOMICS-UK, V7, P791, DOI 10.2217/epi.15.24; Hu K, 2020, BMC CARDIOVASC DISOR, V20, DOI 10.1186/s12872-020-01702-y; Hunyor I, 2018, AM J PHYSIOL-REG I, V315, pR669, DOI 10.1152/ajpregu.00036.2018; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Kukwa W, 2013, SLEEP BREATH, V17, P1063, DOI 10.1007/s11325-013-0801-z; Loor G, 2008, CELL DEATH DIFFER, V15, P686, DOI 10.1038/cdd.2008.13; Martinez CA, 2019, BIO-PROTOCOL, V9, DOI 10.21769/BioProtoc.3371; Martinez CA, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20020445; Masson N, 2019, SCIENCE, V365, P65, DOI 10.1126/science.aaw0112; Mohananey D, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.006133; Philipp S, 2006, EUR J HEART FAIL, V8, P347, DOI 10.1016/j.ejheart.2005.10.009; Pollard PJ, 2008, BIOCHEM J, V416, P387, DOI 10.1042/BJ20081238; Prabhakar NR, 2016, PFLUG ARCH EUR J PHY, V468, P71, DOI 10.1007/s00424-015-1719-z; Reinke C, 2011, J APPL PHYSIOL, V111, P881, DOI 10.1152/japplphysiol.00492.2011; Saxena K, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9080339; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Semenza GL, 2012, TRENDS PHARMACOL SCI, V33, P207, DOI 10.1016/j.tips.2012.01.005; Shah N. A., 2011, HYPOXIA, VA109, pA2485; Shah N, 2013, SLEEP BREATH, V17, P819, DOI 10.1007/s11325-012-0770-7; Shmakova A, 2014, BIOCHEM J, V462, P385, DOI 10.1042/BJ20140754; Vordermark D, 2001, NEOPLASIA, V3, P527, DOI 10.1038/sj.neo.7900192; Weiswald LB, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-106; Wenger RH, 1996, BIOCHEM BIOPH RES CO, V223, P54, DOI 10.1006/bbrc.1996.0845; Wilson JW, 2020, FEBS J, V287, P3888, DOI 10.1111/febs.15374; Xia XB, 2009, P NATL ACAD SCI USA, V106, P4260, DOI 10.1073/pnas.0810067106; Zong P, 2004, EXP BIOL MED, V229, P806, DOI 10.1177/153537020422900813	42	0	0	1	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV	2022	298	11							102536	10.1016/j.jbc.2022.102536	http://dx.doi.org/10.1016/j.jbc.2022.102536			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	6C7OU	36174675	Green Published, gold			2022-12-28	WOS:000882199400002
J	Randolph, CE; Dwyer, MB; Aumiller, JL; Dixon, AJ; Inoue, A; Osei-Owusu, P; Wedegaertner, PB				Randolph, Clinita E.; Dwyer, Morgan B.; Aumiller, Jenna L.; Dixon, Alethia J.; Inoue, Asuka; Osei-Owusu, Patrick; Wedegaertner, Philip B.			Enhanced membrane binding of oncogenic G protein?qQ209L confers resistance to inhibitor YM-254890	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED SUBCELLULAR REDISTRIBUTION; HETEROTRIMERIC G-PROTEINS; COUPLED RECEPTOR KINASE; ACTIVATED G-PROTEIN; G-BETA-GAMMA; PLASMA-MEMBRANE; PHOSPHOLIPASE-C; UVEAL MELANOMA; RGS DOMAIN; G-ALPHA(S)	Heterotrimeric G proteins couple activated G protein- coupled receptors (GPCRs) to intracellular signaling path-ways. They can also function independently of GPCR activation upon acquiring mutations that prevent GTPase activity and result in constitutive signaling, as occurs with the alpha qQ209L mutation in uveal melanoma. YM-254890 (YM) can inhibit signaling by both GPCR-activated WT alpha q and GPCR-independent alpha qQ209L. Although YM inhibits WT alpha q by binding to alpha q-GDP and preventing GDP/GTP exchange, the mechanism of YM inhibition of cellular alpha qQ209L remains to be fully understood. Here, we show that YM promotes a sub -cellular redistribution of alpha qQ209L from the plasma membrane (PM) to the cytoplasm. To test if this loss of PM localization could contribute to the mechanism of inhibition of alpha qQ209L by YM, we developed and examined N-terminal mutants of alpha qQ209L, termed PM-restricted alpha qQ209L, in which the addi-tion of membrane-binding motifs enhanced PM localization and prevented YM-promoted redistribution. Treatment of cells with YM failed to inhibit signaling by these PM-restricted alpha qQ209L. Additionally, pull-down experiments demonstrated that YM promotes similar conformational changes in both alpha qQ209L and PM-restricted alpha qQ209L, resulting in increased binding to beta gamma and decreased binding to regulator RGS2, and effectors p63RhoGEF-DH/PH and phospholipase C-beta. GPCR-dependent signaling by PM-restricted WT alpha q is strongly inhibited by YM, demonstrating that resistance to YM inhibi-tion by membrane-binding mutants is specific to constitutively active alpha qQ209L. Together, these results indicate that changes in membrane binding impact the ability of YM to inhibit alpha qQ209L and suggest that YM contributes to inhibition of alpha qQ209L by promoting its relocalization.	[Randolph, Clinita E.; Dwyer, Morgan B.; Aumiller, Jenna L.; Wedegaertner, Philip B.] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Dept Biochem & Mol Biol, Philadelphia, PA 19144 USA; [Dixon, Alethia J.; Osei-Owusu, Patrick] Case Western Reserve Univ, Dept Physiol & Biophys, Sch Med, Cleveland, OH USA; [Inoue, Asuka] Tohoku Univ, Grad Sch Pharmaceut Sci, Sendai, Japan	Jefferson University; Case Western Reserve University; Tohoku University	Wedegaertner, PB (corresponding author), Thomas Jefferson Univ, Sidney Kimmel Med Coll, Dept Biochem & Mol Biol, Philadelphia, PA 19144 USA.	philip.wedegaertner@jefferson.edu			National Institutes of Health (NIH) [R01 HL139754, R01 GM138943]; NIH [R01 HL139754]; American Heart Association Scientist Development Grant [16SDG27260276]; LEAP [20gm0010004]; Japan Agency for Medical Research and Development (AMED) [JP20am0101095]; Japan Society for the Promotion of Science (JSPS) [21H04791, 21H051130]; Japan Science and Technology Agency (JST) [JPMJFR215T]; Daiichi Sankyo Foundation of Life Science; Uehara Memorial Foundation; Tokyo Biochemical Research Foundation	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association Scientist Development Grant(American Heart Association); LEAP; Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Japan Science and Technology Agency (JST)(Japan Science & Technology Agency (JST)); Daiichi Sankyo Foundation of Life Science; Uehara Memorial Foundation(Uehara Memorial Foundation); Tokyo Biochemical Research Foundation	Funding and additional information-This work was supported by National Institutes of Health (NIH) Grants R01 GM138943 R01 GM56444 and the Dr. Ralph and Marian Falk Medical Research Trust (P. B. W.) ; NIH Grant R01 HL139754 and American Heart Association Scientist Development Grant 16SDG27260276 (P. O.-O.) ; and NIH Grants F31 CA224803 and T32 GM100836 (C. E. R.) . A. I. was funded by the LEAP 20gm0010004 and the BINDS JP20am0101095 from the Japan Agency for Medical Research and Development (AMED) ; KAKENHI 21H04791 and 21H051130 from by the Japan Society for the Promotion of Science (JSPS) ; FOREST Program JPMJFR215T from Japan Science and Technology Agency (JST) ; Daiichi Sankyo Foundation of Life Science; The Uehara Memorial Foundation; The Tokyo Biochemical Research Founda-tion. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Allen JA, 2005, MOL PHARMACOL, V67, P1493, DOI 10.1124/mol.104.008342; Annala S, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aau5948; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; Charpentier TH, 2016, J BIOL CHEM, V291, P25608, DOI 10.1074/jbc.M116.740407; Chen X, 2017, CANCER CELL, V31, P685, DOI 10.1016/j.ccell.2017.04.002; Crouthamel M, 2008, CELL SIGNAL, V20, P1900, DOI 10.1016/j.cellsig.2008.06.019; Cervantes-Villagrana RD, 2019, J BIOL CHEM, V294, P531, DOI 10.1074/jbc.RA118.006254; Day PW, 2004, J BIOL CHEM, V279, P53643, DOI 10.1074/jbc.M401438200; Day PW, 2004, METHOD ENZYMOL, V390, P295; Evanko DS, 2000, J BIOL CHEM, V275, P1327, DOI 10.1074/jbc.275.2.1327; Evanko DS, 2005, CELL SIGNAL, V17, P1218, DOI 10.1016/j.cellsig.2004.12.008; Feng XD, 2019, CANCER CELL, V35, P457, DOI 10.1016/j.ccell.2019.01.009; Feng XD, 2014, CANCER CELL, V25, P831, DOI 10.1016/j.ccr.2014.04.016; Helms MC, 2016, CELL SIGNAL, V28, P43, DOI 10.1016/j.cellsig.2015.10.004; Hitchman TD, 2021, CLIN CANCER RES, V27, P1476, DOI 10.1158/1078-0432.CCR-20-2860; Hu Q, 2018, CELL, V173, P1254, DOI 10.1016/j.cell.2018.03.018; Hughes TE, 2001, J BIOL CHEM, V276, P4227, DOI 10.1074/jbc.M007608200; Johnston CA, 2007, MOL PHARMACOL, V72, P219, DOI 10.1124/mol.107.034348; KLEUSS C, 1994, P NATL ACAD SCI USA, V91, P9828, DOI 10.1073/pnas.91.21.9828; Kostenis E, 2020, J BIOL CHEM, V295, P5206, DOI 10.1074/jbc.REV119.007061; Lapadula D, 2019, MOL CANCER RES, V17, P963, DOI 10.1158/1541-7786.MCR-18-0574; LEE CH, 1992, J BIOL CHEM, V267, P16044; Martin BR, 2016, J BIOL CHEM, V291, P20295, DOI 10.1074/jbc.M116.729731; Maziarz M, 2018, J BIOL CHEM, V293, P19586, DOI 10.1074/jbc.RA118.005291; Milligan G, 2006, BRIT J PHARMACOL, V147, pS46, DOI 10.1038/sj.bjp.0706405; Moore AR, 2018, CELL REP, V22, P2455, DOI 10.1016/j.celrep.2018.01.081; Nishimura A, 2010, P NATL ACAD SCI USA, V107, P13666, DOI 10.1073/pnas.1003553107; Offermanns S, 2003, PROG BIOPHYS MOL BIO, V83, P101, DOI 10.1016/S0079-6107(03)00052-X; Oldham WM, 2008, NAT REV MOL CELL BIO, V9, P60, DOI 10.1038/nrm2299; Onken MD, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aao6852; Robertson AG, 2018, CANCER CELL, V33, P151, DOI 10.1016/j.ccell.2017.12.013; Schlegel JG, 2021, ACS PHARMACOL TRANSL, V4, P888, DOI 10.1021/acsptsci.1c00021; Schrage R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10156; Sprang SR, 2016, BIOPOLYMERS, V105, P449, DOI 10.1002/bip.22836; STERNWEIS PC, 1992, PHILOS T ROY SOC B, V336, P35, DOI 10.1098/rstb.1992.0041; Takasaki J, 2004, J BIOL CHEM, V279, P47438, DOI 10.1074/jbc.M408846200; Thiyagarajan MM, 2002, BIOCHEMISTRY-US, V41, P9470, DOI 10.1021/bi025533u; Tsutsumi R, 2009, MOL CELL BIOL, V29, P435, DOI 10.1128/MCB.01144-08; Van Raamsdonk CD, 2010, NEW ENGL J MED, V363, P2191, DOI 10.1056/NEJMoa1000584; Van Raamsdonk CD, 2009, NATURE, V457, P599, DOI 10.1038/nature07586; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; Wedegaertner PB, 1996, MOL BIOL CELL, V7, P1225, DOI 10.1091/mbc.7.8.1225; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; WU DQ, 1992, J BIOL CHEM, V267, P25798; Xu H, 2014, MOL BIOL CELL, V25, P2105, DOI 10.1091/mbc.E13-09-0547; Yu JZ, 2002, MOL PHARMACOL, V61, P352, DOI 10.1124/mol.61.2.352	46	0	0	1	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV	2022	28	11							102538	10.1016/j.jbc.2022.102538	http://dx.doi.org/10.1016/j.jbc.2022.102538			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	6I4GS	36174676	Green Published, gold			2022-12-28	WOS:000886086000006
J	MARTINERIE, C; VIEGASPEQUIGNOT, E; GUENARD, I; DUTRILLAUX, B; NGUYEN, VC; BERNHEIM, A; PERBAL, B				MARTINERIE, C; VIEGASPEQUIGNOT, E; GUENARD, I; DUTRILLAUX, B; NGUYEN, VC; BERNHEIM, A; PERBAL, B			PHYSICAL MAPPING OF HUMAN LOCI HOMOLOGOUS TO THE CHICKEN NOV PROTOONCOGENE	ONCOGENE			English	Note							ANTI-MULLERIAN HORMONE; IMMEDIATE-EARLY GENE; GROWTH-FACTOR; INDUCIBLE GENE; EXPRESSION; SEQUENCES; CELLS	The human locus (novH) corresponding to the nov proto-oncogene overexpressed in avian nephroblastoma has been identified and mapped on chromosome 8q24.1. Another locus sharing homology with novH and corresponding to the connective tissue growth factor (CTGF) gene has also been mapped on chromosome 6q23.1. The chromosomal assignment of nov and CTGF proximal to c-myc and c-myb respectively is of interest because chromosomal abnormalities involving these regions have been associated with different human tumors including Wilms'.	INST CURIE,ONCOL VIRALE & MOLEC LAB,F-91405 ORSAY,FRANCE; IGR,VILLEJUIF,FRANCE; UNIV PARIS 07,F-75221 PARIS 05,FRANCE; INST CURIE,F-75231 PARIS 05,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie								BAUMGARTNER M, 1991, CELL, V64, P761, DOI 10.1016/0092-8674(91)90505-S; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; COHENHAGUENAUER O, 1987, CYTOGENET CELL GENET, V44, P2, DOI 10.1159/000132332; DOZIER C, 1986, NUCLEIC ACIDS RES, V14, P1928, DOI 10.1093/nar/14.4.1928; DUTRILLAUX B, 1971, CR ACAD SCI D NAT, V272, P2638; HEINE U, 1962, JNCI-J NATL CANCER I, V29, P41; ISHIGURO H, 1962, J NATL CANCER I, V29, P1; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; LEBEAU J, 1991, ONCOGENE, V6, P1125; MARTINERIE C, 1991, CR ACAD SCI III-VIE, V313, P345; NGUYEN VC, 1986, ANN GENET-PARIS, V29, P20; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; PICARD JY, 1986, P NATL ACAD SCI USA, V83, P5464, DOI 10.1073/pnas.83.15.5464; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; SHOWE LC, 1987, P NATL ACAD SCI USA, V84, P2824, DOI 10.1073/pnas.84.9.2824; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; SORET J, 1989, J VIROL, V63, P1803, DOI 10.1128/JVI.63.4.1803-1807.1989; VANSOMEREN H, 1974, HUMANGENETIK, V25, P189; VELLARD M, 1991, ONCOGENE, V6, P505; Viegas-Pequignot E, 1992, IN SITU HYBRIDIZATIO, P137; VIEGASPEQUIGNOT E, 1978, ANN GENET-PARIS, V21, P122; VIEGASPEQUIGNOT E, 1989, P NATL ACAD SCI USA, V86, P582, DOI 10.1073/pnas.86.2.582; WANGWUU S, 1990, CANCER RES, V50, P2786; 1990, CYTOGENET CELL GENET, V55, P358; 1989, CYTOGENET CELL GENET, V51, P1	25	73	86	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1992	7	12					2529	2534						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1334251				2022-12-28	WOS:A1992KA85600020
J	GIBSON, AW; YE, R; JOHNSTON, RN; BROWDER, LW				GIBSON, AW; YE, R; JOHNSTON, RN; BROWDER, LW			A POSSIBLE ROLE FOR C-MYC ONCOPROTEINS IN POSTTRANSCRIPTIONAL REGULATION OF RIBOSOMAL-RNA	ONCOGENE			English	Note							MESSENGER-RNA; XENOPUS-LAEVIS; PROTO-ONCOGENE; DNA-SYNTHESIS; 2-NITRO-5-THIOCYANOBENZOIC ACID; CELL-DIVISION; GROWTH-FACTOR; EXPRESSION; BINDING; GENE	Overexpression of members of the myc family of oncogenes contributes to the development of many vertebrate malignancies. Although several functions for myc gene products have been proposed, the targets for Myc activity during oncogenesis or normal development remain to be identified. Oocytes of Xenopus laevis, which are non-dividing cells that accumulate abundant c-Myc protein, provide an unusual opportunity to examine c-Myc function. We have investigated whether the accumulation of massive amounts of ribosomal RNA (rRNA) by Xenopus laevis oocytes may be related to their elevated expression of myc proto-oncogenes. Our data show that anti-Myc antibodies and some (but not all) c-Myc peptides from conserved regions of the c-Myc protein enhance the turnover of rRNA synthesized in homogenates of oocyte nuclei. These results suggest that one or more members of the Myc protein family may be involved in post-transcriptional regulation of rRNA metabolism. The regulation by c-Myc of rRNA could account, in part, for the generalized stimulation of cells during tumorigenesis.	UNIV CALGARY,DEPT BIOL SCI,CALGARY T2N 1N4,ALBERTA,CANADA	University of Calgary	GIBSON, AW (corresponding author), UNIV CALGARY,SO ALBERTA CANC RES CTR,DEPT MED BIOCHEM,CALGARY T2N 4N1,ALBERTA,CANADA.		Johnston, Randal/B-9247-2009					ABELSON HT, 1979, BIOCHIM BIOPHYS ACTA, V561, P269, DOI 10.1016/0005-2787(79)90136-9; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Cole MD, 1990, CURR OPIN CELL BIOL, V2, P502, DOI 10.1016/0955-0674(90)90134-Z; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COOPER HL, 1970, NATURE, V227, P1105, DOI 10.1038/2271105a0; COOPER HL, 1971, J BIOL CHEM, V246, P5059; COWLEY BD, 1987, P NATL ACAD SCI USA, V84, P8394, DOI 10.1073/pnas.84.23.8394; DEGANI Y, 1974, BIOCHEMISTRY-US, V13, P1, DOI 10.1021/bi00698a001; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; ENDO T, 1986, MOL CELL BIOL, V6, P1412, DOI 10.1128/MCB.6.5.1412; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GIBSON AW, 1992, IN PRESS BIOCH CELL; GODEAU F, 1986, EMBO J, V5, P3571, DOI 10.1002/j.1460-2075.1986.tb04684.x; GRAMMAGE MD, 1991, CLIN SCI, V80, P405; GUTIERREZ C, 1987, MOL CELL BIOL, V7, P4594, DOI 10.1128/MCB.7.12.4594; HANN SR, 1988, CELL, V52, P15; HILL JM, 1975, J CELL BIOL, V64, P260, DOI 10.1083/jcb.64.1.260; HIPSKIND RA, 1980, J BIOL CHEM, V255, P7896; INGHIRAMI G, 1990, SCIENCE, V250, P682, DOI 10.1126/science.2237417; JOHNSON LF, 1976, J CELL BIOL, V71, P933, DOI 10.1083/jcb.71.3.933; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KERKHOFF E, 1991, ONCOGENE, V6, P93; KING MW, 1986, MOL CELL BIOL, V6, P4499, DOI 10.1128/MCB.6.12.4499; LIAO TH, 1979, J BIOL CHEM, V254, P9602; LUSCHER B, 1989, EMBO J, V8, P111; NATH P, 1987, EXP CELL RES, V169, P215, DOI 10.1016/0014-4827(87)90239-4; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; PRENDERGAST GC, 1990, MOL CELL BIOL, V10, P1265, DOI 10.1128/MCB.10.3.1265; PRENDERGAST GC, 1989, MOL CELL BIOL, V9, P124, DOI 10.1128/MCB.9.1.124; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SCHER CD, 1979, BIOCHIM BIOPHYS ACTA, V560, P217, DOI 10.1016/0304-419X(79)90020-9; SPECTOR DL, 1987, ONCOGENE, V1, P5; STECK TL, 1976, BIOCHEMISTRY-US, V15, P1154, DOI 10.1021/bi00650a030; TAYLOR MV, 1986, EMBO J, V5, P3563, DOI 10.1002/j.1460-2075.1986.tb04683.x; VIZE PD, 1990, DEVELOPMENT, V110, P885; VRIZ S, 1989, EMBO J, V8, P4091, DOI 10.1002/j.1460-2075.1989.tb08593.x; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x	38	7	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2363	2367						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437160				2022-12-28	WOS:A1992JW66500033
J	NAKAZAWA, H; AGUELON, AM; YAMASAKI, H				NAKAZAWA, H; AGUELON, AM; YAMASAKI, H			IDENTIFICATION AND QUANTIFICATION OF A CARCINOGEN-INDUCED MOLECULAR INITIATION EVENT IN CELL-TRANSFORMATION	ONCOGENE			English	Article							BALB/C 3T3 CELLS; JUNCTIONAL INTERCELLULAR COMMUNICATION; HARVEY-RAS ONCOGENE; HA-RAS; MOUSE SKIN; CHEMICAL CARCINOGENESIS; TUMOR PROMOTERS; P53 GENE; ACTIVATION; MUTATION	All transformed foci of Balb/c 3T3 clone A31-1-1 cells induced by 7,12-dimethylbenz[a]anthracene (DMBA) (42 out of 42 examined) contained an A to T transversion at codon 61 (A182 to T) of the Ki-ras gene. The transformants induced by other carcinogens tested did not contain such a mutation, except one out of nine 12-O-tetradecanoyl phorbol 13-acetate (TPA)-induced transformed foci. Thus, we hypothesized that this mutation is a specific DMBA-induced initiating event in Balb/c 3T3 cell transformation and we have measured its frequency of induction before transformation occurs, employing our recently developed method. Such mutations can be detected in the cell population as early as 3 days after exposure to DMBA. The same mutation was also detected in the Ha-ras gene. No detectable level (<10(-6)) of these mutations was induced by other carcinogens tested. The mutation frequency of the Ha-ras gene reached a plateau after 1 week's exposure, but that of the Ki-ras gene continued to increase. These results suggest that the A182 to T mutation of the Ki-ras gene, but not that of the Ha-ras gene, contributes to morphological transformation of Balb/c 3T3 cells. We have demonstrated that the level of expression of ras genes determines the rate of recruitment of cells into transformation. Quantitative analysis of the frequencies of ras gene mutations (initiation) and of transformation suggests that about 25% of those cells with the Ki-ras mutation were recruited into the full transformation process and that, in the presence of the tumor promoter TPA, about 56% of them completed morphological cell transformation.			NAKAZAWA, H (corresponding author), INT AGCY RES CANC,MULTISTAGE CARCINOGENESIS UNIT,150 COURS ALBERT THOMAS,F-69372 LYON,FRANCE.				NCI NIH HHS [R01 CA40534] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040534] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTINI RJ, 1991, IN PRESS ANN REV GEN; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARBU V, 1989, NUCLEIC ACIDS RES, V17, P7115, DOI 10.1093/nar/17.17.7115; Barrett J.C., 1985, MECHANISMS TOXICITY, P171; BIGNAMI M, 1988, MOL CARCINOGEN, V1, P67, DOI 10.1002/mc.2940010113; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BIZUB D, 1986, P NATL ACAD SCI USA, V83, P604; BORRELLO MG, 1987, CANCER RES, V47, P75; BRASH DE, 1991, P NATL ACAD SCI US, V88; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CHAKRABORTY AK, 1991, P NATL ACAD SCI USA, V88, P2217, DOI 10.1073/pnas.88.6.2217; CHANDLER LA, 1987, CELL, V50, P711, DOI 10.1016/0092-8674(87)90329-1; DANDEKAR S, 1986, MOL CELL BIOL, V6, P4104, DOI 10.1128/MCB.6.11.4104; ENOMOTO T, 1985, CANCER RES, V45, P2681; ENOMOTO T, 1984, CANCER RES, V44, P5200; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEINBERG AP, 1983, BIOCHEM BIOPH RES CO, V111, P47, DOI 10.1016/S0006-291X(83)80115-6; FITZGERALD DJ, 1989, MUTAGENESIS, V4, P286, DOI 10.1093/mutage/4.4.286; FUJIKI H, 1989, MOL CARCINOGEN, V2, P184, DOI 10.1002/mc.2940020403; GREENHALGH DA, 1989, MOL CARCINOGEN, V2, P199, DOI 10.1002/mc.2940020406; HARRIS CC, 1991, CANCER RES, V51, pS5023; Hayashi K, 1991, PCR Methods Appl, V1, P34; HILLOVA J, 1986, J NATL CANCER I, V77, P721, DOI 10.1093/jnci/77.3.721; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; KAKUNAGA T, 1973, INT J CANCER, V12, P463, DOI 10.1002/ijc.2910120217; KAKUNAGA T, 1980, SCIENCE, V209, P505, DOI 10.1126/science.7394516; KATOH F, 1991, CARCINOGENESIS, V12, P1923, DOI 10.1093/carcin/12.10.1923; KAWASAKI E, 1989, AMPLIFICATIONS PERKI, V4, P5; KOVARY K, 1989, ONCOGENE RES, V4, P55; KUMAR R, 1990, ONCOGENE, V5, P1271; KUROKI T, 1985, TRANSFORMATION ASSAY, P93; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; LERMAN LS, 1987, METHOD ENZYMOL, V155, P482; LERMAN LS, 1984, ANNU REV BIOPHYS BIO, V13, P339; LOKTIONOV A, 1990, MOL CARCINOGEN, V3, P134, DOI 10.1002/mc.2940030306; METTER J, 1989, NUCLEIC ACIDS RES, V17, P7089, DOI 10.1093/nar/17.17.7089; MURRAY AW, 1979, BIOCHEM BIOPH RES CO, V91, P395, DOI 10.1016/0006-291X(79)91535-3; NAKAZAWA H, 1990, MOL CARCINOGEN, V3, P202, DOI 10.1002/mc.2940030407; OHNO S, 1986, Cancer Reviews, V2, P65; PIERCEALL WE, 1991, ONCOGENE, V6, P2085; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; REDMOND SMS, 1988, ONCOGENE, V2, P259; REYNOLDS VL, 1987, ONCOGENE, V1, P323; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; ROSL F, 1988, EMBO J, V7, P1321, DOI 10.1002/j.1460-2075.1988.tb02947.x; Sambrook J., 1989, MOL CLONING; SUGIMURA T, 1986, SCIENCE, V233, P312, DOI 10.1126/science.3088728; THILLY WG, 1985, METHODS DETECTING DN, P511; TOFTGARD R, 1985, CARCINOGENESIS, V6, P655, DOI 10.1093/carcin/6.4.655; TOMATIS L, 1989, JPN J CANCER RES, V80, P795, DOI 10.1111/j.1349-7006.1989.tb01717.x; TOPAL MD, 1988, CARCINOGENESIS, V9, P691, DOI 10.1093/carcin/9.5.691; Trosko J E, 1982, Carcinog Compr Surv, V7, P565; VANDERLUBBE JLM, 1988, ONCOGENE RES, V3, P9; WEINSTEIN IB, 1991, SCIENCE, V251, P387, DOI 10.1126/science.1989073; YAMASAKI H, 1987, CANCER RES, V47, P5658; YAMASAKI H, 1988, CANCER RES, V48, P3490; YOTTI LP, 1979, SCIENCE, P2681; YUSPA SH, 1985, ROLE CHEM RAD ETIOLO, P201; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0; ZHANG R, 1991, CELL GROWTH DIFFER, V2, P1; 1985, CANCER RES, V45, P2395	63	26	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2295	2301						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437151				2022-12-28	WOS:A1992JW66500023
J	YU, DH; HAMADA, JI; ZHANG, H; NICOLSON, GL; HUNG, MC				YU, DH; HAMADA, JI; ZHANG, H; NICOLSON, GL; HUNG, MC			MECHANISMS OF C-ERBB2/NEU ONCOGENE-INDUCED METASTASIS AND REPRESSION OF METASTATIC PROPERTIES BY ADENOVIRUS 5 E1A GENE-PRODUCTS	ONCOGENE			English	Article							TYROSINE KINASE-ACTIVITY; RAT EMBRYO CELLS; TUMOR-CELLS; PROTO-ONCOGENE; C-ERBB-2 GENE; NEU ONCOGENE; CANCER METASTASIS; CARCINOMA-CELLS; OVARIAN-CANCER; INVITRO ASSAY	c-erbB2/neu is a transforming oncogene that encodes a 185-kDa transmembrane glycoprotein. In many but not all studies, amplification and/or overexpression of the human c-erbB2/neu oncogene has been correlated with poor prognosis and the number of lymph node metastases in node-positive breast cancer patients. We have shown that expression of the activated rat c-erbB2/neu oncogene in mouse embryo fibroblast 3T3 cells is sufficient to induce experimental metastases in nude mice. Important steps in the metastatic event are tumor cell adhesion to endothelial cells and invasion of basement membranes. Therefore, we further examined the ability of c-erbB2/neu oncogene-transformed 3T3 cells to adhere to microvessel endothelial cells and secrete basement membrane-degradative enzymes. The c-erbB2/neu oncogene-transformed 3T3 cells were shown to be more adherent and have higher gelatinase activities. Since we had previously shown that the adenovirus 5 E1A gene product can suppress c-erbB2/neu-induced transformation of 3T3 cells, we examined the possibility that E1A can abrogate the metastatic properties of c-erbB2/neu-transformed 3T3 cells. We found that introduction of the EIA gene into c-erbB2/neu-transformed 3T3 cells reduced the formation of experimental metastatic tumors and inhibited metastasis-associated properties, such as adhesion to microvessel endothelial cells, migration through a layer of reconstituted basement membrane (Matrigel) and secretion of basement membrane-degradative enzymes. The results indicate that the mechanism by which the c-erbB2/neu gene induces higher metastatic potential is to promote adhesion and invasion steps of the metastatic cascade. The EIA gene, which functions by inhibiting these steps, is thus a suppressor gene for c-erbB2/neu-induced experimental metastasis.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,BOX 79,1515 HOLCOMBE BLVD,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Yu, Dihua/0000-0001-6231-9381	NCI NIH HHS [R35-CA 44352, R03-CA54989, R01-CA41524] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R03CA054989, R35CA044352, R01CA041524] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBINI A, 1987, CANCER RES, V47, P3239; AUERBACH R, 1987, CANCER RES, V47, P1492; BALLIN M, 1988, BIOCHEM BIOPH RES CO, V154, P832, DOI 10.1016/0006-291X(88)90215-X; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BERCHUCK A, 1990, CANCER RES, V50, P4087; DEMILIA J, 1989, ONCOGENE, V4, P1233; EGAN SE, 1987, SCIENCE, V238, P202, DOI 10.1126/science.3659911; FRISCH SM, 1990, ONCOGENE, V5, P75; GARBISA S, 1987, CANCER RES, V47, P1523; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HAMADA JI, 1992, IN PRESS BR J CANCER; HUNG MC, 1992, CANCER LETT, V61, P95, DOI 10.1016/0304-3835(92)90166-S; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; INOKUCHI J, 1990, CANCER RES, V50, P6731; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LICHTNER RB, 1989, EXP CELL BIOL, V57, P146; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIOTTA LA, 1986, CANCER RES, V46, P1; LIOTTA LA, 1989, MECHANISMS CANCER IN; MENSING H, 1983, EUR J CELL BIOL, V29, P268; MUSCHEL RJ, 1985, AM J PATHOL, V121, P1; NAKAJIMA M, 1989, CANCER RES, V49, P1698; Nicolson GL, 1989, CURR OPIN CELL BIOL, V1, P1009, DOI 10.1016/0955-0674(89)90073-2; NICOLSON G L, 1991, Current Opinion in Oncology, V3, P75, DOI 10.1097/00001622-199102000-00012; NICOLSON GL, 1989, INVAS METAST, V9, P102; NICOLSON GL, 1988, BIOCHIM BIOPHYS ACTA, V948, P175, DOI 10.1016/0304-419X(88)90010-8; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PARK JB, 1989, CANCER RES, V49, P6605; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; POZZATTI R, 1988, MOL CELL BIOL, V8, P2984, DOI 10.1128/MCB.8.7.2984; REPESH LA, 1989, INVAS METAST, V9, P192; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090; SCHNEIDER PM, 1989, CANCER RES, V49, P4968; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P77; STEEG PS, 1988, CANCER RES, V48, P6550; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; THORGEIRSSON UP, 1985, MOL CELL BIOL, V5, P259, DOI 10.1128/MCB.5.1.259; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; WALLICH R, 1985, NATURE, V315, P301, DOI 10.1038/315301a0; WEINER DB, 1990, CANCER RES, V50, P421; WEXLER DH, 1986, J NATL CANCER I, V36, P641; YAN DH, 1991, ONCOGENE, V6, P343; YOKOTA J, 1988, ONCOGENE, V2, P283; YU DH, 1991, MOL CELL BIOL, V11, P1745, DOI 10.1128/MCB.11.3.1745; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; YU DH, 1991, ONCOGENE, V6, P1991; YUSA K, 1990, J NATL CANCER I, V82, P1633, DOI 10.1093/jnci/82.20.1633; ZHANG X, 1989, ONCOGENE, V4, P985	55	105	107	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2263	2270						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1359495				2022-12-28	WOS:A1992JW66500019
J	BLACKMORE, PF; OAKES, SG; SOMERS, KD				BLACKMORE, PF; OAKES, SG; SOMERS, KD			ALTERED H1 HISTAMINE-RECEPTOR SIGNALING IN BALB/3T3 CELLS TRANSFORMED BY V-K-RAS AND V-H-RAS ONCOGENES	ONCOGENE			English	Article							SMOOTH-MUSCLE CELLS; GROWTH-FACTOR; TUMOR; PROTEIN; ACTIVATE; H-1	Transformation of Balb/3T3 cells with the v-K-ras oncogene resulted in the expression of functional Ca2+-mobilizing receptors for histamine, whereas v-H-ras-transformed Balb/3T3 cells failed to show a similar response to histamine. Stimulation of histamine receptors in v-K-ras-transformed cells produced a dose-dependent increase in intracellular free calcium ([Ca2+]i), which was inhibited by the H-1 histamine antagonist pyrilamine but unaffected by the H-1 histamine receptor antagonist cimetidine. Histamine-mediated elevation of [Ca2+]i was partially inhibited by the removal of extracellular Ca2+, which indicates that the H-1 histamine receptors mobilize intracellular Ca2+ and also promote Ca2+ influx. H-1 histamine receptors were identified in both v-K-ras- and v-H-ras-transformed Balb/3T3 cells, but not in untransformed cells, using the specific H-1 antagonist [H-3]-pyrilamine. Transformation of Balb/3T3 cells with the viral ras oncogene results in a complex regulation of H-1 histamine receptors. K-ras and H-ras transformation results in the expression of H-1 histamine receptors; however, H-1 receptor expression and Ca2+ mobilization are uncoupled in v-H-ras-transformed cells.	EASTERN VIRGINIA MED SCH,DEPT MICROBIOL & IMMUNOL,NORFOLK,VA 23501	Eastern Virginia Medical School	BLACKMORE, PF (corresponding author), EASTERN VIRGINIA MED SCH,DEPT PHARMACOL,POB 1980,NORFOLK,VA 23501, USA.							BATHOLEYNS J, 1984, CANCER RES, V44, P639; BATHOLEYNS J, 1985, TRENDS PHARMACOL SCI, V6, P123; BURTIN C, 1982, BRIT J CANCER, V45, P54, DOI 10.1038/bjc.1982.7; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; DOWNWARD J, 1988, P NATL ACAD SCI USA, V85, P5774, DOI 10.1073/pnas.85.16.5774; FISCHER SM, 1990, CARCINOGENESIS, V11, P991, DOI 10.1093/carcin/11.6.991; GALLOPIN L, 1984, AGENTS ACTIONS, V14, P494; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HILL SJ, 1990, PHARMACOL REV, V42, P45; MARSHALL CJ, 1988, J CELL SCI S, V10, P157; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MITSUHASHI M, 1989, MOL PHARMACOL, V35, P751; MITSUHASHI M, 1989, J CELL BIOCHEM, V40, P183, DOI 10.1002/jcb.240400207; MITSUHASHI M, 1988, J CELL PHYSIOL, V134, P367, DOI 10.1002/jcp.1041340307; MITSUHASHI M, 1989, MOL PHARMACOL, V35, P311; SOMERS KD, 1980, CELL BIOL INT REP, V4, P487, DOI 10.1016/0309-1651(80)90036-3; SOMERS KD, 1980, CANCER RES, V40, P4410; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; TILLY BC, 1990, J CELL BIOL, V110, P1211, DOI 10.1083/jcb.110.4.1211; WAKELAM MJO, 1986, NATURE, V323, P173, DOI 10.1038/323173a0; WASYLYK C, 1987, CELL, V48, P525, DOI 10.1016/0092-8674(87)90203-0; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x	26	7	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					2053	2057						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408146				2022-12-28	WOS:A1992JP42400020
J	LARSEN, J; BEUG, H; HAYMAN, MJ				LARSEN, J; BEUG, H; HAYMAN, MJ			THE V-SKI ONCOGENE COOPERATES WITH THE V-SEA ONCOGENE IN ERYTHROID TRANSFORMATION BY BLOCKING ERYTHROID-DIFFERENTIATION	ONCOGENE			English	Article							AVIAN ERYTHROBLASTOSIS VIRUS; MYELOID CELLS; HISTONE H-5; EXPRESSION; TRANSCRIPTION; GROWTH; LEUKEMIA; PROTEIN; MUSCLE; GENES	The avian retrovirus oncogene v-ski was analysed for its ability to alter the differentiation program of erythroid cells and to cooperate with tyrosine kinase oncogenes in leukemogenesis. For this, a retrovirus combining v-ski with a temperature-sensitive version of the v-sea oncogene was constructed. In transformed erythroblasts, v-ski disturbed the concerted expression of several erythrocyte genes, leading to an abnormal erythroblast phenotype. Expression levels of hemoglobin and erythrocyte anion transporter (band 3) were elevated, while expression of the erythroid-specific histone H5 was strongly suppressed. v-ski could also be shown to repress or severely retard the temperature-induced erythroid differentiation of v-ski/ts-v-sea-transformed cells. The undifferentiated celts had an abnormal erythroblast or early reticulocyte phenotype characterized by unusually low levels of histone H5. In chicks, the v-ski/ts-v-sea virus displayed enhanced leukemogenicity compared with viruses containing just the single oncogenes. Thus, v-ski cooperates with tyrosine kinase oncogenes in a similar fashion to the v-erbA oncogene, however the pattern of genes affected by these two oncogenes is different.	SUNY STONY BROOK,DEPT MICROBIOL,STONY BROOK,NY 11794; INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)					NCI NIH HHS [CA28146, CA42573] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042573, P01CA028146] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADKINS B, 1984, CELL, V39, P439, DOI 10.1016/0092-8674(84)90451-3; BERGMAN MG, 1988, J CELL SCI, V91, P201; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BEUG H, 1989, EUR J CLIN INVEST, V19, P491, DOI 10.1111/j.1365-2362.1989.tb00265.x; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BEUG H, 1984, CELL, V36, P963, DOI 10.1016/0092-8674(84)90046-1; BEUG H, 1991, NUCLEAR HORMONE RECE, P355; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; COLMENARES C, 1991, MOL CELL BIOL, V11, P1167, DOI 10.1128/MCB.11.2.1167; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FUERSTENBERG S, 1990, J VIROL, V64, P5891, DOI 10.1128/JVI.64.12.5891-5902.1990; GRAF T, 1978, NATURE, V275, P496, DOI 10.1038/275496a0; HAYMAN MJ, 1991, CANCER CELL-MON REV, V3, P302; HAYMAN MJ, 1992, IN PRESS CANCER SURV; JANSSON M, 1987, ONCOGENE, V1, P167; KAHN P, 1986, 12 S COMP RES LEUK R, P41; KAMPS MP, 1988, ONCOGENE, V2, P305; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KNIGHT J, 1988, GENE DEV, V2, P247, DOI 10.1101/gad.2.2.247; KORNFELD S, 1983, EXP CELL RES, V143, P383, DOI 10.1016/0014-4827(83)90065-4; KOWENZ E, 1987, MODERN TRENDS HUMAN, V7, P199; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; METZ T, 1992, ONCOGENE, V7, P597; NAGASE T, 1990, NUCLEIC ACIDS RES, V18, P337, DOI 10.1093/nar/18.2.337; NESS SA, 1987, CELL, V51, P41, DOI 10.1016/0092-8674(87)90008-0; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLSON EN, 1991, MOL CELL BIOCHEM, V104, P7; PAIN B, 1990, New Biologist, V2, P284; SCHMIDT JA, 1986, CELL, V46, P41, DOI 10.1016/0092-8674(86)90858-5; SCHROEDER C, 1990, ONCOGENE, V5, P1445; STAVNEZER E, 1986, J VIROL, V57, P1073, DOI 10.1128/JVI.57.3.1073-1083.1986; STAVNEZER E, 1981, J VIROL, V39, P920, DOI 10.1128/JVI.39.3.920-934.1981; Stavnezer E., 1988, ONCOGENE HDB, P393; STRIFE A, 1988, CANCER RES, V48, P1035; SUN JM, 1989, SCIENCE, V245, P68, DOI 10.1126/science.2740916; SUTRAVE P, 1991, ONCOGENE, V6, P353; SUTRAVE P, 1990, GENE DEV, V4, P1462, DOI 10.1101/gad.4.9.1462; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P	42	29	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					1903	1911						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408132				2022-12-28	WOS:A1992JP42400002
J	GRIFFITHS, SD; HEALY, LE; FORD, AM; BENNETT, CA; VONCKEN, JW; HEISTERKAMP, N; GROFFEN, J; GREAVES, MF				GRIFFITHS, SD; HEALY, LE; FORD, AM; BENNETT, CA; VONCKEN, JW; HEISTERKAMP, N; GROFFEN, J; GREAVES, MF			CLONAL CHARACTERISTICS OF ACUTE LYMPHOBLASTIC CELLS DERIVED FROM BCR ABL-P190 TRANSGENIC MICE	ONCOGENE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; PHILADELPHIA-CHROMOSOME; ABL ONCOGENE; BONE-MARROW; GENE; REARRANGEMENT; STIMULATION; EXPRESSION; INVITRO; TRANSLOCATION	The clonal and immunophenotypic characteristics of blood leukemic cells from BCR/ABL p190 transgenic mice were investigated. All cell populations evaluated in vivo and in vitro had B-lymphocyte progenitor immunophenotypes. Immunoglobulin (J(H)) rearrangement patterns provided evidence for clonal diversification at different sites in vivo. Multiple clones were established in vitro from two of these mice (nos. 730 and 753). These cells expressed BCR/ABL p190 protein tyrosine kinase (PTK) and were highly malignant on transfer to secondary recipients. Cells independently cloned in vitro shared identical immunophenotypes and clonal IgH rearrangements, but these were distinct from those of the dominant clones in the mouse from which they were derived. Nevertheless, in vitro clones from mouse no. 753 had an abnormal karyotype (chromosome 14 trisomy) in common with the dominant clone in blood, providing evidence for a hierarchy or clonal selection in vivo and in vitro. Two sets of in vitro clones proliferated independently of exogenous growth factors and stroma and released autocrine interleukin 7 growth factor activity. These data provide evidence for rapid divergent clonal evolution and selection of B-cell progenitors initiated by BCR/ABL p190, followed by other, secondary genetic events mirroring similar changes in the equivalent, highly malignant human leukemia Philadelphia (Ph)-positive/B-precursor acute lymphoblastic leukemia (ALL).	CHILDRENS HOSP LOS ANGELES,DEPT PATHOL,MOLEC DIAGNOSIS SECT,LOS ANGELES,CA 90054	Children's Hospital Los Angeles	GRIFFITHS, SD (corresponding author), INST CANC RES,CTR LEUKAEMIA RES FUND,CHESTER BEATTY LABS,237 FULHAM RD,LONDON SW3 6JB,ENGLAND.		Heisterkamp, Nora/C-1698-2012	Heisterkamp, Nora/0000-0003-2769-2273; Healy, Lyn/0000-0002-7044-8789	NATIONAL CANCER INSTITUTE [R01CA050248, R01CA047073] Funding Source: NIH RePORTER; NCI NIH HHS [CA47073, CA50248] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALT FW, 1984, EMBO J, V3, P1209, DOI 10.1002/j.1460-2075.1984.tb01955.x; BEISHUIZEN A, 1992, LEUKEMIA, V6, P60; BIRD J, 1988, J EXP MED, V168, P229, DOI 10.1084/jem.168.1.229; BLOOMFIELD CD, 1989, CANCER GENET CYTOGEN, V40, P171, DOI 10.1016/0165-4608(89)90023-X; BRENNER CA, 1989, BIOTECHNIQUES, V7, P1096; BROWDER TM, 1989, MOL CELL BIOL, V9, P204, DOI 10.1128/MCB.9.1.204; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARK SS, 1987, SCIENCE, V235, P85, DOI 10.1126/science.3541203; COFFMAN RL, 1981, NATURE, V289, P681, DOI 10.1038/289681a0; COLLINS LS, 1987, J IMMUNOL, V138, P1082; COOPER MD, 1986, NATURE, V321, P616, DOI 10.1038/321616a0; COWLING GJ, 1985, MODERN TRENDS HUMAN, V6, P385; DEKLEIN A, 1986, BLOOD, V68, P1369; DHUT S, 1991, LEUKEMIA, V5, P49; DOW LW, 1989, BLOOD, V73, P1291; FORD AM, 1983, EMBO J, V2, P997, DOI 10.1002/j.1460-2075.1983.tb01533.x; GIMBLE JM, 1989, BLOOD, V74, P303; GREAVES MF, 1986, CLIN HAEMATOL, V15, P621; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; HIRSCHGINSBERG C, 1988, BLOOD, V71, P186; Ishihara K, 1991, Dev Immunol, V1, P149, DOI 10.1155/1991/79721; KALOUSEK DK, 1988, BRIT J HAEMATOL, V70, P5, DOI 10.1111/j.1365-2141.1988.tb02426.x; Kincade P W, 1990, Adv Cancer Res, V54, P235, DOI 10.1016/S0065-230X(08)60813-1; KITANO K, 1988, BRIT J HAEMATOL, V70, P21, DOI 10.1111/j.1365-2141.1988.tb02428.x; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LEE G, 1989, J IMMUNOL, V142, P3875; MCLAUGHLIN J, 1989, MOL CELL BIOL, V9, P1866, DOI 10.1128/MCB.9.5.1866; MCNAGNY KM, 1988, J IMMUNOL, V141, P2551; MINOWADA J, 1980, S NEW TRENDS HUMAN I, P188; NAEME PB, 1985, BLOOD, V65, P142; NAMEN AE, 1988, NATURE, V333, P571, DOI 10.1038/333571a0; OCONNOR R, 1991, BLOOD, V77, P1534; OVERELL RW, 1991, MOL CELL BIOL, V11, P1590, DOI 10.1128/MCB.11.3.1590; PALACIOS R, 1987, EMBO J, V6, P3687, DOI 10.1002/j.1460-2075.1987.tb02702.x; PALUMBO GJ, 1990, CANCER RES, V90, P1917; RIBEIRO RC, 1987, BLOOD, V70, P948; RIEDER H, 1991, CANCER GENET CYTOGEN, V53, P139; RUSSO C, 1991, BLOOD, V77, P1050; Sambrook J, 1989, MOL CLONING LABORATO; SCHERLE PA, 1990, P NATL ACAD SCI USA, V87, P1908, DOI 10.1073/pnas.87.5.1908; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; SPOONCER E, 1984, NATURE, V310, P228, DOI 10.1038/310228a0; SPRINGER T, 1978, EUR J IMMUNOL, V8, P539, DOI 10.1002/eji.1830080802; TURHAN AG, 1988, BLOOD, V71, P1495; VONCKEN JW, 1992, BLOOD, V79, P1029; YOUNG JC, 1991, MOL CELL BIOL, V11, P854, DOI 10.1128/MCB.11.2.854	54	27	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1391	1399						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1377812				2022-12-28	WOS:A1992HZ97100018
J	LILLY, M; LE, T; HOLLAND, P; HENDRICKSON, SL				LILLY, M; LE, T; HOLLAND, P; HENDRICKSON, SL			SUSTAINED EXPRESSION OF THE PIM-1 KINASE IS SPECIFICALLY INDUCED IN MYELOID CELLS BY CYTOKINES WHOSE RECEPTORS ARE STRUCTURALLY RELATED	ONCOGENE			English	Article							COLONY-STIMULATING FACTOR; TYROSINE PHOSPHORYLATION; GM-CSF; PROTEIN-KINASES; LEUKEMIA-CELLS; GROWTH-FACTORS; INTERLEUKIN-3; CLONING; LINES; ACTIVATION	We have examined the effects of myeloid growth factors on expression of the pim-1 kinase protein in human and murine myeloid cells. pim-1 protein was identified in K562 cells by immunoblotting as a 33 kDa protein. In the human factor-dependent myeloid leukemia cell line M07E, pim-1 protein was induced by interleukin 3 (IL-3) or granulocyte-macrophage colony-stimulating factor (GM-CSF), with maximum expression by 4 h. Expression continued for the duration of growth factor exposure, but declined rapidly when cytokines were removed. GM-CSF induced pim-1 protein in a dose-dependent manner, with expression being proportional to the proliferative effect of the cytokine. To examine the specificity of pim-1 protein induction, we compared pim-1 protein levels in myeloid cells which demonstrated different GM-CSF response phenotypes. We also examined the effects on pim-1 protein expression of different growth factors which induced similar response phenotypes. GM-CSF induced pim-1 protein in several myeloid cell lines, most of which demonstrated a proliferative response, but did not induce pim-1 protein expression in neutrophils or monocytic cells. In contrast, the murine cell line Mac-11 expressed pim-1 message in response to IL-3 and GM-CSF, but not in response to bryostatin or M-CSF, which were equivalent mitogens. In human U937 myeloid cells sustained expression of pim-1 protein was induced by GM-CSF, G-CSF and IL-6, but not by bryostatin. Expression of the pim-1 kinase protein in response to myeloid cytokines depends on both the nature of the growth factor and the response phenotype. The pim-1 kinase may be an important intermediate in transmembrane signaling or response phenotype induced by IL-3, GM-CSF and other cytokines whose receptors are structurally similar. Its constitutive expression in some myeloid leukemia cell lines suggests activation of signal cascades utilized by myeloid growth factors.	UNIV WASHINGTON, DEPT MED, DIV MED ONCOL, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle	LILLY, M (corresponding author), VET ADM MED CTR, 1660 COLUMBIAN WAY S, SEATTLE, WA 98108 USA.							AMSON R, 1989, P NATL ACAD SCI USA, V86, P8857, DOI 10.1073/pnas.86.22.8857; AVANZI GC, 1988, BRIT J HAEMATOL, V69, P359, DOI 10.1111/j.1365-2141.1988.tb02374.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; CROSIER KE, 1991, P NATL ACAD SCI USA, V88, P7744, DOI 10.1073/pnas.88.17.7744; DANREA A, 1989, CELL, V57, P277; DAUTRY F, 1988, J BIOL CHEM, V263, P17615; DREYFUS F, 1990, LEUKEMIA, V4, P590; EVERSON MP, 1989, BLOOD, V74, P1472; FIELDS AP, 1989, J BIOL CHEM, V264, P21896; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GLINIAK BC, 1990, CELL, V63, P1073, DOI 10.1016/0092-8674(90)90510-L; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; ISFORT R, 1988, J BIOL CHEM, V263, P19203; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KAZLAUSKAS A, 1988, J CELL BIOL, V106, P1395, DOI 10.1083/jcb.106.4.1395; KRAFT AS, 1990, ONCOGENE, V5, P1243; LILLY M, 1989, BLOOD, V74, pA245; LINDEMANN A, 1989, J CLIN INVEST, V83, P1308, DOI 10.1172/JCI114016; MAEKAWA T, 1989, LEUKEMIA, V3, P270; MAEKAWA T, 1990, INT J CANCER, V45, P353, DOI 10.1002/ijc.2910450224; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MEEKER TC, 1987, ONCOGENE RES, V1, P87; MEEKER TC, 1987, J CELL BIOCHEM, V35, P105, DOI 10.1002/jcb.240350204; METCALF D, 1985, SCIENCE, V229, P16, DOI 10.1126/science.2990035; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; RHYNER K, 1986, BRIT J HAEMATOL, V64, P601, DOI 10.1111/j.1365-2141.1986.tb02216.x; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SELTEN G, 1986, CELL, V46, P603, DOI 10.1016/0092-8674(86)90886-X; SORENSEN PHB, 1989, BLOOD, V73, P406; TELERMAN A, 1988, MOL CELL BIOL, V8, P1498, DOI 10.1128/MCB.8.4.1498; TUCKER KA, 1987, BLOOD, V70, P372; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; WHETTON AD, 1988, P NATL ACAD SCI USA, V85, P3284, DOI 10.1073/pnas.85.10.3284; WING EJ, 1989, BLOOD, V73, P643; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0	44	113	115	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1992	7	4					727	732						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1314369				2022-12-28	WOS:A1992HQ68200015
J	FILMUS, J; ZHAO, J; BUICK, RN				FILMUS, J; ZHAO, J; BUICK, RN			OVEREXPRESSION OF H-RAS ONCOGENE INDUCES RESISTANCE TO THE GROWTH-INHIBITORY ACTION OF TRANSFORMING GROWTH-FACTOR BETA-1 (TGF-BETA-1) AND ALTERS THE NUMBER AND TYPE OF TGF-BETA-1 RECEPTORS IN RAT INTESTINAL EPITHELIAL-CELL CLONES	ONCOGENE			English	Article							TGF-BETA; EXPRESSION; LINES; FACTOR-BETA-1; BINDING; CANCER	In this report, we utilize rat intestinal cell (IEC-18) clones expressing an activated human H-ras gene to investigate the relationship between malignant transformation and growth control by transforming growth factor beta (TGF-beta). We demonstrate that clones expressing high levels of H-ras oncogene lose sensitivity to the growth inhibitory action of TGF-beta. The loss of sensitivity is related to the degree of H-ras expression and is shown to be a direct consequence of H-ras expression through the use of a clonal cell line with inducible expression of activated H-ras. Co-incident with the loss of growth inhibition, ras-expressing clones display an altered expression of TGF-beta-binding proteins as detectable by [I-125]TGF-beta cross-linking. While IEC-18 cells express type II (92 kDa) binding protein predominantly, H-ras expression induces a shift to predominantly type I (69 kDa) binding protein expression.	ONTARIO CANC INST, TORONTO M4X 1K9, ONTARIO, CANADA; UNIV TORONTO, DEPT MED BIOPHYS, TORONTO M5S 1A1, ONTARIO, CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto								ANZANO MA, 1985, MOL CELL BIOL, V5, P242, DOI 10.1128/MCB.5.1.242; BALIGA BS, 1985, BIOCHEM BIOPH RES CO, V154, P278; BARNARD JA, 1989, P NATL ACAD SCI USA, V86, P1578, DOI 10.1073/pnas.86.5.1578; BUICK RN, 1987, EXP CELL RES, V170, P300, DOI 10.1016/0014-4827(87)90308-9; CHEIFETZ S, 1987, CELL, V48, P409, DOI 10.1016/0092-8674(87)90192-9; GOUSTIN AS, 1986, CANCER RES, V46, P1015; HOOSEIN NM, 1989, EXP CELL RES, V181, P442, DOI 10.1016/0014-4827(89)90101-8; HOUCK KA, 1989, ONCOGENE, V4, P19; HUGGETT AC, 1990, CANCER RES, V50, P7468; JAGGI R, 1986, EMBO J, V5, P2609, DOI 10.1002/j.1460-2075.1986.tb04541.x; LAIHO M, 1990, J BIOL CHEM, V265, P18518; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MASSAGUE J, 1985, J BIOL CHEM, V260, P2636; MURTHY U, 1989, INT J CANCER, V44, P110, DOI 10.1002/ijc.2910440120; QUARONI A, 1981, J NATL CANCER I, V67, P1353; RIZZINO A, 1988, DEV BIOL, V130, P411, DOI 10.1016/0012-1606(88)90337-5; SEGARINI PR, 1989, MOL ENDOCRINOL, V3, P261, DOI 10.1210/mend-3-2-261; SILBERSTEIN GB, 1987, SCIENCE, V237, P284; SPORN MB, 1986, SCIENCE, V233, P532, DOI 10.1126/science.3487831; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; WAKEFIELD LM, 1987, J CELL BIOL, V105, P965, DOI 10.1083/jcb.105.2.965	21	93	93	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1992	7	3					521	526						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1312703				2022-12-28	WOS:A1992HK00500018
J	Borland, H; Rasmussen, I; Bjerregaard-Andersen, K; Rasmussen, M; Olsen, A; Vilhardt, F				Borland, Helena; Rasmussen, Izabela; Bjerregaard-Andersen, Kaare; Rasmussen, Michel; Olsen, Anders; Vilhardt, Frederik			alpha-synuclein buildup is alleviated via ESCRT-dependent endosomal degradation brought about by p38MAPK inhibition in cells expressing p25 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEWY BODY; AUTOPHAGOSOME MATURATION; LYSOSOMAL DEGRADATION; P38-ALPHA MAPK; PROTEIN; PHOSPHORYLATION; TOXICITY; SER-129; PATHWAY; DISEASE	alpha-synucleinopathy is driven by an imbalance of synthesis and degradation of alpha-synuclein (alpha Syn), causing a build up of alpha Syn aggregates and post-translationally modified species, which not only interfere with normal cellular metabolism but also by their secretion propagates the disease. Therefore, a better under-standing of alpha Syn degradation pathways is needed to address alpha-synucleinopathy. Here, we used the nerve growth factor- differentiated catecholaminergic PC12 neuronal cell line, which was conferred alpha-synucleinopathy by inducible expres-sion of alpha Syn and tubulin polymerization-promoting protein p25 alpha. p25 alpha aggregates alpha Syn, and imposes a partial autophagosome-lysosome block to mimic aspects of lysosomal deficiency common in neurodegenerative disease. Under basal conditions, alpha Syn was degraded by multiple pathways but most prominently by macroautophagy and Nedd4/Ndfip1-mediated degradation. We found that expression of p25 alpha induced strong p38MAPK activity. Remarkably, when opposed by in-hibitor SB203580 or p38MAPK shRNA knockdown, endoly-sosomal localization and degradation of alpha Syn increased, and alpha Syn secretion and cytotoxicity decreased. This effect was specifically dependent on Hsc70 and the endosomal sorting complex required for transport machinery, but different from classical microautophagy, as the alpha Syn Hsc70 binding motif was unnecessary. Furthermore, in a primary neuronal (h)-alpha Syn seeding model, p38MAPK inhibition decreased pathological accumulation of phosphorylated serine-129-alpha Syn and cyto-toxicity. In conclusion, p38MAPK inhibition shifts alpha Syn degradation from various forms of autophagy to an endosomal sorting complex required for transport-dependent uptake mechanism, resulting in increased alpha Syn turnover and cell viability in p25 alpha-expressing cells. More generally, our results suggest that under conditions of autophagolysosomal mal-function, the uninterrupted endosomal pathway offers a pos-sibility to achieve disease-associated protein degradation.	[Borland, Helena; Rasmussen, Izabela; Rasmussen, Michel; Vilhardt, Frederik] Univ Copenhagen, Panum Inst, Fac Hlth Sci, Dept Cellular & Mol Med, Copenhagen, Denmark; [Borland, Helena; Bjerregaard-Andersen, Kaare] H Lundbeck A S, Dept Cell Biol, Valby, Denmark; [Olsen, Anders] Aalborg Univ, Fac Engn & Sci, Dept Chem & Biosci, Aalborg, Denmark	University of Copenhagen; Lundbeck Corporation; Aalborg University	Vilhardt, F (corresponding author), Univ Copenhagen, Panum Inst, Fac Hlth Sci, Dept Cellular & Mol Med, Copenhagen, Denmark.	vilhardt@sund.ku.dk			Lundbeck Foundation [R118-A11718]; Danish Parkinson Foundation [R4 -A211]; Niels Ydes Foundation [1195011]; Beckett Foundation; Aage og Johanne Louis-Hansens Foundation; Innovation Fund Denmark [5189-00051B]; Lundbeck A/S; Laege Sofus Carl Emil Friis Foundation	Lundbeck Foundation(Lundbeckfonden); Danish Parkinson Foundation; Niels Ydes Foundation; Beckett Foundation; Aage og Johanne Louis-Hansens Foundation; Innovation Fund Denmark; Lundbeck A/S(Lundbeck Corporation); Laege Sofus Carl Emil Friis Foundation	Funding and additional information - This study was funded by grants to F. V. from the Lundbeck Foundation (grant no.: R118-A11718) , the Danish Parkinson Foundation (grant no.: R4 -A211) , the Niels Ydes Foundation (grant no.: 1195011) , The Beckett Foundation, The Aage og Johanne Louis-Hansens Foundation, and The Laege Sofus Carl Emil Friis Foundation. A grant from Innovation Fund Denmark (grant no.: 5189-00051B) was ob- tained in partnership with Lundbeck A/S.	Alam J, 2016, AUTOPHAGY, V12, P2516, DOI 10.1080/15548627.2016.1238555; Alvarez-Erviti L, 2011, NEUROBIOL DIS, V42, P360, DOI 10.1016/j.nbd.2011.01.029; Anderson JP, 2006, J BIOL CHEM, V281, P29739, DOI 10.1074/jbc.M600933200; Borland H, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010227; Canovas B, 2021, NAT REV MOL CELL BIO, V22, P346, DOI 10.1038/s41580-020-00322-w; Cavalli V, 2001, MOL CELL, V7, P421, DOI 10.1016/S1097-2765(01)00189-7; Christensen DP, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0519-5; Chung CY, 2013, SCIENCE, V342, P983, DOI 10.1126/science.1245296; Colacurcio DJ, 2016, AGEING RES REV, V32, P75, DOI 10.1016/j.arr.2016.05.004; Cuervo AM, 2004, SCIENCE, V305, P1292, DOI 10.1126/science.1101738; Danzer KM, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-42; Davies SE, 2014, NEUROBIOL DIS, V64, P79, DOI 10.1016/j.nbd.2013.12.011; DeBonis S, 2015, SCI REP-UK, V5, DOI 10.1038/srep13242; Ejlerskov P, 2013, J BIOL CHEM, V288, P17313, DOI 10.1074/jbc.M112.401174; Eyers PA, 1998, CHEM BIOL, V5, P321, DOI 10.1016/S1074-5521(98)90170-3; Fuchs J, 2007, NEUROLOGY, V68, P916, DOI 10.1212/01.wnl.0000254458.17630.c5; Fujiwara H, 2002, NAT CELL BIOL, V4, P160, DOI 10.1038/ncb748; Galluzzi L, 2017, EMBO J, V36, P1811, DOI 10.15252/embj.201796697; Ganley IG, 2013, ESSAYS BIOCHEM, V55, P65, DOI [10.1042/bse0550065, 10.1042/BSE0550065]; Ganley IG, 2011, MOL CELL, V42, P731, DOI 10.1016/j.molcel.2011.04.024; Ghanem SS, 2022, P NATL ACAD SCI USA, V119, DOI 10.1073/pnas.2109617119; Hori I, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02840-8; Jucker M, 2013, NATURE, V501, P45, DOI 10.1038/nature12481; Kaushik S, 2018, NAT REV MOL CELL BIO, V19, P365, DOI 10.1038/s41580-018-0001-6; Keil E, 2013, CELL DEATH DIFFER, V20, P321, DOI 10.1038/cdd.2012.129; Kragh CL, 2009, J BIOL CHEM, V284, P10211, DOI 10.1074/jbc.M809671200; Lebrand C, 2002, EMBO J, V21, P1289, DOI 10.1093/emboj/21.6.1289; Lee HJ, 2014, NAT REV NEUROL, V10, P92, DOI 10.1038/nrneurol.2013.275; Lee JA, 2007, CURR BIOL, V17, P1561, DOI 10.1016/j.cub.2007.07.029; Lee JY, 2010, EMBO J, V29, P969, DOI 10.1038/emboj.2009.405; Li WM, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01609-x; Lindersson E, 2005, J BIOL CHEM, V280, P5703, DOI 10.1074/jbc.M410409200; Luk KC, 2012, SCIENCE, V338, P949, DOI 10.1126/science.1227157; Luk KC, 2012, J EXP MED, V209, P975, DOI 10.1084/jem.20112457; Man WK, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21027-4; Mbefo MK, 2010, J BIOL CHEM, V285, P2807, DOI 10.1074/jbc.M109.081950; McGlinchey RP, 2015, P NATL ACAD SCI USA, V112, P9322, DOI 10.1073/pnas.1500937112; Menon MB, 2015, AUTOPHAGY, V11, P1425, DOI 10.1080/15548627.2015.1059562; Nixon RA, 2013, NAT MED, V19, P983, DOI 10.1038/nm.3232; Oku M, 2018, BIOESSAYS, V40, DOI 10.1002/bies.201800008; Paleologou KE, 2008, J BIOL CHEM, V283, P16895, DOI 10.1074/jbc.M800747200; Pemberton S, 2011, J BIOL CHEM, V286, P34690, DOI 10.1074/jbc.M111.261321; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Putz U, 2008, J BIOL CHEM, V283, P32621, DOI 10.1074/jbc.M804120200; Redeker V, 2012, J BIOL CHEM, V287, P32630, DOI 10.1074/jbc.M112.387530; Rideout HJ, 2001, J NEUROCHEM, V78, P899, DOI 10.1046/j.1471-4159.2001.00474.x; Sahu R, 2011, DEV CELL, V20, P131, DOI 10.1016/j.devcel.2010.12.003; Schnoder L, 2016, J BIOL CHEM, V291, P2067, DOI 10.1074/jbc.M115.695916; Schnoder ML, 2020, FASEB J, V34, P9628, DOI 10.1096/fj.201902731RR; Sevlever D, 2008, BIOCHEMISTRY-US, V47, P9678, DOI 10.1021/bi800699v; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Svanbergsson A, 2021, NEUROTHERAPEUTICS, V18, P1692, DOI 10.1007/s13311-021-01070-1; Tardiff DF, 2013, SCIENCE, V342, P979, DOI 10.1126/science.1245321; Tarutani A, 2016, J BIOL CHEM, V291, P18675, DOI 10.1074/jbc.M116.734707; Tedeschi A, 2013, EMBO REP, V14, P605, DOI 10.1038/embor.2013.64; Tekirdag K, 2018, J BIOL CHEM, V293, P5414, DOI 10.1074/jbc.R117.818237; Tirian L, 2003, P NATL ACAD SCI USA, V100, P13976, DOI 10.1073/pnas.2436331100; Tjelle TE, 1996, J CELL SCI, V109, P2905; Tofaris GK, 2011, P NATL ACAD SCI USA, V108, P17004, DOI 10.1073/pnas.1109356108; Tokesi N, 2010, J BIOL CHEM, V285, P17896, DOI 10.1074/jbc.M109.096578; Valakh V, 2015, NEUROBIOL DIS, V77, P13, DOI 10.1016/j.nbd.2015.02.014; Vilhardt F, 2002, J BIOL CHEM, V277, P42136, DOI 10.1074/jbc.M200862200; Vogiatzi T, 2008, J BIOL CHEM, V283, P23542, DOI 10.1074/jbc.M801992200; Volpicelli-Daley LA, 2014, NAT PROTOC, V9, P2135, DOI 10.1038/nprot.2014.143; Walker DG, 2013, EXP NEUROL, V240, P190, DOI 10.1016/j.expneurol.2012.11.020; Wang B, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4479; Wang RX, 2019, J CELL BIOL, V218, P267, DOI 10.1083/jcb.201804165; Webb JL, 2003, J BIOL CHEM, V278, P25009, DOI 10.1074/jbc.M300227200; Webber JL, 2010, EMBO J, V29, P27, DOI 10.1038/emboj.2009.321; Wei YJ, 2015, ELIFE, V4, DOI 10.7554/eLife.05289; Westerlund M, 2008, MOL CELL NEUROSCI, V39, P586, DOI 10.1016/j.mcn.2008.08.001; Zhou JX, 2011, ACTA NEUROPATHOL, V121, P695, DOI 10.1007/s00401-011-0815-1	73	0	0	2	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV	2022	28	11							102531	10.1016/j.jbc.2022.102531	http://dx.doi.org/10.1016/j.jbc.2022.102531			20	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	6I4GS	36162505	gold, Green Published			2022-12-28	WOS:000886086000003
J	Gao, ZY; Zhang, LX; Ge, ZH; Wang, H; Yue, YR; Jiang, ZB; Wang, X; Xu, CY; Zhang, Y; Yang, MJ; Feng, Y				Gao, Zhengyu; Zhang, Laixing; Ge, Zihao; Wang, Hao; Yue, Yourun; Jiang, Zhuobing; Wang, Xin; Xu, Chenying; Zhang, Yi; Yang, Maojun; Feng, Yue			Anti-CRISPR protein AcrIF4 inhibits the type I-F CRISPR-Cas surveillance complex by blocking nuclease recruitment and DNA cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL BASIS; CRYO-EM; MECHANISMS	The clustered regularly interspaced short palindromic re-peats (CRISPR)-Cas system provides prokaryotes with protec-tion against mobile genetic elements such as phages. In turn, phages deploy anti-CRISPR (Acr) proteins to evade this im-munity. AcrIF4, an Acr targeting the type I-F CRISPR-Cas system, has been reported to bind the crRNA-guided surveil-lance (Csy) complex. However, it remains controversial whether AcrIF4 inhibits target DNA binding to the Csy com-plex. Here, we present structural and mechanistic studies into AcrIF4, exploring its unique anti-CRISPR mechanism. While the Csy-AcrIF4 complex displays decreased affinity for target DNA, it is still able to bind the DNA. Our structural and functional analyses of the Csy-AcrIF4-dsDNA complex revealed that AcrIF4 binding prevents rotation of the helical bundle of the Cas8f subunit induced by dsDNA binding, therefore resulting in failure of nuclease Cas2/3 recruitment and DNA cleavage. Overall, our study provides an interesting example of attack on the nuclease recruitment event by an Acr, but not conventional mechanisms of blocking binding of target DNA.	[Gao, Zhengyu; Ge, Zihao; Wang, Hao; Yue, Yourun; Jiang, Zhuobing; Wang, Xin; Xu, Chenying; Zhang, Yi; Feng, Yue] Beijing Univ Chem Technol, Coll Life Sci & Technol, Beijing Adv Innovat Ctr Soft Matter Sci & Engn, Beijing Key Lab Bioproc,State Key Lab Chem Resourc, Beijing, Peoples R China; [Zhang, Laixing; Yang, Maojun] Tsinghua Univ, Sch Life Sci, Tsinghua Peking Ctr Life Sci, Beijing Adv Innovat Ctr Struct Biol,Beijing Fronti, Beijing, Peoples R China	Beijing University of Chemical Technology; Tsinghua University	Zhang, Y; Feng, Y (corresponding author), Beijing Univ Chem Technol, Coll Life Sci & Technol, Beijing Adv Innovat Ctr Soft Matter Sci & Engn, Beijing Key Lab Bioproc,State Key Lab Chem Resourc, Beijing, Peoples R China.; Yang, MJ (corresponding author), Tsinghua Univ, Sch Life Sci, Tsinghua Peking Ctr Life Sci, Beijing Adv Innovat Ctr Struct Biol,Beijing Fronti, Beijing, Peoples R China.	zhangyishirly@hotmail.com; maojunyang@mail.tsinghua.edu.cn; fengyue@mail.buct.edu.cn	Feng, Yue/HGE-4589-2022	Feng, Yue/0000-0002-1576-1385; Gaw, Zhengyu/0000-0002-6777-8840	National Key Research and Development Program of China; National Natural Science Foundation of China; Beijing Nova program; Fundamental Research Funds for the Central Universities;  [2019YFC1200500];  [2019YFC1200502];  [32000901];  [32171274];  [XK1802-8]	National Key Research and Development Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Nova program(Beijing Municipal Science & Technology Commission); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); ; ; ; ; 	Funding and additional information-This work was supported by the National Key Research and Development Program of China (2019YFC1200500 and 2019YFC1200502) , the National Natural Science Foundation of China (32000901 and 32171274) , Beijing Nova program and the Fundamental Research Funds for the Central Universities (XK1802-8) .	Afonine PV, 2018, ACTA CRYSTALLOGR D, V74, P531, DOI 10.1107/S2059798318006551; Bondy-Denomy J, 2013, NATURE, V493, P429, DOI 10.1038/nature11723; Bondy-Denomy J, 2015, NATURE, V526, P136, DOI 10.1038/nature15254; Borges AL, 2017, ANNU REV VIROL, V4, P37, DOI 10.1146/annurev-virology-101416-041616; Chowdhury S, 2017, CELL, V169, P47, DOI 10.1016/j.cell.2017.03.012; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Gabel C, 2021, NUCLEIC ACIDS RES, V49, P584, DOI 10.1093/nar/gkaa1199; Guo TW, 2017, CELL, V171, P414, DOI 10.1016/j.cell.2017.09.006; Hille F, 2018, CELL, V172, P1239, DOI 10.1016/j.cell.2017.11.032; Hirschi M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16512-1; Jia N, 2021, NAT REV MOL CELL BIO, V22, P563, DOI 10.1038/s41580-021-00371-9; Koonin EV, 2017, CURR OPIN MICROBIOL, V37, P67, DOI 10.1016/j.mib.2017.05.008; Liu X., 2021, NUCLEIC ACIDS RES, V49, P10178, DOI [DOI 10.1093/NAR/GKAB738, 10.1093/nar/gkab738]; Lu WT, 2021, NUCLEIC ACIDS RES, V49, P3381, DOI 10.1093/nar/gkab092; Marraffini LA, 2015, NATURE, V526, P55, DOI 10.1038/nature15386; Niu YY, 2020, MOL CELL, V80, P512, DOI 10.1016/j.molcel.2020.09.015; Peng RC, 2017, CELL RES, V27, P853, DOI 10.1038/cr.2017.79; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Ren JH, 2021, J BIOL CHEM, V298, DOI 10.1016/j.jbc.2022.102124; Rollins MF, 2019, MOL CELL, V74, P132, DOI 10.1016/j.molcel.2019.02.001; Sanchez-Garcia R, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-02399-1; Schindelin J, 2015, MOL REPROD DEV, V82, P518, DOI 10.1002/mrd.22489; Swint-Kruse L, 2005, BIOINFORMATICS, V21, P3327, DOI 10.1093/bioinformatics/bti511; van der Oost J, 2014, NAT REV MICROBIOL, V12, P479, DOI 10.1038/nrmicro3279; Wang H, 2022, J BIOL CHEM, V298, DOI 10.1016/j.jbc.2022.101636; Wang XF, 2016, NAT STRUCT MOL BIOL, V23, P868, DOI 10.1038/nsmb.3269; Xie YC, 2022, NAT CHEM BIOL, V18, P670, DOI 10.1038/s41589-022-00995-8; Yang LG, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-29581-1; Zhang K, 2016, J STRUCT BIOL, V193, P1, DOI 10.1016/j.jsb.2015.11.003; Zhang KM, 2020, P NATL ACAD SCI USA, V117, P7176, DOI 10.1073/pnas.1922638117; Zheng SQ, 2017, NAT METHODS, V14, P331, DOI 10.1038/nmeth.4193; Zivanov J, 2018, ELIFE, V7, DOI 10.7554/eLife.42166	32	0	0	5	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV	2022	28	11							102575	10.1016/j.jbc.2022.102575	http://dx.doi.org/10.1016/j.jbc.2022.102575			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	6I4GS	36209819	gold, Green Published			2022-12-28	WOS:000886086000002
J	WONG, S; REYNOLDS, AB; PAPKOFF, J				WONG, S; REYNOLDS, AB; PAPKOFF, J			PLATELET ACTIVATION LEADS TO INCREASED C-SRC KINASE-ACTIVITY AND ASSOCIATION OF C-SRC WITH AN 85-KDA TYROSINE PHOSPHOPROTEIN	ONCOGENE			English	Article							GLYCOPROTEIN-IIB-IIIA; CELL ANTIGEN RECEPTOR; AMINO-TERMINAL DOMAIN; PROTEIN-KINASE; MONOCLONAL-ANTIBODIES; RAPID PHOSPHORYLATION; SIGNAL TRANSDUCTION; CYTOPLASMIC DOMAINS; STABLE ASSOCIATION; MEMBRANE SKELETON	We have used platelets as a model system to study the function of c-src in signal transduction and cell adhesion. Numerous proteins were found to be phosphorylated on tyrosine in response to thrombin-induced platelet activation and aggregation. Two phases of phosphorylation were observed, with the second phase, but not the first, being inhibited by blocking platelet aggregation with an Arg-Gly-Asp-Ser tetrapeptide. As a first step towards identifying those proteins phosphorylated on tyrosine and to determine the specific role of p60src during platelet activation, we looked for changes in p60src kinase activity and for associations of p60src with other tyrosine phosphoproteins. The data presented here demonstrate an increase in p60src kinase activity within 1 min of thrombin-induced activation. Furthermore, p60src transiently associates with a tyrosine phosphoprotein during platelet activation and aggregation. This tyrosine phosphoprotein, p80/85, is a previously characterized cytoskeletal substrate for v-src in transformed cells. The data presented here suggest a model in which p60src functions in platelets to link upstream events, such as cell-surface adhesive interactions, with changes in platelet shape and cytoskeletal organization.	SYNTEX INC, S3-1, 3401 HILLVIEW AVE, PALO ALTO, CA 94304 USA; ST JUDE CHILDRENS RES HOSP, MEMPHIS, TN 38105 USA	Syntex Corporation; St Jude Children's Research Hospital								AIKEN ML, 1990, BLOOD, V76, P2501; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHALUPNY NJ, 1991, EMBO J, V10, P121; DEGROOT PG, 1990, BRIT J HAEMATOL, V75, P308; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; FERRELL JE, 1990, ONCOGENE, V5, P1033; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; FINDIK D, 1988, FEBS LETT, V235, P51, DOI 10.1016/0014-5793(88)81232-8; FOX JEB, 1988, BIOESSAYS, V8, P14, DOI 10.1002/bies.950080105; FOX JEB, 1990, J CELL BIOL, V111, P483, DOI 10.1083/jcb.111.2.483; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; HARRIS AS, 1990, P NATL ACAD SCI USA, V87, P3009, DOI 10.1073/pnas.87.8.3009; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HORAK ID, 1990, ONCOGENE, V5, P597; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; ISHIHARA N, 1985, THROMB HAEMOSTASIS, V54, P579; KAMPS MP, 1988, ONCOGENE, V2, P305; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KIEFFER N, 1990, ANNU REV CELL BIOL, V6, P329; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KROLL MH, 1989, BLOOD, V74, P1181; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEUNG LLK, 1984, J CLIN INVEST, V74, P1764, DOI 10.1172/JCI111595; LING E, 1988, J BIOL CHEM, V263, P2209; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; MCGREGOR JL, 1989, J BIOL CHEM, V264, P501; MOSHER DF, 1990, ANNU REV MED, V41, P85; NAKAMURA S, 1985, FEBS LETT, V184, P56, DOI 10.1016/0014-5793(85)80652-9; NAKAMURA S, 1989, J BIOL CHEM, V264, P7089; NAKAMURA S, 1988, EUR J BIOCHEM, V174, P471, DOI 10.1111/j.1432-1033.1988.tb14122.x; NIEVELSTEIN PFEM, 1988, HAEMOSTASIS, V18, P342; OCKENHOUSE CF, 1989, J CLIN INVEST, V84, P468, DOI 10.1172/JCI114188; RENDU F, 1989, BLOOD, V73, P1545; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; TREZZINI C, 1990, IMMUNOLOGY, V71, P29; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; TUY FPD, 1983, NATURE, V305, P435; VARSHNEY GC, 1986, FEBS LETT, V205, P97, DOI 10.1016/0014-5793(86)80873-0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1989, MOL CELL BIOL, V9, P4441, DOI 10.1128/MCB.9.10.4441; VEILLETTE A, 1989, NATURE, V338, P275; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; ZHAO YH, 1990, ONCOGENE, V5, P1629	57	84	86	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	1992	7	12					2407	2415						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1281303				2022-12-28	WOS:A1992KA85600005
J	MITCHELL, PJ; COOPER, CS				MITCHELL, PJ; COOPER, CS			THE HUMAN TPR GENE ENCODES A PROTEIN OF 2094 AMINO-ACIDS THAT HAS EXTENSIVE COILED-COIL REGIONS AND AN ACIDIC C-TERMINAL DOMAIN	ONCOGENE			English	Note							MET ONCOGENIC REARRANGEMENT; TYROSINE KINASE; ACTIVATION; SEQUENCES; RAF	We recently provided evidence that the human tpr gene encodes a 726 amino acid protein (designated tpr-S) and identified an alternatively spliced transcript that encodes a larger tpr protein with an extended C-terminal domain. In this study, through isolation and sequencing of tpr cDNA clones, we have established that this alternatively spliced transcript encodes a protein of 2094 amino acids (designated tpr-L). The larger tpr protein is predicted to have extensive regions of alpha-helix and several stretches of a heptad repeat that is characteristic of proteins adopting a coiled-coil conformation. Furthermore the carboxy domain of this protein is very rich in acidic residues and exhibits homology (58-80%) to the acidic regions of several nuclear proteins, including the Drosophila engrailed protein, Escherichia coli RNA polymerase sigma subunit and nucleolin. To gain additional insight into the function of tpr we examined the expression of tpr transcripts in tissues from adult rat. The highest levels of tpr transcripts were observed in testis, lung, thymus and spleen.			MITCHELL, PJ (corresponding author), INST CANC RES,MOLEC CARCINOGENESIS SECT,15 COTSWOLD RD,SUTTON SM2 5NG,SURREY,ENGLAND.		Mitchell, Philip J/F-6393-2013					CHAN AML, 1987, ONCOGENE, V1, P229; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GRECO A, 1992, ONCOGENE, V7, P237; ISHIKAWA F, 1987, MOL CELL BIOL, V7, P1226, DOI 10.1128/MCB.7.3.1226; KARPLUS PA, 1985, NATURWISSENSCHAFTEN, V72, P212, DOI 10.1007/BF01195768; KING HWS, 1988, ONCOGENE, V2, P617; KOPCHICK JJ, 1981, ANAL BIOCHEM, V115, P419, DOI 10.1016/0003-2697(81)90027-0; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; MITCHELL PJ, 1992, ONCOGENE, V7, P383; PARK M, 1986, COLD SPRING HARB SYM, V51, P967, DOI 10.1101/SQB.1986.051.01.110; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOMAN NR, 1991, P NATL ACAD SCI USA, V88, P4892, DOI 10.1073/pnas.88.11.4892; SOMAN NR, 1990, P NATL ACAD SCI USA, V87, P738, DOI 10.1073/pnas.87.2.738; TEMPEST PR, 1986, CARCINOGENESIS, V7, P2051, DOI 10.1093/carcin/7.12.2051; TEMPEST PR, 1986, FEBS LETT, V209, P357, DOI 10.1016/0014-5793(86)81142-5	22	40	43	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2329	2333						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437155				2022-12-28	WOS:A1992JW66500027
J	PENG, M; LUNDGREN, E				PENG, M; LUNDGREN, E			TRANSIENT EXPRESSION OF THE EPSTEIN-BARR-VIRUS LMP1 GENE IN HUMAN PRIMARY B-CELLS INDUCES CELLULAR ACTIVATION AND DNA-SYNTHESIS	ONCOGENE			English	Article							MEMBRANE-PROTEIN LMP1; HUMAN LYMPHOCYTES-B; NUCLEAR ANTIGEN-2; SURFACE-ANTIGEN; GROWTH-FACTOR; RODENT CELLS; 3T3 CELLS; TRANSFORMATION; INFECTION; IMMORTALIZATION	The Epstein- Barr virus (EBV)-encoded latent membrane protein 1 (LMP1) and Epstein-Barr virus nuclear antigen 2 (EBNA2) are expressed in EBV-immortalized human B cells. It has previously been shown that transfection of the LMP1 and EBNA2 genes into Burkitt's lymphoma cell lines results in the up-regulation of CD23, CD21, ICAM-1 and LFA-1 cell-surface proteins. In the present study, the effects of transient expression of the LMP1 and EBNA2 genes were studied in normal primary human B cells pretreated with UV-inactivated EBV particles. To identify and purify cells which express the transfected DNA we used a gene encoding a surface molecule, CD2, as a co-transfection marker. We show that transient expression of the LMP1 gene, from heterologous promoters, is sufficient to induce cellular enlargement and up-regulation of surface expression of the activation markers CD23, CD21, ICAM-1 and LFA-1 in primary B cells. Most importantly, we show that transient expression of the LMP1 gene is sufficient to induce DNA synthesis in human primary B cells. Transient EBNA2 expression enhanced the effect of transient LMP1 expression on CD21 and CD23 cell-surface expression but, under our experimental conditions, inhibited the induction of DNA synthesis by LMP1. We conclude that activation of primary B cells with inactivated EBV particles, followed by transient expression of only two viral genes, EBNA2 and LMP1, is sufficient to reconstitute some of the early events of B-cell immortalization by EBV.			PENG, M (corresponding author), UMEA UNIV,UNIT APPL CELL & MOLEC BIOL,S-90187 UMEA,SWEDEN.		Pilon, Marc/AAY-4082-2020; Pilon, Marc/B-9955-2008	Pilon, Marc/0000-0003-3919-2882; Pilon, Marc/0000-0003-3919-2882				ABBOTT SD, 1900, J VIROL, V64, P2126; ALESMARTINEZ JE, 1991, IMMUNOL TODAY, V12, P201, DOI 10.1016/0167-5699(91)90054-W; ALFIERI C, 1991, VIROLOGY, V181, P595, DOI 10.1016/0042-6822(91)90893-G; ALLDAY MJ, 1989, J GEN VIROL, V70, P1755, DOI 10.1099/0022-1317-70-7-1755; AMAN P, 1990, EMBO J, V9, P147, DOI 10.1002/j.1460-2075.1990.tb08090.x; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BAICHWAL VR, 1988, ONCOGENE, V2, P461; BOOS H, 1990, J GEN VIROL, V71, P1811, DOI 10.1099/0022-1317-71-8-1811; COHEN JI, 1989, P NATL ACAD SCI USA, V86, P9558, DOI 10.1073/pnas.86.23.9558; COLLINS MKL, 1984, J CELL PHYSIOL, V118, P133, DOI 10.1002/jcp.1041180205; CORDIER M, 1990, J VIROL, V64, P1002, DOI 10.1128/JVI.64.3.1002-1013.1990; CUOMO L, 1990, EUR J IMMUNOL, V20, P2293, DOI 10.1002/eji.1830201019; DAMBAUGH T, 1986, J VIROL, V59, P453, DOI 10.1128/JVI.59.2.453-462.1986; DOSCH HM, 1990, INT IMMUNOL, V2, P833, DOI 10.1093/intimm/2.9.833; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FAHRAEUS R, 1990, P NATL ACAD SCI USA, V87, P7390, DOI 10.1073/pnas.87.19.7390; FENNEWALD S, 1984, J VIROL, V51, P411, DOI 10.1128/JVI.51.2.411-419.1984; GORDON J, 1986, IMMUNOLOGY, V58, P591; GORDON J, 1984, J EXP MED, V159, P1554, DOI 10.1084/jem.159.5.1554; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; HAMMERSCHMIDT W, 1989, NATURE, V340, P393, DOI 10.1038/340393a0; HAUER CA, 1989, NUCLEIC ACIDS RES, V17, P1989, DOI 10.1093/nar/17.5.1989; HE Q, 1988, CELL, V54, P979, DOI 10.1016/0092-8674(88)90112-2; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HUTTFLETCHER LM, 1987, J VIROL, V61, P774, DOI 10.1128/JVI.61.3.774-781.1987; KIEFF E, 1990, VIROLOGY, P1889; KISHIMOTO T, 1989, FUNDAMENTAL IMMUNOLO, P385; KLAUS GGB, 1986, EUR J IMMUNOL, V16, P92, DOI 10.1002/eji.1830160118; KLEIN G, 1989, CELL, V58, P5, DOI 10.1016/0092-8674(89)90394-2; KNUTSON JC, 1990, J VIROL, V64, P2530, DOI 10.1128/JVI.64.6.2530-2536.1990; LIEBOWITZ D, 1986, J VIROL, V58, P233, DOI 10.1128/JVI.58.1.233-237.1986; LIEBOWITZ D, 1987, MOL CELL BIOL, V7, P2299, DOI 10.1128/MCB.7.7.2299; MANN KP, 1985, J VIROL, V55, P710, DOI 10.1128/JVI.55.3.710-720.1985; MASUCCI MG, 1987, EUR J IMMUNOL, V17, P815, DOI 10.1002/eji.1830170613; MILLER G, 1973, P NATL ACAD SCI USA, V70, P190, DOI 10.1073/pnas.70.1.190; MONROE JG, 1985, J IMMUNOL, V135, P1674; OHNO H, 1991, J IMMUNOL, V147, P2100; PILON M, 1991, J IMMUNOL, V146, P1047; RETH M, 1991, IMMUNOL TODAY, V12, P196, DOI 10.1016/0167-5699(91)90053-V; RYMO L, 1985, P NATL ACAD SCI USA, V82, P3435, DOI 10.1073/pnas.82.10.3435; SUGDEN B, 1989, CELL, V57, P5, DOI 10.1016/0092-8674(89)90165-7; SWAMINATHAN S, 1991, P NATL ACAD SCI USA, V88, P1546, DOI 10.1073/pnas.88.4.1546; SWENDEMAN S, 1987, EMBO J, V6, P1637, DOI 10.1002/j.1460-2075.1987.tb02412.x; TOSATO G, 1990, J VIROL, V64, P3033, DOI 10.1128/JVI.64.6.3033-3041.1990; TRIVEDI P, 1991, INT J CANCER, V48, P794, DOI 10.1002/ijc.2910480527; WALLS EV, 1987, LYMPHOCYTES PRACTICA, P149; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WANG F, 1990, J VIROL, V64, P3407, DOI 10.1128/JVI.64.7.3407-3416.1990; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; WANG F, 1987, P NATL ACAD SCI USA, V84, P3452, DOI 10.1073/pnas.84.10.3452; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604	53	103	107	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1775	1782						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1354347				2022-12-28	WOS:A1992JJ37600014
J	WANG, YS; SUGIYAMA, H; AXELSON, H; PANDA, CK; BABONITS, M; MA, A; STEINBERG, JM; ALT, FW; KLEIN, G; WIENER, F				WANG, YS; SUGIYAMA, H; AXELSON, H; PANDA, CK; BABONITS, M; MA, A; STEINBERG, JM; ALT, FW; KLEIN, G; WIENER, F			FUNCTIONAL HOMOLOGY BETWEEN N-MYC AND C-MYC IN MURINE PLASMACYTOMAGENESIS - PLASMACYTOMA DEVELOPMENT IN N-MYC TRANSGENIC MICE	ONCOGENE			English	Article							LEUKEMIA-VIRUS; V-ABL; CHROMOSOMAL TRANSLOCATIONS; CELLULAR ONCOGENES; KINASE-ACTIVITY; BALB/C MICE; B-CELLS; GENE; EXPRESSION; AMPLIFICATION	Mouse plasmacytomas induced by pristane oil alone, or in combination with Abelson murine leukemia virus (A-MuLV), regularly carry one of three alternative chromosomal translocations that juxtapose c-myc to immunoglobulin heavy- or light-chain loci. E-mu-c-myc transgenic mice develop translocation-free plasmacytomas after induction by pristane oil and/or A-MuLV [Sugiyama, H., Silva, S., Wang, Y., Weber, G., Babonits, M., Rosen, A., Wiener, F. & Klein, G. (1990). Int. J. Cancer, 46, 845-8521. In order to test whether another member of the myc family, N-myc, could play a similar role as c-myc, we treated E-mu- N -myc transgenic mice with pristane and helper-free A-MuLV. Of 20 mice that received a single pristane injection followed by A-MuLV, 17 developed plasmacytomas with a mean latency period of 54 +/- 20 days. In a corresponding group that only received a single pristane injection, five out of six transgenic mice developed plasmacytomas with a mean latency period of 142 +/- 32 days. However, after three monthly injections of pristane, all 15 transgenic mice developed plasmacytomas with a mean latency period of 128 +/- 20 days. All plasmacytomas expressed the N-myc transgene, while none of them expressed either c-myc or endogenous N-myc. None of the tumors carried the usual plasmacytoma-associated translocations.	COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT MICROBIOL,NEW YORK,NY 10032; NCI,GENET LAB,BETHESDA,MD 20892	Columbia University; Howard Hughes Medical Institute; Columbia University; Columbia University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	WANG, YS (corresponding author), KAROLINSKA INST,DEPT TUMOR BIOL,BOX 60400,S-10401 STOCKHOLM 60,SWEDEN.				NATIONAL CANCER INSTITUTE [R01CA014054] Funding Source: NIH RePORTER; NCI NIH HHS [5 RO1 CA 14054-15] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ADAMS JM, 1991, BIOCHIM BIOPHYS ACTA, V1072, P9, DOI 10.1016/0304-419X(91)90004-5; ALEXANDER WS, 1989, MOL CELL BIOL, V9, P67, DOI 10.1128/MCB.9.1.67; ALT FW, 1986, COLD SPRING HARB SYM, V1, P931; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BROOKS BJ, 1987, ADV VIRAL ONCOL, V7, P155; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DEPINHO R, 1987, J CELL BIOCHEM, V33, P257, DOI 10.1002/jcb.240330404; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; DILDROP R, 1989, EMBO J, V8, P1121, DOI 10.1002/j.1460-2075.1989.tb03482.x; GERONDAKIS S, 1984, CELL, V36, P973, DOI 10.1016/0092-8674(84)90047-3; GOUGH NM, 1981, P NATL ACAD SCI-BIOL, V78, P509, DOI 10.1073/pnas.78.1.509; GREEN PL, 1987, P NATL ACAD SCI USA, V84, P5932, DOI 10.1073/pnas.84.16.5932; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; KLEIN G, 1985, IMMUNOL TODAY, V6, P208, DOI 10.1016/0167-5699(85)90036-2; KONOPKA JB, 1984, J VIROL, V51, P223, DOI 10.1128/JVI.51.1.223-232.1984; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LEE WH, 1984, NATURE, V309, P458, DOI 10.1038/309458a0; MA A, 1991, MOL CELL BIOL, V11, P440, DOI 10.1128/MCB.11.1.440; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; OHNO S, 1984, J EXP MED, V159, P1762, DOI 10.1084/jem.159.6.1762; PEAR WS, 1988, MOL CELL BIOL, V8, P441, DOI 10.1128/MCB.8.1.441; POTTER M, 1973, SCIENCE, V182, P592, DOI 10.1126/science.182.4112.592; POTTER M, 1987, SCIENCE, V235, P787, DOI 10.1126/science.3810165; POTTER M, 1984, ADV VIRAL ONCOL, V4, P139; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P3623, DOI 10.1073/pnas.80.12.3623; ROSEN A, 1979, J IMMUNOL METHODS, V28, P1, DOI 10.1016/0022-1759(79)90322-3; ROSENBAUM H, 1989, EMBO J, V8, P749, DOI 10.1002/j.1460-2075.1989.tb03435.x; ROSENBAUM H, 1990, EMBO J, V9, P897, DOI 10.1002/j.1460-2075.1990.tb08187.x; Sambrook J, 1989, MOL CLONING LABORATO; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; SUGIYAMA H, 1990, INT J CANCER, V46, P845, DOI 10.1002/ijc.2910460516; SUGIYAMA H, 1989, INT J CANCER, V44, P348, DOI 10.1002/ijc.2910440227; VANLOHUIZEN M, 1989, EMBO J, V8, P133, DOI 10.1002/j.1460-2075.1989.tb03357.x; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; WIENER F, 1984, J EXP MED, V159, P276, DOI 10.1084/jem.159.1.276; WONG AJ, 1986, SCIENCE, V233, P461, DOI 10.1126/science.3014659; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	38	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1992	7	6					1241	1247						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1375720				2022-12-28	WOS:A1992HU64200023
J	CROW, DS; KURATA, WE; LAU, AF				CROW, DS; KURATA, WE; LAU, AF			PHOSPHORYLATION OF CONNEXIN43 IN CELLS CONTAINING MUTANT SRC ONCOGENES	ONCOGENE			English	Note							JUNCTIONAL INTERCELLULAR COMMUNICATION; INTER-CELLULAR COMMUNICATION; CHICKEN-EMBRYO FIBROBLASTS; AVIAN-SARCOMA VIRUS; GENE-PRODUCT; GAP JUNCTION; TYROSINE PHOSPHORYLATION; TRANSFORMED-CELLS; PLASMA-MEMBRANE; V-SRC	Disruption of gap junctional communication (measured by intercellular dye transfer) in cultured fibroblasts by pp60v-src is correlated with phosphorylation of the gap junction protein, connexin43 (cx43), on tyrosine. In this report, we examine the functional relevance of these observations by studying cx43 phosphorylation in cells containing kinase-active, non-myristylated pp60(2A527F) or pp60v-src temperature sensitive (ts) for transformation. Non-transformed cells expressing pp60(2A527F) transferred fluorescent dye at high levels and contained cx43 that was phosphorylated predominately on serine. In contrast, cells transformed by kinase-active, myristylated pp60(527F) did not transfer dye and contained cx43 proteins which were phosphorylated on serine and tyrosine. Additionally, activation of ts pp60v-src tyrosine kinase activity upon shift of cells to the permissive temperature was correlated with a rapid increase in the phosphorylated tyrosine content of cx43 proteins and loss of gap junctional communication. These combined results suggested that cx43 is a substrate of pp60v-src whose phosphorylation on tyrosine may be involved in the disruption of gap junctional communication observed in Rous sarcoma virus (RSV)-transformed cells.	UNIV HAWAII,CANC RES CTR,HONOLULU,HI 96813	Cancer Research Center of Hawaii; University of Hawaii System					NCI NIH HHS [CA 52098] Funding Source: Medline; NCRR NIH HHS [RR030601] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052098] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATKINSON MM, 1981, J CELL BIOL, V91, P573, DOI 10.1083/jcb.91.2.573; AZARNIA R, 1989, ONCOGENE, V4, P1161; AZARNIA R, 1988, SCIENCE, V239, P398, DOI 10.1126/science.2447651; AZARNIA R, 1984, J MEMBRANE BIOL, V82, P207, DOI 10.1007/BF01871630; BRUGGE JS, 1977, NATURE, V269, P346, DOI 10.1038/269346a0; CHANG CC, 1985, P NATL ACAD SCI USA, V82, P5360, DOI 10.1073/pnas.82.16.5360; CROW DS, 1990, MOL CELL BIOL, V10, P1754, DOI 10.1128/MCB.10.4.1754; DOWNING JR, 1991, ONCOGENE, V6, P607; FILSON AJ, 1990, CELL GROWTH DIFFER, V1, P661; HAMAGUCHI M, 1990, MOL CELL BIOL, V10, P830, DOI 10.1128/MCB.10.2.830; HUNTER T, 1979, COLD SPRING HARB SYM, V44, P931; JOHNSON RM, 1989, SCIENCE, V246, P121, DOI 10.1126/science.2506643; KAMPS MP, 1988, ONCOGENE, V2, P305; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KAMPS MP, 1986, CELL, V45, P105, DOI 10.1016/0092-8674(86)90542-8; KANNER SB, 1991, MOL CELL BIOL, V11, P713, DOI 10.1128/MCB.11.2.713; KOZMA LM, 1990, MOL CELL BIOL, V10, P837, DOI 10.1128/MCB.10.2.837; LAU AF, 1986, VIROLOGY, V151, P86, DOI 10.1016/0042-6822(86)90106-6; LAU AF, 1989, ONCOGENE RES, V1, P185; LINDER ME, 1988, P NATL ACAD SCI USA, V85, P2608, DOI 10.1073/pnas.85.8.2608; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LOEWENSTEIN WR, 1981, PHYSIOL REV, V61, P829, DOI 10.1152/physrev.1981.61.4.829; LOEWENSTEIN WR, 1979, BIOCHIM BIOPHYS ACTA, V560, P1, DOI 10.1016/0304-419X(79)90002-7; LOEWENSTEIN WR, 1984, BIOCH SOC S, V50, P43; MEHTA PP, 1986, CELL, V44, P187, DOI 10.1016/0092-8674(86)90497-6; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; SAEZ JC, 1986, P NATL ACAD SCI USA, V83, P2473, DOI 10.1073/pnas.83.8.2473; SPRAY DC, 1981, SCIENCE, V211, P712, DOI 10.1126/science.6779379; STAGG RB, 1990, ENDOCR REV, V11, P302, DOI 10.1210/edrv-11-2-302; SWENSON KI, 1990, CELL REGUL, V1, P989, DOI 10.1091/mbc.1.13.989; WARNER A, 1988, J CELL SCI, V89, P1; WENDLER PA, 1989, ONCOGENE, V4, P231; WILLINGHAM MC, 1979, CELL, V18, P125, DOI 10.1016/0092-8674(79)90361-1; YAMASAKI H, 1988, CANCER RES, V48, P3490; YOUNG JDE, 1987, CELL, V48, P733, DOI 10.1016/0092-8674(87)90071-7	36	47	47	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1992	7	5					999	1003						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1315016				2022-12-28	WOS:A1992HP64200021
J	PERRAUD, F; YOSHIMURA, K; LOUIS, B; DALEMANS, W; ALIHADJI, D; SCHULTZ, H; CLAUDEPIERRE, MC; CHARTIER, C; DANEL, C; BELLOCQ, JP; CRYSTAL, RG; LECOCQ, JP; PAVIRANI, A				PERRAUD, F; YOSHIMURA, K; LOUIS, B; DALEMANS, W; ALIHADJI, D; SCHULTZ, H; CLAUDEPIERRE, MC; CHARTIER, C; DANEL, C; BELLOCQ, JP; CRYSTAL, RG; LECOCQ, JP; PAVIRANI, A			THE PROMOTER OF THE HUMAN CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE DIRECTING SV40 T-ANTIGEN EXPRESSION INDUCES MALIGNANT PROLIFERATION OF EPENDYMAL CELLS IN TRANSGENIC MICE	ONCOGENE			English	Note							IDENTIFICATION; MUTATIONS; PROTEIN; TUMORS; LINES; DEFECT	Transgenic mice bearing a human cystic fibrosis transmembrane conductance regulator (CFTR) promoter-SV40 T antigen fusion transgene were generated in order to localize in vivo the potential oncogenesis linked to the tissue-specific activity of the promoter for the CFTR gene. Surprisingly, the only site of tumors resulting from expression of the reporter onc gene was ependymal cells lining the brain ventricles. SV40 T antigen expression in these cells led to a consistent pathology in the first weeks of age: ependymoma and consequent hydrocephaly. Tumor-derived cell lines were established, characterized and shown to originate from SV40 T antigen-induced ependymoma. No pathological alterations were found in other organs, such as lungs and pancreas, in which cystic fibrosis is pathologically manifest in humans. Such transgenic mice and derived cell lines may represent valid models for analysing (1) the role of SV40 T antigen in ependymoma formation and (2) CFTR function in ependymal cells.	TRANSGENE SA,DEPT ANIM SYST,11 RUE MOLSHEIM,F-67082 STRASBOURG,FRANCE; NHLBI,PULM BRANCH,BETHESDA,MD 20892; HOP HAUTE PIERRE,SERV ANAT PATHOL GEN,F-67200 STRASBOURG,FRANCE	Transgene SA; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); CHU Strasbourg								ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; ARAKI M, 1983, ARCH HISTOL JAPON, V46, P191, DOI 10.1679/aohc.46.191; BABINET C, 1989, GENOME, V31, P938, DOI 10.1139/g89-165; BECKER LE, 1983, HUM PATHOL, V14, P538, DOI 10.1016/S0046-8177(83)80006-9; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; BRINSTER RL, 1984, CELL, V37, P367, DOI 10.1016/0092-8674(84)90367-2; BRUNI JE, 1985, BRAIN RES REV, V9, P1, DOI 10.1016/0165-0173(85)90016-5; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; DALEMANS W, 1990, BIOLOGICALS, V18, P191, DOI 10.1016/1045-1056(90)90006-L; DEAN M, 1990, CELL, V61, P863, DOI 10.1016/0092-8674(90)90196-L; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; Flint S. J, 1981, DNA TUMOR VIRUSES; GABRION J, 1988, NEUROSCIENCE, V24, P993, DOI 10.1016/0306-4522(88)90082-6; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; HANAHAN D, 1989, SCIENCE, V246, P1265, DOI 10.1126/science.2686032; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HOGAN B, 1986, MANIPULATING MOUSE E; JAENISCH R, 1988, SCIENCE, V240, P1468, DOI 10.1126/science.3287623; JALLAT S, 1990, EMBO J, V9, P3295, DOI 10.1002/j.1460-2075.1990.tb07529.x; JETTEN AM, 1989, SCIENCE, V244, P1472, DOI 10.1126/science.2472008; JOHANSEN HK, 1991, LANCET, V337, P631, DOI 10.1016/0140-6736(91)92449-C; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KEREM E, 1990, NEW ENGL J MED, V323, P1517, DOI 10.1056/NEJM199011293232203; LANDRY DW, 1989, SCIENCE, V244, P1469, DOI 10.1126/science.2472007; LEVITAN IB, 1989, SCIENCE, V244, P1423, DOI 10.1126/science.2544028; MANTHORPE CM, 1977, BRAIN RES, V134, P407, DOI 10.1016/0006-8993(77)90818-6; MESSING A, 1985, NATURE, V316, P461, DOI 10.1038/316461a0; PALMITER RD, 1985, NATURE, V316, P457, DOI 10.1038/316457a0; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PAVIRANI A, 1989, BIO-TECHNOL, V7, P1049; PERRAUD F, 1991, EXP CELL RES, V195, P59, DOI 10.1016/0014-4827(91)90500-T; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROESSMANN U, 1980, BRAIN RES, V200, P13, DOI 10.1016/0006-8993(80)91090-2; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SANTIS G, 1990, LANCET, V336, P1081, DOI 10.1016/0140-6736(90)92566-Z; TRAPNELL BC, 1991, J BIOL CHEM, V266, P10319; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WHITE MB, 1990, NATURE, V344, P665, DOI 10.1038/344665a0; YOSHIMURA K, 1991, J BIOL CHEM, V266, P9140	46	13	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1992	7	5					993	997						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1373882				2022-12-28	WOS:A1992HP64200020
J	RICHARDSON, AL; HUMPHRIES, CG; TUCKER, PW				RICHARDSON, AL; HUMPHRIES, CG; TUCKER, PW			MOLECULAR-CLONING AND CHARACTERIZATION OF THE T(2 14) TRANSLOCATION ASSOCIATED WITH CHILDHOOD CHRONIC LYMPHOCYTIC-LEUKEMIA	ONCOGENE			English	Article							C-MYC ONCOGENE; GAMMA-GENES; B-CELL; PSEUDOAUTOSOMAL REGION; T(2-14) TRANSLOCATION; GENOMIC SEQUENCES; BURKITT-LYMPHOMA; RESTRICTION MAP; CHAIN; SWITCH	Two rare cases of chronic lymphocytic leukemia (CLL) in children, patients AS and LH, have been found to be associated with a unique chromosomal translocation, t(2;14)(p13;q32). Previous studies have shown the breakpoints of this translocation to be in the gamma-2 switch region of the Ig heavy-chain locus on chromosome 14 and in an uncharacterized region of chromosome 2. We have cloned and characterized the translocation breakpoints to examine the possibility that an oncogene contributed to the pathogenesis of these cases of CLL. Sequence analysis of AS and LH breakpoints established that the chromosome 2 breakage in the two patients occurred only 38 bp apart and within a strong non-methylated CpG island. Furthermore, human probes from the region cross-hybridized to other species, indicating strong evolutionary conservation. Northern analysis using the chromosome 2 probes detected a 2.85-kb transcript in the tumor cells and in a CD5+ B-cell line. These data suggest that a potential oncogene located near the 2p13 breakpoint may have been activated by the t(2;14) translocation in these two cases of chronic lymphocytic leukemia.			RICHARDSON, AL (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MICROBIOL,DALLAS,TX 75235, USA.				NIGMS NIH HHS [GM08014] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIRD AP, 1986, NATURE, V321, P9; BOUMSELL L, 1980, J EXP MED, V151, P1539; BRISSENDEN JE, 1985, CANCER RES, V45, P5593; BROWN WRA, 1988, EMBO J, V7, P2377, DOI 10.1002/j.1460-2075.1988.tb03082.x; BROWNELL E, 1988, ONCOGENE, V3, P93; BROWNELL E, 1988, ONCOGENE, V2, P527; CASALI P, 1987, SCIENCE, V236, P77, DOI 10.1126/science.3105056; DUNN IS, 1987, NUCLEIC ACIDS RES, V15, P2677; DUNNICK W, 1980, NATURE, V286, P669, DOI 10.1038/286669a0; FELL HP, 1986, SCIENCE, V232, P491, DOI 10.1126/science.3961491; FERAMISCO JR, 1982, J BIOL CHEM, V257, P1024; FLANAGAN JG, 1982, NATURE, V300, P709, DOI 10.1038/300709a0; FULTON TR, 1989, NUCLEIC ACIDS RES, V17, P271, DOI 10.1093/nar/17.1.271; GARDINER K, 1990, EMBO J, V9, P25, DOI 10.1002/j.1460-2075.1990.tb08076.x; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; KAMOUN M, 1981, J IMMUNOL, V127, P987; KINGSMORE SF, 1989, EMBO J, V8, P4073, DOI 10.1002/j.1460-2075.1989.tb08591.x; LEVINE EG, 1986, CANCER RES, V46, P6481; LINDSAY S, 1987, NATURE, V327, P336, DOI 10.1038/327336a0; Maniatis T., 1982, MOL CLONING; MARCU KB, 1982, NATURE, V298, P87, DOI 10.1038/298087a0; MITELMAN F, 1988, CANCER RES, V48, P7115; MONACO AP, 1986, NATURE, V323, P646, DOI 10.1038/323646a0; NIKAIDO T, 1982, J BIOL CHEM, V257, P7322; NISHIDA K, 1989, CANCER RES, V49, P1275; NOWELL PC, 1986, CANCER GENET CYTOGEN, V19, P219, DOI 10.1016/0165-4608(86)90050-6; PETIT C, 1988, EMBO J, V7, P2369, DOI 10.1002/j.1460-2075.1988.tb03081.x; PICCOLI SP, 1984, NATURE, V310, P327, DOI 10.1038/310327a0; RAPPOLD GA, 1988, NUCLEIC ACIDS RES, V16, P5361, DOI 10.1093/nar/16.12.5361; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANGER F, 1978, J MOL BIOL, V125, P225, DOI 10.1016/0022-2836(78)90346-7; SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561; SHOWE LC, 1985, MOL CELL BIOL, V5, P501, DOI 10.1128/MCB.5.3.501; SONNIER JA, 1983, NEW ENGL J MED, V309, P590, DOI 10.1056/NEJM198309083091005; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEINMETZ M, 1986, CELL, V44, P895, DOI 10.1016/0092-8674(86)90012-7; TAKAHASHI N, 1982, CELL, V29, P671, DOI 10.1016/0092-8674(82)90183-0; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; TRICOLI JV, 1985, CYTOGENET CELL GENET, V40, P762; VESHIMA Y, 1985, INT J CANCER, V36, P287; YOFFE G, 1990, J PEDIATR-US, V116, P114, DOI 10.1016/S0022-3476(05)81658-0	43	26	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1992	7	5					961	970						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1373880				2022-12-28	WOS:A1992HP64200016
J	SCHROEDER, C; GIBSON, L; BEUG, H				SCHROEDER, C; GIBSON, L; BEUG, H			THE V-ERBA ONCOGENE REQUIRES COOPERATION WITH TYROSINE KINASES TO ARREST ERYTHROID-DIFFERENTIATION INDUCED BY LIGAND-ACTIVATED ENDOGENOUS C-ERBA AND RETINOIC ACID RECEPTOR	ONCOGENE			English	Article							THYROID-HORMONE RECEPTOR; AVIAN ERYTHROBLASTOSIS VIRUS; TISSUE-SPECIFIC EXPRESSION; GROWTH-FACTOR RECEPTOR; LEUKEMIA VIRUSES; GENE-EXPRESSION; CELLS; PROTEIN; TRANSFORMATION; TRANSCRIPTION	The v-erbA oncogene, a mutated version of the thyroid hormone receptor alpha (c-erbA/TR-alpha), cooperates with tyrosine kinase oncogenes in erythroblast transformation. Here we show that the ligand-activated, endogenous retinoic acid receptor (RAR-alpha), in cooperation with c-erbA/TR-alpha, efficiently reverses the transforming effect of kinase oncogenes, overcoming oncogene-induced self-renewal by triggering terminal differentiation of the transformed cells into healthy erythrocytes. This differentiation induction was accompanied by up-regulation of erythrocyte gene expression. Similarly, RAR-alpha and overexpressed exogenous c-erbA/TR-alpha efficiently abolished the differentiation arrest caused by v-erbA, while the low levels of endogenous TR-alpha had no effect. In contrast, transformation by v-erbA plus a kinase oncogene was not affected at all by ligand-activated endogenous or overexpressed exogenous TR-alpha and RAR-alpha. These results suggest that oncogene cooperation is required to protect leukemic erythroblasts from differentiation induction via endogenous, nuclear hormone receptors. Endogenous c-erbA/TR-alpha and RAR-alpha apparently cooperated in abolishing erythroblast self-renewal and inducing differentiation, since the respective ligands acted in a synergistic fashion, and overexpressed, non-ligand-bound c-erbA/TR-alpha suppressed endogenous RAR-alpha function in differentiation induction. Genetic evidence is presented that this functional cooperation requires the receptor dimerization domain, suggesting that TR-alpha/RAR-alpha heterodimers play a role in regulation of erythroid differentiation.	INST MOLEC PATHOL, DR BOHR GASSE 7, A-1030 VIENNA, AUSTRIA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)			Gibson, Leonie/AAM-5917-2021	Gibson, Leonie/0000-0002-0904-8145				BEUG H, 1982, J CELL PHYSIOL, P195; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BEUG H, 1985, PROC R SOC SER B-BIO, V226, P121, DOI 10.1098/rspb.1985.0086; BEUG H, 1985, VIROLOGY, V145, P141, DOI 10.1016/0042-6822(85)90209-0; BEUG H, 1989, EUR J CLIN INVEST, V19, P491, DOI 10.1111/j.1365-2362.1989.tb00265.x; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BEUG H, 1984, CELL, V36, P963, DOI 10.1016/0092-8674(84)90046-1; BEUG H, 1991, NUCLEAR HORMONE RECE, P355; BEUG H, 1985, MODERN TRENDS HUMA 6, V29, P290; BEUG H, 1991, MYERS S NUCLEAR PROC, V15; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FALCONE G, 1991, MOL CELL BIOL, V11, P3331, DOI 10.1128/MCB.11.6.3331; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FORREST D, 1990, EMBO J, V9, P1519, DOI 10.1002/j.1460-2075.1990.tb08270.x; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; FUERSTENBERG S, 1990, J VIROL, V64, P5891, DOI 10.1128/JVI.64.12.5891-5902.1990; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GLINEUR C, 1990, GENE DEV, V4, P1663, DOI 10.1101/gad.4.10.1663; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; HAYMAN MJ, 1982, J CELL BIOCHEM, V18, P351, DOI 10.1002/jcb.1982.240180308; HOUSMAN D, 1980, COLD SPRING HARB SYM, V44, P1177, DOI 10.1101/SQB.1980.044.01.127; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; KNIGHT J, 1988, GENE DEV, V2, P247, DOI 10.1101/gad.2.2.247; KOWENZ E, 1987, MODERN TRENDS HUMA 7, V31, P199; MAIHLE NJ, 1989, BIOCHIM BIOPHYS ACTA, V948, P287, DOI 10.1016/0304-419X(89)90003-6; Maniatis T., 1982, MOL CLONING; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; PAIN B, 1991, CELL, V65, P37, DOI 10.1016/0092-8674(91)90405-N; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; ROSS J, 1976, CELL, V8, P513, DOI 10.1016/0092-8674(76)90219-1; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHMIDT JA, 1986, LEUKEMIA RES, V10, P257, DOI 10.1016/0145-2126(86)90023-8; SCHROEDER C, 1990, ONCOGENE, V5, P1445; SCHROEDER C, 1992, ONCOGENE, V7, P217; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P	48	52	52	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1992	7	2					203	216						14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1347913				2022-12-28	WOS:A1992HG98200002
J	BAUNOCH, DA; XU, M; TEWARI, A; CHRISTMAN, JK; LANE, MA				BAUNOCH, DA; XU, M; TEWARI, A; CHRISTMAN, JK; LANE, MA			INSITU DEPHOSPHORYLATION OF P53 PROTEIN BY CALF INTESTINAL ALKALINE-PHOSPHATASE TREATMENT	ONCOGENE			English	Note							BREAST	The monoclonal antibody (mAb) 1801 has been reported to identify an N-terminal determinant within the tumor-suppressor protein p53 located between amino acids 32 and 79. This region contains two potential sites for serine phosphorylation at amino acids 33 and 46. Using a novel technique which dephosphorylates proteins in situ in fixed permeabilized cells, we have unmasked determinants in p53 recognized by mAb 1801, allowing additional sites of p53 protein to be detected in immunohistochemically reacted cells. This result indicates that phosphorylation at one or both sites within the determinant recognized by mAb 1801 previously blocked antibody-ligand interaction. It further suggests that in situ dephosphorylation may be of more general use in identifying antibodies which can only bind to epitopes in a particular phosphorylation state.	MICHIGAN CANC FDN,MOLEC GENET LAB,110 E WARREN AVE,DETROIT,MI 48201; WAYNE STATE UNIV,SCH MED,DEPT MOLEC BIOL & GENET,DETROIT,MI 48201; MICHIGAN CANC FDN,MOLEC BIOL PROGRAM,DETROIT,MI 48201	Wayne State University					NCI NIH HHS [P30 CA-22453, T32 CA09531] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA022453, T32CA009531] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTEK J, 1991, ONCOGENE, V6, P1699; BUCHKOVICH K, 1989, CELL, V58, P1079; CATTORETTI G, 1988, INT J CANCER, V41, P178, DOI 10.1002/ijc.2910410204; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; TAIT L, 1990, CANCER RES, V50, P6087	6	9	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2351	2353						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437159				2022-12-28	WOS:A1992JW66500031
J	HEVEZI, P; ALIN, K; REESJONES, R; GOFF, SP				HEVEZI, P; ALIN, K; REESJONES, R; GOFF, SP			BONE MARROW-TRANSFORMING ACTIVITY OF LINKER INSERTION MUTANTS OF ABELSON MURINE LEUKEMIA-VIRUS	ONCOGENE			English	Note							SRC HOMOLOGY REGION-2; PROTEIN-TYROSINE KINASE; LYMPHOID-CELLS; SIGNAL TRANSDUCTION; CHAIN GENES; C-SRC; V-ABL; SEQUENCES; DOMAINS; SEGMENT	Two sets of mutants of the Abelson murine leukemia virus, generated by linker insertion mutagenesis of a cloned proviral DNA, were tested for their ability to transform bone marrow cultures in vitro. All the viruses retained an intact tyrosine kinase domain and were competent for transformation of NIH3T3 fibroblasts in culture. One series contained 12-bp linker insertions in the regions flanking the kinase domain, and the other contained frameshift mutations that truncated the gene product downstream of the kinase domain. The majority of the 12-bp insertion mutants retained full bone marrow-transforming activity; only one insertion in the SH2 domain showed reduced activity. This mutant suggests that some aspect of the SH2 domain may be more important in transformation of lymphocytes than fibroblasts. In contrast to the first set of mutants, the bone marrow-transforming activity of the majority of the truncation mutants was significantly reduced or completely lost. We conclude that there is a broad requirement for an intact C-terminal domain of the v-abl protein for the transformation of pre-B cells, but that no single part of this domain is critical.	COLUMBIA UNIV, DEPT MICROBIOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV, DEPT MED, NEW YORK, NY 10032 USA	Columbia University; Columbia University								ABELSON HT, 1970, CANCER RES, V30, P2208; ABELSON HT, 1970, CANCER RES, V30, P2213; ALT F, 1981, CELL, V27, P381, DOI 10.1016/0092-8674(81)90421-9; BALTIMORE D, 1979, IMMUNOL REV, V48, P3, DOI 10.1111/j.1600-065X.1979.tb00296.x; COLICELLI J, 1988, J MOL BIOL, V199, P47, DOI 10.1016/0022-2836(88)90378-6; COOK WD, 1982, P NATL ACAD SCI-BIOL, V79, P2917, DOI 10.1073/pnas.79.9.2917; ENGELMAN A, 1990, J VIROL, V64, P4242, DOI 10.1128/JVI.64.9.4242-4251.1990; GOFF SP, 1982, J VIROL, V41, P271, DOI 10.1128/JVI.41.1.271-285.1982; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; GOFF SP, 1982, ADV VIRAL ONCOL, P127; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; HIRAI H, 1990, GENE DEV, V4, P2342, DOI 10.1101/gad.4.12b.2342; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MATHEYPREVOT B, 1988, MOL CELL BIOL, V8, P234, DOI 10.1128/MCB.8.1.234; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MURTAGH K, 1986, J VIROL, V60, P599, DOI 10.1128/JVI.60.2.599-606.1986; PARMAR K, 1991, IN PRESS J VIROL, V65; PAWSON T, 1988, ONCOGENE, V3, P491; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PERRY RP, 1980, P NATL ACAD SCI-BIOL, V77, P1937, DOI 10.1073/pnas.77.4.1937; PRATT DM, 1977, CELL, V12, P683, DOI 10.1016/0092-8674(77)90268-9; PRYWES R, 1985, J VIROL, V54, P123, DOI 10.1128/JVI.54.1.123-132.1985; PRYWES R, 1983, CELL, V34, P569, DOI 10.1016/0092-8674(83)90389-6; PRYWES R, 1985, J VIROL, V54, P114, DOI 10.1128/JVI.54.1.114-122.1985; RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0; REESJONES RW, 1989, MOL CELL BIOL, V9, P278, DOI 10.1128/MCB.9.1.278; REESJONES RW, 1988, J VIROL, V62, P978, DOI 10.1128/JVI.62.3.978-986.1988; REYNOLDS FH, 1980, J VIROL, V36, P374, DOI 10.1128/JVI.36.2.374-386.1980; RISSER R, 1989, CURR TOP MICROBIOL, V147, P129; ROSENBERG N, 1976, J EXP MED, V143, P1453, DOI 10.1084/jem.143.6.1453; ROSENBERG N, 1975, P NATL ACAD SCI USA, V72, P1932, DOI 10.1073/pnas.72.5.1932; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; ROSENBERG N, 1980, VIRAL ONCOLOGY, P187; ROSENBERG NE, 1980, J VIROL, V36, P766, DOI 10.1128/JVI.36.3.766-774.1980; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SCHER CD, 1975, NATURE, V253, P729, DOI 10.1038/253729a0; SEFTON BM, 1981, P NATL ACAD SCI-BIOL, V78, P1552, DOI 10.1073/pnas.78.3.1552; SIDEN E, 1981, P NATL ACAD SCI-BIOL, V78, P1823, DOI 10.1073/pnas.78.3.1823; SIDEN EJ, 1979, CELL, V16, P389, DOI 10.1016/0092-8674(79)90014-X; SRINIVASAN A, 1982, P NATL ACAD SCI-BIOL, V79, P5508, DOI 10.1073/pnas.79.18.5508; WATANABE SM, 1983, J VIROL, V45, P1028, DOI 10.1128/JVI.45.3.1028-1036.1983; WITTE ON, 1980, P NATL ACAD SCI-BIOL, V77, P4993, DOI 10.1073/pnas.77.8.4993; WITTE ON, 1980, NATURE, V283, P826, DOI 10.1038/283826a0; WITTE ON, 1983, CURR TOP MICROBIOL, V103, P127; ZIEGLER SF, 1981, CELL, V27, P477, DOI 10.1016/0092-8674(81)90389-5	48	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1992	7	11					2323	2328						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437154				2022-12-28	WOS:A1992JW66500026
J	MOLL, J; EIBEL, H; BOTTERI, F; SANSIG, G; REGNIER, C; VANDERPUTTEN, H				MOLL, J; EIBEL, H; BOTTERI, F; SANSIG, G; REGNIER, C; VANDERPUTTEN, H			TRANSGENES ENCODING MUTANT SIMIAN-VIRUS 40 LARGE T-ANTIGENS UNMASK PHENOTYPIC AND FUNCTIONAL CONSTRAINTS IN THYMIC EPITHELIAL-CELLS	ONCOGENE			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; SV40 LARGE-T; HEMATOPOIETIC GROWTH-FACTORS; LARGE TUMOR-ANTIGEN; PROGENITOR CELLS; THYMOCYTE DEVELOPMENT; EXTRACELLULAR-MATRIX; BASEMENT-MEMBRANES; HYDROPHOBIC REGION; MESSENGER-RNA	Transgenes encoding simian virus 40 (SV40) T antigen (Tag) can cause hyperplastic or tumorigenic lesions of desired but also of unforeseen cellular origin. Unexpectedly the human growth hormone-releasing factor (GRF) gene promoter directs expression of SV40 Tag specifically in thymic epithelial (TE) cells. Expression starts in the neonate, in which GRF-Tag+ cells display strict numerical and spatial constraints. Tag supersedes mechanisms that constrain these features and GRF-Tag mice develop thymic hyperplasia. To characterize GRF-Tag+ TE cells and their putative normal counterparts we compared phenotypic and functional effects caused by transgenes encoding mutant large T antigens. This strategy is applicable to any situation in which T antigen is used to alter development. One large Tag mutant (K1 + 5080) does not cause thymic hyperplasia. GRF-Tag (K1 + 5080)+ TE cells display strict temporal and spatial constraints throughout life. TE cells expressing other mutant large T antigens that cause thymic hyperplasia do not obey these rules and reveal that phenotypically distinct GRF-Tag+ TE-cell stages exist in vivo. Analysis of conditional immortal GRF-Tag(tsA58)+ TE cells expressing a temperature-sensitive large Tag shows that large Tag blocks differentiation in these cells. Phenotype and functions in these cells are regulated by cellular differentiation and interleukin 4 (IL-4).	CIBA GEIGY AG,DEPT BIOTECHNOL,DIV PHARMA,K681447,CH-4002 BASEL,SWITZERLAND; MAX PLANCK INST IMMUNBIOL,W-7800 FREIBURG,GERMANY; FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND	Novartis; Max Planck Society; Friedrich Miescher Institute for Biomedical Research				Regnier, Catherine/0000-0002-4386-1324				BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; BARTEK J, 1992, ONCOGENE, V7, P101; BAUVOIS B, 1989, J IMMUNOL, V143, P1077; BERRIH S, 1985, J HISTOCHEM CYTOCHEM, V33, P655, DOI 10.1177/33.7.3891843; BOSCH FX, 1988, J CELL BIOL, V106, P1635, DOI 10.1083/jcb.106.5.1635; BOTTERI FM, 1987, MOL CELL BIOL, V7, P3178, DOI 10.1128/MCB.7.9.3178; BOYD RL, 1991, IMMUNOL TODAY, V12, P71, DOI 10.1016/0167-5699(91)90161-L; Brekelmans P, 1990, Semin Immunol, V2, P13; BROMBACHER F, 1989, EMBO J, V8, P3719, DOI 10.1002/j.1460-2075.1989.tb08547.x; BROXMEYER HE, 1991, EXP HEMATOL, V19, P143; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CARDING SR, 1991, IMMUNOL TODAY, V12, P239, DOI 10.1016/0167-5699(91)90037-T; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHERINGTON V, 1988, MOL CELL BIOL, V8, P1380, DOI 10.1128/MCB.8.3.1380; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; CRISPE IN, 1987, J IMMUNOL, V138, P2013; DARGEMONT C, 1989, SCIENCE, V246, P803, DOI 10.1126/science.2683083; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; EZINE S, 1991, INT IMMUNOL, V3, P237; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FUCHS E, 1988, TRENDS GENET, V4, P277, DOI 10.1016/0168-9525(88)90169-2; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GODFREY DI, 1990, IMMUNOLOGY, V70, P66; GUTIERREZ JC, 1991, P NATL ACAD SCI USA, V88, P642, DOI 10.1073/pnas.88.2.642; HRONIS TS, 1984, CANCER RES, V44, P5797; JAT PS, 1989, MOL CELL BIOL, V9, P1672, DOI 10.1128/MCB.9.4.1672; Jenkinson E J, 1990, Semin Immunol, V2, P51; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KAMPINGA J, 1990, J IMMUNOL, V145, P1659; KANARIOU M, 1989, CLIN EXP IMMUNOL, V78, P263; KENDALL MD, 1989, THYMUS, V13, P157; KRAAL G, 1986, J EXP MED, V163, P981, DOI 10.1084/jem.163.4.981; KUEHN R, 1991, Science (Washington D C), V254, P707; LEWIS DB, 1991, J EXP MED, V173, P89, DOI 10.1084/jem.173.1.89; LOBACH DF, 1987, J CLIN IMMUNOL, V7, P81, DOI 10.1007/BF00916002; LOEWENTHAL J, 1988, J IMMUNOL, V140, P456; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MARTINEZ J, 1991, GENE DEV, V5, P51; MATSUSHIME H, 1991, BLOOD, V78, P616; MCNIECE IK, 1991, J IMMUNOL, V146, P3785; MCNIECE IK, 1991, EXP HEMATOL, V19, P226; MILLNER J, 1990, ONCOGENE, V5, P1683; MIYAMAINABA M, 1988, J EXP MED, V168, P811, DOI 10.1084/jem.168.2.811; MOLL J, 1992, IN PRESS EUR J IMMUN; MONROE JG, 1988, CLIN IMMUNOL IMMUNOP, V49, P292, DOI 10.1016/0090-1229(88)90119-5; MURPHY ED, 1971, P AM ASSOC CANC RES, V12, P45; NAGAMINE J, 1991, J IMMUNOL, V147, P1147; OKADA S, 1991, BLOOD, V78, P1706; PALACIOS R, 1989, EMBO J, V8, P4053, DOI 10.1002/j.1460-2075.1989.tb08589.x; PALACIOS R, 1987, EMBO J, V6, P91, DOI 10.1002/j.1460-2075.1987.tb04723.x; PALACIOS R, 1990, J EXP MED, V172, P219, DOI 10.1084/jem.172.1.219; PALACIOS R, 1991, EUR J IMMUNOL, V21, P109, DOI 10.1002/eji.1830210117; PAUL WE, 1991, BLOOD, V77, P1859; PEDEN KWC, 1989, VIROLOGY, V168, P13, DOI 10.1016/0042-6822(89)90398-X; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; PLUM J, 1990, J IMMUNOL, V145, P1066; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; RENNICK D, 1989, BLOOD, V73, P1828; RESNICKSILVERMAN L, 1991, J VIROL, V65, P2845, DOI 10.1128/JVI.65.6.2845-2852.1991; RUOSLAHTI E, 1989, CANCER CELL-MON REV, V1, P119; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SAMARIDIS J, 1991, EUR J IMMUNOL, V21, P453, DOI 10.1002/eji.1830210230; Sambrook J, 1989, MOL CLONING LABORATO; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHORES EW, 1991, EUR J IMMUNOL, V21, P1657, DOI 10.1002/eji.1830210711; SHORES EW, 1991, EUR J IMMUNOL, V21, P973, DOI 10.1002/eji.1830210417; Shortman K, 1990, Semin Immunol, V2, P3; SMALL M, 1989, IMMUNOLOGY, V68, P371; SPRANGRUDE CJ, 1990, J IMMUNOLY, V145, P3661; STANLEY ER, 1990, GENETICS OF PATTERN FORMATION AND GROWTH CONTROL, P165; STUDA T, 1991, J IMMUNOL, V146, P3068; TACK LC, 1989, J VIROL, V63, P3362, DOI 10.1128/JVI.63.8.3362-3367.1989; TEPPER RI, 1990, CELL, V62, P457, DOI 10.1016/0092-8674(90)90011-3; THOMPSON DL, 1990, VIROLOGY, V178, P15, DOI 10.1016/0042-6822(90)90375-2; TRUEB B, 1985, J CELL BIOL, V100, P638, DOI 10.1083/jcb.100.2.638; VANEWIJK W, 1991, ANNU REV IMMUNOL, V9, P591, DOI 10.1146/annurev.iy.09.040191.003111; VANVLIET E, 1985, EUR J IMMUNOL, V15, P675, DOI 10.1002/eji.1830150707; WELHAM MJ, 1991, MOL CELL BIOL, V11, P2901, DOI 10.1128/MCB.11.5.2901; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; WU L, 1991, J EXP MED, V174, P1617, DOI 10.1084/jem.174.6.1617; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767	87	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2175	2187						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1279498				2022-12-28	WOS:A1992JW66500010
J	NEUMANN, M; TSAPOS, K; SCHEPPLER, JA; ROSS, J; FRANZA, BR				NEUMANN, M; TSAPOS, K; SCHEPPLER, JA; ROSS, J; FRANZA, BR			IDENTIFICATION OF COMPLEX-FORMATION BETWEEN 2 INTRACELLULAR TYROSINE KINASE SUBSTRATES - HUMAN C-REL AND THE P105 PRECURSOR OF P50 NF-KAPPA-B	ONCOGENE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ENHANCER-BINDING-PROTEIN; LONG TERMINAL REPEAT; DNA-BINDING; V-REL; TRANSCRIPTION FACTORS; CELLULAR PROTEINS; STRAIN-T; ACTIVATION; CELLS	Immune complexes of the product of the c-rel protooncogene and of p105, the p50 NF-kappaB precursor, isolated from human T-lymphoblastoid cell lines are comprised of multiple proteins. Only p105 and human c-Rel (hc-Rel) are common to complexes precipitated with antiserum directed against either p105 or hc-Rel. Both proteins are inducible by phytohemagglutinin (PHA) and phorbol 12-myristate 13-acetate (PMA) and their subcellular distribution is affected by this induction. We demonstrate that the Rel immune complex contains a protein with a molecular weight in the 40 kDa range (p40) which apparently is exclusively cytoplasmic. We were not able to detect p40 in the p105 immune complex, though hc-Rel is present. This indicates that hc-Rel exists in different multi-protein complexes and fits a model of functional regulation mediated by differential protein-protein interaction. We also demonstrate considerable isoform diversity of both hc-Rel and p105. We show that this heterogeneity is, in part, the result of phosphorylation. Furthermore, we demonstrate that p105 and hc-Rel are tyrosine kinase substrates. This finding indicates a role for both proteins in intracellular signal transduction pathways which are modulated by modification of their phosphorylation status.	COLD SPRING HARBOR LAB, FREEMAN LAB CANC CELL BIOL, COLD SPRING HARBOR, NY 11724 USA	Cold Spring Harbor Laboratory					NIAID NIH HHS [NIAID 32028] Funding Source: Medline; NCPDCID CDC HHS [NCI 40512] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032028] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCPDCID CDC HHS; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CROSS SL, 1989, SCIENCE, V244, P466, DOI 10.1126/science.2497520; DALEY GQ, 1991, ADV CANCER RES, V57, P151; DAVIS JN, 1990, ONCOGENE, V5, P1109; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINTER H, 1987, EMBO J, V6, P4067, DOI 10.1002/j.1460-2075.1987.tb02752.x; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FRANZA BR, 1990, UCLA SYM BI, V119, P181; FRANZA BR, 1987, NATURE, V330, P391, DOI 10.1038/330391a0; GARRELS JI, 1989, J BIOL CHEM, V264, P5283; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GILMORE TD, 1991, TRENDS GENET, V7, P318, DOI 10.1016/0168-9525(91)90200-A; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; IP YT, 1991, CELL, V64, P439; KABRUN N, 1991, P NATL ACAD SCI USA, V88, P1783, DOI 10.1073/pnas.88.5.1783; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KAUFMAN JD, 1987, MOL CELL BIOL, V7, P3759, DOI 10.1128/MCB.7.10.3759; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KOCHEL T, 1991, ONCOGENE, V6, P615; KOCHEL T, 1992, ONCOGENE, V7, P567; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JH, 1991, ONCOGENE, V6, P665; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; LI YC, 1991, MOL CELL BIOL, V11, P1883, DOI 10.1128/MCB.11.4.1883; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MORRISON LE, 1989, ONCOGENE, V4, P677; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NAKAYAMA K, 1992, MOL CELL BIOL, V12, P1736, DOI 10.1128/MCB.12.4.1736; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; NSRURTLR PS, 1988, DVIRNVR, V242, P540; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; RICE NR, 1988, ONCOGENE HDB, P495; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; RIVIERE Y, 1991, NATURE, V350, P625, DOI 10.1038/350625a0; ROBINSON FR, 1974, AVIAN DIS, V18, P278, DOI 10.2307/1589142; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; STOVER DR, 1991, P NATL ACAD SCI USA, V88, P7704, DOI 10.1073/pnas.88.17.7704; TONGSTARKSEN SE, 1987, P NATL ACAD SCI USA, V84, P6845, DOI 10.1073/pnas.84.19.6845; URBAN MB, 1990, GENE DEV, V4, P1975, DOI 10.1101/gad.4.11.1975; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984	61	45	45	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1992	7	11					2095	2104						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437141				2022-12-28	WOS:A1992JW66500001
J	NEGRINI, M; CASTAGNOLI, A; SABBIONI, S; RECANATINI, E; GIOVANNINI, G; POSSATI, L; STANBRIDGE, EJ; NENCI, I; BARBANTIBRODANO, G				NEGRINI, M; CASTAGNOLI, A; SABBIONI, S; RECANATINI, E; GIOVANNINI, G; POSSATI, L; STANBRIDGE, EJ; NENCI, I; BARBANTIBRODANO, G			SUPPRESSION OF TUMORIGENESIS BY THE BREAST-CANCER CELL-LINE MCF-7 FOLLOWING TRANSFER OF A NORMAL HUMAN CHROMOSOME-11	ONCOGENE			English	Article							MESSENGER RIBONUCLEIC-ACID; WILMS TUMOR; RETINOBLASTOMA GENE; RECEPTOR ASSAYS; CARCINOMA-CELLS; PROTO-ONCOGENE; TRANSFER XMMCT; ARM DELETIONS; HUMAN HOMOLOG; ALLELE LOSS	Breast cancer development is associated with several genetic abnormalities. Loss of heterozygosity in the short arm of chromosome 11 has been observed in 30% of tumors. We found homozygosity at five chromosome 11 polymorphic loci in genomic DNA of the MCF-7 breast carcinoma cell line, suggesting a possible loss of one chromosome 11. We have studied the transformed and tumorigenic phenotypes of MCF-7 cells following introduction of a normal human chromosome 11 via microcell fusion. MCF-7/H11 cell hybrids, containing chromosome 11, showed in vitro characteristics similar to the parental cell line. However, tumorigenicity in athymic mice was completely suppressed. Since tumor formation by MCF-7 cells is estrogen dependent, we have analysed the expression of the estrogen receptor and of the estrogen-activated gene pS2. No difference was detected between the parental MCF-7 cells and the derived chromosome 11 cell hybrids, indicating that the mechanism of MCF-7 tumor suppression by chromosome 11-associated functions does not directly involve the estrogen/estrogen receptor molecular pathway.	UNIV ANCONA,INST BIOMED SCI,I-60131 MONTE DAGO,ITALY; UNIV CALIF IRVINE,DEPT MICROBIOL & MOLEC GENET,IRVINE,CA 92717; UNIV FERRARA,INST MICROBIOL,I-44100 FERRARA,ITALY; UNIV FERRARA,INST RADIOL,I-44100 FERRARA,ITALY; UNIV FERRARA,INST PATHOL ANAT & HISTOL,I-44100 FERRARA,ITALY	Marche Polytechnic University; University of California System; University of California Irvine; University of Ferrara; University of Ferrara; University of Ferrara	NEGRINI, M (corresponding author), UNIV FERRARA,INTERDEPT CTR CANC RES,VIA LUIGI BORSARI 46,I-44100 FERRARA,ITALY.		Negrini, Massimo/J-2377-2016	Negrini, Massimo/0000-0002-0007-1920	PHS HHS [19104] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; BARKER D, 1984, AM J HUM GENET, V36, P1159; BARTEK J, 1990, ONCOGENE, V5, P893; BATES SE, 1988, MOL ENDOCRINOL, V2, P543, DOI 10.1210/mend-2-6-543; BERGER SL, 1979, BIOCHEMISTRY-US, V18, P5143, DOI 10.1021/bi00590a018; BROWN AMC, 1984, P NATL ACAD SCI-BIOL, V81, P6344, DOI 10.1073/pnas.81.20.6344; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; CHEN LC, 1989, P NATL ACAD SCI USA, V86, P7204, DOI 10.1073/pnas.86.18.7204; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; DEVILEE P, 1991, ONCOGENE, V6, P1705; DEVILEE P, 1991, ONCOGENE, V6, P311; DICKSON RB, 1987, P NATL ACAD SCI USA, V84, P837, DOI 10.1073/pnas.84.3.837; DICKSON RB, 1986, SCIENCE, V232, P1540, DOI 10.1126/science.3715461; DOWDY SF, 1990, GENE CHROMOSOME CANC, V2, P318, DOI 10.1002/gcc.2870020410; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FOURNIER REK, 1977, P NATL ACAD SCI USA, V74, P319, DOI 10.1073/pnas.74.1.319; GENDLER SJ, 1990, INT J CANCER, V45, P431, DOI 10.1002/ijc.2910450309; GENUARDI M, 1989, AM J HUM GENET, V45, P73; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KOENDERS A, 1983, EUR J CANCER CLIN ON, V19, P1221, DOI 10.1016/0277-5379(83)90199-2; KOI M, 1989, MOL CARCINOGEN, V2, P12, DOI 10.1002/mc.2940020103; KOUFOS A, 1985, NATURE, V316, P330, DOI 10.1038/316330a0; KOUFOS A, 1984, NATURE, V309, P170, DOI 10.1038/309170a0; KUGOH HM, 1990, ONCOGENE, V5, P1637; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE JH, 1989, CANCER RES, V49, P1220; LOH WE, 1992, P NATL ACAD SCI USA, V89, P1755, DOI 10.1073/pnas.89.5.1755; LOTHE RA, 1989, GENOMICS, V5, P134, DOI 10.1016/0888-7543(89)90097-9; LUNDBERG C, 1987, P NATL ACAD SCI USA, V84, P2372, DOI 10.1073/pnas.84.8.2372; MACKAY J, 1988, LANCET, V2, P1384; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MCGUIRE WL, 1977, CANCER RES, V37, P637; MISRA BC, 1989, AM J HUM GENET, V45, P565; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OSHIMURA M, 1990, J CELL BIOCHEM, V42, P135, DOI 10.1002/jcb.240420304; PROSSER J, 1990, ONCOGENE, V5, P1573; QUAN F, 1986, NUCLEIC ACIDS RES, V14, P5321, DOI 10.1093/nar/14.13.5321; READ LD, 1989, MOL ENDOCRINOL, V3, P295, DOI 10.1210/mend-3-2-295; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; SACEDA M, 1989, MOL ENDOCRINOL, V3, P1782, DOI 10.1210/mend-3-11-1782; Sambrook J, 1989, MOL CLONING LABORATO; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; Saxon P J, 1987, Methods Enzymol, V151, P313, DOI 10.1016/S0076-6879(87)51026-6; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHMIDTKE J, 1984, HUM GENET, V67, P428, DOI 10.1007/BF00291404; SCRABLE HJ, 1987, NATURE, V329, P645, DOI 10.1038/329645a0; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOULE HD, 1980, CANCER LETT, V10, P177, DOI 10.1016/0304-3835(80)90042-7; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; THEILLET C, 1990, ONCOGENE, V5, P147; THEILLET C, 1989, ONCOGENE, V4, P915; THEILLET C, 1986, CANCER RES, V46, P4776; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; VARLEY JM, 1988, ONCOGENE, V3, P87; VARLEY JM, 1989, ONCOGENE, V4, P725; WANG HP, 1988, CYTOGENET CELL GENET, V48, P72, DOI 10.1159/000132593; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; WILLIAMS BP, 1988, ONCOGENE, V3, P345; YEE D, 1988, CANCER RES, V48, P6691; ZHOU DJ, 1988, ONCOGENE, V2, P279	70	20	20	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					2013	2018						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408142				2022-12-28	WOS:A1992JP42400015
J	REYNOLDS, PJ; HURLEY, TR; SEFTON, BM				REYNOLDS, PJ; HURLEY, TR; SEFTON, BM			FUNCTIONAL-ANALYSIS OF THE SH2 AND SH3 DOMAINS OF THE LCK TYROSINE PROTEIN-KINASE	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; PHOSPHORYLATED CELLULAR PROTEINS; AMINO-TERMINAL DOMAIN; PHOSPHOLIPASE-C; SRC GENE; TRANSFORMING ACTIVITY; DIRECTED MUTAGENESIS; COMPLEMENTARY-DNA; POINT MUTATIONS; V-SRC	p56lck is a lymphoid cell-specific member of the src family of cytoplasmic tyrosine kinases. In helper and cytotoxic T cells it is physically associated with the CD4 and CD8 surface antigens and appears to play a role in signal transduction during T-cell activation. p56lck contains both an SH3 and an SH2 Src homology domain. Such domains have been suggested to play a role in the regulation of the activity or function of both receptor and non-receptor tyrosine protein kinases. Deletion of either or both domains in p56lck was found here to activate the protein and to lead to increased phosphorylation of the autophosphorylation site, Tyr-394, in vivo. These findings are consistent with the hypothesis that these domains participate in repression of the kinase activity of p56lck. None of the deleted forms was capable of transformation of fibroblasts. Deletion of the SH3 domain of a constitutively activated form of p56lck, p56lckF505, did not diminish the transforming activity of this protein. This suggests that this domain is dispensable for the transformation of fibroblasts by p56lck. In contrast, deletion of the SH2 domain abolished the transforming potential of activated p56lckF505. However, interpretation of this effect is made somewhat difficult because the mutation also lowered the steady-state abundance of the protein.	SALK INST,MOLEC BIOL & VIROL LAB,POB 85800,SAN DIEGO,CA 92186; UNIV CALIF SAN DIEGO,DEPT CHEM,LA JOLLA,CA 92093	Salk Institute; University of California System; University of California San Diego					NCI NIH HHS [CA 14129, CA 42350] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042350] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; BRYANT D, 1982, J VIROL, V44, P683, DOI 10.1128/JVI.44.2.683-691.1982; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HIRAI J, 1990, MOL CELL BIOL, V10, P1307; HURLEY TR, 1989, ONCOGENE, V4, P265; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KAMPS MP, 1988, ONCOGENE, V2, P305; KANNER SB, 1989, J IMMUNOL METHODS, V120, P115, DOI 10.1016/0022-1759(89)90296-2; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KITAMURA N, 1983, J VIROL, V46, P985, DOI 10.1128/JVI.46.3.985-992.1983; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOGA Y, 1988, CANCER RES, V48, P856; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LUO K, 1990, ONCOGENE, V5, P921; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; Potts W M, 1988, Oncogene Res, V3, P343; RAYMOND VW, 1987, VIROLOGY, V160, P400, DOI 10.1016/0042-6822(87)90011-0; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SHORE SK, 1990, P NATL ACAD SCI USA, V87, P6502, DOI 10.1073/pnas.87.17.6502; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1987, ONCOGENE RES, V1, P357; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; VORONOVA AF, 1985, MOL CELL BIOL, V4, P2705; WANG HCR, 1989, J VIROL, V63, P291, DOI 10.1128/JVI.63.1.291-302.1989; WASENIUS VM, 1989, J CELL BIOL, V108, P79, DOI 10.1083/jcb.108.1.79; WENDLER PA, 1989, ONCOGENE, V4, P231; ZAMOYSKA R, 1989, NATURE, V342, P278, DOI 10.1038/342278a0; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	54	43	47	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					1949	1955						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408136				2022-12-28	WOS:A1992JP42400007
J	WALKER, CW; BOOM, JDG; MARSH, AG				WALKER, CW; BOOM, JDG; MARSH, AG			1ST NONVERTEBRATE MEMBER OF THE MYC GENE FAMILY IS SEASONALLY EXPRESSED IN AN INVERTEBRATE TESTIS	ONCOGENE			English	Article							HUMAN C-MYC; STAR PISASTER-OCHRACEUS; DNA-BINDING; SEA STAR; DROSOPHILA-MELANOGASTER; NUCLEOTIDE-SEQUENCE; ASTERIAS-VULGARIS; GERMINAL CELLS; PROTEIN; ONCOGENES	We have cloned and characterized the first non-vertebrate member of the myc gene family, pAv-myc, from testes of the Northern sea star, Asterias vulgaris (Echinodermata). We have used an oligonucleotide that is complementary to the virtually 100% conserved vertebrate c-myc box A in the second exon and a cDNA library constructed from spermatogenically active testes. Relatives of this echinoderm existed approximately 100 million years prior to the origin of the earliest known organism for which c-myc sequence is currently available (the trout). Nonetheless, our cDNA encodes a protein with approximately 30% amino acid identity and 46% overall conservation to human c-myc. Regions of substantially higher conservation (63-95%) correspond in order to the transcriptional activation (boxes A, B and C), casein kinase II phosphorylation, nuclear-targeting, basic DNA-binding and oligomerization domains in the second and third exons of human c-myc. Sea star c-myc cDNA detects a 2.7-kb transcript on Northern blots of monthly samples of testicular tissue from field-collected individuals (n = 6-8), indicating peak expression during active spermatogenesis. This is also the first example of seasonal variation in expression of c-myc during spermatogenesis in laboratory or natural populations of any animal. It is intriguing to speculate about the potential oncogenic character of c-myc in this invertebrate, in which tumors have not yet been observed, and about the possibility that c-myc is more widely present in eucaryotes than has been anticipated.	UNIV MARYLAND,COMB,BALTIMORE,MD 21203; SIMON FRASER UNIV,INST MOLEC BIOL & BIOCHEM,BURNABY V5A 1S6,BC,CANADA	University System of Maryland; University of Maryland Baltimore; Simon Fraser University	WALKER, CW (corresponding author), UNIV NEW HAMPSHIRE,DEPT ZOOL,DURHAM,NH 03824, USA.							ARGUAT C, 1991, GENE, V97, P231; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CHENG GH, 1989, MOL CELL BIOL, V9, P2332, DOI 10.1128/MCB.9.6.2332; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DANG CV, 1989, MOL CELL BIOL, V9, P2477, DOI 10.1128/MCB.9.6.2477; DANG CV, 1991, BIOCHIM BIOPHYS ACTA, V1072, P103, DOI 10.1016/0304-419X(91)90009-A; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DEPINHO RA, 1987, GENE DEV, V1, P1131; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GEORGE DG, 1990, METHOD ENZYMOL, V183, P333; HOWELL AM, 1987, J MOL EVOL, V25, P29, DOI 10.1007/BF02100038; IGUCHIARIGA SMM, 1987, EMBO J, V6, P2365, DOI 10.1002/j.1460-2075.1987.tb02513.x; INGVARSSON S, 1988, MOL CELL BIOL, V8, P3168, DOI 10.1128/MCB.8.8.3168; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KHANDJIAN EW, 1986, MOL BIOL REP, V11, P107, DOI 10.1007/BF00364822; KING MW, 1986, MOL CELL BIOL, V6, P4499, DOI 10.1128/MCB.6.12.4499; KOHL NE, 1986, NATURE, V319, P73, DOI 10.1038/319073a0; KOVESDI I, 1985, MOL CELL BIOL, V5, P3001, DOI 10.1128/MCB.5.11.3001; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LUDWIG SR, 1989, P NATL ACAD SCI USA, V86, P7092, DOI 10.1073/pnas.86.18.7092; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MAKELA TP, 1991, THESIS HELSINKI FINL; MIFFLIN D, 1988, BIOSCIENCE REP, V8, P415, DOI 10.1007/BF01121638; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PETERS EC, 1988, AM FISH SOC SPECIAL, V18, P74; PRENDERGAST GC, 1990, NATURE, V342, P392; Sambrook J, 1989, MOL CLONING LABORATO; SARID J, 1987, P NATL ACAD SCI USA, V84, P170, DOI 10.1073/pnas.84.1.170; SARID J, 1988, NUCLEIC ACIDS RES, V16, P4725, DOI 10.1093/nar/16.10.4725; SHILO BZ, 1981, P NATL ACAD SCI-BIOL, V78, P6789, DOI 10.1073/pnas.78.11.6789; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SPARKS AK, 1972, INVERTEBRATE PATHOLO, P271; STEWART MA, 1986, VIROLOGY, V154, P121, DOI 10.1016/0042-6822(86)90435-6; STEWART TA, 1984, SCIENCE, V226, P707, DOI 10.1126/science.6494906; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; SUGIYAMA A, 1989, P NATL ACAD SCI USA, V86, P9144, DOI 10.1073/pnas.86.23.9144; VANBENEDEN RJ, 1986, P NATL ACAD SCI USA, V83, P3698; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8; WALKER CW, 1980, J MORPHOL, V166, P81, DOI 10.1002/jmor.1051660107; WATSON DK, 1983, P NATL ACAD SCI-BIOL, V80, P2146, DOI 10.1073/pnas.80.8.2146; WATTS SA, 1990, TISSUE CELL, V22, P435, DOI 10.1016/0040-8166(90)90073-I; WATTS SA, 1990, BIOL BULL, V179, P159, DOI 10.2307/1541750; WOLFES H, 1989, SCIENCE, V245, P740, DOI 10.1126/science.2475907	50	29	33	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					2007	2012						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408141				2022-12-28	WOS:A1992JP42400014
J	STURZBECHER, HW; BRAIN, R; ADDISON, C; RUDGE, K; REMM, M; GRIMALDI, M; KEENAN, E; JENKINS, JR				STURZBECHER, HW; BRAIN, R; ADDISON, C; RUDGE, K; REMM, M; GRIMALDI, M; KEENAN, E; JENKINS, JR			A C-TERMINAL ALPHA-HELIX PLUS BASIC REGION MOTIF IS THE MAJOR STRUCTURAL DETERMINANT OF P53 TETRAMERIZATION	ONCOGENE			English	Article							LARGE T-ANTIGEN; TUMOR SUPPRESSOR PROTEIN; DNA-BINDING PROTEINS; MONOCLONAL-ANTIBODIES; WILD-TYPE; TRANSFORMED-CELLS; TRANS-ACTIVATION; CELLULAR PROTEIN; LEUCINE ZIPPER; SV40 ORIGIN	The p53 gene product has been implicated in both human and animal tumorigenesis. p53 forms heterologous complexes with the transforming proteins encoded by several different DNA tumor viruses. p53 also assembles into stable homo-oligomers. We demonstrate that the major structural determinant for the tetramerization of p53 is an alpha-helical plus basic region motif near the C-terminus of the protein. A monomeric p53 mutant adopts a conformation distinct from both `wild-type' and `mutant' form as defined by PAb1620 and PAb240 monoclonal antibody recognition. Nevertheless, monomeric and dimeric mutant p53 proteins retain the ability to suppress SV40 origin-directed DNA replication in vivo. Thus, p53-p53 interaction and expression of the PAb1620 epitope is not a prerequisite for such activity. We present data suggesting that suppression of replication by p53 may occur by a mechanism that is independent of detectable p53-T antigen association.	MARIE SKLODOWSKA CURIE MEM INST,CELL PROLIFERAT LAB,OXTED RH8 0TL,SURREY,ENGLAND; ESTONIAN BIOCTR,TARTU,ESTONIA,USSR	Estonian Biocentre			Remm, Maido/L-9072-2019	Remm, Maido/0000-0003-3966-8422				ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; ADDISON C, 1990, ONCOGENE, V5, P423; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUNG MC, 1988, J VIROL METHODS, V19, P33, DOI 10.1016/0166-0934(88)90005-5; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GENTZ R, 1989, P NATL ACAD SCI USA, V86, P821, DOI 10.1073/pnas.86.3.821; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; JENKINS JR, 1988, ONCOGENE HDB, P403; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; MCCORMICK F, 1981, NATURE, V292, P63, DOI 10.1038/292063a0; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHMIEG FI, 1988, VIROLOGY, V164, P132, DOI 10.1016/0042-6822(88)90628-9; STURZBECHER HW, 1990, ONCOGENE, V5, P795; STURZBECHER HW, 1988, ONCOGENE, V3, P405; STURZBECHER HW, 1987, ONCOGENE, V1, P201; STURZBECHER HW, 1988, MOL CELL BIOL, V8, P3740; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WILLIAMS T, 1991, SCIENCE, V251, P1067, DOI 10.1126/science.1998122	53	247	254	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1513	1523						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1321401				2022-12-28	WOS:A1992JE81300007
J	FAUST, M; EBENSPERGER, C; SCHULZ, AS; SCHLEITHOFF, L; HAMEISTER, H; BARTRAM, CR; JANSSEN, JWG				FAUST, M; EBENSPERGER, C; SCHULZ, AS; SCHLEITHOFF, L; HAMEISTER, H; BARTRAM, CR; JANSSEN, JWG			THE MURINE UFO RECEPTOR - MOLECULAR-CLONING, CHROMOSOMAL LOCALIZATION AND INSITU EXPRESSION ANALYSIS	ONCOGENE			English	Article							TYROSINE KINASES; PROTEIN-KINASE; HYBRIDIZATION; DOMAINS; FAMILY; SIGNAL; AMPLIFICATION; FIBRONECTIN; RECOGNITION; HOMOLOGY	We have cloned the mouse homologue of the ufo oncogene. It encodes a novel tyrosine kinase receptor characterized by a unique extracellular domain containing two immunoglobulin-like and two fibronectin type III repeats. Comparison of the predicted ufo amino acid sequences of mouse and man revealed an overall identity of 87.6%. The ufo locus maps to mouse chromosome 7A3-B1 and thereby extends the known conserved linkage group between mouse chromosome 7 and human chromosome 19. RNA in situ hyrbridization analysis established the onset of specific ufo expression in the late embryogenesis at day 12.5 post coitum (p.c.) and localized ufo transcription to distinct substructures of a broad spectrum of developing tissues (e.g. subepidermal cells of the skin, mesenchymal cells of the periosteum). In adult animals ufo is expressed in cells forming organ capsules as well as in connective tissue structures. ufo may function as a signal transducer between specific cell types of mesodermal origin.	UNIV ULM,DEPT PEDIAT 2,MOLEC BIOL SECT,PRITTWITZSTR 43,W-7900 ULM,GERMANY; UNIV ULM,DEPT CLIN GENET,W-7900 ULM,GERMANY	Ulm University; Ulm University								ADOLPH S, 1987, CYTOGENET CELL GENET, V44, P65, DOI 10.1159/000132345; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIRNING U, 1991, MECH DEVELOP, V33, P119, DOI 10.1016/0925-4773(91)90078-K; HUNTER T, 1982, J BIOL CHEM, V257, P4843; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; Lyon M., 1989, GENETIC VARIANTS STR; LYON MF, 1987, MOUSE NEWS LETT, V787, P12; Maniatis T., 1982, MOL CLONING; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PATTHY L, 1990, CELL, V61, P13, DOI 10.1016/0092-8674(90)90208-V; PETERSEN TE, 1983, P NATL ACAD SCI-BIOL, V80, P137, DOI 10.1073/pnas.80.1.137; RENTROP M, 1986, HISTOCHEM J, V18, P271, DOI 10.1007/BF01676237; RESCIGNO J, 1991, ONCOGENE, V6, P1909; Rinchik E M, 1991, Mamm Genome, V1 Spec No, pS97, DOI 10.1007/BF00656488; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMID P, 1989, SCIENCE, V243, P226, DOI 10.1126/science.2911736; SEALEY PG, 1985, NUCLEIC ACIDS RES, V13, P1905, DOI 10.1093/nar/13.6.1905; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SONNENBERG E, 1991, EMBO J, V10, P3693, DOI 10.1002/j.1460-2075.1991.tb04937.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	35	66	70	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1287	1293						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1320243				2022-12-28	WOS:A1992HZ97100006
J	FLYNN, DC; SCHALLER, MD; PARSONS, JT				FLYNN, DC; SCHALLER, MD; PARSONS, JT			TYROSINE PHOSPHORYLATION OF A 120000 DALTON MEMBRANE-ASSOCIATED PROTEIN BY THE NEURAL FORM OF PP60C-SRC, PP60C-SRC+	ONCOGENE			English	Note							CELLULAR SRC GENE; C-SRC; MONOCLONAL-ANTIBODIES; SIGNAL TRANSDUCTION; CARBOXY TERMINUS; PHOSPHOLIPASE-C; KINASE-ACTIVITY; MESSENGER-RNA; CELLS; PRODUCT	The c-src proto-oncogene encodes a 60000 dalton tyrosine kinase, pp60c-src, which is the prototype member of the family of non-receptor tyrosine kinases. A neural-specific form of pp60c-src, pp60c-src+, is detected only in neurons of the central nervous system. pp60c-src+ contains a six amino acid insert (neural insert) in the SH3 region that is generated by alternative splicing. Previous reports indicate that the profiles of proteins phosphorylated on tyrosine in chick embryo fibroblast (CEF) cells by pp60c-sec+ or pp60c-src are equivalent. In this report, the activities of pp60c-src+ and pp60c-src, as well as the activated variants, pp60(527F+) and pp60(527F), were compared in CEF cells by examining the steady-state levels of tyrosine phosphorylation of several known pp60src substrates. Most substrates examined were phosphorylated on tyrosine to equivalent levels in CEF cells expressing either the neural- or fibroblast-specific src gene products. However, the relative extent of tyrosine phosphorylation of a 120 kDa protein (p120) was increased in cells expressing the neuronal forms of either c-src or c-src527F. The increased tyrosine phosphorylation of p120 did not appear to be caused by the neural insert facilitating a specific interaction between pp60c-src+ and p120. These data indicate that preferential phosphorylation of p120 in neural cells may contribute to the specialized function of pp60c-src+ in neural cells.	UNIV VIRGINIA,SCH MED,DEPT MICROBIOL,BOX 441,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,SCH MED,CTR CANC,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Virginia					NCI NIH HHS [CA29243, CA40042] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA029243, R37CA029243, P01CA040042] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; BARNEKOW A, 1984, MOL CELL BIOL, V4, P1179, DOI 10.1128/MCB.4.6.1179; BJELFMAN C, 1990, MOL CELL BIOL, V10, P361, DOI 10.1128/MCB.10.1.361; BOLEN JB, 1985, P NATL ACAD SCI USA, V82, P7275, DOI 10.1073/pnas.82.21.7275; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; CARTWRIGHT CA, 1987, MOL CELL BIOL, V7, P1830, DOI 10.1128/MCB.7.5.1830; COLLETT MS, 1978, CELL, V15, P1363, DOI 10.1016/0092-8674(78)90061-2; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; DOWNING JR, 1991, ONCOGENE, V6, P607; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; DRUBIN DG, 1988, J CELL BIOL, V107, P2551, DOI 10.1083/jcb.107.6.2551; GOULD KL, 1989, MOL ENDOCRINOL, V3, P79, DOI 10.1210/mend-3-1-79; GUNNING PW, 1981, J CELL BIOL, V89, P240, DOI 10.1083/jcb.89.2.240; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; KANNER SB, 1991, MOL CELL BIOL, V11, P713, DOI 10.1128/MCB.11.2.713; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBEAU JM, 1987, MOL CELL BIOL, V7, P4115, DOI 10.1128/MCB.7.11.4115; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; LEVY JB, 1989, MOL CELL BIOL, V9, P3332, DOI 10.1128/MCB.9.8.3332; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LYNCH SA, 1986, SCIENCE, V234, P873, DOI 10.1126/science.3095923; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCCAFFREY G, 1987, MOL CELL BIOL, V7, P2680, DOI 10.1128/MCB.7.8.2680; OPPERMANN H, 1979, P NATL ACAD SCI USA, V76, P1804, DOI 10.1073/pnas.76.4.1804; PAWSON T, 1988, ONCOGENE, V3, P491; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; PYPER JM, 1990, MOL CELL BIOL, V10, P2035, DOI 10.1128/MCB.10.5.2035; RAULF F, 1989, ONCOGENE RES, V5, P39; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; ROHRSCHNEIDER LR, 1979, P NATL ACAD SCI USA, V76, P4479, DOI 10.1073/pnas.76.9.4479; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; WASENIUS VM, 1989, J CELL BIOL, V108, P79, DOI 10.1083/jcb.108.1.79; WIESTLER OD, 1988, MOL CELL BIOL, V8, P502, DOI 10.1128/MCB.8.1.502; YANG XM, 1988, ONCOGENE, V3, P237	44	9	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1992	7	3					579	583						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1372401				2022-12-28	WOS:A1992HK00500027
J	LEECHANACHAI, P; BANKS, L; MOREAU, F; MATLASHEWSKI, G				LEECHANACHAI, P; BANKS, L; MOREAU, F; MATLASHEWSKI, G			THE E5 GENE FROM HUMAN PAPILLOMAVIRUS TYPE-16 IS AN ONCOGENE WHICH ENHANCES GROWTH FACTOR-MEDIATED SIGNAL TRANSDUCTION TO THE NUCLEUS	ONCOGENE			English	Article								Although human papillomavirus type 16 (HPV-16) is believed to be a major etiological agent in the development of cervical cancer, the biological function of several of its early genes remains to be established. In the present study, we have defined some of the biological properties of the E5 gene from HPV-16. Expression of the HPV-16 E5 gene in 3T3-A31 cells induced transformation to anchorage-independent growth (colony formation in soft agar). Addition of epidermal growth factor (EGF) to the soft-agar medium caused the E5-expressing cells to form larger colonies than those formed in the absence of EGF. Parental 3T3-A31 cells did not form colonies in soft agar either in the presence or in the absence of EGF. Analysis of clones expressing high levels of E5 mRNA revealed that these cells also expressed higher levels of c-fos mRNA in response to serum, EGF and platelet-derived growth factor (PDGF) than did the parental 3T3-A31 cells. Cells expressing the E5 gene were also capable of accelerated growth in low serum and were more tumorigenic in nude mice than were control cells. We conclude that the E5 gene from HPV-16 is an oncogene which transforms cells in part through enhancing signal transduction from growth factors to the nucleus.	MCGILL UNIV, INST PARASITOL, MACDONALD CAMPUS, 21111 LAKESHORE RD, ST ANNE BELLEVUE H9X 1C0, QUEBEC, CANADA; INT CTR GENET ENGN & BIOTECHNOL, I-34012 TRIESTE, ITALY	McGill University; International Center for Genetic Engineering & Biotechnology (ICGEB)								BANKS L, 1990, ONCOGENE, V5, P1383; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BOSHART M, 1984, EMBO J, V3, P1151, DOI 10.1002/j.1460-2075.1984.tb01944.x; BUBB V, 1988, VIROLOGY, V163, P243, DOI 10.1016/0042-6822(88)90259-0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAN WK, 1990, NUCLEIC ACIDS RES, V18, P763, DOI 10.1093/nar/18.4.763; CHEN SL, 1990, J VIROL, V64, P3226, DOI 10.1128/JVI.64.7.3226-3233.1990; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DEGEN JL, 1983, J BIOL CHEM, V258, P2153; DIMAIO D, 1986, P NATL ACAD SCI USA, V83, P1797, DOI 10.1073/pnas.83.6.1797; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; DURST M, 1985, J GEN VIROL, V66, P1515, DOI 10.1099/0022-1317-66-7-1515; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; HALBERT CL, 1988, J VIROL, V62, P1071, DOI 10.1128/JVI.62.3.1071-1075.1988; HARRIS AL, 1990, CANCER CELL-MON REV, V2, P321; HAUSEN HZ, 1988, MOL CARCINOGEN, V1, P147, DOI 10.1002/mc.2940010302; KOHLER M, 1989, ANTICANCER RES, V9, P1537; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; MCDONNELL SE, 1990, MOL CELL BIOL, V10, P4284, DOI 10.1128/MCB.10.8.4284; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; MUNGER K, 1989, J VIROL, V63, P4417; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; RO J, 1988, CANCER RES, V48, P161; SCHLEGEL R, 1986, SCIENCE, V233, P464, DOI 10.1126/science.3014660; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOUSDEN KH, 1989, CANCER CELL-MON REV, V1, P43; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899	35	197	202	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1992	7	1					19	25						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1311062				2022-12-28	WOS:A1992HC22700003
J	Valvano, MA				Valvano, Miguel A.			Bacterial conversion of a host weapon into a nutritional signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXIA; IMPACT	Bacteria engulfed by phagocytic cells must resist oxidation damage and adapt to cellular hypoxia, but the mechanisms involved in this process are not completely elucidated. Recent investigated how the intracellular pathogen Salmonella enterica activates gene expression required to counteract oxidative damage. The authors show that this bacterium utilizes host oxidative molecules to activate regulatory proteins that enhance the production of effector molecules, counteracting the host weapon NADPH oxidase and inducing a protective response.	[Valvano, Miguel A.] Queens Univ Belfast, Wellcome Wolfson Inst Expt Med, Belfast, North Ireland	Queens University Belfast	Valvano, MA (corresponding author), Queens Univ Belfast, Wellcome Wolfson Inst Expt Med, Belfast, North Ireland.	m.valvano@qub.ac.uk	Valvano, Miguel/G-8759-2012	Valvano, Miguel/0000-0001-8229-3641	Biotechnology and Biological Sciences [BB/T005807/1, BB/S006281/1]; Medical Research Councils [MR/P022480/1]; U.S. Cystic Fibrosis Foundation [VALVAN19G0]	Biotechnology and Biological Sciences(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Councils(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); U.S. Cystic Fibrosis Foundation	The author thanks Dr Ken Farabaugh for helpful comments on the text. The author's research is funded by the Biotechnology and Biological Sciences (BB/T005807/1 and BB/S006281/1) and Medical Research Councils (MR/P022480/1) , and by the U.S. Cystic Fibrosis Foundation (VALVAN19G0) .	Andre AC, 2022, TRENDS MICROBIOL, V30, P643, DOI 10.1016/j.tim.2022.01.002; Arena ET, 2017, MICROBES INFECT, V19, P157, DOI 10.1016/j.micinf.2016.10.011; Beebout CJ, 2022, NAT MICROBIOL, V7, P1348, DOI 10.1038/s41564-022-01205-w; Chou WK, 2019, FREE RADICAL BIO MED, V130, P288, DOI 10.1016/j.freeradbiomed.2018.10.435; Eltzschig HK, 2011, NEW ENGL J MED, V364, P656, DOI 10.1056/NEJMra0910283; Friedrich D, 2017, MICROBES INFECT, V19, P204, DOI 10.1016/j.micinf.2016.10.008; Galan JE, 2021, NAT REV MICROBIOL, V19, P716, DOI 10.1038/s41579-021-00561-4; Henard CA, 2010, J BIOL CHEM, V285, P36785, DOI 10.1074/jbc.M110.160960; Kim HY, 2018, J BIOL CHEM, V293, P5679, DOI [10.1074/jbc.RA117.000383, 10.1074/jbc.ra117.000383]; Kim JS, 2022, J BIOL CHEM, V298, DOI 10.1016/j.jbc.2022.102130; Krzywinska E, 2018, BIOMEDICINES, V6, DOI 10.3390/biomedicines6020056; Lee P, 2020, NAT REV MOL CELL BIO, V21, P268, DOI 10.1038/s41580-020-0227-y; Lodge KM, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041183; Prosser G, 2017, MICROBES INFECT, V19, P177, DOI 10.1016/j.micinf.2016.10.001; Sadiku P, 2019, EMBO REP, V20, DOI 10.15252/embr.201847388; Schaffer K, 2015, FEBS J, V282, P2260, DOI 10.1111/febs.13270; Zhang W, 2022, MSYSTEMS, V7, DOI 10.1128/msystems.00380-22	17	0	0	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV	2022	298	11							102600	10.1016/j.jbc.2022.102600	http://dx.doi.org/10.1016/j.jbc.2022.102600			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	6C1SV	36244456	gold, Green Published			2022-12-28	WOS:000881802600002
J	BONHAM, L; MACKENZIE, K; WOOD, S; ROWE, PB; SYMONDS, G				BONHAM, L; MACKENZIE, K; WOOD, S; ROWE, PB; SYMONDS, G			BOTH MYELOPROLIFERATIVE DISEASE AND LEUKEMIA ARE INDUCED BY TRANSPLANTATION OF BONE-MARROW CELLS EXPRESSING V-MYC	ONCOGENE			English	Article							HEMATOPOIETIC STEM-CELLS; RECOMBINANT MURINE RETROVIRUS; CHRONIC MYELOGENOUS LEUKEMIA; C-MYC; TRANSGENIC MICE; ADENOSINE-DEAMINASE; MEDIATED TRANSFER; GENE-TRANSFER; VIRUS; TRANSFORMATION	An in vivo system has been established to investigate v-myc-induced hematopoietic neoplasia in mice. A Moloney murine leukemia virus (Mo-MLV)-derived recombinant retrovirus containing v-myc was used to infect immature bone marrow cells, and these celts were then transplanted into lethally irradiated recipients. All provirus-positive reconstituted mice were found to develop hematopoietic proliferative disorders and, in certain cases, overt leukemia-myeloblastic, myelomonocytic and T lymphocytic. In all cases expression of v-myc was high and the disease type did not correlate with the level of expression. We have isolated immortalized monocytes, myeloid progenitors and T lymphocytes from several of these mice and shown tumorigenicity in secondary syngeneic recipients. This system provides a model for investigating the progression from a pre-leukemic disease to malignancy. In addition, we describe a recombinant v-myc-containing retrovirus that directs high-level v-myc expression from the Mo-MLV promoter in all the hematopoietic cell types examined.	CHILDRENS MED RES FDN, 214 HAWKESBURY RD, SYDNEY, NSW 2145, AUSTRALIA	Children's Medical Research Institute - Australia			Wood, Stephen A/E-8357-2011; Mackenzie, Karen/F-1310-2011; MacKenzie, Karen/N-5849-2019	Wood, Stephen A/0000-0002-2576-7457; MacKenzie, Karen/0000-0003-2996-1617				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ALITALO K, 1983, NATURE, V306, P274, DOI 10.1038/306274a0; BAUMBACH WR, 1986, J VIROL, V59, P276, DOI 10.1128/JVI.59.2.276-283.1986; BECKENGESER G, 1991, HUM GENE THER, V2, P61, DOI 10.1089/hum.1991.2.1-61; BENDER MA, 1987, J VIROL, V61, P1639, DOI 10.1128/JVI.61.5.1639-1646.1987; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BIRCHENALLROBERTS MC, 1989, ONCOGENE, V4, P731; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BISHOP JM, 1985, MOL BIOL TUMOR VIRUS, P249; BOWTELL DDL, 1988, J VIROL, V62, P2464, DOI 10.1128/JVI.62.7.2464-2473.1988; BOWTELL DDL, 1987, MOL BIOL MED, V4, P229; BRIGHTMAN BK, 1988, J IMMUNOL, V141, P2844; BRIGHTMAN BK, 1986, J VIROL, V60, P68, DOI 10.1128/JVI.60.1.68-81.1986; BURGESS A, 1983, GROWTH FACTORS STEM, P68; CHANG JM, 1989, BLOOD, V73, P1487; CHATIS PA, 1983, P NATL ACAD SCI-BIOL, V80, P4408, DOI 10.1073/pnas.80.14.4408; CHISHOLM O, 1992, IN PRESS ONCOGENE; CHUNG SW, 1991, P NATL ACAD SCI USA, V88, P1585, DOI 10.1073/pnas.88.4.1585; COFFMAN RL, 1983, IMMUNOL REV, V69, P5, DOI 10.1111/j.1600-065X.1983.tb00446.x; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DARLIX JL, 1986, J MOL BIOL, V189, P421, DOI 10.1016/0022-2836(86)90314-1; DUNBAR CE, 1991, ONCOGENE RES, V6, P39; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; EMERMAN M, 1984, J VIROL, V50, P42, DOI 10.1128/JVI.50.1.42-49.1984; EMERMAN M, 1986, MOL CELL BIOL, V6, P792, DOI 10.1128/MCB.6.3.792; ERBA HP, 1988, MOL CELL BIOL, V8, P1775, DOI 10.1128/MCB.8.4.1775; GAUSTCH JW, 1976, VIROLOGY, V72, P509; GONDA TJ, 1989, EMBO J, V8, P1767, DOI 10.1002/j.1460-2075.1989.tb03570.x; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GREEN SM, 1989, ONCOGENE, V4, P737; GREENBERG PL, 1983, BLOOD, V61, P1035; GREZ M, 1990, P NATL ACAD SCI USA, V87, P9202, DOI 10.1073/pnas.87.23.9202; GREZ M, 1991, J VIROL, V65, P4691, DOI 10.1128/JVI.65.9.4691-4698.1991; GRIESSER H, 1989, BLOOD, V73, P1402; HAYFLICK J, 1985, P NATL ACAD SCI USA, V82, P2718, DOI 10.1073/pnas.82.9.2718; HEARD JM, 1987, CELL, V51, P663, DOI 10.1016/0092-8674(87)90135-8; HIDDEMANN W, 1984, CYTOMETRY, V5, P445, DOI 10.1002/cyto.990050502; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; JOHNSON GR, 1989, EMBO J, V8, P441, DOI 10.1002/j.1460-2075.1989.tb03396.x; KELLER G, 1985, NATURE, V318, P149, DOI 10.1038/318149a0; KELLER G, 1989, GENE DEV, V3, P827, DOI 10.1101/gad.3.6.827; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; Maniatis T, 1989, MOL CLONING; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MCIVOR RS, 1990, VIROLOGY, V176, P652, DOI 10.1016/0042-6822(90)90039-T; MCIVOR RS, 1987, MOL CELL BIOL, V7, P838, DOI 10.1128/MCB.7.2.838; MORELLO D, 1989, ONCOGENE RES, V4, P111; PULSINELLI GA, 1991, J VIROL, V65, P4786, DOI 10.1128/JVI.65.9.4786-4797.1991; RALPH P, 1975, J IMMUNOL, V114, P898; SACHS L, 1987, SCIENCE, V238, P1374, DOI 10.1126/science.3317831; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; SCOTT ML, 1991, P NATL ACAD SCI USA, V88, P6506, DOI 10.1073/pnas.88.15.6506; STAPLETON P, 1991, ONCOGENE, V6, P807; SYMONDS G, 1982, EMBO J, V1, P1343, DOI 10.1002/j.1460-2075.1982.tb01320.x; SYMONDS G, 1989, ONCOGENE, V4, P285; THIESEN HJ, 1988, J VIROL, V62, P614, DOI 10.1128/JVI.62.2.614-618.1988; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VENNSTROM B, 1984, EMBO J, V3, P3223, DOI 10.1002/j.1460-2075.1984.tb02282.x; WAGNER EF, 1990, EMBO J, V9, P3025, DOI 10.1002/j.1460-2075.1990.tb07498.x; WEINBERG RA, 1989, CANCER RES, V49, P3713; WILLIAMS DA, 1986, P NATL ACAD SCI USA, V83, P2566, DOI 10.1073/pnas.83.8.2566; WILLIAMS WJ, 1983, HEMATOLOGY; WOLFF L, 1990, J VIROL, V64, P155, DOI 10.1128/JVI.64.1.155-160.1990; WONG PMC, 1989, MOL CELL BIOL, V9, P798, DOI 10.1128/MCB.9.2.798; XU L, 1989, VIROLOGY, V171, P331, DOI 10.1016/0042-6822(89)90600-4	69	15	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1992	7	11					2219	2229						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437146				2022-12-28	WOS:A1992JW66500014
J	VANDERHOORN, FA				VANDERHOORN, FA			IDENTIFICATION OF THE TESTIS C-MOS PROMOTER - SPECIFIC ACTIVITY IN A SEMINIFEROUS TUBULE-DERIVED EXTRACT AND BINDING OF A TESTIS-SPECIFIC NUCLEAR FACTOR	ONCOGENE			English	Article							PROTO-ONCOGENE; INVITRO TRANSCRIPTION; MOUSE PROTAMINE-1; TRANSGENIC MICE; GERM-CELLS; EXPRESSION; GENE; PRODUCT; RNA; ENHANCER	The c-mos proto-oncogene is predominantly expressed in male and female germ cells and is involved in the regulation of meiosis. To investigate the mechanism of testis-specific regulation of c-mos transcription, I set out to identify the rat testis c-mos promoter. This was achieved by characterization of the rat testis c-mos transcription start site by primer extension and sequence analysis of cDNAs obtained by polymerase chain reaction amplification of 5' ends of c-mos RNA. The rat testis c-mos transcription start site is located 0.56 kb upstream of the coding region. A fragment containing the rat testis c-mos promoter directs transcription in a nuclear extract derived from rat seminiferous tubules, but not in a liver nuclear extract. DNAase I footprint analysis and gel-retardation assays showed binding of a novel testis-specific nuclear factor to the rat testis c-mos promoter at a site homologous to the testis-specific cis-acting element identified in the promoter of the RT7 gene, which is specifically expressed in haploid male germ cells.			VANDERHOORN, FA (corresponding author), UNIV CALGARY, DEPT MED BIOCHEM, 3330 HOSP DR NW, CALGARY T2N 4N1, ALBERTA, CANADA.							BUNICK D, 1990, P NATL ACAD SCI USA, V87, P891, DOI 10.1073/pnas.87.3.891; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOLDMAN DS, 1987, P NATL ACAD SCI USA, V84, P4509, DOI 10.1073/pnas.84.13.4509; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HERZOG NK, 1988, ONCOGENE, V3, P225; HOWARD TE, 1990, MOL CELL BIOL, V10, P4294, DOI 10.1128/MCB.10.8.4294; JOHNSON PA, 1988, BIOCHIM BIOPHYS ACTA, V950, P45, DOI 10.1016/0167-4781(88)90071-1; LANGFORD KG, 1991, J BIOL CHEM, V266, P15559; LEIBOVITCH SA, 1990, ONCOGENE, V5, P1149; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; OLIVA R, 1991, PROG NUCLEIC ACID RE, V40, P25; PAL SK, 1991, MOL CELL BIOL, V11, P5190, DOI 10.1128/MCB.11.10.5190; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; PESCHON JJ, 1989, ANN NY ACAD SCI, V564, P186, DOI 10.1111/j.1749-6632.1989.tb25897.x; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; ROBINSON MO, 1989, P NATL ACAD SCI USA, V86, P8437, DOI 10.1073/pnas.86.21.8437; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SAMBROOK J, 1988, MOL CLONING LABORATO; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; STEWART TA, 1988, MOL CELL BIOL, V8, P1748, DOI 10.1128/MCB.8.4.1748; VANDERHOORN FA, 1987, J MOL BIOL, V193, P255, DOI 10.1016/0022-2836(87)90217-8; VANDERHOORN FA, 1992, P NATL ACAD SCI USA, V89, P703, DOI 10.1073/pnas.89.2.703; VANDERHOORN FA, 1991, ONCOGENE, V6, P929; VANDERHOORN FA, 1990, DEV BIOL, V142, P147, DOI 10.1016/0012-1606(90)90158-F; VANDERHOORN FA, 1989, BIOCHEM BIOPH RES CO, V161, P8, DOI 10.1016/0006-291X(89)91552-0; WOOD TG, 1984, P NATL ACAD SCI-BIOL, V81, P7817, DOI 10.1073/pnas.81.24.7817	29	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1992	7	6					1093	1099						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1375715				2022-12-28	WOS:A1992HU64200006
J	HILBERG, F; WAGNER, EF				HILBERG, F; WAGNER, EF			EMBRYONIC STEM (ES) CELLS LACKING FUNCTIONAL C-JUN - CONSEQUENCES FOR GROWTH AND DIFFERENTIATION, AP-1 ACTIVITY AND TUMORIGENICITY	ONCOGENE			English	Article							TRANSCRIPTION FACTOR AP-1; OSTEO-SARCOMA VIRUS; BINDING AFFINITIES; CYCLE PROGRESSION; MOUSE FIBROBLASTS; CARCINOMA-CELLS; GENE-EXPRESSION; PROTO-ONCOGENE; LEUCINE ZIPPER; FOS PROTEINS	The proto-oncogene c-jun encodes the major component of the transcription factor AP-1 and is thought to have important functions in cell proliferation and differentiation as well as in the cellular response to a variety of external stimuli. To investigate directly the role of c-jun in growth, differentiation and tumorigenicity we generated mouse embryonic stem (ES) cell lines in which both copies of the c-jun gene have been inactivated by homologous recombination. The disruption of both copies of the c-jun gene had no apparent effect on ES cell viability, growth rate and in vitro differentiation potential. Transcriptional activation of the c-jun, junB and c-fos genes following TPA/serum induction was unaffected and efficient transactivation of AP-1 reporter constructs was demonstrated in these cells. Remarkably, subcutaneous injection of ES cells lacking c-Jun into syngeneic mice led to a drastic reduction in the formation of teratocarcinomas. We propose that whereas most of the functions of c-Jun in ES cells appear to be complemented by other Jun proteins in vitro, functional c-Jun protein is essential for efficient tumor growth in vivo.	RES INST MOLEC PATHOL, A-1030 VIENNA, AUSTRIA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)				Wagner, Erwin F/0000-0001-7872-0196				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BURKERT U, 1991, NEW BIOL, V3, P698; CARTER R, 1991, ONCOGENE, V6, P229; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; CURRAN T, 1984, VIROLOGY, V135, P218, DOI 10.1016/0042-6822(84)90132-6; DEGROOT RP, 1990, EMBO J, V9, P1831, DOI 10.1002/j.1460-2075.1990.tb08308.x; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HANDYSIDE AH, 1989, ROUX ARCH DEV BIOL, V198, P48, DOI 10.1007/BF00376370; HASTY P, 1991, MOL CELL BIOL, V11, P5586, DOI 10.1128/MCB.11.11.5586; HILBERG F, 1987, P NATL ACAD SCI USA, V84, P5232, DOI 10.1073/pnas.84.15.5232; IMBRA RJ, 1987, MOL CELL BIOL, V7, P1358, DOI 10.1128/MCB.7.4.1358; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MATSUI M, 1990, ONCOGENE, V5, P249; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; REDNER RL, 1992, ONCOGENE, V7, P43; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; RYSECK RP, 1991, ONCOGENE, V6, P533; SAWAI S, 1991, NEW BIOL, V3, P861; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VANBEVEREN C, 1984, VIROLOGY, V135, P229, DOI 10.1016/0042-6822(84)90133-8; WANG ZQ, 1991, EMBO J, V10, P2437, DOI 10.1002/j.1460-2075.1991.tb07783.x; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; YANG-YEN H-F, 1990, New Biologist, V2, P351; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	50	73	75	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1992	7	12					2371	2380						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1281302				2022-12-28	WOS:A1992KA85600001
J	LAMMIE, GA; SMITH, R; SILVER, J; BROOKES, S; DICKSON, C; PETERS, G				LAMMIE, GA; SMITH, R; SILVER, J; BROOKES, S; DICKSON, C; PETERS, G			PROVIRAL INSERTIONS NEAR CYCLIN D1 IN MOUSE LYMPHOMAS - A PARALLEL FOR BCL1 TRANSLOCATIONS IN HUMAN B-CELL NEOPLASMS	ONCOGENE			English	Article							MURINE LEUKEMIA-VIRUS; T(11-14) CHROMOSOME-TRANSLOCATION; MAMMARY-TUMOR VIRUS; C-MYC ONCOGENE; T-CELL; CANDIDATE ONCOGENE; MOLECULAR-CLONING; PUTATIVE ONCOGENE; VIRAL INTEGRATION; ACTIVATION	By isolating genomic DNA clones that encompass the mouse Cyl-1 (cyclin D1) locus, we have identified a putative CpG island close to the 5' end of the gene. Pulsed-field gel electrophoresis with probes derived from either the 5' or 3' side of the CpG island established physical linkage to two independent markers on mouse chomosome 7, in a region that is syntenic with human chromosome 11q13. On the 3' side, Cyl-1 is approximately 75 kb from Hst-1 and Int-2, although there is an additional CpG island in the intervening DNA, while on the 5' side, Cyl-1 is less than 300 kb from Fis-1, an integration site for Friend murine leukaemia virus. As there is no intervening CpG island, proviral insertions at Fis-1 could influence the expression of Cyl-1 and we describe two virally induced tumours in which this appears to be the case. The data suggest that proviral insertions near Cyl-1 in mouse lymphomas are functionally equivalent to the BCL1 translocations that activate cyclin D1 expression in human B-cell malignancies.	IMPERIAL CANC RES FUND, MOLEC ONCOL LABS, 44 LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND; IMPERIAL CANC RES FUND, VIRAL CARCINOGENESIS LABS, LONDON WC2A 3PX, ENGLAND; NIH, BETHESDA, MD 20982 USA	Cancer Research UK; Cancer Research UK; National Institutes of Health (NIH) - USA								ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; BROOKES S, 1992, GENE CHROMOSOME CANC, V4, P290, DOI 10.1002/gcc.2870040404; BROOKES S, 1989, NUCLEIC ACIDS RES, V17, P4037, DOI 10.1093/nar/17.11.4037; CORY S, 1985, EMBO J, V4, P675, DOI 10.1002/j.1460-2075.1985.tb03682.x; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; ENOCH T, 1986, MOL CELL BIOL, V6, P801, DOI 10.1128/MCB.6.3.801; GAUDRAY P, 1992, MUTAT RES, V276, P317, DOI 10.1016/0165-1110(92)90018-5; GRAHAM M, 1986, EMBO J, V5, P2845, DOI 10.1002/j.1460-2075.1986.tb04578.x; GRAHAM M, 1985, NATURE, V314, P740, DOI 10.1038/314740a0; HENGLEIN B, 1989, MOL CELL BIOL, V9, P2105, DOI 10.1128/MCB.9.5.2105; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; KIOUSSIS D, 1987, EMBO J, V6, P355, DOI 10.1002/j.1460-2075.1987.tb04762.x; KOEHNE CF, 1989, J VIROL, V63, P2366, DOI 10.1128/JVI.63.5.2366-2369.1989; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LAMMIE GA, 1991, ONCOGENE, V6, P439; LAZO PA, 1990, P NATL ACAD SCI USA, V87, P170, DOI 10.1073/pnas.87.1.170; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MENGLEGAW L, 1987, EMBO J, V6, P1959, DOI 10.1002/j.1460-2075.1987.tb02458.x; MOORE R, 1986, EMBO J, V5, P919, DOI 10.1002/j.1460-2075.1986.tb04304.x; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MUCENSKI ML, 1987, ONCOGENE RES, V2, P33; NUSSE R, 1991, CURR TOP MICROBIOL, V171, P44; PETERS G, 1986, NATURE, V320, P628, DOI 10.1038/320628a0; PETERS G, 1989, P NATL ACAD SCI USA, V86, P5678, DOI 10.1073/pnas.86.15.5678; PETERS G, 1990, CELL GROWTH DIFFER, V1, P503; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SCHUURING E, 1992, ONCOGENE, V7, P355; SETO M, 1992, ONCOGENE, V7, P1401; SHTIVELMAN E, 1989, P NATL ACAD SCI USA, V86, P3257, DOI 10.1073/pnas.86.9.3257; SILVER J, 1986, J VIROL, V60, P1156, DOI 10.1128/JVI.60.3.1156-1158.1986; SILVER J, 1986, J VIROL, V57, P526, DOI 10.1128/JVI.57.2.526-533.1986; TSICHLIS PN, 1990, J VIROL, V64, P2236, DOI 10.1128/JVI.64.5.2236-2244.1990; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; VILLENEUVE L, 1986, MOL CELL BIOL, V6, P1834, DOI 10.1128/MCB.6.5.1834; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	41	59	59	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1992	7	12					2381	2387						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1461646				2022-12-28	WOS:A1992KA85600002
J	BAIRD, PN; GROVES, N; HABER, DA; HOUSMAN, DE; COWELL, JK				BAIRD, PN; GROVES, N; HABER, DA; HOUSMAN, DE; COWELL, JK			IDENTIFICATION OF MUTATIONS IN THE WT1 GENE IN TUMORS FROM PATIENTS WITH THE WAGR SYNDROME	ONCOGENE			English	Article							ZINC-FINGER GENE; WILMS-TUMOR; BAND 11P13; HUMAN CHROMOSOME-11; ANIRIDIA; DELETION; HETEROZYGOSITY; ASSOCIATION; REGION; LOCUS	Individuals with constitutional, heterozygous deletions of chromosome region 11p13 are predisposed to the development of Wilms' tumour, indicating the site of the tumour predisposition gene. The WT1 gene is a candidate for this cancer predisposition gene. If this gene is truely involved in tumorigenesis it would be expected to be mutant in tumour tissue from patients with 11p13 deletions. We have used single-stranded conformation polymorphism (SSCP) and polymerase chain reaction sequencing to test this hypothesis in an exon-by-exon analysis of the gene. Four tumours were analysed, two of which were from unilaterally affected individuals and two from a bilaterally affected patient. SSCP analysis identified mutations in the two unilateral tumours which, on sequencing, were shown to involve a 10-bp insertion in exon 7 and a single base pair change in exon 8. Both mutations result in the generation of premature stop codons and the predicted proteins would lack part of the zinc finger motif. Despite complete sequencing of the WT] gene in both of the bilateral tumours, no mutations were identified. These results possibly suggest that WT1 may not be involved in tumorigenesis in all tumours. All four tumours retained heterozygosity in the 11p15 region, making it unlikely that a second recessive oncogene in this re ion was involved in tumorigenicity.	ICRF ONCOL GRP,INST CHILD HLTH,30 GUILFORD ST,LONDON WC1N 1EH,ENGLAND; MIT,CTR CANC RES,CAMBRIDGE,MA 02139	University of London; University College London; Massachusetts Institute of Technology (MIT)				Baird, Paul/0000-0002-1305-3502; Cowell, John/0000-0002-2079-5950				BAIRD P, 1991, ONCOGENE, V6, P1147; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHOMCZYNSKI P, 1988, ANAL BIOCHEM, V173, P93; COUILLIN P, 1989, HUM GENET, V82, P171, DOI 10.1007/BF00284053; COWELL JK, 1991, ONCOGENE, V6, P595; COWELL JK, 1989, HUM GENET, V82, P123, DOI 10.1007/BF00284042; DANGIO GJ, 1989, CANCER-AM CANCER SOC, V64, P349, DOI 10.1002/1097-0142(19890715)64:2<349::AID-CNCR2820640202>3.0.CO;2-Q; FEARON ER, 1984, NATURE, V309, P176, DOI 10.1038/309176a0; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GRUNDY P, 1988, NATURE, V336, P375; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HENRY I, 1989, HUM GENET, V81, P273, DOI 10.1007/BF00279003; HENRY I, 1991, NATURE, V351, P665, DOI 10.1038/351665a0; HOGG A, 1992, ONCOGENE, V7, P1444; HUFF V, 1991, AM J HUM GENET, V48, P997; HUFF V, 1988, NATURE, V336, P377, DOI 10.1038/336377a0; JEANPIERRE C, 1990, GENOMICS, V7, P434, DOI 10.1016/0888-7543(90)90179-X; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; KOUFOS A, 1984, NATURE, V309, P170, DOI 10.1038/309170a0; LEMOINE NR, 1992, IN PRESS J PATHOL; LEWIS W H, 1988, Genomics, V3, P25, DOI 10.1016/0888-7543(88)90154-1; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MANNENS M, 1988, HUM GENET, V81, P41, DOI 10.1007/BF00283727; MANNENS M, 1990, CANCER RES, V50, P3279; MCGEE TL, 1989, GENE, V80, P119, DOI 10.1016/0378-1119(89)90256-4; MORRIS JF, 1991, ONCOGENE, V6, P2339; NARAHARA K, 1984, HUM GENET, V66, P181, DOI 10.1007/BF00286597; NOONAN KE, 1988, NUCLEIC ACIDS RES, V16, P10366, DOI 10.1093/nar/16.21.10366; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; ORKIN SH, 1984, NATURE, V309, P172, DOI 10.1038/309172a0; PAL N, 1990, ONCOGENE, V5, P1665; PAL N, 1991, ONCOGENE, V252, P800; PAVLETICH NP, 1991, SCIENCE, V252, P800; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PORTEOUS DJ, 1987, P NATL ACAD SCI USA, V84, P5355, DOI 10.1073/pnas.84.15.5355; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; PRRITCHARDJONES K, 1991, ONCOGENE, V6, P2211; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RICCARDI VM, 1980, CANCER GENET CYTOGEN, V2, P131, DOI 10.1016/0165-4608(80)90056-4; RICCARDI VM, 1978, PEDIATRICS, V61, P604; SCHWARTZ CE, 1991, GENOMICS, V10, P927, DOI 10.1016/0888-7543(91)90181-D; TON CCT, 1991, GENOMICS, V10, P293, DOI 10.1016/0888-7543(91)90516-H; WADEY RB, 1990, ONCOGENE, V5, P901	47	89	89	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2141	2149						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1331933				2022-12-28	WOS:A1992JW66500006
J	SAKAMOTO, KM; NIMER, SD; ROSENBLATT, JD; GASSON, JC				SAKAMOTO, KM; NIMER, SD; ROSENBLATT, JD; GASSON, JC			HTLV-I AND HTLV-II TAX TRANSACTIVATE THE HUMAN EGR-1 PROMOTER THROUGH DIFFERENT CIS-ACTING SEQUENCES	ONCOGENE			English	Article							T-CELL LEUKEMIA; HUMAN IMMUNODEFICIENCY VIRUS; PRIMARY HUMAN-LYMPHOCYTES; LONG TERMINAL REPEAT; GENE-EXPRESSION; C-FOS; GROWTH; PROTEIN; TRANSFORMATION; IDENTIFICATION	The immediate-early response gene, EGR-1, encodes a zinc finger-containing transcription factor that is involved in growth and differentiation of a variety of cell types. EGR-1 is induced in normal T cells following mitogenic stimulation and has recently been shown to be constitutively expressed in human T-cell leukemia virus type I (HTLV-I)- and type II (HTLV-II)-transformed T-cell lines. The trans-activating protein of HTLV-I, Tax, has been demonstrated to trans-activate promoters of a number of cellular genes, some of which may be critical in regulating T-cell proliferation. In this study, we examine the effect of Tax on expression of EGR-1 in three T-cell lines and demonstrate that both HTLV-I and -II Tax are capable of trans-activating human EGR-1 recombinant promoter constructs. Interestingly, HTLV-I and -II Tax trans-activate the human EGR-1 promoter through different promoter regions in the Jurkat cell line, suggesting that HTLV-I and -II Tax may lead to constitutive expression of EGR-1 through different signaling pathways. Deregulated expression of EGR-1 may contribute to uncontrolled cell growth and transformation during early stages of T-cell activation in HTLV-I and -II-infected cells.	UNIV CALIF LOS ANGELES, JONSSON COMPREHENS CANC CTR, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, DIV HEMATOL ONCOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, JONSSON COMPREHENS CANC CTR, LOS ANGELES, CA 90024 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	SAKAMOTO, KM (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, DEPT PEDIAT, DIV HEMATOL ONCOL, A2-312, LOS ANGELES, CA 90024 USA.				NCI NIH HHS [CA08974, CA01314] Funding Source: Medline; NIDDK NIH HHS [DK43025] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K11CA001314, F32CA008974] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043025] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDRE C, 1991, ONCOGENE, V6, P543; ALEXANDRE C, 1991, ONCOGENE, V6, P1851; CANN AJ, 1985, NATURE, V318, P571, DOI 10.1038/318571a0; CANN AJ, 1988, ONCOGENE, V3, P123; CHEN ISY, 1983, P NATL ACAD SCI-BIOL, V80, P7006, DOI 10.1073/pnas.80.22.7006; CHEN SJ, 1985, P NATL ACAD SCI USA, V82, P7284, DOI 10.1073/pnas.82.21.7284; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P1023; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; GREEN PL, 1990, FASEB J, V4, P169, DOI 10.1096/fasebj.4.2.2404818; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; KALYANARAMAN VS, 1982, SCIENCE, V218, P571, DOI 10.1126/science.6981847; KUMAR A, 1972, P NATL ACAD SCI USA, V69, P681, DOI 10.1073/pnas.69.3.681; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; NIMER SD, 1989, ONCOGENE, V4, P671; PETERLIN BM, 1986, P NATL ACAD SCI USA, V83, P9734, DOI 10.1073/pnas.83.24.9734; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; ROSENBLATT JD, 1986, NEW ENGL J MED, V315, P372, DOI 10.1056/NEJM198608073150606; ROSENBLATT JD, 1988, BLOOD, V71, P363; SAKAMOTO KM, 1991, ONCOGENE, V6, P867; SMITH MR, 1991, J CLIN INVEST, V87, P761, DOI 10.1172/JCI115078; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Takatsuki K, 1990, RETROVIRUS BIOL HUMA, P147; TAN TH, 1989, MOL CELL BIOL, V9, P1733, DOI 10.1128/MCB.9.4.1733; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; VARNUM BC, 1989, MOL CELL BIOL, V9, P3580, DOI 10.1128/MCB.9.8.3580; WATERS CM, 1990, ONCOGENE, V5, P669; WRIGHT JJ, 1990, SCIENCE, V248, P588, DOI 10.1126/science.2110381; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x	37	35	35	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1992	7	11					2125	2130						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1359492				2022-12-28	WOS:A1992JW66500004
J	SOZERI, O; VOLLMER, K; LIYANAGE, M; FRITH, D; KOUR, G; MARK, GE; STABEL, S				SOZERI, O; VOLLMER, K; LIYANAGE, M; FRITH, D; KOUR, G; MARK, GE; STABEL, S			ACTIVATION OF THE C-RAF PROTEIN-KINASE BY PROTEIN-KINASE-C PHOSPHORYLATION	ONCOGENE			English	Note							TYROSINE PHOSPHORYLATION; GROWTH; CELLS; EXPRESSION; INSULIN; C-RAF-1; SERINE; RECEPTOR; PROTOONCOGENE; DEFINITION	The product of the c-raf-1 proto-oncogene is a cytoplasmic serine/threonine protein kinase that appears to be activated in signal transduction from a variety of cell-surface receptors. The mechanism of c-Raf activation upon stimulation of cell-surface receptors is not clear, but there seem to exist multiple pathways of activation which involve tyrosine and/or serine phosphorylation of the c-Raf protein in vivo. The activated state of Raf is reflected in an increased apparent molecular weight of the Raf protein in sodium dodecyl sulfate-polyacrylamide gels owing to hyperphosphorylation. The tumor promoter 12-O-tetradecanoyl phorbol 13-acetate (TPA) is one of the agents able to induce this hyperphosphorylation of Raf in vivo, suggesting that protein kinase C (PKC) may be involved in the activation of c-Raf in particular situations. Using recombinant baculoviruses expressing PKC and Raf polypeptides, we show here that conventional PKC types (alpha, beta, gamma) but not novel types (delta, zeta, eta) or the unrelated Mos kinase are able to activate c-Raf in a TPA-dependent manner upon coexpression in insect cells. Direct phosphorylation of the Raf protein with PKC in vitro also enhanced the kinase activity of c-Raf, suggesting that c-Raf acts immediately down-stream of PKC in a protein kinase cascade which is triggered by TPA and may lead to transcriptional activation of TPA-inducible genes and tumor promotion.	MAX PLANCK GESELL, MAX DELBRUCK LAB, CARL VON LINNE WEG 10, W-5000 COLOGNE 30, GERMANY; MERCK SHARP & DOHME LTD, RAHWAY, NJ 07065 USA; IMPERIAL CANC RES FUND, LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND	Max Planck Society; Merck & Company; Cancer Research UK								ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; BACCARINI M, 1991, J BIOL CHEM, V266, P10941; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; FREISEWINKEL I, 1991, FEBS LETT, V280, P262, DOI 10.1016/0014-5793(91)80307-O; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; IZUMI T, 1991, J BIOL CHEM, V266, P7933; JAMAL S, 1990, ANTURE, V344, P43; KAIBUCHI K, 1989, J BIOL CHEM, V264, P20855; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; LEE RM, 1991, J BIOL CHEM, V266, P10351; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; LIYANAGE M, 1992, BIOCHEM J, V283, P781, DOI 10.1042/bj2830781; MOLDERS H, 1985, EMBO J, V4, P693, DOI 10.1002/j.1460-2075.1985.tb03685.x; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; PATEL G, 1989, CELL SIGNAL, V1, P227, DOI 10.1016/0898-6568(89)90040-5; PFEIFER AMA, 1989, P NATL ACAD SCI USA, V86, P10075, DOI 10.1073/pnas.86.24.10075; RAPP UR, 1991, ONCOGENE, V6, P495; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; SIEGFRIED Z, 1990, MOL CELL BIOL, V10, P6073, DOI 10.1128/MCB.10.11.6073; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; STABEL S, 1991, METHOD ENZYMOL, V200, P670; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; WASYLYK C, 1989, MOL CELL BIOL, V9, P247; WAYS DK, 1992, J BIOL CHEM, V267, P4799; WSIEGEL JN, 1990, J BIOL CHEM, V265, P18472; ZMUIDZINAS A, 1991, MOL CELL BIOL, V11, P2794, DOI 10.1128/MCB.11.5.2794	36	304	305	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1992	7	11					2259	2262						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437148				2022-12-28	WOS:A1992JW66500018
J	BERGSAGEL, PL; TIMBLIN, CR; ECKHARDT, L; LASKOV, R; KUEHL, WM				BERGSAGEL, PL; TIMBLIN, CR; ECKHARDT, L; LASKOV, R; KUEHL, WM			SEQUENCE AND EXPRESSION OF A MURINE CDNA-ENCODING PC326, A NOVEL GENE EXPRESSED IN PLASMACYTOMAS BUT NOT NORMAL PLASMA-CELLS	ONCOGENE			English	Article							TRANSLOCATED MYC GENE; C-MOS; SACCHAROMYCES-CEREVISIAE; MOUSE MYELOMA; BETA-SUBUNIT; G-PROTEIN; EXTINCTION; ONCOGENE; ENHANCER; HYBRIDS	Using a subtractive cDNA approach we have identified a gene, PC326, expressed in 13 of 14 murine plasmacytoma cell lines, but not in any B- or pre-B-lymphoma cell lines. It expresses 4.6-kb and 5.2-kb mRNAs that encode a 747 amino acid protein containing two highly acidic domains flanking a novel, moderately acidic 20 amino acid sequence that is repeated 7.5 times. Sequence comparison identifies an additional 43 amino acid domain that is homologous to a repeated sequence found in the members of the beta-transducin gene family. The PC326 mRNA is detectable in testis but in no other murine tissues, including plasma cells induced by lipopolysaccharide stimulation of splenocytes. Somatic cell hybrids derived from plasmacytomas and fibroblast or T-cell lines have a fibroblastic or T-cell phenotype respectively. Unlike B-cell-specific genes (e.g. immunoglobulin), the expression of which is extinguished in these hybrids, PC326 mRNA appears to be irreversibly turned on in these hybrids. Since PC326 is not expressed in normal plasma cells, it appears that its expression is a cause or consequence of the tumorigenic process that generates murine plasmacytomas.	NCI, USN, MED ONCOL BRANCH, BLDG 8, ROOM 5101, BETHESDA, MD 20889 USA; COLUMBIA UNIV, DEPT BIOL SCI, NEW YORK, NY 10027 USA; HEBREW UNIV JERUSALEM, HADASSAH MED SCH, HUBERT H HUMPHREY CTR EXPTL MED & CANC RES, IL-91010 JERUSALEM, ISRAEL	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Defense; United States Navy; Columbia University; Hebrew University of Jerusalem			Bergsagel, Peter Leif/A-7842-2011	Bergsagel, Peter Leif/0000-0003-1523-7388				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BANROQUES J, 1989, MOL CELL BIOL, V9, P3710, DOI 10.1128/MCB.9.9.3710; Battey, 1986, BASIC METHODS MOL BI; BERGMAN Y, 1990, EMBO J, V9, P849, DOI 10.1002/j.1460-2075.1990.tb08182.x; BERGSAGEL PL, 1992, J IMMUNOL, V148, P590; BRANDT SJ, 1990, J CLIN INVEST, V86, P592, DOI 10.1172/JCI114749; CANAANI E, 1983, P NATL ACAD SCI-BIOL, V80, P7118, DOI 10.1073/pnas.80.23.7118; COHEN JB, 1983, NATURE, V306, P797, DOI 10.1038/306797a0; DELIDAKIS C, 1991, GENETICS, V129, P803; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DURONIO RJ, 1992, PROTEINS, V13, P41, DOI 10.1002/prot.340130105; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; GATTONICELLI S, 1983, NATURE, V306, P795, DOI 10.1038/306795a0; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; GREENBERG A, 1987, MOL CELL BIOL, V7, P936, DOI 10.1128/MCB.7.2.936; GREENBERG A, 1989, INT J CANCER, V43, P87, DOI 10.1002/ijc.2910430118; HARTLEY DA, 1988, CELL, V55, P785, DOI 10.1016/0092-8674(88)90134-1; HERMANSON GG, 1988, P NATL ACAD SCI USA, V85, P6890, DOI 10.1073/pnas.85.18.6890; ICHO T, 1988, J BIOL CHEM, V263, P1467; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KOSHLAND ME, 1985, ANNU REV IMMUNOL, V3, P425; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRAYEV AS, 1980, NUCLEIC ACIDS RES, V8, P1201, DOI 10.1093/nar/8.6.1201; LASKOV R, 1991, INT J CANCER, V48, P574, DOI 10.1002/ijc.2910480416; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; PONZETTO C, 1985, MOL CELL BIOL, V5, P1791, DOI 10.1128/MCB.5.7.1791; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; ROSENBAUM H, 1990, EMBO J, V9, P897, DOI 10.1002/j.1460-2075.1990.tb08187.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SETHI N, 1991, MOL CELL BIOL, V11, P5592, DOI 10.1128/MCB.11.11.5592; TIMBLIN C, 1990, CURR TOP MICROBIOL, V166, P141; TIMBLIN C, 1990, NUCLEIC ACIDS RES, V18, P1587, DOI 10.1093/nar/18.6.1587; WEISSINGER EM, 1991, P NATL ACAD SCI USA, V88, P8735, DOI 10.1073/pnas.88.19.8735; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; WILLIAMS FE, 1990, MOL CELL BIOL, V10, P6500, DOI 10.1128/MCB.10.12.6500; YOCHEM J, 1987, J MOL BIOL, V195, P233, DOI 10.1016/0022-2836(87)90646-2; YU H, 1989, CELL, V58, P441, DOI 10.1016/0092-8674(89)90425-X; ZALLER DM, 1988, MOL CELL BIOL, V8, P1932, DOI 10.1128/MCB.8.5.1932	39	16	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1992	7	10					2059	2064						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408147				2022-12-28	WOS:A1992JP42400021
J	BRUSTLE, O; AGUZZI, A; TALARICO, D; BASILICO, C; KLEIHUES, P; WIESTLER, OD				BRUSTLE, O; AGUZZI, A; TALARICO, D; BASILICO, C; KLEIHUES, P; WIESTLER, OD			ANGIOGENIC ACTIVITY OF THE K-FGF/HST ONCOGENE IN NEURAL TRANSPLANTS	ONCOGENE			English	Article							FIBROBLAST GROWTH-FACTOR; FACTOR GENE FAMILY; NIH 3T3 CELLS; ENDOTHELIAL-CELLS; TRANSFORMING GENE; FACTOR RECEPTOR; MESODERM INDUCTION; STOMACH CANCERS; DOWN-REGULATION; MESSENGER-RNA	Using retrovirus-mediated gene transfer into neural transplants, we have expressed the human K-fgf/hst oncogene in the central nervous system. Single-cell suspensions of fetal rat brains were removed at embryonic days 13 and 14, exposed to a retroviral vector encoding the K-fgf oncogene and stereotaxically implanted into the caudate putamen of syngenic adult Fisher rats. Recipient animals were sacrificed at intervals of 6-16 months without evidence of neurological impairment. Mock-infected grafts showed the characteristic histopathological appearance of organotypically differentiated neural transplants. In contrast, grafts exposed to the K-fgf gene exhibited abundant capillary proliferation and capillary angiomas. By in situ hybridization analysis and immunohistochemistry, expression of K-fgf was detected in neural cells adjacent to vascular proliferations. Neurons and glia with abundant K-fgf transcripts were morphologically unaffected. In order to examine the transforming potential of the K-fgf gene in the nervous system, we combined retrovirus-mediated transfer of the K-fgf oncogene with a single transplacental exposure of the donor animals to the neurotropic carcinogen N-ethyl-N-nitrosourea (NEU). However, this combination of transforming agents did not result in tumor formation in the grafts. These results provide evidence for a powerful angiogenic effect of K-fgf on the developing brain in vivo.	UNIV ZURICH, DEPT PATHOL, NEUROPATHOL LAB, CH-8091 ZURICH, SWITZERLAND; RES INST MOLEC PATHOL, A-1030 VIENNA, AUSTRIA; NYU HOSP, DEPT MICROBIOL, NEW YORK, NY 10016 USA	University of Zurich; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); New York University			Aguzzi, Adriano/A-3351-2008; Talarico, Daniela/AAN-5608-2020	Talarico, Daniela/0000-0001-5814-9244; Aguzzi, Adriano/0000-0002-0344-6708				ADELAIDE J, 1988, ONCOGENE, V2, P413; AGUZZI A, 1991, ONCOGENE, V6, P113; AGUZZI A, 1990, New Biologist, V2, P533; BAIRD A, 1989, BRIT MED BULL, V45, P438, DOI 10.1093/oxfordjournals.bmb.a072333; BENHARROCH D, 1990, ISRAEL J MED SCI, V26, P212; BOVI PD, 1987, P NATL ACAD SCI USA, V84, P5660, DOI 10.1073/pnas.84.16.5660; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BURGER PC, 1988, CANCER RES, V48, P2871; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CONNOLLY DT, 1987, BIOCHEM BIOPH RES CO, V144, P705, DOI 10.1016/S0006-291X(87)80022-0; DELLIBOVI P, 1988, MOL CELL BIOL, V8, P2933, DOI 10.1128/MCB.8.7.2933; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; DRUCKREY H, 1966, NATURE, V210, P1378, DOI 10.1038/2101378a0; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1987, NATURE, V329, P671, DOI 10.1038/329671a0; FRIESEL R, 1991, MOL CELL BIOL, V11, P2481, DOI 10.1128/MCB.11.5.2481; GOSPODAROWICZ D, 1974, P NATL ACAD SCI USA, V71, P2295, DOI 10.1073/pnas.71.6.2295; Hannan RL, 1988, GROWTH FACTORS, V1, P7, DOI 10.3109/08977198809000242; HAYEK A, 1987, BIOCHEM BIOPH RES CO, V147, P876, DOI 10.1016/0006-291X(87)91011-4; HEBERT JM, 1990, DEV BIOL, V138, P454, DOI 10.1016/0012-1606(90)90211-Z; HERBERT JM, 1988, INT J TISSUE REACT, V10, P133; HOLLAND PWH, 1987, J CELL BIOL, V105, P473, DOI 10.1083/jcb.105.1.473; HUEBNER K, 1988, ONCOGENE RES, V3, P263; KLEIHUES P, 1990, TOXICOL PATHOL, V18, P193, DOI 10.1177/019262339001800125; KLEIHUES P, 1989, IARC SCI PUBLIC, V96, P121; KNIGHTON DR, 1990, J TRAUMA, V30, pS134; KODA T, 1987, JPN J CANCER RES, V78, P325; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; LAFAGE M, 1990, GENE CHROMOSOME CANC, V2, P171, DOI 10.1002/gcc.2870020302; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MARICS I, 1989, ONCOGENE, V4, P335; MILLER WH, 1990, ONCOGENE, V5, P511; MIYAGAWA K, 1988, ONCOGENE, V3, P383; MOSCATELLI D, 1989, J CELL BIOL, V109, P2519, DOI 10.1083/jcb.109.5.2519; NAKAGAMA H, 1987, JPN J CANCER RES, V78, P651; NEUFELD G, 1988, J CELL PHYSIOL, V136, P537, DOI 10.1002/jcp.1041360321; NEUFELD G, 1987, J CELL PHYSIOL, V131, P131, DOI 10.1002/jcp.1041310119; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PATERNO GD, 1989, DEVELOPMENT, V106, P79; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; SAFRAN A, 1990, ONCOGENE, V5, P635; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; SCHWEIGERER L, 1987, NATURE, V325, P257, DOI 10.1038/325257a0; Singer B., 1983, MOL BIOL MUTAGENS CA; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SMITH JC, 1989, DEVELOPMENT, V105, P665; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; TALARICO D, 1991, MOL CELL BIOL, V11, P1138, DOI 10.1128/MCB.11.2.1138; THEILLET C, 1989, ONCOGENE, V4, P915; THOMAS KA, 1980, J BIOL CHEM, V255, P5517; TIESMAN J, 1989, IN VITRO CELL DEV B, V25, P1193; TOGARI A, 1985, J NEUROSCI, V5, P307; TSUDA T, 1989, CANCER RES, V49, P5505; TSUTSUMI M, 1988, JPN J CANCER RES, V79, P428, DOI 10.1111/j.1349-7006.1988.tb01609.x; VELCICH A, 1989, ONCOGENE RES, V5, P31; WALICKE P, 1986, P NATL ACAD SCI USA, V83, P3012, DOI 10.1073/pnas.83.9.3012; WIESTLER OD, 1989, IARC SCI PUBL, V96, P267; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487; ZHOU DJ, 1988, ONCOGENE, V2, P279	66	17	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1992	7	6					1177	1183						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1375717				2022-12-28	WOS:A1992HU64200015
J	CHEN, SJ; CHEN, Z; CHEN, A; TONG, JH; DONG, S; WANG, ZY; WAXMAN, S; ZELENT, A				CHEN, SJ; CHEN, Z; CHEN, A; TONG, JH; DONG, S; WANG, ZY; WAXMAN, S; ZELENT, A			OCCURRENCE OF DISTINCT PML RAR-ALPHA FUSION GENE ISOFORMS IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA DETECTED BY REVERSE-TRANSCRIPTASE POLYMERASE CHAIN-REACTION	ONCOGENE			English	Article							RETINOIC ACID RECEPTOR; CHRONIC MYELOGENOUS LEUKEMIA; BCR-ABL ONCOGENE; MESSENGER-RNA; PHILADELPHIA-CHROMOSOME; CELL-LINE; DIFFERENTIATION; TRANSLOCATION; EXPRESSION; BREAKPOINT	A specific 'nested' reverse transcriptase/polymerase chain reaction (RT/PCR) procedure was used to characterize the expression patterns of PML-RAR-alpha chimeric mRNAs in 32 patients with acute promyelocytic leukemia (APL). The sensitivity of the technique was such that the fusion gene transcript could be detected from as little as 2.5 pg of total leukemic cell RNA against a background of 1-mu-g of cellular RNA lacking the PML-RAR-alpha fusion gene transcript(s). In 19 cases the PML-RAR-alpha isoform referred to here as long was identified. A short isoform, which in comparison with the long form lacks three PML exons, was detected in 11 other cases. A third PML-RAR-alpha mRNA isoform, in which the most 3' PML exon present in the long-type isoform was truncated in its sequences lying immediately upstream of RAR-alpha B region, was found and characterized in a single patient. In one APL patient with a variant translocation t(11;17), the PCR product corresponding to PML-RAR-alpha chimeric mRNAs could not be amplified despite the presence of RAR-alpha gene rearrangement. Genomic and PCR analysis showed that the different PML-RAR-alpha isoforms found in APL patients arise as a result of distinct translocation breakpoints. In each case the exons encoding the B-F regions of RAR-alpha are expressed and are spliced downstream from variable PML gene exons. The 'nested' RT/PCR analysis of the PML-RAR-alpha fusion gene proved to be a rapid and sensitive tool for the diagnosis of the APL and for monitoring the residual APL chimeric mRNA expression during complete remission.	SHANGHAI MED UNIV 2, RUI JIN HOSP, SHANGHAI INST HEMATOL, 197 RUI-JIN RD II, SHANGHAI 200025, PEOPLES R CHINA; MT SINAI MED CTR, DEPT MED, DIV MED ONCOL, ROCHELLE BELFER CHEMOTHERAPY FDN LAB, NEW YORK, NY 10029 USA	Shanghai Jiao Tong University; Icahn School of Medicine at Mount Sinai			Zelent, Arthur/B-3532-2009	Zelent, Arthur/0000-0002-7968-9888				ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BRAND NJ, 1990, NUCLEIC ACIDS RES, V18, P6799, DOI 10.1093/nar/18.23.6799; BREITMAN TR, 1981, BLOOD, V57, P1000; BROCKES JP, 1989, NEURON, V2, P1285, DOI 10.1016/0896-6273(89)90066-4; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHAMBON P, 1991, RETINOIDS : 10 YEARS ON, P10; CHAMPLIN RE, 1985, BLOOD, V65, P1039; CHANG KS, 1991, LEUKEMIA, V5, P200; CHEN SJ, 1991, BLOOD, V78, P2696; CHEN Z, 1991, LEUKEMIA, V5, P288; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOMIENNE C, 1990, BLOOD, V76, P1710; CHOMIENNE C, 1990, LEUKEMIA, V4, P802; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; COLLINS SJ, 1987, BLOOD, V70, P1233; DAVIDSON JN, 1951, J PATHOL BACTERIOL, V63, P471, DOI 10.1002/path.1700630314; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; EICHELE G, 1989, TRENDS GENET, V5, P246, DOI 10.1016/0168-9525(89)90096-6; ERIKSON J, 1986, P NATL ACAD SCI USA, V83, P1807, DOI 10.1073/pnas.83.6.1807; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FLYNN PJ, 1983, BLOOD, V62, P1211; GLASS CK, 1991, HORMONAL CONTROL GEN, P129; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; GUDAS LJ, 1991, PERSPECTIVES CELLULA, P121; HAUNG ME, 1988, BLOOD, V7251, P5673; HEIM S, 1987, CANCER CYTOGENETICS; HUGHES TP, 1991, BLOOD, V77, P874; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KASTNER P, 1990, P NATL ACAD SCI USA, V87, P2700, DOI 10.1073/pnas.87.7.2700; KELLIHER M, 1991, MOL CELL BIOL, V11, P4710, DOI 10.1128/MCB.11.9.4710; LANOTTE M, 1991, BLOOD, V77, P1080; LARSON RA, 1984, AM J MED, V76, P827, DOI 10.1016/0002-9343(84)90994-X; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; LONGO L, 1990, J EXP MED, V172, P1571, DOI 10.1084/jem.172.6.1571; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MACCUMBER M, 1984, SCIENCE, V224, P402, DOI 10.1126/science.6200933; MCLAUGHLIN J, 1989, MOL CELL BIOL, V9, P1866, DOI 10.1128/MCB.9.5.1866; MENTEN ML, 1953, CANCER RES, V13, P733; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; MILLER WH, 1990, J NATL CANCER I, V82, P1932, DOI 10.1093/jnci/82.24.1932; MILLS KI, 1991, BLOOD, V78, P1155; MORGAN GJ, 1990, BRIT J HAEMATOL, V76, P33, DOI 10.1111/j.1365-2141.1990.tb07833.x; NEGRIN RS, 1991, BLOOD, V78, P255; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; RIBEIRO RC, 1987, BLOOD, V70, P948; ROBERTS AB, 1984, RETINOIDS, V2, P209; ROTH MS, 1992, BLOOD, V79, P276; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SHAPIRO SS, 1985, RETINOIDS CELL DIFFE, P30; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SUMMERBELL D, 1990, TRENDS NEUROSCI, V13, P142, DOI 10.1016/0166-2236(90)90006-V; SUN GL, 1992, IN PRESS BR J HAEMAT; TONG JH, 1992, ONCOGENE, V7, P311; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WAXMAN S, 1983, BLOOD S, V62, pA154; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; 1985, CYTOGENET CELL GENET, V21, P309	72	93	105	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1992	7	6					1223	1232						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1375719				2022-12-28	WOS:A1992HU64200021
J	WHITE, MRA; HUNG, MC				WHITE, MRA; HUNG, MC			CLONING AND CHARACTERIZATION OF THE MOUSE NEU PROMOTER	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; TYROSINE KINASE-ACTIVITY; FACTOR RECEPTOR; TRANSCRIPTION FACTOR; PROTO-ONCOGENE; EGF RECEPTOR; EUKARYOTIC TRANSCRIPTION; MOLECULAR-CLONING; C-ERBB-2 ONCOGENE; MAMMALIAN-CELLS	We have isolated a genomic clone containing the mouse neu gene. The 5' end of the mouse neu gene was localized by Southern analysis, subcloned and characterized. DNA sequence analysis revealed that the promoter region is 67% G + C-rich and lacks a TATA box, although a CAAT box is present. By sequence comparison, we identified several consensus recognition sequences for general transcription factors such as Sp1, E4TF1, AP2, OTF-1 and GCF, as well as recognition sequences for RVF, E1A and GTG, which have recently been identified in the rat neu promoter. Functional promoter activity was demonstrated by the ability of the promoter to drive transcription of the bacterial chloramphenicol acetyltransferase gene. Using a series of 5'-end deletion mutants, we have identified multiple positive and negative cis-acting elements that regulate mouse neu gene transcription.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT TUMOR BIOL, 1515 HOLCOMBE BLVD, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center			Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740				BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BERCHUCK A, 1990, CANCER RES, V50, P4087; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DEMILIA J, 1989, ONCOGENE, V4, P1233; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; FERNANDEZPOL JA, 1989, J BIOL CHEM, V264, P4151; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; FUKUSHIGE S, 1986, MOL CELL BIOL, V6, P955, DOI 10.1128/MCB.6.3.955; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; HUDSON LG, 1990, J BIOL CHEM, V265, P4389; HUNG M, 1991, IN PRESS CANCER LETT; HUNG M-C, 1988, Cancer Bulletin (Houston), V40, P300; HUNG MC, 1989, P NATL ACAD SCI USA, V86, P2545, DOI 10.1073/pnas.86.8.2545; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; ISHII S, 1987, P NATL ACAD SCI USA, V84, P4374, DOI 10.1073/pnas.84.13.4374; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; Jones N, 1990, Semin Cancer Biol, V1, P5; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KOKAI Y, 1987, P NATL ACAD SCI USA, V84, P8498, DOI 10.1073/pnas.84.23.8498; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACGREGOR GR, 1987, SOMAT CELL MOLEC GEN, V13, P253, DOI 10.1007/BF01535207; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PARK JB, 1989, CANCER RES, V49, P6605; POLYANOVSKY OL, 1990, BIOESSAYS, V12, P205, DOI 10.1002/bies.950120503; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090; SCHNEIDER PM, 1989, CANCER RES, V49, P4968; SCHWAB M, 1990, GENE CHROMOSOME CANC, V1, P181, DOI 10.1002/gcc.2870010302; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; SUEN TC, 1990, MOL CELL BIOL, V10, P6306, DOI 10.1128/MCB.10.12.6306; SUEN TC, 1991, MOL CELL BIOL, V11, P354, DOI 10.1128/MCB.11.1.354; TAL M, 1987, MOL CELL BIOL, V7, P2597, DOI 10.1128/MCB.7.7.2597; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; WATANABE H, 1988, MOL CELL BIOL, V8, P1290, DOI 10.1128/MCB.8.3.1290; WEINER DB, 1990, CANCER RES, V50, P421; WINGENDER E, 1988, NUCLEIC ACIDS RES, V16, P1879, DOI 10.1093/nar/16.5.1879; WINGENDER E, 1990, Critical Reviews in Eukaryotic Gene Expression, V1, P11; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YAN DH, 1991, ONCOGENE, V6, P343; YAN DH, 1991, MOL CELL BIOL, V11, P1875, DOI 10.1128/MCB.11.4.1875; YOKOTA J, 1988, ONCOGENE, V2, P283; YOSHIDA K, 1989, VIRCHOWS ARCH B, V57, P285, DOI 10.1007/BF02899093; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; ZHANG X, 1989, ONCOGENE, V4, P985	63	44	45	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1992	7	4					677	683						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1348855				2022-12-28	WOS:A1992HQ68200009
J	STOREY, A; GREENFIELD, I; BANKS, L; PIM, D; CROOK, T; CRAWFORD, L; STANLEY, M				STOREY, A; GREENFIELD, I; BANKS, L; PIM, D; CROOK, T; CRAWFORD, L; STANLEY, M			LACK OF IMMORTALIZING ACTIVITY OF A HUMAN PAPILLOMAVIRUS TYPE-16 VARIANT DNA WITH A MUTATION IN THE E2 GENE ISOLATED FROM NORMAL HUMAN CERVICAL KERATINOCYTES	ONCOGENE			English	Article							HUMAN FORESKIN KERATINOCYTES; EPITHELIAL-CELLS; TRANSCRIPTIONAL REPRESSOR; REGULATORY REGION; ACTIVATED RAS; TRANSFORMATION; CARCINOMA; PRODUCT; PROTEIN; LINE	The oncogenic potential of a human papillomavirus type 16 (HPV16) variant cloned from normal human cervical keratinocytes has been tested in vitro using primary rodent epithelial cells and human cervical keratinocytes. The HPV16 variant was able to extend the lifespan of, but failed to immortalize, human keratinocytes. It could however cooperate with an activated ras oncogene to transform primary rodent cells. Radioimmunoprecipitation assays of the rodent cells showed that they expressed the E7 protein. DNA sequence analysis of the URR/E6/E7 and E5 regions of the HPV16 showed them to be fully functional, but a deletion in the viral E2 open reading frame was detected. This truncated E2 only weakly stimulated transcription of the viral regulatory region. Complementation assays using the HPV16 variant and a full-length E2 enabled the cloned variant to immortalize human cervical keratinocytes with wild-type efficiency. These results suggest that other viral gene products in addition to E6/E7 may play an important role in the in vitro immortalization of cervical keratinocytes in HPV16 and the development of cervical cancer.	UNIV CAMBRIDGE, DEPT PATHOL, IMPERIAL CANC RES FUND TUMOR VIRUS GRP, CAMBRIDGE CB2 1QP, ENGLAND; ST MARYS HOSP, SCH MED, LUDWIG INST CANC RES, LONDON W2 1PG, ENGLAND	University of Cambridge; Imperial College London; Ludwig Institute for Cancer Research	STOREY, A (corresponding author), INT CTR GENET ENGN & BIOTECHNOL, PADRICIANO 99, I-34012 TRIESTE, ITALY.			Storey, Alan/0000-0003-2001-9772				ANDROPHY EJ, 1987, NATURE, V325, P70, DOI 10.1038/325070a0; BARBOSA MS, 1989, ONCOGENE, V4, P1529; CHAN WK, 1989, J VIROL, V63, P3261, DOI 10.1128/JVI.63.8.3261-3269.1989; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOE J, 1989, J VIROL, V63, P1743, DOI 10.1128/JVI.63.4.1743-1755.1989; CRIPE TP, 1987, EMBO J, V6, P3745, DOI 10.1002/j.1460-2075.1987.tb02709.x; CROOK T, 1988, P NATL ACAD SCI USA, V85, P8820, DOI 10.1073/pnas.85.23.8820; DEVILLIERS EM, 1987, LANCET, V2, P703; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; DURST M, 1987, ONCOGENE, V1, P251; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FARR A, 1987, CANCER CELL, V5, P171; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GERGELY L, 1987, LANCET, V2, P513; GISSMANN L, 1983, P NATL ACAD SCI-BIOL, V80, P560, DOI 10.1073/pnas.80.2.560; GLOSS B, 1990, J VIROL, V64, P5577, DOI 10.1128/JVI.64.11.5577-5584.1990; GLOSS B, 1987, EMBO J, V6, P3735, DOI 10.1002/j.1460-2075.1987.tb02708.x; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; KAUR P, 1988, J VIROL, V62, P1917, DOI 10.1128/JVI.62.6.1917-1924.1988; KAUR P, 1989, J GEN VIROL, V70, P1261, DOI 10.1099/0022-1317-70-5-1261; LAMBERT PF, 1987, CELL, V50, P69, DOI 10.1016/0092-8674(87)90663-5; LEES E, 1990, J GEN VIROL, V71, P183, DOI 10.1099/0022-1317-71-1-183; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGER K, 1989, J VIROL, V63, P4417; OLTERSDORF T, 1987, J GEN VIROL, V68, P2933, DOI 10.1099/0022-1317-68-11-2933; PECORARO G, 1989, P NATL ACAD SCI USA, V86, P563, DOI 10.1073/pnas.86.2.563; PHELPS WC, 1987, J VIROL, V61, P1630, DOI 10.1128/JVI.61.5.1630-1638.1987; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; ROMANCZUK H, 1990, J VIROL, V64, P2849, DOI 10.1128/JVI.64.6.2849-2859.1990; ROMANCZUK H, 1991, J VIROL, V65, P2739, DOI 10.1128/JVI.65.5.2739-2744.1991; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHLEGEL R, 1988, EMBO J, V7, P3181, DOI 10.1002/j.1460-2075.1988.tb03185.x; SEEDORF K, 1985, VIROLOGY, V145, P181, DOI 10.1016/0042-6822(85)90214-4; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPALHOLZ BA, 1985, CELL, V42, P183, DOI 10.1016/S0092-8674(85)80114-8; STANLEY MA, 1989, INT J CANCER, V43, P672, DOI 10.1002/ijc.2910430422; STANLEY MA, 1979, INT J CANCER, V24, P407, DOI 10.1002/ijc.2910240406; STERLING J, 1990, J VIROL, V64, P6305, DOI 10.1128/JVI.64.12.6305-6307.1990; STOREY A, 1990, J GEN VIROL, V71, P165, DOI 10.1099/0022-1317-71-1-165; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; THIERRY F, 1987, EMBO J, V6, P3391, DOI 10.1002/j.1460-2075.1987.tb02662.x; VANDENBRULE AJC, 1989, J MED VIROL, V29, P20, DOI 10.1002/jmv.1890290105; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WOODWORTH CD, 1989, J VIROL, V63, P159, DOI 10.1128/JVI.63.1.159-164.1989	51	21	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1992	7	3					459	465						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1312701				2022-12-28	WOS:A1992HK00500009
J	DAMICO, D; CARBONE, D; MITSUDOMI, T; NAU, M; FEDORKO, J; RUSSELL, E; JOHNSON, B; BUCHHAGEN, D; BODNER, S; PHELPS, R; GAZDAR, A; MINNA, JD				DAMICO, D; CARBONE, D; MITSUDOMI, T; NAU, M; FEDORKO, J; RUSSELL, E; JOHNSON, B; BUCHHAGEN, D; BODNER, S; PHELPS, R; GAZDAR, A; MINNA, JD			HIGH-FREQUENCY OF SOMATICALLY ACQUIRED P53 MUTATIONS IN SMALL-CELL LUNG-CANCER CELL-LINES AND TUMORS	ONCOGENE			English	Article							POLYMERASE CHAIN-REACTION; POINT MUTATIONS; T-ANTIGEN; SHORT ARM; WILD-TYPE; GENE; CHROMOSOME-17; EXPRESSION; IDENTIFICATION; LOCALIZATION	We analysed the p53 open reading frame (ORF) in 16 small-cell lung cancer (SCLC) cell lines by direct sequencing of cDNA/PCR products and in 20 SCLC tumors by chemical cleavage and single-strand conformation polymorphism analyses of genomic DNA/PCR products. Abnormalities of p53 were found in 16/16 cell lines (100%) and in 16/20 tumors (80%). In the SCLC cell lines, mutations (59% missense, 18% nonsense and 23% splicing) changing the coding sequence were dispersed between amino acids 68 and 342. In the tumor samples, while the mutations occurred predominantly in exons 5-8, other mutations were located outside these regions. G to T transversions were common, occurring in 32% of the cases. We found no p53 mutations in the corresponding normal tissue from 19 patients whose tumors had p53 lesions, indicating that the mutations were all somatically acquired. In analysing the clinical data of the patients we found no correlation between tumor response to therapy or survival and the location or type of mutations. We conclude from these data that: (1) p53 mutations are found in SCLC with high frequency; (2) p53 mutations in a significant fraction of cases generate cDNAs with nonsense or splicing mutations; and (3) to date, these mutations have all been somatically acquired events.	NATL NAVAL MED CTR, NCI, NAVY MED ONCOL BRANCH, BETHESDA, MD 20814 USA; UNIFORMED SERV UNIV HLTH SCI, BETHESDA, MD 20814 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Walter Reed National Military Medical Center; Uniformed Services University of the Health Sciences - USA	DAMICO, D (corresponding author), UNIV TEXAS, SW MED CTR DALLAS, SIMMONS CANC CTR, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA.			Mitsudomi, Tetsuya/0000-0001-9860-8505				ADDISON C, 1990, ONCOGENE, V5, P423; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARTEK J, 1990, ONCOGENE, V5, P893; Battey, 1986, BASIC METHODS MOL BI; BODNER S, 1991, IN PRESS ONCOGENE; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CAPORASO NE, 1990, J NATL CANCER I, V82, P1264, DOI 10.1093/jnci/82.15.1264; CARNEY DN, 1985, CANCER RES, V45, P2913; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHIBA I, 1990, ONCOGENE, V5, P1603; CURIEL DT, 1990, AM J RESP CELL MOL, V3, P405, DOI 10.1165/ajrcmb/3.5.405; DOHERTY PJ, 1989, ANAL BIOCHEM, V177, P7, DOI 10.1016/0003-2697(89)90003-1; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FUJIMORI M, 1991, CANCER RES, V51, P89; HEIGHWAY J, 1986, BRIT J CANCER, V53, P453, DOI 10.1038/bjc.1986.72; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LOECHLER EL, 1984, P NATL ACAD SCI-BIOL, V81, P6271, DOI 10.1073/pnas.81.20.6271; LYNCH H, 1986, CANCER, V57, P640; MACKAY J, 1988, LANCET, V2, P1384; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MASHAL R, 1990, BLOOD, V75, P180; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MAZUR M, 1988, SOMAT CELL MOLEC GEN, V14, P393, DOI 10.1007/BF01534647; MCBRIDE OW, 1986, P NATL ACAD SCI USA, V83, P130, DOI 10.1073/pnas.83.1.130; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; Minna JD, 1989, CANCER PRINCIPLES PR, P591; MITSUDOMI T, 1991, IN PRESS ONCOGENE; MORI N, 1989, CANCER RES, V49, P5130; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OOI WL, 1986, J NATL CANCER I, V76, P217; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROMANO JW, 1989, ONCOGENE, V4, P1483; SELLERS TA, 1990, J NATL CANCER I, V82, P1272, DOI 10.1093/jnci/82.15.1272; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SLAGLE BL, 1991, CANCER RES, V51, P49; SOUSSI T, 1990, J VIROL, V64, P967; SOUSSI T, 1989, J VIROL, V63, P3894, DOI 10.1128/JVI.63.9.3894-3901.1989; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; SUZUKI Y, 1990, ONCOGENE, V5, P1037; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKAHASHI T, 1991, ONCOGENE, V6, P1775; TAKAHASHI T, 1990, J CLIN INVEST, V86, P363, DOI 10.1172/JCI114710; TALERICO M, 1990, MOL CELL BIOL, V10, P6299, DOI 10.1128/MCB.10.12.6299; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252	58	219	221	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1992	7	2					339	346						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1312696				2022-12-28	WOS:A1992HG98200020
J	Gayen, M; Benoit, MR; Fan, QY; Hudobenko, J; Yan, RQ				Gayen, Manoshi; Benoit, Marc R.; Fan, Qingyuan; Hudobenko, Jacob; Yan, Riqiang			The CX3CL1 intracellular domain exhibits neuroprotection via insulin receptor/insulin-like growth factor receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTORS; PHOSPHATIDYLINOSITOL 3-KINASE; ALZHEIMERS-DISEASE; FOXO; NEURODEGENERATION; PHOSPHORYLATION; FRACTALKINE; MECHANISMS; RESISTANCE; MIGRATION	CX3CL1, also known as fractalkine, is best known for its signaling activity through interactions with its cognate receptor CX3CR1. However, its intrinsic function that is independent of interaction with CX3CR1 remains to be fully understood. We demonstrate that the intracellular domain of CX3CL1 (CX3CL1-ICD), generated upon sequential cleavages by alpha-/beta secretase and gamma-secretase, initiates a back signaling activity, which mediates direct signal transmission to gene expression in the nucleus. To study this, we fused a synthetic peptide derived from CX3CL1-ICD, named Tet34, with a 13-amino acid tetanus sequence at the N terminus to facilitate translocation into neuronal cells. We show that treatment of mouse neuroblastoma Neuro-2A cells with Tet34, but not its scrambled control (Tet34s), induced cell proliferation, as manifested by changes in protein levels of transcription factors and progrowth molecules cyclin D1, PCNA, Sox5, and Cdk2. Further biochemical assays reveal elevation of phosphorylated insulin receptor beta subunit, insulin-like growth factor-1 receptor beta subunit, and insulin receptor substrates as well as activation of proliferation-linked kinase AKT. In addition, transgenic mice overexpressing membrane-anchored C-terminal CX3CL1 also exhibited activation of insulin/insulin-like growth factor-1 receptor signaling. Remarkably, we found that this Tet34 peptide, but not Tet34s, protected against endoplasmic reticulum stress and cellular apoptosis when Neuro-2A cells were challenged with toxic oligomers of beta-amyloid peptide or hydrogen peroxide. Taken together, our results suggest that CX3CL1ICD may have translational potential for neuroprotection in Alzheimer's disease and for disorders resulting from insulin resistance.	[Gayen, Manoshi; Benoit, Marc R.; Fan, Qingyuan; Hudobenko, Jacob; Yan, Riqiang] Univ Connecticut Hlth, Dept Neurosci, Farmington, CT 06030 USA; [Fan, Qingyuan] Cleveland Clin, Lerner Res Inst, Dept Neurosci, Cleveland Hts, OH 44195 USA	University of Connecticut; Cleveland Clinic Foundation	Yan, RQ (corresponding author), Univ Connecticut Hlth, Dept Neurosci, Farmington, CT 06030 USA.	riyan@uchc.edu		Benoit, Marc/0000-0001-6777-8472; Hudobenko, Jacob/0000-0001-9064-4149				Akhtar A, 2020, NEUROCHEM INT, V135, DOI 10.1016/j.neuint.2020.104707; Amador-Arjona A, 2015, P NATL ACAD SCI USA, V112, pE1936, DOI 10.1073/pnas.1421480112; Arnold SE, 2018, NAT REV NEUROL, V14, P168, DOI 10.1038/nrneurol.2017.185; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Benoit MR, 2019, AGING-US, V11, P10783, DOI 10.18632/aging.102504; Bunk EC, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.13; Calissi G, 2021, NAT REV DRUG DISCOV, V20, P21, DOI 10.1038/s41573-020-0088-2; Chell JM, 2010, CELL, V143, P1161, DOI 10.1016/j.cell.2010.12.007; de la Monte SM, 2017, DRUGS, V77, P47, DOI 10.1007/s40265-016-0674-0; de Mollo NP, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00491; Diep CH, 2016, MOL CANCER RES, V14, P141, DOI 10.1158/1541-7786.MCR-15-0431; Eijkelenboom A, 2013, NAT REV MOL CELL BIO, V14, P83, DOI 10.1038/nrm3507; Fan QY, 2020, J NEUROSCI, V40, P1133, DOI 10.1523/JNEUROSCI.1333-19.2019; Fan QY, 2019, J EXP MED, V216, P1891, DOI 10.1084/jem.20182238; Finneran DJ, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1412-9; Fricker M, 2018, PHYSIOL REV, V98, P813, DOI 10.1152/physrev.00011.2017; Fu HJ, 2018, NAT NEUROSCI, V21, P1350, DOI 10.1038/s41593-018-0221-2; Guven A, 2020, ELIFE, V9, DOI 10.7554/eLife.49808; Guo TT, 2020, MOL NEURODEGENER, V15, DOI 10.1186/s13024-020-00391-7; Hatori K, 2002, J NEUROSCI RES, V69, P418, DOI 10.1002/jnr.10304; Holscher C, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00088; Huang HJ, 2006, SCIENCE, V314, P294, DOI 10.1126/science.1130512; Iatrou A, 2021, MOL NEURODEGENER, V16, DOI 10.1186/s13024-021-00489-6; Iida Mari, 2013, Cancer Biol Ther, V14, P481, DOI 10.4161/cbt.24342; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; Kellar D, 2020, LANCET NEUROL, V19, P758, DOI 10.1016/S1474-4422(20)30231-3; Kennedy LM, 2013, CELL REP, V4, P996, DOI 10.1016/j.celrep.2013.07.045; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Lees SJ, 2008, AM J PHYSIOL-CELL PH, V295, pC1238, DOI 10.1152/ajpcell.00349.2008; Lei H, 2009, MOL CANCER RES, V7, P1294, DOI 10.1158/1541-7786.MCR-08-0531; Limatola C, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00229; Link W, 2019, METHODS MOL BIOL, V1890, P1, DOI 10.1007/978-1-4939-8900-3_1; Liu JK, 2005, NEUROBIOL DIS, V19, P407, DOI 10.1016/j.nbd.2005.01.022; Lu HR, 2011, CURR DRUG TARGETS, V12, P1235, DOI 10.2174/138945011796150280; Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001; Manzoni C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024909; Martinez-Morales PL, 2010, EMBO REP, V11, P466, DOI 10.1038/embor.2010.61; Monsalve M, 2011, CURR DRUG TARGETS, V12, P1322, DOI 10.2174/138945011796150307; Nieto-Estevez V, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00052; Oakley H, 2006, J NEUROSCI, V26, P10129, DOI 10.1523/JNEUROSCI.1202-06.2006; Paik JH, 2009, CELL STEM CELL, V5, P540, DOI 10.1016/j.stem.2009.09.013; Parrizas M, 1997, J BIOL CHEM, V272, P154; Pfisterer U, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.64; Querfurth H, 2021, MOL NEURODEGENER, V16, DOI 10.1186/s13024-021-00428-5; Ro SH, 2013, ARCH BIOCHEM BIOPHYS, V534, P55, DOI 10.1016/j.abb.2012.07.017; Ryu JR, 2016, MOL BRAIN, V9, DOI 10.1186/s13041-016-0224-4; Saltiel AR, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI142241; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; Soto M, 2019, P NATL ACAD SCI USA, V116, P6379, DOI 10.1073/pnas.1817391116; Spinelli M, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00788; Sun W, 2004, J NEUROSCI, V24, P11205, DOI 10.1523/JNEUROSCI.1436-04.2004; van der Heide LP, 2006, PROG NEUROBIOL, V79, P205, DOI 10.1016/j.pneurobio.2006.06.003; van der Heide LP, 2004, BIOCHEM J, V380, P297, DOI 10.1042/BJ20040167; Vogt PK, 2005, CELL CYCLE, V4, P908, DOI 10.4161/cc.4.7.1796; Webb AE, 2014, TRENDS BIOCHEM SCI, V39, P159, DOI 10.1016/j.tibs.2014.02.003; Yoshiyama Y, 2012, NEUROBIOL DIS, V45, P329, DOI 10.1016/j.nbd.2011.08.017; Zanella F, 2010, CURR CANCER DRUG TAR, V10, P135, DOI 10.2174/156800910791054158	57	0	0	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV	2022	298	11							102532	10.1016/j.jbc.2022.102532	http://dx.doi.org/10.1016/j.jbc.2022.102532			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	6C7OU	36162508	gold, Green Published			2022-12-28	WOS:000882199400011
J	Morinaga, S; Nagata, K; Ihara, S; Yumita, T; Niimura, Y; Sato, K; Touhara, K				Morinaga, Satoshi; Nagata, Koji; Ihara, Sayoko; Yumita, Tomohiro; Niimura, Yoshihito; Sato, Koji; Touhara, Kazushige			Structural model for ligand binding and channel opening of an insect gustatory receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLFACTORY RECEPTORS; CAFFEINE RESPONSE; HYDROPHOBIC GATE; TASTE; SPECIFICITY; PRINCIPLES; RESIDUES; MUTATION; FAMILY; GENES	Insect gustatory receptors play roles in sensing tastants, such as sugars and bitter substances. We previously demonstrated that the BmGr9 silkworm gustatory receptor is a n-fructose- gated ion channel receptor. However, the molecular mechanism of how n-fructose could initiate channel opening were unclear. Herein, we present a structural model for a channel pore and a n-fructose-binding site in BmGr9. Since the membrane topology and oligomeric state of BmGr9 appeared to be similar to those of an insect odorant receptor coreceptor, Orco, we constructed a structural model of BmGr9 based on the cryo-EM Orco structure. Our site-directed mutagenesis data suggested that the transmembrane region 7 forms channel pore and controls channel gating. This model also suggested that a pocket formed by transmembrane helices 2 to 4 and 6 binds n-fructose. Using mutagenesis experiments in combination with docking simulations, we were able to determine the potent binding mode of n-fructose. Finally, based on these data, we propose a conformational change that leads to channel opening upon n-fructose binding. Taken together, these findings detail the molecular mechanism by which an insect gustatory receptor can be activated by its ligand molecule.	[Morinaga, Satoshi; Nagata, Koji; Ihara, Sayoko; Yumita, Tomohiro; Niimura, Yoshihito; Sato, Koji; Touhara, Kazushige] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Tokyo, Japan; [Touhara, Kazushige] Univ Tokyo, Inst Adv Study, Int Res Ctr Neurointelligence WPI IRCN, Tokyo, Japan; [Niimura, Yoshihito] Univ Miyazaki, Fac Agr, Dept Vet Sci, Miyazaki 8892192, Japan	University of Tokyo; University of Tokyo; University of Miyazaki	Ihara, S; Touhara, K (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Tokyo, Japan.; Touhara, K (corresponding author), Univ Tokyo, Inst Adv Study, Int Res Ctr Neurointelligence WPI IRCN, Tokyo, Japan.	ktouhara@mail.ecc.u-tokyo.ac.jp; asihara@mail.ecc.u-tokyo.ac.jp		Nagata, Koji/0000-0002-4704-0603	Naito Foundation; MEXT Quantum Leap Flagship Program (MEXT Q -LEAP) [JPMXS0120330644]; JST ERATO Touhara Chemosensory Signal Project [JPMJER1202]; JSPS KAKENHI [19H02531]	Naito Foundation(Naito Memorial Foundation); MEXT Quantum Leap Flagship Program (MEXT Q -LEAP); JST ERATO Touhara Chemosensory Signal Project; JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by the Naito Foundation to K. T., MEXT Quantum Leap Flagship Program (MEXT Q -LEAP) Grant Number JPMXS0120330644 (to K. T.) , JST ERATO Touhara Chemosensory Signal Project Grant Number JPMJER1202 (to K. T.) , and JSPS KAKENHI Grant Number 19H02531 (to K. S.) .	Andersson MN, 2019, BMC GENOMICS, V20, DOI 10.1186/s12864-019-6054-x; Ashkenazy H, 2016, NUCLEIC ACIDS RES, V44, pW344, DOI 10.1093/nar/gkw408; Beckstein O, 2006, PHYS BIOL, V3, P147, DOI 10.1088/1478-3975/3/2/007; Butterwick JA, 2018, NATURE, V560, P447, DOI 10.1038/s41586-018-0420-8; Chang YC, 1998, MOL PHARMACOL, V53, P511, DOI 10.1124/mol.53.3.511; Dahanukar A, 2007, NEURON, V56, P503, DOI 10.1016/j.neuron.2007.10.024; del Marmol J, 2021, NATURE, V597, P126, DOI 10.1038/s41586-021-03794-8; Dweck HKM, 2020, CURR BIOL, V30, P17, DOI 10.1016/j.cub.2019.11.005; Gabius HJ, 2011, TRENDS BIOCHEM SCI, V36, P298, DOI 10.1016/j.tibs.2011.01.005; Guo HZ, 2017, INSECT BIOCHEM MOLEC, V82, P74, DOI 10.1016/j.ibmb.2017.02.001; Holm L, 2022, NUCLEIC ACIDS RES, V50, pW210, DOI 10.1093/nar/gkac387; Hudson KL, 2015, J AM CHEM SOC, V137, P15152, DOI 10.1021/jacs.5b08424; Hughes DT, 2014, CHEM SENSES, V39, P761, DOI 10.1093/chemse/bju048; Jensen MO, 2010, P NATL ACAD SCI USA, V107, P5833, DOI 10.1073/pnas.0911691107; Jiao YC, 2008, CURR BIOL, V18, P1797, DOI 10.1016/j.cub.2008.10.009; Jumper J, 2021, NATURE, V596, P583, DOI 10.1038/s41586-021-03819-2; Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010; Kaur J, 2009, ANAL BIOCHEM, V384, P348, DOI 10.1016/j.ab.2008.10.005; Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Larsson MC, 2004, NEURON, V43, P703, DOI 10.1016/j.neuron.2004.08.019; Leary GP, 2012, P NATL ACAD SCI USA, V109, P14081, DOI 10.1073/pnas.1204661109; Lee Y, 2010, NEURON, V67, P555, DOI 10.1016/j.neuron.2010.07.006; Lee Y, 2009, P NATL ACAD SCI USA, V106, P4495, DOI 10.1073/pnas.0811744106; Asensio JL, 2013, ACCOUNTS CHEM RES, V46, P946, DOI 10.1021/ar300024d; Malak OA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00155-2; Moon SJ, 2006, CURR BIOL, V16, P1812, DOI 10.1016/j.cub.2006.07.024; Moon SJ, 2009, CURR BIOL, V19, P1623, DOI 10.1016/j.cub.2009.07.061; Nakagawa T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032372; Neuhaus EM, 2005, NAT NEUROSCI, V8, P15, DOI 10.1038/nn1371; Nichols AS, 2010, J BIOL CHEM, V285, P11854, DOI 10.1074/jbc.M109.058321; Rao SL, 2019, P NATL ACAD SCI USA, V116, P13989, DOI 10.1073/pnas.1902702116; Robertson HM, 2003, P NATL ACAD SCI USA, V100, P14537, DOI 10.1073/pnas.2335847100; Robertson HM, 2018, GENOME BIOL EVOL, V10, P2997, DOI 10.1093/gbe/evy232; Robertson HM, 2019, ANNU REV ENTOMOL, V64, P227, DOI 10.1146/annurev-ento-020117-043322; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sato K, 2008, NATURE, V452, P1002, DOI 10.1038/nature06850; Sato K, 2011, P NATL ACAD SCI USA, V108, P11680, DOI 10.1073/pnas.1019622108; Schoonhoven LM, 2002, ACTA ZOOL ACAD SCI H, V48, P215; Scott K, 2001, CELL, V104, P661, DOI 10.1016/S0092-8674(01)00263-X; Seebohm G, 2005, J PHYSIOL-LONDON, V563, P359, DOI 10.1113/jphysiol.2004.080887; Shim J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9867; Sukhareva M, 2003, J GEN PHYSIOL, V122, P541, DOI 10.1085/jgp.200308905; Sung HY, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01639-5; Touhara K, 2009, ANNU REV PHYSIOL, V71, P307, DOI 10.1146/annurev.physiol.010908.163209; Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334; Vosshall LB, 2007, ANNU REV NEUROSCI, V30, P505, DOI 10.1146/annurev.neuro.30.051606.094306; Vyas NK, 1991, CURR OPIN STRUC BIOL, V1, P732, DOI 10.1016/0959-440X(91)90172-P; Wanner KW, 2008, INSECT MOL BIOL, V17, P621, DOI 10.1111/j.1365-2583.2008.00836.x; Wicher D, 2008, NATURE, V452, P1007, DOI 10.1038/nature06861; Yachdav G, 2014, NUCLEIC ACIDS RES, V42, pW337, DOI 10.1093/nar/gku366; Yamashita M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14512; Yang K, 2017, ELIFE, V6, DOI [10.7554/eLife.29100, 10.7554/elife.29100]; Yarmolinsky DA, 2009, CELL, V139, P234, DOI 10.1016/j.cell.2009.10.001; Yu Y, 2009, P NATL ACAD SCI USA, V106, P11558, DOI 10.1073/pnas.0903684106; Zhang HN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022874; Zheng W, 2018, FASEB J, V32, P639, DOI 10.1096/fj.201700599RR	57	0	0	5	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV	2022	298	11							102573	10.1016/j.jbc.2022.102573	http://dx.doi.org/10.1016/j.jbc.2022.102573			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	6W5WW	36209821	Green Published, gold			2022-12-28	WOS:000895801300003
J	FREUND, R; BRONSON, RT; BENJAMIN, TL				FREUND, R; BRONSON, RT; BENJAMIN, TL			SEPARATION OF IMMORTALIZATION FROM TUMOR-INDUCTION WITH POLYOMA LARGE T-MUTANTS THAT FAIL TO BIND THE RETINOBLASTOMA GENE-PRODUCT	ONCOGENE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; ADENOVIRUS E1A PROTEINS; MIDDLE-T; CELL-CYCLE; TRANSCRIPTION FACTOR; SUSCEPTIBILITY GENE; KINASE-ACTIVITY; EMBRYO FIBROBLASTS; SIMIAN VIRUS-40; WILD-TYPE	The mouse polyomavirus encodes a tumor-suppressor gene inactivator in its large T protein and a proto-oncogene activator in its middle T protein. We have used site-directed mutagenesis to selectively inactivate the former function without affecting the latter. Two mutant viruses were constructed to encode altered large T proteins that fail to bind the retinoblastoma tumor-suppressor gene product pRB, along with normal small and middle T proteins. The pRB-binding mutants proved to be defective in immortalization of primary rat embryo fibroblasts by a variety of tests. Yet they proved capable of transforming both primary and established fibroblasts in culture. Most importantly, the inability of these mutants to bind pRB had little effect on their ability to induce tumors in mice. We conclude that induction of multiple tumor types in this system does not depend on large T-pRB interactions but rather on middle T-dependent pathways. In addition, the ability of this virus to immortalize cells in culture is not essential to its ability to induce tumors in the animal.	HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Harvard Medical School					NCI NIH HHS [R35-CA44343] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044343] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BENJAMIN T, 1990, VIROLOGY, P317; BENJAMIN TL, 1970, P NATL ACAD SCI USA, V67, P394, DOI 10.1073/pnas.67.1.394; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CARMICHAEL GG, 1982, P NATL ACAD SCI-BIOL, V79, P3579, DOI 10.1073/pnas.79.11.3579; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHEN S, 1990, J VIROL, V64, P3350, DOI 10.1128/JVI.64.7.3350-3357.1990; CHENG SH, 1986, EMBO J, V5, P325, DOI 10.1002/j.1460-2075.1986.tb04216.x; CHESTERS PM, 1990, J GEN VIROL, V71, P449, DOI 10.1099/0022-1317-71-2-449; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; COURTNEIDGE SA, 1991, J VIROL, V65, P3301, DOI 10.1128/JVI.65.6.3301-3308.1991; COWIE A, 1986, MOL CELL BIOL, V6, P4344, DOI 10.1128/MCB.6.12.4344; DAWE CJ, 1987, AM J PATHOL, V127, P243; DEBENSKY TW, 1984, J VIROL, V50, P779; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DUBENSKY TW, 1991, J VIROL, V65, P342, DOI 10.1128/JVI.65.1.342-349.1991; DYSON N, 1989, CANCER CEL, V7, P235; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; ECKHART W, 1969, VIROLOGY, V38, P120, DOI 10.1016/0042-6822(69)90133-0; ECKHART W, 1977, VIROLOGY, V77, P589, DOI 10.1016/0042-6822(77)90484-6; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEUTEUN J, 1976, P NATL ACAD SCI USA, V73, P4169; FLUCK MM, 1979, VIROLOGY, V96, P205, DOI 10.1016/0042-6822(79)90185-5; FLUCK MM, 1977, VIROLOGY, V77, P610, DOI 10.1016/0042-6822(77)90486-X; FREUND R, 1991, J VIROL, V65, P335, DOI 10.1128/JVI.65.1.335-341.1991; FREUND R, 1987, J VIROL, V61, P2232, DOI 10.1128/JVI.61.7.2232-2239.1987; FRIED M, 1965, P NATL ACAD SCI USA, V53, P486, DOI 10.1073/pnas.53.3.486; GLENN GM, 1990, J VIROL, V64, P2193, DOI 10.1128/JVI.64.5.2193-2201.1990; GORGA FR, 1990, J VIROL, V64, P105, DOI 10.1128/JVI.64.1.105-112.1990; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; JAT PS, 1986, J VIROL, V59, P746, DOI 10.1128/JVI.59.3.746-750.1986; JEWERS RJ, 1992, J VIROL, V66, P1329, DOI 10.1128/JVI.66.3.1329-1335.1992; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LAROSE A, 1991, J VIROL, V65, P2308, DOI 10.1128/JVI.65.5.2308-2313.1991; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PARTRIDGE JF, 1991, EMBO J, V10, P3819, DOI 10.1002/j.1460-2075.1991.tb04951.x; RAPTIS L, 1985, MOL CELL BIOL, V5, P2476, DOI 10.1128/MCB.5.9.2476; RASSOULZADEGAN M, 1983, P NATL ACAD SCI-BIOL, V80, P4354, DOI 10.1073/pnas.80.14.4354; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; RICHARDSON WD, 1986, CELL, V44, P77, DOI 10.1016/0092-8674(86)90486-1; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SILVER J, 1978, CELL, V15, P485, DOI 10.1016/0092-8674(78)90018-1; STANELONI RJ, 1977, VIROLOGY, V77, P598, DOI 10.1016/0042-6822(77)90485-8; TALMAGE DA, 1992, VIROLOGY, V187, P734, DOI 10.1016/0042-6822(92)90476-6; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TALMAGE DA, 1991, CELL GROWTH DIFFER, V2, P51; THOMPSON DL, 1990, VIROLOGY, V178, P15, DOI 10.1016/0042-6822(90)90375-2; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TREISMAN R, 1981, NATURE, V292, P595, DOI 10.1038/292595a0; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468; ZULLO J, 1987, P NATL ACAD SCI USA, V84, P1210, DOI 10.1073/pnas.84.5.1210	73	53	55	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					1979	1987						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1328987				2022-12-28	WOS:A1992JP42400011
J	RIM, M; QURESHI, SA; GIUS, D; NHO, J; SUKHATME, VP; FOSTER, DA				RIM, M; QURESHI, SA; GIUS, D; NHO, J; SUKHATME, VP; FOSTER, DA			EVIDENCE THAT ACTIVATION OF THE EGR-1 PROMOTER BY V-RAF INVOLVES SERUM RESPONSE ELEMENTS	ONCOGENE			English	Note							PROTEIN-KINASE-C; SIGNAL TRANSDUCTION; GENE-EXPRESSION; GROWTH-FACTORS; FOS; BINDING; PHOSPHORYLATION; ENCODES; FAMILY; CELLS	The constitutively active serine/threonine kinase encoded by the v-raf oncogene, v-Raf, activates the Egr-1 promoter in transient expression assays. To characterize the v-Raf-responsive transcriptional control elements, deletion mutants of the Egr-1 promoter were used in transient expression assays. A v-Raf expression vector was co-transfected into NIH3T3 cells with reporter chloramphenicol acetyl transferase (CAT) expression vectors under the control of the Egr-1 promoter or the Egr-1 promoter containing various deletions. Responsiveness to v-Raf was restricted to a region that contained repeated CC(A/T)6GG sequences, known as CArG boxes. CArG boxes form the core of serum response elements (SREs). v-Raf-induced Egr-I promoter activation was lost by removal of the four tandemly repeated SREs. This region, between - 425 and - 250, which was necessary for v-Raf responsiveness, was also found to be sufficient for maximal Egr-1 induction by v-Raf when placed upstream from a minimal heterologous promoter. Three out of four SREs from this region were able to respond to v-Raf, however the activation of the individual SREs was lower than the clustered SREs. This cluster of SREs has previously been shown to be responsive to several mitogenic stimuli and the oncogene v-src. Thus, the SREs contained in this cluster may be an important target for cell division signals.	CUNY HUNTER COLL, INST BIOMOLEC STRUCT & FUNCT, 695 PK AVE, NEW YORK, NY 10021 USA; UNIV CHICAGO, DEPT MED MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, HOWARD HUGHES MED INST, CHICAGO, IL 60637 USA; CUNY HUNTER COLL, DEPT BIOL SCI, NEW YORK, NY 10021 USA	City University of New York (CUNY) System; Hunter College (CUNY); University of Chicago; Howard Hughes Medical Institute; University of Chicago; City University of New York (CUNY) System; Hunter College (CUNY)			Sukhatme, Vikas/W-2776-2019		NATIONAL CANCER INSTITUTE [R29CA046677, R01CA046677] Funding Source: NIH RePORTER; NCI NIH HHS [CA46677] Funding Source: Medline; NCRR NIH HHS [RRO-3037-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; Battey, 1986, BASIC METHODS MOL BI; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; KAIBUCHI K, 1989, J BIOL CHEM, V264, P20855; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; PATWARDHAN S, 1991, ONCOGENE, V6, P917; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; QURESHI SA, 1991, J BIOL CHEM, V266, P20594; QURESHI SA, 1991, ONCOGENE, V6, P995; RAPP UR, 1991, ONCOGENE, V6, P495; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Treisman R, 1990, Semin Cancer Biol, V1, P47; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2	27	25	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1992	7	10					2065	2068						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408148				2022-12-28	WOS:A1992JP42400022
J	ROBINSON, HL; TRACY, SE; NAIR, N; TAGLIENTISIAN, C; GAMETT, DC				ROBINSON, HL; TRACY, SE; NAIR, N; TAGLIENTISIAN, C; GAMETT, DC			CHARACTERIZATION FO AN ANGIOSARCOMA-INDUCING MUTATION IN THE ERBB ONCOGENE	ONCOGENE			English	Article							AVIAN ERYTHROBLASTOSIS VIRUS; GROWTH-FACTOR RECEPTOR; TISSUE-SPECIFIC TRANSFORMATION; C-ERBB; V-ERBB; TYROSINE KINASE; EGF RECEPTOR; CELLS; GENE; DOMAIN	The erbB oncogenes of two transducing viruses that arose in chicken 5005 have been molecularly characterized. One of these viruses, AEV-5005, caused erythroblastosis. The other, AAV-5005, caused angiosarcoma. Both viruses had identical 5' junctions of viral and host sequences, indicating that both arose from the same proviral insertion. The erbB oncogenes of both viruses encoded transmembrane, kinase and C-terminal domains of the chicken epidermal growth factor receptor. The C-terminal domain of the AEV-5005 erbB was complete, whereas that of AAV-5005 contained a 59 amino acid internal deletion (amino acids 993-1051 of the chicken epidermal growth factor receptor). Oncogenicity tests using retroviral constructs containing the erbB sequences from AEV-5005 and AAV-5005 demonstrated that both erbB genes caused erythroblastosis and that the 59 amino acid deletion conferred the ability to induce angiosarcoma. The 59 amino acid deletion also caused increased levels of erbB autophosphorylation in cells grown in the presence of sodium orthovanadate.	UNIV MASSACHUSETTS,MED CTR,DEPT MOLEC GENET & MICROBIOL,WORCESTER,MA 01655	University of Massachusetts System; University of Massachusetts Worcester	ROBINSON, HL (corresponding author), UNIV MASSACHUSETTS,MED CTR,DEPT PATHOL,55 LAKE AVE N,WORCESTER,MA 01655, USA.			Tracy, Sharon/0000-0002-5731-5228	NATIONAL CANCER INSTITUTE [R01CA023086] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 23772, R01 CA 23086] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEUG H, 1986, J VIROL, V57, P1127, DOI 10.1128/JVI.57.3.1127-1138.1986; BRUSKIN A, 1990, ONCOGENE, V5, P15; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CHOI OR, 1986, MOL CELL BIOL, V6, P1751, DOI 10.1128/MCB.6.5.1751; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; DEBUIRE B, 1984, SCIENCE, V224, P1456, DOI 10.1126/science.6328658; Enzinger FM, 1983, SOFT TISSUE TUMORS, V1, P422; GAMETT DC, 1986, P NATL ACAD SCI USA, V83, P6053, DOI 10.1073/pnas.83.16.6053; GULLICK WJ, 1985, EMBO J, V4, P2869, DOI 10.1002/j.1460-2075.1985.tb04016.x; HIHARA H, 1983, J NATL CANCER I, V70, P891; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; JANSSON M, 1987, ONCOGENE, V1, P167; LAX I, 1988, MOL CELL BIOL, V8, P1970, DOI 10.1128/MCB.8.5.1970; MAIHLE N J, 1988, Biochimica et Biophysica Acta, V948, P287; MILES BD, 1985, J VIROL, V54, P295, DOI 10.1128/JVI.54.2.295-303.1985; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; NAIR N, 1992, MOL CELL BIOL, V12, P2010, DOI 10.1128/MCB.12.5.2010; NILSEN TW, 1985, CELL, V41, P719, DOI 10.1016/S0092-8674(85)80052-0; PELLEY RJ, 1989, P NATL ACAD SCI USA, V86, P7164, DOI 10.1073/pnas.86.18.7164; PELLEY RJ, 1988, J VIROL, V62, P1840, DOI 10.1128/JVI.62.5.1840-1844.1988; RAINES MA, 1985, P NATL ACAD SCI USA, V82, P2287, DOI 10.1073/pnas.82.8.2287; RAINES MA, 1988, J VIROL, V62, P2444, DOI 10.1128/JVI.62.7.2444-2452.1988; ROBINSON HL, 1985, J VIROL, V55, P617, DOI 10.1128/JVI.55.3.617-622.1985; SASAKI T, 1984, J BIOL CHEM, V259, P2489; SCHWARTZ DE, 1983, CELL, V32, P853, DOI 10.1016/0092-8674(83)90071-5; SHU HKG, 1991, J VIROL, V65, P6173, DOI 10.1128/JVI.65.11.6173-6180.1991; SHU HKG, 1990, P NATL ACAD SCI USA, V87, P9103, DOI 10.1073/pnas.87.23.9103; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; THEROUX SJ, 1992, J BIOL CHEM, V267, P7967; TRACY SE, 1985, J VIROL, V54, P304, DOI 10.1128/JVI.54.2.304-310.1985; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VIJAYA S, 1986, J VIROL, V60, P683, DOI 10.1128/JVI.60.2.683-692.1986; WALTON GM, 1990, J BIOL CHEM, V265, P1750; YAMAMOTO T, 1983, CELL, V34, P225, DOI 10.1016/0092-8674(83)90153-8; YAMAMOTO T, 1983, CELL, V35, P71, DOI 10.1016/0092-8674(83)90209-X; YONEMOTO W, 1987, MOL CELL BIOL, V7, P905, DOI 10.1128/MCB.7.2.905	37	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					2025	2030						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408143				2022-12-28	WOS:A1992JP42400017
J	TALMAGE, DA; LACKEY, RS				TALMAGE, DA; LACKEY, RS			RETINOIC ACID RECEPTOR-ALPHA SUPPRESSES POLYOMAVIRUS TRANSFORMATION AND C-FOS EXPRESSION IN RAT FIBROBLASTS	ONCOGENE			English	Article							MIDDLE-T-ANTIGEN; ACUTE PROMYELOCYTIC LEUKEMIA; DEPENDENT PROTEIN-KINASE; EMBRYONAL CARCINOMA-CELLS; MESSENGER-RNA; TRANSCRIPTION FACTOR; BINDING PROTEIN; NEGATIVE REGULATION; MOUSE FIBROBLASTS; GROWTH-FACTOR	To explore the molecular mechanisms by which retinoic acid inhibits oncogenic transformation, we have examined the effects of retinoic acid on the polyomavirus-induced transformation of rat fibroblasts. Treatment of rat F111 fibroblasts with high concentrations of retinoic acid (10(-6)M) partially inhibited the ability of polyomavirus to induce dense focus formation (50-70%). This effect was not secondary to a retinoic acid-dependent block of cellular proliferation. To address the role of the retinoic acid receptor (RAR-alpha) in mediating the transformation-inhibitory effect of retinoic acid, we have overexpressed either RAR-alpha or cellular retinoic acid-binding protein I (CRABP) cDNAs in F111 cells. Introduction of a CRABP I expression vector did not alter the responsiveness of F111 cells to retinoic acid in any detectable fashion. In contrast, overexpression of RAR-alpha increased the sensitivity of F111 cells to the transformation-inhibitory action of retinoic acid by 10- to 100-fold. At high concentrations, retinoic acid inhibited transformation of F111-RAR cells by polyomavirus by about 90%. At near physiological concentrations, retinoic acid inhibited transformation by 25-50% in F111-RAR cells but not in control cells. Retinoic acid did not inhibit either the synthesis of polyoma middle T (mT) or pp60c-src, the cellular target for mT action, or the formation of mT:pp60c-src:PI-3 kinase (phosphatidylinositol-3 kinase) complexes. Therefore, RAR-alpha was not acting as a negative regulator of expression of either the polyomavirus middle T oncogene or the cellular proto-oncogene. c-src. It seems likely that RAR-alpha regulates the expression of cellular genes whose products interact in some way with mT-regulated signaling pathways. leading to a ligand-dependent suppression of polyoma transformation. In addition, RAR-alpha overexpression selectively inhibits the serum-stimulated expression of the c-fos gene, but does not affect the expression of a number of other serum- and polyomavirus-inducible genes including c-jun, junB, c-myc and actin.			TALMAGE, DA (corresponding author), COLUMBIA UNIV,INST HUMAN NUTR,630 W 168 ST,NEW YORK,NY 10032, USA.			Talmage, David/0000-0003-4627-3007	NICHD NIH HHS [HD 26854] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD026854] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BENJAMIN TL, 1982, BIOCHIM BIOPHYS ACTA, V695, P69, DOI 10.1016/0304-419X(82)90018-X; BLUMHOFF R, 1990, SCIENCE, V250, P399; BOYLAN JF, 1991, J CELL BIOL, V112, P965, DOI 10.1083/jcb.112.5.965; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; CHYTIL F, 1987, ANNU REV NUTR, V7, P321, DOI 10.1146/annurev.nu.07.070187.001541; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; FELLI MP, 1991, MOL CELL BIOL, V11, P4771, DOI 10.1128/MCB.11.9.4771; GARCEA RL, 1989, VIROLOGY, V168, P312, DOI 10.1016/0042-6822(89)90271-7; GEBERT JF, 1991, ONCOGENE, V6, P1858; GIGUERE V, 1990, P NATL ACAD SCI USA, V87, P6233, DOI 10.1073/pnas.87.16.6233; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GIGUERE V, 1989, NATURE, V337, P566, DOI 10.1038/337566a0; GINSBERG D, 1991, ONCOGENE, V6, P669; GLENN GM, 1990, J VIROL, V64, P2193, DOI 10.1128/JVI.64.5.2193-2201.1990; GOODMAN DS, 1984, NEW ENGL J MED, V310, P1023, DOI 10.1056/NEJM198404193101605; GORGA FR, 1990, J VIROL, V64, P105, DOI 10.1128/JVI.64.1.105-112.1990; GROSS L, 1983, ONCOGENIC VIRUSES, P737; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; KRAFT AS, 1983, J BIOL CHEM, V258, P9178; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LIPPMAN SM, 1987, CANCER TREAT REP, V71, P391; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MATHEWS JT, 1986, J VIROL, V58, P239; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; MURAKAMI Y, 1991, P NATL ACAD SCI USA, V88, P3947, DOI 10.1073/pnas.88.9.3947; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PIETTE J, 1988, P NATL ACAD SCI USA, V85, P3401, DOI 10.1073/pnas.85.10.3401; PLET A, 1982, J BIOL CHEM, V257, P889; RAJAN N, 1991, J LIPID RES, V32, P1195; RAMEH LE, 1991, ONCOGENE, V6, P1049; RAPTIS L, 1988, BIOCHEM BIOPH RES CO, V154, P306, DOI 10.1016/0006-291X(88)90685-7; RAPTIS L, 1985, MOL CELL BIOL, V5, P2476, DOI 10.1128/MCB.5.9.2476; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; RYSECK RP, 1991, ONCOGENE, V6, P533; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; STRICKLAND S, 1980, DEV BIOL, V78, P76, DOI 10.1016/0012-1606(80)90319-X; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TALMAGE DA, 1988, MOL CELL BIOL, V8, P2309, DOI 10.1128/MCB.8.6.2309; TALMAGE DA, 1991, CELL GROWTH DIFFER, V2, P851; UHLER MD, 1986, P NATL ACAD SCI USA, V83, P1300, DOI 10.1073/pnas.83.5.1300; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; WANG CY, 1990, MOL CELL BIOL, V10, P6781, DOI 10.1128/MCB.10.12.6781; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; YANG-YEN H-F, 1990, New Biologist, V2, P351; YOO WD, 1991, J VIROL, V65, P5391, DOI 10.1128/JVI.65.10.5391-5400.1991; ZULLO J, 1987, P NATL ACAD SCI USA, V84, P1210, DOI 10.1073/pnas.84.5.1210; [No title captured]	65	20	20	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1837	1845						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1380150				2022-12-28	WOS:A1992JJ37600020
J	SATO, H; KIDA, Y; MAI, M; ENDO, Y; SASAKI, T; TANAKA, J; SEIKI, M				SATO, H; KIDA, Y; MAI, M; ENDO, Y; SASAKI, T; TANAKA, J; SEIKI, M			EXPRESSION OF GENES ENCODING TYPE-IV COLLAGEN-DEGRADING METALLOPROTEINASES AND TISSUE INHIBITORS OF METALLOPROTEINASES IN VARIOUS HUMAN TUMOR-CELLS	ONCOGENE			English	Article							HUMAN FIBROBLAST COLLAGENASE; EXTRACELLULAR-MATRIX; BASEMENT-MEMBRANE; SYNOVIAL FIBROBLASTS; TRANSIN GENE; INVASION; STROMELYSIN; ONCOGENE; COMPLEX; TIMP-2	Uncontrolled expression of matrix metalloproteinases 2, 3 and 9 (MMP-2, -3 and -9) is believed to be a critical part of the invasive potential of tumor cells because of their ability to degrade type IV collagen, a major structural component of basement membranes. Availability of proteolytic activity in the vicinity of the cell surface is further affected by a local balance between the enzymes and their inhibitors produced by the cell. To determine how frequently deregulated expression of the MMPs and tissue inhibitors of metalloproteinases (TIMPs) is associated with tumor cells, 26 human tumor cell lines were examined by Northern blotting. Transcripts for MMP-2 and MMP-9 were more frequently expressed in mesenchymal tumor cells (9/9 for MMP-2 and 6/9 for MMP-9) than in epithelial tumor cells (4/17 for MMP-2 and 2/17 for MMP-9). Although expression of MMP-2 mRNA was clearly cell type-specific, MMP-9 mRNA expression in mesenchymal cells correlated well with the reported tumorigenicity of the cells. Enhanced expression of MMP-9 mRNA was also associated with the tumorigenic transformation of cells by an activated c-H-ras gene in human embryonic fibroblasts. Only 3 of the 26 tumor cells expressed MMP-3 mRNA, and 2 of the 3 were epithelial tumor cells which coordinately expressed MMP-9 and TIMP-1 mRNAs. TIMP-1 mRNA was almost undetectable in 50% of the tumor cells, but TIMP-2 mRNA was expressed in the majority of the cells. These findings provide comprehensive information about mRNA expression of the NIMPs and TIMPs in tumor cells, the deregulation of which is thought to be an integral part of the invasive potential of tumor cells.	KANAZAWA UNIV,CANC RES INST,DEPT VIROL,KANAZAWA,ISHIKAWA 920,JAPAN; KANAZAWA UNIV,CANC RES INST,DEPT SURG,KANAZAWA,ISHIKAWA 921,JAPAN; KANAZAWA UNIV,CANC RES INST,DEPT EXPTL THERAPEUT,KANAZAWA,ISHIKAWA 920,JAPAN	Kanazawa University; Kanazawa University; Kanazawa University			SATO, Hiroshi/D-8454-2015; ENDO, Yoshio/D-8428-2015; Seiki, Motoharu/K-9443-2015	ENDO, Yoshio/0000-0003-0785-2006; 				Alexander CM, 1989, CURR OPIN CELL BIOL, V1, P974, DOI 10.1016/0955-0674(89)90068-9; ALITALO R, 1990, BLOOD, V75, P1974; ASAI T, 1991, J JUZEN MED SOC, V100, P1; BRENNER CA, 1989, GENE DEV, V3, P848, DOI 10.1101/gad.3.6.848; CARMICHAEL DF, 1986, P NATL ACAD SCI USA, V83, P2407, DOI 10.1073/pnas.83.8.2407; CHIN JR, 1985, J BIOL CHEM, V260, P2367; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DECLERCK YA, 1991, J BIOL CHEM, V266, P3893; DEDHAR S, 1990, J CELL BIOL, V110, P481, DOI 10.1083/jcb.110.2.481; ENDO Y, 1990, JPN J CANCER RES, V81, P723, DOI 10.1111/j.1349-7006.1990.tb02635.x; FRISCH SM, 1990, MOL CELL BIOL, V10, P6524, DOI 10.1128/MCB.10.12.6524; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; GRANT GA, 1987, J BIOL CHEM, V262, P5886; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; JONES PA, 1980, CANCER RES, V40, P3222; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KO T, 1976, TOKYO IKA DAIGAKU ZA, V34, P577; KRAMER RH, 1986, CANCER RES, V46, P1980; KRIEG P, 1988, CARCINOGENESIS, V9, P95, DOI 10.1093/carcin/9.1.95; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIOTTA LA, 1986, ANNU REV BIOCHEM, V55, P1037, DOI 10.1146/annurev.biochem.55.1.1037; LIOTTA LA, 1986, CANCER RES, V46, P1; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MOSCATELLI D, 1988, BIOCHIM BIOPHYS ACTA, V948, P67, DOI 10.1016/0304-419X(88)90005-4; NAKAJIMA M, 1987, CANCER RES, V47, P4869; NAKAJIMA M, 1990, J NATL CANCER I, V82, P1890, DOI 10.1093/jnci/82.24.1890; NAMBA M, 1985, INT J CANCER, V35, P275, DOI 10.1002/ijc.2910350221; OKADA Y, 1990, BIOCHEM BIOPH RES CO, V171, P610, DOI 10.1016/0006-291X(90)91190-4; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; OKADA Y, 1986, J BIOL CHEM, V261, P14245; PAULI BU, 1983, CANCER METAST REV, V2, P129, DOI 10.1007/BF00048966; RASHEED S, 1974, CANCER, V33, P127; SCHONTHAL A, 1988, CELL, V54, P324; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; STETLERSTEVENSON WG, 1990, J BIOL CHEM, V265, P13933; STRICKLIN GP, 1983, BIOCHEMISTRY-US, V22, P1173; TRYGGVASON K, 1987, BIOCHIM BIOPHYS ACTA, V907, P191, DOI 10.1016/0304-419X(87)90006-0; Werb Z., 1989, TXB RHEUMATOLOGY, P300; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WILHELM SM, 1987, P NATL ACAD SCI USA, V84, P6725, DOI 10.1073/pnas.84.19.6725; WILHELM SM, 1989, J BIOL CHEM, V264, P17213	44	258	265	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1992	7	1					77	83						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1311064				2022-12-28	WOS:A1992HC22700011
J	Noguchi, M; Shimizu, M; Lu, P; Takahashi, Y; Yamauchi, Y; Sato, S; Kiyono, H; Kishino, S; Ogawa, J; Nagata, K; Sato, R				Noguchi, Makoto; Shimizu, Makoto; Lu, Peng; Takahashi, Yu; Yamauchi, Yoshio; Sato, Shintaro; Kiyono, Hiroshi; Kishino, Shigenobu; Ogawa, Jun; Nagata, Koji; Sato, Ryuichiro			Lactic acid bacteria-derived gamma-linolenic acid metabolites are PPAR delta ligands that reduce lipid accumulation in human intestinal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATOR-ACTIVATED RECEPTORS; POLYUNSATURATED FATTY-ACIDS; NUCLEAR RECEPTOR; EXPRESSION; HEALTH; MICROBIOTA; SYSTEM; ALPHA; EICOSANOIDS; PATTERNS	Gut microbiota regulate physiological functions in various hosts, such as energy metabolism and immunity. Lactic acid bacteria, including Lactobacillus plantarum, have a specific polyunsaturated fatty acid saturation metabolism that gener-ates multiple fatty acid species, such as hydroxy fatty acids, oxo fatty acids, conjugated fatty acids, and trans-fatty acids. How these bacterial metabolites impact host physiology is not fully understood. Here, we investigated the ligand activity of lactic acid bacteria-produced fatty acids in relation to nuclear hormone receptors expressed in the small intestine. Our re-porter assays revealed two bacterial metabolites of gamma-linolenic acid (GLA), 13-hydroxy-cis-6,cis-9-octadecadienoic acid (gamma HYD), and 13-oxo-cis-6,cis-9-octadecadienoic acid (gamma KetoD) activated peroxisome proliferator-activated receptor delta (PPARS) more potently than GLA. We demonstrate that both gamma HYD and gamma KetoD bound directly to the ligand-binding domain of human PPARS. A docking simulation indicated that four polar residues (T289, H323, H449, and Y473) of PPARS donate hydrogen bonds to these fatty acids. Interest-ingly, T289 does not donate a hydrogen bond to GLA, sug-gesting that bacterial modification of GLA introducing hydroxy and oxo group determines ligand selectivity. In hu-man intestinal organoids, we determined gamma HYD and gamma KetoD increased the expression of PPARS target genes, enhanced fatty acid II-oxidation, and reduced intracellular triglyceride accumulation. These findings suggest that gamma HYD and gamma KetoD, which gut lactic acid bacteria could generate, are naturally occurring PPARS ligands in the intestinal tract and may improve lipid metabolism in the human intestine.	[Noguchi, Makoto; Shimizu, Makoto; Yamauchi, Yoshio; Sato, Ryuichiro] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Nutri Life Sci Lab, Tokyo, Japan; [Lu, Peng; Nagata, Koji] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Food Biotechnol & Struct Biol Lab, Tokyo, Japan; [Takahashi, Yu; Yamauchi, Yoshio] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Food Biochem Lab, Tokyo, Japan; [Sato, Shintaro] Wakayama Med Univ, Sch Pharmaceut Sci, Dept Microbiol & Immunol, Wakayama, Japan; [Kiyono, Hiroshi] Chiba Univ, Inst Global Prominent Res, Mucosal Immunol & Allergy Therapeut, Future Med Educ & Res Org, Chiba, Japan; [Kishino, Shigenobu; Ogawa, Jun] Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Kyoto, Japan	University of Tokyo; University of Tokyo; University of Tokyo; Wakayama Medical University; Chiba University; Kyoto University	Shimizu, M; Sato, R (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Nutri Life Sci Lab, Tokyo, Japan.	amshimizu@g.ecc.u-tokyo.ac.jp; roysato@g.ecc.u-tokyo.ac.jp			JSPS KAKENHI [19H02906, 20H00408]; New Energy and Industrial Technology Development Or-ganization (NEDO) [P20011]; Ministry of Health and Welfare of Japan; Public/Private R&D Investment Strategic Expansion PrograM: PRISM; JST-Mirai Program [JPMJMI21C1]; Japan Agency for Medical Research and Development (AMED) [21ek0410062h0003]	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); New Energy and Industrial Technology Development Or-ganization (NEDO)(New Energy and Industrial Technology Development Organization (NEDO)); Ministry of Health and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Public/Private R&D Investment Strategic Expansion PrograM: PRISM; JST-Mirai Program; Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED))	This work was supported by JSPS KAKENHI Grant-in-Aid for Scientific Research (B) 19H02906 (to M. S.), Grant-in-Aid for Scientific Research (A) 20H00408 (to R. S.), the New Energy and Industrial Technology Development Organization (NEDO) P20011 (to J. O.), the Ministry of Health and Welfare of Japan and Public/Private R&D Investment Strategic Expansion PrograM: PRISM (to J. O.), JST-Mirai Program JPMJMI21C1 (to J. O.), and the Japan Agency for Medical Research and Development (AMED) 21ek0410062h0003 (to J. O.).	Auwerx J, 1999, CELL, V97, P161; Bookout AL, 2006, CELL, V126, P789, DOI 10.1016/j.cell.2006.06.049; Bouchoux J, 2011, BIOL CELL, V103, P499, DOI 10.1042/BC20110024; Brunham LR, 2006, J CLIN INVEST, V116, P1052, DOI 10.1172/JCI27352; Chakravarthy MV, 2009, CELL, V138, P476, DOI 10.1016/j.cell.2009.05.036; Chiarelli F, 2008, VASC HEALTH RISK MAN, V4, P297; D'Aquila T, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00180; De Bosscher K, 2020, NAT REV ENDOCRINOL, V16, P363, DOI 10.1038/s41574-020-0349-5; de Urquiza AM, 2000, SCIENCE, V290, P2140, DOI 10.1126/science.290.5499.2140; Doktorova M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00889-z; Drouin-Chartier JP, 2018, AM J CLIN NUTR, V107, P26, DOI 10.1093/ajcn/nqx013; Eckburg PB, 2005, SCIENCE, V308, P1635, DOI 10.1126/science.1110591; Evans RM, 2014, CELL, V157, P255, DOI 10.1016/j.cell.2014.03.012; Fernandez ML, 2005, J NUTR, V135, P2075, DOI 10.1093/jn/135.9.2075; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Fyffe SA, 2006, J MOL BIOL, V356, P1005, DOI 10.1016/j.jmb.2005.12.047; Gerritsen J, 2011, GENES NUTR, V6, P209, DOI 10.1007/s12263-011-0229-7; Giordano Attianese Greta M P, 2015, Nucl Recept Signal, V13, pe001, DOI 10.1621/nrs.13001; Girroir EE, 2008, BIOCHEM BIOPH RES CO, V371, P456, DOI 10.1016/j.bbrc.2008.04.086; Goto T, 2015, BIOCHEM BIOPH RES CO, V459, P597, DOI 10.1016/j.bbrc.2015.02.154; Hara T, 2014, BBA-MOL CELL BIOL L, V1841, P1292, DOI 10.1016/j.bbalip.2014.06.002; Hatae T, 2001, J BIOL CHEM, V276, P46260, DOI 10.1074/jbc.M107180200; Hira T, 2018, MOL NUTR FOOD RES, V62, DOI 10.1002/mnfr.201800146; Hirata A, 2015, J LIPID RES, V56, P1340, DOI 10.1194/jlr.M059444; Kaczmarczyk MM, 2012, METABOLISM, V61, P1058, DOI 10.1016/j.metabol.2012.01.017; Kang ZF, 2020, FASEB J, V34, P8796, DOI 10.1096/fj.202000055RR; Keenan MJ, 2015, ADV NUTR, V6, P198, DOI 10.3945/an.114.007419; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Khuchua Z, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113464; Kimura I, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2852; Kimura I, 2011, P NATL ACAD SCI USA, V108, P8030, DOI 10.1073/pnas.1016088108; Kishino S, 2013, P NATL ACAD SCI USA, V110, P17808, DOI 10.1073/pnas.1312937110; Klepsch V, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01070; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; Lagakos WS, 2011, AM J PHYSIOL-GASTR L, V300, pG803, DOI 10.1152/ajpgi.00229.2010; Lawrence JW, 2001, J BIOL CHEM, V276, P31521, DOI 10.1074/jbc.M103306200; Levi L, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9794; LEVY E, 1995, FASEB J, V9, P626, DOI 10.1096/fasebj.9.8.7768354; Ley RE, 2006, NATURE, V444, P1022, DOI 10.1038/4441022a; Lim H, 1999, GENE DEV, V13, P1561, DOI 10.1101/gad.13.12.1561; Lu YY, 2016, SCI REP-UK, V6, DOI 10.1038/srep37589; Mathur SN, 2007, J LIPID RES, V48, P395, DOI 10.1194/jlr.M600325-JLR200; McCarville JL, 2020, ANNU REV IMMUNOL, V38, P147, DOI 10.1146/annurev-immunol-071219-125715; Miyamoto J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11978-0; Miyamoto J, 2015, J BIOL CHEM, V290, P2902, DOI 10.1074/jbc.M114.610733; Modica S, 2010, GASTROENTEROLOGY, V138, P636, DOI 10.1053/j.gastro.2009.09.060; Nagatake T, 2022, MUCOSAL IMMUNOL, V15, P289, DOI 10.1038/s41385-021-00477-5; Neels JG, 2014, PHYSIOL REV, V94, P795, DOI 10.1152/physrev.00027.2013; Nordestgaard BG, 2007, JAMA-J AM MED ASSOC, V298, P299, DOI 10.1001/jama.298.3.299; Ohue-Kitano R, 2018, FASEB J, V32, P304, DOI 10.1096/fj.201700273R; Peters JM, 2019, NPJ PRECIS ONCOL, V3, DOI 10.1038/s41698-019-0098-x; Rossi G, 2018, NAT REV GENET, V19, P671, DOI 10.1038/s41576-018-0051-9; Sampath H, 2005, ANNU REV NUTR, V25, P317, DOI 10.1146/annurev.nutr.25.051804.101917; Sasaki T, 2021, J BIOL CHEM, V296, DOI 10.1074/jbc.RA120.016203; Schmidt DR, 2008, NUTR REV, V66, pS88, DOI 10.1111/j.1753-4887.2008.00092.x; Sonnenburg JL, 2016, NATURE, V535, P56, DOI 10.1038/nature18846; Takahashi Y, 2022, ISCIENCE, V25, DOI 10.1016/j.isci.2022.104542; Takahashi Y, 2018, STEM CELL REP, V10, P314, DOI 10.1016/j.stemcr.2017.11.004; Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334; Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414; Uchinomiya S, 2020, CHEM COMMUN, V56, P3023, DOI 10.1039/c9cc09993j; Umetani M, 2007, NAT MED, V13, P1185, DOI 10.1038/nm1641; van der Veen JN, 2005, J LIPID RES, V46, P526, DOI 10.1194/jlr.M400400-JLR200; Vrieze A, 2012, GASTROENTEROLOGY, V143, P913, DOI 10.1053/j.gastro.2012.06.031; Vrins CLJ, 2009, J LIPID RES, V50, P2046, DOI 10.1194/jlr.M800579-JLR200; Walker AW, 2011, ISME J, V5, P220, DOI 10.1038/ISMEJ.2010.118; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; Xiao CT, 2019, CELL MOL GASTROENTER, V7, P487, DOI 10.1016/j.jcmgh.2018.10.015; Xu HE, 1999, MOL CELL, V3, P397, DOI 10.1016/S1097-2765(00)80467-0; Zembroski AS, 2021, AM J PHYSIOL-GASTR L, V321, pG75, DOI 10.1152/ajpgi.00084.2021	73	0	0	3	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV	2022	298	11							102534	10.1016/j.jbc.2022.102534	http://dx.doi.org/10.1016/j.jbc.2022.102534			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	6G4BI	36162507	Green Published, gold			2022-12-28	WOS:000884698500008
J	REYNOLDS, AB; HERBERT, L; CLEVELAND, JL; BERG, ST; GAUT, JR				REYNOLDS, AB; HERBERT, L; CLEVELAND, JL; BERG, ST; GAUT, JR			P120, A NOVEL SUBSTRATE OF PROTEIN TYROSINE KINASE RECEPTORS AND OF P60V-SRC IS RELATED TO CADHERIN-BINDING FACTORS BETA-CATENIN, PLAKOGLOBIN AND ARMADILLO	ONCOGENE			English	Article							SEGMENT POLARITY GENE; PHOSPHORYLATION; REGION; PDGF; SEQUENCE; CLONING; COMPLEX; HOMOLOG; CELLS; GAP	A novel protein tyrosine kinase (PTK) substrate, p120, has been previously implicated in ligand-induced signaling through the epidermal growth factor, platelet-derived growth factor and colony-stimulating factor 1 receptors, and in cell transformation by p60v-src. We have isolated a near full-length cDNA encoding murine p120. The encoded protein lacks significant homology with any reported protein, but it contains four copies of an imperfect 42 amino acid repeat that occurs 12.5 times in the protein encoded by Drosophila armadillo (arm), and its direct homologs, human plakoglobin (plak) and Xenopus laevis beta-catenin (beta-cat). The presence of this motif implies that p120 may share at least one aspect of its function with the arm protein and its homologs.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA	St Jude Children's Research Hospital	REYNOLDS, AB (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, 332 N LAUDERDALE, MEMPHIS, TN 38105 USA.				NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765] Funding Source: Medline; NCRR NIH HHS [RR05584] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		CHIRGWIN JM, 1977, BIOCHEMISTRY-US, V1, P5294; Cleveland J L, 1988, Oncogene Res, V3, P357; DOWNING JR, 1991, ONCOGENE, V6, P607; FRANKE WW, 1989, P NATL ACAD SCI USA, V86, P4027, DOI 10.1073/pnas.86.11.4027; HIRANO S, 1987, J CELL BIOL, V105, P2501, DOI 10.1083/jcb.105.6.2501; HONG W, 1991, MOL CELL BIOL, V11, P5113; KANNER SB, 1991, MOL CELL BIOL, V11, P713, DOI 10.1128/MCB.11.2.713; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LINDER ME, 1988, P NATL ACAD SCI USA, V85, P2608, DOI 10.1073/pnas.85.8.2608; Maniatis T., 1982, MOL CLONING; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; RIGGLEMAN B, 1989, GENE DEV, V3, P96, DOI 10.1101/gad.3.1.96; SCHALLER MD, 1992, IN PRESS P NATL ACAD; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WALLACE RB, 1987, METHOD ENZYMOL, V152, P432	25	250	257	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	1992	7	12					2439	2445						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1334250				2022-12-28	WOS:A1992KA85600008
J	KOVAR, H; AUINGER, A; JUG, G; MULLER, T; PILLWEIN, K				KOVAR, H; AUINGER, A; JUG, G; MULLER, T; PILLWEIN, K			P53 MOSAICISM WITH AN EXON 8 GERMLINE MUTATION IN THE FOUNDER OF A CANCER-PRONE PEDIGREE	ONCOGENE			English	Article							TUMOR-ANTIGEN; SV40-TRANSFORMED CELLS; ACTIVATING MUTATIONS; TRANSFORMED-CELLS; GENE-MUTATIONS; BREAST-CANCER; LINE MUTATION; DNA; PROTEIN; CARCINOMAS	Changes in the tumor-suppressor gene p53 are frequently acquired during the course of malignant development of human tumors. Recently, constitutional heterozygous mutations in p53 exon 7 have been identified as the primary cause of cancer predisposition in cases of the familial Li-Fraumeni cancer syndrome. These findings underline the need for extensive mutation screening in families with high cancer incidence. This report describes the detection and follow-up by two-dimensional single-strand conformation polymorphism analysis (2DSSCP) of a new germline mutation of p53 exon 8 in a case of suspected Li-Fraumeni syndrome. Although a high cancer incidence had been reported in the family history of the father of siblings suffering from brain tumor and rhabdomyosarcoma, a constitutional heterozygous p53 mutation was identified only in the affected children. Retrospective analysis of archival tissue of a half-sister who died several years ago from a tumor of previously uncertain diagnosis revealed the same mutation. The mutation had therefore occurred in the germ cells of the mother, who thus appears to be a mosaic. The cancer predisposition of the paternal ancestors must have been due to other factors.	ST ANNA CHILDRENS HOSP,CHILDRENS CANC RES INST,VIENNA,AUSTRIA; UNIV VIENNA,DEPT PEDIAT,A-1010 VIENNA,AUSTRIA	Saint Anna Children's Hospital; University of Vienna				Kovar, Heinrich/0000-0001-6873-9109				BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARTEK J, 1990, ONCOGENE, V5, P893; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; BUDOWLE B, 1991, AM J HUM GENET, V48, P137; CASANOVA JL, 1990, NUCLEIC ACIDS RES, V18, P4028, DOI 10.1093/nar/18.13.4028; CHIBA I, 1990, ONCOGENE, V5, P1603; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HELMUTH R, 1990, AM J HUM GENET, V47, P515; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORN GT, 1989, NUCLEIC ACIDS RES, V17, P2140, DOI 10.1093/nar/17.5.2140; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; JENKINS JR, 1988, ONCOGENE HDB, P403; KOVAR H, 1991, NUCLEIC ACIDS RES, V19, P3507, DOI 10.1093/nar/19.13.3507; KRESS M, 1979, J VIROL, V31, P472, DOI 10.1128/JVI.31.2.472-483.1979; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LAW JC, 1991, CANCER RES, V51, P6385; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; METZGER AK, 1991, P NATL ACAD SCI USA, V88, P7825, DOI 10.1073/pnas.88.17.7825; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OREN M, 1985, BIOCHIM BIOPHYS ACTA, V823, P67, DOI 10.1016/0304-419X(85)90015-0; PROSSER J, 1990, ONCOGENE, V5, P1573; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P755; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STRATTON MR, 1990, ONCOGENE, V5, P1297; STURZBECHER HW, 1990, ONCOGENE, V5, P795; VARLEY JM, 1991, ONCOGENE, V6, P413; WIGGS J, 1988, NEW ENGL J MED, V318, P151, DOI 10.1056/NEJM198801213180305; WILLIAMS WR, 1985, FAM CANCER, P151; WONG Z, 1987, ANN HUM GENET, V51, P269, DOI 10.1111/j.1469-1809.1987.tb01062.x; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153; YOUNG JL, 1977, NATL CANCER I MONOGR, V57, P70	42	33	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2169	2173						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1359493				2022-12-28	WOS:A1992JW66500009
J	BARDELLI, A; MAINA, F; GOUT, I; FRY, MJ; WATERFIELD, MD; COMOGLIO, PM; PONZETTO, C				BARDELLI, A; MAINA, F; GOUT, I; FRY, MJ; WATERFIELD, MD; COMOGLIO, PM; PONZETTO, C			AUTOPHOSPHORYLATION PROMOTES COMPLEX-FORMATION OF RECOMBINANT HEPATOCYTE GROWTH-FACTOR RECEPTOR WITH CYTOPLASMIC EFFECTORS CONTAINING SH2 DOMAINS	ONCOGENE			English	Article							TYROSINE KINASE-ACTIVITY; FACTOR SCATTER FACTOR; C-MET; SIGNAL TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; BINDING-SITE; PROTEINS; PHOSPHOTYROSINE; IDENTIFICATION; PEPTIDE	Hepatocyte growth factor (HGF), also known as scatter factor (SF), is a polypeptide which induces motility and/or mitogenesis in epithelial cells. The receptor for HGF/SF, p190MET, is a two-chain transmembrane tyrosine kinase encoded by the MET proto-oncogene. To identify the cytoplasmic effectors involved in signal transduction we have produced the human HGF/SF receptor in insect cells (Sf9) by means of a recombinant baculovirus. Two 170-kDa forms of the receptor were synthesized in Sf9 cells: the uncleaved single-chain precursor (which is by far the more abundant) and the proteolytically processed two-chain molecule. Both receptor species are phosphorylated on tyrosine in vivo and are active kinases in vitro. The recombinant receptor binds and phosphorylates in vitro four known cytoplasmic transducers containing src homology region 2 (SH2) domains: the 85-kDa subunit of phosphatidylinositol 3-kinase (Pl 3-kinase), rasGAP, phospholipase-C-gamma (PLC-gamma), and p59Fyn, a tyrosine kinase of the src family. In all cases the association is strictly dependent on tyrosine phosphorylation of the receptor, indicating that it occurs via specific interaction with the SH2 domains. These results show that the HGF/SF receptor has the sequence requirements for binding a spectrum of cytoplasmic transducers whose different combinations in target cells may result in the observed pleiotropic biological response.	UNIV TURIN,DEPT BIOMED SCI & ONCOL,CSO MASSIMO AZEGLIO 52,I-10126 TURIN,ITALY; LUDWIG INST CANC RES,LONDON,ENGLAND	University of Turin; Ludwig Institute for Cancer Research			Maina, Flavio/J-9962-2019; BARDELLI, Alberto/J-9721-2018	Maina, Flavio/0000-0001-6100-4695; BARDELLI, Alberto/0000-0003-1647-5070; Fry, Michael/0000-0001-8518-1370; Comoglio, Paolo/0000-0002-7056-5328				BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COMOGLIO PM, 1984, EMBO J, V3, P483, DOI 10.1002/j.1460-2075.1984.tb01834.x; DOWNING JR, 1991, MOL CELL BIOL, V11, P2489, DOI 10.1128/MCB.11.5.2489; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GREENFIELD C, 1988, EMBO J, V7, P139, DOI 10.1002/j.1460-2075.1988.tb02793.x; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MAEDA S, 1990, FEBS LETT, V269, P386, DOI 10.1016/0014-5793(90)81199-X; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PONZETTO C, 1991, ONCOGENE, V6, P553; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; YU JC, 1991, MOL CELL BIOL, V11, P3780, DOI 10.1128/MCB.11.7.3780	24	87	89	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					1973	1978						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1328986				2022-12-28	WOS:A1992JP42400010
J	EDWARDS, PAW; HIBY, SE; PAPKOFF, J; BRADBURY, JM				EDWARDS, PAW; HIBY, SE; PAPKOFF, J; BRADBURY, JM			HYPERPLASIA OF MOUSE MAMMARY EPITHELIUM INDUCED BY EXPRESSION OF THE WNT-1 (INT-1) ONCOGENE IN RECONSTITUTED MAMMARY-GLAND	ONCOGENE			English	Article							CELL-LINE; TRANSGENIC MICE; RETROVIRAL VECTORS; GENE-TRANSFER; MYC ONCOGENE; TUMOR VIRUS; HA-RAS; PROTEIN; GROWTH; DIFFERENTIATION	We have expressed the Wnt-1 (formerly int-1) oncogene in Balb/c mouse mammary epithelium in vivo, using a tissue reconstitution method in which primary cultures of mammary epithelial cells are infected with a retrovirus vector and then transplanted into mouse mammary fat pads from which the natural epithelium has been removed. Transplants carrying the Wnt-1 gene grew in a hyperplastic pattern, the duct epithelium showing abundant fine side-branches, but without development of clusters of alveoli. The hyperplasias were similar, but not identical, to transplants of normal epithelium in a mid-pregnant host. Transplants of epithelium that expressed Wnt-1 into mammary fat pads of male or ovari-ectomized females grew to form a similar three-dimensional pattern, but the extent of growth, and so presumably the rate of growth, was slower than in intact females, and there were no terminal end buds at the edges of the outgrowths. Thus, although Wnt-1 may enhance growth of epithelium in the male or ovari-ectomized-female environment, it does not restore the major mode of growth in the intact female, the extension of major ducts from terminal end buds. Normal epithelium showed no change in morphology when in close proximity to hyperplasia induced by Wnt-1, confirming the limited range of diffusion of Wnt-1 protein in vivo. Our results are consistent with the hypothesis that Wnt-1 acts principally by mimicking the signal that causes ducts to develop side-branches in pregnancy.	INST CANC & DEV BIOL,PALO ALTO,CA 94304		EDWARDS, PAW (corresponding author), UNIV CAMBRIDGE,DEPT PATHOL,DIV CELL & GENET PATHOL,TENNIS COURT RD,CAMBRIDGE CB2 1QP,ENGLAND.		Edwards, Paul A/M-8291-2014	Edwards, Paul A/0000-0002-4789-3374				ADAMS LM, 1987, CANCER RES, V47, P4425; AGUILARCORDOVA E, 1991, ONCOGENE, V6, P1601; AIDELLS BD, 1974, J NATL CANCER I, V52, P1855, DOI 10.1093/jnci/52.6.1855; ANDRES AC, 1988, GENE DEV, V2, P1486, DOI 10.1101/gad.2.11.1486; BANERJEE M R, 1976, TCA (Tissue Culture Association) Manual, V2, P457, DOI 10.1007/BF00918341; BLASBAND A, 1992, ONCOGENE, V7, P153; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; BRADBURY JM, 1988, INT J CANCER, V42, P923, DOI 10.1002/ijc.2910420623; BRADBURY JM, 1991, INT J CANCER, V48, P908, DOI 10.1002/ijc.2910480619; BRADLEY A, 1990, CELL, V62, P1073; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; BUHLER TA, 1992, UNPUB DEV BIOL; Daniel C. W., 1987, The mammary gland. Development, regulation, and function., P3; DANIEL CW, 1989, DEV BIOL, V135, P20, DOI 10.1016/0012-1606(89)90154-1; DANIEL CW, 1987, CANCER RES, V47, P6052; DEOME KB, 1959, CANCER RES, V19, P515; EDWARDS PAW, 1988, ONCOGENE, V2, P407; FAULKIN LJ, 1960, J NATL CANCER I, V24, P953; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GAVIN BJ, 1992, MOL CELL BIOL, V12, P2418, DOI 10.1128/MCB.12.5.2418; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; GUNZBURG WH, 1988, CARCINOGENESIS, V9, P1849, DOI 10.1093/carcin/9.10.1849; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MEDINA D, 1988, CARCINOGENESIS, V9, P1113, DOI 10.1093/carcin/9.7.1113; MEDINA D, 1973, METHOD CANCER RES, V7, P3; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MIYAMOTO S, 1990, CANCER RES, V50, P6010; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Morris D. W., 1987, ADV VIRAL ONCOL, V7, P123; MORRIS DW, 1990, J VIROL, V64, P1794, DOI 10.1128/JVI.64.4.1794-1802.1990; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; NUSSE R, 1988, TRENDS GENET, V4, P291, DOI 10.1016/0168-9525(88)90172-2; PAPKOFF J, 1989, MOL CELL BIOL, V9, P3377, DOI 10.1128/MCB.9.8.3377; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PETERS G, 1986, NATURE, V320, P628, DOI 10.1038/320628a0; RICHARDS J, 1988, ENDOCRINOLOGY, V123, P1335, DOI 10.1210/endo-123-3-1335; RIJSEWIJK F, 1987, EMBO J, V6, P127, DOI 10.1002/j.1460-2075.1987.tb04729.x; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; ROELINK H, 1992, P NATL ACAD SCI USA, V7, P487; SCULLY JL, 1991, INT J CANCER, V48, P128; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; SILBERSTEIN GB, 1987, SCIENCE, V237, P291, DOI 10.1126/science.3474783; STRANGE R, 1989, ONCOGENE, V4, P309; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WILLIAMS JM, 1983, DEV BIOL, V97, P274, DOI 10.1016/0012-1606(83)90086-6; WILLIAMS RL, 1989, CELL, V57, P1053, DOI 10.1016/0092-8674(89)90343-7	52	61	61	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					2041	2051						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408145				2022-12-28	WOS:A1992JP42400019
J	GOKKEL, E; GROSSMAN, Z; RAMOT, B; YARDEN, Y; RECHAVI, G; GIVOLI, D				GOKKEL, E; GROSSMAN, Z; RAMOT, B; YARDEN, Y; RECHAVI, G; GIVOLI, D			STRUCTURAL ORGANIZATION OF THE MURINE C-KIT PROTOONCOGENE	ONCOGENE			English	Article								The murine Kit receptor gene on chromosome 5 has been found to be frequently involved in germline mutations and rearrangements, leading to a characteristic set of severe developmental defects, known as the W phenotype. Here we describe the structure of the murine c-kit gene, based on restriction analysis of genomic phage clones and sequence determination of exon-intron boundaries. The Kit-coding region is distributed over 21 exons, most of which have sizes that range between 100 and 200 base pairs. The 3' non-translated sequence and the 3' end of the coding region form a single large exon, which encompasses 2.3 kb and is flanked by polyadenylation signals. The entire region spans a genomic distance of at least 70 kb. Though the exonic demarcations of c-kit show remarkable similarity to those of the human c-fms gene (which encodes the highly related colony-stimulating factor 1 receptor), no correlation could be found between the sizes of introns that separate homologous exon pairs. The data suggest that evolutionary pressures were confined to the conservation of structures of coding exons, whereas flanking regions were subject to large changes, owing to insertions and deletions. Finally, the analysis of the Kit genomic structure reveals that the inherited mutations of the Kit gene that have been reported thus far occur at various dispersed positions within the gene. Hence, the entire gene appears to have as yet unknown features which cause it to be frequently subject to mutations in murine germline tissues.	CHAIM SHEBA MED CTR, INST HEMATOL, IL-52621 TEL HASHOMER, ISRAEL	Chaim Sheba Medical Center	GOKKEL, E (corresponding author), WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL.		YARDEN, YOSEF/K-1467-2012					BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BLAKE CCF, 1985, INT REV CYTOL, V93, P149, DOI 10.1016/S0074-7696(08)61374-1; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; CRAIK CS, 1982, NATURE, V299, P180, DOI 10.1038/299180a0; CRAIK CS, 1983, SCIENCE, V220, P1125, DOI 10.1126/science.6344214; DUBREUIL P, 1990, ANN NY ACAD SCI, V599, P58; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GIEBEL LB, 1991, P NATL ACAD SCI USA, V88, P8696, DOI 10.1073/pnas.88.19.8696; GILBERT W, 1985, SCIENCE, V228, P823, DOI 10.1126/science.4001923; HAMPE A, 1989, ONCOGENE RES, V4, P9; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAYASHI SI, 1991, NUCLEIC ACIDS RES, V19, P1267, DOI 10.1093/nar/19.6.1267; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; HUNKAPILLER T, 1989, ADV IMMUNOL, V44, P1; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KESHET E, 1991, EMBO J, V10, P2425, DOI 10.1002/j.1460-2075.1991.tb07782.x; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; MAJUMDER S, 1988, MOL CELL BIOL, V8, P4896, DOI 10.1128/MCB.8.11.4896; MATSUI Y, 1990, NATURE, V347, P667, DOI 10.1038/347667a0; MATSUSHIME H, 1986, MOL CELL BIOL, V6, P3000, DOI 10.1128/MCB.6.8.3000; MAYER TC, 1968, DEV BIOL, V18, P62, DOI 10.1016/0012-1606(68)90023-7; McLachlan A.D., 1980, PROTEINS RELATED SUB, V28, P29; MIETTINEN HM, 1989, CELL, V58, P317, DOI 10.1016/0092-8674(89)90846-5; NISHIKAWA S, 1991, EMBO J, V10, P2111, DOI 10.1002/j.1460-2075.1991.tb07744.x; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; ORRURTREGER A, 1990, DEVELOPMENT, V109, P911; OWENS GC, 1987, P NATL ACAD SCI USA, V84, P294, DOI 10.1073/pnas.84.1.294; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; ROBERTS WM, 1988, CELL, V55, P655, DOI 10.1016/0092-8674(88)90224-3; ROGERS J, 1985, NATURE, V315, P458, DOI 10.1038/315458a0; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SANTONI MJ, 1989, EMBO J, V8, P385, DOI 10.1002/j.1460-2075.1989.tb03389.x; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SMITH EA, 1991, P NATL ACAD SCI USA, V88, P4811, DOI 10.1073/pnas.88.11.4811; STENMAN G, 1989, GENE CHROMOSOME CANC, V1, P155, DOI 10.1002/gcc.2870010208; STEPHENSON DA, 1991, P NATL ACAD SCI USA, V88, P6, DOI 10.1073/pnas.88.1.6; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; TOBAL K, 1990, LEUKEMIA, V4, P486; VISVADER J, 1989, MOL CELL BIOL, V9, P1336, DOI 10.1128/MCB.9.3.1336; VU TH, 1989, MOL CELL BIOL, V9, P4563, DOI 10.1128/MCB.9.10.4563; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4	62	44	49	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1992	7	7					1423	1429						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1377813				2022-12-28	WOS:A1992HZ97100022
J	JUCKER, M; ROEBROEK, AJM; MAUTNER, J; KOCH, K; EICK, D; DIEHL, V; VANDEVEN, WJM; TESCH, H				JUCKER, M; ROEBROEK, AJM; MAUTNER, J; KOCH, K; EICK, D; DIEHL, V; VANDEVEN, WJM; TESCH, H			EXPRESSION OF TRUNCATED TRANSCRIPTS OF THE PROTOONCOGENE C-FPS/FES IN HUMAN LYMPHOMA AND LYMPHOID LEUKEMIA-CELL LINES	ONCOGENE			English	Article							FUJINAMI SARCOMA-VIRUS; CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE-ACTIVITY; HODGKINS-DISEASE; BURKITTS-LYMPHOMA; TRANSFORMING GENE; ANTIGEN RECEPTOR; TRANSGENIC MICE; FPS PROTEIN; DIFFERENTIATION	The human c-fps/fes proto-oncogene is expressed as a transcript of about 3.0 kb in both normal and leukemic myeloid cells. We have detected truncated c-fps/fes transcripts of about 0.9 kb in a panel of human lymphoma and lymphoid leukemia cell lines, but not in normal untransformed hematopoietic cells. Analysis of the chromatin structure of the c-fps/fes gene revealed DNAase I-hypersensitive sites in the 5' region of the gene and in exon 16. The presence and absence of these sites correlates with the expression of the 3.0 kb and 0.9 kb c-fps/fes RNAs respectively. The truncated transcripts initiate at two distinct sites within exon 16 of the c-fps/fes gene. The genomic region 5' to the transcription initiation sites is G + C rich but does not contain typical promoter consensus sequences. Sequence analysis of a cDNA clone of the truncated c-fps/fes transcripts did not reveal any point mutation and the truncated transcripts are normally spliced using the regular splice donor and acceptor sites. A putative open reading frame encompasses the phosphotransfer motif and the autophosphorylation site of the fps/fes kinase domain. In vitro transcription/translation of a cDNA clone corresponding to the truncated c-fps/fes transcripts revealed a protein of 17 kDa. There are no translocations or rearrangements in or around the c-fps/fes gene in cell lines which express the truncated c-fps/fes transcripts. This alternative transcription of c-fps/fes may indicate a novel activation process of this proto-oncogene.	UNIV COLOGNE,MED KLIN 1,JOSEPH STELZMANNSTR 9,W-5000 COLOGNE 41,GERMANY; CATHOLIC UNIV LEUVEN,CTR HUMAN GENET,MOLEC ONCOL SECT,B-3000 LOUVAIN,BELGIUM; GESELL STRAHLEN & UMWELTFORSCH MBH,FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT,INST MED MOLEK BIOL,W-8000 MUNICH,GERMANY	University of Cologne; KU Leuven								ALCALAY M, 1990, ONCOGENE, V5, P267; ARRUSHDI A, 1983, SCIENCE, V222, P390, DOI 10.1126/science.6414084; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BERNHEIM A, 1981, CANCER GENET CYTOGEN, V3, P307, DOI 10.1016/0165-4608(81)90039-X; BERNHEIM A, 1983, CANCER GENET CYTOGEN, V8, P223, DOI 10.1016/0165-4608(83)90138-3; CARMIER JF, 1986, CELL, V44, P159, DOI 10.1016/0092-8674(86)90494-0; CLARK SS, 1987, SCIENCE, V235, P85, DOI 10.1126/science.3541203; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; COLLINS SJ, 1984, SCIENCE, V225, P72, DOI 10.1126/science.6587568; DUBY AD, 1986, P NATL ACAD SCI USA, V83, P4890, DOI 10.1073/pnas.83.13.4890; DYNYN WS, 1983, CELL, V35, P79; EICK D, 1985, EMBO J, V4, P3717, DOI 10.1002/j.1460-2075.1985.tb04140.x; FAINSTEIN E, 1987, NATURE, V330, P386, DOI 10.1038/330386a0; FALK MH, 1987, INT J CANCER, V40, P262, DOI 10.1002/ijc.2910400223; FELDMAN RA, 1989, J VIROL, V63, P5469, DOI 10.1128/JVI.63.12.5469-5474.1989; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; FELDMAN RA, 1987, ONCOGENE RES, V1, P441; FELDMAN RA, 1980, CELL, V22, P757, DOI 10.1016/0092-8674(80)90552-8; FERRARI S, 1985, BRIT J HAEMATOL, V59, P21, DOI 10.1111/j.1365-2141.1985.tb02959.x; FISCHMAN K, 1990, MOL CELL BIOL, V10, P146, DOI 10.1128/MCB.10.1.146; FOLEY GE, 1965, CANCER, V18, P522, DOI 10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO;2-J; FONATSCH C, 1982, INT J CANCER, V30, P321, DOI 10.1002/ijc.2910300311; FONATSCH C, 1986, CANCER GENET CYTOGEN, V20, P39, DOI 10.1016/0165-4608(86)90106-8; GALE RP, 1984, P NATL ACAD SCI-BIOL, V81, P5648, DOI 10.1073/pnas.81.18.5648; GARDNER MB, 1970, NATURE, V226, P807, DOI 10.1038/226807a0; GREER P, 1990, MOL CELL BIOL, V10, P2521, DOI 10.1128/MCB.10.6.2521; GREER PA, 1988, MOL CELL BIOL, V8, P578, DOI 10.1128/MCB.8.2.578; HANAFUSA T, 1980, P NATL ACAD SCI-BIOL, V77, P3009, DOI 10.1073/pnas.77.5.3009; HARPER ME, 1983, NATURE, V304, P169, DOI 10.1038/304169a0; JONES DB, 1985, HEMATOL ONCOL, V3, P133, DOI 10.1002/hon.2900030205; JUCKER M, 1990, HEMATOL ONCOL, V8, P191, DOI 10.1002/hon.2900080404; Kamesaki H, 1989, Recent Results Cancer Res, V117, P83; KAMESAKI H, 1986, BLOOD, V68, P285; KOCH K, 1990, NUCLEIC ACIDS RES, V18, P5918, DOI 10.1093/nar/18.19.5918; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOZAK M, 1984, NATURE, V308, P241, DOI 10.1038/308241a0; LEE WH, 1980, P NATL ACAD SCI-BIOL, V77, P2018, DOI 10.1073/pnas.77.4.2018; LENOIR GM, 1982, NATURE, V298, P474, DOI 10.1038/298474a0; LENOIR GM, 1985, IARC SCI PUBL, V60, P309; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MOOS M, 1983, EMBO J, V2, P757, DOI 10.1002/j.1460-2075.1983.tb01496.x; MORAN MF, 1988, ONCOGENE, V3, P665; PARK M, 1986, CELL, V45, P95; PAULES RS, 1988, ONCOGENE, V3, P59; PAWSON T, 1980, CELL, V22, P767, DOI 10.1016/0092-8674(80)90553-X; ROEBROEK AJM, 1986, MOL BIOL REP, V11, P117, DOI 10.1007/BF00364823; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; ROTH MS, 1988, BLOOD, V71, P1744; SADOWSKI I, 1987, ONCOGENE, V1, P181; SAMARUT J, 1985, MOL CELL BIOL, V5, P1067, DOI 10.1128/MCB.5.5.1067; SAVELYEVA L, 1988, CANCER GENET CYTOGEN, V34, P63, DOI 10.1016/0165-4608(88)90170-7; SCHAADT M, 1988, Cancer Reviews, V10, P108; SCHWENK HU, 1975, BLUT, V31, P299, DOI 10.1007/BF01634146; SHACKELFORD DA, 1987, J IMMUNOL, V138, P613; SNYDER SP, 1969, NATURE, V221, P1074, DOI 10.1038/2211074a0; VANBOKHOVEN A, 1991, IN PRESS MOL BIOL RE; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; YEE SP, 1989, MOL CELL BIOL, V9, P5491, DOI 10.1128/MCB.9.12.5491; YU G, 1989, J BIOL CHEM, V264, P10276; ZIEGLER A, 1987, J CLIN CHEM CLIN BIO, V25, P578	61	32	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1992	7	5					943	952						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1373879				2022-12-28	WOS:A1992HP64200014
J	NEUBAUER, A; NEUBAUER, B; HE, M; EFFERT, P; IGLEHART, D; FRYE, RA; LIU, E				NEUBAUER, A; NEUBAUER, B; HE, M; EFFERT, P; IGLEHART, D; FRYE, RA; LIU, E			ANALYSIS OF GENE AMPLIFICATION IN ARCHIVAL TISSUE BY DIFFERENTIAL POLYMERASE CHAIN-REACTION	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; BREAST-CANCER; DNA AMPLIFICATION; INTERFERON GENE; EXPRESSION; CARCINOMA; SEQUENCE; ERBB-2	Oncogene amplification is found in many human tumors, and its detection may have important prognostic value. However, analysis of gene amplification may be hampered by inadequate tissue or poor DNA quality. We have previously described a polymerase chain reaction (PCR)-based procedure called differential PCR that can detect variations in gene dosage using miniscule amounts of tumor DNA [Frye, R.A., Benz, C.C. & Liu, E. (1989). Oncogene, 4, 1153-1157]. We now report the optimization of this technique for the analysis of oncogene amplification in paraffin-embedded archival tissues. We find that differential PCR is able to detect amplification of the HER2 (c-erbB-2) and the epidermal growth factor receptor (EGFR) genes and can be used to arrive at a semiquantitative estimate of gene dosage. Furthermore, our approach can determine gene amplification in samples in which the DNA is significantly degraded. Using differential PCR on paraffin-embedded tissues from cases previously investigated by standard DNA extraction and dot-blot procedures, good correlation between the two methods was found. Approaches are described to overcome technical problems posed by factors that affect the differential PCR, including the method of DNA extraction and extreme fragmentation of the DNA (< 200 base pairs). Furthermore, the resulting analytical algorithm reported herein has proved effective in detecting oncogene amplification in archival breast cancer specimens from standard pathology laboratories. Thus, differential PCR will be particularly helpful in the analysis of tumor specimens that are archived, small in size or rare in occurrence.	UNIV N CAROLINA, LINEBERGER CANC RES CTR, DEPT MED & GENET, CB 7295, CHAPEL HILL, NC 27599 USA; DUKE UNIV, DEPT SURG, DURHAM, NC 27710 USA	University of North Carolina; University of North Carolina Chapel Hill; Duke University			Liu, Edison/C-4141-2008					ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BALLABIO A, 1990, HUM GENET, V84, P571; BENEZRA J, 1991, J HISTOCHEM CYTOCHEM, V39, P351, DOI 10.1177/39.3.1704393; CALLAHAN R, 1989, BREAST CANCER RES TR, V13, P191, DOI 10.1007/BF02106570; EHRLICH HA, 1989, PCR TECHNOLOGY; FRYE RA, 1989, ONCOGENE, V4, P1153; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; GRAY PW, 1982, NATURE, V298, P859, DOI 10.1038/298859a0; IGLEHART JD, 1990, CANCER RES, V50, P6701; IMPRAIM CC, 1987, BIOCHEM BIOPH RES CO, V142, P710, DOI 10.1016/0006-291X(87)91472-0; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LIU E, 1992, ONCOGENE, V7, P1027; Maniatis T., 1982, MOL CLONING; MIES C, 1991, AM J SURG PATHOL, V15, P169, DOI 10.1097/00000478-199102000-00010; NEUBAUER A, 1990, NUCLEIC ACIDS RES, V18, P993, DOI 10.1093/nar/18.4.993; OHNO S, 1982, NUCLEIC ACIDS RES, V10, P967, DOI 10.1093/nar/10.3.967; RESNICK RM, 1990, JNCI-J NATL CANCER I, V82, P1477, DOI 10.1093/jnci/82.18.1477; SHIBATA DK, 1988, J EXP MED, V167, P225, DOI 10.1084/jem.167.1.225; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; TSUDA H, 1990, CANCER, V65, P1794, DOI 10.1002/1097-0142(19900415)65:8<1794::AID-CNCR2820650821>3.0.CO;2-Y; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; ZHOU DJ, 1989, ONCOGENE, V4, P105	24	130	134	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1992	7	5					1019	1025						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1349162				2022-12-28	WOS:A1992HP64200025
J	PIM, D; COLLINS, M; BANKS, L				PIM, D; COLLINS, M; BANKS, L			HUMAN PAPILLOMAVIRUS TYPE-16 E5 GENE STIMULATES THE TRANSFORMING ACTIVITY OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR	ONCOGENE			English	Article							CARCINOMA CELL-LINES; OPEN READING FRAME; CERVICAL-CARCINOMA; ADENOVIRUS E1A; EGF RECEPTOR; E7 PROTEIN; DNA; IDENTIFICATION; ENCODES; EXPRESSION	We have until recently made several unsuccessful attempts to assign any activity to the human papillomavirus type 16 (HPV-16) E5 gene product. However, studies with the bovine papilloma virus 1 (BPV-1) E5 protein indicated an interaction with the epidermal growth factor receptor (EGFR). In light of the overall similarity between the HPV and BPV E5 proteins we attempted to determine whether the HPV-16 E5 gene had any common activity. In cells expressing high levels of EGFR plus HPV-16 E5 we found a dramatically increased proliferative activity in soft-agar assays in the presence of EGF. The specificity of this activity was monitored by the addition of other mitogenic agents. The phorbol ester phorbol 12-myristate 13-acetate (PMA) had no effect on the E5-containing cells, although insulin weakly stimulated their growth in soft agar. Further analysis revealed the same number of EGF receptors were present on the E5-containing cells as on the control cells, although the E5 cells were more sensitive to lower concentrations of EGF. These results imply that E5 is amplifying the mitogenic signals from the EGFR in an as yet unknown manner, but which may form the basis of interactions with a variety of growth factor receptors. This report brings to three the number of transforming genes encoded by HPV-16.	INT CTR GENET ENGN & BIOTECHNOL,PADRICIANO 99,I-34012 TRIESTE,ITALY; ROYAL CANC HOSP,INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND	International Center for Genetic Engineering & Biotechnology (ICGEB); Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK								ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; BANKNECHT T, 1989, J CLIN RES CLIN ONCO, V115, P193; BANKS L, 1990, ONCOGENE, V5, P1383; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BURKHARDT A, 1987, EMBO J, V6, P2381, DOI 10.1002/j.1460-2075.1987.tb02515.x; CHEN SL, 1990, J VIROL, V64, P3226, DOI 10.1128/JVI.64.7.3226-3233.1990; COLLINS MKL, 1988, J CELL PHYSIOL, V137, P293, DOI 10.1002/jcp.1041370212; COLLINS MKL, 1983, J BIOL CHEM, V258, P1689; CROOK T, 1989, EMBO J, V8, P513, DOI 10.1002/j.1460-2075.1989.tb03405.x; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; GISSMANN L, 1983, P NATL ACAD SCI-BIOL, V80, P560, DOI 10.1073/pnas.80.2.560; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; GOPPINGER A, 1989, J CANCER RES CLIN, V115, P259, DOI 10.1007/BF00391699; GREEN M, 1987, CELL, V51, P795, DOI 10.1016/0092-8674(87)90102-4; HALBERT CL, 1988, J VIROL, V62, P1071, DOI 10.1128/JVI.62.3.1071-1075.1988; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HOROWITZ BH, 1989, J VIROL, V63, P4515; KOHLER M, 1989, ANTICANCER RES, V9, P1537; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; KRIS RM, 1985, CELL, V40, P619, DOI 10.1016/0092-8674(85)90210-7; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; MUNGER K, 1989, J VIROL, V63, P4417; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; SCHILLER JT, 1984, P NATL ACAD SCI-BIOL, V81, P7880, DOI 10.1073/pnas.81.24.7880; SCHILLER JT, 1986, J VIROL, V57, P1; SCHLEGEL R, 1986, SCIENCE, V233, P464, DOI 10.1126/science.3014660; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; VANDENBRULE AJC, 1989, J MED VIROL, V29, P20, DOI 10.1002/jmv.1890290105; VOUSDEN KH, 1988, ONCOGENE RES, V3, P167; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WILKINSON D, 1988, J EXP MED, V164, P14; YANG YC, 1985, P NATL ACAD SCI USA, V82, P1030, DOI 10.1073/pnas.82.4.1030	41	226	230	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1992	7	1					27	32						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1311063				2022-12-28	WOS:A1992HC22700004
J	Sekiguchi, T; Yoshida, K; Wakabayashi, KI; Hisabori, T				Sekiguchi, Takatoshi; Yoshida, Keisuke; Wakabayashi, Ken-Ichi; Hisabori, Toru			Dissipation of the proton electrochemical gradient in chloroplasts promotes the oxidation of ATP synthase by thioredoxin-like proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SUBUNIT; THIOL MODULATION; REGULATORY REGION; PLASTIDIAL THIOREDOXINS; INTACT CHLOROPLASTS; INVERSE REGULATION; ARABIDOPSIS; ACTIVATION; MUTATION; LIGHT	Chloroplast FoF1-ATP synthase (CFoCF1) uses an electro-chemical gradient of protons across the thylakoid membrane (Delta mu H+) as an energy source in the ATP synthesis reaction. CFoCF1 activity is regulated by the redox state of a Cys pair on its central axis, that is, the gamma subunit (CF1-gamma). When the Delta mu H+ is formed by the photosynthetic electron transfer chain under light conditions, CF1-gamma is reduced by thioredoxin (Trx), and the entire CFoCF1 enzyme is activated. The redox regulation of CFoCF1 is a key mechanism underlying the control of ATP synthesis under light conditions. In contrast, the oxidative deactivation process involving CFoCF1 has not been clarified. In the present study, we analyzed the oxidation of CF1-gamma by two physiological oxidants in the chloroplast, namely the proteins Trx-like 2 and atypical Cys-His-rich Trx. Using the thylakoid membrane containing the reduced form of CFoCF1, we were able to assess the CF1-gamma oxidation ability of these Trx-like proteins. Our kinetic analysis indicated that these proteins oxidized CF1-gamma with a higher efficiency than that achieved by a chemical oxidant and typical chloroplast Trxs. Additionally, the CF1-gamma oxidation rate due to Trx-like proteins and the af-finity between them were changed markedly when Delta mu H+ for-mation across the thylakoid membrane was manipulated artificially. Collectively, these results indicate that the forma-tion status of the Delta mu H+ controls the redox regulation of CFoCF1 to prevent energetic disadvantages in plants.	[Sekiguchi, Takatoshi; Yoshida, Keisuke; Wakabayashi, Ken-Ichi; Hisabori, Toru] Tokyo Inst Technol, Inst Innovat Res, Lab Chem & Life Sci, Midori Ku, Yokohama, Japan; [Sekiguchi, Takatoshi; Yoshida, Keisuke; Wakabayashi, Ken-Ichi; Hisabori, Toru] Tokyo Inst Technol, Sch Life Sci & Technol, Midori Ku, Yokohama, Japan	Tokyo Institute of Technology; Tokyo Institute of Technology	Hisabori, T (corresponding author), Tokyo Inst Technol, Inst Innovat Res, Lab Chem & Life Sci, Midori Ku, Yokohama, Japan.; Hisabori, T (corresponding author), Tokyo Inst Technol, Sch Life Sci & Technol, Midori Ku, Yokohama, Japan.	thisabor@res.titech.ac.jp	Hisabori, Toru/E-5205-2014; Yoshida, Keisuke/E-5231-2014; Wakabayashi, Ken-ichi/D-2440-2015	Hisabori, Toru/0000-0003-2046-0277; Yoshida, Keisuke/0000-0001-6542-6254; Wakabayashi, Ken-ichi/0000-0002-1025-9249; Sekiguchi, Takatoshi/0000-0003-4193-2683	Japan Society for the Promotion of Science [21H02502]; Dynamic Alliance for Open Innovation Bridging Human, Environment, and Materials [21H02502];  [22J13334]	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Dynamic Alliance for Open Innovation Bridging Human, Environment, and Materials; 	This study was supported by Grants-in-Aid for Scientific Research (Grant 21H02502 to T. H.) from the Japan Society for the Promotion of Science and partly by a Grant-in-Aid for JSPS Research Fellows (Grant 22J13334 to T. S.) as well as the Dynamic Alliance for Open Innovation Bridging Human, Environment, and Materials.	Akanuma G, 2019, MICROBIOLOGYOPEN, V8, DOI 10.1002/mbo3.815; Arsova B, 2010, PLANT CELL, V22, P1498, DOI 10.1105/tpc.109.071001; BUCHANAN BB, 1980, ANNU REV PLANT PHYS, V31, P341, DOI 10.1146/annurev.pp.31.060180.002013; Cain P, 2009, PLANT MOL BIOL, V70, P273, DOI 10.1007/s11103-009-9471-4; Chibani K, 2009, MOL PLANT, V2, P308, DOI 10.1093/mp/ssn076; Collin V, 2004, PLANT PHYSIOL, V136, P4088, DOI 10.1104/pp.104.052233; Collin V, 2003, J BIOL CHEM, V278, P23747, DOI 10.1074/jbc.M302077200; Dal Bosco C, 2004, J BIOL CHEM, V279, P1060, DOI 10.1074/jbc.M308435200; Dangoor I, 2009, PLANT PHYSIOL, V149, P1240, DOI 10.1104/pp.108.128314; Hahn A, 2018, SCIENCE, V360, P620, DOI 10.1126/science.aat4318; Hightower KE, 1996, BIOCHEMISTRY-US, V35, P4846, DOI 10.1021/bi952913p; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HUANG CS, 1983, BIOCHIM BIOPHYS ACTA, V722, P107, DOI 10.1016/0005-2728(83)90163-9; Jacquot JP, 1997, NEW PHYTOL, V136, P543, DOI 10.1046/j.1469-8137.1997.00784.x; JAGENDORF AT, 1966, P NATL ACAD SCI USA, V55, P170, DOI 10.1073/pnas.55.1.170; JUNESCH U, 1987, BIOCHIM BIOPHYS ACTA, V893, P275, DOI 10.1016/0005-2728(87)90049-1; Kanazawa A, 2002, P NATL ACAD SCI USA, V99, P12789, DOI 10.1073/pnas.182427499; KETCHAM SR, 1984, J BIOL CHEM, V259, P7286; Kohzuma K, 2017, FRONT PLANT SCI, V8, DOI 10.3389/fpls.2017.01248; Kohzuma K, 2013, J BIOL CHEM, V288, P13156, DOI 10.1074/jbc.M113.453225; KomatsuTakaki M, 1996, EUR J BIOCHEM, V236, P470, DOI 10.1111/j.1432-1033.1996.00470.x; Konno H, 2000, BIOCHEM J, V352, P783, DOI 10.1042/0264-6021:3520783; Konno H, 2012, PLANT CELL PHYSIOL, V53, P626, DOI 10.1093/pcp/pcs018; KRAMER DM, 1989, BIOCHIM BIOPHYS ACTA, V976, P28, DOI 10.1016/S0005-2728(89)80186-0; Lemaire SD, 2007, CURR GENET, V51, P343, DOI 10.1007/s00294-007-0128-z; McCarty RE, 2005, J BIOENERG BIOMEMBR, V37, P289, DOI 10.1007/s10863-005-8640-7; MCKINNEY DW, 1979, BIOCHEM BIOPH RES CO, V86, P1178, DOI 10.1016/0006-291X(79)90241-9; Meyer Y, 2005, PHOTOSYNTH RES, V86, P419, DOI 10.1007/s11120-005-5220-y; Meyer Y, 2006, PHOTOSYNTH RES, V89, P179, DOI 10.1007/s11120-006-9095-3; MIKI J, 1988, FEBS LETT, V232, P221, DOI 10.1016/0014-5793(88)80421-6; MILLS JD, 1980, FEBS LETT, V112, P173, DOI 10.1016/0014-5793(80)80173-6; MILLS JD, 1982, BIOCHIM BIOPHYS ACTA, V679, P75, DOI 10.1016/0005-2728(82)90257-2; MITCHELL P, 1966, BIOL REV, V41, P445, DOI 10.1111/j.1469-185X.1966.tb01501.x; NALIN CM, 1984, J BIOL CHEM, V259, P7275; Okegawa Y, 2015, PLANT J, V84, P900, DOI 10.1111/tpj.13049; Peltier JB, 2006, MOL CELL PROTEOMICS, V5, P114, DOI 10.1074/mcp.M500180-MCP200; QUICK WP, 1986, BIOCHIM BIOPHYS ACTA, V851, P166, DOI 10.1016/0005-2728(86)90122-2; SCHMID GH, 1978, Z NATURFORSCH C, V33, P723; Schwarz O, 1997, J BIOL CHEM, V272, P16924, DOI 10.1074/jbc.272.27.16924; Sekiguchi T, 2020, BBA-BIOENERGETICS, V1861, DOI 10.1016/j.bbabio.2020.148261; Sugiyama K, 2003, BIOCHEM BIOPH RES CO, V301, P311, DOI 10.1016/S0006-291X(02)03022-X; Ueoka-Nakanishi H, 2004, J BIOL CHEM, V279, P16272, DOI 10.1074/jbc.M400607200; Vaseghi MJ, 2018, ELIFE, V7, DOI 10.7554/eLife.38194; Wu G, 2007, J BIOL CHEM, V282, P36782, DOI 10.1074/jbc.M707007200; Yang JH, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-01221-8; Yokochi Y, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2114952118; Yokochi Y, 2019, J BIOL CHEM, V294, P17437, DOI 10.1074/jbc.RA119.010401; Yoshida K, 2021, PLANT CELL PHYSIOL, V62, P401, DOI 10.1093/pcp/pcaa174; Yoshida K, 2019, FRONT PLANT SCI, V10, DOI 10.3389/fpls.2019.01534; Yoshida K, 2019, BIOCHEM J, V476, P1781, DOI 10.1042/BCJ20190336; Yoshida K, 2018, P NATL ACAD SCI USA, V115, pEB296, DOI 10.1073/pnas.1808284115; Yoshida K, 2017, BIOCHEM J, V474, P1347, DOI 10.1042/BCJ20161089; Yoshida K, 2015, J BIOL CHEM, V290, P14278, DOI 10.1074/jbc.M115.647545; Yoshida K, 2014, PLANT CELL PHYSIOL, V55, P1415, DOI 10.1093/pcp/pcu066; Yoshida M, 2001, NAT REV MOL CELL BIO, V2, P669, DOI 10.1038/35089509	55	0	0	1	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV	2022	298	11							102541	10.1016/j.jbc.2022.102541	http://dx.doi.org/10.1016/j.jbc.2022.102541			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	6C7OU	36174673	Green Published, gold			2022-12-28	WOS:000882199400009
J	WU, WS; LIN, JK; WU, FYH				WU, WS; LIN, JK; WU, FYH			DIFFERENTIAL INDUCTION OF C-FOS AND C-JUN PROTOONCOGENES AND AP-1 ACTIVITY BY TUMOR PROMOTER 12-O-TETRADECANOYL PHORBOL 13-ACETATE IN CELLS AT DIFFERENT STAGES OF TUMOR PROMOTION INVITRO	ONCOGENE			English	Article							TRANSCRIPTION FACTOR AP-1; INDUCIBLE ENHANCER ELEMENTS; IMMEDIATE EARLY GENES; EPIDERMAL JB6 CELLS; KINASE-C; CHEMICAL CARCINOGENESIS; 67-BASE-PAIR SEQUENCE; COORDINATE REGULATION; TRANSFORMING GENE; NONCODING REGION	A two-stage (initiation and promotion) model of chemical transformation of mouse embryonic fibroblasts was used to elucidate the molecular mechanisms of tumor promotion in vitro. C3H10T1/2 cells which had been initiated with a subcarcinogenic dose (0.5 mug ml-1) of benzo[a]pyrene (B[a]P) were isolated after 12-O-tetradecanoyl phorbol 13-acetate (TPA) treatment lasting 12, 24 or 36 days. These series of partially promoted cells were designated T-12, T-24 and T-36 cells. T-12 and T-24 cells exhibited higher anchorage-independent growth on soft agar in the presence of TPA than did the initiated or T-36 cells. Cytosolic protein kinase C (PKC) in the resting state was slightly depleted in T-24 and T-36 cells. Proteolytic down-regulation of membrane-bound PKC was enhanced in T-12 cells compared with the initiated cells after 3h of TPA treatment. Induction of c-fos and c-jun proto-oncogene expression increased two- to threefold in T-12 cells. Moreover, the basal level of c-fos mRNA progressively increased in T-12, T-24 and T-36 cells. As compared with other cell types, T-12 cells had the highest AP-1 DNA-binding activity at both the basal level and at 30 min after TPA treatment. These results indicate that deregulation of the TPA-induced cellular responses occurs in the cells at various stages of tumor promotion, and might be associated with transforming processes.	ACAD SINICA,INST BIOMED SCI,TAIPEI 11529,TAIWAN	Academia Sinica - Taiwan								ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BALLESTER R, 1985, J BIOL CHEM, V260, P5194; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CARTER TH, 1987, MECH ENV CARCINOGENE, P47; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHIDA K, 1986, CANCER RES, V46, P1055; CHIDA K, 1986, J BIOL CHEM, V261, P3013; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; FOURNIER A, 1987, NATURE, V330, P767, DOI 10.1038/330767a0; GREENBERG ME, 1985, CANCER CELL, V3, P307; HANSEN LA, 1990, CANCER RES, V50, P5740; ITO M, 1988, BIOCHEM BIOPH RES CO, V153, P648, DOI 10.1016/S0006-291X(88)81144-6; KIKKAWA U, 1983, J BIOL CHEM, V258, P1442; KISCHEL T, 1989, BIOCHEM BIOPH RES CO, V165, P981, DOI 10.1016/0006-291X(89)92699-5; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LERMAN MI, 1988, TUMOR PROMOTION BIOL, P357; Maniatis T., 1982, MOL CLONING; MANIATIS T, 1982, MOL CLONING, V2; MARC C, 1990, ONCOGENE, V5, P1541; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; MILLER EC, 1978, CANCER RES, V38, P1479; MONDAL S, 1976, CANCER RES, V36, P2254; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PIETTE J, 1988, P NATL ACAD SCI USA, V85, P3401, DOI 10.1073/pnas.85.10.3401; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; Sambrook J, 1989, MOL CLONING LABORATO; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; WEINSTEIN IB, 1981, J SUPRAMOL STR CELL, V17, P99, DOI 10.1002/jsscb.380170202; WEINSTEIN IB, 1988, CANCER RES, V48, P4135; WEINSTEIN IB, 1987, J CELL BIOCHEM, V33, P213, DOI 10.1002/jcb.240330308; WEINSTEIN IB, 1984, CANCER CELL, V1, P229; WEYMAN CM, 1988, CANCER RES, V48, P5740	43	29	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2287	2294						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437150				2022-12-28	WOS:A1992JW66500022
J	NAIR, APK; HIRSCH, HH; MORONI, C				NAIR, APK; HIRSCH, HH; MORONI, C			MAST-CELLS SENSITIVE TO V-H-RAS TRANSFORMATION ARE HYPERINDUCIBLE FOR INTERLEUKIN-3 EXPRESSION AND HAVE LOST TUMOR-SUPPRESSOR ACTIVITY	ONCOGENE			English	Article							COLONY-STIMULATING FACTOR; HEMATOPOIETIC GROWTH-FACTORS; ACUTE LYMPHOCYTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; CSF MESSENGER-RNA; GM-CSF; AUTOCRINE GROWTH; FACTOR GENE; MALIGNANT TRANSFORMATION; SIGNAL-TRANSDUCTION	Subcloning of interleukin 3 (IL-3)-dependent PB-3c mastocyte cells revealed two populations, of which only one is sensitive to oncogenic transformation by v-H-ras. The corresponding tumors produce IL-3 and grow in vitro in the absence of exogenous IL-3 [Nair, A.P.K., Diamantis, I.D., Conscience, J.F., Kindler, V., Hofer, P. & Moroni, Ch. (1989). Mol. Cell. Biol., 9, 1183-11901. In the present investigation, IL-3 gene regulation was compared in ras transformable (rT) and ras nontransformable (rNT) lines. We report that upon expression of v-H-ras rT clones but not rNT clones express low levels of IL-3 mRNA as detected by reverse polymerase chain reaction. Treatment with ionomycin, a calcium ionophore, induced high levels of IL-3 expression only in ras-expressing rT clones. Somatic cell fusion between the rNT clone 20 and the IL-3-expressing mastocytoma line V2D1 led to down-regulation of IL-3 expression and to the requirement for exogenous IL-3 for in vitro growth and tumor suppression. In contrast, rT clone 15 lacked tumor-suppressor activity and failed to down-regulate IL-3 expression in somatic hybrids which grew in vitro without added IL-3. Our results indicate that IL-3 gene expression is a critical determinant for the generation of v-H-ras-induced mast cell tumors and show that disturbances in IL-3 gene regulation can be detected already at the premalignant level in v-H-ras transformation-sensitive cells.			NAIR, APK (corresponding author), UNIV BASEL,INST MED MICROBIOL,PETERSPL 10,CH-4003 BASEL,SWITZERLAND.			Hirsch, Hans H./0000-0003-0883-0423				ADKINS B, 1984, CELL, V39, P439, DOI 10.1016/0092-8674(84)90451-3; ANDREJAUSKAS E, 1989, EMBO J, V8, P2575, DOI 10.1002/j.1460-2075.1989.tb08396.x; BALL PE, 1983, DIFFERENTIATION, V24, P74, DOI 10.1111/j.1432-0436.1983.tb01305.x; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BAUMBACH WR, 1987, MOL CELL BIOL, V7, P664, DOI 10.1128/MCB.7.2.664; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; BOS JL, 1985, NATURE, V315, P726, DOI 10.1038/315726a0; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; CHIAO PJ, 1991, ONCOGENE, V6, P713; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; COX PM, 1991, BRIT J CANCER, V63, P651, DOI 10.1038/bjc.1991.151; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DIAMANTIS ID, 1989, P NATL ACAD SCI USA, V86, P9299, DOI 10.1073/pnas.86.23.9299; DUHRSEN U, 1990, EMBO J, V9, P1087, DOI 10.1002/j.1460-2075.1990.tb08214.x; DUNBAR CE, 1989, SCIENCE, V245, P1493, DOI 10.1126/science.2789432; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GAMBKE C, 1984, NATURE, V307, P476, DOI 10.1038/307476a0; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; GOUGH NM, 1984, NATURE, V309, P763, DOI 10.1038/309763a0; GRAF T, 1986, CELL, V45, P357, DOI 10.1016/0092-8674(86)90321-1; GRIMALDI JC, 1989, BLOOD, V73, P2081; HAHN S, 1991, ONCOGENE, V6, P2327; HAPEL AJ, 1986, LYMPHOKINE RES, V5, P249; HIRAI H, 1987, NATURE, V327, P430, DOI 10.1038/327430a0; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KELLER G, 1985, NATURE, V318, P149, DOI 10.1038/318149a0; KOEFFLER HP, 1988, MOL CELL BIOL, V8, P3432, DOI 10.1128/MCB.8.8.3432; KOI M, 1989, P NATL ACAD SCI USA, V86, P8773, DOI 10.1073/pnas.86.22.8773; KRIZMAN DB, 1990, SOMAT CELL MOLEC GEN, V16, P15, DOI 10.1007/BF01650476; LAKER C, 1987, P NATL ACAD SCI USA, V84, P8458, DOI 10.1073/pnas.84.23.8458; LAKER C, 1989, MOL CELL BIOL, V9, P5746, DOI 10.1128/MCB.9.12.5746; MEEKER TC, 1990, BLOOD, V76, P285; MIYATAKE S, 1985, P NATL ACAD SCI USA, V82, P316, DOI 10.1073/pnas.82.2.316; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MUSER J, 1989, ONCOGENE, V4, P1433; NAIR APK, 1989, MOL CELL BIOL, V9, P1183, DOI 10.1128/MCB.9.3.1183; NEEDLEMAN SW, 1986, BLOOD, V67, P753; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; REIN A, 1985, MOL CELL BIOL, V5, P2257, DOI 10.1128/MCB.5.9.2257; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SCHWARTZ RC, 1986, MOL CELL BIOL, V6, P3221, DOI 10.1128/MCB.6.9.3221; SENN HP, 1988, INT J CANCER, V41, P59, DOI 10.1002/ijc.2910410112; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STOCKING C, 1988, CELL, V53, P869, DOI 10.1016/S0092-8674(88)90329-7; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; THORENS B, 1987, CELL, V48, P671, DOI 10.1016/0092-8674(87)90245-5; TOKSOZ D, 1987, ONCOGENE, V1, P409; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WISEMAN RW, 1988, J CELL BIOCHEM, V12, pD35; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0	56	25	26	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					1963	1972						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408138				2022-12-28	WOS:A1992JP42400009
J	BAI, WL; SINGH, B; YANG, YD; ARLINGHAUS, RB				BAI, WL; SINGH, B; YANG, YD; ARLINGHAUS, RB			EVIDENCE FOR INTERACTION BETWEEN V-MOS AND A P34CDC2 ISOFORM, P35CDK	ONCOGENE			English	Article							MURINE SARCOMA-VIRUS; MATURATION-PROMOTING FACTOR; PROTEIN-KINASE ACTIVITY; CELL-CYCLE; PROTOONCOGENE PRODUCT; MEIOTIC MATURATION; ONCOGENE PRODUCT; XENOPUS OOCYTES; GENE; EGGS	The c-mos gene product (c-Mos) encodes a serine/threonine kinase required for activation of pre-MPF (maturation-promoting factor) to MPF in oocytes undergoing meiosis and also for stabilization of MPF leading to metaphase arrest in unfertilized eggs. In order to determine whether the v-mos gene product (v-Mos) causes neoplastic transformation via interaction with cell cycle control elements, we have searched for proteins that interact with v-Mos. Extracts of NIH3T3 cells transformed by v-Mos encoded by Moloney murine sarcoma virus (Mo-MuSV) were examined by gel filtration by immunoprecipitation with antibodies to a conserved region of p34cdc2, and by binding to beads that contain cross-linked p13scu1, a protein known to bind p34cdc2. Gel filtration detected a 500-kDa complex that contained v-Mos and a p34cdc2 isoform, termed p35cdk. The 500-kDa macromolecular complex also exhibited histone H1 phosphorylation activity, consistent with the presence of a cdc2 isoform. The identity of p35cdk is based on its recognition by anti-cdc2 PSTAIR but not by anti-cdc2 C-terminal antibodies, which detect authentic p34cdc2. Structures containing v-Mos and p35cdk were also detected by experiments involving co-immunoprecipitation of v-Mos with anti-cdc2 PSTAIR antibodies. Furthermore. both v-Mos and the p35cdk co-precipitated with p13scu1-Sepharose beads. Our findings raise the possibility of a v-Mos-p35cdk regulatory interaction in cells transformed by Mo-MuSV.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC PATHOL,1515 HOLCOMBE BLVD,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Bai, Wenlong/A-8977-2013	Bai, Wenlong/0000-0002-9536-0556	NATIONAL CANCER INSTITUTE [P30CA016672, R01CA045125] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16672, CA 45125] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAI W, 1992, IN PRESS ONCOGENE; BAI WL, 1991, ONCOGENE, V6, P1715; BAILLY E, 1989, EMBO J, V8, P3985, DOI 10.1002/j.1460-2075.1989.tb08581.x; BALL JK, 1973, VIROLOGY, V56, P268, DOI 10.1016/0042-6822(73)90305-X; BLAIR DG, 1979, VIROLOGY, V95, P303, DOI 10.1016/0042-6822(79)90486-0; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DAAR I, 1991, J CELL BIOL, V114, P329, DOI 10.1083/jcb.114.2.329; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FREEMAN RS, 1991, MOL CELL BIOL, V11, P1713, DOI 10.1128/MCB.11.3.1713; GALLICK GE, 1984, VIROLOGY, V139, P366, DOI 10.1016/0042-6822(84)90382-9; GALLICK GE, 1985, J GEN VIROL, V66, P945, DOI 10.1099/0022-1317-66-5-945; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HERZOG NK, 1988, ONCOGENE, V3, P225; KANKI JP, 1991, P NATL ACAD SCI USA, V88, P5794, DOI 10.1073/pnas.88.13.5794; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KROHNE G, 1982, J CELL BIOL, V94, P749, DOI 10.1083/jcb.94.3.749; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LIU JX, 1990, ONCOGENE, V5, P171; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; LORCA T, 1991, EMBO J, V10, P2087, DOI 10.1002/j.1460-2075.1991.tb07741.x; MAXWELL SA, 1985, J GEN VIROL, V66, P2135, DOI 10.1099/0022-1317-66-10-2135; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SINGH B, 1988, ONCOGENE, V3, P79; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; VANBEVEREN C, 1981, CELL, V27, P97, DOI 10.1016/0092-8674(81)90364-0; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WATANABE N, 1991, NATURE, V352, P247, DOI 10.1038/352247a0; WEHBER M, 1991, DEV BIOL, V148, P393; ZHAO X, 1990, ONCOGENE, V5, P1727; ZHAO X, 1991, ONCOGENE, V6, P1423; ZHOU R, 1991, CELL GROWTH DIFFER, V2, P257; ZHOU RP, 1991, SCIENCE, V251, P671, DOI 10.1126/science.1825142	46	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1757	1763						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1323818				2022-12-28	WOS:A1992JJ37600012
J	PAGANO, M; DURST, M; JOSWIG, S; DRAETTA, G; JANSENDURR, P				PAGANO, M; DURST, M; JOSWIG, S; DRAETTA, G; JANSENDURR, P			BINDING OF THE HUMAN E2F TRANSCRIPTION FACTOR TO THE RETINOBLASTOMA PROTEIN BUT NOT TO CYCLIN-A IS ABOLISHED IN HPV-16-IMMORTALIZED CELLS	ONCOGENE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; GENE-PRODUCT; SUSCEPTIBILITY GENE; CELLULAR PROTEINS; E1A PROTEINS; DNA-BINDING; ADENOVIRUS-E1A; KERATINOCYTES; EXPRESSION; INTERACT	The adenovirus E1A, SV40 large T and papillomavirus E7 proteins immortalize primary cells by virtue of their ability to bind the retinobtastoma gene product (pRB) and other cellular proteins, including cyclin A and the prRB-related protein, p107. It has been demonstrated that these viral oncogene products will prevent the inhibition of positive growth regulators by pRB, one of them being the E2F transcription factor. Here we show that the interactions of pRB and cyclin A with E2F are present also in normal keratinocytes and in primary human fibroblasts. In human keratinocytes immortalized by human papillomavirus 16 (HPV-16), expressing high levels of HPV-16 E7 protein, complexes between E2F and pRB are disrupted. In this cell line, as well as in HeLa cells which express HPV-18 E7, complexes containing E2F and cyclin A are maintained, indicating that this interaction is not sensitive to the viral oncoprotein and that cyclin A can associate with E2F independently of pRB. In vitro binding experiments suggest that the E7 gene product is able to preferentially abolish the interaction of pRB with E2F, leaving the cyclin A complexes intact. Our findings suggest that E7-dependent immortalization of human cells is associated with modifications of E2F multiprotein complexes.	DEUTSCH KREBSFORSCHUNGSZENTRUM,PROJEKTGRP ANGEW TUMORVIROL,NEUENHEIMER FELD 506,W-6900 HEIDELBERG,GERMANY; DEUTSCH KREBSFORSCHUNGSZENTRUM,EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,W-6900 HEIDELBERG,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); European Molecular Biology Laboratory (EMBL); Helmholtz Association; German Cancer Research Center (DKFZ)			Jansen-Dürr, Pidder/ABG-2466-2020	Jansen-Dürr, Pidder/0000-0001-7771-3429; pagano, michele/0000-0003-3210-2442				BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BARTEK J, 1992, ONCOGENE, V7, P101; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BOEUF H, 1990, P NATL ACAD SCI USA, V87, P1782, DOI 10.1073/pnas.87.5.1782; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DURST M, 1987, ONCOGENE, V1, P251; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GIARD F, 1991, CELL, V67, P1169; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; JANSENDURR P, 1990, J VIROL, V64, P2384, DOI 10.1128/JVI.64.5.2384-2387.1990; JANSENDURR P, 1989, EMBO J, V8, P3365, DOI 10.1002/j.1460-2075.1989.tb08499.x; KUMAR V, 1988, CELL, V55, P507; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1991, Progress in Growth Factor Research, V3, P267, DOI 10.1016/0955-2235(91)90004-N; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; ROHLFS M, 1991, VIROLOGY, V183, P331, DOI 10.1016/0042-6822(91)90146-3; SCHOLER HR, 1991, CELL, V66, P291, DOI 10.1016/0092-8674(91)90619-A; SEEDORF K, 1987, EMBO J, V6, P139, DOI 10.1002/j.1460-2075.1987.tb04731.x; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578; ZURHAUSEN H, 1987, PAPOVAVIRIDAE PAPILL	42	91	91	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1681	1686						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1323816				2022-12-28	WOS:A1992JJ37600002
J	DAVIDPFEUTY, T; NOUVIANDOOGHE, Y				DAVIDPFEUTY, T; NOUVIANDOOGHE, Y			SLOW TIME-DEPENDENT CELLULAR-TRANSFORMATION INDUCED AT RESTRICTIVE TEMPERATURE BY TS-SRC MUTANTS	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; PROTEIN-KINASE ACTIVITY; ATP-BINDING SITE; GENE-PRODUCT; MONOCLONAL-ANTIBODIES; CELLS; PP60SRC; PP60V-SRC; LOCALIZATION; PARAMETERS	Cell lines infected with a temperature-sensitive Rous sarcoma virus have been widely used to study the temporal dynamics of various transformation parameters following downshift from the non-permissive temperature to the permissive temperature as it is considered that, at the non-permissive temperature, the infected cells exhibit the morphological and growth characteristics of normal cell whereas, at the permissive temperature, they exhibit characteristics of the transformed state. We show here that the apparently normal state in which tsPA1-infected FR3T3 cells are directed at the restrictive temperature is not a stationary stable state, but rather a transient one which continuously drifts as the cells are grown and passaged at this temperature and which eventually ends up as a new transformed state (T2) with morphological and growth properties definitely different from those belonging to the transformed state (T1) at the permissive temperature. The establishment of the transformed T2 state at the restrictive temperature occurs concomitantly with a steady accumulation of an intracellular pool of pp60v-src in the vicinity of the nucleus, whose traffic towards the plasma membrane is released following downshift to the permissive temperature, leading to the reappearance of transformation parameters characteristic of the transformed T1 state. Our finding raises the possibility that the v-src protein encoded by the tsPA1 mutant of Rous sarcoma virus may induce cellular transformation via two different pathways, leading to two different transformation states, depending on at which temperature the infected cells are grown. Various possible mechanisms that could be involved in the time-dependent establishment of a transformed state by ts-src mutants at the restrictive temperature are discussed.			DAVIDPFEUTY, T (corresponding author), CTR UNIV ORSAY, INST CURIE BIOL, BATIMENT 110, F-91405 ORSAY, FRANCE.							BARAK LS, 1980, P NATL ACAD SCI-BIOL, V77, P980, DOI 10.1073/pnas.77.2.980; BIQUARD J-M, 1970, Comptes Rendus Hebdomadaires des Seances de l'Academie des Sciences Serie D Sciences Naturelles, V271, P2430; BIQUARD JM, 1972, VIROLOGY, V47, P444, DOI 10.1016/0042-6822(72)90280-2; BRE MH, 1987, J CELL BIOL, V105, P1283, DOI 10.1083/jcb.105.3.1283; BRUGGE JS, 1981, CELL, V25, P363, DOI 10.1016/0092-8674(81)90055-6; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; BRUGGE JS, 1977, NATURE, V269, P346, DOI 10.1038/269346a0; BRYANT DL, 1984, MOL CELL BIOL, V4, P862, DOI 10.1128/MCB.4.5.862; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CALOTHY G, 1978, VIROLOGY, V89, P75, DOI 10.1016/0042-6822(78)90041-7; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLLETT MS, 1978, P NATL ACAD SCI USA, V75, P2021, DOI 10.1073/pnas.75.4.2021; COURTNEIDGE SA, 1982, P NATL ACAD SCI-BIOL, V79, P7117, DOI 10.1073/pnas.79.23.7117; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; CROSS FR, 1985, MOL CELL BIOL, V5, P2789, DOI 10.1128/MCB.5.10.2789; DAVIDPFEUTY T, 1990, J CELL BIOL, V111, P3097, DOI 10.1083/jcb.111.6.3097; DAVIDPFEUTY T, 1980, P NATL ACAD SCI-BIOL, V77, P6687, DOI 10.1073/pnas.77.11.6687; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GARBER EA, 1982, VIROLOGY, V118, P419, DOI 10.1016/0042-6822(82)90361-0; GIONTI E, 1980, VIROLOGY, V100, P219, DOI 10.1016/0042-6822(80)90515-2; HANAFUSA H, 1977, COMPREHENSIVE VIROLO, V10, P401; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; JOVE R, 1986, J VIROL, V60, P849, DOI 10.1128/JVI.60.3.849-857.1986; JOVE R, 1986, J VIROL, V60, P840, DOI 10.1128/JVI.60.3.840-848.1986; KAMPS MP, 1986, MOL CELL BIOL, V6, P751, DOI 10.1128/MCB.6.3.751; LEVINSON AD, 1981, P NATL ACAD SCI-BIOL, V78, P1624, DOI 10.1073/pnas.78.3.1624; LEVINSON AD, 1978, CELL, V15, P561, DOI 10.1016/0092-8674(78)90024-7; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; OPPERMANN H, 1981, P NATL ACAD SCI-BIOL, V78, P1067, DOI 10.1073/pnas.78.2.1067; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; RESH MD, 1985, J CELL BIOL, V100, P409, DOI 10.1083/jcb.100.2.409; ROHRSCHNEIDER LR, 1979, CELL, V16, P11, DOI 10.1016/0092-8674(79)90183-1; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SCHLIWA M, 1986, CYTOSKELETON INTRO S, P47; SEIF R, 1977, J VIROL, V24, P721, DOI 10.1128/JVI.24.3.721-728.1977; SNYDER MA, 1985, MOL CELL BIOL, V5, P1772, DOI 10.1128/MCB.5.7.1772; STEHELIN D, 1976, NATURE, V260, P170, DOI 10.1038/260170a0; STOKER AW, 1986, J VIROL, V58, P876, DOI 10.1128/JVI.58.3.876-883.1986; WEBER MJ, 1979, CELL, V16, P25, DOI 10.1016/0092-8674(79)90184-3	41	2	2	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1992	7	8					1611	1623						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1321405				2022-12-28	WOS:A1992JE81300018
J	LIU, E; THOR, A; HE, M; BARCOS, M; LJUNG, BM; BENZ, C				LIU, E; THOR, A; HE, M; BARCOS, M; LJUNG, BM; BENZ, C			THE HER2 (C-ERBB-2) ONCOGENE IS FREQUENTLY AMPLIFIED IN INSITU CARCINOMAS OF THE BREAST	ONCOGENE			English	Note							SURGICAL ADJUVANT BREAST; PROTEIN OVEREXPRESSION; CANCER; AMPLIFICATION; EXPRESSION; SURVIVAL; PROJECT; GENE	Amplification and overexpression of the HER2 (c-erbB-2) oncogene was assessed in paraffin-embedded specimens from 27 in situ carcinomas of the breast and from 122 stage II breast cancers. Gene amplification detected in these archival tissues by differential polymerase chain reaction (PCR) was found in 48% of in situ carcinomas and in 21% of stage II lesions (chi(2) = 7.62, p less-than-or-equal-to 0.01). In addition, the level of gene amplification correlated with the level of HER2 oncoprotein expression as measured by immunohistochemistry for both in situ cancers (p less-than-or-equal-to 0.025) and stage II cancers (p less-than-or-equal-to 0.0005). This high incidence of HER2 gene amplification with accompanying overexpression in non-invasive breast tumors suggests that perturbations of the HER2 oncogene are among the earliest and most common genetic lesions in human breast cancer.	UNIV CALIF SAN FRANCISCO,CANC RES INST,M-1283,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,BOSTON,MA 02114; UNIV N CAROLINA,DEPT MED,CURRICULUM GENET,CHAPEL HILL,NC 27599; ROSWELL PK CANC INST,DEPT PATHOL,BUFFALO,NY; UNIV N CAROLINA,LINEBERGER CANC RES CTR,CHAPEL HILL,NC 27599	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; University of North Carolina; University of North Carolina Chapel Hill; Roswell Park Cancer Institute; University of North Carolina; University of North Carolina Chapel Hill			Liu, Edison/C-4141-2008		NATIONAL CANCER INSTITUTE [U10CA037055, P01CA044768, U10CA031946] Funding Source: NIH RePORTER; NCI NIH HHS [5U10-CA31946-08, 5U10-CA37055-08, P01 CA 44768] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTKOVA J, 1990, HUM PATHOL, V21, P1164, DOI 10.1016/0046-8177(90)90154-W; BORG A, 1990, CANCER RES, V50, P4332; BORG A, 1989, LANCET, V1, P1268; BRESEN AL, 1990, BRIT J CANCER, V62, P585; CLARK GM, 1991, CANCER RES, V51, P944; FISHER ER, 1986, CANCER-AM CANCER SOC, V57, P197, DOI 10.1002/1097-0142(19860115)57:2<197::AID-CNCR2820570203>3.0.CO;2-N; FRYE RA, 1989, ONCOGENE, V4, P1153; HANNA W, 1990, MODERN PATHOL, V3, P455; IGLEHART JD, 1990, CANCER RES, V50, P6701; LODATO RF, 1990, MODERN PATHOL, V3, P449; NEUBAUER A, 1992, ONCOGENE, V7, P1019; PAIK S, 1990, J CLIN ONCOL, V8, P103, DOI 10.1200/JCO.1990.8.1.103; RAMACHANDRA S, 1990, J PATHOL, V161, P7, DOI 10.1002/path.1711610104; ROGERS LW, 1989, DIAGNOSTIC HISTOPATH; RUSSO J, 1990, LAB INVEST, V62, P244; SCHWAB M, 1985, NATURE, V315, P345, DOI 10.1038/315345a0; SESHADRI R, 1989, INT J CANCER, V43, P270, DOI 10.1002/ijc.2910430218; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1989, INT J CANCER, V43, P270; TANDON AK, 1989, J CLIN ONCOL, V7, P1120, DOI 10.1200/JCO.1989.7.8.1120; THOR AD, 1989, CANCER RES, V49, P7147; TSUDA H, 1990, CANCER, V65, P1794, DOI 10.1002/1097-0142(19900415)65:8<1794::AID-CNCR2820650821>3.0.CO;2-Y; TSUDA H, 1989, CANCER RES, V49, P3104; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902	24	193	205	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1992	7	5					1027	1032						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1349163				2022-12-28	WOS:A1992HP64200026
J	MAZARS, GR; PORTIER, M; ZHANG, XG; JOURDAN, M; BATAILLE, R; THEILLET, C; KLEIN, B				MAZARS, GR; PORTIER, M; ZHANG, XG; JOURDAN, M; BATAILLE, R; THEILLET, C; KLEIN, B			MUTATIONS OF THE P53 GENE IN HUMAN MYELOMA CELL-LINES	ONCOGENE			English	Note							MULTIPLE-MYELOMA; GROWTH; INTERLEUKIN-6; EVOLUTION; LEUKEMIA; PROTEIN	Mutations affecting the p53 gene have been found associated with many human malignancies, but little is as yet known about multile myeloma. We investigated p53 gene alterations in 10 human myeloma cell lines (HMCL), half of these being dependent upon exogenous interleukin 6(IL-6) for in vitro growth, similar to freshly explanted myeloma cells. Using a polymerase chain reaction - single-strand conformation polymorphism (PCR-SSCP) approach, eight of the 10 HMCL were found to bear a mutated p53 gene. All the mutations were single base substitutions with a predominance of G:C to A:T transitions. There was no apparent relation between the presence of a mutation and IL-6 requirement of the cell line. Interestingly, in two cell lines (XG-2 and XG-4) the SSCP pattern showed the presence of both the wild-type and the mutated allele and, upon reverse PCR on RNA, both alleles were found to be concomitantly expressed at the RNA level. Moreover, three freshly explanted tumor samples had the same p53 gene status (mutated versus wild type) as the HMCL that were derived from them. These results show that p53 mutations are frequent in HMCL. Although no apparent relation could be evidenced with the loss of exogenous IL-6 requirement, it may prove interesting to investigate further potential relations between the presence of a mutated p53 allele and gradual autonomy for cell growth.	INSERM,U291,99 RUE PUECH VILLA,F-34100 MONTPELLIER,FRANCE; UNIV MONTPELLIER 2,GENET MOLEC LAB,CNRS,UA 1191,F-34094 MONTPELLIER 5,FRANCE; HOP ST ELOI,CTR GUI DE CHAULIAC,CONSULAT IMMUNORHUMATOL,F-34059 MONTPELLIER,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Universite de Montpellier; CHU de Montpellier			Theillet, Charles/O-7634-2018	Theillet, Charles/0000-0001-5555-2759				AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; DURIE BGM, 1985, BLOOD, V66, P548; ELIYAHU D, 1988, ONCOGENE, V3, P313; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; HAMILTON MS, 1990, BRIT J HAEMATOL, V75, P378, DOI 10.1111/j.1365-2141.1990.tb04352.x; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JACKSON N, 1989, CLIN EXP IMMUNOL, V75, P93; JOURDAN M, 1991, J IMMUNOL, V147, P4402; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; Klein B, 1990, Eur Cytokine Netw, V1, P193; KLEIN B, 1989, BLOOD, V73, P517; KLEIN B, 1991, BLOOD, V78, P1198; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MOORE GE, 1968, NEW YORK STATE J MED, V68, P2054; NILSSON K, 1970, CLIN EXP IMMUNOL, V7, P447; PALUMBO AP, 1989, CANCER RES, V49, P4701; PORTIER M, 1991, EUR J IMMUNOL, V21, P1759, DOI 10.1002/eji.1830210727; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; Sambrook J., 1989, MOL CLONING; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SLINGERLAND JM, 1991, BLOOD, V77, P1500; SNATHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605; SOUSSI T, 1990, ONCOGENE, V5, P945; SUGIMOTO K, 1991, BLOOD, V77, P1153; TAKAHASHI T, 1990, J CLIN INVEST, V86, P363, DOI 10.1172/JCI114710; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHANG XG, 1989, BLOOD, V74, P11	30	97	98	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1992	7	5					1015	1018						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1373872				2022-12-28	WOS:A1992HP64200024
J	Geromella, MS; Ryan, CR; Braun, JL; Finch, MS; Maddalena, LA; Bagshaw, O; Hockey, BL; Moradi, F; Fenech, RK; Ryoo, J; Marko, DM; Dhaliwal, R; Sweezey-Munroe, J; Hamstra, SI; Gardner, G; Silvera, S; Vandenboom, R; Roy, BD; Stuart, JA; MacPherson, REK; Fajardo, VA				Geromella, Mia S.; Ryan, Chantal R.; Braun, Jessica L.; Finch, Michael S.; Maddalena, Lucas A.; Bagshaw, Olivia; Hockey, Briana L.; Moradi, Fereshteh; Fenech, Rachel K.; Ryoo, Jisook; Marko, Daniel M.; Dhaliwal, Roopan; Sweezey-Munroe, Jake; Hamstra, Sophie I.; Gardner, Georgina; Silvera, Sebastian; Vandenboom, Rene; Roy, Brian D.; Stuart, Jeffrey A.; MacPherson, Rebecca E. K.; Fajardo, Val A.			Low-dose lithium supplementation promotes adipose tissue browning and sarco(endo)plasmic reticulum Ca2+ATPase uncoupling in muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; DIET-INDUCED THERMOGENESIS; HIGH-FAT DIET; SKELETAL-MUSCLE; CA2+ TRANSPORT; METABOLIC-RATE; SARCOLIPIN; CALCINEURIN; CA2+-ATPASE; ACTIVATION	Sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA) uncoupling in skeletal muscle and mitochondrial uncoupling via uncoupling protein 1 (UCP1) in brown/beige adipose tissue are two mechanisms implicated in energy expenditure. Here, we investigated the effects of glycogen synthase kinase 3 (GSK3) inhibition via lithium chloride (LiCl) treatment on SERCA uncoupling in skeletal muscle and UCP1 expression in adipose. C2C12 and 3T3-L1 cells treated with LiCl had increased SERCA uncoupling and UCP1 protein levels, respectively, ultimately raising cellular respiration; however, this was only observed when LiCl treatment occurred throughout differentiation. In vivo, LiCl treatment (10 mg/kg/ day) increased food intake in chow-fed diet and high-fat diet (HFD; 60% kcal)-fed male mice without increasing body mass -a result attributed to elevated daily energy expenditure. In soleus muscle, we determined that LiCl treatment promoted SERCA uncoupling via increased expression of SERCA uncouplers, sarcolipin and/or neuronatin, under chow-fed and HFD-fed conditions. We attribute these effects to the GSK3 inhibition observed with LiCl treatment as partial muscle -specific GSK3 knockdown produced similar effects. In adi-pose, LiCl treatment inhibited GSK3 in inguinal white adipose tissue (iWAT) but not in brown adipose tissue under chow-fed conditions, which led to an increase in UCP1 in iWAT and a beiging-like effect with a multilocular phenotype. We did not observe this beiging-like effect and increase in UCP1 in mice fed a HFD, as LiCl could not overcome the ensuing over -activation of GSK3. Nonetheless, our study establishes novel regulatory links between GSK3 and SERCA uncoupling in muscle and GSK3 and UCP1 and beiging in iWAT.	[Geromella, Mia S.; Braun, Jessica L.; Hockey, Briana L.; Ryoo, Jisook; Hamstra, Sophie I.; Silvera, Sebastian; Vandenboom, Rene; Roy, Brian D.; Fajardo, Val A.] Brock Univ, Dept Kinesiol, St Catharines, ON, Canada; [Geromella, Mia S.; Braun, Jessica L.; Hockey, Briana L.; Ryoo, Jisook; Hamstra, Sophie I.; Silvera, Sebastian; Vandenboom, Rene; Roy, Brian D.; Fajardo, Val A.] Brock Univ, Ctr Bone & Muscle Hlth, St Catharines, ON, Canada; [Ryan, Chantal R.; Finch, Michael S.; Fenech, Rachel K.; Marko, Daniel M.; Dhaliwal, Roopan; Sweezey-Munroe, Jake; MacPherson, Rebecca E. K.] Brock Univ, Dept Hlth Sci, St Catharines, ON, Canada; [Maddalena, Lucas A.; Bagshaw, Olivia; Moradi, Fereshteh; Gardner, Georgina; Stuart, Jeffrey A.] Brock Univ, Dept Biol Sci, St Catharines, ON, Canada	Brock University; Brock University; Brock University; Brock University	Fajardo, VA (corresponding author), Brock Univ, Dept Kinesiol, St Catharines, ON, Canada.; Fajardo, VA (corresponding author), Brock Univ, Ctr Bone & Muscle Hlth, St Catharines, ON, Canada.; MacPherson, REK (corresponding author), Brock Univ, Dept Hlth Sci, St Catharines, ON, Canada.	rmacpherson@brocku.ca; vfajardo@brocku.ca		Hockey, Briana/0000-0002-6764-0120; Braun, Jessica/0000-0002-9196-0757; Finch, Michael/0000-0002-6902-5885	Natural Sciences and Engineering Research Council of Canada (NSERC); Alzheimer's Society of Brant; Alzheimer's Society of Haldimand Norfolk; Alzheimer's Society of Hamilton Halton; Canada Research Chair Tier II in Tissue Plasticity and Remodeling; OGS; NSERC CGS-M; Canadian Institutes of Health Research CGS-M	Natural Sciences and Engineering Research Council of Canada (NSERC)(Natural Sciences and Engineering Research Council of Canada (NSERC)); Alzheimer's Society of Brant; Alzheimer's Society of Haldimand Norfolk; Alzheimer's Society of Hamilton Halton; Canada Research Chair Tier II in Tissue Plasticity and Remodeling; OGS(Ontario Graduate Scholarship); NSERC CGS-M(Natural Sciences and Engineering Research Council of Canada (NSERC)); Canadian Institutes of Health Research CGS-M(Canadian Institutes of Health Research (CIHR))	This study was supported by the Natural Sciences and Engineering Research Council of Canada (NSERC) discovery grant to V. A. F. and R. E. K. M. as well as an Alzheimer's Society of Brant, Haldimand Norfolk, Hamilton Halton grant to R. E. K. M. and V. A. F. is supported by a Canada Research Chair Tier II in Tissue Plasticity and Remodeling. C. R. R. is supported by OGS. S. I. H. is supported by an NSERC CGS-M. J. L. B. is supported by a Canadian Institutes of Health Research CGS-M. D. M. M. is supported by an NSERC CGS-M. M. S. F. is supported by OGS and NSERC CGS-M.	Bal NC, 2012, NAT MED, V18, P1575, DOI 10.1038/nm.2897; Berchtold MW, 2000, PHYSIOL REV, V80, P1215, DOI 10.1152/physrev.2000.80.3.1215; Beurel E, 2015, PHARMACOL THERAPEUT, V148, P114, DOI 10.1016/j.pharmthera.2014.11.016; Bombardier E, 2013, FASEB J, V27, P3871, DOI 10.1096/fj.13-230631; Bombardier E, 2013, FEBS LETT, V587, P1687, DOI 10.1016/j.febslet.2013.04.019; Braun JL, 2021, FEBS LETT, V595, P2756, DOI 10.1002/1873-3468.14213; Braun JL, 2020, FASEB BIOADV, V2, P579, DOI 10.1096/fba.2020-00052; Choi SE, 2010, VASC PHARMACOL, V53, P264, DOI 10.1016/j.vph.2010.09.004; Davis J, 2018, NEPHROLOGY, V23, P897, DOI 10.1111/nep.13263; Fajardo VA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084304; Fajardo VA, 2018, J ALZHEIMERS DIS, V61, P425, DOI 10.3233/JAD-170744; Fajardo VA, 2015, CHEM PHYS LIPIDS, V187, P56, DOI 10.1016/j.chemphyslip.2015.03.001; Feldmann HM, 2009, CELL METAB, V9, P203, DOI 10.1016/j.cmet.2008.12.014; da Costa DCF, 2009, AM J PHYSIOL-REG I, V297, pR1460, DOI 10.1152/ajpregu.90993.2008; Freland L, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00014; Gamu D, 2020, APPL PHYSIOL NUTR ME, V45, P1, DOI 10.1139/apnm-2019-0067; Gamu D, 2019, AM J PHYSIOL-ENDOC M, V316, pE432, DOI 10.1152/ajpendo.00288.2018; Hamstra SI, 2020, AM J PHYSIOL-CELL PH, V319, pC694, DOI 10.1152/ajpcell.00318.2020; Hamstra SI, 2020, EXP PHYSIOL, V105, P666, DOI 10.1113/EP088061; Ikeda K, 2017, NAT MED, V23, P1454, DOI 10.1038/nm.4429; Jain SS, 2014, DIABETES, V63, P1907, DOI 10.2337/db13-0816; Jakobsson E, 2017, J MEMBRANE BIOL, V250, P587, DOI 10.1007/s00232-017-9998-2; Jiang LQ, 2010, AM J PHYSIOL-ENDOC M, V298, pE8, DOI 10.1152/ajpendo.00403.2009; Kurgan N, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111340; Kurgan N, 2019, BIOCHEM BIOPH RES CO, V511, P394, DOI 10.1016/j.bbrc.2019.02.066; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; MacLennan DH, 2011, BBA-MOL CELL RES, V1813, P948, DOI 10.1016/j.bbamcr.2010.11.009; Maddalena LA, 2017, BBA-BIOENERGETICS, V1858, P73, DOI 10.1016/j.bbabio.2016.11.005; Mangge H, 2019, FRONT NUTR, V6, DOI 10.3389/fnut.2019.00076; Markussen LK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21795-y; Maurya SK, 2015, J BIOL CHEM, V290, P10840, DOI 10.1074/jbc.M115.636878; Mirzoev TM, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22105081; Pearce NJ, 2004, METABOLISM, V53, P1322, DOI 10.1016/j.metabol.2004.05.008; PESELOW ED, 1980, J AFFECT DISORDERS, V2, P303, DOI 10.1016/0165-0327(80)90031-2; Robb EL, 2017, BIOCHEM BIOPH RES CO, V485, P249, DOI 10.1016/j.bbrc.2017.02.102; Rotter D, 2018, EMBO REP, V19, DOI 10.15252/embr.201744706; Rowland LA, 2016, OBESITY, V24, P1430, DOI 10.1002/oby.21542; Ryder JW, 2003, J BIOL CHEM, V278, P44298, DOI 10.1074/jbc.M304510200; Sehgal P, 2016, METHODS MOL BIOL, V1377, P157, DOI 10.1007/978-1-4939-3179-8_15; Shen TS, 2007, J PHYSIOL-LONDON, V579, P535, DOI 10.1113/jphysiol.2006.120048; Smith IC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068924; Smith WS, 2002, BIOCHEM J, V361, P277, DOI 10.1042/0264-6021:3610277; Theeuwes WF, 2020, BBA-MOL CELL RES, V1867, DOI 10.1016/j.bbamcr.2019.118610; Theeuwes WF, 2018, BBA-MOL BASIS DIS, V1864, P2913, DOI 10.1016/j.bbadis.2018.06.002; Theeuwes WF, 2017, BBA-MOL BASIS DIS, V1863, P3075, DOI 10.1016/j.bbadis.2017.09.018; Toyoshima C, 2004, ANNU REV BIOCHEM, V73, P269, DOI 10.1146/annurev.biochem.73.011303.073700; Valente AJ, 2019, ADV EXP MED BIOL, V1158, P183, DOI 10.1007/978-981-13-8367-0_10; Valente AJ, 2017, ACTA HISTOCHEM, V119, P315, DOI 10.1016/j.acthis.2017.03.001; Verkerke ARP, 2019, NAT METAB, V1, P876, DOI 10.1038/s42255-019-0111-2; Whitley KC, 2020, PHYSIOL REP, V8, DOI 10.14814/phy2.14517	50	0	0	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV	2022	298	11							102568	10.1016/j.jbc.2022.102568	http://dx.doi.org/10.1016/j.jbc.2022.102568			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	6W5WW	36209826	gold, Green Published			2022-12-28	WOS:000895801300008
J	Jiang, Y; Wang, T; Sheng, DD; Han, CQ; Xu, T; Zhang, P; You, WY; Fan, WW; Zhang, ZY; Jin, TC; Duan, XT; Yuan, X; Liu, X; Zhang, KG; Ruan, K; Shi, J; Guo, J; Cheng, AX; Yang, ZY				Jiang, Ya; Wang, Ting; Sheng, Dandan; Han, Chaoqiang; Xu, Tian; Zhang, Peng; You, Weiyi; Fan, Weiwei; Zhang, Zhiyong; Jin, Tengchuan; Duan, Xiaotao; Yuan, Xiao; Liu, Xing; Zhang, Kaiguang; Ruan, Ke; Shi, Jue; Guo, Jing; Cheng, Aoxing; Yang, Zhenye			Aurora A-mediated pyruvate kinase M2 phosphorylation promotes biosynthesis with glycolytic metabolites and tumor cell cycle progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER METABOLISM; PKM2; SERINE; HALLMARKS; GENE	Cancer cells have distinctive demands for intermediates from glucose metabolism for biosynthesis and energy in different cell cycle phases. However, how cell cycle regulators and glycolytic enzymes coordinate to orchestrate the essential metabolic processes are still poorly characterized. Here, we report a novel interaction between the mitotic kinase, Aurora A, and the glycolytic enzyme, pyruvate kinase M2 (PKM2), in the interphase of the cell cycle. We found Aurora A-mediated phosphorylation of PKM2 at threonine 45. This phosphoryla-tion significantly attenuated PKM2 enzymatic activity by reducing its tetramerization and also promoted glycolytic flux and the branching anabolic pathways. Replacing the endoge-nous PKM2 with a nonphosphorylated PKM2 T45A mutant inhibited glycolysis, glycolytic branching pathways, and tumor growth in both in vitro and in vivo models. Together, our study revealed a new protumor function of Aurora A through modulating a rate-limiting glycolytic enzyme, PKM2, mainly during the S phase of the cell cycle. Our findings also showed that although both Aurora A and Aurora B kinase phosphor-ylate PKM2 at the same residue, the spatial and temporal regulations of the specific kinase and PKM2 interaction are context dependent, indicating intricate interconnectivity be-tween cell cycle and glycolytic regulators.	[Jiang, Ya; Han, Chaoqiang; Jin, Tengchuan; Zhang, Kaiguang; Guo, Jing; Cheng, Aoxing; Yang, Zhenye] Univ Sci & Technol China, Anhui Prov Hosp, Dept Digest Dis, Affiliated Hosp 1, Hefei, Peoples R China; [Jiang, Ya; Wang, Ting; Sheng, Dandan; Xu, Tian; Zhang, Peng; You, Weiyi; Fan, Weiwei; Zhang, Zhiyong; Yuan, Xiao; Liu, Xing; Ruan, Ke; Yang, Zhenye] Univ Sci & Technol China, MOE Key Lab Cellular Dynam, Hefei, Peoples R China; [Duan, Xiaotao] Beijing Inst Pharmacol & Toxicol, State Key Lab Toxicol & Med Countermeasures, Beijing, Peoples R China; [Yuan, Xiao; Liu, Xing] Anhui Key Lab Cellular Dynam & Chem Biol, Hefei, Anhui, Peoples R China; [Yuan, Xiao; Liu, Xing] CAS Ctr Excellence Mol Cell Sci, Hefei, Anhui, Peoples R China; [Shi, Jue] Hong Kong Baptist Univ, Ctr Quantitat Syst Biol, Dept Phys, Hong Kong, Peoples R China; [Shi, Jue] Hong Kong Baptist Univ, Ctr Quantitat Syst Biol, Dept Biol, Hong Kong, Peoples R China; [Yang, Zhenye] Univ Sci & Technol China, Biomed Sci & Hlth Lab Anhui Prov, Hefei, Peoples R China	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Academy of Military Medical Sciences - China; Hong Kong Baptist University; Hong Kong Baptist University; Chinese Academy of Sciences; University of Science & Technology of China, CAS	Cheng, AX; Yang, ZY (corresponding author), Univ Sci & Technol China, Anhui Prov Hosp, Dept Digest Dis, Affiliated Hosp 1, Hefei, Peoples R China.; Yang, ZY (corresponding author), Univ Sci & Technol China, MOE Key Lab Cellular Dynam, Hefei, Peoples R China.; Yang, ZY (corresponding author), Univ Sci & Technol China, Biomed Sci & Hlth Lab Anhui Prov, Hefei, Peoples R China.	chengax@mail.ustc.edu.cn; zhenye@ustc.edu.cn		Cheng, Aoxing/0000-0001-9143-2199	National Science Foundation of China [92057104, 31970670, 32170736, 32000528]; Fundamental Research Funds for the Central Universities; Open Project of the CAS Key Laboratory of Innate Immunity and Chronic Disease; "Laboratory for Synthetic Chemistry and Chemical Biology" under the Health@InnoHK Program by the Innovation and Technology Commission of Hong Kong	National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Open Project of the CAS Key Laboratory of Innate Immunity and Chronic Disease; "Laboratory for Synthetic Chemistry and Chemical Biology" under the Health@InnoHK Program by the Innovation and Technology Commission of Hong Kong	This work was National Science Foundation of China (92057104 to Z. Y., 31970670 and 32170736 to J. G., and 32000528 to A. C.); the Fundamental Research Funds for the Central Universities to A. C. and Z. Y. This work was also supported in part by the Open Project of the CAS Key Laboratory of Innate Immunity and Chronic Disease to Z. Y. J. S. is partly supported by the "Laboratory for Synthetic Chemistry and Chemical Biology" under the Health@InnoHK Program by the Innovation and Technology Commission of Hong Kong.	Alam Muhammad S, 2018, Curr Protoc Immunol, V123, pe58, DOI 10.1002/cpim.58; Almeida A, 2010, P NATL ACAD SCI USA, V107, P738, DOI 10.1073/pnas.0913668107; Amelio I, 2014, TRENDS BIOCHEM SCI, V39, P191, DOI 10.1016/j.tibs.2014.02.004; Bertolin G, 2018, ELIFE, V7, DOI 10.7554/eLife.38111; Briassouli P, 2007, CANCER RES, V67, P1689, DOI 10.1158/0008-5472.CAN-06-2272; Cheng AX, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13485-8; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Dayton TL, 2016, EMBO REP, V17, P1721, DOI 10.15252/embr.201643300; den Hollander J, 2010, BLOOD, V116, P1498, DOI 10.1182/blood-2009-11-251074; Du RJ, 2021, MOL CANCER, V20, DOI 10.1186/s12943-020-01305-3; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hannak E, 2001, J CELL BIOL, V155, P1109, DOI 10.1083/jcb.200108051; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Icard P, 2019, TRENDS BIOCHEM SCI, V44, P490, DOI 10.1016/j.tibs.2018.12.007; Ishrat I, 2022, MOL BIOL REP, V49, P1, DOI 10.1007/s11033-021-06693-3; Jiang P, 2011, NAT CELL BIOL, V13, P310, DOI 10.1038/ncb2172; Jiang YH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6566; Jiang YH, 2014, MOL CELL, V53, P75, DOI 10.1016/j.molcel.2013.11.001; Leal-Esteban LC, 2020, BBA-MOL BASIS DIS, V1866, DOI 10.1016/j.bbadis.2020.165715; Liang J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12431; Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001; Lv L, 2013, MOL CELL, V52, P340, DOI 10.1016/j.molcel.2013.09.004; Nikonova AS, 2013, CELL MOL LIFE SCI, V70, P661, DOI 10.1007/s00018-012-1073-7; NOGUCHI T, 1986, J BIOL CHEM, V261, P3807; Olson KA, 2016, TRENDS BIOCHEM SCI, V41, P219, DOI 10.1016/j.tibs.2016.01.002; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; Salazar-Roa M, 2017, TRENDS CELL BIOL, V27, P69, DOI 10.1016/j.tcb.2016.08.009; Sun LC, 2015, CELL RES, V25, P429, DOI 10.1038/cr.2015.33; Tian SY, 2019, LIFE SCI ALLIANCE, V2, DOI 10.26508/lsa.201900413; Wang HZ, 2017, NATURE, V546, P426, DOI 10.1038/nature22797; Yalcin A, 2009, J BIOL CHEM, V284, P24223, DOI 10.1074/jbc.M109.016816; Yan M, 2016, MED RES REV, V36, P1036, DOI 10.1002/med.21399; Yang M, 2016, NAT REV CANCER, V16, P650, DOI 10.1038/nrc.2016.81; Yang WW, 2013, CELL CYCLE, V12, P3154, DOI 10.4161/cc.26182; Yang WW, 2012, CELL, V150, P685, DOI 10.1016/j.cell.2012.07.018; Ye JB, 2012, P NATL ACAD SCI USA, V109, P6904, DOI 10.1073/pnas.1204176109; Yu FZ, 2017, CELL DISCOV, V3, DOI 10.1038/celldisc.2016.49; Zhang JJ, 2021, NAT METAB, V3, P859, DOI 10.1038/s42255-021-00405-8; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	39	0	0	1	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV	2022	298	11							102561	10.1016/j.jbc.2022.102561	http://dx.doi.org/10.1016/j.jbc.2022.102561			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	6G4BI	36198360	gold, Green Published			2022-12-28	WOS:000884698500009
J	Rocco-Machado, N; Lai, L; Kim, G; He, Y; Luczak, ED; Anderson, ME; Levine, RL				Rocco-Machado, Nathalia; Lai, Lo; Kim, Geumsoo; He, Yi; Luczak, Elizabeth D.; Anderson, Mark E.; Levine, Rodney L.			Oxidative stress-induced autonomous activation of the calcium/calmodulin-dependent kinase II involves disulfide formation in the regulatory domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; INDEPENDENT ACTIVATION; METHIONINE RESIDUES; CELL-DEATH; CAMKII; CALMODULIN; AUTOPHOSPHORYLATION; ANTIOXIDANTS; INHIBITION; HISTAMINE	Calcium/calmodulin-dependent protein kinase II 8 (CaMKII8) has a pivotal role in cardiac signaling. Constitutive and deleterious CaMKII "autonomous" activation is induced by oxidative stress, and the previously reported mechanism involves oxidation of methionine residues in the regulatory domain. Here, we demonstrate that covalent oxidation leads to a disulfide bond with Cys273 in the regulatory domain causing autonomous activity. Autonomous activation was induced by treating CaMKII with diamide or histamine chloramine, two thiol-oxidizing agents. Autonomy was reversed when the protein was incubated with DTT or thioredoxin to reduce disulfide bonds. Tryptic mapping of the activated CaMKII revealed formation of a disulfide between Cys273 and Cys290 in the regulatory domain. We determined the apparent pKa of those Cys and found that Cys273 had a low pKa while that of Cys290 was elevated. The low pKa of Cys273 facilitates oxidation of its thiol to the sulfenic acid at physiological pH. The reactive sulfenic acid then attacks the thiol of Cys290 to form the disulfide. The previously reported CaMKII mutant in which methionine residues 281 and 282 were mutated to valine (MMVV) protects mice and flies from cardiac decompensation induced by oxidative stress. Our initial hypothesis was that the MMVV mutant underwent a conformational change that prevented disulfide formation and autonomous activation. However, we found that the thiol-oxidizing agents induced autonomy in the MMVV mutant nistic details of CaMKII autonomous activation.	[Rocco-Machado, Nathalia; Lai, Lo; Kim, Geumsoo; Levine, Rodney L.] NHLBI, Lab Biochem, Bethesda, MD 20892 USA; [He, Yi] NHLBI, Fermentat Facil, NIH, Bethesda, MD USA; [Luczak, Elizabeth D.; Anderson, Mark E.] Johns Hopkins Univ, Dept Med, Div Cardiol, Baltimore, MD USA; [Anderson, Mark E.] Johns Hopkins Univ, Dept Physiol, Sch Med, Baltimore, MD USA; [Anderson, Mark E.] Johns Hopkins Univ, Program Cellular & Mol Med, Sch Med, Baltimore, MD USA; [Anderson, Mark E.] Johns Hopkins Univ Sch Med, Program Cellular & Mol Med, Sch Med, Baltimore, MD USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Levine, RL (corresponding author), NHLBI, Lab Biochem, Bethesda, MD 20892 USA.	rlevine@nih.gov		Luczak, Elizabeth/0000-0002-7753-089X	National Institutes of Health NHLBI Intramural Research Program grant [ZIA HL000225]; NIH [R35 HL140034]	National Institutes of Health NHLBI Intramural Research Program grant; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by the National Institutes of Health NHLBI Intramural Research Program grant ZIA HL000225 to R. L. L. and by NIH grant R35 HL140034 to M. E. A. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	APFFEL A, 1995, J CHROMATOGR A, V712, P177, DOI 10.1016/0021-9673(95)00175-M; Aricescu AR, 2006, EMBO J, V25, P701, DOI 10.1038/sj.emboj.7600974; Backs J, 2009, P NATL ACAD SCI USA, V106, P2342, DOI 10.1073/pnas.0813013106; Bussey CT, 2018, CURR OPIN PHYSIOL, V1, P52, DOI 10.1016/j.cophys.2017.07.003; Chaanine AH, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221910579; Chang AHK, 2011, J BIOL CHEM, V286, P23698, DOI 10.1074/jbc.M110.216788; Chen WJ, 2019, J MOL CELL CARDIOL, V135, P67, DOI 10.1016/j.yjmcc.2019.08.006; Duran J, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.644630; Ebenebe OV, 2018, HEART LUNG CIRC, V27, P560, DOI 10.1016/j.hlc.2017.12.003; Erickson JR, 2008, CELL, V133, P462, DOI 10.1016/j.cell.2008.02.048; Erickson JR, 2015, J BIOL CHEM, V290, P25646, DOI 10.1074/jbc.M115.650234; Erickson JR, 2013, NATURE, V502, P372, DOI 10.1038/nature12537; Feng N, 2017, J MOL CELL CARDIOL, V103, P102, DOI 10.1016/j.yjmcc.2016.12.007; GRASSETTI DR, 1967, ARCH BIOCHEM BIOPHYS, V119, P41, DOI 10.1016/0003-9861(67)90426-2; Grohmann C, 2022, MOL MICROBIOL, V117, P670, DOI 10.1111/mmi.14849; Hart PC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7053; He BJ, 2011, NAT MED, V17, P1610, DOI 10.1038/nm.2506; Hoffman L, 2011, EMBO J, V30, P1251, DOI 10.1038/emboj.2011.40; Howe CJ, 2004, J BIOL CHEM, V279, P44573, DOI 10.1074/jbc.M404175200; Hudmon A, 2002, ANNU REV BIOCHEM, V71, P473, DOI 10.1146/annurev.biochem.71.110601.135410; KELLY PT, 1988, P NATL ACAD SCI USA, V85, P4991, DOI 10.1073/pnas.85.14.4991; Klont F, 2018, ANAL CHEM, V90, P5405, DOI 10.1021/acs.analchem.8b00600; Konstantinidis K, 2020, J CLIN INVEST, V130, P4663, DOI 10.1172/JCI133181; LAI Y, 1987, P NATL ACAD SCI USA, V84, P5710, DOI 10.1073/pnas.84.16.5710; Levine RL, 1996, P NATL ACAD SCI USA, V93, P15036, DOI 10.1073/pnas.93.26.15036; Levine RL, 2006, RAPID COMMUN MASS SP, V20, P1828, DOI 10.1002/rcm.2519; Lu CS, 2003, NEURON, V40, P1185, DOI 10.1016/S0896-6273(03)00786-4; Luczak ED, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18165-6; Luczak ED, 2014, J MOL CELL CARDIOL, V73, P112, DOI 10.1016/j.yjmcc.2014.02.004; Maier LS, 2007, CARDIOVASC RES, V73, P631, DOI 10.1016/j.cardiores.2006.11.005; Mesubi OO, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI95747; Nabet B, 2018, NAT CHEM BIOL, V14, P431, DOI 10.1038/s41589-018-0021-8; PATTON BL, 1990, J BIOL CHEM, V265, P11204; Peskin AV, 2003, FREE RADICAL BIO MED, V35, P1252, DOI 10.1016/S0891-5849(03)00502-1; Purohit A, 2013, CIRCULATION, V128, P1748, DOI 10.1161/CIRCULATIONAHA.113.003313; Qu JJ, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.90139; Regino CAS, 2007, INORG CHIM ACTA, V360, P3971, DOI 10.1016/j.ica.2007.05.020; Rellos P, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000426; Saadatmand AR, 2019, P NATL ACAD SCI USA, V116, P22282, DOI 10.1073/pnas.1816521116; Sanders PN, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006135; Stratton M, 2014, ELIFE, V3, DOI 10.7554/eLife.01610; Suetomi T, 2018, CIRCULATION, V138, P2530, DOI 10.1161/CIRCULATIONAHA.118.034621; Swaminathan PD, 2011, J CLIN INVEST, V121, P3277, DOI 10.1172/JCI57833; Valley CC, 2012, J BIOL CHEM, V287, P34979, DOI 10.1074/jbc.M112.374504; Wang QCA, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23549-3; Wang QL, 2018, CIRC-ARRHYTHMIA ELEC, V11, DOI 10.1161/CIRCEP.117.005682; Westenbrink BD, 2015, CIRC RES, V116, pE28, DOI 10.1161/CIRCRESAHA.116.304682; Willeford A, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.97054; WRIGHT CD, 1989, BIOCHEM BIOPH RES CO, V165, P1018, DOI 10.1016/0006-291X(89)92704-6; Yang YB, 2006, AM J PHYSIOL-HEART C, V291, pH3065, DOI 10.1152/ajpheart.00353.2006; Yang YJ, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.668129; Yin J, 2004, PHARM RES-DORDR, V21, P2377, DOI 10.1007/s11095-004-7692-4; Zhang T, 2016, NAT MED, V22, P175, DOI 10.1038/nm.4017; Zhang T, 2007, J BIOL CHEM, V282, P35078, DOI 10.1074/jbc.M707083200; Zhao ZH, 2018, FASEB J, V32, P4229, DOI 10.1096/fj.201701516R; Zhu WZ, 2003, J CLIN INVEST, V111, P617, DOI 10.1172/JCI200316326	56	0	0	1	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV	2022	298	11							102579	10.1016/j.jbc.2022.102579	http://dx.doi.org/10.1016/j.jbc.2022.102579			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	6W5WW	36220393	gold, Green Published			2022-12-28	WOS:000895801300012
J	KESSLER, DJ; SPICER, DB; LAROSA, FA; SONENSHEIN, GE				KESSLER, DJ; SPICER, DB; LAROSA, FA; SONENSHEIN, GE			A NOVEL NF-KB ELEMENT WITHIN EXON-1 OF THE MURINE C-MYC GENE	ONCOGENE			English	Article							TUMOR NECROSIS FACTOR; DNA-BINDING SUBUNIT; EXPRESS CHLORAMPHENICOL ACETYLTRANSFERASE; CELLS INDUCES TRANSCRIPTION; FOS PROTO-ONCOGENE; I-KAPPA-B; MAMMALIAN-CELLS; RECOMBINANT GENOMES; NEGATIVE REGULATOR; FACTOR-ALPHA	We have mapped a site within exon 1 of the murine c-myc gene that forms a variety of complexes with nuclear proteins derived from the murine WEHI 231 B-lymphoma cell line in exponential growth that are altered following treatment with phorbol ester, when transcription of this gene is reduced [Levine, R.A., McCormack, J.E., Buckler, A.J. & Sonenshein, G.E. (1986). Mol. Cell Biol., 6, 4112-4116]. This site, located at +440 to +459 bp relative to the Pl promoter, contains an NK-kappaB-like binding element. The sequence of this element, AGGGAATTTTT, is unusual in that the stretch of pyrimidines is entirely T residues. Binding of NF-kappaB protein was demonstrated by oligonucleotide competition, induction of binding upon 70Z/3 pre-B- to B-cell differentiation, response to GTP in the binding reaction, reduction of binding upon addition of IkappaB protein and uv cross-linking analysis. Functional activity of this internal regulatory element (IRE) was demonstrated in transfection assays using chloramphenicol acetyl transferase (CAT) reporter constructs containing multimerized copies of the IRE driving a heterologous promoter. Mutation of the IRE within the context of the c-myc promoter prevented NF-kappaB-mediated induction of transcription of this oncogene. Thus additional NF-kappaB elements may be defined by this new sequence.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,80 E CONCORD ST,BOSTON,MA 02118	Boston University					NATIONAL CANCER INSTITUTE [R01CA036355] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023454] Funding Source: NIH RePORTER; NCI NIH HHS [CA 36355] Funding Source: Medline; NIAID NIH HHS [AI 23454, AI 07309] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; Bencini DA, 1984, BIOTECHNIQUES, V2, P4; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; BOYD AW, 1981, J IMMUNOL, V126, P2466; BUCKLER AJ, 1990, J IMMUNOL, V145, P732; CHANG J, 1991, ONCOGENE, V6, P1979; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DONOGHUE M, 1988, GENE DEV, V2, P1779, DOI 10.1101/gad.2.12b.1779; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; DUYAO MP, 1992, IN PRESS J BIOL CHEM; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAY N, 1989, GENE DEV, V3, P293, DOI 10.1101/gad.3.3.293; HOYOS B, 1989, SCIENCE, V244, P457, DOI 10.1126/science.2497518; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; KESSLER DJ, 1992, IN PRESS J EXP MED; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; LENARDO MJ, 1988, P NATL ACAD SCI USA, V85, P8825, DOI 10.1073/pnas.85.23.8825; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEVINE RA, 1986, MOL CELL BIOL, V6, P4112, DOI 10.1128/MCB.6.11.4112; LIEBER MR, 1987, GENE DEV, V1, P751, DOI 10.1101/gad.1.8.751; LIN JX, 1987, J BIOL CHEM, V262, P11908; LINDSTEN T, 1988, EMBO J, V7, P2787, DOI 10.1002/j.1460-2075.1988.tb03133.x; LOWENTHAL JW, 1989, P NATL ACAD SCI USA, V86, P2331, DOI 10.1073/pnas.86.7.2331; MECHTI N, 1986, NUCLEIC ACIDS RES, V14, P9653, DOI 10.1093/nar/14.24.9653; MIKSICEK R, 1986, CELL, V46, P283, DOI 10.1016/0092-8674(86)90745-2; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PRENDERGAST GC, 1989, NATURE, V341, P392, DOI 10.1038/341392a0; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; TAKIMOTO M, 1989, J BIOL CHEM, V264, P8992; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; ZABEL U, 1991, J BIOL CHEM, V266, P252	42	35	35	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1992	7	12					2447	2453						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1461649				2022-12-28	WOS:A1992KA85600009
J	KUSSICK, SJ; COOPER, JA				KUSSICK, SJ; COOPER, JA			OVEREXPRESSED DROSOPHILA SRC 64B IS PHOSPHORYLATED AT ITS CARBOXY-TERMINAL TYROSINE, BUT IS NOT CATALYTICALLY REPRESSED, IN CULTURED DROSOPHILA CELLS	ONCOGENE			English	Article							EGF RECEPTOR HOMOLOG; EXPRESS HIGH-LEVELS; FAINT-LITTLE-BALL; KINASE-ACTIVITY; PROTEIN-KINASE; C-SRC; PP60C-SRC; GENE; TRANSFORMATION; DOMAIN	Little is known about the regulation of non-receptor tyrosine kinases in invertebrates. We have studied the relationship between the phosphorylation state of the Drosophila src 64B (Dsrc) gene product, p62D, and its tyrosine kinase activity in Drosophila Schneider 2 cells, using wild-type and mutated Dsrc constructs that were overexpressed by transient transfection. Phosphopeptide mapping showed that the putative regulatory C-terminal tyrosine (Tyr-547) of p62D was phosphorylated in vivo. In contrast to vertebrate src family kinases overexpressed in fibroblasts, wild-type p62D overexpressed in Schneider 2 cells was phosphorylated at additional tyrosines outside of the C-terminus. These tyrosines corresponded to the major in vitro autophosphorylation sites. Overexpression of wild-type p62D or several catalytically active p62D mutants significantly increased the phosphorylation of numerous Schneider cell proteins on tyrosine, while expression of catalytically inactive mutants of p62D had no such effect. Thus, in contrast to the repression of src family kinase activity in fibroblasts, p62D is catalytically active when overexpressed in Drosophila cells, perhaps because of substoichiometric C-terminal tyrosine phosphorylation. These results raise the possibility that fly development will be sensitive to ectopic expression of p62D.	UNIV WASHINGTON, SCH MED, DEPT PATHOL, 1124 COLUMBIA ST, SEATTLE, WA 98104 USA; FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA	University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center					NATIONAL CANCER INSTITUTE [R01CA041072, R37CA041072] Funding Source: NIH RePORTER; NCI NIH HHS [CA-41072] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; BAKER NE, 1989, NATURE, V340, P150, DOI 10.1038/340150a0; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; BOULTER CA, 1991, DEVELOPMENT, V111, P357; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CHENG SH, 1991, J VIROL, V65, P170, DOI 10.1128/JVI.65.1.170-179.1991; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1981, MOL CELL BIOL, V1, P165, DOI 10.1128/MCB.1.2.165; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; GLAZER L, 1991, GENE DEV, V5, P697, DOI 10.1101/gad.5.4.697; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HENKEMEYER MJ, 1987, CELL, V51, P821, DOI 10.1016/0092-8674(87)90105-X; HOFFMANN FM, 1983, CELL, V35, P393, DOI 10.1016/0092-8674(83)90172-1; HURLEY TR, 1989, ONCOGENE, V4, P265; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; KORNBLUTH S, 1987, P NATL ACAD SCI USA, V84, P4455, DOI 10.1073/pnas.84.13.4455; KUSSICK SJ, 1991, CELLULAR REGULATIO H, V56, P295; KUSSICK SJ, 1992, IN PRESS ONCOGENE; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MCKEOWN M, 1990, NEW BIOL, V2, P828; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; PETERSEN RB, 1989, CELL REGUL, V1, P135, DOI 10.1091/mbc.1.1.135; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; RIO DC, 1985, MOL CELL BIOL, V5, P1833, DOI 10.1128/MCB.5.8.1833; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SCHUH SM, 1988, MOL CELL BIOL, V8, P2465, DOI 10.1128/MCB.8.6.2465; SHIELDS G, 1977, DROSOPHILA INF SERVI, V52, P161; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; SIMON MA, 1983, NATURE, V302, P837, DOI 10.1038/302837a0; SIMON MA, 1987, THESIS U CALIFORNIA; SMART JE, 1981, P NATL ACAD SCI-BIOL, V78, P6013, DOI 10.1073/pnas.78.10.6013; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SORGE LK, 1984, CELL, V36, P249, DOI 10.1016/0092-8674(84)90218-6; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; WEINMASTER GA, 1988, J VIROL, V62, P2016, DOI 10.1128/JVI.62.6.2016-2025.1988; WIDES RJ, 1990, EUR J BIOCHEM, V189, P637, DOI 10.1111/j.1432-1033.1990.tb15532.x	54	10	10	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1992	7	12					2461	2470						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1281305				2022-12-28	WOS:A1992KA85600011
J	YU, Q; LENARDO, T; WEINBERG, RA				YU, Q; LENARDO, T; WEINBERG, RA			THE N-TERMINAL AND C-TERMINAL DOMAINS OF A RECEPTOR TYROSINE PHOSPHATASE ARE ASSOCIATED BY NONCOVALENT LINKAGE	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; PROTEIN; DROSOPHILA; KINASES; FAMILY	We have cloned the rat homolog of the human leukocyte common antigen-related gene (LAR), which encodes a transmembrane receptor phosphotyrosine phosphatase, and raised antibodies against its protein product. We present evidence here for a processing event resulting in a two-chain structure of the mature receptor on the cell surface. The LAR protein is synthesized as a 190-kDa precursor which is subsequently cleaved into 145-kDa and 85-kDa fragments. The 145-kDa fragment, representing the amino terminus of the protein, is exclusively extracellular and is modified by N-linked glycosylation. The 85-kDa component, derived from the C-terminus of the protein, contains the transmembrane region and intracellular phosphotyrosine phosphatase domains. The two products, associated in a non-covalent manner, comprise the functional LAR cell-surface receptor.	MIT,WHITEHEAD INST BIOMED RES,DEPT BIOL,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT); Whitehead Institute					NCI NIH HHS [CA-39852] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; SCHLESSINGER J, 1988, BIOCHEMISTRY-US, V27, P3119, DOI 10.1021/bi00409a002; SIMON MA, 1989, P NATL ACAD SCI USA, V86, P8333, DOI 10.1073/pnas.86.21.8333; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; STREULI M, 1988, J EXP MED, V168, P1553; TAKATSUKI A, 1975, AGR BIOL CHEM TOKYO, V39, P2089, DOI 10.1080/00021369.1975.10861914; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	16	61	64	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1992	7	6					1051	1057						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1317540				2022-12-28	WOS:A1992HU64200001
J	HOWARD, OMZ; DEAN, M; YOUNG, H; RAMSBURG, M; TURPIN, JA; MICHIEL, DF; KELVIN, DJ; LEE, L; FARRAR, WL				HOWARD, OMZ; DEAN, M; YOUNG, H; RAMSBURG, M; TURPIN, JA; MICHIEL, DF; KELVIN, DJ; LEE, L; FARRAR, WL			CHARACTERIZATION OF A CLASS-3 TYROSINE KINASE	ONCOGENE			English	Article							COLONY-STIMULATING FACTOR; SIGNAL TRANSDUCTION; CATALYTIC DOMAINS; CELL-LINES; EXPRESSION; GENE; IDENTIFICATION; ACTIVATION; SEQUENCE; P56LCK	In an effort to identify unique tyrosine kinases found in human leukemia cell lines, we utilized polymerase chain reaction (PCR) technology and degenerate oligonucleotide primers to produce a cDNA library of kinase catalytic domains found in the human monocytic cell line AML-193. This search yielded a member of the class 3 tyrosine kinases closely related to the murine kinase FD-22. Previous work has identified this kinase as JAK1. This class of tyrosine kinases is characterized by being ubiquitously expressed, lacking both a ligand-binding domain and a SH2 domain, while containing a second domain similar to a degenerate kinase domain. Our studies focused on the further characterization of this class 3 tyrosine kinase using Northern blot analysis to demonstrate an increase in steady-state mRNA by interferon-gamma in human monocytes. A human-hamster somatic cell hybrid panel and linkage mapping was used to assign JAK1 (aml-116) to human chromosome 1.	NCI,FREDERICK CANC RES & DEV CTR,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21701; NCI,FREDERICK CANC RES & DEV CTR,BIOL RESPONSE MODIFIERS PROGRAM,FREDERICK,MD 21701; WALTER REED ARMY MED CTR,DEPT CELLULAR IMMUNOL,WASHINGTON,DC 20307	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; United States Department of Defense; United States Army; Walter Reed National Military Medical Center	HOWARD, OMZ (corresponding author), NCI,PROGRAM RESOURCES INC DYNCORP,FREDERICK CANC RES & DEV CTR,FREDERICK,MD 21701, USA.		Dean, Michael/R-7501-2019; Dean, Michael C/G-8172-2012; Howard, O M Zack/B-6117-2012; Young, Howard/A-6350-2008	Dean, Michael C/0000-0003-2234-0631; Howard, O M Zack/0000-0002-0505-7052; Young, Howard/0000-0002-3118-5111	NCI NIH HHS [N01-CO-74102] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074102] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAUSSET J, 1990, GENOMICS, V6, P575, DOI 10.1016/0888-7543(90)90491-C; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRACOPOLI NC, 1991, GENOMICS, V9, P686, DOI 10.1016/0888-7543(91)90362-I; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; FISCHER T, 1990, J IMMUNOL, V145, P2914; GOLDBERG M, 1990, J CLIN INVEST, V85, P563, DOI 10.1172/JCI114473; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HART PH, 1991, BLOOD, V77, P841; HOWARD OMZ, 1987, BIOCHEMISTRY-US, V26, P3565, DOI 10.1021/bi00386a047; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; KALTER DC, 1991, J IMMUNOL, V146, P298; KROLEWSKI JJ, 1990, ONCOGENE, V5, P277; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; LANGE B, 1987, BLOOD, V70, P192; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LINNEKIN D, 1990, BIOCHEM J, V271, P317, DOI 10.1042/bj2710317; Maniatis T., 1982, MOL CLONING; MITELMAN F, 1990, CYTOGENET CELL GENET, V55, P358, DOI 10.1159/000133022; PAWSON T, 1988, ONCOGENE, V3, P491; THOMASSEN MJ, 1991, CANCER RES, V51, P857; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237; YI TL, 1989, ONCOGENE, V4, P1081; ZIEGLER SF, 1988, J EXP MED, V168, P1801, DOI 10.1084/jem.168.5.1801	28	14	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1992	7	5					895	900						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1373877				2022-12-28	WOS:A1992HP64200008
J	TONG, JH; DONG, S; GENG, JP; HUANG, W; WANG, ZY; SUN, GL; CHEN, SJ; CHEN, Z; LARSEN, CJ; BERGER, R				TONG, JH; DONG, S; GENG, JP; HUANG, W; WANG, ZY; SUN, GL; CHEN, SJ; CHEN, Z; LARSEN, CJ; BERGER, R			MOLECULAR-REARRANGEMENTS OF THE MYL GENE IN ACUTE PROMYELOCYTIC LEUKEMIA (APL, M3) DEFINE A BREAKPOINT CLUSTER REGION AS WELL AS SOME MOLECULAR VARIANTS	ONCOGENE			English	Article							TRANS RETINOIC ACID; RECEPTOR-ALPHA GENE; CHROMOSOME-TRANSLOCATION; PRE-B; DIFFERENTIATION	Genomic DNA probes generated from the retinoic acid receptor alpha (RARA) gene located on chromosome 17 and from the MYL gene located on chromosome 15 were used to study the chromosome 15 breakpoints resulting from the t(15; 17) translocation in 26 patients with acute promyelocytic leukemia (APL). In 20 out of 22 patients with a detectable MYL rearrangement, the breakpoints were clustered within a 4.4 kb segment designated MYL(bcr).The two remaining patients exhibited a more 5' rearrangement at about 10 kb upstream of the MYL(bcr) region, implying the lack of at least one MYL gene exon in the resulting MYL-RARA fusion gene. The variation of chromosome breakpoints within the MYL gene may explain size heterogeneity previously observed in some MYL-RARA fusion transcripts expressed in APL cells.	SHANGHAI MED UNIV 2,SHANGHAI RUI JIN HOSP,SHANGHAI INST HEMATOL,MOLEC BIOL LAB,SHANGHAI 200025,PEOPLES R CHINA; INST GENET MOLEC,CNRS,INSERM,U301,F-75010 PARIS,FRANCE; INST GENET MOLEC,CNRS,SDI 15954 1,F-75010 PARIS,FRANCE	Shanghai Jiao Tong University; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS)								ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; BIONDI A, 1991, BLOOD, V77, P1418; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BRAND NJ, 1990, NUCLEIC ACIDS RES, V18, P6799, DOI 10.1093/nar/18.23.6799; BREITMAN TR, 1981, BLOOD, V57, P1000; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHANG KS, 1991, LEUKEMIA, V5, P200; CHEN SJ, 1989, NUCLEIC ACIDS RES, V17, P7631, DOI 10.1093/nar/17.19.7631; CHEN Z, 1991, LEUKEMIA, V5, P288; CHOMIENNE C, 1990, BLOOD, V76, P1710; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LONGO L, 1990, J EXP MED, V172, P1571, DOI 10.1084/jem.172.6.1571; Maniatis T., 1982, MOL CLONING; MELLENTIN JD, 1990, GENE CHROMOSOME CANC, V2, P239, DOI 10.1002/gcc.2870020313; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; VONLINDERN M, 1990, MOL CELL BIOL, V10, P4016, DOI 10.1128/MCB.10.8.4016; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002	24	51	56	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1992	7	2					311	316						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1312695				2022-12-28	WOS:A1992HG98200016
J	Kendall, AK; Chandra, M; Xie, BY; Wan, W; Jackson, LP				Kendall, Amy K.; Chandra, Mintu; Xie, Boyang; Wan, William; Jackson, Lauren P.			Improved mammalian retromer cryo-EM structures reveal a new interface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARGO-RECOGNITION; COAT COMPLEX; TRANSPORT; FOLD; ARCHITECTURE; MOLPROBITY; ENDOSOMES; MECHANISM; PROTEINS; DOMAINS	Retromer (VPS26/VPS35/VPS29 subunits) assembles with multiple sorting nexin proteins on membranes to mediate endosomal recycling of transmembrane protein cargoes. Ret-romer has been implicated in other cellular processes, including mitochondrial homeostasis, nutrient sensing, auto-phagy, and fission events. Mechanisms for mammalian retro-mer assembly remain undefined, and retromer engages multiple sorting nexin proteins to sort cargoes to different destinations. Published structures demonstrate mammalian retromer forms oligomers in vitro, but several structures were poorly resolved. We report here improved retromer oligomer structures using single-particle cryo-EM by combining data collected from tilted specimens with multiple advancements in data processing, including using a 3D starting model for enhanced automated particle picking in RELION. We used a retromer mutant (3KE retromer) that breaks VPS35-mediated interfaces to determine a structure of a new assembly interface formed by the VPS26A and VPS35 N-termini. The inter-face reveals how an N-terminal VPS26A arrestin saddle can link retromer chains by engaging a neighboring VPS35 N-terminus, on the opposite side from the well-characterized C-VPS26/N-VPS35 interaction observed within heterotrimers. The new interaction interface exhibits substantial buried surface area (similar to 7000 angstrom(2)) and further suggests that metazoan retromer may serve as an adaptable scaffold.	[Kendall, Amy K.; Chandra, Mintu; Xie, Boyang; Jackson, Lauren P.] Vanderbilt Univ, Dept Biol Sci, Nashville, TN 37235 USA; [Kendall, Amy K.; Chandra, Mintu; Wan, William; Jackson, Lauren P.] Vanderbilt Univ, Ctr Struct Biol, Nashville, TN 37235 USA; [Wan, William; Jackson, Lauren P.] Vanderbilt Univ, Dept Biochem, Nashville, TN 37235 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Jackson, LP (corresponding author), Vanderbilt Univ, Dept Biol Sci, Nashville, TN 37235 USA.; Jackson, LP (corresponding author), Vanderbilt Univ, Ctr Struct Biol, Nashville, TN 37235 USA.; Jackson, LP (corresponding author), Vanderbilt Univ, Dept Biochem, Nashville, TN 37235 USA.	lauren.p.jackson@vanderbilt.edu	Kendall, Amy/F-6780-2013; CHANDRA, MINTU/GLQ-8529-2022	Kendall, Amy/0000-0002-6176-9177; CHANDRA, MINTU/0000-0003-2382-5024; Jackson, Lauren/0000-0002-3705-6126	National Institutes of Health Common Fund Transformative High Resolution Cryo-Electron Microscopy program [U24 GM129539]; Simons Foundation [SF349247]; NY State Assembly	National Institutes of Health Common Fund Transformative High Resolution Cryo-Electron Microscopy program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Simons Foundation; NY State Assembly	We thank Kevin Chen and Brett Collins for generously providing the RT-L4 peptide used in 3KE retromer sample preparation and data collection. Screening was conducted at the Center for Structural Biology Cryo-EM Facility at Vanderbilt University. Data collection was performed at the National Center for CryoEM Access and Training and the Simons Electron Microscopy Center located at the New York Structural Biology Center, supported by the National Institutes of Health Common Fund Transformative High Resolution Cryo-Electron Microscopy program (U24 GM129539) and by grants from the Simons Foundation (SF349247) and NY State Assembly.	Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; Andersen OM, 2005, P NATL ACAD SCI USA, V102, P13461, DOI 10.1073/pnas.0503689102; Arighi CN, 2004, J CELL BIOL, V165, P123, DOI 10.1083/jcb.200312055; Ashkenazy H, 2016, NUCLEIC ACIDS RES, V44, pW344, DOI 10.1093/nar/gkw408; Bean BDM, 2017, TRAFFIC, V18, P110, DOI 10.1111/tra.12459; Braschi E, 2010, CURR BIOL, V20, P1310, DOI 10.1016/j.cub.2010.05.066; Burd C, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016774; Carlton J, 2004, CURR BIOL, V14, P1791, DOI 10.1016/j.cub.2004.09.077; Carragher B, 2000, J STRUCT BIOL, V132, P33, DOI 10.1006/jsbi.2000.4314; Chandra M, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.642378; Chandra M, 2020, BIOCHEM SOC T, V48, P2261, DOI 10.1042/BST20200552; Chen KE, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abg4007; Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073; Choy RWY, 2014, NEURON, V82, P55, DOI 10.1016/j.neuron.2014.02.018; Collins BM, 2005, NAT STRUCT MOL BIOL, V12, P594, DOI 10.1038/nsmb954; Collins BM, 2008, TRAFFIC, V9, P366, DOI 10.1111/j.1600-0854.2007.00688.x; Courtellemont T, 2022, EMBO J, V41, DOI 10.15252/embj.2021109646; Curtis ME, 2020, ANN NEUROL, V88, P137, DOI 10.1002/ana.25752; Daniloski Z, 2021, CELL, V184, P92, DOI 10.1016/j.cell.2020.10.030; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Farmer T, 2019, MOL BIOL CELL, V30, P1138, DOI 10.1091/mbc.E19-01-0044; Farmer T, 2018, TRAFFIC, V19, P569, DOI 10.1111/tra.12573; Filippone A, 2021, ANN NEUROL, V90, P4, DOI 10.1002/ana.26042; Fjorback AW, 2012, J NEUROSCI, V32, P1467, DOI 10.1523/JNEUROSCI.2272-11.2012; Greber BJ, 2021, BIOPHYS J, V120, P677, DOI 10.1016/j.bpj.2020.12.030; Harrison MS, 2014, P NATL ACAD SCI USA, V111, P267, DOI 10.1073/pnas.1316482111; Hesketh GG, 2020, SCIENCE, V370, P351, DOI 10.1126/science.aaz0863; Hierro A, 2007, NATURE, V449, P1063, DOI 10.1038/nature06216; Kendall AK, 2020, STRUCTURE, V28, P393, DOI 10.1016/j.str.2020.01.009; Kovtun O, 2018, NATURE, V561, P561, DOI 10.1038/s41586-018-0526-z; Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022; Kvainickas A, 2019, J CELL BIOL, V218, P3019, DOI 10.1083/jcb.201812110; Kvainickas A, 2017, J CELL BIOL, V216, P3677, DOI 10.1083/jcb.201702137; Lauffer BEL, 2010, J CELL BIOL, V190, P565, DOI 10.1083/jcb.201004060; Lu L, 2014, SEMIN CELL DEV BIOL, V31, P30, DOI 10.1016/j.semcdb.2014.04.024; Lucas M, 2016, CELL, V167, P1623, DOI 10.1016/j.cell.2016.10.056; McNally KE, 2017, NAT CELL BIOL, V19, P1214, DOI 10.1038/ncb3610; McNicholas S, 2011, ACTA CRYSTALLOGR D, V67, P386, DOI 10.1107/S0907444911007281; Mecozzi VJ, 2014, NAT CHEM BIOL, V10, P443, DOI [10.1038/NCHEMBIO.1508, 10.1038/nchembio.1508]; Morris KL, 2019, NAT STRUCT MOL BIOL, V26, P890, DOI 10.1038/s41594-019-0292-0; Norwood SJ, 2011, TRAFFIC, V12, P56, DOI 10.1111/j.1600-0854.2010.01124.x; Nothwehr SF, 2000, J CELL BIOL, V151, P297, DOI 10.1083/jcb.151.2.297; Paraan M, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba8397; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Reitz C, 2011, ANN NEUROL, V69, P47, DOI 10.1002/ana.22308; Romano-Moreno M, 2017, P NATL ACAD SCI USA, V114, pE11151, DOI 10.1073/pnas.1715361115; Roy S, 2017, MOL CELL, V67, P84, DOI 10.1016/j.molcel.2017.05.020; Scheres SHW, 2012, J STRUCT BIOL, V180, P519, DOI 10.1016/j.jsb.2012.09.006; Seaman MNJ, 1998, J CELL BIOL, V142, P665, DOI 10.1083/jcb.142.3.665; Seaman MNJ, 2004, J CELL BIOL, V165, P111, DOI 10.1083/jcb.200312034; Shi H, 2006, NAT STRUCT MOL BIOL, V13, P540, DOI 10.1038/nsmb1103; Simonetti B, 2019, NAT CELL BIOL, V21, P1219, DOI 10.1038/s41556-019-0393-3; Simonetti B, 2018, CURR BIOL, V28, pR1350, DOI 10.1016/j.cub.2018.10.040; Simonetti B, 2017, J CELL BIOL, V216, P3695, DOI 10.1083/jcb.201703015; Small SA, 2005, ANN NEUROL, V58, P909, DOI 10.1002/ana.20667; Steinberg F, 2013, NAT CELL BIOL, V15, P461, DOI 10.1038/ncb2721; Strochlic TI, 2007, J CELL BIOL, V177, P115, DOI 10.1083/jcb.200609161; Sztul E, 2019, MOL BIOL CELL, V30, P1249, DOI 10.1091/mbc.E18-12-0820; Temkin P, 2011, NAT CELL BIOL, V13, P715, DOI 10.1038/ncb2252; Wan W, 2017, NATURE, V551, P394, DOI 10.1038/nature24490; Wang DQ, 2005, J BIOL CHEM, V280, P22962, DOI 10.1074/jbc.M500464200; Wang WY, 1999, BIOTECHNIQUES, V26, P680, DOI 10.2144/99264st03; Williams CJ, 2018, PROTEIN SCI, V27, P293, DOI 10.1002/pro.3330; Yin J, 2016, TRAFFIC, V17, P1286, DOI 10.1111/tra.12451; Zhang K, 2016, J STRUCT BIOL, V193, P1, DOI 10.1016/j.jsb.2015.11.003; Zheng SQ, 2017, NAT METHODS, V14, P331, DOI 10.1038/nmeth.4193; Zimprich A, 2011, AM J HUM GENET, V89, P168, DOI 10.1016/j.ajhg.2011.06.008; Zivanov J, 2018, ELIFE, V7, DOI 10.7554/eLife.42166	69	0	0	1	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV	2022	28	11							102523	10.1016/j.jbc.2022.102523	http://dx.doi.org/10.1016/j.jbc.2022.102523			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	6I4GS	36174678	Green Submitted, Green Published, gold			2022-12-28	WOS:000886086000007
J	Yuan, HW; Zhu, YT; Cheng, YL; Hou, JJ; Jin, FJ; Li, ML; Jia, W; Cheng, ZZ; Xing, HM; Liu, MK; Han, T				Yuan, Hongwei; Zhu, Yutong; Cheng, Yalong; Hou, Junjie; Jin, Fengjiao; Li, Menglin; Jia, Wei; Cheng, Zhenzhen; Xing, Haimei; Liu, Mike; Han, Ting			BTK kinase activity is dispensable for the survival of diffuse large B-cell lymphoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUTONS TYROSINE KINASE; RECEPTOR ENGAGEMENT; OPEN-LABEL; IBRUTINIB; ACTIVATION; MECHANISMS; RESISTANCE; RECOGNITION; RESPONSES; LEUKEMIA	Inhibitors targeting Bruton's tyrosine kinase (BTK) have revolutionized the treatment for various B-cell malignancies but are limited by acquired resistance after prolonged treat-ment as a result of mutations in BTK. Here, by a combination of structural modeling, in vitro assays, and deep phospho-tyrosine proteomics, we demonstrated that four clinically observed BTK mutations-C481F, C481Y, C481R, and L528W -inactivated BTK kinase activity both in vitro and in diffused large B-cell lymphoma (DLBCL) cells. Paradoxically, we found that DLBCL cells harboring kinase-inactive BTK exhibited intact B cell receptor (BCR) signaling, unperturbed transcrip-tion, and optimal cellular growth. Moreover, we determined that DLBCL cells with kinase-inactive BTK remained addicted to BCR signaling and were thus sensitive to targeted BTK degradation by the proteolysis-targeting chimera. By per-forming parallel genome-wide CRISPR-Cas9 screening in DLBCL cells with WT or kinase-inactive BTK, we discovered that DLBCL cells with kinase-inactive BTK displayed increased dependence on Toll-like receptor 9 (TLR9) for their growth and/or survival. Our study demonstrates that the kinase ac-tivity of BTK is not essential for oncogenic BCR signaling and suggests that BTK's noncatalytic function is sufficient to sus-tain the survival of DLBCL.	[Yuan, Hongwei; Zhu, Yutong; Han, Ting] Beijing Normal Univ, Coll Life Sci, Beijing, Peoples R China; [Yuan, Hongwei; Cheng, Yalong; Han, Ting] Natl Inst Biol Sci, Beijing, Peoples R China; [Zhu, Yutong; Cheng, Zhenzhen; Xing, Haimei; Liu, Mike] BeiGene Beijing Co Ltd, Beijing, Peoples R China; [Hou, Junjie; Jin, Fengjiao; Li, Menglin; Jia, Wei] Deepkinase Co Ltd, Beijing, Peoples R China; [Han, Ting] Tsinghua Univ, Tsinghua Inst Multidisciplinary Biomed Res, Beijing, Peoples R China	Beijing Normal University; National Institute of Biological Sciences, Beijing; Tsinghua University	Han, T (corresponding author), Beijing Normal Univ, Coll Life Sci, Beijing, Peoples R China.; Han, T (corresponding author), Natl Inst Biol Sci, Beijing, Peoples R China.; Han, T (corresponding author), Tsinghua Univ, Tsinghua Inst Multidisciplinary Biomed Res, Beijing, Peoples R China.	hanting@nibs.ac.cn			Chinese Ministry of Science and Technology, Beijing Municipal Commission of Science and Tech-nology; Tsinghua Institute of Multidisciplinary Biomedical Research;  [Z201100005320010];  [Z211100003321009]	Chinese Ministry of Science and Technology, Beijing Municipal Commission of Science and Tech-nology; Tsinghua Institute of Multidisciplinary Biomedical Research; ; 	Funding and additional information-This work was supported by institutional grants from the Chinese Ministry of Science and Technology, Beijing Municipal Commission of Science and Tech-nology (Z201100005320010 and Z211100003321009) , and Tsinghua Institute of Multidisciplinary Biomedical Research to T. H. The funders had no role in study design, data collection and interpre-tation, or the decision to submit the work for publication.	Bian YY, 2016, NAT CHEM BIOL, V12, P959, DOI [10.1038/NCHEMBIO.2178, 10.1038/nchembio.2178]; Brinkmann MM, 2007, J CELL BIOL, V177, P265, DOI 10.1083/jcb.200612056; Burger JA, 2015, NEW ENGL J MED, V373, P2425, DOI 10.1056/NEJMoa1509388; Burger JA, 2018, NAT REV CANCER, V18, P148, DOI 10.1038/nrc.2017.121; Davis RE, 2010, NATURE, V463, P88, DOI 10.1038/nature08638; de Rooij MFM, 2012, BLOOD, V119, P2590, DOI 10.1182/blood-2011-11-390989; Dhami K, 2022, SCI SIGNAL, V15, DOI 10.1126/scisignal.abg5216; Dimopoulos MA, 2017, LANCET ONCOL, V18, P241, DOI 10.1016/S1470-2045(16)30632-5; Doench JG, 2016, NAT BIOTECHNOL, V34, P184, DOI 10.1038/nbt.3437; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Doyle SL, 2007, J BIOL CHEM, V282, P36953, DOI 10.1074/jbc.M707682200; Dreyling M, 2016, LANCET, V387, P770, DOI 10.1016/S0140-6736(15)00667-4; Fluckiger AC, 1998, EMBO J, V17, P1973, DOI 10.1093/emboj/17.7.1973; Furman RR, 2014, NEW ENGL J MED, V370, P2352, DOI 10.1056/NEJMc1402716; Guo YH, 2019, J MED CHEM, V62, P7923, DOI 10.1021/acs.jmedchem.9b00687; Hamasy A, 2017, LEUKEMIA, V31, P177, DOI 10.1038/leu.2016.153; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hu X, 2020, BIOORG CHEM, V97, DOI 10.1016/j.bioorg.2020.103695; Hu YG, 2004, NAT GENET, V36, P453, DOI 10.1038/ng1343; Hughes CS, 2019, NAT PROTOC, V14, P68, DOI 10.1038/s41596-018-0082-x; Jiang W, 2015, SCI REP-UK, V5, DOI 10.1038/srep13875; Kim YM, 2008, NATURE, V452, P234, DOI 10.1038/nature06726; Kong AT, 2017, NAT METHODS, V14, P513, DOI [10.1038/NMETH.4256, 10.1038/nmeth.4256]; Krug A, 2004, IMMUNITY, V21, P107, DOI 10.1016/j.immuni.2004.06.007; Krug A, 2004, BLOOD, V103, P1433, DOI 10.1182/blood-2003-08-2674; Kung JE, 2016, STRUCTURE, V24, P7, DOI 10.1016/j.str.2015.10.020; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Latz E, 2004, NAT IMMUNOL, V5, P190, DOI 10.1038/ni1028; Lee KG, 2008, J BIOL CHEM, V283, P11189, DOI 10.1074/jbc.M708516200; Lenz G, 2008, SCIENCE, V319, P1676, DOI 10.1126/science.1153629; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Li W, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0554-4; Liu QH, 2005, J IMMUNOL, V174, P68, DOI 10.4049/jimmunol.174.1.68; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lund J, 2003, J EXP MED, V198, P513, DOI 10.1084/jem.20030162; Maddocks KJ, 2015, JAMA ONCOL, V1, P80, DOI 10.1001/jamaoncol.2014.218; Marcucci F, 2011, BLOOD, V117, P1792, DOI 10.1182/blood-2010-06-275818; Morin RD, 2011, NATURE, V476, P298, DOI 10.1038/nature10351; Ngo VN, 2011, NATURE, V470, P115, DOI 10.1038/nature09671; Pan ZY, 2007, CHEMMEDCHEM, V2, P58, DOI 10.1002/cmdc.200600221; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; Phelan JD, 2018, NATURE, V560, P387, DOI 10.1038/s41586-018-0290-0; Phillips A. J., 2018, N O LINKED DEGRONS D, Patent No. WO2018237026A1; Podar K, 2004, J BIOL CHEM, V279, P21658, DOI 10.1074/jbc.M305783200; Ponader S, 2012, BLOOD, V119, P1182, DOI 10.1182/blood-2011-10-386417; Reekie TA, 2017, CHEM-EUR J, V23, P6357, DOI 10.1002/chem.201700043; Rodriguez R, 2001, J BIOL CHEM, V276, P47982, DOI 10.1074/jbc.M107577200; Sharma S, 2016, ONCOTARGET, V7, P68833, DOI 10.18632/oncotarget.11932; Sun YH, 2018, CELL RES, V28, P779, DOI 10.1038/s41422-018-0055-1; Takahashi K, 2007, J EXP MED, V204, P2963, DOI 10.1084/jem.20071132; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; Tomlinson M G, 2001, BMC Immunol, V2, P4, DOI 10.1186/1471-2172-2-4; Tomlinson MG, 1999, J BIOL CHEM, V274, P13577, DOI 10.1074/jbc.274.19.13577; Wang E, 2022, NEW ENGL J MED, V386, P735, DOI 10.1056/NEJMoa2114110; Woyach JA, 2014, NEW ENGL J MED, V370, P2286, DOI 10.1056/NEJMoa1400029; Young RM, 2015, P NATL ACAD SCI USA, V112, P13447, DOI 10.1073/pnas.1514944112; Yu FC, 2021, MOL CELL PROTEOMICS, V20, DOI 10.1016/j.mcpro.2021.100077; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	59	0	0	1	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV	2022	298	11							102555	10.1016/j.jbc.2022.102555	http://dx.doi.org/10.1016/j.jbc.2022.102555			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	6C7OU	36183831	gold, Green Published			2022-12-28	WOS:000882199400008
J	LIEBL, EC; MARTIN, GS				LIEBL, EC; MARTIN, GS			INTRACELLULAR TARGETING OF PP60SRC EXPRESSION - LOCALIZATION OF V-SRC TO ADHESION PLAQUES IS SUFFICIENT TO TRANSFORM CHICKEN-EMBRYO FIBROBLASTS	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; INSOLUBLE CELLULAR MATRIX; GENE-PRODUCT; PROTEIN-PHOSPHORYLATION; MORPHOLOGICAL TRANSFORMATION; TYROSINE PHOSPHORYLATION; MONOCLONAL-ANTIBODIES; PLATELET PROTEIN; PLASMA-MEMBRANE; FOREIGN DNA	To define the effects of pp60v-src activity at different intracellular sites, we have constructed chimeric molecules which target the pp60v-src kinase to specific intracellular locations. pp60v-src was targeted to the nucleus by insertion of the SV40 large T antigen nuclear localization signal. Nuclear pp60v-src was active as a tyrosine kinase and phosphorylated nuclear proteins at tyrosine. However, cells expressing the nuclear pp60v-src were phenotypically normal by a number of criteria, and nuclear src kinase did not induce the expression of an mRNA (CEF-4) whose induction is characteristic of transformation by wild-type v-src. pp60v-src was targeted to perinuclear membranes by fusion to rat growth hormone and vesicular stomatis G protein sequences. Cells expressing this chimeric molecule were phenotypically normal by most criteria. However the perinuclear src protein did induce elevated levels of CEF-4 mRNA, indicating that the v-src kinase expressed at this site induces partial transformation. The v-src and activated c-src kinases were targeted to adhesion plaques by fusion to the talin-binding sequence of vinculin. Cells expressing these fusion proteins were transformed by morphological, physiological and biochemical criteria, although the foci induced by these viruses were distinct from those induced by wild-type v-src. A chimeric protein which targeted c-src to adhesion plaques was not transforming. Thus targeting pp60src to adhesion plaques, although not sufficient to activate the transforming capacity of c-src, is sufficient to allow transformation by v-src.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,401 BARKER HALL,BERKELEY,CA 94720	University of California System; University of California Berkeley					NATIONAL CANCER INSTITUTE [R37CA017542, R01CA017542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007232] Funding Source: NIH RePORTER; NCI NIH HHS [CA09041, CA-17542] Funding Source: Medline; NIGMS NIH HHS [GM07232] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARRICK BA, 1990, CANCER RES, V50, P299; BEDARD PA, 1987, P NATL ACAD SCI USA, V84, P6715, DOI 10.1073/pnas.84.19.6715; BELL JC, 1987, NATURE, V325, P552, DOI 10.1038/325552a0; BENDORI R, 1989, J CELL BIOL, V108, P2383, DOI 10.1083/jcb.108.6.2383; BRYAN WR, 1958, ACTA UNION INT CONTR, V15, P764; BRZESKI H, 1980, CELL, V22, P513, DOI 10.1016/0092-8674(80)90361-X; BURR JG, 1980, P NATL ACAD SCI USA, V77, P3483; BURRIDGE K, 1983, CELL MOTIL CYTOSKEL, V3, P405, DOI 10.1002/cm.970030509; BURRIDGE K, 1983, J CELL BIOL, V97, P359, DOI 10.1083/jcb.97.2.359; BUSS JE, 1985, J VIROL, V53, P7, DOI 10.1128/JVI.53.1.7-12.1985; CALOTHY G, 1987, J VIROL, V61, P1678, DOI 10.1128/JVI.61.5.1678-1681.1987; CARTER VC, 1986, J CELL BIOL, V103, P2017, DOI 10.1083/jcb.103.5.2017; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DAVIDPFEUTY T, 1990, J CELL BIOL, V111, P3097, DOI 10.1083/jcb.111.6.3097; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; DECLUE JE, 1987, MOL CELL BIOL, V7, P371, DOI 10.1128/MCB.7.1.371; DELORBE WJ, 1980, J VIROL, V36, P50, DOI 10.1128/JVI.36.1.50-61.1980; FERRELL JE, 1990, MOL CELL BIOL, V10, P3020, DOI 10.1128/MCB.10.6.3020; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; FUKUI Y, 1991, MOL CELL BIOL, V11, P1207, DOI 10.1128/MCB.11.3.1207; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GROUDINE M, 1980, P NATL ACAD SCI-BIOL, V77, P5351, DOI 10.1073/pnas.77.9.5351; GUAN JL, 1984, CELL, V37, P779, DOI 10.1016/0092-8674(84)90413-6; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HIRST R, 1986, P NATL ACAD SCI USA, V83, P6470, DOI 10.1073/pnas.83.17.6470; HUGHES S, 1984, VIROLOGY, V136, P89, DOI 10.1016/0042-6822(84)90250-2; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Hunter E, 1979, Methods Enzymol, V58, P379; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JONES P, 1989, J CELL BIOL, V109, P2917, DOI 10.1083/jcb.109.6.2917; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KAMPS MP, 1988, ONCOGENE, V2, P305; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KAMPS MP, 1986, CELL, V45, P1005; KAPLAN JM, 1990, MOL CELL BIOL, V10, P1000, DOI 10.1128/MCB.10.3.1000; KARESS RE, 1981, CELL, V24, P155, DOI 10.1016/0092-8674(81)90511-0; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KELLIE S, 1986, EXP CELL RES, V165, P216, DOI 10.1016/0014-4827(86)90546-X; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KRUEGER JG, 1983, CURR TOP MICROBIOL, V107, P51; KRUEGER JG, 1984, MOL CELL BIOL, V4, P454, DOI 10.1128/MCB.4.3.454; KRUEGER JG, 1980, VIROLOGY, V101, P25, DOI 10.1016/0042-6822(80)90480-8; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LOEB DM, 1987, J VIROL, V61, P2420, DOI 10.1128/JVI.61.8.2420-2427.1987; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MARTINSGREEN M, 1990, J CELL BIOL, V101, P581; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PAWSON T, 1980, CELL, V22, P767, DOI 10.1016/0092-8674(80)90553-X; PELLMAN D, 1985, P NATL ACAD SCI USA, V82, P1623, DOI 10.1073/pnas.82.6.1623; PRICE GJ, 1987, BIOCHEM J, V245, P595, DOI 10.1042/bj2450595; PRICE GJ, 1989, BIOCHEM J, V259, P453, DOI 10.1042/bj2590453; RADKE K, 1979, P NATL ACAD SCI USA, V76, P5212, DOI 10.1073/pnas.76.10.5212; RADKE K, 1980, CELL, V21, P821, DOI 10.1016/0092-8674(80)90445-6; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; RESH MD, 1985, J CELL BIOL, V100, P409, DOI 10.1083/jcb.100.2.409; ROHRSCHNEIDER L, 1985, MOL CELL BIOL, V5, P3097, DOI 10.1128/MCB.5.11.3097; ROHRSCHNEIDER L, 1983, MOL CELL BIOL, V3, P731, DOI 10.1128/MCB.3.4.731; ROHRSCHNEIDER LR, 1980, P NATL ACAD SCI-BIOL, V77, P3514, DOI 10.1073/pnas.77.6.3514; ROHRSCHNEIDER LR, 1979, CELL, V16, P11, DOI 10.1016/0092-8674(79)90183-1; ROYCHOUDHURY R, 1983, GENE, V25, P161, DOI 10.1016/0378-1119(83)90179-8; Sambrook J, 1989, MOL CLONING LABORATO; SCHULTZ AM, 1985, SCIENCE, V227, P427, DOI 10.1126/science.3917576; SEFTON BM, 1981, CELL, V24, P165, DOI 10.1016/0092-8674(81)90512-2; SHAWVER LK, 1987, MOL CELL BIOL, V7, P2112, DOI 10.1128/MCB.7.6.2112; SHILO BZ, 1987, TRENDS GENET, V3, P69, DOI 10.1016/0168-9525(87)90178-8; SUDOL M, 1986, NUCLEIC ACIDS RES, V14, P2391, DOI 10.1093/nar/14.5.2391; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VIRTANEN I, 1980, J CELL BIOL, V85, P429, DOI 10.1083/jcb.85.2.429; WHITE MK, 1988, MOL CELL BIOL, V8, P138, DOI 10.1128/MCB.8.1.138; WILLINGHAM MC, 1979, CELL, V18, P125, DOI 10.1016/0092-8674(79)90361-1	74	29	29	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1992	7	12					2417	2428						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1334249				2022-12-28	WOS:A1992KA85600006
J	ECCLES, DM; RUSSELL, SEH; HAITES, NE; ATKINSON, R; BELL, DW; GRUBER, L; HICKEY, I; KELLY, K; KITCHENER, H; LEONARD, R; LESSELLS, A; LOWRY, S; MILLER, I; MILNER, B; STEEL, M				ECCLES, DM; RUSSELL, SEH; HAITES, NE; ATKINSON, R; BELL, DW; GRUBER, L; HICKEY, I; KELLY, K; KITCHENER, H; LEONARD, R; LESSELLS, A; LOWRY, S; MILLER, I; MILNER, B; STEEL, M			EARLY LOSS OF HETEROZYGOSITY ON 17Q IN OVARIAN-CANCER	ONCOGENE			English	Note							P53 GENE; BREAST-CANCER; ALLELE LOSS; CHROMOSOME-17; TRANSMISSION; MUTATIONS; CARCINOMA; TUMORS; FAMILY	We have studied 146 ovarian tumours (94 carcinomas, 22 tumours of low malignant potential and 30 benign tumours) for evidence of allele loss on chromosome 17p and 17q sufficient to imply the proximity of a tumour-suppressor gene. We have examined two polymorphic loci (YNZ22.2 and BHP53) on 17p13 and one on chromosome 17q (17q23-qter). Loss of heterozygosity (LOH) was detected in 34/63 (54%) informative malignant tumours at YNZ22.2 and 22/47 (47%) at BHP53; on 17q, 45/64 (70%) had LOH. Allele loss was detected in a small number of benign and borderline tumours. There was a statistically significant difference between the patterns of allele loss in serous and endometrioid groups of tumours, and allele loss occurred with significantly greater frequency on 17q than on 17p. Comparison of all malignant tumours presenting with either localized (FIGO stage I/II) or widespread (FIGO stage III/IV) disease showed that, particularly on 17q, allele loss increases in the more advanced stages. The p53 tumour-suppressor gene is implicated in ovarian carcinogenesis, and our findings suggest that an important tumour-suppressor gene may be located in the region 17q23-qter. Loss of function in this gene may be responsible for the frequently observed rapid progression of serous-type adenocarcinomas to an advanced stage.	QUEENS UNIV BELFAST,DEPT ONCOL,97 LISBURN RD,BELFAST BT9 7BL,ANTRIM,NORTH IRELAND; UNIV ABERDEEN,SCH MED,DEPT MED GENET,ABERDEEN AB9 22D,SCOTLAND; QUEENS UNIV BELFAST,DIV GENET ENGN,BELFAST BT9 7BL,ANTRIM,NORTH IRELAND; WESTERN GEN HOSP,ICRF MED ONCOL UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	Queens University Belfast; University of Aberdeen; Queens University Belfast; University of Edinburgh; University of Edinburgh			Eccles, Diana/K-6327-2019	Eccles, Diana/0000-0002-9935-3169				Anderson MC, 1990, OVARIAN CANCER BIOL, P187; BAAK JPA, 1986, J CLIN PATHOL, V39, P1340, DOI 10.1136/jcp.39.12.1340; BAKER SJ, 1990, CANCER RES, V50, P7717; CAMPBELL S, 1989, BMJ-BRIT MED J, V299, P1363, DOI 10.1136/bmj.299.6712.1363; DELACALLEMARTIN O, 1990, NUCLEIC ACIDS RES, V18, P4963, DOI 10.1093/nar/18.16.4963; ECCLES DM, 1990, ONCOGENE, V5, P1599; FOULKES W, 1991, LANCET, V338, P444, DOI 10.1016/0140-6736(91)91065-3; FOX H, 1990, OVARIAN CANC BIOL TH, P185; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HARLOW BL, 1989, AM J EPIDEMIOL, V130, P1071, DOI 10.1093/oxfordjournals.aje.a115414; JACOBS I, 1988, LANCET, V1, P268; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KOCH M, 1989, INT J EPIDEMIOL, V18, P782, DOI 10.1093/ije/18.4.782; LEE JH, 1990, CANCER RES, V50, P2724; LYNCH HT, 1991, CANCER, V67, P1460, DOI 10.1002/1097-0142(19910301)67:5<1460::AID-CNCR2820670534>3.0.CO;2-S; LYNCH HT, 1986, AM J MED, V81, P1073, DOI 10.1016/0002-9343(86)90411-0; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; NAROD SA, 1991, LANCET, V338, P82; PANANI A, 1985, CANCER GENET CYTOGEN, V16, P65, DOI 10.1016/0165-4608(85)90078-0; PONDER B, 1988, NATURE, V335, P400, DOI 10.1038/335400a0; RUSSELL SEH, 1990, ONCOGENE, V5, P1581; SATO T, 1991, CANCER RES, V51, P5118; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STENBACK F, 1981, PATHOL RES PRACT, V172, P58, DOI 10.1016/S0344-0338(81)80123-9; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0	27	95	96	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					2069	2072						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408149				2022-12-28	WOS:A1992JP42400023
J	MERZAK, A; DOOGHE, Y; PIRONIN, M; PERBAL, B; VIGIER, P				MERZAK, A; DOOGHE, Y; PIRONIN, M; PERBAL, B; VIGIER, P			COOPERATION BETWEEN THE H-RAS ONCOGENE AND A TRUNCATED DERIVATIVE OF THE V-MYB ONCOGENE IN TRANSFORMATION OF HAMSTER-EMBRYO FIBROBLASTS	ONCOGENE			English	Article							AVIAN-MYELOBLASTOSIS VIRUS; C-MYB; MONOCLONAL-ANTIBODIES; FUNCTIONAL DOMAINS; COLONY FORMATION; CELLS; DNA; PRODUCT; SEQUENCES; PROTEIN	The ras oncogenes alone fully transform established (immortalized) rodent fibroblasts in a few days, but generally transform early-passage fibroblasts only partially, unless their action is complemented by that of a nuclear, immortalizing, oncogene. Here we show that transfection of second-passage Syrian hamster embryo fibroblasts (HEFs) by the EJ-H-ras oncogene coupled to the neo gene, followed by selection with G418, gives rise to apparently normal, or only slightly transformed, clonal colonies, only a few of which become established. The study of two established clonal fines showed that they acquired only after some weeks, and stepwise, the main characteristics of full neoplastic transformation, i.e. anchorage independence, reduced requirement for serum growth factors and tumorigenicity. Later both clonal lines became increasingly tumorigenic and completely independent of exogenous growth and attachment factors, without increase in the expression of the H-ras oncogene. Transfection of one of the clones, early after its isolation, with a truncated derivative of the nuclear v-myb oncogene devoid of its transcriptional negative regulatory domain and able to partially transform chicken embryo fibroblasts [(myb(KXANM)] gave rise to more transformed cells, expressing both EJ-H-ras and myb(KXANM), which became tumorigenic earlier than the controls and remained more tumorigenic later on. With more efficient transfection techniques, numerous foci of fully transformed cells were subsequently obtained, in a few days, in cultures transfected sequentially with EJ-H-ras(neo) and myb(KXANM) and in cultures co-transfected with the two oncogenes. Highly tumorigenic, serum-independent and immortalized clones expressing both oncogenes were obtained from these cultures. Hence, the truncated myb(KXANM) oncogene accelerates the stepwise transformation of unestablished HEFs by the EJ-HH-ras oncogene and, together with this oncogene, fully transforms these same cells in a single step. The two oncogenes acting in cooperation also induce cell immortalization, but myb(KXANM), by itself, is not an immortalizing oncogene. No cooperation was observed between EJ-H-ras(neo) and the unaltered v-myb oncogene.	CTR UNIV ORSAY,INST CURIE,BIOL SECT,BATIMENT 110,F-91405 ORSAY,FRANCE; UNIV PARIS 07,F-75221 PARIS 05,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Cite			MERZAK, Abderrahim/AAW-9746-2021	MERZAK, Abderrahim/0000-0002-7269-2224				ANTCZAK M, 1990, J VIROL, V64, P1451, DOI 10.1128/JVI.64.4.1451-1458.1990; BADING H, 1989, ONCOGENE, V4, P33; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BART LMC, 1991, CANCER RES, V51, P1177; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOYLE WJ, 1985, MOL CELL BIOL, V5, P3017, DOI 10.1128/MCB.5.11.3017; BOYLE WJ, 1986, P NATL ACAD SCI USA, V83, P4685, DOI 10.1073/pnas.83.13.4685; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; DOOLEY S, 1989, Methods in Molecular and Cellular Biology, V1, P95; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; IBANEZ CE, 1988, J VIROL, V62, P1981, DOI 10.1128/JVI.62.6.1981-1988.1988; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; KRYCEVEMARTINERIE C, 1987, FEBS LETT, V214, P81, DOI 10.1016/0014-5793(87)80017-0; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LIPSICK JS, 1984, CANCER CELLS, V2, P143; MARTINERIE C, 1987, NUCLEIC ACIDS RES, V15, P1329, DOI 10.1093/nar/15.3.1329; MCCLURE DB, 1983, CELL, V32, P999, DOI 10.1016/0092-8674(83)90084-3; MERZAK A, 1991, ONCOGENE, V7, P535; PERBAL B, 1986, BIOCHIMIE, V68, P969, DOI 10.1016/S0300-9084(86)80040-2; Perbal B., 1988, PRACTICAL GUIDE MOL; PIRONIN M, 1992, INT J CANCER, V52, P1; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SCHWARTZ SA, 1988, CANCER RES, V48, P3470; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SORET J, 1985, J VIROL, V55, P193, DOI 10.1128/JVI.55.1.193-205.1985; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WEINBERG RA, 1989, CANCER RES, V49, P3713; ZHAN X, 1986, MOL CELL BIOL, V6, P3541, DOI 10.1128/MCB.6.10.3541	36	5	5	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					2031	2039						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408144				2022-12-28	WOS:A1992JP42400018
J	TROPPMAIR, J; BRUDER, JT; APP, H; HONG, C; LIPTAK, L; SZEBERENYI, J; COOPER, GM; RAPP, UR				TROPPMAIR, J; BRUDER, JT; APP, H; HONG, C; LIPTAK, L; SZEBERENYI, J; COOPER, GM; RAPP, UR			RAS CONTROLS COUPLING OF GROWTH-FACTOR RECEPTORS AND PROTEIN-KINASE-C IN THE MEMBRANE TO RAF-1 AND B-RAF PROTEIN SERINE KINASES IN THE CYTOSOL	ONCOGENE			English	Article							STIMULATING FACTOR-I; SIGNAL TRANSDUCTION; PC12 CELLS; PHOSPHORYLATION; ONCOGENES; DIFFERENTIATION; ACTIVATION; INSULIN; TYROSINE; GENE	A dominant negative mutant of Ras, M17 Ras, was used to study the role of Ras in receptor coupling of Raf-1 and B-Raf protein serine/threonine kinases (PSKs). We found that mutant Ras blocks serum- and 12-O-tetradecanoyl phorbol 13-acetate-induced activation of Raf-1 kinase in NIH3T3 cells and Raf-1 as well as B-Raf PSK stimulation by nerve growth factor (NGF) in PC12 pheochromocytoma cells. Mitogen stimulation of Raf kinase was measured by determination of Raf hyperphosphorylation and activity towards exogenous substrates and both of these events were inhibited in cells expressing M17 Ras. In contrast, tyrosine phosphorylation of a direct substrate of activated tyrosine kinase receptors, phospholipase C-gamma-1 (PLC-gamma-1), was unaffected. These data indicate that tyrosine phosphorylation of PLC-gamma-1 is not sufficient for growth induction in NIH3T3 cells and that Ras mediates signal transfer from activated membrane receptors to Raf kinases in the cytosol. As activated Raf induced differentiation in PC12 cells expressing M17 Ras we conclude that Raf kinase activation may be sufficient to account for this aspect of NGF function.	NCI,VIRAL CARCINOGENESIS LAB,VIRAL PATHOL SECT,FREDERICK,MD 21702; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School				Troppmair, Jakob/0000-0002-0611-3837				ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BACCARINI M, 1991, EMBO J, V11, P3649; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BORTNER DM, 1991, GENE DEV, V5, P1777, DOI 10.1101/gad.5.10.1777; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; LEE RM, 1991, J BIOL CHEM, V266, P10351; LEE RM, 1992, J BIOL CHEM, V267, P1088; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MORRISON DK, 1989, CELL, V58, P648; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OSHIMA M, 1991, J BIOL CHEM, V266, P23753; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAPP UR, 1991, ONCOGENE, V6, P495; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; REED JC, 1991, CELL GROWTH DIFFER, V2, P235; SCHULTZ AM, 1985, VIROLOGY, V146, P78, DOI 10.1016/0042-6822(85)90054-6; SENGUPTA A, 1988, P NATL ACAD SCI USA, V85, P8062, DOI 10.1073/pnas.85.21.8062; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; SITHANANDAM G, 1990, ONCOGENE, V5, P1775; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; THOMPSON PA, 1991, CELL GROWTH DIFFER, V2, P609; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	45	119	119	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1867	1873						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1386920				2022-12-28	WOS:A1992JJ37600024
J	ALBINO, AP; SOZZI, G; NANUS, DM; JHANWAR, SC; HOUGHTON, AN				ALBINO, AP; SOZZI, G; NANUS, DM; JHANWAR, SC; HOUGHTON, AN			MALIGNANT TRANSFORMATION OF HUMAN MELANOCYTES - INDUCTION OF A COMPLETE MELANOMA PHENOTYPE AND GENOTYPE	ONCOGENE			English	Note							MOUSE MONOCLONAL-ANTIBODY; MURINE SARCOMA-VIRUS; SURFACE-ANTIGENS; CELL-LINES; TUMOR PROGRESSION; CYTOGENETIC ANALYSIS; METASTATIC MELANOMA; GROWTH-FACTOR; HUMAN HOMOLOG; RAS ONCOGENE	Human melanoma provides a model to study malignant transformation and tumor progression. Expression of ras oncogenes in cultured normal human diploid melanocytes has induced a subset of phenotypic traits that are characteristic of malignant melanoma cells, including altered morphology, anchorage independence, induction of class II MHC antigens, up-regulation of the ganglioside G(D3), and chromosomal abnormalities. However, other characteristics of melanoma, such as loss of expression of adenosine deaminase-binding protein and tumorigenicity, were not observed. We report here that melanocytes infected with a retrovirus containing the viral Ha-ras oncogene underwent complete transformation, acquiring all phenotypic characteristics of malignant melanomas observed in vivo. Transformation occurred in a sequential manner and was associated with spontaneous chromosomal instability. Cytogenetic analysis of transformed melanocytes indicated that the earliest structural chromosomal abnormalities were isochromosomes 6p and 9q followed by complete loss of chromosome 1p, all common karyotypic abnormalities described in human melanomas. The findings suggest that these chromosome regions which are deleted or relatively deficient may contain genes that are critical for the initiation and progression of the melanoma phenotype.	IST NAZL TUMORI,I-20133 MILAN,ITALY	Fondazione IRCCS Istituto Nazionale Tumori Milan	ALBINO, AP (corresponding author), MEM SLOAN KETTERING CANC CTR,1275 YORK AVE,NEW YORK,NY 10021, USA.		sozzi, gabriella/G-8259-2011	sozzi, gabriella/0000-0001-9360-6914	NCI NIH HHS [CA-33049, CA-37907] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037907, P01CA033049] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBINO AP, 1981, J EXP MED, V154, P1764, DOI 10.1084/jem.154.6.1764; ALBINO AP, 1991, CANCER RES, V51, P4815; ALBINO AP, 1986, J EXP MED, V164, P1710, DOI 10.1084/jem.164.5.1710; ALBINO AP, 1991, J EXP MED, V51, P4815; ALBINO AP, 1988, PIGMENT CELL RES S, V1, P169; BALABAN GB, 1986, CANCER GENET CYTOGEN, V19, P113, DOI 10.1016/0165-4608(86)90378-X; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BECHER R, 1983, CANCER GENET CYTOGEN, V9, P173, DOI 10.1016/0165-4608(83)90038-9; CHATTOPADHYAY SK, 1981, J VIROL, V39, P777, DOI 10.1128/JVI.39.3.777-791.1981; CHERESH DA, 1984, P NATL ACAD SCI-BIOL, V81, P5767, DOI 10.1073/pnas.81.18.5767; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK WH, 1984, HUM PATHOL, V15, P1147, DOI 10.1016/S0046-8177(84)80310-X; COWAN JM, 1986, CANCER GENET CYTOGEN, V20, P255, DOI 10.1016/0165-4608(86)90081-6; COWAN JM, 1988, J NATL CANCER I, V80, P1159, DOI 10.1093/jnci/80.14.1159; CUYPERS HT, 1986, HUM GENET, V72, P262, DOI 10.1007/BF00291892; DONIGER J, 1983, SCIENCE, V222, P1144, DOI 10.1126/science.6648529; DRACOPOLI NC, 1987, CANCER RES, V47, P3995; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; EISINGER M, 1985, SCIENCE, V229, P984, DOI 10.1126/science.4023718; EISINGER M, 1982, P NATL ACAD SCI-BIOL, V79, P2018, DOI 10.1073/pnas.79.6.2018; ELDER DE, 1989, CANCER RES, V49, P5091; FOUNTAIN JW, 1990, CANCER SURV, V9, P645; GRIFFIN CA, 1988, CANCER GENET CYTOGEN, V32, P129, DOI 10.1016/0165-4608(88)90319-6; HALABAN R, 1988, ONCOGENE RES, V3, P177; Harnden DG, 1985, INT SYSTEM HUMAN CYT; HEIM S, 1987, CANCER CYTOGENETICS; HERLYN M, 1988, ANNU REV IMMUNOL, V6, P283; HOLZMANN B, 1985, J EXP MED, V161, P366, DOI 10.1084/jem.161.2.366; HOUGHTON AN, 1984, J EXP MED, V160, P255, DOI 10.1084/jem.160.1.255; HOUGHTON AN, 1988, J EXP MED, V167, P197, DOI 10.1084/jem.167.1.197; HOUGHTON AN, 1982, J EXP MED, V156, P1755, DOI 10.1084/jem.156.6.1755; HOUGHTON AN, 1987, J EXP MED, V164, P812; HUME CR, 1987, P NATL ACAD SCI USA, V84, P8603, DOI 10.1073/pnas.84.23.8603; ICHIKAWA T, 1990, CANCER RES, V50, P6349; JANSSEN JWG, 1986, CYTOGENET CELL GENET, V41, P129, DOI 10.1159/000132217; JHANWAR SC, 1992, HEREDITARY COLON CAN; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MATYAS GR, 1987, P NATL ACAD SCI USA, V84, P6065, DOI 10.1073/pnas.84.17.6065; MILLIKIN D, 1991, CANCER RES, V51, P5449; MUSCHEL RJ, 1986, CANCER RES, V46, P4104; NAGARAJAN L, 1986, P NATL ACAD SCI USA, V83, P6568, DOI 10.1073/pnas.83.17.6568; NAKAKUMA H, 1984, J BIOCHEM-TOKYO, V96, P1471, DOI 10.1093/oxfordjournals.jbchem.a134976; NAKAMURA Y, 1988, AM J HUM GENET, V16, P9369; ODELBERG SJ, 1989, GENOMICS, V5, P915, DOI 10.1016/0888-7543(89)90134-1; OFFIT K, 1991, GENE CHROMOSOME CANC, V3, P189, DOI 10.1002/gcc.2870030304; OHYASHIKI JH, 1986, CANCER GENET CYTOGEN, V23, P77, DOI 10.1016/0165-4608(86)90151-2; PATHAK S, 1983, CYTOGENET CELL GENET, V36, P573, DOI 10.1159/000131975; PEDERSEN MI, 1989, CANCER GENET CYTOGEN, V41, P185, DOI 10.1016/0165-4608(89)90245-8; PFEFFER LM, 1977, CELL, V10, P313, DOI 10.1016/0092-8674(77)90225-2; PRATT CI, 1992, CANCER RES, V52, P688; PRESTI JC, 1991, CANCER RES, V51, P1544; PUKEL CS, 1982, J EXP MED, V155, P1133, DOI 10.1084/jem.155.4.1133; RAPPOLEE DA, 1989, J CELL BIOCHEM, V39, P1, DOI 10.1002/jcb.240390102; REAL FX, 1985, CANCER RES, V45, P4401; REICHMANN A, 1984, CANCER GENET CYTOGEN, V13, P275, DOI 10.1016/0165-4608(84)90049-9; REY JA, 1985, CANCER GENET CYTOGEN, V16, P179, DOI 10.1016/0165-4608(85)90013-5; RICHMOND A, 1986, J INVEST DERMATOL, V86, P295, DOI 10.1111/1523-1747.ep12285452; RODRIGUEZ E, 1990, CANCER RES, V50, P6410; SAGER R, 1983, P NATL ACAD SCI-BIOL, V80, P7601, DOI 10.1073/pnas.80.24.7601; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J, 1989, MOL CLONING LABORATO; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SEYFRIED TN, 1985, MOL CELL BIOCHEM, V68, P3; THOMSON TM, 1988, J INVEST DERMATOL, V90, P459, DOI 10.1111/1523-1747.ep12460906; THOMSON TM, 1985, J INVEST DERMATOL, V85, P169, DOI 10.1111/1523-1747.ep12276608; TRAYLOR TD, 1980, J NEUROCHEM, V34, P126, DOI 10.1111/j.1471-4159.1980.tb04630.x; TRENT JM, 1989, CANCER RES, V49, P420; TRENT JM, 1990, NEW ENGL J MED, V322, P1508, DOI 10.1056/NEJM199005243222107; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; TRENT JM, 1983, CANCER GENET CYTOGEN, V9, P177, DOI 10.1016/0165-4608(83)90039-0; VIJAYASARADHI S, 1990, J EXP MED, V171, P1375, DOI 10.1084/jem.171.4.1375; YOAKUM GH, 1985, SCIENCE, V227, P1174, DOI 10.1126/science.3975607	72	60	62	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2315	2321						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437153				2022-12-28	WOS:A1992JW66500025
J	AVIVI, A; SKORECKI, K; YAYON, A; GIVOL, D				AVIVI, A; SKORECKI, K; YAYON, A; GIVOL, D			PROMOTER REGION OF THE MURINE FIBROBLAST GROWTH-FACTOR RECEPTOR-2 (BEK KGFR) GENE	ONCOGENE			English	Article							MAMMALIAN-CELLS; EXPRESSION; CLONING; FAMILY; PURIFICATION; MECHANISMS; PLASMIDS; BINDING; MEMBER; FGF	Fibroblast growth factors (FGFs) and their receptors play an important role in cell growth, angiogenesis and embryonal development. Four distinct genes encoding fibroblast growth factor receptors (FGFRs) were identified: flg, encoding FGFR1, bek encoding FGFR2, and the genes for FGFR3 and FGFR4. Both FGFR2 and keratinocyte growth factor receptor (KGFR) are encoded by the same gene, bek. To study the regulation of expression of the FGF receptors we analysed the DNA sequence flanking the 5' region of the cDNA of murine FGFR2 to seek elements that control its transcription. A 5-kbp fragment containing the 5' end of the cDNA was isolated from mouse genomic library and used to map the promoter region. We found that the sequence encoding the 5' non-translated region of the FGFR2/KGFR cDNA contains an intron located 210 bp upstream from the translation start site. Using RNAase protection and primer extension, we identified the mRNA start 37 bp upstream from the beginning of the bek cDNA. The promoter activity was found to reside in a 1.3-kbp fragment upstream from the cDNA, and deletion mapping further localized the promoter to a 0.7-kbp fragment. The sequence of this region shows high G + C content (62%), which is particularly emphasized in the 200 bp upstream from the mRNA start (80% G + C). This region contains the CCGCCC, GGGCGG AND GGAGG motifs also found in promoters of other growth factor receptors. Neither TATA nor CAAT boxes were found near the RNA start site. The characterization of this promoter will allow studies of the regulation of expression of the FGFR2 during development and in pathophysiological states. The differences between the promoter sequence of the gene for FGFR2 (bek) and FGFR1 (flg) may explain their differential expression during development.	WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science								AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; AVIVI A, 1991, ONCOGENE, V6, P1089; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955-2235(89)90012-4; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; Maniatis T., 1982, MOL CLONING; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; ORRURTREGER A, 1991, DEVELOPMENT, V113, P1419; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PETERS KG, 1992, DEVELOPMENT, V114, P233; RAZ V, 1991, ONCOGENE, V6, P753; RUTA M, 1988, ONCOGENE, V3, P9; SAFRAN A, 1990, ONCOGENE, V5, P635; SAITO H, 1992, BIOCHEM BIOPH RES CO, V183, P688, DOI 10.1016/0006-291X(92)90537-U; SANGER F, 1977, P NATL ACAD SCI USA, V83, P7137; SMITH JC, 1989, DEVELOPMENT, V105, P665; TAKIMOTO Y, 1991, P NATL ACAD SCI USA, V88, P1686, DOI 10.1073/pnas.88.5.1686; TAL M, 1987, MOL CELL BIOL, V7, P2597, DOI 10.1128/MCB.7.7.2597; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WHITMAN M, 1989, ANNU REV CELL BIOL, V5, P93; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	34	33	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1992	7	10					1957	1962						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408137				2022-12-28	WOS:A1992JP42400008
J	ZHU, W; KRIAJEVSKAIA, M; CHOU, WG				ZHU, W; KRIAJEVSKAIA, M; CHOU, WG			A RETROVIRAL SEQUENCE OF THE CHINESE-HAMSTER OVARY CELL-LINE	ONCOGENE			English	Note							MURINE LEUKEMIA-VIRUS; EMBRYONAL CARCINOMA-CELLS; LONG TERMINAL REPEAT; EXPRESSION; GENOMES	A partial cDNA (B52) molecule with the characteristics of retroviral sequences was isolated from the Chinese hamster ovary (CHO) K1 cell line. The B52 cDNA contains 1184 nucleotides. The first 452 nucleotides (nt) are 71% homologous to the env gene of Moloney murine leukemia virus (MMLV) and murine endogenous retroviruses. The 139 amino acids predicted from the 452 nt have 82% homology with the carboxy-terminal amino acids of the env protein of MMLV. The remaining 732 nt have several features of a typical retroviral long terminal repeat (LTR). For example, the first 14 nt are identical to the 5' inverted repeat of the retroviral LTRs. The 41-nt sequence at the 3' end is common to the R region of retroviral LTRs. The 732-nt sequence was shown to have promoter activity. The activity is approximately twofold higher than that of the Rous sarcoma virus LTR, and 1.5-fold lower than that of the early promoter of SV40 virus. Two species of mRNA of 5.2 and 2.7 kb in size were readily detected by B52 cDNA in the CHO K1 cells.	UNIV ROCHESTER,MED CTR,DEPT RADIAT ONCOL,CTR CANC,ROCHESTER,NY 14642; UNIV ROCHESTER,MED CTR,DEPT BIOCHEM,ROCHESTER,NY 14642	University of Rochester; University of Rochester					NATIONAL CANCER INSTITUTE [R01CA051064] Funding Source: NIH RePORTER; NCI NIH HHS [CA51064] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARKLIS E, 1986, CELL, V47, P391, DOI 10.1016/0092-8674(86)90596-9; BOSZE Z, 1986, EMBO J, V5, P1615, DOI 10.1002/j.1460-2075.1986.tb04404.x; CELANDER D, 1984, NATURE, V312, P159, DOI 10.1038/312159a0; COFFIN JM, 1979, J GEN VIROL, V42, P1, DOI 10.1099/0022-1317-42-1-1; CULLEN BR, 1983, P NATL ACAD SCI-BIOL, V80, P2946, DOI 10.1073/pnas.80.10.2946; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; LENZ J, 1984, NATURE, V308, P467, DOI 10.1038/308467a0; LINNEY E, 1984, NATURE, V308, P470, DOI 10.1038/308470a0; LOH TP, 1990, MOL CELL BIOL, V10, P4045, DOI 10.1128/MCB.10.8.4045; LOSARDO JE, 1989, J VIROL, V63, P1087, DOI 10.1128/JVI.63.3.1087-1094.1989; NICOLAS JF, 1976, CANCER RES, V36, P4224; PRINCE VE, 1991, J VIROL, V65, P1803, DOI 10.1128/JVI.65.4.1803-1811.1991; ROBINSON HL, 1982, P NATL ACAD SCI-BIOL, V79, P1225, DOI 10.1073/pnas.79.4.1225; SHINNICK TM, 1981, NATURE, V293, P543, DOI 10.1038/293543a0; SILVER JE, 1983, J EXP MED, V158, P1693, DOI 10.1084/jem.158.5.1693; WEBER F, 1985, EMBO J, V4, P946; ZHU W, 1992, IN PRESS MUTATION RE	18	2	2	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					2081	2083						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408151				2022-12-28	WOS:A1992JP42400026
J	FALETTO, DL; TSARFATY, I; KMIECIK, TE; GONZATTI, M; SUZUKI, T; WOUDE, GFV				FALETTO, DL; TSARFATY, I; KMIECIK, TE; GONZATTI, M; SUZUKI, T; WOUDE, GFV			EVIDENCE FOR NONCOVALENT CLUSTERS OF THE C-MET PROTOONCOGENE PRODUCT	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; SCATTER FACTOR; SIGNAL TRANSDUCTION; TYROSINE KINASES; PURIFICATION; HEPATOCYTES; CELLS; DIMERIZATION; MECHANISM; MOBILITY	The met proto-oncogene is a member of the tyrosine kinase growth factor receptor family and is the receptor for hepatocyte growth factor (HGF) or scatter factor. The primary met product is a 150 kDa precursor that is glycosylated to generate a 170 kDa (p170met) proreceptor protein. The mature form of the receptor is generated by cleavage of p170met to yield a disulfide-linked 140 kDa beta-subunit (p140met) and a 45 kDa alpha-subunit (p45met). Both products are glycosylated. Under non-reducing conditions both p170met and the alpha, beta-disulfide-linked protein are detected as a 185 kDa product (p185met), but only alpha-beta heterodimeric p185met is cross-linked and rendered resistant to disulfide reduction with membrane-impermeable 6.4 angstrom. linker length cross-linking reagents. These data indicate that the p170 precursor is not on the cell surface. Cross-linking experiments using 12-angstrom linker reagents yield multimeric forms of alpha-beta heterodimeric p185met greater than 500 kDa in size. These multimeric forms are produced in all cell lines tested regardless of the levels of protein expressed. These data suggest that alpha-beta heterodimeric p185met occurs in clusters or patches on the cell surface. Immunohistochemical analysis of met protein in the absence of ligand reveals a clustered staining pattern on the cell surface.	FUKUSHIMA MED SCH,DEPT PATHOL 2,FUKUSHIMA 96012,JAPAN	Fukushima Medical University	WOUDE, GFV (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,ABL,BASIC RES PROGRAM,POB B,FREDERICK,MD 21702, USA.			Tsarfaty, Ilan/0000-0002-5230-7093; Kmiecik, Thomas/0000-0002-1367-443X; Gonzatti, Mary Isabel/0000-0003-4266-2988	OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASAMI O, 1991, J BIOCHEM-TOKYO, V109, P8; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BONISCHNETZLER M, 1987, P NATL ACAD SCI USA, V84, P7832, DOI 10.1073/pnas.84.22.7832; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CHAN AML, 1988, ONCOGENE, V2, P593; COCHET C, 1988, J BIOL CHEM, V263, P3290; GEIGER B, 1991, Current Biology, V1, P237, DOI 10.1016/0960-9822(91)90068-8; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GHERARDI E, 1990, NATURE, V346, P228, DOI 10.1038/346228b0; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; HAMILTON TC, 1983, CANCER RES, V43, P5379; IGAWA T, 1991, BIOCHEM BIOPH RES CO, V174, P831, DOI 10.1016/0006-291X(91)91493-V; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; LI W, 1991, EMBO J, V10, P277, DOI 10.1002/j.1460-2075.1991.tb07948.x; MATSUMOTO K, 1991, BIOCHEM BIOPH RES CO, V176, P45, DOI 10.1016/0006-291X(91)90887-D; MOTOYAMA T, 1979, Acta Medica et Biologica, V27, P49; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; ROSEN EM, 1989, IN VITRO CELL DEV B, V25, P163; ROSEN EM, 1990, P SOC EXP BIOL MED, V195, P34; ROSEN EM, 1990, INVAS METAST, V10, P49; ROSEN EM, 1990, J CELL SCI, V96, P639; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SELDEN C, 1986, BIOCHEM BIOPH RES CO, V139, P361; SHIMIZU I, 1991, J BIOCHEM-TOKYO, V109, P14, DOI 10.1093/oxfordjournals.jbchem.a123335; STOKER M, 1991, BIOCHIM BIOPHYS ACTA, V1072, P81, DOI 10.1016/0304-419X(91)90008-9; STOKER M, 1985, J CELL SCI, V77, P209; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; VANBELZEN N, 1988, J CELL PHYSIOL, V134, P413, DOI 10.1002/jcp.1041340312; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; ZARNEGAR R, 1989, CANCER RES, V49, P3314	40	47	48	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1992	7	6					1149	1157						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1317541				2022-12-28	WOS:A1992HU64200012
J	SRIVASTAVA, S; TONG, YA; DEVADAS, K; ZOU, ZQ; SYKES, VW; CHEN, Y; BLATTNER, WA; PIROLLO, K; CHANG, EH				SRIVASTAVA, S; TONG, YA; DEVADAS, K; ZOU, ZQ; SYKES, VW; CHEN, Y; BLATTNER, WA; PIROLLO, K; CHANG, EH			DETECTION OF BOTH MUTANT AND WILD-TYPE P53-PROTEIN IN NORMAL SKIN FIBROBLASTS AND DEMONSTRATION OF A SHARED 2ND HIT ON P53 IN DIVERSE TUMORS FROM A CANCER-PRONE FAMILY WITH LI-FRAUMENI SYNDROME	ONCOGENE			English	Note							ONCOGENE; GENE; SUPPRESSION; MUTATIONS; PROTEIN; GROWTH	Germline transmission of mutant p53 gene in cancerprone families with Li-Fraumeni syndrome has revealed a new role for p53 in the genetic predisposition to cancer. The studies reported here focus on the analysis of the expression of normal and mutant p53 RNA and protein in germline configuration and demonstrate that normal skin fibroblasts derived from members of a family with Li-Fraumeni syndrome express mutant p53Gly --> Asp(245) protein and RNA at levels similar to the wild-type p53. Thus, these fibroblasts represent a unique biological system in which endogenous promoters are utilized for the expression of both mutant and normal p53. We have further extended the earlier observations on the analysis of mutant p53 with a limited number of tumors derived from individuals with Li-Fraumeni syndrome. Tumors arising from two different germ layers in four individuals in a single family clearly exhibited the loss of the wild-type allele and the retention of the mutant allele observed in the normal skin fibroblasts derived from the same individuals. These observations further support the notion that germline p53 mutation plays a key role in the tumorigenesis of individuals with Li-Fraumeni syndrome.	UNIFORMED SERV UNIV HLTH SCI,DEPT PATHOL,BETHESDA,MD 20814; UNIFORMED SERV UNIV HLTH SCI,DEPT SURG,BETHESDA,MD 20814; NCI,ENVIRONM EPIDEMIOL BRANCH,BETHESDA,MD 20892	Uniformed Services University of the Health Sciences - USA; Uniformed Services University of the Health Sciences - USA; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARKER D, 1987, SCIENCE, V236, P1100, DOI 10.1126/science.3107130; CHANG EH, 1987, SCIENCE, V237, P1036, DOI 10.1126/science.3616624; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; DEMARS R, 1970, 23RD ANN S FUND CANC, P105; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; PONDER BAJ, 1990, TRENDS GENET, V6, P213, DOI 10.1016/0168-9525(90)90181-5; Scrable H J, 1990, Adv Cancer Res, V54, P25, DOI 10.1016/S0065-230X(08)60807-6; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; SRIVASTAVA SK, 1986, P NATL ACAD SCI USA, V83, P8868, DOI 10.1073/pnas.83.23.8868; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0	25	65	65	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1992	7	5					987	991						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1373881				2022-12-28	WOS:A1992HP64200019
J	Fox, S; Tran, A; Trinkle-Mulcahy, L; Copeland, JW				Fox, Sarah; Tran, Amanda; Trinkle-Mulcahy, Laura; Copeland, John W.			Cooperative assembly of filopodia by the formin FMNL2 and I-BAR domain protein IRTKS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRSP53; DOWNSTREAM; PROTRUSION; MIGRATION; ADHESION; COMPLEX; WAVE2; FRL2	Filopodia are long finger-like actin-based structures that project out from the plasma membrane as cells navigate and explore their extracellular environment. The initiation of filo-podia formation requires release of tension at the plasma membrane followed by the coordinated assembly of long un-branched actin filaments. Filopodia growth is maintained by a tip complex that promotes actin polymerization and protects the growing barbed ends of the actin fibers from capping proteins. Filopodia growth also depends on additional F-actin bundling proteins to stiffen the actin filaments as well as extension of the membrane sheath projecting from the cell periphery. These activities can be provided by a number of actin-binding and membrane-binding proteins including formins such as formin-like 2 (FMNL2) and FMNL3, and Inverse-Bin-Amphiphysin-Rvs (I-BAR) proteins such as IRTKS and IRSp53, but the specific requirement for these proteins in filopodia assembly is not clear. We report here that IRTKS and IRSp53 are FMNL2-binding proteins. Coexpression of FMNL2 with either I-BAR protein promotes cooperative filopodia assembly. We find IRTKS, but not IRSp53, is required for FMNL2-induced filopodia assembly, and FMNL2 and IRTKS are mutually dependent cofactors in this process. Our results suggest that the primary function for FMNL2 during filopodia assembly is binding to the plasma membrane and that regula-tion of actin dynamics by its formin homology 2 domain is secondary. From these results, we conclude that FMNL2 initiates filopodia assembly via an unexpected novel mecha-nism, by bending the plasma membrane to recruit IRTKS and thereby nucleate filopodia assembly.	[Fox, Sarah; Tran, Amanda; Trinkle-Mulcahy, Laura; Copeland, John W.] Univ Ottawa, Fac Med, Dept Cellular & Mol Med, Ottawa, ON, Canada	University of Ottawa	Copeland, JW (corresponding author), Univ Ottawa, Fac Med, Dept Cellular & Mol Med, Ottawa, ON, Canada.	jcopelan@uottawa.ca			Cancer Research Society of Canada;  [102616]	Cancer Research Society of Canada; 	Funding and additional information-This work was supported by grant 102616 to J. W. C. from the Cancer Research Society of Canada.	Ahmed S, 2010, SEMIN CELL DEV BIOL, V21, P350, DOI 10.1016/j.semcdb.2009.11.008; Arjonen A, 2011, CELL ADHES MIGR, V5, P421, DOI 10.4161/cam.5.5.17723; Block J, 2012, CURR BIOL, V22, P1005, DOI 10.1016/j.cub.2012.03.064; Copeland JW, 2004, J BIOL CHEM, V279, P50250, DOI 10.1074/jbc.M404429200; Copeland SJ, 2018, MOL BIOL CELL, V29, P1611, DOI 10.1091/mbc.E18-02-0088; Dimchev V, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.634708; Disanza A, 2013, EMBO J, V32, P2735, DOI 10.1038/emboj.2013.208; Dobramysl U, 2021, J CELL BIOL, V220, DOI 10.1083/jcb.202003052; Gallop JL, 2020, SEMIN CELL DEV BIOL, V102, P81, DOI 10.1016/j.semcdb.2019.11.017; Gardberg M, 2016, J PATHOL CLIN RES, V2, P41, DOI 10.1002/cjp2.34; GONDA MA, 1976, J NATL CANCER I, V56, P245, DOI 10.1093/jnci/56.2.245; Harris ES, 2010, CYTOSKELETON, V67, P755, DOI 10.1002/cm.20485; Heimsath EG, 2012, J BIOL CHEM, V287, P3087, DOI 10.1074/jbc.M111.312207; Jacquemet G, 2019, CURR BIOL, V29, P202, DOI 10.1016/j.cub.2018.11.053; Jacquemet G, 2015, CURR OPIN CELL BIOL, V36, P23, DOI 10.1016/j.ceb.2015.06.007; Kage F, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14832; Kitzing TM, 2010, ONCOGENE, V29, P2441, DOI 10.1038/onc.2009.515; Krugmann S, 2001, CURR BIOL, V11, P1645, DOI 10.1016/S0960-9822(01)00506-1; Kuhn S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8088; Lambert JP, 2015, J PROTEOMICS, V118, P81, DOI 10.1016/j.jprot.2014.09.011; Lim KB, 2008, J BIOL CHEM, V283, P20454, DOI 10.1074/jbc.M710185200; Lynch J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078428; Meenderink LM, 2019, DEV CELL, V50, P545, DOI 10.1016/j.devcel.2019.07.008; Mejillano MR, 2004, CELL, V118, P363, DOI 10.1016/j.cell.2004.07.019; Millard TH, 2007, J CELL SCI, V120, P1663, DOI 10.1242/jcs.001776; Moriya K, 2012, BIOSCI BIOTECH BIOCH, V76, P1201, DOI 10.1271/bbb.120069; Nakagawa H, 2003, J CELL SCI, V116, P2577, DOI 10.1242/jcs.00462; Peladeau C, 2016, BMC CELL BIOL, V17, DOI 10.1186/s12860-016-0110-z; Pfisterer K, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.201906111; Postema MM, 2018, CURR BIOL, V28, P2876, DOI 10.1016/j.cub.2018.07.022; Roux Kyle J, 2013, Curr Protoc Protein Sci, V74, DOI 10.1002/0471140864.ps1923s74; Saarikangas J, 2009, CURR BIOL, V19, P95, DOI 10.1016/j.cub.2008.12.029; SCHLIWA M, 1981, J CELL BIOL, V90, P222, DOI 10.1083/jcb.90.1.222; Shekhar S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9730; Sudhaharan T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38851-w; Sudhaharan T, 2016, J CELL SCI, V129, P2829, DOI 10.1242/jcs.179655; Vaggi F, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002088; Vaillant DC, 2008, J BIOL CHEM, V283, P33750, DOI 10.1074/jbc.M803156200; Xu YW, 2004, CELL, V116, P711, DOI 10.1016/S0092-8674(04)00210-7; Yang CS, 2011, CELL ADHES MIGR, V5, P402, DOI 10.4161/cam.5.5.16971; Yang CS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005678; Yost EA, 2007, MOL PHARMACOL, V72, P812, DOI 10.1124/mol.107.038075; Young LE, 2018, J CELL SCI, V131, DOI 10.1242/jcs.220814; Young LE, 2015, MOL BIOL CELL, V26, P4646, DOI 10.1091/mbc.E15-09-0626; Zhao HX, 2011, CURR OPIN CELL BIOL, V23, P14, DOI 10.1016/j.ceb.2010.10.005	45	0	0	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV	2022	298	11							102512	10.1016/j.jbc.2022.102512	http://dx.doi.org/10.1016/j.jbc.2022.102512			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	6C1SV	36259517	gold, Green Published			2022-12-28	WOS:000881802600004
J	CHEN, ML; TSAI, CN; LIANG, CL; SHU, CH; HUANG, CR; SULITZEANU, D; LIU, ST; CHANG, YS				CHEN, ML; TSAI, CN; LIANG, CL; SHU, CH; HUANG, CR; SULITZEANU, D; LIU, ST; CHANG, YS			CLONING AND CHARACTERIZATION OF THE LATENT MEMBRANE-PROTEIN (LMP) OF A SPECIFIC EPSTEIN-BARR-VIRUS VARIANT DERIVED FROM THE NASOPHARYNGEAL CARCINOMA IN THE TAIWANESE POPULATION	ONCOGENE			English	Article							EPITHELIAL-CELLS; DNA; TRANSFORMATION; ANTIBODIES; SEQUENCES; AMPLIFICATION; TRANSCRIPTION; REPLICATION; ANTIGENS; REGION	A DNA fragment containing Epstein-Barr virus (EBV) terminal fragment sequence was obtained from a genomic library of nasopharyngeal carcinoma (NPC). One of the clones (clone 1510) contained the gene encoding latent membrane protein (LMP). Sequence analysis revealed that this gene had 95% homology with the LMP sequence of the B95-8 strain. Among the sequence variations, there was a change from G to T at nucleotide position 169 426, resulting in the loss of an XhoI site in exon 1 of the LMP gene. A pair of primers bracketing the XhoI site were designed to synthesize the EBV DNA fragment from nucleotides 169 081-169 577 by using the polymerase chain reaction (PCR) method. The PCR products were then subject to XhoI digestion and to DNA sequencing analysis. This restriction enzyme site polymorphism along with the sequence variations were also observed in 50 biopsy tissues as well as in the throat washings of 6 out of 20 healthy individuals that we examined, indicating that the EBV strain predominantly existing in these biopsy tissues was different from strains of B95-8, Jijoye or nude mouse passaged cells (C15) with an African origin, but closely resembled other nude mouse passaged CAO cells which were originally derived from China. Balb/c 3T3 cells carrying this NPC-LMP gene showed a transformed cell morphology and were tumorigenic in nude mice. The relationship between this unique type of EBV and NPC has yet to be established.	CHANG GUNG MED COLL,DEPT MICROBIOL & IMMUNOL,259 WEN HWA IST RD,TAOYUAN 33332,TAIWAN; NATL YANG MING MED COLL,GRAD INST MICROBIOL & IMMUNOL,SHIH PAI 11221,TAIWAN; VET GEN HOSP TAIPEI,DEPT OTOLARYNGOL,TAIPEI 11217,TAIWAN; HEBREW UNIV JERUSALEM,HADASSAH MED CTR,DEPT IMMUNOL,JERUSALEM,ISRAEL	Chang Gung University; Hebrew University of Jerusalem; Hadassah University Medical Center			Tsai, Chi neu/C-3373-2011; Tsai, Chi-Neu/AAZ-2558-2020	Tsai, Chi neu/0000-0002-5940-0696; Tsai, Chi-Neu/0000-0002-5940-0696; Chang, Yu-Sun/0000-0002-6457-3890				BAICHWAL VR, 1989, ONCOGENE, V4, P67; BENDER MA, 1987, J VIROL, V61, P1639, DOI 10.1128/JVI.61.5.1639-1646.1987; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; CHANG YS, 1990, J CLIN MICROBIOL, V28, P2398, DOI 10.1128/JCM.28.11.2398-2402.1990; CHANG YS, 1990, LEUKEMIA RES, V14, P309, DOI 10.1016/0145-2126(90)90157-5; CHANG YS, 1991, NUCLEIC ACIDS RES, V20, P139; DAMBAUGH T, 1980, P NATL ACAD SCI-BIOL, V77, P2999, DOI 10.1073/pnas.77.5.2999; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; DESGRANGES C, 1975, INT J CANCER, V16, P7, DOI 10.1002/ijc.2910160103; EPSTEIN MA, 1964, LANCET, V1, P702, DOI 10.1016/s0140-6736(64)91524-7; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; GILLIGAN K, 1990, J VIROL, V64, P4948, DOI 10.1128/JVI.64.10.4948-4956.1990; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAMMERSCHMIDT W, 1989, J VIROL, V63, P2469, DOI 10.1128/JVI.63.6.2469-2475.1989; HANTO DW, 1985, TRANSPLANTATION, V39, P461, DOI 10.1097/00007890-198505000-00001; HENLE G, 1971, JNCI-J NATL CANCER I, V46, P861; HENLE G, 1976, INT J CANCER, V17, P1, DOI 10.1002/ijc.2910170102; HENLE W, 1970, J NATL CANCER I, V44, P225; HU LF, 1991, J GEN VIROL, V72, P2399, DOI 10.1099/0022-1317-72-10-2399; HUDSON GS, 1985, J VIROL, V53, P528, DOI 10.1128/JVI.53.2.528-535.1985; KLEIN G, 1980, P NATL ACAD SCI USA, V77, P6162; LUPTON S, 1985, MOL CELL BIOL, V5, P2533, DOI 10.1128/MCB.5.10.2533; MANN KP, 1985, J VIROL, V55, P710, DOI 10.1128/JVI.55.3.710-720.1985; MILLER G, 1972, P NATL ACAD SCI USA, V69, P383, DOI 10.1073/pnas.69.2.383; MILLER G, 1973, P NATL ACAD SCI USA, V70, P4006; RAABTRAUB N, 1983, J VIROL, V48, P580, DOI 10.1128/JVI.48.3.580-590.1983; RAABTRAUB N, 1987, INT J CANCER, V39, P25, DOI 10.1002/ijc.2910390106; RICKINSON AB, 1987, J VIROL, V61, P1310, DOI 10.1128/JVI.61.5.1310-1317.1987; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROWE M, 1992, J VIROL, V66, P122, DOI 10.1128/JVI.66.1.122-131.1992; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHU CH, 1991, IN PRESS J VIROL MET; SIXBEY JW, 1983, NATURE, V306, P480, DOI 10.1038/306480a0; SIXBEY JW, 1989, LANCET, V2, P761; SMITH PR, 1992, J VIROL, V66, P706, DOI 10.1128/JVI.66.2.706-714.1992; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P2337, DOI 10.1128/JVI.62.7.2337-2346.1988	40	187	203	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2131	2140						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1331932				2022-12-28	WOS:A1992JW66500005
J	GRAZIANI, G; NEBREDA, AR; SRIVASTAVA, S; SANTOS, E; EVA, A				GRAZIANI, G; NEBREDA, AR; SRIVASTAVA, S; SANTOS, E; EVA, A			INDUCTION OF XENOPUS OOCYTE MEIOTIC MATURATION BY THE DBL ONCOGENE PRODUCT	ONCOGENE			English	Article							CDC2 PROTEIN-KINASE; H-1 HISTONE KINASE; CELL-CYCLE; PROMOTING FACTOR; M-PHASE; MOLECULAR-CLONING; PHOSPHOLIPASE-C; RAS PROTEINS; GENE-PRODUCT; EXPRESSION	The dbl oncogene was originally identified by transfection of NIH3T3 cells with DNA from a human diffuse B-cell lymphoma. The dbl oncogene product is a cytoplasmic phosphoprotein distributed between the cytosolic and cytoskeletal matrix-associated membrane fractions. Nucleotide sequence analysis has indicated that the predicted dbl product is very hydrophilic with no detectable similarity to known oncogene products. We have more recently discovered that a region of dbl essential for its transforming activity shows significant sequence similarity to a yeast cell cycle gene, CDC24, which is involved in cell polarity and bud formation in the division cycle of Saccharomyces cerevisiae. This sequence similarity suggests a possible role for dbl in cell division. We report here that the dbl oncogene product is able to induce maturation of Xenopus oocytes. Germinal vesicle breakdown (GVBD) was observed when oocytes were microinjected with the soluble fraction of SF9 insect cells infected with a dbl recombinant baculovirus as well as with the in vitro-transcribed dbl mRNA. Moreover, extracts of oocytes microinjected with dbl mRNA showed activation of H1 histone kinase activity. These findings define a new biologic activity of the dbl product and provide the opportunity to analyse dbl interactions with other components of signaling pathways involved in oocyte maturation.	NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892; UNIFORMED SERV UNIV HLTH SCI,DEPT PATHOL & SURG,BETHESDA,MD 20814; NIAID,MOLEC MICROBIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Uniformed Services University of the Health Sciences - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Nebreda, Angel Rodriguez/R-9594-2019; Eva, Alessandra/J-8268-2016; Graziani, Grazia/G-5747-2012	Eva, Alessandra/0000-0003-2949-078X; Graziani, Grazia/0000-0002-0221-768X	NCI NIH HHS [CA-46455] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA046455] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BARRETT CB, 1990, MOL CELL BIOL, V10, P310, DOI 10.1128/MCB.10.1.310; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CHEN ZQ, 1990, SCIENCE, V250, P1416, DOI 10.1126/science.2255913; DAAR I, 1991, SCIENCE, V253, P74, DOI 10.1126/science.1829549; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; EVA A, 1988, P NATL ACAD SCI USA, V85, P2061, DOI 10.1073/pnas.85.7.2061; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; GRAZIANI G, 1989, ONCOGENE, V4, P823; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; LABBE JC, 1989, CELL, V57, P253, DOI 10.1016/0092-8674(89)90963-X; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MALLER JL, 1990, BIOCHEMISTRY-US, V29, P3157, DOI 10.1021/bi00465a001; Masui Y., 1987, MOL REGULATION NUCLE, P1; MIYAMOTO C, 1985, MOL CELL BIOL, V5, P2860, DOI 10.1128/MCB.5.10.2860; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; OLLO R, 1987, P NATL ACAD SCI USA, V84, P5700, DOI 10.1073/pnas.84.16.5700; PINES J, 1987, EMBO J, V6, P2987, DOI 10.1002/j.1460-2075.1987.tb02604.x; PRINGLE JR, 1986, UCLA S MOL CELL BIOL, V33, P47; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; RON D, 1991, NEW BIOL, V3, P372; RON D, 1989, ONCOGENE, V4, P1067; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SANTOS E, 1988, J BIOL CHEM, V263, P9853; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; SRIVASTAVA SK, 1986, P NATL ACAD SCI USA, V83, P8868, DOI 10.1073/pnas.83.23.8868; STRUHL K, 1987, CELL, V50, P841, DOI 10.1016/0092-8674(87)90511-3; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; SUMMERS MD, 1987, TEXAS EXP STATION B, V1555; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TRONICK SR, 1989, GENOMICS, V5, P546, DOI 10.1016/0888-7543(89)90022-0	45	6	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1992	7	2					229	235						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1312693				2022-12-28	WOS:A1992HG98200004
J	LASSAM, N; BICKFORD, S				LASSAM, N; BICKFORD, S			LOSS OF C-KIT EXPRESSION IN CULTURED MELANOMA-CELLS	ONCOGENE			English	Article							TYROSINE KINASE RECEPTOR; W-MUTANT MICE; PROTO-ONCOGENE; SI-LOCUS; MOUSE; MELANOCYTES; LIGAND; MUTATIONS; GROWTH; KL	The proto-oncogene c-kit encodes a receptor tyrosine kinase which has been shown to play a key role in melanocyte development. In this report we asked whether the c-kit gene product is also involved in promoting the growth of transformed melanocytes. We found that, while c-Kit protein was readily observed in normal human neonatal and adult melanocytes, the majority of cell lines established from human melanoma samples did not express detectable levels of c-kit mRNA or protein. A similar pattern of differential expression was also observed in normal and transformed murine melanocytes. Our findings raise the possibility that a marked reduction in c-kit gene expression either promotes or is a consequence of transformation in melanocytes.	UNIV TORONTO,DEPT MED,TORONTO M5S 1A1,ONTARIO,CANADA; TORONTO BAYVIEW REG CANC CTR,TORONTO M4N 3M5,ONTARIO,CANADA; SUNNYBROOK MED CTR,TORONTO M4N 3M5,ONTARIO,CANADA	University of Toronto; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	LASSAM, N (corresponding author), UNIV TORONTO,DIV MED ONCOL,TORONTO M5S 1A1,ONTARIO,CANADA.							BEAN MA, 1975, CANCER RES, V35, P2902; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; BENNETT DOROTHEA, 1956, J MORPH, V98, P199, DOI 10.1002/jmor.1050980202; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CAJAL SRY, 1991, AM J PATHOL, V138, P349; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DOTTO GP, 1989, J CELL BIOL, V109, P3115, DOI 10.1083/jcb.109.6.3115; FEINBERG AP, 1963, ANAL BIOCHEM, V132, P6; FIDLER IJ, 1973, NATURE-NEW BIOL, V242, P148, DOI 10.1038/newbio242148a0; FITZPATRICK TB, 1987, DERMATOLOGY GENERAL; FLANAGAN JG, 1990, CELL, V63, P85; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; HALABAN R, 1986, J INVEST DERMATOL, V87, P95, DOI 10.1111/1523-1747.ep12523594; HERLYN M, 1985, CANCER RES, V45, P5670; HOUGHTON AN, 1982, J EXP MED, V156, P1755, DOI 10.1084/jem.156.6.1755; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KRIPKE ML, 1979, JNCI-J NATL CANCER I, V63, P541, DOI 10.1093/jnci/63.3.541; MAYER TC, 1970, DEV BIOL, V23, P297, DOI 10.1016/0012-1606(70)90100-4; MAYER TC, 1968, DEV BIOL, V18, P62, DOI 10.1016/0012-1606(68)90023-7; MINTZ B, 1957, J EXP ZOOL, V134, P207, DOI 10.1002/jez.1401340202; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; ROTTAPEL R, 1991, P NATL ACAD SCI USA, V88, P2341; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; Sambrook J, 1989, MOL CLONING LABORATO; Silvers W.K., 1979, COAT COLORS MICE, P206; SILVERS WILLYS KENT, 1956, J MORPH, V99, P41, DOI 10.1002/jmor.1050990103; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; ULRICH A, 1990, CELL, V61, P23; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	37	150	152	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1992	7	1					51	56						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1371338				2022-12-28	WOS:A1992HC22700007
J	Deng, O; Dash, S; Nepomuceno, TC; Fang, B; Yun, SY; Welsh, EA; Lawrence, HR; Marchion, D; Koomen, JM; Monteiro, AN; Rix, U				Deng, Ou; Dash, Sweta; Nepomuceno, Thales C.; Fang, Bin; Yun, Sang Y.; Welsh, Eric A.; Lawrence, Harshani R.; Marchion, Douglas; Koomen, John M.; Monteiro, Alvaro N.; Rix, Uwe			Integrated proteomics identifies PARP inhibitor-induced prosurvival signaling changes as potential vulnerabilities in ovarian cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SET ENRICHMENT ANALYSIS; DOUBLE-STRAND BREAKS; POLY(ADP-RIBOSE) POLYMERASE; OLAPARIB MONOTHERAPY; MAINTENANCE THERAPY; AKT ACTIVATION; MUTATION; GERMLINE; SURVIVAL; REPAIR	BRCA1/2-deficient ovarian carcinoma (OC) has been shown to be particularly sensitive to poly (ADP-ribose) polymerase inhibitors (PARPis). Furthermore, BRCA1/2 mutation status is currently used as a predictive biomarker for PARPi therapy. Despite providing a major clinical benefit to the majority of patients, a significant proportion of BRCA1/2-deficient OC tu-mors do not respond to PARPis for reasons that are incom-pletely understood. Using an integrated chemical, phospho-and ADP-ribosylation proteomics approach, we sought here to develop additional mechanism-based biomarker candidates for PARPi therapy in OC and identify new targets for combination therapy to overcome primary resistance. Using chemical prote-omics with PARPi baits in a BRCA1-isogenic OC cell line pair, as well as patient-derived BRCA1-proficient and BRCA1-deficient tumor samples, and subsequent validation by coimmunopreci-pitation, we showed differential PARP1 and PARP2 protein complex composition in PARPi-sensitive, BRCA1-deficient UWB1.289 (UWB) cells compared to PARPi-insensitive, BRCA1-reconstituted UWB1.289+BRCA1 (UWB+B) cells. In addition, global phosphoproteomics and ADP-ribosylation proteomics furthermore revealed that the PARPi rucaparib induced the cell cycle pathway and nonhomologous end joining (NHEJ) pathway in UWB cells but downregulated ErbB signaling in UWB+B cells. In addition, we observed AKT PARylation and prosurvival AKT-mTOR signaling in UWB+B cells after PARPi treatment. Consistently, we found the synergy of PARPis with DNAPK or AKT inhibitors was more pronounced in UWB+B cells, highlighting these pathways as actionable vulnerabilities. In conclusion, we demonstrate the combination of chemical proteomics, phosphoproteomics, and ADP-ribosylation prote-omics can identify differential PARP1/2 complexes and diverse, but actionable, drug compensatory signaling in OC.	[Deng, Ou; Yun, Sang Y.; Lawrence, Harshani R.; Rix, Uwe] H Lee Moffitt Canc Ctr & Res Inst, Dept Drug Discovery, Tampa, FL 33612 USA; [Dash, Sweta; Nepomuceno, Thales C.; Monteiro, Alvaro N.] H Lee Moffitt Canc Ctr & Res Inst, Dept Canc Epidemiol, Tampa, FL 33612 USA; [Fang, Bin] H Lee Moffitt Canc Ctr & Res Inst, Prote & Metabol Core, Tampa, FL USA; [Yun, Sang Y.; Lawrence, Harshani R.] H Lee Moffitt Canc Ctr & Res Inst, Chem Biol Core, Tampa, FL USA; [Welsh, Eric A.] H Lee Moffitt Canc Ctr & Res Inst, Biostat & Bioinformat Shared Resource, Tampa, FL USA; [Marchion, Douglas] H Lee Moffitt Canc Ctr & Res Inst, Tissue Core, Tampa, FL USA; [Koomen, John M.] H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol, Tampa, FL USA	H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute	Rix, U (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Dept Drug Discovery, Tampa, FL 33612 USA.; Monteiro, AN (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Dept Canc Epidemiol, Tampa, FL 33612 USA.	alvaro.monteiro@moffitt.org; uwe.rix@moffitt.org		Monteiro, Alvaro/0000-0002-8448-4801; Deng, Ou/0000-0002-9933-1832; Nepomuceno, Thales/0000-0002-1171-1030	NIH/NCI [R21 CA252373]; Rivkin Center for Ovarian Cancer; Moffitt Team Science; Moffitt Innovation and Technology Committee; Sarasota Innovation Fund/Moffitt Foundation; Miles for Moffitt; Ovarian Cancer Whisper Jacquie Liggett Fellowship; Ovarian Cancer Research Alliance - NIH/NCI [R50 CA211447]	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Rivkin Center for Ovarian Cancer; Moffitt Team Science; Moffitt Innovation and Technology Committee; Sarasota Innovation Fund/Moffitt Foundation; Miles for Moffitt; Ovarian Cancer Whisper Jacquie Liggett Fellowship; Ovarian Cancer Research Alliance - NIH/NCI	This project was supported by the NIH/NCI R21 CA252373 (to A. N. M. and U. R.) , the Rivkin Center for Ovarian Cancer (to A. N. M.) , as well as Moffitt Team Science (to A. N. M. and U. R.) , Moffitt Innovation and Technology Committee (to U. R. and J. M. K.) , the Sarasota Innovation Fund/Moffitt Foundation (to A. N. M. and U. R.) , and Miles for Moffitt (to U. R.) pilot funding. O.D. is the recipient of a Hearing the Ovarian Cancer Whisper Jacquie Liggett Fellowship and T.N. is the recipient of the Ann and Sol Schreiber Mentored Investigator Award from the Ovarian Cancer Research Alliance. The synthesis of compounds was in part funded by NIH/NCI grant R50 CA211447 (to H. R. L.) . The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Audeh MW, 2010, LANCET, V376, P245, DOI 10.1016/S0140-6736(10)60893-8; Becker JR, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07855-x; Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101; Chandrasekaran A, 2021, MOL CANCER THER, V20, P2117, DOI 10.1158/1535-7163.MCT-21-0500; Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128; Conrad LB, 2020, MOL CANCER THER, V19, P282, DOI 10.1158/1535-7163.MCT-19-0569; Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511; Ctortecka C, 2018, MOL CELL PROTEOMICS, V17, P2434, DOI 10.1074/mcp.RA118.000713; DelloRusso C, 2007, MOL CANCER RES, V5, P35, DOI 10.1158/1541-7786.MCR-06-0234; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Fong PC, 2010, J CLIN ONCOL, V28, P2512, DOI 10.1200/JCO.2009.26.9589; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Gallyas F, 2020, CANCERS, V12, DOI 10.3390/cancers12030532; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Jiang GC, 2013, J BIOL CHEM, V288, P8966, DOI 10.1074/jbc.M112.412650; Kalesh K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43154-1; Kaufman B, 2015, J CLIN ONCOL, V33, P244, DOI 10.1200/JCO.2014.56.2728; Kim G, 2015, CLIN CANCER RES, V21, P4257, DOI 10.1158/1078-0432.CCR-15-0887; Knezevic CE, 2016, CELL CHEM BIOL, V23, P1490, DOI 10.1016/j.chembiol.2016.10.011; Krastev DB, 2022, NAT CELL BIOL, V24, P62, DOI 10.1038/s41556-021-00807-6; Kuenzi BM, 2017, NAT CHEM BIOL, V13, P1222, DOI [10.1038/NCHEMBIO.2489, 10.1038/nchembio.2489]; Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377; Lawlor MA, 2001, J CELL SCI, V114, P2903; Ledermann J, 2014, LANCET ONCOL, V15, P852, DOI 10.1016/S1470-2045(14)70228-1; Li JN, 2010, NAT CHEM BIOL, V6, P291, DOI [10.1038/NCHEMBIO.332, 10.1038/nchembio.332]; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Lin KK, 2019, CANCER DISCOV, V9, P210, DOI 10.1158/2159-8290.CD-18-0715; Matulonis UA, 2016, ANN ONCOL, V27, P1013, DOI 10.1093/annonc/mdw133; Mirza MR, 2016, NEW ENGL J MED, V375, P2154, DOI 10.1056/NEJMoa1611310; Mohyuddin GR, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-06948-5; Oza AM, 2017, GYNECOL ONCOL, V147, P267, DOI 10.1016/j.ygyno.2017.08.022; Patel AG, 2011, P NATL ACAD SCI USA, V108, P3406, DOI 10.1073/pnas.1013715108; Pommier Y, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf9246; Rix U, 2012, METHODS MOL BIOL, V803, P25, DOI 10.1007/978-1-61779-364-6_3; Sandhu SK, 2013, LANCET ONCOL, V14, P882, DOI 10.1016/S1470-2045(13)70240-7; Stronach EA, 2011, NEOPLASIA, V13, P1069, DOI 10.1593/neo.111032; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sumi NJ, 2019, CELL CHEM BIOL, V26, P1240, DOI 10.1016/j.chembiol.2019.06.003; Tapodi A, 2005, J BIOL CHEM, V280, P35767, DOI 10.1074/jbc.M507075200; Vaughan S, 2011, NAT REV CANCER, V11, P719, DOI 10.1038/nrc3144; Wang ML, 2006, NUCLEIC ACIDS RES, V34, P6170, DOI 10.1093/nar/gkl840; Welsh EA, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-153; Westcott NP, 2017, NAT CHEM BIOL, V13, P302, DOI [10.1038/NCHEMBIO.2280, 10.1038/nchembio.2280]; Whicker ME, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2598-1; Xu F, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578-020-00416-0; Xu J, 2022, CANCER CHEMOTH PHARM, V89, P683, DOI 10.1007/s00280-022-04403-9; Yang G, 2018, NUCLEIC ACIDS RES, V46, P3446, DOI 10.1093/nar/gky088; Yap TA, 2020, CANCER DISCOV, V10, P1528, DOI 10.1158/2159-8290.CD-20-0163; Zhao W, 2014, J BIOMOL SCREEN, V19, P817, DOI 10.1177/1087057114521867; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zhou P, 2020, PRECIS CLIN MED, V3, P187, DOI 10.1093/pcmedi/pbaa030; Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09234-6	52	0	0	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV	2022	298	11							102550	10.1016/j.jbc.2022.102550	http://dx.doi.org/10.1016/j.jbc.2022.102550			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	6D3XI	36183837	gold, Green Published			2022-12-28	WOS:000882627400002
J	Monjes, NM; Wagner, PM; Guido, ME				Monjes, Natalia M.; Wagner, Paula M.; Guido, Mario E.			"Disruption of the molecular clock severely affects lipid metabolism in a hepatocellular carcinoma cell model"	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCADIAN CLOCK; CHOLINE KINASE; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; GLYCEROPHOSPHOLIPID SYNTHESIS; DAILY RHYTHMS; PHOSPHATIDYLETHANOLAMINE; CANCER; SUSCEPTIBILITY; PHOSPHOLIPIDS; TRANSCRIPTION	Involved in triglyceride (TG) and glycerophospholipid metabolism, the liver plays a crucial physiological role in the human body both as a major metabolic integrator and a central hub for lipid and energy homeostasis. Metabolic disorders can be caused by various factors that promote abnormal lipid accumulation in storage organelles called lipid droplets (LDs), as in hepatic steatosis, a metabolic syndrome manifestation that can progress to a hepatocellular carcinoma, the most common primary liver malignancy worldwide. Modern life involves conditions that disrupt the biological clock, causing metabolic disorders and higher cancer risk. A circadian clock is present in the liver and in immortalized cell lines and temporally regulates physiological processes by driving transcriptional and metabolic rhythms. Here we investigated metabolic rhythms in HepG2 cells, a human hepatocellular carcinoma- derived cell line, and the link between these rhythms and the circadian clock in control (Bmal1-wildtype) and Bmal1-disrupted (B-D) cells having their molecular clock impaired. Rhythms in the expression of lipid-synthesizing enzymes ChoK alpha, Pcyt2, and Lipin1, in the metabolism of particular glycerophospholipids such as phosphatidylcholine (PC) and phosphatidylethanolamine, and in the phosphatidylcholine/ phosphatidylethanolamine ratio and TG and LD content were observed in Bmal1-wildtype cells. By contrast, in the B-D model, the whole hepatic metabolism was severely altered with a significant reduction in the TG and LD content as well as in ChoK alpha and other related lipid enzymes. Together, our results suggest a very strong crosstalk between the molecular clock and lipid metabolism, which exhibits an exacerbated pathological condition in B-D cells.	[Monjes, Natalia M.; Wagner, Paula M.; Guido, Mario E.] Univ Nacl Cordoba, CIQUIB CONICET, Cordoba, Argentina; [Monjes, Natalia M.; Wagner, Paula M.; Guido, Mario E.] Univ Nacl Cordoba, Fac Ciencias Quim, Dept Quim Biol Ranwel Caputto, Cordoba, Argentina	National University of Cordoba; National University of Cordoba	Guido, ME (corresponding author), Univ Nacl Cordoba, CIQUIB CONICET, Cordoba, Argentina.; Guido, ME (corresponding author), Univ Nacl Cordoba, Fac Ciencias Quim, Dept Quim Biol Ranwel Caputto, Cordoba, Argentina.	mario.guido@unc.edu.ar			Agencia Nacional de Promocion Cientifica y Tecnica (FONCyT, PICT 2017) [631]; Consejo Nacional de Investigaciones Cientificas y Tecnologicas de la Republica Argentina (CONICET) [PIP 2014]; Secretaria de Ciencia y Tecnologia de la Uni-versidad Nacional de Cordoba (SeCyT-UNC); John Simon Guggenheim Memorial Foundation for Latinoamerica and Caribe (2009) in Natural Sciences, USA	Agencia Nacional de Promocion Cientifica y Tecnica (FONCyT, PICT 2017); Consejo Nacional de Investigaciones Cientificas y Tecnologicas de la Republica Argentina (CONICET)(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)); Secretaria de Ciencia y Tecnologia de la Uni-versidad Nacional de Cordoba (SeCyT-UNC)(Secretaria de Ciencia y Tecnologia (SECYT)); John Simon Guggenheim Memorial Foundation for Latinoamerica and Caribe (2009) in Natural Sciences, USA	This work has been supported by Agencia Nacional de Promocion Cientifica y Tecnica (FONCyT, PICT 2017 No 631), Consejo Nacional de Investigaciones Cientificas y Tecnologicas de la Republica Argentina (CONICET) (PIP 2014), and Secretaria de Ciencia y Tecnologia de la Uni-versidad Nacional de Cordoba (SeCyT-UNC) and John Simon Guggenheim Memorial Foundation for Latinoamerica and Caribe (2009) in Natural Sciences, USA.	Acosta-Rodriguez VA, 2013, J LIPID RES, V54, P1798, DOI 10.1194/jlr.M034264; Andersen LW, 2013, MAYO CLIN PROC, V88, P1127, DOI 10.1016/j.mayocp.2013.06.012; Aoyama C, 2004, PROG LIPID RES, V43, P266, DOI 10.1016/j.plipres.2003.12.001; Balogh J, 2016, J HEPATOCELL CARCINO, V3, P41, DOI 10.2147/JHC.S61146; Bell-Pedersen D, 2005, NAT REV GENET, V6, P544, DOI 10.1038/nrg1633; Brooks GA, 2009, J PHYSIOL-LONDON, V587, P5591, DOI 10.1113/jphysiol.2009.178350; Chao HC, 2017, ANAL CHIM ACTA, V971, P68, DOI 10.1016/j.aca.2017.03.033; Chen-Goodspeed M, 2007, J BIOL RHYTHM, V22, P291, DOI 10.1177/0748730407303387; Damato AR, 2022, SEMIN CELL DEV BIOL, V126, P27, DOI 10.1016/j.semcdb.2021.07.017; Dibner C, 2015, J INTERN MED, V277, P513, DOI 10.1111/joim.12347; Dunlap J.C., 2004, CHRONOBIOLOGY BIOL T; Edgar RS, 2012, NATURE, V485, P459, DOI 10.1038/nature11088; Eruslanov E, 2010, METHODS MOL BIOL, V594, P57, DOI 10.1007/978-1-60761-411-1_4; Farese RV, 2009, CELL, V139, P855, DOI 10.1016/j.cell.2009.11.005; Froy O, 2010, ENDOCR REV, V31, P1, DOI 10.1210/er.2009-0014; Garbarino-Pico E, 2005, NEUROCHEM INT, V47, P260, DOI 10.1016/j.neuint.2005.04.024; Garbarino-Pico E, 2004, J NEUROSCI RES, V76, P642, DOI 10.1002/jnr.20126; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Gluchowski NL, 2017, NAT REV GASTRO HEPAT, V14, P343, DOI 10.1038/nrgastro.2017.32; Gorne LD, 2015, CHRONOBIOL INT, V32, P11, DOI 10.3109/07420528.2014.949734; Grechez-Cassiau A, 2015, CHRONOBIOL INT, V32, P774, DOI 10.3109/07420528.2015.1046601; Green CB, 2008, CELL, V134, P728, DOI 10.1016/j.cell.2008.08.022; Guido ME, 2022, MOL NEUROBIOL, V59, P326, DOI 10.1007/s12035-021-02595-4; Guido ME, 2001, J NEUROCHEM, V76, P835, DOI 10.1046/j.1471-4159.2001.00081.x; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hughes ME, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000442; Johnson PCD, 2014, METHODS ECOL EVOL, V5, P944, DOI 10.1111/2041-210X.12225; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; Kent C, 2005, BBA-MOL CELL BIOL L, V1733, P53, DOI 10.1016/j.bbalip.2004.12.008; Kiessling S, 2017, BMC BIOL, V15, DOI 10.1186/s12915-017-0349-7; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Krishnaiah SY, 2017, CELL METAB, V25, P1206, DOI 10.1016/j.cmet.2017.04.023; Lahti T, 2012, ANN MED, V44, P847, DOI 10.3109/07853890.2012.727018; Lahti TA, 2008, INT J CANCER, V123, P2148, DOI 10.1002/ijc.23566; Li ZY, 2008, J LIPID RES, V49, P1187, DOI 10.1194/jlr.R700019-JLR200; Li ZY, 2006, CELL METAB, V3, P321, DOI 10.1016/j.cmet.2006.03.007; Lowrey PL, 2004, ANNU REV GENOM HUM G, V5, P407, DOI 10.1146/annurev.genom.5.061903.175925; Marcucci H, 2010, J BIOL CHEM, V285, P25382, DOI 10.1074/jbc.M110.139477; Mashek DG, 2013, ADV NUTR, V4, P697, DOI 10.3945/an.113.004648; Maury E, 2010, CIRC RES, V106, P447, DOI 10.1161/CIRCRESAHA.109.208355; Niebergall LJ, 2012, BBA-MOL CELL BIOL L, V1821, P324, DOI 10.1016/j.bbalip.2011.10.018; Pavlovic Z, 2013, INT J MOL SCI, V14, P2529, DOI 10.3390/ijms14022529; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Preitner N, 2002, CELL, V110, P251, DOI 10.1016/S0092-8674(02)00825-5; Rios MN, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00376; Sookoian S, 2008, AM J CLIN NUTR, V87, P1606, DOI 10.1093/ajcn/87.6.1606; Sookoian S, 2019, ALIMENT PHARM THER, V49, P516, DOI 10.1111/apt.15163; Sztolsztener K, 2021, BIOCHEM BIOPH RES CO, V585, P132, DOI 10.1016/j.bbrc.2021.11.044; Takahashi JS, 2008, NAT REV GENET, V9, P764, DOI 10.1038/nrg2430; Takiguchi T, 2007, PHARMACOGENET GENOM, V17, P1047, DOI 10.1097/FPC.0b013e3282f12a61; Thaben PF, 2014, J BIOL RHYTHM, V29, P391, DOI 10.1177/0748730414553029; van der Veen JN, 2017, BBA-BIOMEMBRANES, V1859, P1558, DOI 10.1016/j.bbamem.2017.04.006; Wagner PM, 2021, FASEB J, V35, DOI 10.1096/fj.202001753R; Wagner PM, 2019, ASN NEURO, V11, DOI 10.1177/1759091419892713; Wagner PM, 2019, MOL NEUROBIOL, V56, P1276, DOI 10.1007/s12035-018-1152-3; Wu G, 2021, BIOINFORMATICS, V37, P4581, DOI 10.1093/bioinformatics/btab731; Wu GS, 2010, BIOCHEM CELL BIOL, V88, P559, DOI 10.1139/O09-160; Yang R, 2010, BIOINFORMATICS, V26, pi168, DOI 10.1093/bioinformatics/btq189; Zhang Y, 2015, ACTA PHARMACOL SIN, V36, P71, DOI 10.1038/aps.2014.120	60	0	0	1	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV	2022	298	11							102551	10.1016/j.jbc.2022.102551	http://dx.doi.org/10.1016/j.jbc.2022.102551			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	6D3XI	36183836	gold, Green Published			2022-12-28	WOS:000882627400010
J	GHOSN, CR; RAL, BBA; WINOKUR, ST; UNGER, TF; STEELE, RE				GHOSN, CR; RAL, BBA; WINOKUR, ST; UNGER, TF; STEELE, RE			STRUCTURAL ORGANIZATION OF A SRC GENE FROM XENOPUS-LAEVIS	ONCOGENE			English	Note							MURINE HCK GENE; C-SRC; NUCLEOTIDE-SEQUENCE; PROTO-ONCOGENE; CHLORAMPHENICOL ACETYLTRANSFERASE; EUKARYOTIC RIBOSOMES; SECONDARY STRUCTURE; MAMMALIAN-CELLS; MESSENGER-RNA; FYN GENES	By sequence analysis of genomic clones, the exon-intron structure of one of the two src genes from Xenopus laevis has been determined. The coding region of the gene is interrupted by 10 introns whose locations are identical to the introns in the coding regions of the src genes of human and chicken. The 5' untranslated region is contained on a separate exon with no sequence conservation relative to the corresponding region of the chicken gene. The 5' untranslated region of the Xenopus gene contains a G + C-rich stem-loop sequence and two ATG triplets. A 1.4-kb fragment containing the 5' untranslated region and sequences upstream of it acts as a promoter when introduced in the correct orientation into X. laevis cell lines. The DNA sequence of this fragment lacks the typical arrangement of TATA and CCAAT sequences but contains the ATGCAAAT octamer sequence and a (TA)39 sequence.	UNIV CALIF IRVINE,DEPT BIOL CHEM,IRVINE,CA 92717; UNIV CALIF IRVINE,CTR DEV BIOL,IRVINE,CA 92717	University of California System; University of California Irvine; University of California System; University of California Irvine								ANDERSON SK, 1985, MOL CELL BIOL, V5, P1122, DOI 10.1128/MCB.5.5.1122; BOSCH TCG, 1989, MOL CELL BIOL, V9, P4141, DOI 10.1128/MCB.9.10.4141; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHIEN YH, 1984, MOL CELL BIOL, V4, P507, DOI 10.1128/MCB.4.3.507; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; CILIBERTO G, 1985, EMBO J, V4, P1537, DOI 10.1002/j.1460-2075.1985.tb03814.x; COLLETT JW, 1992, IN PRESS DEV BIOL; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; CRABB DW, 1987, ANAL BIOCHEM, V163, P88, DOI 10.1016/0003-2697(87)90096-0; DORAI T, 1991, MOL CELL BIOL, V11, P4165, DOI 10.1128/MCB.11.8.4165; GARVIN AM, 1988, MOL CELL BIOL, V8, P3058, DOI 10.1128/MCB.8.8.3058; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREAVES DR, 1985, EMBO J, V4, P2617, DOI 10.1002/j.1460-2075.1985.tb03979.x; GREAVES DR, 1985, J MOL BIOL, V185, P461, DOI 10.1016/0022-2836(85)90064-6; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GUTKIND JS, 1991, MOL CELL BIOL, V11, P1500, DOI 10.1128/MCB.11.3.1500; HANIFORD DB, 1985, NUCLEIC ACIDS RES, V13, P4343, DOI 10.1093/nar/13.12.4343; HANNIG G, 1991, ONCOGENE, V6, P361; HOFFMANN FM, 1983, CELL, V35, P393, DOI 10.1016/0092-8674(83)90172-1; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1987, MOL CELL BIOL, V7, P3438, DOI 10.1128/MCB.7.10.3438; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; LOCK P, 1990, MOL CELL BIOL, V10, P4603, DOI 10.1128/MCB.10.9.4603; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MATSUZAWA Y, 1991, ONCOGENE, V6, P1561; MATTAJ IW, 1985, NATURE, V316, P163, DOI 10.1038/316163a0; MURPHY JT, 1982, CELL, V29, P265, DOI 10.1016/0092-8674(82)90111-8; NECKAMEYER WS, 1986, MOL CELL BIOL, V6, P1478, DOI 10.1128/MCB.6.5.1478; PATEL M, 1990, ONCOGENE, V5, P201; PYPER JM, 1989, J NEUROSCI RES, V24, P89, DOI 10.1002/jnr.490240113; RAFFERTY KA, 1969, BIOL AMPHIBIAN TUMOR, P52; RAULF F, 1989, J NEUROSCI RES, V24, P81, DOI 10.1002/jnr.490240112; SCHARTL M, 1989, ONCOGENE, V4, P1185; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; SIVE HL, 1986, MOL CELL BIOL, V6, P3329, DOI 10.1128/MCB.6.10.3329; STEELE RE, 1985, NUCLEIC ACIDS RES, V13, P1747, DOI 10.1093/nar/13.5.1747; STEELE RE, 1989, J BIOL CHEM, V264, P10649; STEELE RE, 1989, ONCOGENE RES, V4, P223; STEELE RE, 1990, ONCOGENE, V5, P369; SUDOL M, 1986, MOL CELL BIOL, V6, P2839, DOI 10.1128/MCB.6.8.2839; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TANAKA A, 1987, MOL CELL BIOL, V7, P1978, DOI 10.1128/MCB.7.5.1978; TINOCO I, 1973, NATURE-NEW BIOL, V246, P40, DOI 10.1038/newbio246040a0; VORONOVA AF, 1987, MOL CELL BIOL, V7, P4407, DOI 10.1128/MCB.7.12.4407; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0; ZIEGLER SF, 1991, ONCOGENE, V6, P283	49	3	3	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2345	2350						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437158				2022-12-28	WOS:A1992JW66500030
J	FALCONE, G; PROVENZANO, C; ALEMA, S; TATO, F				FALCONE, G; PROVENZANO, C; ALEMA, S; TATO, F			TRANSFORMATION OF NIH3T3 CELLS BY ROUS-SARCOMA VIRUS OCCURS WITH HIGH-EFFICIENCY IN THE ABSENCE OF PROVIRAL REARRANGEMENTS OR AMPLIFICATION	ONCOGENE			English	Article							RAT-CELLS; INTEGRATION SITES; RETROVIRUS INTEGRATION; GENE AMPLIFICATION; DNA; EXPRESSION; CHROMATIN; REGIONS; MAP	NIH3T3 cells could be transformed by a mammaltropic strain of Rous sarcoma virus (RSV) with an efficiency 10(3) times greater than that observed in Balb/c 3T3 cells or other mammalian cell lines and almost identical to that of chick embryo fibroblasts. In infected NIH3T3 cells a single, properly integrated, provirus was sufficient to induce focus formation; moreover, kinase activity of pp60v-src and tyrosine phosphorylation of cellular proteins could be detected very soon after infection in the majority of cells. On the other hand, in transformed foci from RSV-infected Balb/c 3T3 cells both rearrangements and amplification of proviral sequences were frequently detected. Accordingly, expression of pp60v-src and ensuing tyrosine phosphorylation of cellular proteins occurred, at high levels, only in a minority of the infected cells. Furthermore, by using a murine retrovirus carrying the v-src oncogene and an independent selectable marker, we found that Balb/c 3T3 cells were transformed with a 100-fold lower efficiency than NIH3T3 cells, yet the majority of infected untransformed Balb/c 3T3 cells expressed active pp60v-src. These findings are consistent with the existence in most mammalian cell lines of a major restriction to v-src-induced transformation, operating at the level of proviral expression, that is apparently absent in NIH3T3 cells.	UNIV ROME LA SAPIENZA,DIPARTIMENTO BIOL CELLULARE & SVILUPPO,I-00185 ROME,ITALY	Sapienza University Rome	FALCONE, G (corresponding author), CNR,IST BIOL CELLULARE,VIALE MARX 43,I-00137 ROME,ITALY.		Falcone, Germana/A-3735-2016	Falcone, Germana/0000-0002-3508-7623; Alema, Stefano/0000-0002-9869-6354				AKROYD J, 1987, ONCOGENE, V1, P347; ALTANER C, 1970, VIROLOGY, V70, P118; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOETTIGER D, 1975, J VIROL, V15, P108, DOI 10.1128/JVI.15.1.108-114.1975; BOETTIGER D, 1974, VIROLOGY, V62, P522, DOI 10.1016/0042-6822(74)90412-7; BOULTER CA, 1988, ONCOGENE, V2, P207; CHISWELL DJ, 1982, NUCLEIC ACIDS RES, V10, P3967, DOI 10.1093/nar/10.13.3967; CHISWELL DJ, 1982, VIROLOGY, V116, P428, DOI 10.1016/0042-6822(82)90137-4; COPELAND NG, 1979, CELL, V17, P993, DOI 10.1016/0092-8674(79)90338-6; DENG CT, 1977, VIROLOGY, V76, P313, DOI 10.1016/0042-6822(77)90305-1; FEINSTEIN SC, 1982, J MOL BIOL, V156, P549, DOI 10.1016/0022-2836(82)90266-2; FINCHAM VJ, 1991, J VIROL, V65, P461, DOI 10.1128/JVI.65.1.461-463.1991; GILLESPIE DAF, 1985, CELL, V41, P279, DOI 10.1016/0092-8674(85)90081-9; GILMER TM, 1987, CANCER RES, V47, P4663; GREEN AR, 1986, EMBO J, V5, P707, DOI 10.1002/j.1460-2075.1986.tb04271.x; HJELLE B, 1988, P NATL ACAD SCI USA, V85, P4355, DOI 10.1073/pnas.85.12.4355; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; Maniatis T, 1989, DECONTAMINATION DILU; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARIANI BD, 1984, J BIOL CHEM, V259, P1901; MOOSLEHNER K, 1990, J VIROL, V64, P3056, DOI 10.1128/JVI.64.6.3056-3058.1990; ROGUEL N, 1986, BIOCHIM BIOPHYS ACTA, V908, P12; ROHDEWOHLD H, 1987, J VIROL, V61, P336, DOI 10.1128/JVI.61.2.336-343.1987; RYNDITCH A, 1991, GENE, V106, P165, DOI 10.1016/0378-1119(91)90196-I; SCHERDIN U, 1990, J VIROL, V64, P907, DOI 10.1128/JVI.64.2.907-912.1990; SHIH C, 1979, P NATL ACAD SCI USA, V76, P5714, DOI 10.1073/pnas.76.11.5714; TATO F, 1978, VIROLOGY, V88, P71, DOI 10.1016/0042-6822(78)90111-3; VARMUS HE, 1975, SPR COLD HARB S QUAN, V39, P118; WEISS R, 1985, RNA TUMOR VIRUSES MO; Wyke J A, 1975, Cold Spring Harb Symp Quant Biol, V39 Pt 2, P897; WYKE JA, 1980, VIROLOGY, V106, P217, DOI 10.1016/0042-6822(80)90246-9	31	9	9	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					1913	1920						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1328985				2022-12-28	WOS:A1992JP42400003
J	MING, L; NAN, Z; HO, AD				MING, L; NAN, Z; HO, AD			GENOMIC ORGANIZATION OF THE PUTATIVE HUMAN HOMEOBOX PROTOONCOGENE HOX-11 (TCL-3) AND ITS ENDOGENOUS EXPRESSION IN T-CELLS	ONCOGENE			English	Article								The HOX-11 (TCL-3) gene, which is abnormally expressed in the leukemic cells of some patients with T-cell acute lymphoblastic leukemia, is a new member of the homeobox gene family. It is structurally altered by the t(10;14) chromosomal translocation, resulting in head-to-tail juxtaposition of HOX-11 with the T-cell receptor delta-chain gene. In order to understand the normal functions of HOX-11 and its role in T-cell leukemia, we have determined the exon-intron structure of the HOX-11 gene. By using oligonucleotide primers flanking an intron of the HOX-11 gene, we have developed a quantitative reverse transcription-polymerase chain reaction (RT-PCR) assay for the expression of HOX-11. We detected HOX-11 expression in multiple cell lineages including normal T cells and two T-cell lines in which the HOX-11 gene appeared to be unaltered in structure. Our results suggest that deregulation of the endogenous expression of HOX-11 in normal T cells represents an essential step towards the formation of this type of T-cell leukemia.	UNIV OTTAWA, DEPT MED, OTTAWA K1N 6N5, ONTARIO, CANADA	University of Ottawa	MING, L (corresponding author), UNIV OTTAWA, NE ONTARIO REG CANC CTR, 41 RAMSEY LAKE RD, SUDBURY P3E 5J1, ONTARIO, CANADA.							BOEHM T, 1991, ONCOGENE, V6, P695; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; CROCE CM, 1991, CANCER RES, V51, pS5015; FINGER LR, 1986, SCIENCE, V234, P982, DOI 10.1126/science.3490692; GEHRING WJ, 1990, TRENDS GENET, V6, P323, DOI 10.1016/0168-9525(90)90253-3; GREEN AR, 1991, ONCOGENE, V6, P475; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KONGSUWAN K, 1988, EMBO J, V7, P2131, DOI 10.1002/j.1460-2075.1988.tb03052.x; LU M, 1991, EMBO J, V10, P2905, DOI 10.1002/j.1460-2075.1991.tb07840.x; MCGUIRE EA, 1991, BLOOD, V77, P599; NOWELL PC, 1988, FASEB J, V2, P3054, DOI 10.1096/fasebj.2.15.3056765; PEVERALI FA, 1990, DIFFERENTIATION, V45, P61, DOI 10.1111/j.1432-0436.1990.tb00458.x; ROWLEY JD, 1982, SCIENCE, V216, P749, DOI 10.1126/science.7079737; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; SCHUGHART K, 1988, BRIT J CANCER, V58, P9; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SHEN WF, 1989, P NATL ACAD SCI USA, V86, P8536, DOI 10.1073/pnas.86.21.8536; VISVADER J, 1991, ONCOGENE, V6, P187; ZUTTER M, 1990, P NATL ACAD SCI USA, V87, P3161, DOI 10.1073/pnas.87.8.3161	22	32	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1992	7	7					1325	1330						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1352396				2022-12-28	WOS:A1992HZ97100010
J	CHEN, JD; TOBIN, GJ; PIPAS, JM; VANDYKE, T				CHEN, JD; TOBIN, GJ; PIPAS, JM; VANDYKE, T			T-ANTIGEN MUTANT ACTIVITIES INVIVO - ROLES OF P53-BINDING AND PRB-BINDING IN TUMORIGENESIS OF THE CHOROID-PLEXUS	ONCOGENE			English	Article							SV40 LARGE-T; RETINOBLASTOMA SUSCEPTIBILITY GENE; LARGE TUMOR-ANTIGEN; RAT EMBRYO FIBROBLASTS; SIMIAN VIRUS-40; TRANSGENIC MICE; SV40-TRANSFORMED CELLS; HYDROPHOBIC REGION; P53 GENE; TRANSFORMATION	To study the mechanism by which SV40 large T antigen transforms cells under physiological conditions, we analysed several mutant forms of T antigen for their ability to induce cell proliferation and tumorigenesis in transgenic mice. These mutant proteins, which differ in their ability to form complexes with the tumor suppressors pRB and p53, were analysed under conditions in which wild-type T antigen induces choroid plexus papillomas as a result of uniform proliferation of the entire choroid plexus epithelium. The results presented here show that binding of T antigen to p53 is not required for induction of choroid plexus tumors. However, tumorigenesis does appear to require the binding of T antigen to pRB/p107. An additional activity, resident in the amino-terminal one-fifth of the protein, may also play a role. These experiments indicate the importance of whole-animal assays in determining the molecular basis of transformation, since each of these mutants possessed similar transformation phenotypes in culture but showed distinct phenotypes in the choroid plexus of the animal.			VANDYKE, T (corresponding author), UNIV PITTSBURGH,DEPT BIOL SCI,PITTSBURGH,PA 15260, USA.			Tobin, Gregory/0000-0002-8396-0466	NATIONAL CANCER INSTITUTE [R01CA040586, R37CA040586, R01CA046283] Funding Source: NIH RePORTER; NCI NIH HHS [CA-46283, CA40586] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASSELIN C, 1985, J VIROL, V56, P958, DOI 10.1128/JVI.56.3.958-968.1985; CHEN J, 1991, IN PRESS MOL CELL BI, V11; CHEN JD, 1989, J VIROL, V63, P2204, DOI 10.1128/JVI.63.5.2204-2214.1989; CHEN S, 1990, J VIROL, V64, P3350, DOI 10.1128/JVI.64.7.3350-3357.1990; CHOI YW, 1988, MOL CELL BIOL, V8, P3382, DOI 10.1128/MCB.8.8.3382; CLARK R, 1983, MOL CELL BIOL, V3, P220, DOI 10.1128/MCB.3.2.220; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; ERSELIUS JR, 1990, J VIROL, V64, P1657, DOI 10.1128/JVI.64.4.1657-1666.1990; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; HANAHAN D, 1989, SCIENCE, V246, P1265, DOI 10.1126/science.2686032; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; JENKINS JR, 1988, ONCOGENE HDB, P403; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIVINGSTON DM, 1987, MOL BIOL MED, V4, P63; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MANFREDI JJ, 1990, J VIROL, V64, P5250, DOI 10.1128/JVI.64.11.5250-5259.1990; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MICHALOVITZ D, 1987, J VIROL, V61, P2648, DOI 10.1128/JVI.61.8.2648-2654.1987; MOLE SE, 1987, PHILOS T ROY SOC B, V317, P455, DOI 10.1098/rstb.1987.0072; MONIER R, 1986, PAPOVAVIRIDAE; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PAWLITA M, 1984, CURR TOP MICROBIOL, V113, P26; PEDEN KWC, 1990, J VIROL, V64, P2912, DOI 10.1128/JVI.64.6.2912-2921.1990; PEDEN KWC, 1989, VIROLOGY, V168, P13, DOI 10.1016/0042-6822(89)90398-X; PINKERT CA, 1987, VIROLOGY, V160, P169, DOI 10.1016/0042-6822(87)90057-2; PIPAS JM, 1983, MOL CELL BIOL, V3, P203, DOI 10.1128/MCB.3.2.203; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIEG FI, 1988, VIROLOGY, V164, P132, DOI 10.1016/0042-6822(88)90628-9; SEPULVEDA AR, 1989, CANCER RES, V49, P6108; SOMPAYRAC L, 1988, VIROLOGY, V163, P391, DOI 10.1016/0042-6822(88)90279-6; SOMPAYRAC L, 1991, VIROLOGY, V181, P412, DOI 10.1016/0042-6822(91)90516-E; SRINIVASAN A, 1989, J VIROL, V63, P5459, DOI 10.1128/JVI.63.12.5459-5463.1989; TACK LC, 1989, J VIROL, V63, P3362, DOI 10.1128/JVI.63.8.3362-3367.1989; TEITELMAN G, 1988, CELL, V52, P97, DOI 10.1016/0092-8674(88)90534-X; THOMPSON DL, 1990, VIROLOGY, V178, P15, DOI 10.1016/0042-6822(90)90375-2; YACIUK P, 1991, MOL CELL BIOL, V11, P2116, DOI 10.1128/MCB.11.4.2116; YAN C, 1990, EMBO J, V9, P869, DOI 10.1002/j.1460-2075.1990.tb08184.x; [No title captured]	51	97	101	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1992	7	6					1167	1175						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1317542				2022-12-28	WOS:A1992HU64200014
J	LITTLE, MH; DUNN, R; BYRNE, JA; SEAWRIGHT, A; SMITH, PJ; PRITCHARDJONES, K; VANHEYNINGEN, V; HASTIE, ND				LITTLE, MH; DUNN, R; BYRNE, JA; SEAWRIGHT, A; SMITH, PJ; PRITCHARDJONES, K; VANHEYNINGEN, V; HASTIE, ND			EQUIVALENT EXPRESSION OF PATERNALLY AND MATERNALLY INHERITED WT1 ALLELES IN NORMAL FETAL TISSUE AND WILMS-TUMORS	ONCOGENE			English	Article							GROWTH FACTOR-II; WIEDEMANN-BECKWITH SYNDROME; POLYMERASE CHAIN-REACTION; INTERSTITIAL DELETION; HUMAN CHROMOSOME-11; GENE; TUMORS; HETEROZYGOSITY; LOCUS; RETINOBLASTOMA	Observations of non-random maternal 11p allele loss in Wilms' tumour (WT) have implied the possible involvement of an imprinted 11p locus in WT aetiology. A proposed 11p13 Wilms' tumour gene, WT1, has recently been isolated and encodes a zinc finger DNA-binding protein, the 3' untranslated region of which contains a polymorphic dinucleotide repeat (CA repeat) motif. We have exploited this transcribed CA repeat to examine the allelic expression pattern of WT1 and thereby determine whether transcriptional imprinting of this gene occurs. DNA and reverse-transcribed RNA from tumours and normal tissue were subjected to the polymerase chain reaction (PCR) using radiolabelled primers flanking the CA repeat. The gene was seen to be expressed from both of the constitutive alleles in 9-week human fetal kidney, all informative Wilm's tumours and neonatal kidney tissue adjacent to the tumours. In one tumour, known to be heterozygous for a point mutation in zinc finger 2, direct sequencing confirmed that both mutant and wild-type transcripts were being expressed. These results demonstrate that this gene is not subject to transcriptional imprinting in tumours or normal fetal kidney.	WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,CREWE RD,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; UNIV QUEENSLAND,SCH MED,DEPT PATHOL,BRISBANE 4006,AUSTRALIA; ROYAL CHILDRENS HOSP,BRISBANE 4029,AUSTRALIA; ROYAL HOSP SICK CHILDREN,EDINBURGH EH9 1LF,MIDLOTHIAN,SCOTLAND	University of Edinburgh; University of Queensland; Royal Children's Hospital Brisbane			Pritchard-Jones, Kathy/F-4286-2014; van Heyningen, Veronica/B-8039-2008; Little, Melissa H/A-6170-2010; VAN HEYNINGEN, Veronica/GYE-0531-2022	Pritchard-Jones, Kathy/0000-0002-2384-9475; van Heyningen, Veronica/0000-0003-0359-0141; Little, Melissa H/0000-0003-0380-2263; Byrne, Jennifer Anne/0000-0002-8923-0587	Medical Research Council [MC_U127527199] Funding Source: Medline; MRC [MC_U127527199] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BENEDICT WF, 1987, CANCER RES, V47, P4189; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COWELL JK, 1991, ONCOGENE, V6, P595; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; FEARON ER, 1984, NATURE, V309, P176, DOI 10.1038/309176a0; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; HAAS OA, 1986, CANCER GENET CYTOGEN, V23, P95, DOI 10.1016/0165-4608(86)90409-7; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HASELBACHER GK, 1987, P NATL ACAD SCI USA, V84, P1104, DOI 10.1073/pnas.84.4.1104; HENRY I, 1991, NATURE, V351, P665, DOI 10.1038/351665a0; HORN GT, 1989, NUCLEIC ACIDS RES, V17, P2140, DOI 10.1093/nar/17.5.2140; HUFF V, 1991, AM J HUM GENET, V48, P997; KANEKO Y, 1981, CANCER RES, V41, P4577; KOUFOS A, 1984, NATURE, V309, P170, DOI 10.1038/309170a0; KOUFOS A, 1989, AM J HUM GENET, V44, P711; LITT M, 1989, AM J HUM GENET, V44, P397; LITTLE M, 1991, NATURE, V351, P609, DOI 10.1038/351609a0; LITTLE MH, 1992, IN PRESS EUR J CANCE; LITTLE MH, 1992, IN PRESS P NATL ACAD; Maniatis T., 1982, MOL CLONING; MANNENS M, 1988, HUM GENET, V81, P41, DOI 10.1007/BF00283727; MANNENS M, 1990, CANCER RES, V50, P3279; ORKIN SH, 1984, NATURE, V309, P172, DOI 10.1038/309172a0; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PING AJ, 1989, AM J HUM GENET, V44, P720; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RALL LB, 1985, NATURE, V313, P228, DOI 10.1038/313228a0; REEVE AE, 1984, NATURE, V309, P174, DOI 10.1038/309174a0; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; SCHROEDER WT, 1987, AM J HUM GENET, V40, P413; SCOTT J, 1985, NATURE, V317, P260, DOI 10.1038/317260a0; VANHEYNINGEN V, 1990, P NATL ACAD SCI USA, V87, P5383, DOI 10.1073/pnas.87.14.5383; WADEY RB, 1990, ONCOGENE, V5, P901; WEBER JL, 1989, AM J HUM GENET, V44, P388; WILKINS RJ, 1988, LANCET, V1, P329; WILLIAMS JC, 1989, LANCET, V1, P283; WINSHIP PR, 1989, NUCLEIC ACIDS RES, V17, P1266, DOI 10.1093/nar/17.3.1266; ZHU XP, 1989, NATURE, V340, P312, DOI 10.1038/340312a0	43	60	60	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					635	641						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1314367				2022-12-28	WOS:A1992HQ68200004
J	JELINEK, MA; HASSELL, JA				JELINEK, MA; HASSELL, JA			REVERSION OF MIDDLE T ANTIGEN-TRANSFORMED RAT-2 CELLS BY KREV-1 - IMPLICATIONS FOR THE ROLE OF P21C-RAS IN POLYOMAVIRUS-MEDIATED TRANSFORMATION	ONCOGENE			English	Article							GTPASE-ACTIVATING PROTEIN; PHOSPHATIDYLINOSITOL KINASE-ACTIVITY; PUTATIVE EFFECTOR DOMAIN; GENE-PRODUCT; CELLULAR PROTEINS; TUMOR-ANTIGEN; BOVINE BRAIN; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; MOLECULAR-CLONING	Polyomavirus middle T antigen mediates transformation of cells, at least in part, by its association with and activation of the intrinsic protein tyrosine kinase activity of pp60c-src. pp60c-src, by analogy with pp60v-src, elicits cell proliferation through a signal transduction pathway that includes p21c-ras. Therefore, we tested the possibility that middle T antigen acts upstream of and in the same proliferative signaling pathway as p21c-ras. Co-transfection of Rat-2 cells with plasmids expressing human Krev-1, a dominant suppressor of Ki-ras transformation, and mT antigen resulted in a dose-dependent reduction of mT antigen-induced foci. Krev-1 did not affect the transforming activity of SV40 large T antigen, demonstrating that the transformation-suppressing activity of Krev-1 is specific. To determine the effect of Krev-1 on stably transformed cell lines, Krev-1 DNA was introduced into middle T antigen-transformed Rat-2 cells along with a G418 resistance marker. Of the G418-resistant colonies examined, 1% were morphologically untransformed. Characterization of several morphological revertants revealed that, with the exception of one cell line, all of the cell lines expressed middle T antigen, which was associated with pp60c-src, whose tyrosine kinase activity was similar to that found in the parental transformed cell lines. To determine whether other phenotypic traits associated with transformation were altered in these cell lines, their growth rates and ability to form colonies in agar suspension were examined. The majority of the revertants had longer doubling times, and grew less efficiently in agar suspension compared with their transformed parents. A direct correlation was observed between Krev-1 RNA and protein expression and the efficiency with which the revertants formed colonies in suspension. These results suggest that p21c-ras lies downstream of middle T antigen and pp60c-src in the same proliferative signal transduction pathway.	MCMASTER UNIV,INST MOLEC BIOL & BIOTECHNOL,1280 MAIN ST W,HAMILTON L8S 4K1,ONTARIO,CANADA	McMaster University								ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; AMINI S, 1986, MOL CELL BIOL, V6, P2305, DOI 10.1128/MCB.6.7.2305; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BAUTCH VL, 1987, CELL, V51, P529, DOI 10.1016/0092-8674(87)90122-X; BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; BOLEN JB, 1985, J VIROL, V53, P114, DOI 10.1128/JVI.53.1.114-119.1985; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; BOLEN JB, 1987, J VIROL, V61, P3299, DOI 10.1128/JVI.61.10.3299-3305.1987; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CAPRENTER CL, 1990, J BIOL CHEM, V265, P19704; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; CHENG SH, 1986, EMBO J, V5, P325, DOI 10.1002/j.1460-2075.1986.tb04216.x; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; COOK DN, 1990, J VIROL, V64, P1879, DOI 10.1128/JVI.64.5.1879-1887.1990; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; DAVIDSON D, 1987, J VIROL, V61, P1226, DOI 10.1128/JVI.61.4.1226-1239.1987; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DRUKER BJ, 1990, J VIROL, V64, P4454, DOI 10.1128/JVI.64.9.4454-4461.1990; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FEATHERSTONE MS, 1984, NUCLEIC ACIDS RES, V12, P7235, DOI 10.1093/nar/12.18.7235; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; FUKUI Y, 1991, ONCOGENE, V6, P407; FUKUI Y, 1991, MOL CELL BIOL, V11, P1972, DOI 10.1128/MCB.11.4.1972; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GORGA FR, 1990, J VIROL, V64, P105, DOI 10.1128/JVI.64.1.105-112.1990; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; GRUSSENMEYER T, 1987, J VIROL, V61, P3902, DOI 10.1128/JVI.61.12.3902-3909.1987; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HART PA, 1990, ONCOGENE, V5, P1099; HATA Y, 1990, J BIOL CHEM, V265, P7104; HOSHIJIMA M, 1988, BIOCHEM BIOPH RES CO, V157, P851, DOI 10.1016/S0006-291X(88)80953-7; HUNTER T, 1984, EMBO J, V3, P73, DOI 10.1002/j.1460-2075.1984.tb01763.x; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KORNBLUTH S, 1990, J VIROL, V64, P1584, DOI 10.1128/JVI.64.4.1584-1589.1990; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LIPS DL, 1989, J BIOL CHEM, V264, P19911; LIPS DL, 1989, J BIOL CHEM, V264, P8759; MARUYAMA K, 1981, J VIROL, V37, P1028, DOI 10.1128/JVI.37.3.1028-1043.1981; MATHEYPREVOT B, 1984, J VIROL, V50, P325, DOI 10.1128/JVI.50.2.325-334.1984; MATTHEWS JT, 1986, J VIROL, V58, P239, DOI 10.1128/JVI.58.2.239-246.1986; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MYERS RM, 1985, SCIENCE, V230, P1242, DOI 10.1126/science.4071043; NAGATA K, 1989, BIOCHEM BIOPH RES CO, V160, P235, DOI 10.1016/0006-291X(89)91646-X; NILSSON SV, 1983, J VIROL, V46, P284, DOI 10.1128/JVI.46.1.284-287.1983; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; PALLAS DC, 1988, J VIROL, V62, P3934, DOI 10.1128/JVI.62.11.3934-3940.1988; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PIZON V, 1988, ONCOGENE, V3, P201; POLAKIS PG, 1991, P NATL ACAD SCI USA, V88, P239, DOI 10.1073/pnas.88.1.239; PONTE P, 1983, MOL CELL BIOL, V3, P1783, DOI 10.1128/MCB.3.10.1783; RAPTIS L, 1986, BIOCHEM BIOPH RES CO, V136, P995, DOI 10.1016/0006-291X(86)90431-6; RAPTIS L, 1991, J VIROL, V65, P5203, DOI 10.1128/JVI.65.10.5203-5210.1991; ROEBROEK AJM, 1986, VIRUS RES, V6, P15, DOI 10.1016/0168-1702(86)90053-5; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SERUNIAN LA, 1990, J VIROL, V64, P4718, DOI 10.1128/JVI.64.10.4718-4725.1990; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STEINBERG B, 1978, CELL, V13, P19, DOI 10.1016/0092-8674(78)90134-4; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TALMAGE DA, 1988, MOL CELL BIOL, V8, P2309, DOI 10.1128/MCB.8.6.2309; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TSAI MH, 1991, MOL CELL BIOL, V11, P2785, DOI 10.1128/MCB.11.5.2785; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; VARA JA, 1986, NUCLEIC ACIDS RES, V14, P4616; VARMUS HE, 1981, VIROLOGY, V108, P28, DOI 10.1016/0042-6822(81)90525-0; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988; ZHU Z, 1984, J VIROL, V51, P170, DOI 10.1128/JVI.51.1.170-180.1984	86	37	38	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1687	1698						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1380149				2022-12-28	WOS:A1992JJ37600003
J	SEGATTO, O; LONARDO, F; HELIN, K; WEXLER, D; FAZIOLI, F; RHEE, SG; DIFIORE, PP				SEGATTO, O; LONARDO, F; HELIN, K; WEXLER, D; FAZIOLI, F; RHEE, SG; DIFIORE, PP			ERBB-2 AUTOPHOSPHORYLATION IS REQUIRED FOR MITOGENIC ACTION AND HIGH-AFFINITY SUBSTRATE COUPLING	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; PHOSPHOLIPASE-C-GAMMA; PHOSPHOTYROSINE-CONTAINING PROTEINS; TYROSINE KINASE-ACTIVITY; FACTOR RECEPTOR; EGF RECEPTOR; ONCOGENE PRODUCT; NEU ONCOGENE; 3T3 CELLS; GENE	Autophosphorylation of gp185(erbB-2) in vivo is confined to its carboxy terminus and is required for optimal erbB-2 transforming activity under conditions of receptor overexpression. It remains unresolved, however, to what extent autophosphorylation regulates erhB-2 mitogenic signaling in normal cells, nor is the biochemical basis for such a regulatory function known. To address these issues, we utilized a chimeric molecule encompassing the extracellular domain of the epidermal growth factor (EGF) receptor (EGFR) fused to the transmembrane and intracellular domains of the erbB-2 product. In this EGFR/erbB-2 chimera, erbB-2 kinase activity is regulated by EGF binding. An EGFR/erbB-2 mutant bearing multiple Tyr --> Phe substitutions at erbB-2 autophosphorylation sites (EGFR/erbB-2 5P) displayed markedly reduced phosphotyrosine content following EGF stimulation in comparison with the non-mutated chimera. When expressed in NR6 cells, the EGFR/erhB-2 5P mutant was unable to deliver a sizeable mitogenic signal when activated by EGF at physiological levels. In intact cells, the 5P mutant was still able to stimulate phosphorylation of the gamma-isozyme of phospholipase C (PLC-gamma), a prototype erhB-2 substrate, although with a delayed time course, indicating that the 5P mutation decreased the affinity of the erbB-2 kinase for this substrate. This conclusion was further supported by the inability of the 5P mutant to associate with PLC-gamma in co-immunoprecipitation experiments. We infer that a major role of autophosphorylation is to increase the affinity of the erbB-2 kinase for its cellular substrates, so that, under physiological conditions, autophosphorylation is absolutely required for erbB-2 mitogenic signaling.	NCI,CELLULAR & MOLEC BIOL LAB,BLDG 37,ROOM 1D23,BETHESDA,MD 20892; REGINA ELENA INST CANC RES,I-00158 ROME,ITALY; UNIV COPENHAGEN,INST MICROBIOL,DK-1168 COPENHAGEN,DENMARK; NHLBI,BIOCHEM LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Copenhagen; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Di Fiore, Pier Paolo/K-2130-2012; Helin, Kristian/HDM-8306-2022; Helin, Kristian/K-2526-2019	Di Fiore, Pier Paolo/0000-0002-2252-0950; Helin, Kristian/0000-0003-1975-6097; Segatto, Oreste/0000-0003-2561-1142				AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BERTICS PJ, 1985, J BIOL CHEM, V260, P4642; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1990, MOL CELL BIOL, V10, P2749, DOI 10.1128/MCB.10.6.2749; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOWNING JR, 1989, EMBO J, V8, P3345, DOI 10.1002/j.1460-2075.1989.tb08496.x; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; HALEY JD, 1989, ONCOGENE, V4, P273; HAZAN R, 1990, CELL GROWTH DIFFER, V1, P3; HELIN K, 1991, ONCOGENE, V6, P825; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LONARDO F, 1990, New Biologist, V2, P992; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; PANG DT, 1985, ARCH BIOCHEM BIOPHYS, V242, P176, DOI 10.1016/0003-9861(85)90491-6; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; SEGATTO O, 1990, New Biologist, V2, P187; SEGATTO O, 1991, MOL CELL BIOL, V11, P3191, DOI 10.1128/MCB.11.6.3191; SORKIN A, 1991, J BIOL CHEM, V266, P8355; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; SUH PG, 1988, J BIOL CHEM, V263, P14497; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VELU TJ, 1989, MOL CELL BIOL, V9, P1771; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1989, P NATL ACAD SCI USA, V86, P3719	41	22	22	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1339	1346						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1352397				2022-12-28	WOS:A1992HZ97100012
J	BORZILLO, GV; ENDO, K; TSUJIMOTO, Y				BORZILLO, GV; ENDO, K; TSUJIMOTO, Y			BCL-2 CONFERS GROWTH AND SURVIVAL ADVANTAGE TO INTERLEUKIN-7-DEPENDENT EARLY PRE-B CELLS WHICH BECOME FACTOR INDEPENDENT BY A MULTISTEP PROCESS IN CULTURE	ONCOGENE			English	Article							HUMAN FOLLICULAR LYMPHOMA; BONE-MARROW; CHROMOSOMAL BREAKPOINT; GENE; EXPRESSION; PROTEIN; T(14-18); ONCOGENE; DEATH; TRANSLOCATION	Early pre-B cells derived from mouse lymphoid bone marrow cultures were expanded on a surrogate stromal cell line composed of NIH3T3 fibroblasts engineered to secrete interleukin 7 (IL-7). Three immortal, IL-7-dependent cell lines were generated and infected with recombinant retroviruses to determine the effects of the human follicular B-cell lymphoma gene, bcl-2, on immature stages of B-cell development. Cells expressing bcl-2 grew at rates similar to those of control (vector only) cells when plated on bone marrow stromal lines, but exhibited a c. two-fold net proliferative advantage when grown in liquid medium supplemented with IL-7 alone. Bcl-2 prevented apoptosis when the infected early pre-B-cell lines were deprived of IL-7 and other growth factors provided by stromal cells. Following factor deprivation, a subset of cells expressing bcl-2 survived indefinitely. Two such cultures spontaneously gave rise to factor-independent variants which grew slowly in unsupplemented liquid culture and formed agar colonies, yet still responded positively to IL-7 and kit ligand, and negatively to gamma-interferon. Bcl-2 thus provides a survival capacity and modest growth advantage to early pre-B cells, which may recapitulate its effects in human B cells bearing t(14;18) translocations and ultimately contribute to transformation.	ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38105 USA; WISTAR INST, PHILADELPHIA, PA 19104 USA	St Jude Children's Research Hospital; The Wistar Institute					NCI NIH HHS [CA-51864, CA-50551, CA-09346] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009346, R01CA051864, R01CA050551] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BANCHEREAU J, 1991, SCIENCE, V251, P70, DOI 10.1126/science.1702555; BERTOLI LF, 1988, BLOOD, V72, P94; BORZILLO GV, 1990, MOL CELL BIOL, V10, P2703, DOI 10.1128/MCB.10.6.2703; BORZILLO GV, 1989, MOL CELL BIOL, V9, P3973, DOI 10.1128/MCB.9.9.3973; BUTTYAN R, 1989, MOL CELL BIOL, V9, P3473, DOI 10.1128/MCB.9.8.3473; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; DORSHKIND K, 1989, J IMMUNOL METHODS, V123, P93, DOI 10.1016/0022-1759(89)90033-1; FUKUHARA S, 1979, CANCER RES, V39, P3119; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; MARCU KB, 1980, CELL, V22, P187, DOI 10.1016/0092-8674(80)90167-1; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; MCDONNELL TJ, 1990, MOL CELL BIOL, V10, P1901, DOI 10.1128/MCB.10.5.1901; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OWENS GP, 1991, MOL CELL BIOL, V11, P4177, DOI 10.1128/MCB.11.8.4177; PEZZELLA F, 1990, AM J PATHOL, V137, P225; REED JC, 1987, SCIENCE, V236, P1295, DOI 10.1126/science.3495884; RICHARDSON ME, 1987, BLOOD, V70, P444; SANDBERG AA, 1990, CHROMOSOMES HUMAN CA; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TSUJIMOTO Y, 1987, ONCOGENE, V2, P3; TSUJIMOTO Y, 1989, P NATL ACAD SCI USA, V86, P1958, DOI 10.1073/pnas.86.6.1958; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WHITLOCK CA, 1987, METHOD ENZYMOL, V150, P275; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; YUNIS JJ, 1984, CANCER GENET CYTOGEN, V13, P17, DOI 10.1016/0165-4608(84)90084-0	39	74	78	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	1992	7	5					869	876						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1373874				2022-12-28	WOS:A1992HP64200005
J	ANDRE, C; MARTIN, E; CORNU, F; HU, WX; WANG, XP; GALIBERT, F				ANDRE, C; MARTIN, E; CORNU, F; HU, WX; WANG, XP; GALIBERT, F			GENOMIC ORGANIZATION OF THE HUMAN C-KIT GENE - EVOLUTION OF THE RECEPTOR TYROSINE KINASE SUBCLASS-III	ONCOGENE			English	Article							W-MUTANT MICE; PROTO-ONCOGENE; GROWTH-FACTOR; MOUSE; LOCUS; SEQUENCE; REGION; FAMILY; CHROMOSOME-4; CONSERVATION	The c-kit proto-oncogene encodes a transmembrane tyrosine kinase receptor. It belongs to receptor tyrosine kinase subclass III, which also includes the colony-stimulating factor I receptor (c-fms), platelet-derived growth factor receptors A and B (PDGFRA and PDGFRB), as well as FLT1 and FLT3/FLK2. c-kit and PDGFRA, c-fms and PDGFRB, FLT1 and FLT3/FLK2 are grouped by pair in three clusters in man on chromosome 4 band q11-q13. chromosome 5 band q31-q33 and chromosome 13 band q12 respectively. Here, we report the genomic organization of the human c-kit gene, which is composed of 21 small coding exons, distributed over 80 kb. Comparison of the c-kit and c-fms oncogenes shows that they share identical exon/intron boundaries in their two kinase domains, as well as a similar exon/intron organization in the extracytoplasmic domain. Comparison with the kinase domains of tyrosine kinase genes not belonging to subclass III suggests that the exon/intron organization of c-kit and c-fms is a characteristic feature of subclass III. The genomic similarities between c-kit and c-fms, in conjunction with the location in pairs on different chromosomes of the subclass III genes, has led us to hypothesize that cis and trans duplications gave rise to this group of genes.			ANDRE, C (corresponding author), HOP ST LOUIS,CTR HAYEM,HEMATOL EXPTL LAB,CNRS,UPR 41,F-75475 PARIS 10,FRANCE.							ANDRE C, 1989, ONCOGENE, V4, P1047; BANKIER AT, 1987, METHOD ENZYMOL, V155, P51; BERNSTEIN A, 1991, SEMIN HEMATOL, V28, P138; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; CARLBERG K, 1991, EMBO J, V10, P877, DOI 10.1002/j.1460-2075.1991.tb08020.x; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; COMINGS DE, 1972, NATURE, V238, P455, DOI 10.1038/238455a0; DAURIOL L, 1988, HUM GENET, V78, P374, DOI 10.1007/BF00291740; ELADARI ME, 1986, BIOCHEM BIOPH RES CO, V140, P313, DOI 10.1016/0006-291X(86)91092-2; ESTBROOK CA, 1991, GENOMICS, V10, P1105; FROLOVA EI, 1991, P NATL ACAD SCI USA, V88, P4821, DOI 10.1073/pnas.88.11.4821; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; HALEY J, 1987, ONCOGENE RES, V1, P375; HAMPE A, 1989, ONCOGENE RES, V7, P9; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; LALLEY PA, 1989, CYTOGENET CELL GENET, V51, P503, DOI 10.1159/000132806; LEV S, 1991, EMBO J, V10, P647, DOI 10.1002/j.1460-2075.1991.tb07993.x; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATSUSHIME H, 1986, MOL CELL BIOL, V6, P3000, DOI 10.1128/MCB.6.8.3000; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MURRAY JC, 1990, CYTOGENET CELL GENET, V55, P97, DOI 10.1159/000133000; NISHIKAWA S, 1991, EMBO J, V10, P2111, DOI 10.1002/j.1460-2075.1991.tb07744.x; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; RACKWITZ HR, 1984, GENE, V30, P195, DOI 10.1016/0378-1119(84)90120-3; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; REITH AD, 1991, GENE DEV, V5, P1115, DOI 10.1101/gad.5.7.1115; ROBERTS WM, 1988, CELL, V55, P655, DOI 10.1016/0092-8674(88)90224-3; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; ROSNET O, 1991, ONCOGENE, V6, P1641; ROSNET O, 1991, GENOMICS, V9, P380, DOI 10.1016/0888-7543(91)90270-O; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; Silvers W.K., 1979, COAT COLORS MICE, P206; SMITH AE, 1991, P NATL ACAD SCI USA, V88, P4811; SORRENTINO V, 1991, ONCOGENE, V6, P149; STADEN R, 1986, NUCLEIC ACIDS RES, V14, P217, DOI 10.1093/nar/14.1.217; STENMAN G, 1989, GENE CHROMOSOME CANC, V1, P155, DOI 10.1002/gcc.2870010208; SUNDARESAN S, 1989, SOMAT CELL MOLEC GEN, V15, P367, DOI 10.1007/BF01534975; TANAKA A, 1987, MOL CELL BIOL, V7, P1978, DOI 10.1128/MCB.7.5.1978; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VISVADER J, 1989, MOL CELL BIOL, V9, P1336, DOI 10.1128/MCB.9.3.1336; WILBUR WJ, 1983, P NATL ACAD SCI-BIOL, V80, P726, DOI 10.1073/pnas.80.3.726; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	51	75	75	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					685	691						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1373482				2022-12-28	WOS:A1992HQ68200010
J	Meyer, MB; Benkusky, NA; Lee, SM; Yoon, SH; Mannstadt, M; Wein, MN; Pike, JW				Meyer, Mark B.; Benkusky, Nancy A.; Lee, Seong Min; Yoon, Sung-Hee; Mannstadt, Michael; Wein, Marc N.; Pike, J. Wesley			Rapid genomic changes by mineralotropic hormones and kinase SIK inhibition drive coordinated renal Cyp27b1 and Cyp24a1 expression via CREB modules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-D-RECEPTOR; GENE-EXPRESSION; 1,25-DIHYDROXYVITAMIN D-3; 25-HYDROXYVITAMIN D-3; WIDE ANALYSIS; TARGET GENES; ACTIVATION; CALCIUM; COACTIVATOR; METABOLISM	Vitamin D metabolism centers on kidney regulation of Cyp27b1 by mineralotropic hormones, including induction by parathyroid hormone (PTH), suppression by fibroblast growth factor 23 (FGF23) and 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), and reciprocal regulations for Cyp24a1. This coordinated genomic regulation results in production of endocrine 1,25(OH)2D3, which, together with PTH and FGF23, controls mineral homeostasis. However, how these events are coordi-nated is unclear. Here, using in vivo chromatin immunoprecip-itation sequencing in mouse kidney, we demonstrate that PTH activation rapidly induces increased recruitment of phosphory-lated (p-133) CREB (pCREB) and its coactivators, CBP (CREB-binding protein) and CRTC2 (CREB-regulated transcription coactivator 2), to previously defined kidney-specific M1 and M21 enhancers near the Cyp27b1 gene. At distal enhancers of the Cyp24a1 gene, PTH suppression dismisses CBP with only minor changes in pCREB and CRTC2 occupancy, all of which correlate with decreased genomic activity and reduced transcripts. Treatment of mice with salt-inducible kinase inhibitors (YKL-05-099 and SK-124) yields rapid genomic recruitment of CRTC2 to Cyp27b1, limited interaction of CBP, and a transcriptional response for both Cyp27b1 and Cyp24a1 that mirrors the actions of PTH. Surprisingly, we find that 1,25(OH)2D3 suppression in-creases the occupancy of CRTC2 in the M1 enhancer, a novel observation for CRTC2 and 1,25(OH)2D3 action. Suppressive actions of 1,25(OH)2D3 and FGF23 at the Cyp27b1 gene are associated with reduced CBP recruitment at these CREB-module enhancers that disrupts full PTH induction. Our findings show that CRTC2 contributes to transcription of both Cyp27b1 and Cyp24a1, demonstrate salt-inducible kinase inhibition as a key modulator of vitamin D metabolism, and provide molecular insight into the coordinated mechanistic actions of PTH, FGF23, and 1,25(OH)2D3 in the kidney that regulate mineral homeostasis.	[Meyer, Mark B.; Benkusky, Nancy A.; Lee, Seong Min; Pike, J. Wesley] Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; [Yoon, Sung-Hee; Mannstadt, Michael; Wein, Marc N.] Harvard Med Sch, Massachusetts Gen Hosp, Endocrine Unit, Boston, MA USA	University of Wisconsin System; University of Wisconsin Madison; Harvard University; Harvard Medical School; Massachusetts General Hospital	Meyer, MB (corresponding author), Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA.	markmeyer@wisc.edu		LEE, Seong Min/0000-0001-5017-5456	National Institutes of Health;  [DK117475];  [DK116716];  [DK011794];  [AR075042]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; ; ; 	Funding and additional information-Our funding came from the National Institutes of Health grants DK117475 to J. W. P. and DK116716, DK011794, AR075042 to M. N. W. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106; Bittinger MA, 2004, CURR BIOL, V14, P2156, DOI 10.1016/j.cub.2004.11.002; BOYLE IT, 1971, P NATL ACAD SCI USA, V68, P2131, DOI 10.1073/pnas.68.9.2131; Brenza HL, 2000, ARCH BIOCHEM BIOPHYS, V381, P143, DOI 10.1006/abbi.2000.1970; Christakos S, 2016, PHYSIOL REV, V96, P365, DOI 10.1152/physrev.00014.2015; Conkright MD, 2003, MOL CELL, V12, P413, DOI 10.1016/j.molcel.2003.08.013; Core LJ, 2008, SCIENCE, V322, P1845, DOI 10.1126/science.1162228; Filippakopoulos P, 2012, CELL, V149, P214, DOI 10.1016/j.cell.2012.02.013; GARABEDIAN M, 1972, P NATL ACAD SCI USA, V69, P1673, DOI 10.1073/pnas.69.7.1673; Goodman RH, 2000, GENE DEV, V14, P1553; Haussler M R, 1980, Prog Biochem Pharmacol, V17, P134; Hill MJ, 2016, MOL ENDOCRINOL, V30, P104, DOI 10.1210/me.2015-1237; Homer-Bouthiette C, 2014, J BIOL CHEM, V289, P36303, DOI 10.1074/jbc.M114.619569; Impey S, 2004, CELL, V119, P1041, DOI 10.1016/j.cell.2004.10.032; Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193; Lee SM, 2015, J BIOL CHEM, V290, P30573, DOI 10.1074/jbc.M115.693614; Lee SM, 2015, J BIOL CHEM, V290, P18199, DOI 10.1074/jbc.M115.665794; Louet JF, 2010, CELL METAB, V12, P606, DOI 10.1016/j.cmet.2010.11.009; Meyer MB, 2007, J BIOL CHEM, V282, P22344, DOI 10.1074/jbc.M703475200; Meyer MB, 2020, J STEROID BIOCHEM, V196, DOI 10.1016/j.jsbmb.2019.105500; Meyer MB, 2019, J BIOL CHEM, V294, P14467, DOI 10.1074/jbc.RA119.010173; Meyer MB, 2019, J BIOL CHEM, V294, P9518, DOI 10.1074/jbc.RA119.008760; Meyer MB, 2017, J BIOL CHEM, V292, P17541, DOI 10.1074/jbc.M117.806901; Meyer MB, 2016, J BIOL CHEM, V291, P17829, DOI 10.1074/jbc.M116.736538; Meyer MB, 2014, J BIOL CHEM, V289, P19539, DOI 10.1074/jbc.M114.578104; Meyer MB, 2014, J BIOL CHEM, V289, P16016, DOI 10.1074/jbc.M114.552216; Meyer MB, 2014, J STEROID BIOCHEM, V144, P19, DOI 10.1016/j.jsbmb.2013.09.005; Meyer MB, 2012, MOL ENDOCRINOL, V26, P37, DOI 10.1210/me.2011-1109; Meyer MB, 2010, J STEROID BIOCHEM, V121, P136, DOI 10.1016/j.jsbmb.2010.02.011; Meyer MB, 2010, J BIOL CHEM, V285, P15599, DOI 10.1074/jbc.M110.119958; Nishimori S, 2019, J CLIN INVEST, V129, P5187, DOI 10.1172/JCI130126; OMDAHL JL, 1972, NATURE-NEW BIOL, V237, P63, DOI 10.1038/newbio237063a0; Pike JW, 2021, JBMR PLUS, V5, DOI 10.1002/jbm4.10433; Pike JW, 2017, J CLIN INVEST, V127, P1146, DOI 10.1172/JCI88887; Pike JW, 2016, VITAM HORM, V100, P21, DOI 10.1016/bs.vh.2015.10.011; Prosser DE, 2004, TRENDS BIOCHEM SCI, V29, P664, DOI 10.1016/j.tibs.2004.10.005; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Saito H, 2005, J BIOL CHEM, V280, P2543, DOI 10.1074/jbc.M408903200; Screaton RA, 2004, CELL, V119, P61, DOI 10.1016/j.cell.2004.09.015; Shimada T, 2004, J CLIN INVEST, V113, P561, DOI 10.1172/JCI200419081; Shimada T, 2001, P NATL ACAD SCI USA, V98, P6500, DOI 10.1073/pnas.101545198; Sundberg TB, 2016, ACS CHEM BIOL, V11, P2105, DOI 10.1021/acschembio.6b00217; Tagami T, 1998, BIOCHEM BIOPH RES CO, V253, P358, DOI 10.1006/bbrc.1998.9799; Tang C. C., 2021, J BONE MINER RES, V36, P1; Tang CC, 2021, ELIFE, V10, DOI 10.7554/eLife.67772; Van de Velde S, 2019, MOL CELL BIOL, V39, DOI 10.1128/MCB.00200-19; Veldurthy V, 2016, VITAM HORM, V100, P137, DOI 10.1016/bs.vh.2015.10.005; Wein MN, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031237; Wein MN, 2018, TRENDS ENDOCRIN MET, V29, P723, DOI 10.1016/j.tem.2018.08.004; Wein MN, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13176; Zhang XM, 2005, P NATL ACAD SCI USA, V102, P4459, DOI 10.1073/pnas.0501076102; ZIEROLD C, 1995, J BIOL CHEM, V270, P1675, DOI 10.1074/jbc.270.4.1675	52	0	0	2	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV	2022	298	11							102559	10.1016/j.jbc.2022.102559	http://dx.doi.org/10.1016/j.jbc.2022.102559			18	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	6D3XI	36183832	Green Published, gold			2022-12-28	WOS:000882627400011
J	JEFFERS, M; PELLICER, A				JEFFERS, M; PELLICER, A			MULTIPLE INTRAGENIC ELEMENTS REGULATE THE EXPRESSION OF THE MURINE N-RAS GENE	ONCOGENE			English	Article							ADENOSINE-DEAMINASE GENE; RNA POLYMERASE-II; C-MYC GENE; TRANSCRIPTIONAL ARREST; SEQUENCE REQUIREMENTS; PREMATURE TERMINATION; TRANSFORMING GENES; RIBONUCLEIC-ACID; MAMMALIAN-CELLS; SARCOMA-VIRUSES	We have identified two separate regions within the murine N-ras transcription unit which may participate in the regulation of N-ras gene expression. One of these regions, localized to the first half of intron 1, contains a site of premature transcriptional arrest. We propose that premature transcription termination, which has been identified as an important control mechanism for several genes, may also play a role in the regulation of the N-ras gene. In addition, we have identified a positively acting region within the N-ras transcription unit. This region, localized to the end of intron 1/beginning of exon 1, was found to greatly increase expression from the N-ras promoter.	NYU MED CTR,DEPT PATHOL,NEW YORK,NY 10016; NYU MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016	New York University; New York University			MARTINEZ, ANTONIO PELLICER/C-4832-2015	Pellicer, Angel/0000-0002-5062-0692	NATIONAL CANCER INSTITUTE [R37CA036327, R01CA036327, R01CA050434] Funding Source: NIH RePORTER; NCI NIH HHS [CA36327, CA50434] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARONOW B, 1989, GENE DEV, V3, P1384, DOI 10.1101/gad.3.9.1384; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BENTLEY DL, 1991, J CELL BIOCH SG, V15, P268; BESMOND C, 1987, CURRENT PROTOCOLS MO, V1; CHANG EH, 1982, NATURE, V297, P479, DOI 10.1038/297479a0; CHANG HY, 1987, ONCOGENE RES, V1, P129; CHEN Z, 1990, MOL CELL BIOL, V10, P4555, DOI 10.1128/MCB.10.9.4555; CHEN Z, 1991, MOL CELL BIOL, V11, P6248, DOI 10.1128/MCB.11.12.6248; CHINSKY JM, 1989, J BIOL CHEM, V264, P14561; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOI T, 1991, MOL CELL BIOL, V11, P3070, DOI 10.1128/MCB.11.6.3070; CHUNG S, 1989, MOL CELL BIOL, V9, P2075, DOI 10.1128/MCB.9.5.2075; COHEN JB, 1988, NATURE, V334, P119, DOI 10.1038/334119a0; DER CJ, 1982, P NATL ACAD SCI-BIOL, V79, P3637, DOI 10.1073/pnas.79.11.3637; DONIGER J, 1988, NUCLEIC ACIDS RES, V16, P969, DOI 10.1093/nar/16.3.969; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; FARNHAM PJ, 1990, MOL CELL BIOL, V10, P1390, DOI 10.1128/MCB.10.4.1390; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FUJITA J, 1985, P NATL ACAD SCI USA, V82, P3849, DOI 10.1073/pnas.82.11.3849; GEROSA MA, 1989, J NATL CANCER I, V81, P63, DOI 10.1093/jnci/81.1.63; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERG M, 1987, CURRENT PROTOCOLS MO, V1; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GUERRERO I, 1986, J CELL PHYSIOL, V129, P71, DOI 10.1002/jcp.1041290111; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HALL A, 1985, NUCLEIC ACIDS RES, V13, P5255, DOI 10.1093/nar/13.14.5255; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; HONKAWA H, 1987, MOL CELL BIOL, V7, P2933, DOI 10.1128/MCB.7.8.2933; INGOLIA DE, 1986, MOL CELL BIOL, V6, P4458, DOI 10.1128/MCB.6.12.4458; INNIS JW, 1991, MOL CELL BIOL, V11, P5398, DOI 10.1128/MCB.11.11.5398; JEFFERS M, 1990, NUCLEIC ACIDS RES, V18, P4891; LATTIER DL, 1989, NUCLEIC ACIDS RES, V17, P1061, DOI 10.1093/nar/17.3.1061; LEE PC, 1973, DEV BIOL, V31, P227, DOI 10.1016/0012-1606(73)90259-5; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; LONDON L, 1991, MOL CELL BIOL, V11, P4599, DOI 10.1128/MCB.11.9.4599; LOWNDES NF, 1989, MOL CELL BIOL, V9, P3758, DOI 10.1128/MCB.9.9.3758; MANGUES R, 1992, IN PRESS ONCOGENE; MCKAY IA, 1986, EMBO J, V5, P2617, DOI 10.1002/j.1460-2075.1986.tb04542.x; MECHTI N, 1991, MOL CELL BIOL, V11, P2832, DOI 10.1128/MCB.11.5.2832; MICOLAIEW N, 1991, ONCOGENE, V6, P721; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; PACIUCCI R, 1991, MOL CELL BIOL, V11, P1334, DOI 10.1128/MCB.11.3.1334; PROUDFOOT NJ, 1986, NATURE, V322, P562, DOI 10.1038/322562a0; PULCIANI S, 1985, MOL CELL BIOL, V5, P2836, DOI 10.1128/MCB.5.10.2836; RAMAMURTHY V, 1990, MOL CELL BIOL, V10, P1484, DOI 10.1128/MCB.10.4.1484; ROEDER RG, 1974, J BIOL CHEM, V249, P241; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SCHWAB M, 1983, NATURE, V303, P497, DOI 10.1038/303497a0; SPENCER CA, 1990, ONCOGENE, V5, P777; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; THORN JT, 1991, ONCOGENE, V65, P1843; WINTER E, 1986, MOL CELL BIOL, V6, P2562, DOI 10.1128/MCB.6.7.2562; YAMAMOTO F, 1988, ONCOGENE RES, V3, P125; YANG JQ, 1986, EMBO J, V5, P3553, DOI 10.1002/j.1460-2075.1986.tb04682.x	60	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2115	2123						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437142				2022-12-28	WOS:A1992JW66500003
J	LANZI, C; BORRELLO, MG; BONGARZONE, I; MIGLIAZZA, A; FUSCO, A; GRIECO, M; SANTORO, M; GAMBETTA, RA; ZUNINO, F; DELLAPORTA, G; PIEROTTI, MA				LANZI, C; BORRELLO, MG; BONGARZONE, I; MIGLIAZZA, A; FUSCO, A; GRIECO, M; SANTORO, M; GAMBETTA, RA; ZUNINO, F; DELLAPORTA, G; PIEROTTI, MA			IDENTIFICATION OF THE PRODUCT OF 2 ONCOGENIC REARRANGED FORMS OF THE RET PROTOONCOGENE IN PAPILLARY THYROID CARCINOMAS	ONCOGENE			English	Article							TYROSINE KINASE; AFFINITY-CHROMATOGRAPHY; PHOSPHORYLATION; NEUROBLASTOMA; ACTIVATION; PROTEINS; PTC; PROTOONCOGENE; EXPRESSION; RECEPTOR	In papillary thyroid carcinomas, we have identified two tumor-specific rearrangements of the RET protooncogene leading to the formation of different transforming fusion products sharing the tyrosine kinase (tk) domain of the proto-oncogene and designated ptc-1 and ptc-2. We have analysed ptc-1 and ptc-2 products by immunoprecipitation with specific anti-RET antibodies followed by immunoblotting with the same reagent or with antibodies specific for phosphotyrosine (P-tyr) residues. The anti-RET antibodies were reactive with 64-kDa (p64ptc-1) and 81-kDa (p81ptc-2) proteins from lysates of ptc-1 and ptc-2 transformed cells, respectively, and identified two proteins of 140 kDa and 160 kDa from extracts of SK-N-SH, a neuroblastoma cell line previously shown to express two differently glycosylated forms of the normal RET product. The anti P-tyr antibodies, while detecting the same p64ptc-1 and p81ptc-2 proteins from ptc-1 and ptc-2 extracts, did not show any specific band in the neuroblastoma lysates. An additional set of experiments led us to conclude that, whereas the normal product of the RET proto-oncogene is a membrane-associated receptor-like molecule not intrinsically phosphorylated on tyrosine, both oncogenic forms of RET, ptc-1 and ptc-2, are constitutively phosphorylated on tyrosine, display an 'in vitro' autophosphorylation activity, are translocated from the membrane to the cytoplasm and are apparently unaffected by protein kinase C modulation.	IST NAZL TUMORI, DIV ONCOL SPERIMENTALE B, VIA G VENEZIAN 1, I-20133 MILAN, ITALY; NAPLES UNIV, DIPARTIMENTO BIOL PATOL CELLULARE & MOLEC, CNR, I-80134 NAPLES, ITALY; IST NAZL TUMORI, DIV ONCOL SPERIMENTALE A, I-20133 MILAN, ITALY; UNIV REGGIO CALABRIA, FAC MED & CHIRURG CATANZARO, DIPARTIMENTO MED SPERIMENTALE & CLIN, CALABRIA, ITALY	Fondazione IRCCS Istituto Nazionale Tumori Milan; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Fondazione IRCCS Istituto Nazionale Tumori Milan; Universita Mediterranea di Reggio Calabria			Borrello, Maria Grazia/C-3161-2017; Lanzi, Cinzia/J-6539-2016; Pierotti, Marco Alessandro/AAC-4728-2022; Bongarzone, Italia/B-9544-2017	Borrello, Maria Grazia/0000-0002-6854-2848; Lanzi, Cinzia/0000-0002-4480-9413; Pierotti, Marco Alessandro/0000-0002-7431-8332; Bongarzone, Italia/0000-0003-2530-9170; Fusco, Alfredo/0000-0003-3332-5197; Grieco, Michele/0000-0002-4212-7814				BARBACID M, 1981, J VIROL, V40, P812, DOI 10.1128/JVI.40.3.812-821.1981; BONGARZONE I, 1989, ONCOGENE, V4, P1457; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CIRILLO DM, 1986, MOL CELL BIOL, V6, P4641, DOI 10.1128/MCB.6.12.4641; DONGHI R, 1989, ONCOGENE, V4, P521; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; GANDINO L, 1990, ONCOGENE, V5, P721; GIORDANO S, 1989, ONCOGENE, V4, P1383; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; IKEDA I, 1990, ONCOGENE, V5, P1291; ISHIZAKA Y, 1989, ONCOGENE, V4, P789; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; KODA T, 1988, Hokkaido Journal of Medical Science, V63, P913; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDT M, 1978, BIOCHEMISTRY-US, V17, P915, DOI 10.1021/bi00598a027; LAU KHW, 1989, BIOCHEM J, V257, P23, DOI 10.1042/bj2570023; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; PIEROTTI MA, 1992, P NATL ACAD SCI USA, V89, P1616, DOI 10.1073/pnas.89.5.1616; ROSS AH, 1981, NATURE, V294, P654, DOI 10.1038/294654a0; SANTORO M, 1992, IN PRESS J CLIN INVE, V3; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; SOZZI G, 1991, ONCOGENE, V6, P339; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1991, ONCOGENE, V6, P297; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VAUGHAN JM, 1989, METHOD ENZYMOL, V168, P588	29	77	81	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1992	7	11					2189	2194						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437145				2022-12-28	WOS:A1992JW66500011
J	OKUDA, T; CLEVELAND, JL; DOWNING, JR				OKUDA, T; CLEVELAND, JL; DOWNING, JR			PCTAIRE-1 AND PCTAIRE-3, 2 MEMBERS OF A NOVEL CDC2/CDC28-RELATED PROTEIN-KINASE GENE FAMILY	ONCOGENE			English	Review							CELL-CYCLE CONTROL; SEA-URCHIN EGGS; SACCHAROMYCES-CEREVISIAE; FISSION YEAST; TYROSINE PHOSPHORYLATION; SCHIZOSACCHAROMYCES-POMBE; M-PHASE; DIVISION CYCLE; CDC25 PROTEIN; MESSENGER-RNA	We have isolated two murine cDNAs designated PCTAIRE-1 and -3 which encode putative serine/threonine-specific protein kinases. The predicted products of PCTAIRE-1 and -3 are 65% homologous and are organized into a core 295-residue kinase domain flanked by unique 161 and 117 amino acid N-terminal and 40 and 39 amino acid C-terminal domains respectively. The kinase domains are approximately 50-55% homologous to members of the cdc2/CDC28 kinase gene family, and each contains a cysteine-for-serine substitution within the conserved PSTAIRE motif. PCTAIRE-1 was ubiquitously expressed as a predominant 3.0-kb transcript and a minor 2.2-kb mRNA resulting from differential polyadenylation. In contrast, PCTAIRE-3 exhibited a more restricted pattern of expression with a single 3.0-kb mRNA detected in brain, kidney and intestine. The PCTAIRE-1 and -3 products produced by in vitro transcription-translation failed to bind to p13suc1 but were precipitated by antibodies directed to Schizosaccharomyces pombe p34cdc2 or to the human PSTAIRE motif. Thus, PCTAIRE-1 and -3 are members of a novel subfamily of cdc2/CDC28-related protein kinases.	ST JUDE CHILDRENS RES HOSP, DEPT PATHOL, 575 ST JUDE PL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital			Downing, James R./N-8102-2018		NCI NIH HHS [CA-21765, CA-01429] Funding Source: Medline; NIDDK NIH HHS [DK-44158] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA001429, P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044158] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON SJ, 1984, J VIROL, V51, P730, DOI 10.1128/JVI.51.3.730-741.1984; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BLENIS J, 1991, CANCER CELL-MON REV, V3, P445; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; BUNNELL BA, 1990, P NATL ACAD SCI USA, V87, P7467, DOI 10.1073/pnas.87.19.7467; BUSTOS JG, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Cleveland J L, 1988, Oncogene Res, V3, P357; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUCOMMUN B, 1991, MOL CELL BIOL, V11, P6177, DOI 10.1128/MCB.11.12.6177; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FERAMISCO JR, 1980, J BIOL CHEM, V255, P4240; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HADWIGER JA, 1989, MOL CELL BIOL, V9, P2034, DOI 10.1128/MCB.9.5.2034; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HAYLES J, 1986, MOL GEN GENET, V202, P291, DOI 10.1007/BF00331653; HAYLES J, 1986, EMBO J, V5, P3373, DOI 10.1002/j.1460-2075.1986.tb04653.x; HINDLEY J, 1987, MOL CELL BIOL, V7, P504, DOI 10.1128/MCB.7.1.504; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; IGARASHI M, 1991, NATURE, V353, P80, DOI 10.1038/353080a0; JOHNSON KW, 1991, J BIOL CHEM, V266, P3402; KIDD VJ, 1991, CELL GROWTH DIFFER, V2, P85; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LAPIDOTLIFSON Y, 1992, DEV BIOL, V89, P579; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LORINCZ AT, 1984, NATURE, V307, P183, DOI 10.1038/307183a0; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MATSUSHIME H, 1990, MOL CELL BIOL, V10, P2261, DOI 10.1128/MCB.10.5.2261; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PINES J, 1987, EMBO J, V6, P2987, DOI 10.1002/j.1460-2075.1987.tb02604.x; PINES J, 1990, New Biologist, V2, P389; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; REED SI, 1980, GENETICS, V95, P561; REID BJ, 1977, J CELL BIOL, V75, P355, DOI 10.1083/jcb.75.2.355; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; RICHARDSON HE, 1990, GENE DEV, V4, P1332, DOI 10.1101/gad.4.8.1332; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SAMIEI M, 1991, J BIOL CHEM, V266, P14889; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SUDBERY PE, 1980, NATURE, V288, P401, DOI 10.1038/288401a0; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; UESONO Y, 1987, NUCLEIC ACIDS RES, V15, P10299, DOI 10.1093/nar/15.24.10299; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	104	98	103	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1992	7	11					2249	2258						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437147				2022-12-28	WOS:A1992JW66500017
J	WOLDA, SL; MOON, RT				WOLDA, SL; MOON, RT			CLONING AND DEVELOPMENTAL EXPRESSION IN XENOPUS-LAEVIS OF 7 ADDITIONAL MEMBERS OF THE WNT FAMILY	ONCOGENE			English	Article							PROTO-ONCOGENE INT-1; MOUSE DEVELOPMENT; NEURAL-TUBE; EMBRYOS; GENE; PROTOONCOGENE; INSERTION; PRODUCTS; PROTEINS; SEQUENCE	Degenerate oligonucleotide primers encoding highly conserved regions of Wnt-related proteins were used with the polymerase chain reaction (PCR) to amplify cDNA derived from Xenopus laevis embryos. cDNA sequences partially encoding seven additional members of the Xwnt gene family were isolated using this strategy. These cDNAs have been given the designation Xwnt-2, Xwnt-6, Xwnt-7A, Xwnt-7B, Xwnt-7C, Xwnt-8B and Xwnt-10 based on their amino acid identity with previously described Wnts. With regard to the timing of expression of these Xwnts during embryonic development, Xwnt-2, the least abundant transcript, was first detected during the neurula stage, while Xwnt-8B transcripts were first detected at the gastrula stage, and decreased by the tailbud stage. Multiple transcripts of Xwnt-6 were detected at varied times during development beginning at the gastrula stage. In contrast, Xwnt-7A, -7B and -10 transcripts were not detected until the tailbud stage. With regard to expression in adult tissues, Xwnt-6, -7A, -7B, -8B and -10 were all expressed abundantly in the brain, and to a lesser extent in a variety of other tissues. Whole-mount in situ hybridization was then employed to monitor the spatial expression of selected Xwnts. Xwnt-7A and -10 transcripts were detected in distinct areas of the developing brain of tailbud-stage embryos. The temporal and spatial differences in expression suggest different roles for these new Xwnt family members in Xenopus development.	UNIV WASHINGTON,SCH MED,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle			Moon, Randall T/B-1743-2014	Moon, Randall T/0000-0002-9352-1408	NHLBI NIH HHS [T32HL07312] Funding Source: Medline; NIAMS NIH HHS [K04AR1837] Funding Source: Medline; NICHD NIH HHS [R01HD27525] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027525] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007312] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K04AR001837] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; BROWN AMC, 1987, MOL CELL BIOL, V7, P3971, DOI 10.1128/MCB.7.11.3971; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTIAN JL, 1992, EMBO J, V11, P33, DOI 10.1002/j.1460-2075.1992.tb05024.x; CHRISTIAN JL, 1991, DEV BIOL, V143, P230, DOI 10.1016/0012-1606(91)90073-C; CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; KELLY GM, 1991, METHOD CELL BIOL, V36, P389; Maniatis T., 1982, MOL CLONING; MCGREW LL, 1992, IN PRESS DEVELOPMENT; MCMAHON AP, 1989, DEVELOPMENT, V107, P161; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MCMAHON AP, 1992, ADV DEV BIOL, V1, P31; MCMAHON JA, 1989, DEVELOPMENT, V107, P643; Moon R. T., 1989, TECHNIQUE, V1, P76; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NOORDERMEER J, 1989, NUCLEIC ACIDS RES, V17, P11, DOI 10.1093/nar/17.1.11; NUSSE R, 1988, TRENDS GENET, V4, P291, DOI 10.1016/0168-9525(88)90172-2; NUSSE R, 1990, MOL CELL BIOL, V10, P4170, DOI 10.1128/MCB.10.8.4170; OLSON DJ, 1991, SCIENCE, V252, P1173, DOI 10.1126/science.252.5009.1173; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PAPKOFF J, 1987, MOL CELL BIOL, V7, P3978, DOI 10.1128/MCB.7.11.3978; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; ROELINK H, 1991, GENE DEV, V5, P381, DOI 10.1101/gad.5.3.381; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7	35	54	62	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					1941	1947						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408135				2022-12-28	WOS:A1992JP42400006
J	ITOH, F; ISHIZAKA, Y; TAHIRA, T; YAMAMOTO, M; MIYA, A; IMAI, K; YACHI, A; TAKAI, S; SUGIMURA, T; NAGAO, M				ITOH, F; ISHIZAKA, Y; TAHIRA, T; YAMAMOTO, M; MIYA, A; IMAI, K; YACHI, A; TAKAI, S; SUGIMURA, T; NAGAO, M			IDENTIFICATION AND ANALYSIS OF THE RET PROTOONCOGENE PROMOTER REGION IN NEUROBLASTOMA CELL-LINES AND MEDULLARY-THYROID CARCINOMAS FROM MEN2A-PATIENTS	ONCOGENE			English	Article							FACTOR RECEPTOR GENE; MESSENGER-RNA; MOLECULAR-CLONING; EXPRESSION; DNA; PROTOONCOGENE; TRANSCRIPTION; SEQUENCES; VECTORS; TRANSFORMATION	The human ret proto-oncogene (proto-ret), encoding a receptor tyrosine kinase, is highly expressed in neuroblastomas, medullary thyroid carcinomas (MTCs) and pheochromocytomas, which are all tumors of cells originating from the neural crest. In studies on the transcription mechanism of proto-ret, we identified the transcription start site and the promoter region by chloramphenicol acetyl transferase (CAT) assay. A sequence upstream from the transcription start site (- 167 to + 98 bp) showed definite promoter activity in both proto-ret mRNA-positive neuroblastoma NB39-nu cells and proto-ret mRNA-negative HeLa cells. The promoter sequence had a high GC content and contained four tandemly repeated GC boxes without a TATA box. Putative binding sequences for SP-1, AP-2 and epidermal growth factor receptor-specific transcription factor (ETF) and also the transcription-suppressing factor, GC factor (GCF), were found in the repeated GC box region. Southern blot analysis of DNAs of neuroblastoma cell lines and primary MTCs showed that the high proto-ret expression in these tumors is not caused by gross genetic changes in the promoter region, suggesting the possible involvement of a region(s) other than the sequence from - 167 to + 98 bp or a minor genetic change(s) in the promoter region.	NATL CANC CTR,DIV CARCINOGENESIS,1-1 TSUKIJI-5,CHUO KU,TOKYO 104,JAPAN; OSAKA UNIV,SCH MED,DEPT SURG 2,FUKUSHIMA KU,OSAKA 553,JAPAN; SAPPORO MED COLL,DEPT INTERNAL MED 1,CHUO KU,SAPPORO,HOKKAIDO 060,JAPAN; OSAKA UNIV,SCH MED,BIOMED RES CTR,DIV MED GENET,FUKUSHIMA KU,OSAKA 553,JAPAN	National Cancer Center - Japan; Osaka University; Sapporo Medical University; Osaka University								ARAKI E, 1987, J BIOL CHEM, V262, P16186; ARAKI E, 1988, NUCLEIC ACIDS RES, V16, P1627, DOI 10.1093/nar/16.4.1627; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; EFSTRATIADIS A, 1980, CELL, V21, P653, DOI 10.1016/0092-8674(80)90429-8; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GREEN MR, 1980, CELL, V22, P231, DOI 10.1016/0092-8674(80)90171-3; GROSSCHEDL R, 1980, P NATL ACAD SCI-BIOL, V77, P1432, DOI 10.1073/pnas.77.3.1432; IKEDA I, 1990, ONCOGENE, V5, P1291; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; ISHIZAKA Y, 1989, ONCOGENE, V4, P1519; ISHIZAKA Y, 1988, ONCOGENE RES, V3, P193; ITOH F, 1989, Tumor Research, V24, P1; KAGEYAMA R, 1988, P NATL ACAD SCI USA, V85, P5016, DOI 10.1073/pnas.85.14.5016; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KAGEYAMA R, 1989, J BIOL CHEM, V264, P15508; LAU YF, 1983, P NATL ACAD SCI-BIOL, V80, P5225, DOI 10.1073/pnas.80.17.5225; MAEKAWA T, 1989, J BIOL CHEM, V264, P5488; MATHEW CGP, 1987, NATURE, V328, P527, DOI 10.1038/328527a0; MELTON DW, 1984, P NATL ACAD SCI-BIOL, V81, P2147, DOI 10.1073/pnas.81.7.2147; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MIYAZAKI J, 1989, GENE, V79, P269; NAGAO M, 1990, JPN J CANCER RES, V81, P309, DOI 10.1111/j.1349-7006.1990.tb02566.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO M, 1990, ONCOGENE, V5, P1595; SZENTIRMAY Z, 1990, ONCOGENE, V5, P701; TAHIRA T, 1991, ONCOGENE, V6, P2333; TAHIRA T, 1988, BIOCHEM BIOPH RES CO, V153, P1290, DOI 10.1016/S0006-291X(88)81368-8; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1988, ONCOGENE, V3, P571; VALERIO D, 1985, EMBO J, V4, P437, DOI 10.1002/j.1460-2075.1985.tb03648.x; YAMAMOTO F, 1988, ONCOGENE RES, V3, P125; YAMAMOTO M, 1991, JPN J CLIN ONCOL, V21, P149; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	38	49	49	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1992	7	6					1201	1206						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1350670				2022-12-28	WOS:A1992HU64200018
J	KHANDJIAN, EW; TREMBLAY, S				KHANDJIAN, EW; TREMBLAY, S			PHOSPHORYLATION OF THE RETINOBLASTOMA PROTEIN IS MODULATED IN MOUSE KIDNEY-CELLS INFECTED WITH POLYOMAVIRUS	ONCOGENE			English	Article							LARGE T-ANTIGEN; SUSCEPTIBILITY GENE-PRODUCT; LARGE TUMOR-ANTIGEN; RESOLUTION 2-DIMENSIONAL ELECTROPHORESIS; DNA-BINDING PROTEIN; SIMIAN-VIRUS 40; CELLULAR RNA; RB GENE; NUCLEAR MATRIX; EXPRESSION	Lytic infection with polyomavirus, an oncogenic DNA-containing virus, leads in G0-arrested primary baby mouse kidney (BMK) cell cultures to a mitotic host reaction. In the present work, we examined the expression of the retinoblastoma gene (RB) and of its product (Rb) in virus-infected BMK with the aim of correlating its modulation with the sequential activation of cellular processes leading to the induction of S phase by virus. In contrast to cell cycle-regulated genes whose expression is induced by viral infection, expression of RB is not altered during the transition from G0/G1 to S phase. In BMK cell cultures irreversibly arrested in the G0 phase of the cell cycle, an unphosphorylated species is the only detectable form of the RB protein (Rb). Time course analysis showed that in polyoma-infected cells induced to re-enter the S phase of the cell cycle the appearance of the phosphorylated forms of Rb coincided in time with the accumulation of large T antigen and preceded DNA synthesis. During the late phase of infection, the majority of Rb was present as phosphorylated forms. Ongoing DNA synthesis was not required for the cells to phosphorylate Rb, indicating that this post-translational modification takes place during the activation of the cellular DNA-synthesizing apparatus. Using hamster anti-polyoma tumor serum, it was observed that the underphosphorylated form of Rb co-precipitated with polyoma large T antigen extracted from infected cells late during infection. Our data add more evidence to the proposal that interactions between viral early proteins encoded by DNA tumor viruses and the product of RB may play a pivotal role in the mitogenic effect induced by viral infection.	HOP ST FRANCOIS ASSISE,UNITE RECH GENET HUMAINE & MOLEC,QUEBEC CITY G1L 3L5,QUEBEC,CANADA	Laval University	KHANDJIAN, EW (corresponding author), UNIV LAVAL,FAC MED,DEPT BIOCHIM,QUEBEC CITY G1K 7P4,QUEBEC,CANADA.							BASERGA R, 1985, BIOL CELL REPRODUCTI; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CARROLL RB, 1988, ONCOGENE, V2, P437; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CLEGHON VG, 1986, P NATL ACAD SCI USA, V83, P8947, DOI 10.1073/pnas.83.23.8947; CRAWFORD LV, 1979, J VIROL, V29, P587, DOI 10.1128/JVI.29.2.587-596.1979; DARLIX JL, 1984, P NATL ACAD SCI-BIOL, V81, P5425, DOI 10.1073/pnas.81.17.5425; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEFROMENTEL CC, 1986, EXP CELL RES, V164, P35, DOI 10.1016/0014-4827(86)90452-0; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; DUTHU A, 1985, VIROLOGY, V147, P275, DOI 10.1016/0042-6822(85)90130-8; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1350; Fakan S, 1980, Int Rev Cytol, V65, P255; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; GALLINARO H, 1983, EMBO J, V2, P953, DOI 10.1002/j.1460-2075.1983.tb01527.x; GRENSPAN DS, 1979, VIROLOGY, V99, P413; HANCOCK R, 1982, INT REV CYTOL, V79, P165; HASSOUNA N, 1984, NUCLEIC ACIDS RES, V12, P3563, DOI 10.1093/nar/12.8.3563; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HRABARENEVEY S, 1989, ONCOGENE, V4, P601; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; HUMPHREY GW, 1987, EXP CELL RES, V171, P122, DOI 10.1016/0014-4827(87)90256-4; KESSLER SW, 1975, J IMMUNOL, V115, P1617; KHANDJIAN EW, 1982, P NATL ACAD SCI-BIOL, V79, P1139, DOI 10.1073/pnas.79.4.1139; KHANDJIAN EW, 1983, MOL CELL BIOL, V3, P1; KHANDJIAN EW, 1980, P NATL ACAD SCI-BIOL, V77, P1476, DOI 10.1073/pnas.77.3.1476; KHANDJIAN EW, 1986, MOL BIOL REP, V11, P107, DOI 10.1007/BF00364822; KHANDJIAN EW, 1988, ONCOGENE, V3, P195; KLEIN H, 1979, J BIOL CHEM, V254, P1051; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAROSE A, 1991, J VIROL, V65, P2308, DOI 10.1128/JVI.65.5.2308-2313.1991; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LIU HT, 1985, MOL CELL BIOL, V5, P2936, DOI 10.1128/MCB.5.11.2936; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MARRIOTT SJ, 1985, J VIROL, V56, P365, DOI 10.1128/JVI.56.2.365-372.1985; MATTER JM, 1983, NUCLEIC ACIDS RES, V11, P6611, DOI 10.1093/nar/11.19.6611; MATTER JM, 1983, NUCLEIC ACIDS RES, V11, P1039, DOI 10.1093/nar/11.4.1039; MATTER JM, 1982, NUCLEIC ACIDS RES, V10, P7643, DOI 10.1093/nar/10.23.7643; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MURPHREE AL, 1984, SCIENCE, V223, P1028, DOI 10.1126/science.6320372; NIELSCH U, 1991, ONCOGENE, V6, P1031; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; PALME K, 1980, FEBS LETT, V118, P229, DOI 10.1016/0014-5793(80)80225-0; PALME K, 1983, ELECTROPHORESIS, P403; PARDEE AB, 1978, ANNU REV BIOCHEM, V47, P715, DOI 10.1146/annurev.bi.47.070178.003435; POCHRON S, 1980, J BIOL CHEM, V255, P4411; PUVION E, 1988, EXP CELL RES, V177, P73, DOI 10.1016/0014-4827(88)90026-2; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROSE TM, 1992, BIOCHEM CELL BIOL, V70, P149, DOI 10.1139/o92-022; ROSSINI M, 1979, P NATL ACAD SCI USA, V76, P4441, DOI 10.1073/pnas.76.9.4441; SALOMON C, 1977, NUCLEIC ACIDS RES, V4, P1483, DOI 10.1093/nar/4.5.1483; SALZMAN NP, 1986, PAPOVAVIRUSES, V1; SAMAD A, 1991, MOL CELL BIOL, V11, P1598, DOI 10.1128/MCB.11.3.1598; SCHWYZER M, 1980, J BIOL CHEM, V255, P5627; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; THOMAS NSB, 1991, ONCOGENE, V6, P317; TOGUCHIDA J, 1988, CANCER RES, V48, P3939; Tooze J., 1980, MOL BIOL TUMOR VIR 2; TURLER H, 1980, MOL CELL BIOCHEM, V32, P63; WAHRMANN JP, 1980, BIOCHIM BIOPHYS ACTA, V612, P421, DOI 10.1016/0005-2744(80)90125-4; WEIL R, 1978, BIOCHIM BIOPHYS ACTA, V516, P301, DOI 10.1016/0304-419X(78)90012-4; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; XU HJ, 1989, ONCOGENE, V4, P807; XU HJ, 1991, ONCOGENE, V6, P1139; YOKOTA J, 1988, ONCOGENE, V3, P471	73	15	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1992	7	5					909	917						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1373878				2022-12-28	WOS:A1992HP64200010
J	MAKELA, TP; SHIRAISHI, M; BORRELLO, MG; SEKIYA, T; ALITALO, K				MAKELA, TP; SHIRAISHI, M; BORRELLO, MG; SEKIYA, T; ALITALO, K			REARRANGEMENT AND CO-AMPLIFICATION OF L-MYC AND RLF IN PRIMARY LUNG-CANCER	ONCOGENE			English	Article							HUMAN NEURO-BLASTOMA; N-MYC; CELL-LINES; GENE AMPLIFICATION; FAMILY ONCOGENES; TUMOR-CELLS; DNA; ACTIVATION; EXPRESSION; REPEATS	We have recently characterized a gene fusion and chimeric protein product formed by L-myc and part of a novel gene named rlf in two small-cell lung cancer (SCLC) cell lines. The rlf-L-myc fusion gene is formed by intrachromosomal rearrangements placing the regulatory region and (at least) the first exon of rlf upstream of the L-myc gene. In the characterized cases the fusion gene has also been involved in DNA amplification. Here we report on a similar in vivo rearrangement involving rlf and L-myc in a primary SCLC tumor. In addition, we have found co-amplification of L-myc and rlf without visible rearrangements in either gene in three other SCLC tumors, confirming the physical linkage of these loci.	UNIV HELSINKI,DEPT VIROL,CANC BIOL LAB,HAARTMANINKATU 3,SF-00290 HELSINKI 29,FINLAND; UNIV HELSINKI,DEPT PATHOL,SF-00290 HELSINKI 29,FINLAND; NATL CANC CTR,RES INST,DIV ONCOGENE,CHUO KU,TOKYO 104,JAPAN; IST NAZL TUMORI,DIV EXPTL ONCOL A,I-20133 MILAN,ITALY	University of Helsinki; University of Helsinki; National Cancer Center - Japan; Fondazione IRCCS Istituto Nazionale Tumori Milan			Borrello, Maria Grazia/C-3161-2017; makela, tomi/B-3734-2009; Alitalo, Kari K/J-5013-2014	Borrello, Maria Grazia/0000-0002-6854-2848; makela, tomi/0000-0002-4869-8044; Alitalo, Kari K/0000-0002-7331-0902				ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; ALITALO K, 1987, BIOCHIM BIOPHYS ACTA, V907, P1, DOI 10.1016/0304-419X(87)90016-3; AMLER LC, 1989, MOL CELL BIOL, V9, P4903, DOI 10.1128/MCB.9.11.4903; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BRENNAN J, 1991, CANCER RES, V51, P1708; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; GAZZERI S, 1991, CANCER RES, V51, P2566; HIRVONEN H, 1990, ONCOGENE, V5, P1787; HYIYAMA E, 1991, CANCER RES, V51, P1946; HYRIEN O, 1987, EMBO J, V6, P2401, DOI 10.1002/j.1460-2075.1987.tb02518.x; JOHNSON BE, 1988, CANCER RES, V48, P5163; KATO H, 1989, FEBS LETT, V250, P529, DOI 10.1016/0014-5793(89)80790-2; KINZLER KW, 1986, P NATL ACAD SCI USA, V83, P1031, DOI 10.1073/pnas.83.4.1031; MAKELA TP, 1991, MOL CELL BIOL, V11, P4015; MAKELA TP, 1991, EMBO J, V10, P1331, DOI 10.1002/j.1460-2075.1991.tb07652.x; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; NOGUCHI M, 1990, CANCER, V66, P2053, DOI 10.1002/1097-0142(19901115)66:10<2053::AID-CNCR2820661002>3.0.CO;2-K; SCHWAB M, 1986, MOL CELL BIOL, V6, P2800; SHIRAISHI M, 1989, CANCER RES, V49, P6474; SHTIVELMAN E, 1989, MOL CELL BIOL, V9, P1148, DOI 10.1128/MCB.9.3.1148; STARK GR, 1984, ANNU REV BIOCHEM, V53, P447, DOI 10.1146/annurev.bi.53.070184.002311; TAKAHASHI T, 1989, CANCER RES, V49, P2683; TAYA Y, 1984, EMBO J, V3, P2943, DOI 10.1002/j.1460-2075.1984.tb02236.x; TONIN PN, 1989, ONCOGENE, V4, P1117; YOKOTA J, 1988, ONCOGENE, V2, P607; ZEHNBAUER BA, 1988, MOL CELL BIOL, V8, P522, DOI 10.1128/MCB.8.2.522; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	29	14	14	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1992	7	3					405	409						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1312699				2022-12-28	WOS:A1992HK00500002
J	Chang, C; Ma, G; Cheung, E; Hutchins, AP				Chang, Chen; Ma, Gang; Cheung, Edwin; Hutchins, Andrew P.			A programmable system to methylate and demethylate N6-methyladenosine (m6A) on specific RNA transcripts in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-CHROMOSOME INACTIVATION; MESSENGER-RNA; CRISPR SYSTEMS; M(6)A; GENE; TRANSLATION; ALKBH5; METTL3; N-6-METHYLADENOSINE; DISCOVERY	RNA N6-methyladenosine (m6A) is the most abundant in-ternal mRNA modification and forms part of an epitran-scriptomic system that modulates RNA function. m6A is reversibly catalyzed by specific enzymes, and those modifica-tions can be recognized by RNA-binding proteins that in turn regulate biological processes. Although there are many re-ports demonstrating m6A participation in critical biological functions, this exploration has mainly been conducted through the global KO or knockdown of the writers, erasers, or readers of m6A. Consequently, there is a lack of informa-tion about the role of m6A on single transcripts in biological processes, posing a challenge in understanding the biological functions of m6A. Here, we demonstrate a CRISPR/dCas13a-based RNA m6A editors, which can target RNAs using a sin-gle or multiple CRISPR RNA array to methylate or demeth-ylate m6A in human 293T cells and mouse embryonic stem cells. We systematically assay its capabilities to enable the targeted rewriting of m6A dynamics, including modulation of circular RNA translation and transcript half-life. Finally, we use the system to specifically modulate m6A levels on the noncoding JUST (X-inactive specific transcript) to modulate X chromosome silencing and activation. The editors described here can be used to explore the roles of m6A in biological processes.	[Chang, Chen; Ma, Gang; Hutchins, Andrew P.] Southern Univ Sci & Technol, Sch Life Sci, Dept Biol, Shenzhen, Peoples R China; [Chang, Chen; Cheung, Edwin] Univ Macau, Fac Hlth Sci, Canc Ctr, Taipa, Peoples R China; [Ma, Gang; Hutchins, Andrew P.] Southern Univ Sci & Technol, Sch Life Sci, Shenzhen Key Lab Gene Regulat & Syst Biol, Shenzhen, Peoples R China	Southern University of Science & Technology; University of Macau; Southern University of Science & Technology	Hutchins, AP (corresponding author), Southern Univ Sci & Technol, Sch Life Sci, Dept Biol, Shenzhen, Peoples R China.; Cheung, E (corresponding author), Univ Macau, Fac Hlth Sci, Canc Ctr, Taipa, Peoples R China.; Hutchins, AP (corresponding author), Southern Univ Sci & Technol, Sch Life Sci, Shenzhen Key Lab Gene Regulat & Syst Biol, Shenzhen, Peoples R China.	echeung@um.edu.mo; andrewh@sustech.edu.cn	Hutchins, Andrew/O-5708-2018	Hutchins, Andrew/0000-0001-7784-2255	National Natural Science Foundation of China [31970589, 32150710521]; Shenzhen Innovation Committee of Science and Technology [ZDSYS20200811144002008]; Stable Support Plan Program of Shenzhen Natural Science Fund [20200925153035002]; University of Macau [MYRG2020-00100-FHS]; Macau Science and Technology Development Fund [0011/2019/AKP]; Center for Computational Science and Engineering of Southern University of Science and Technology	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shenzhen Innovation Committee of Science and Technology; Stable Support Plan Program of Shenzhen Natural Science Fund; University of Macau; Macau Science and Technology Development Fund; Center for Computational Science and Engineering of Southern University of Science and Technology	We thank Jacob Hanna for the kind gift of the Mettl3 KO mESCs. This work was supported by the National Natural Science Foundation of China (grant nos.: 31970589 and 32150710521) , the Shenzhen Innovation Committee of Science and Technology (grant no.: ZDSYS20200811144002008) , the Stable Support Plan Program of Shenzhen Natural Science Fund (grant no.: 20200925153035002) , the University of Macau (grant no.: MYRG2020-00100-FHS) , and the Macau Science and Technology Development Fund (grant no.: 0011/2019/AKP) . This work was supported by the Center for Computational Science and Engineering of Southern University of Science and Technology.	Abakir A, 2020, NAT GENET, V52, P48, DOI 10.1038/s41588-019-0549-x; Abudayyeh OO, 2017, NATURE, V550, P280, DOI 10.1038/nature24049; Abudayyeh OO, 2016, SCIENCE, V353, DOI 10.1126/science.aaf5573; Barbieri I, 2017, NATURE, V552, P126, DOI 10.1038/nature24678; Barrangou R, 2007, SCIENCE, V315, P1709, DOI 10.1126/science.1138140; Batista PJ, 2014, CELL STEM CELL, V15, P707, DOI 10.1016/j.stem.2014.09.019; Bhaya D, 2011, ANNU REV GENET, V45, P273, DOI 10.1146/annurev-genet-110410-132430; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; Chen XN, 2021, ADV SCI, V8, DOI 10.1002/advs.202003902; Chu C, 2015, CELL, V161, P404, DOI 10.1016/j.cell.2015.03.025; Coker H, 2019, BBA-GENE REGUL MECH, V1862, P310, DOI 10.1016/j.bbagrm.2018.12.002; Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143; Cox DBT, 2017, SCIENCE, V358, P1019, DOI 10.1126/science.aaq0180; Deng XL, 2018, CELL RES, V28, P507, DOI 10.1038/s41422-018-0034-6; DESROSIERS R, 1974, P NATL ACAD SCI USA, V71, P3971, DOI 10.1073/pnas.71.10.3971; Dominissini D, 2012, NATURE, V485, P201, DOI 10.1038/nature11112; East-Seletsky A, 2016, NATURE, V538, P270, DOI 10.1038/nature19802; Engel M, 2018, NEURON, V99, P389, DOI 10.1016/j.neuron.2018.07.009; Engreitz JM, 2016, NAT REV MOL CELL BIO, V17, P756, DOI 10.1038/nrm.2016.126; Feng C, 2014, J BIOL CHEM, V289, P11571, DOI 10.1074/jbc.M113.546168; Fu Y, 2020, NAT CHEM BIOL, V16, P955, DOI 10.1038/s41589-020-0524-y; Fu Y, 2014, NAT REV GENET, V15, P293, DOI 10.1038/nrg3724; Fu Y, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2822; Gafni O, 2013, NATURE, V504, P282, DOI 10.1038/nature12745; Geula S, 2015, SCIENCE, V347, P1002, DOI 10.1126/science.1261417; Goell JH, 2021, TRENDS BIOTECHNOL, V39, P678, DOI 10.1016/j.tibtech.2020.10.012; Han ZF, 2010, NATURE, V464, P1205, DOI 10.1038/nature08921; Hernadez-Munoz I, 2005, P NATL ACAD SCI USA, V102, P7635, DOI 10.1073/pnas.0408918102; Huang J, 2019, PROTEIN CELL, V10, P272, DOI 10.1007/s13238-018-0518-7; Huisman B, 2017, TRENDS BIOCHEM SCI, V42, P85, DOI 10.1016/j.tibs.2016.12.004; Ji PF, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/3256524; Jinek M, 2012, SCIENCE, V337, P816, DOI 10.1126/science.1225829; Jones AN, 2022, NUCLEIC ACIDS RES, V50, P2350, DOI 10.1093/nar/gkac080; Knott GJ, 2018, SCIENCE, V361, P866, DOI 10.1126/science.aat5011; Komor AC, 2017, CELL, V168, P20, DOI 10.1016/j.cell.2016.10.044; Konermann S, 2018, CELL, V173, P665, DOI 10.1016/j.cell.2018.02.033; Koonin EV, 2017, CURR OPIN MICROBIOL, V37, P67, DOI 10.1016/j.mib.2017.05.008; Li JX, 2020, NUCLEIC ACIDS RES, V48, P5684, DOI 10.1093/nar/gkaa269; Li L, 2020, MOL CELL, V80, P525, DOI 10.1016/j.molcel.2020.09.022; Li ZJ, 2017, CANCER CELL, V31, P127, DOI 10.1016/j.ccell.2016.11.017; Li ZH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16306-5; Liang DM, 2014, GENE DEV, V28, P2233, DOI 10.1101/gad.251926.114; Lin SB, 2016, MOL CELL, V62, P335, DOI 10.1016/j.molcel.2016.03.021; Lin YC, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5767; Linder B, 2015, NAT METHODS, V12, P767, DOI [10.1038/nmeth.3453, 10.1038/NMETH.3453]; Liu JD, 2021, NATURE, V591, P322, DOI 10.1038/s41586-021-03313-9; Liu J, 2020, SCIENCE, V367, P580, DOI 10.1126/science.aay6018; Liu J, 2018, NAT CELL BIOL, V20, P1074, DOI 10.1038/s41556-018-0174-4; Liu L, 2017, CELL, V168, P121, DOI 10.1016/j.cell.2016.12.031; Liu XM, 2019, NAT CHEM BIOL, V15, P865, DOI 10.1038/s41589-019-0327-1; Makarova KS, 2017, CELL, V168, P946, DOI [10.1016/j.cell.2017.02.018, 10.1016/j.cell.2016.12.038]; Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033; Mauer J, 2017, NATURE, V541, P371, DOI 10.1038/nature21022; Meyer KD, 2012, CELL, V149, P1635, DOI 10.1016/j.cell.2012.05.003; Mo J, 2020, ADV SCI, V7, DOI 10.1002/advs.202001402; Panning B, 1997, CELL, V90, P907, DOI 10.1016/S0092-8674(00)80355-4; Patil DP, 2016, NATURE, V537, P369, DOI 10.1038/nature19342; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; Petropoulos S, 2016, CELL, V167, P285, DOI [10.1016/j.cell.2016.08.009, 10.1016/j.cell.2016.03.023]; Roignant JY, 2017, TRENDS GENET, V33, P380, DOI 10.1016/j.tig.2017.04.003; Roundtree IA, 2017, CELL, V169, P1187, DOI 10.1016/j.cell.2017.05.045; Sheardown SA, 1997, CELL, V91, P99, DOI 10.1016/S0092-8674(01)80012-X; Shi HL, 2018, NATURE, V563, P249, DOI 10.1038/s41586-018-0666-1; Sledz P, 2016, ELIFE, V5, DOI 10.7554/eLife.18434; Smargon AA, 2020, NAT CELL BIOL, V22, P143, DOI 10.1038/s41556-019-0454-7; Sun L, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.637309; Sun X, 2022, METHODS, V203, P56, DOI 10.1016/j.ymeth.2022.03.006; Terns MP, 2011, CURR OPIN MICROBIOL, V14, P321, DOI 10.1016/j.mib.2011.03.005; Wang P, 2016, MOL CELL, V63, P306, DOI 10.1016/j.molcel.2016.05.041; Wang X, 2016, NATURE, V534, P575, DOI 10.1038/nature18298; Wang X, 2014, NATURE, V505, P117, DOI 10.1038/nature12730; Wang Y, 2015, RNA, V21, P172, DOI 10.1261/rna.048272.114; Wang Y, 2020, NAT CHEM BIOL, V16, P896, DOI 10.1038/s41589-020-0525-x; Wei JB, 2021, CURR OPIN CELL BIOL, V70, P109, DOI 10.1016/j.ceb.2020.11.005; Wilson C, 2020, NAT BIOTECHNOL, V38, DOI 10.1038/s41587-020-0572-6; Wright AV, 2016, CELL, V164, P29, DOI 10.1016/j.cell.2015.12.035; Xia Z, 2021, NUCLEIC ACIDS RES, V49, P7361, DOI 10.1093/nar/gkab517; Xiang JF, 2018, MOL CELL, V69, P126, DOI 10.1016/j.molcel.2017.12.006; Xiao W, 2016, MOL CELL, V61, P507, DOI 10.1016/j.molcel.2016.01.012; Xiao Y, 2018, ANGEW CHEM INT EDIT, V57, P15995, DOI 10.1002/anie.201807942; Xu C, 2014, J BIOL CHEM, V289, P17299, DOI 10.1074/jbc.M114.550350; Xu WQ, 2021, NATURE, V591, P317, DOI 10.1038/s41586-021-03210-1; Yang Y, 2018, CELL RES, V28, P616, DOI 10.1038/s41422-018-0040-8; Yang Y, 2017, CELL RES, V27, P626, DOI 10.1038/cr.2017.31; Yu J, 2018, NUCLEIC ACIDS RES, V46, P1412, DOI 10.1093/nar/gkx1182; Zaccara S, 2020, CELL, V181, P1582, DOI 10.1016/j.cell.2020.05.012; Zhang X, 2019, P NATL ACAD SCI USA, V116, P2919, DOI 10.1073/pnas.1820574116; Zhang ZY, 2018, CELL RES, V28, P1050, DOI 10.1038/s41422-018-0092-9; Zhao J, 2020, SMALL, V16, DOI 10.1002/smll.201907301; Zheng GQ, 2013, MOL CELL, V49, P18, DOI 10.1016/j.molcel.2012.10.015	90	0	0	6	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV	2022	298	11							102525	10.1016/j.jbc.2022.102525	http://dx.doi.org/10.1016/j.jbc.2022.102525			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	6D3XI	36162509	Green Published, gold			2022-12-28	WOS:000882627400009
J	TWAMLEY, GM; KYPTA, RM; HALL, B; COURTNEIDGE, SA				TWAMLEY, GM; KYPTA, RM; HALL, B; COURTNEIDGE, SA			ASSOCIATION OF FYN WITH THE ACTIVATED PLATELET-DERIVED GROWTH-FACTOR RECEPTOR - REQUIREMENTS FOR BINDING AND PHOSPHORYLATION	ONCOGENE			English	Article							MIDDLE T-ANTIGEN; PROTEIN-TYROSINE KINASE; PHOSPHATIDYLINOSITOL-3 KINASE; SIGNAL TRANSDUCTION; PDGF RECEPTOR; PHOSPHOLIPASE-C; SRC FAMILY; DOMAINS; PRODUCT; IDENTIFICATION	Three members of the Src family of tyrosine kinases [pp60c-src (Src), p59fyn (Fyn) and pp62c-yes (Yes)] are ubiquitously expressed, and are thus likely to have general roles in growth control. We have previously shown that, after addition of platelet-derived growth factor (PDGF) to quiescent cells, all three kinases become activated and associated with the PDGF receptor. We have now addressed the requirements for this association. First, we have used a baculovirus expression system to show that Fyn associates with the activated PDGF receptor in vitro in the absence of other proteins, demonstrating that the association between the two molecules is direct. Second, by generating cell lines expressing chimeric molecules consisting of Fyn sequences fused to a portion of beta-galactosidase, we found that the SH2 domain of Fyn is necessary for ligand-stimulated association with the PDGF receptor in vivo. Third, those fusion proteins that associated with the PDGF receptor also became phosphorylated in vivo following PDGF treatment, and in in vitro kinase assays, suggesting that the amino-terminal half of Fyn contains the sites of PDGF-stimulated phosphorylation. Partially purified, kinase-negative Fyn also became phosphorylated in the activated PDGF receptor complex in vitro, demonstrating that the PDGF receptor phosphorylates Fyn, rather than the novel phosphorylations occurring by autophosphorylation.	EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,W-6900 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Hall, Belinda/AGU-6214-2022; Kypta, Robert/F-7699-2011	Kypta, Robert/0000-0002-2389-310X; Hall, Belinda/0000-0002-3753-1978				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1991, CELL GROWTH DIFFER, V2, P483; COURTNEIDGE SA, 1991, J VIROL, V65, P3301, DOI 10.1128/JVI.65.6.3301-3308.1991; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FUKUI Y, 1991, ONCOGENE, V6, P407; FUKUI Y, 1991, MOL CELL BIOL, V11, P1972, DOI 10.1128/MCB.11.4.1972; FUKUI Y, 1989, ONCOGENE RES, V4, P283; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KORNBLUTH S, 1990, J VIROL, V64, P1584, DOI 10.1128/JVI.64.4.1584-1589.1990; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LUO K, 1990, ONCOGENE, V5, P921; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SUGIMOTO Y, 1984, P NATL ACAD SCI-BIOL, V81, P2117, DOI 10.1073/pnas.81.7.2117; SULTZMAN L, 1991, MOL CELL BIOL, V11, P2018, DOI 10.1128/MCB.11.4.2018; Summers MD, 1987, TEXAS AGR EXP STATIO, V1555; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922	34	90	90	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					1893	1901						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408131				2022-12-28	WOS:A1992JP42400001
J	BIESALSKI, HK; DOEPNER, G; TZIMAS, G; GAMULIN, V; SCHRODER, HC; BATEL, R; NAU, H; MULLER, WEG				BIESALSKI, HK; DOEPNER, G; TZIMAS, G; GAMULIN, V; SCHRODER, HC; BATEL, R; NAU, H; MULLER, WEG			MODULATION OF MYB GENE-EXPRESSION IN SPONGES BY RETINOIC ACID	ONCOGENE			English	Article							HORMONE RESPONSE ELEMENTS; AMINO-TERMINAL REGION; DNA-BINDING DOMAIN; AGGREGATION FACTOR; VITAMIN-A; GEODIA-CYDONIUM; C-MYB; DIFFERENTIAL EXPRESSION; ONCOGENE PRODUCTS; PROTEIN	We demonstrate that the cells of the sponge Geodia cydonium are equipped with the basic elements required for a retinoic acid (RA)-dependent response pathway; RA was identified and quantitated, the cellular RA-binding protein (CRABP) was detected and the nuclear RA receptor (RAR) was found. In the isolated cell system the level of CRABP, but not of RAR, is strongly induced after incubating the cells for 10 h with the homologous aggregation factor. In induced cells incubation with 0.3-mu-M RA results in a strong down-regulation of the c-myb (or c-myb-related) proto-oncogene (M(r) 63 000; mRNA 3.3 kb). We postulate that this pathway is also functionally active and that R.A acts as a natural morphogen.	UNIV MAINZ, INST PHYSIOL CHEM, MOLEK BIOL ABT, DUESBERGWEG 6, W-6500 MAINZ, GERMANY; FREE UNIV BERLIN, INST TOXIKOL & EMBRYONALPHARMAKOL, W-1000 BERLIN 33, GERMANY; RUDJER BOSKOVIC INST, CTR ORGAN CHEM & BIOCHEM, YU-41001 ZAGREB, CROATIA; INST RUDER BOSKOVIC, CTR MARINE RES, YU-552210 ROVINJ, CROATIA	Johannes Gutenberg University of Mainz; Free University of Berlin; Rudjer Boskovic Institute; Rudjer Boskovic Institute			Müller, W. E. G./AAR-8651-2020; Tzimas, Giannis/R-5550-2019	Müller, W. E. G./0000-0002-8223-3689; Tzimas, Giannis/0000-0002-4073-7256; Schroder, Heinz C./0000-0003-0992-6427				AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BACHMANN M, 1986, P NATL ACAD SCI USA, V83, P7770, DOI 10.1073/pnas.83.20.7770; Battey, 1986, BASIC METHODS MOL BI; Biesalski H. K., 1990, METHOD ENZYMOL, V189, P83; BIESALSKI HK, 1990, INT J VITAM NUTR RES, V60, P4; BIESALSKI HK, 1989, J CLIN CHEM CLIN BIO, V27, P65; BIESALSKI HK, 1990, J MICRONUTR ANAL, V7, P97; BIESALSKI HK, 1992, PROGR RETINOIDS; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BOROJEVIC R, 1964, Z ZELLFORSCH MIK ANA, V64, P708, DOI 10.1007/BF01258544; BOYLAN JF, 1991, J CELL BIOL, V112, P965, DOI 10.1083/jcb.112.5.965; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; BOYLE WJ, 1986, P NATL ACAD SCI USA, V83, P4685, DOI 10.1073/pnas.83.13.4685; BROCKES JP, 1989, NEURON, V2, P1285, DOI 10.1016/0896-6273(89)90066-4; CARBALLEIRA NM, 1991, COMP BIOCHEM PHYS B, V100, P489, DOI 10.1016/0305-0491(91)90209-V; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CONRAD J, 1982, J CELL BIOCHEM, V19, P395, DOI 10.1002/jcb.240190408; DESUTTER D, 1977, ROUX ARCH DEV BIOL, V181, P151, DOI 10.1007/BF00848439; DIEHLSEIFERT B, 1989, TISSUE CELL, V21, P25, DOI 10.1016/0040-8166(89)90018-9; DOEPNER G, 1992, IN PRESS DRUG RES; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; DUNHAM P, 1983, P NATL ACAD SCI-BIOL, V80, P4756, DOI 10.1073/pnas.80.15.4756; ECKHOFF C, 1989, TOXICOL LETT, V48, P171, DOI 10.1016/0378-4274(89)90172-0; EICHELE G, 1989, TRENDS GENET, V5, P246, DOI 10.1016/0168-9525(89)90096-6; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GERLACH T, 1989, AM J CLIN NUTR, V50, P1029, DOI 10.1093/ajcn/50.5.1029; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; Goodwin TW, 1984, BIOCH CAROTENOIDS, VII; GRAMZOW M, 1989, CELL, V59, P939, DOI 10.1016/0092-8674(89)90616-8; GRAMZOW M, 1986, J CELL BIOL, V102, P1344, DOI 10.1083/jcb.102.4.1344; GRIPPO JF, 1987, J BIOL CHEM, V262, P4492; HAMADA H, 1988, J BIOL CHEM, V263, P1454; HARLOW E, 1988, ANTIBODIES LABORATOR; HENKART P, 1973, BIOCHEMISTRY-US, V12, P3045, DOI 10.1021/bi00740a016; HUMPHREYS T, 1963, DEV BIOL, V8, P27, DOI 10.1016/0012-1606(63)90024-1; JANICKBUCKNER D, 1991, FASEB J, V5, P320, DOI 10.1096/fasebj.5.3.2001792; JETTEN AM, 1990, METHOD ENZYMOL, V189, P248; KATZEN AL, 1985, CELL, V41, P449, DOI 10.1016/S0092-8674(85)80018-0; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAVITT J, 1984, MOL CELL BIOL, V4, P1961, DOI 10.1128/MCB.4.10.1961; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LITAN R, 1991, IN PRESS BIOMEDICINE; MARTINEZ E, 1991, EMBO J, V10, P263, DOI 10.1002/j.1460-2075.1991.tb07946.x; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MIGITA M, 1990, MICROBIOL IMMUNOL, V34, P937, DOI 10.1111/j.1348-0421.1990.tb01072.x; MILLER WH, 1990, ONCOGENE, V5, P511; MOSCONA AA, 1963, P NATL ACAD SCI USA, V49, P742, DOI 10.1073/pnas.49.5.742; MULLER WEG, 1990, ELECTRON MICROSC REV, V3, P97, DOI 10.1016/0892-0354(90)90016-L; MULLER WEG, 1982, INT REV CYTOL, V77, P129, DOI 10.1016/S0074-7696(08)62466-3; MULLER WEG, 1976, J CELL SCI, V21, P227; MULLER WEG, 1978, DIFFERENTIATION, V10, P45, DOI 10.1111/j.1432-0436.1978.tb00944.x; MULLER WEG, 1987, J BIOL CHEM, V262, P9850; MULLER WEG, 1973, EXP CELL RES, V80, P95, DOI 10.1016/0014-4827(73)90279-6; NERVI C, 1989, P NATL ACAD SCI USA, V86, P5854, DOI 10.1073/pnas.86.15.5854; ORO AE, 1988, NATURE, V336, P493, DOI 10.1038/336493a0; ORO AE, 1990, NATURE, V347, P298, DOI 10.1038/347298a0; ORO AE, 1989, DEVELOPMENT, V107, P133; PAZARES J, 1987, EMBO J, V6, P3553, DOI 10.1002/j.1460-2075.1987.tb02684.x; PEARCE JC, 1986, J CHROMATOGR, V353, P371, DOI 10.1016/S0021-9673(01)87107-7; PETERS CWB, 1987, EMBO J, V6, P3085, DOI 10.1002/j.1460-2075.1987.tb02616.x; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; ROBITZKI A, 1990, EUR J BIOCHEM, V192, P499, DOI 10.1111/j.1432-1033.1990.tb19253.x; ROSSON D, 1987, ANN NY ACAD SCI, V511, P219, DOI 10.1111/j.1749-6632.1987.tb36250.x; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; ROTTMANN M, 1987, EMBO J, V6, P3939, DOI 10.1002/j.1460-2075.1987.tb02735.x; SCHRODER HC, 1988, BIOCHEM J, V252, P777, DOI 10.1042/bj2520777; SCHRODER HC, 1989, LABORATORY MANUAL; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SUMMERBELL D, 1990, TRENDS NEUROSCI, V13, P142, DOI 10.1016/0166-2236(90)90006-V; TAKENAWA T, 1980, LAB INVEST, V42, P490; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALLACE RB, 1987, METHOD ENZYMOL, V152, P432; WEIGELE M, 1973, BIOCHEM BIOPH RES CO, V50, P352, DOI 10.1016/0006-291X(73)90847-4; WEINBAUM G, 1973, NATURE, V244, P510, DOI 10.1038/244510a0; WEISSENFELS N, 1985, ZOOMORPHOLOGY, V105, P12, DOI 10.1007/BF00312068; WELLNER U, 1985, LECTURE NOTES MED IN, V25, P579; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WHITE BA, 1982, J BIOL CHEM, V257, P8569; WOLF G, 1991, NUTR REV, V49, P1, DOI 10.1111/j.1753-4887.1991.tb07349.x; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	83	35	35	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1992	7	9					1765	1774						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1323819				2022-12-28	WOS:A1992JJ37600013
J	CHEN, TM; DEFENDI, V				CHEN, TM; DEFENDI, V			FUNCTIONAL INTERACTION OF P53 WITH HPV18 E6, C-MYC AND H-RAS IN 3T3 CELLS	ONCOGENE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; WILD-TYPE P53; CERVICAL-CARCINOMA; SV40-TRANSFORMED CELLS; BIOLOGICAL-ACTIVITIES; CELLULAR ONCOGENE; TRANSFORMING GENE; ESCHERICHIA-COLI; SIMIAN VIRUS-40; DNA	Wild-type (wt) p53 has been suggested to be the product of a tumor-suppressor gene. Recently, it has been shown that the E6 oncoproteins of human papillomavirus (HPV) types 16 and 18, like the SV40 large T antigen, are physically associated with wt p53. We have investigated the functional interaction of wt p53 with the viral oncogene products of HPV16 and 18 and with cellular oncogenes by transfection of NIH3T3 cells with p53 wt alone or with several oncogene(s). We found that over-expression of HPV18 E6, c-myc or activated H-ras, like SV40 large T, can partially overcome the growth-inhibitory effect of wt p53 in NIH3T3 cells, while HPV16 E6 and E7, HPV18 E7, k-fgf, c-fos and mutant (mt) p53 do not. Further studies indicate that HPV18 E6 and c-myc can overcome the antiproliferative effect, but not the antitransforming effect, of wt p53, while activated H-ras can overcome both the antiproliferative and antitransforming effects of wt p53. These data show evidence of a functional interaction between HPV18 E6 and wt p53, and suggest that the cooperation of HPV E6 and cellular oncogenes c-myc and H-ras, which are activated in several cases of human cervical cancers, may be necessary to overcome completely the anti-oncogenic function of p53 in the development of these tumors.	NYU MED CTR, DEPT PATHOL, 550 1ST AVE, NEW YORK, NY 10016 USA; NYU MED CTR, KAPLAN CANC CTR, NEW YORK, NY 10016 USA	New York University; New York University				defendi, vittorio/0000-0002-0707-6900				ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; BARTLETT PF, 1988, P NATL ACAD SCI USA, V85, P3255, DOI 10.1073/pnas.85.9.3255; BEDELL MA, 1989, J VIROL, V63, P1247, DOI 10.1128/JVI.63.3.1247-1255.1989; BOURHIS J, 1990, J CLIN ONCOL, V8, P1789, DOI 10.1200/JCO.1990.8.11.1789; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLE ST, 1987, J MOL BIOL, V193, P599, DOI 10.1016/0022-2836(87)90343-3; CRAWFORD LV, 1982, INT J CANCER, V30, P403, DOI 10.1002/ijc.2910300404; CROOK T, 1989, P NATL ACAD SCI USA, V86, P5713, DOI 10.1073/pnas.86.15.5713; CROOK T, 1991, ONCOGENE, V6, P873; DAVID YB, 1988, ONCOGENE, V3, P179; DIPAOLO JA, 1989, ONCOGENE, V4, P395; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUKASAWA K, 1991, MOL CELL BIOL, V11, P3472, DOI 10.1128/MCB.11.7.3472; GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRITZ L, 1983, GENE, V25, P179, DOI 10.1016/0378-1119(83)90223-8; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HURLIN PJ, 1991, P NATL ACAD SCI USA, V88, P570, DOI 10.1073/pnas.88.2.570; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; KURMAN RJ, 1988, AM J OBSTET GYNECOL, V159, P293, DOI 10.1016/S0002-9378(88)80070-X; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHAELMICHALOVITZ D, 1991, J VIROL, V65, P4160, DOI 10.1128/JVI.65.8.4160-4168.1991; MILLER AD, 1984, CELL, V36, P51; MOUGNEAU E, 1984, P NATL ACAD SCI-BIOL, V81, P5758, DOI 10.1073/pnas.81.18.5758; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; PECORARO G, 1989, P NATL ACAD SCI USA, V86, P563, DOI 10.1073/pnas.86.2.563; PECORARO G, 1991, AM J PATHOL, V138, P1; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; QUARTO N, 1989, ONCOGENE RES, V5, P101; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RIOU G, 1988, ONCOGENE, V3, P329; RIOU G, 1990, LANCET, V335, P1171; ROMANCZUK H, 1991, J VIROL, V65, P2739, DOI 10.1128/JVI.65.5.2739-2744.1991; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHLEGEL R, 1988, EMBO J, V7, P3181, DOI 10.1002/j.1460-2075.1988.tb03185.x; SEEDORF K, 1985, VIROLOGY, V145, P181, DOI 10.1016/0042-6822(85)90214-4; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; TUCK SP, 1989, ONCOGENE RES, V4, P81; VOUSDEN KH, 1988, ONCOGENE RES, V3, P167; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0	55	40	42	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1992	7	8					1541	1547						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1321402				2022-12-28	WOS:A1992JE81300010
J	PRIGENT, SA; LEMOINE, NR; HUGHES, CM; PLOWMAN, GD; SELDEN, C; GULLICK, WJ				PRIGENT, SA; LEMOINE, NR; HUGHES, CM; PLOWMAN, GD; SELDEN, C; GULLICK, WJ			EXPRESSION OF THE C-ERBB-3 PROTEIN IN NORMAL HUMAN ADULT AND FETAL TISSUES	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; TYROSINE KINASE; ANTIBODIES; LOCALIZATION; CELLS	c-erbB-3 is a member of the type I family of growth factor receptors which includes the epidermal growth factor (EGF) receptor and c-erhB-2. Whereas for EGF receptor and c-erbB-2 the expression patterns in normal tissues are well documented, there is currently little information available about the sites of c-erhB-3 expression. In order to examine the normal tissue distribution of c-erbB-3, polyclonal antibodies were raised against eight synthetic peptides corresponding to distinct sites on the intracellular domain of c-erbB-3. Of these, three produced antibodies which reacted with a 160-kDa protein on immunoblots of human embryonal cells (293 cells) transfected with the cDNA encoding c-erbB-3, and two of the three antibodies immunoprecipitated a protein of similar size from the same cells. These antibodies were used for immunochemical staining of a wide variety of normal human adult and fetal tissues employing formalin-fixed, paraffin-embedded material. The c-erbB-3 protein was identified in cells of the gastrointestinal, reproductive, respiratory and urinary tracts as well as the skin, endocrine and nervous system in a distribution distinctly different from that observed for EGF receptor and c-erbB-2. The level of expression of the mRNA for c-erbB-3 was also examined in extracts of a selection of fetal tissues. In general the sites of mRNA and protein expression were concordant.	HAMMERSMITH HOSP,MOLEC PATHOL LAB,ICRF,ONCOL GRP,LONDON W12 0HS,ENGLAND; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA; HAMMERSMITH HOSP,RPMS,GASTROENTEROL UNIT,LONDON W12 0HS,ENGLAND	Imperial College London; Bristol-Myers Squibb; Imperial College London	PRIGENT, SA (corresponding author), HAMMERSMITH HOSP,MOLEC ONCOL LAB,DU CANE RD,LONDON W12 0HS,ENGLAND.		PLOWMAN, Greg D/E-2012-2011	Selden, Angela/0000-0003-2648-443X				CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAMJANOV I, 1986, LAB INVEST, V55, P588; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; GULLICK WJ, 1986, CANCER RES, V46, P285; GULLICK WJ, 1986, EUR J BIOCHEM, V158, P245, DOI 10.1111/j.1432-1033.1986.tb09744.x; GULLICK WJ, 1985, EMBO J, V4, P2869, DOI 10.1002/j.1460-2075.1985.tb04016.x; GULLICK WJ, 1991, BRIT MED BULL, V47, P87, DOI 10.1093/oxfordjournals.bmb.a072464; GULLICK WJ, 1987, INT J CANCER, V40, P246, DOI 10.1002/ijc.2910400221; GULLICK WJ, 1989, MOL BIOL CANCER, P38; GUSTERSON B, 1984, CELL BIOL INT REP, V8, P649, DOI 10.1016/0309-1651(84)90045-6; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KUMAR R, 1991, MOL CELL BIOL, V11, P979, DOI 10.1128/MCB.11.2.979; LEMOINE NR, 1991, BRIT J CANCER, V64, P79, DOI 10.1038/bjc.1991.243; Merrifield RB, 1976, SCIENCE, V232, P341, DOI DOI 10.1126/SCIENCE.3961484; PERLMAN R, 1989, J BIOL CHEM, V264, P8946; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; PRESS MF, 1990, ONCOGENE, V5, P953; QUIRKE P, 1989, BRIT J CANCER, V60, P64, DOI 10.1038/bjc.1989.221; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; WATERFIELD MD, 1982, J CELL BIOCHEM, V20, P149, DOI 10.1002/jcb.240200207	21	166	176	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1273	1278						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1377811				2022-12-28	WOS:A1992HZ97100004
J	LINK, DC; GUTKIND, SJ; ROBBINS, KC; LEY, TJ				LINK, DC; GUTKIND, SJ; ROBBINS, KC; LEY, TJ			CHARACTERIZATION OF THE 5' UNTRANSLATED REGION OF THE HUMAN C-FGR GENE AND IDENTIFICATION OF THE MAJOR MYELOMONOCYTIC C-FGR PROMOTER	ONCOGENE			English	Article							NF-KAPPA-B; PROTO-ONCOGENE; MESSENGER-RNA; CELL-LINES; EXPRESSION; PROTOONCOGENE; VIRUS; DIFFERENTIATION; TRANSCRIPTS; ACTIVATION	In this study, we have characterized the 5' region of the human c-fgr proto-oncogene and identified the major myelomonocytic c-fgr promoter. Seven distinct 5' untranslated exons were identified and localized to a region extending 13 kb upstream from the first coding exon. Two major promoters were identified, one utilized exclusively in Epstein-Barr virus (EBV)-infected B-lymphocyte cell lines, and the other functional only in myelomonocytic cells. Differential promoter utilization and alternative splicing of the 5' untranslated exons give rise to at least six distinct c-fgr mRNA species that differ only in their 5' untranslated regions. Two major mRNAs were identified, c-fgr A and c-fgr 4; these two mRNAs were detected exclusively in EBV-infected B-lymphocyte cell lines and myelomonocytic cells respectively. We have previously demonstrated that c-fgr is transcriptionally activated in U937 cells treated with either 12-O-tetradecanoyl-phorbol-13-acetate (TPA) or cycloheximide (CHX). We now show that a DNA fragment extending from -772 to +97 (with respect to the transcription initiation site upstream from exon M4) is responsive to TPA but not CHX treatment in U937 cells. These results suggest that TPA and CHX induce c-fgr mRNA accumulation by different mechanisms.	WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT MED,DIV HEMATOL ONCOL,ST LOUIS,MO 63110; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT GENET,ST LOUIS,MO 63110; NIDR,CELLULAR DEV & ONCOL LAB,BETHESDA,MD 20892	Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)			Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009	Gutkind, J. Silvio/0000-0002-5150-4482; 	NATIONAL CANCER INSTITUTE [P01CA049712] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038682, R37DK038682, R56DK038682] Funding Source: NIH RePORTER; NCI NIH HHS [CA 49712] Funding Source: Medline; NIDDK NIH HHS [DK 38682] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRICKELL PM, 1988, BRIT J CANCER, V58, P704, DOI 10.1038/bjc.1988.294; CHEAH MSC, 1986, NATURE, V319, P238, DOI 10.1038/319238a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; DORAI T, 1991, MOL CELL BIOL, V11, P4165, DOI 10.1128/MCB.11.8.4165; FAHEY JL, 1971, ANN NY ACAD SCI, V190, P221, DOI 10.1111/j.1749-6632.1971.tb13537.x; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; GUTKIND JS, 1991, MOL CELL BIOL, V11, P1500, DOI 10.1128/MCB.11.3.1500; INOUE K, 1987, ONCOGENE, V1, P301; INOUE K, 1990, MOL CELL BIOL, V10, P1789, DOI 10.1128/MCB.10.4.1789; KATAMINE S, 1988, MOL CELL BIOL, V8, P259, DOI 10.1128/MCB.8.1.259; KLEIN C, 1988, INT J CANCER, V42, P29, DOI 10.1002/ijc.2910420107; LEY TJ, 1989, MOL CELL BIOL, V9, P92, DOI 10.1128/MCB.9.1.92; LOCK P, 1991, MOL CELL BIOL, V11, P4363, DOI 10.1128/MCB.11.9.4363; LOCK P, 1990, MOL CELL BIOL, V10, P4603, DOI 10.1128/MCB.10.9.4603; MARTH JD, 1988, NATURE, V332, P171, DOI 10.1038/332171a0; NISHIZAWA M, 1986, MOL CELL BIOL, V6, P511, DOI 10.1128/MCB.6.2.511; NOTARIO V, 1989, J CELL BIOL, V109, P3129, DOI 10.1083/jcb.109.6.3129; PATEL M, 1990, ONCOGENE, V5, P201; PERKINS SL, 1991, IN PRESS J LEUKOCYTE; PIERCE JW, 1991, MOL CELL BIOL, V11, P1431, DOI 10.1128/MCB.11.3.1431; RAO CD, 1988, MOL CELL BIOL, V8, P284, DOI 10.1128/MCB.8.1.284; RASHEED S, 1982, VIROLOGY, V117, P238, DOI 10.1016/0042-6822(82)90522-0; REYNOLDS PJ, 1990, MOL CELL BIOL, V10, P4266, DOI 10.1128/MCB.10.8.4266; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; TAKADERA T, 1989, MOL CELL BIOL, V9, P2173, DOI 10.1128/MCB.9.5.2173; TRONICK SR, 1985, P NATL ACAD SCI USA, V82, P6595, DOI 10.1073/pnas.82.19.6595; ULRICH MJ, 1990, BLOOD, V75, P990; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232	31	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1992	7	5					877	884						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1373875				2022-12-28	WOS:A1992HP64200006
J	BRATTHAUER, GL; FANNING, TG				BRATTHAUER, GL; FANNING, TG			ACTIVE LINE-1 RETROTRANSPOSONS IN HUMAN TESTICULAR CANCER	ONCOGENE			English	Article							EMBRYONAL CARCINOMA-CELLS; DNA-SEQUENCES; FAMILY; ELEMENT; END	An antibody to the protein encoded by the first open reading frame of the human LINE-1 (L1Hs) element was used to examine immunohistochemically 59 formalin-fixed, human testicular germ cell tumors. Six tumors were positive for L1Hs expression. In all cases the L1Hs-positive cells were epithelial and most had the very characteristic, undifferentiated appearance of embryonal carcinoma or yolk sac tumor cells. One L1Hs-positive tumor had metastasized to the lung and lymph nodes and the metastatic cells also expressed L1Hs. This is the first observation of widespread retrotransposon expression in human tissue. These observations raise the possibility that L1Hs-encoded proteins may function as oncoproteins in some cancers.	ARMED FORCES INST PATHOL,DEPT CELLULAR PATHOL,WASHINGTON,DC 20306	United States Department of Defense								ANDREWS PW, 1987, TERATOCARCINOMAS EMB, P207; BRAWN PN, 1987, CANCER, V59, P2042, DOI 10.1002/1097-0142(19870615)59:12<2042::AID-CNCR2820591213>3.0.CO;2-R; DERAGON JM, 1990, EMBO J, V9, P3363, DOI 10.1002/j.1460-2075.1990.tb07537.x; FANNING TG, 1987, BIOCHIM BIOPHYS ACTA, V910, P203, DOI 10.1016/0167-4781(87)90112-6; GRIMALDI G, 1984, EMBO J, V3, P1753, DOI 10.1002/j.1460-2075.1984.tb02042.x; HATTORI M, 1986, NATURE, V321, P625, DOI 10.1038/321625a0; KAZAZIAN HH, 1988, NATURE, V332, P164, DOI 10.1038/332164a0; LEIBOLD DM, 1990, P NATL ACAD SCI USA, V87, P6990, DOI 10.1073/pnas.87.18.6990; LOEB DD, 1986, MOL CELL BIOL, V6, P168, DOI 10.1128/MCB.6.1.168; LOEHRER PL, 1987, SEMIN ONCOL, V12, P304; MORSE B, 1988, NATURE, V333, P87, DOI 10.1038/333087a0; SINGER MF, 1988, BANBURY REPORT, V30, P71; SKOWRONSKI J, 1985, P NATL ACAD SCI USA, V82, P6050, DOI 10.1073/pnas.82.18.6050; SKOWRONSKI J, 1988, MOL CELL BIOL, V8, P1385, DOI 10.1128/MCB.8.4.1385; SKOWRONSKI J, 1986, COLD SPRING HARB SYM, V51, P457, DOI 10.1101/SQB.1986.051.01.055; STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615; SWERGOLD GD, 1990, MOL CELL BIOL, V10, P6718, DOI 10.1128/MCB.10.12.6718; VARMUS H, 1989, ONCOGENES MOL ORIGIN, P3; [No title captured]	19	82	91	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1992	7	3					507	510						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1312702				2022-12-28	WOS:A1992HK00500016
J	TELERMAN, A; DODEMONT, H; DEGRAEF, C; GALAND, P; BAUWENS, S; VANOOSTVELDT, P; AMSON, RB				TELERMAN, A; DODEMONT, H; DEGRAEF, C; GALAND, P; BAUWENS, S; VANOOSTVELDT, P; AMSON, RB			IDENTIFICATION OF THE CELLULAR PROTEIN ENCODED BY THE HUMAN WILMS-TUMOR (WT1) GENE	ONCOGENE			English	Note							HUMAN CHROMOSOME-11; PHYSICAL MAP; PRODUCT; DELETION; BINDING; REGION; GROWTH; LOCUS	A putative tumor-suppressor gene (wt1) located at chromosome 11p13 and involved in Wilms' tumor development has recently been identified as a zinc finger polypeptide-encoding gene. The purpose of this study was to characterize the protein encoded by the human wt1 gene. The region spanning the entire zinc finger domain was amplified by polymerase chain reaction (PCR) and subcloned in the pATH 3 expression vector. Polyclonal antibodies against the fused TrpE-WT protein were raised. These antibodies immunoprecipitated a 49- to 51-kDa protein from hematopoietic tumor cells labeled in vivo with [S-35]methionine. Subcellular fractionation and immunohistochemistry followed by confocal microscopy indicated that the Wilms' tumor gene product (WT1) is mainly localized within the nucleus.	FREE UNIV BRUSSELS,SCH MED,INST INTERDISCIPLINARY RES,CAMPUS ERASME,BLDG C,ROUTE LENNIK 808,B-1070 BRUSSELS,BELGIUM; MAX PLANCK INST BIOPHYS CHEM,DEPT BIOCHEM,W-3400 GOTTINGEN,GERMANY; FREE UNIV BRUSSELS,SCH MED,CYTOL & EXPTL ONCOL LAB,B-1050 BRUSSELS,BELGIUM; STATE UNIV GHENT,GENET LAB,B-9000 GENT,BELGIUM; STATE UNIV GHENT,BIOCHEM LAB,B-9000 GENT,BELGIUM	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Max Planck Society; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Ghent University; Ghent University								AMSON R, 1989, P NATL ACAD SCI USA, V86, P8857, DOI 10.1073/pnas.86.22.8857; AMSON RB, 1989, ONCOGENE, V4, P243; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COMPTON DA, 1988, CELL, V55, P827, DOI 10.1016/0092-8674(88)90138-9; GALAND P, 1989, CELL TISSUE KINET, V22, P383, DOI 10.1111/j.1365-2184.1989.tb00223.x; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; ROSE EA, 1990, CELL, V60, P495, DOI 10.1016/0092-8674(90)90600-J; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TELERMAN A, 1988, MOL CELL BIOL, V8, P1498, DOI 10.1128/MCB.8.4.1498; VANHEYNINGEN V, 1990, P NATL ACAD SCI USA, V87, P5383, DOI 10.1073/pnas.87.14.5383	19	21	28	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1992	7	12					2545	2548						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1334252				2022-12-28	WOS:A1992KA85600023
J	BECKER, D; LEE, PL; RODECK, U; HERLYN, M				BECKER, D; LEE, PL; RODECK, U; HERLYN, M			INHIBITION OF THE FIBROBLAST GROWTH-FACTOR RECEPTOR 1 (FGFR-1) GENE IN HUMAN MELANOCYTES AND MALIGNANT MELANOMAS LEADS TO INHIBITION OF PROLIFERATION AND SIGNS INDICATIVE OF DIFFERENTIATION	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASE; TUMOR-NECROSIS-FACTOR; STRUCTURAL ARRANGEMENT UNDERLIES; 3RD IMMUNOGLOBULIN DOMAIN; MOLECULAR-CLONING; ANTISENSE OLIGODEOXYNUCLEOTIDES; NUCLEOTIDE-SEQUENCE; MESSENGER-RNA; CELL-SURFACE; EXPRESSION	Fibroblast growth factor receptor (FGFR-1) is expressed as a single 3.5-kb mRNA transcript in normal human melanocytes and in malignant melanomas as determined upon Northern hybridization to a cDNA clone encoding the membrane-spanning form of the human FGFR-1. Polyclonal antisera directed against the chicken FGFR recognized a 145-kDa protein in primary and metastatic melanomas. Antisense oligodeoxynucleotides targeted against the translation start site and a splice donor-acceptor site of human FGFR-1, in addition to inhibiting the proliferation of normal human melanocytes and malignant melanomas, caused extensive dendrite formation and severe disruption of cell-cell contact - morphological changes that were not observed upon inhibition of the genes encoding basic fibroblast, growth factor (bFGF) and retinoic acid-alpha receptor. Thus, unlike in the case of the ligand bFGF, expression of the FGFR-1 may represent a requisite to prevent human melanocytes and malignant melanomas from undergoing (terminal) differentiation.	SCRIPPS CLIN & RES FDN,DIV BIOCHEM,LA JOLLA,CA 92037; WISTAR INST,PHILADELPHIA,PA 19104	Scripps Research Institute; The Wistar Institute	BECKER, D (corresponding author), UNIV PITTSBURGH,PITTSBURGH CANC INST,DEPT MED,BIOMED SCI TOWER,E1057,PITTSBURGH,PA 15261, USA.							ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; BECKER D, 1984, MOL CELL BIOL, V4, P2247, DOI 10.1128/MCB.4.11.2247; BECKER D, 1989, GENOMICS, V4, P97, DOI 10.1016/0888-7543(89)90320-0; BECKER D, 1990, ONCOGENE, V5, P1133; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; BLAM SB, 1988, ONCOGENE, V3, P129; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; EISINGER M, 1982, P NATL ACAD SCI-BIOL, V79, P2018, DOI 10.1073/pnas.79.6.2018; FEIGE JJ, 1988, J BIOL CHEM, V263, P14023; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GIALLONGO A, 1986, P NATL ACAD SCI USA, V83, P6741, DOI 10.1073/pnas.83.18.6741; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; HALABAN R, 1986, J INVEST DERMATOL, V87, P95, DOI 10.1111/1523-1747.ep12523594; HALABAN R, 1988, J CELL BIOL, V107, P1611, DOI 10.1083/jcb.107.4.1611; HALABAN R, 1987, IN VITRO CELL DEV B, V23, P47; HALABAN R, 1988, ONCOGENE RES, V3, P177; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; HERLYN M, 1988, EXP CELL RES, V179, P322, DOI 10.1016/0014-4827(88)90271-6; HERLYN M, 1987, LAB INVEST, V56, P461; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; HOUSSAINT E, 1990, P NATL ACAD SCI USA, V87, P8180, DOI 10.1073/pnas.87.20.8180; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KOIKE S, 1990, EMBO J, V9, P3247; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; NOPHAR Y, 1990, EMBO J, V9, P3269, DOI 10.1002/j.1460-2075.1990.tb07526.x; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PASQUALE EB, 1990, P NATL ACAD SCI USA, V87, P5812, DOI 10.1073/pnas.87.15.5812; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; RODECK U, 1991, J INVEST DERMATOL, V97, P20, DOI 10.1111/1523-1747.ep12477822; RODECK U, 1987, INT J CANCER, V40, P687, DOI 10.1002/ijc.2910400520; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; RUTA M, 1988, ONCOGENE, V3, P9; SAFRAN A, 1990, ONCOGENE, V5, P635; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SZCZYLIK C, 1991, SCIENCE, V253, P562, DOI 10.1126/science.1857987; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WRNER S, 1992, MOL CELL BIOL, V12, P82; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	52	94	98	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2303	2313						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437152				2022-12-28	WOS:A1992JW66500024
J	REISS, K; PORCU, P; SELL, C; PIETRZKOWSKI, Z; BASERGA, R				REISS, K; PORCU, P; SELL, C; PIETRZKOWSKI, Z; BASERGA, R			THE INSULIN-LIKE GROWTH FACTOR-I RECEPTOR IS REQUIRED FOR THE PROLIFERATION OF HEMATOPOIETIC-CELLS	ONCOGENE			English	Article							MYELOID LEUKEMIC-CELLS; HUMAN-BREAST-CANCER; FACTOR-I RECEPTORS; HUMAN-LYMPHOCYTES; NUCLEAR ANTIGEN; C-MYC; EXPRESSION; DIFFERENTIATION; BINDING; CYCLE	We have investigated the role of the insulin-like growth factor one (IGF1) receptor and its relationship to the proto-oncogene c-myb in the growth of two types of hemopoietic cells: mitogen-stimulated human peripheral blood mononuclear cells and a human promyelocytic cell line (HL-60). Using the antisense strategy and the reverse transcriptase polymerase chain reaction (RT-PCR), we show that expression of the IGF1 receptor is required for the entry into S phase of both stimulated lymphocytes and HL-60 cells. The inhibition of DNA synthesis by antisense oligomers to the IGF1 receptor RNA is accompanied by an inhibition of the expression of the mRNA for a DNA synthesis gene, proliferating cell nuclear antigen (PCNA), the co-factor of DNA polymerase delta. Inhibition of c-myb expression results in a decrease in IGF1 receptor mRNA levels; on the other hand, inhibition of IGF1 receptor expression has no effect on c-myb mRNA levels. A tentative temporal relationship between these three genes (c-myb, IGF1 receptor, PCNA) is proposed.	THOMAS JEFFERSON UNIV,JEFFERSON CANC CTR,BLUEMLE LIFE SCI BLGD,233 S 10TH ST,PHILADELPHIA,PA 19107	Jefferson University					NATIONAL CANCER INSTITUTE [R01CA053484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042383] Funding Source: NIH RePORTER; NCI NIH HHS [CA53484] Funding Source: Medline; NIGMS NIH HHS [GM 42383] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMENDRAL JM, 1987, P NATL ACAD SCI USA, V84, P1575, DOI 10.1073/pnas.84.6.1575; ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; BASERGA R, IN PRESS CELL BIOL B; BASERGA R, 1992, IN PRESS ANN NY ACAD; BRAVO R, 1987, NATURE, V326, P545; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; CLEMMONS DR, 1981, TISSUE GROWTH FACTOR, P161; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; CRAIG RW, 1984, CANCER RES, V44, P442; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GOLDRING MB, 1991, EUKARYOTIC GENE EXPR, V1, P301; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; GROSSO LE, 1985, CANCER RES, V45, P847; HARTMANN W, 1988, LEUKEMIA, V2, P241; HIZUKA N, 1987, ENDOCRINOL JAPON, V34, P81; JANICOT M, 1991, J BIOL CHEM, V266, P9382; JASKULSKI D, 1988, SCIENCE, V240, P1544, DOI 10.1126/science.2897717; KACZMAREK L, 1985, P NATL ACAD SCI USA, V82, P5375, DOI 10.1073/pnas.82.16.5375; KACZMAREK L, 1987, J CELL BIOL, V104, P183, DOI 10.1083/jcb.104.2.183; KELLERER M, 1990, J BIOL CHEM, V265, P9340; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KOZAK RW, 1987, CELL IMMUNOL, V109, P318, DOI 10.1016/0008-8749(87)90315-7; LEE PDK, 1986, J CLIN ENDOCR METAB, V62, P28, DOI 10.1210/jcem-62-1-28; LIPSON KE, 1989, P NATL ACAD SCI USA, V86, P9774, DOI 10.1073/pnas.86.24.9774; LIU YC, 1989, BIOCHEMISTRY-US, V28, P2967, DOI 10.1021/bi00433a034; MIGLIACCIO G, 1990, EXP HEMATOL, V18, P1049; PEKONEN F, 1988, CANCER RES, V48, P1353; PEPE MG, 1987, J CELL PHYSIOL, V133, P219, DOI 10.1002/jcp.1041330204; PEYRAT JP, 1988, CANCER RES, V48, P6429; PHILLIPS PD, 1987, J CELL PHYSIOL, V133, P135, DOI 10.1002/jcp.1041330117; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; RAPPOLEE DA, 1989, J CELL BIOCHEM, V39, P1, DOI 10.1002/jcb.240390102; REED JC, 1986, P NATL ACAD SCI USA, V84, P3892; REISS K, 1991, CANCER RES, V51, P5997; SELL C, 1992, IN PRESS J CELL PHYS; SHEINESS D, 1984, MOL CELL BIOL, V4, P1206, DOI 10.1128/MCB.4.7.1206; STEWART AJ, 1990, J BIOL CHEM, V265, P21172; SURMACZ E, 1992, EXP CELL RES, V199, P275, DOI 10.1016/0014-4827(92)90435-B; THOMAS PS, 1983, METHOD ENZYMOL, V100, P255; TRAVALI S, 1991, MOL CELL BIOL, V11, P731, DOI 10.1128/MCB.11.2.731; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; VENTURELLI D, 1990, CANCER RES, V50, P7371; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194	46	99	101	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2243	2248						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1359494				2022-12-28	WOS:A1992JW66500016
J	WHETSELL, L; MAW, G; NADON, N; RINGER, DP; SCHAEFER, FV				WHETSELL, L; MAW, G; NADON, N; RINGER, DP; SCHAEFER, FV			POLYMERASE CHAIN-REACTION MICROANALYSIS OF TUMORS FROM STAINED HISTOLOGICAL SLIDES	ONCOGENE			English	Article							ENZYMATIC AMPLIFICATION; TISSUE-SECTIONS; DNA; HEPATOCARCINOGENESIS; GENE		CHILDRENS MED CTR,HA CHAPMAN RES INST MED GENET,5300 E SKELLY DR,TULSA,OK 74135; SAMUAL ROBERTS NOBLE FDN INC,DIV BIOMED,ARDMORE,OK 73402; UNIV TULSA,DEPT BIOL,TULSA,OK 74104; HILLCREST MED CTR,TULSA,OK 74104	Noble Research Institute; University of Tulsa								ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; Dukes CE, 1940, J PATHOL BACTERIOL, V50, P527, DOI 10.1002/path.1700500314; FOULDS L, 1954, CANCER RES, V14, P327; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; Greer C E, 1991, PCR Methods Appl, V1, P46; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; IMPRAIM CC, 1987, BIOCHEM BIOPH RES CO, V142, P710, DOI 10.1016/0006-291X(87)91472-0; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; Luna LG, 1968, MANUAL HISTOLOGIC ST, V3; ONADIM Z, 1991, J MED GENET, V28, P312, DOI 10.1136/jmg.28.5.312; RINGER DP, 1990, CANCER RES, V50, P5301; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHIBATA D, 1988, CANCER RES, V48, P4564; TEEBOR GW, 1971, CANCER RES, V31, P1; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901	16	78	82	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2355	2361						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1279500				2022-12-28	WOS:A1992JW66500032
J	HOGG, A; ONADIM, Z; BAIRD, PN; COWELL, JK				HOGG, A; ONADIM, Z; BAIRD, PN; COWELL, JK			DETECTION OF HETEROZYGOUS MUTATIONS IN THE RB1 GENE IN RETINOBLASTOMA PATIENTS USING SINGLE-STRAND CONFORMATION POLYMORPHISM ANALYSIS AND POLYMERASE CHAIN-REACTION SEQUENCING	ONCOGENE			English	Article							BASE-PAIR SUBSTITUTIONS; SUSCEPTIBILITY GENE; POINT MUTATIONS; DNA FRAGMENTS; EXPRESSION; GERMLINE	Several families segregating the autosomal dominant form of the hereditary retinoblastoma predisposition gene have been analysed for the causative mutation. We have used the single-strand conformation polymorphism (SSCP) technique to screen for mutations, exon by exon, in the RBI gene in affected patients from these families. The SSCP technique has proved a rapid and simple technique which relies on the sequence-dependent migration of single-stranded DNA in a non-denaturing polyacrylamide gel. Oligonucleotide primers flanking all 27 exons and the promoter region of the RB1 gene are reported here. The polymerase chain reaction (PCR)amplified products range in size from 212 to 625 bp and include a flanking intron sequence which allows detection of mutations in these regions. The sensitivity of SSCP is optimal when DNA fragments are approximately 200 bp long. Consequently, restriction enzyme sites for each amplified region were identified, reducing the size of the PCR products analysed to less than 250 bp. Bands with aberrant migration patterns were observed on SSCP gels in the lymphocyte DNA from two patients with bilateral, familial retinoblastoma. Sequence analysis of these DNA fragments revealed the causative mutations. These consisted of a 1-bp insertion of a T in the coding strand of exon 20 and a G --> A mutation in the coding strand of exon 14. This approach has proved to be a powerful method for the rapid detection of germline mutations in the RB1 gene, a programme which can be extended to individuals with new mutations.	INST CHILD HLTH,DEPT HAEMATOL & ONCOL,ICRF,ONCOL GRP,30 GUILFORD ST,LONDON WC1N 1EH,ENGLAND	University of London; University College London			Onadim, Zerrin/AAX-6490-2021	Onadim, Zerrin/0000-0002-8594-9586; Baird, Paul/0000-0002-1305-3502; Cowell, John/0000-0002-2079-5950				BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CAVENEE WK, 1985, SCIENCE, V228, P501, DOI 10.1126/science.3983638; COTTON RGH, 1988, P NATL ACAD SCI USA, V85, P4397, DOI 10.1073/pnas.85.12.4397; DEAN M, 1990, CELL, V61, P863, DOI 10.1016/0092-8674(90)90196-L; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; DUNN JM, 1989, MOL CELL BIOL, V9, P4596, DOI 10.1128/MCB.9.11.4596; FISCHER SG, 1983, P NATL ACAD SCI-BIOL, V80, P1579, DOI 10.1073/pnas.80.6.1579; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GANGULY A, 1990, NUCLEIC ACIDS RES, V18, P3933, DOI 10.1093/nar/18.13.3933; GODDARD AD, 1988, MOL CELL BIOL, V8, P2082, DOI 10.1128/MCB.8.5.2082; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; INNES MA, 1990, PCR PROTOCOLS GUIDE, P54; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MAZARS R, 1991, ONCOGENE, V6, P1685; MCGEE TL, 1989, GENE, V80, P119, DOI 10.1016/0378-1119(89)90256-4; MURAKAMI Y, 1991, ONCOGENE, V6, P37; MYERS RM, 1985, NATURE, V313, P495, DOI 10.1038/313495a0; ONADIM Z, 1991, J MED GENET, V28, P312, DOI 10.1136/jmg.28.5.312; ONADIM ZO, 1990, ARCH DIS CHILD-FETAL, V65, P651, DOI 10.1136/adc.65.7_Spec_No.651; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VOGEL W, 1979, HUM GENET, V51, P1; WARTELL RM, 1990, NUCLEIC ACIDS RES, V18, P2699, DOI 10.1093/nar/18.9.2699; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WILLIAMS JF, 1989, BIOTECHNIQUES, V7, P283; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501; ZHU XP, 1989, NATURE, V340, P312, DOI 10.1038/340312a0	31	79	80	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1445	1451						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1352398				2022-12-28	WOS:A1992HZ97100026
J	MARONEY, AC; QURESHI, SA; FOSTER, DA; BRUGGE, JS				MARONEY, AC; QURESHI, SA; FOSTER, DA; BRUGGE, JS			CLONING AND CHARACTERIZATION OF A THERMOLABILE V-SRC GENE FOR USE IN REVERSIBLE TRANSFORMATION OF MAMMALIAN-CELLS	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; PROTEIN KINASE-C; 3T3 CELLS; GROWTH; DIFFERENTIATION; FIBROBLASTS; EXPRESSION; PP60V-SRC; COMMUNICATION; POLYMERASE	The use of temperature-sensitive (ts) src mutants for studies of cell transformation and differentiation has been limited by the availability of cloned ts-src genes that are inactivated at temperatures compatible with growth of mammalian celts. In this report, we describe the cloning and characterization of the tsLA90src gene, which displays tight thermal sensitivity at 39.5-degrees-C. Nucleotide sequence comparison of tsLA90 and wild-type src genes from the Schmidt-Ruppin subgroup A and D strains of Rous sarcoma virus (RSV) revealed four amino acid differences in tsLA90src. Substitution of one of these residues (Lys-280) from tsLA90src with its wild-type homolog (Glu-280) caused a reversion to a wild-type src phenotype. The cloned tsLA90 gene, designated tsUP1, was introduced into avian and mammalian retroviral vectors. Chicken embryo fibroblasts and immortalized mouse 3T3 cells infected with these viral vectors displayed a temperature-dependent transformed phenotype as assessed by cell morphology, secretion of plasminogen activator, transcriptional activation of the primary response genes, Egr-1 and TIS 10, and stimulation of tyrosine phosphorylation. In addition, chicken myoblasts (infected with RSVtsUP1) showed a temperature-dependent differentiation into myotubes. Thus, this cloned src gene should be ideally suited for inducing reversible transformation and differentiation of mammalian cells in culture.	UNIV PENN,SCH MED,HOWARD HUGHES MED INST,DEPT MICROBIOL,PHILADELPHIA,PA 19104; CUNY HUNTER COLL,DEPT BIOL SCI,INST BIOMOLEC STRUCT & FUNCT,NEW YORK,NY 10021	Howard Hughes Medical Institute; University of Pennsylvania; City University of New York (CUNY) System; Hunter College (CUNY)					NCI NIH HHS [CA46677, CA27951, CA08900-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA027951, R01CA046677, R29CA046677, R37CA027951, F32CA008900] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEMA S, 1987, ADV CANCER RES, V49, P1, DOI 10.1016/S0065-230X(08)60792-7; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; AZARNIA R, 1984, J MEMBRANE BIOL, V82, P191, DOI 10.1007/BF01871629; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CRISANTICOMBES P, 1982, CELL DIFFER DEV, V11, P45, DOI 10.1016/0045-6039(82)90016-1; CZERNILOFSKY AP, 1983, NATURE, V301, P736, DOI 10.1038/301736b0; DAVIS LG, 1986, BASIC METHODS MOL BI, P286; GIOTTA GJ, 1980, BRAIN RES, V202, P445, DOI 10.1016/0006-8993(80)90154-7; GOLDBERG AR, 1974, CELL, V2, P95, DOI 10.1016/0092-8674(74)90097-X; GRAY GM, 1988, J BIOL CHEM, V263, P10714; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAN JW, 1990, ONCOGENE, V5, P467; HAN JW, 1990, P NATL ACAD SCI USA, V87, P3373, DOI 10.1073/pnas.87.9.3373; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HATCH CL, 1987, ANAL BIOCHEM, V162, P283, DOI 10.1016/0003-2697(87)90038-8; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JOVE R, 1986, J VIROL, V60, P849, DOI 10.1128/JVI.60.3.849-857.1986; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LIM RW, 1987, ONCOGENE, V1, P263; MENKO AS, 1987, CELL, V51, P51, DOI 10.1016/0092-8674(87)90009-2; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MUTO M, 1977, P NATL ACAD SCI USA, V74, P4173, DOI 10.1073/pnas.74.10.4173; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; OSSWOSKI L, 1973, J EXP MED, V138, P1056; PANET R, 1985, J BIOL CHEM, V260, P5752; PATWARDHAN S, 1991, ONCOGENE, V6, P917; QURESHI SA, 1991, MOL CELL BIOL, V11, P102, DOI 10.1128/MCB.11.1.102; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; QURESHI SA, 1991, ONCOGENE, V6, P995; REDDY S, 1990, J VIROL, V64, P3545, DOI 10.1128/JVI.64.7.3545-3550.1990; ROSE B, 1986, J MEMBRANE BIOL, V94, P129, DOI 10.1007/BF01871193; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; STOKER AW, 1984, MOL CELL BIOL, V4, P1508, DOI 10.1128/MCB.4.8.1508	36	37	38	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1992	7	6					1207	1214						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1375718				2022-12-28	WOS:A1992HU64200019
J	SCHUH, AC; KEATING, SJ; YEUNG, MC; BREITMAN, ML				SCHUH, AC; KEATING, SJ; YEUNG, MC; BREITMAN, ML			SKELETAL-MUSCLE ARISES AS A LATE EVENT DURING DEVELOPMENT OF WOUND SARCOMAS IN V-JUN TRANSGENIC MICE	ONCOGENE			English	Article							TRANSCRIPTION FACTOR AP-1; C-JUN; PROTO-ONCOGENE; DNA-BINDING; GLUCOCORTICOID RECEPTOR; ENHANCER ELEMENTS; GROWTH-FACTORS; GENE FAMILY; EXPRESSION; DIFFERENTIATION	Mice carrying an H-2K-v-jun transgene develop malignant sarcomas by a multistage mechanism following wounding. Here we show that these malignancies are often heterogeneous in composition, containing both undifferentiated mesenchymal cells as well as focal areas of skeletal muscle. Such myogenic areas are not detectable in premalignant precursor lesions, suggesting that cells competent for muscle differentiation arise at a late stage of tumorigenesis. Immunohistochemical staining of transgenic sarcomas reveals that levels of v-Jun correlate inversely with muscle-specific gene expression, suggesting that high levels may be inhibitory to myogenesis. Consistent with this idea, we demonstrate that whereas high levels of v-Jun are able to block MyoD-dependent gene expression in vitro, the levels of v-Jun in sarcoma-derived myogenic cells are below the threshold required to produce this effect. The cell of origin of v-jun wound sarcomas, as well as the relationship between myogenic determination and multistage tumorigenesis, are discussed in the light of these results.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,DIV MOLEC & DEV BIOL,600 UNIV AVE,TORONTO M5G 1X5,ONTARIO,CANADA; UNIV TORONTO,DEPT MED GENET,TORONTO M5S 1A8,ONTARIO,CANADA; MT SINAI HOSP,DEPT PATHOL,TORONTO M5G 1X5,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute								ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BENBROOK DM, 1990, ONCOGENE, V5, P295; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BORRAS T, 1988, DEV BIOL, V127, P209, DOI 10.1016/0012-1606(88)90202-3; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clark R.A.F., 1988, MOL CELLULAR BIOL WO, P3, DOI [10.1007/978-1-4615-1795-5_1, DOI 10.1007/978-1-4615-1795-5_1]; CONSTANTINIDES PG, 1977, NATURE, V267, P364, DOI 10.1038/267364a0; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; ENZINGER FM, 1988, SOFT TISSUE TUMORS, P448; FLORINI JR, 1989, AM J PHYSIOL, V256, pC701, DOI 10.1152/ajpcell.1989.256.4.C701; GARCIA M, 1990, J VIROL, V64, P4684, DOI 10.1128/JVI.64.10.4684-4690.1990; GILMAN M, 1987, CURRENT PROTOCOLS MO, V1; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GROSSI M, 1991, ONCOGENE, V6, P1767; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HERRLICH P, 1989, TRENDS GENET, V5, P112, DOI 10.1016/0168-9525(89)90041-3; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HITI AL, 1989, MOL CELL BIOL, V9, P4722, DOI 10.1128/MCB.9.11.4722; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MEAKIN SO, 1989, EXP EYE RES, V48, P131, DOI 10.1016/0014-4835(89)90026-2; MEAKIN SO, 1987, MOL CELL BIOL, V7, P2671, DOI 10.1128/MCB.7.8.2671; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; PINNEY DF, 1988, CELL, V53, P781, DOI 10.1016/0092-8674(88)90095-5; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1991, ONCOGENE, V6, P533; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SCHUH AC, 1990, NATURE, V346, P756, DOI 10.1038/346756a0; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCRABLE H, 1989, GENE CHROMOSOME CANC, V1, P23, DOI 10.1002/gcc.2870010106; Skalli O, 1988, MOL CELLULAR BIOL WO, P373; SU HY, 1991, ONCOGENE, V6, P1759; TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; VOGT PK, 1988, ONCOGENE, V3, P3; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YU CCK, 1990, DEVELOPMENT, V110, P131	53	10	10	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					667	676						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1314368				2022-12-28	WOS:A1992HQ68200008
J	MOEN, CJA; SNOEK, M; HART, AAM; DEMANT, P				MOEN, CJA; SNOEK, M; HART, AAM; DEMANT, P			SCC-1, A NOVEL COLON CANCER SUSCEPTIBILITY GENE IN THE MOUSE - LINKAGE TO CD44 (LY-24, PGP-1) ON CHROMOSOME-2	ONCOGENE			English	Article							COLORECTAL CARCINOMAS; MUTATIONS; MODEL; MAPS; ARM	Mutations of proto-oncogenes and tumor-suppressor genes lead to neoplastic development. Some germline mutations of these genes increase the tumor susceptibility of their carriers, but the relationship between genes controlling tumor susceptibility and the known oncogenes and tumor-suppressor genes remains unelucidated. Moreover, as tumor susceptibility in mouse is controlled by multiple genes, their identification has been virtually impossible. We therefore developed a new system, the recombinant congenic strains (RCS), which separates individual susceptibility genes into different RC strains, thus facilitating their analysis. To map genes controlling the development of colon cancer, we used the Balb/c-c-STS (CcS/Dem) RC strains. Owing to several unidentified genes, Balb/cHeA mice are relatively resistant and STS/A mice highly susceptible to 1,2-dimethylhydrazine-(DMH)-induced colon adenocarcinomas. Each CcS/Dem strain carries a different subset of about 12.5% of genes of the STS strain on the Balb/c background, and individual STS susceptibility genes became segregated into different RC strains. Using CcS-19, one of the highly susceptible RC strains, we mapped a novel colon tumor susceptibility gene, Scc-1, different from the oncogenes and tumor-suppressor genes known to be involved in colon tumorigenesis, in the vicinity of CD44 (Ly-24, Pgp-1) on chromosome 2. The mapping of the Scc-1 gene indicates that the RCS system can be used to map and study the presently unknown genes which control cancer development.	NETHERLANDS CANC INST, DIV MOLEC GENET, PLESMANLAAN 121, 1066 CX AMSTERDAM, NETHERLANDS; NETHERLANDS CANC INST, DIV RADIOTHERAPY, 1066 CX AMSTERDAM, NETHERLANDS	Netherlands Cancer Institute; Netherlands Cancer Institute								BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; DANIEL F, 1983, EMBO J, V2, P1061, DOI 10.1002/j.1460-2075.1983.tb01546.x; Davisson MT, 1989, GENETIC VARIANTS STR, P432; DEMANT P, 1986, IMMUNOGENETICS, V24, P416, DOI 10.1007/BF00377961; DEMANT P, 1989, ADV CANCER RES, V53, P117; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FLEISZER D, 1988, CURR TOP MICROBIOL, V137, P243; GLASER T, 1990, SCIENCE, V250, P823, DOI 10.1126/science.2173141; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HESTON WE, 1963, METHODOLOGY MAMMALIA, P247; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; LANDER ES, 1989, GENETICS, V121, P185; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; LOVE JM, 1990, NUCLEIC ACIDS RES, V18, P4123, DOI 10.1093/nar/18.14.4123; MOCK B, 1987, NUCLEIC ACIDS RES, V15, P4700, DOI 10.1093/nar/15.11.4700; MOEN CJA, 1991, MAMM GENOME, V1, P217, DOI 10.1007/BF00352328; MURPHY ED, 1966, BIOL LABORATORY MOUS; NADEAU J, 1990, MOUSE GENOME, V87, P55; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; SOLOMON E, 1987, NATURE, V328, P616, DOI 10.1038/328616a0; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; WATKINS PC, 1987, DNA-J MOLEC CELL BIO, V6, P205, DOI 10.1089/dna.1987.6.205; WETSEL RA, 1987, BIOCHEMISTRY-US, V26, P737, DOI 10.1021/bi00377a013; [No title captured]	26	57	60	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1992	7	3					563	566						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1347918				2022-12-28	WOS:A1992HK00500024
J	TAPLEY, P; LAMBALLE, F; BARBACID, M				TAPLEY, P; LAMBALLE, F; BARBACID, M			K252A IS A SELECTIVE INHIBITOR OF THE TYROSINE PROTEIN-KINASE ACTIVITY OF THE TRK FAMILY OF ONCOGENES AND NEUROTROPHIN RECEPTORS	ONCOGENE			English	Article							NERVE GROWTH-FACTOR; PC12 CELLS; POTENT INHIBITORS; MICROBIAL ORIGIN; K-252A; SEQUENCES; DOMAIN; RECOMBINATION; STAUROSPORINE; ASSOCIATION	K252a, an efficient serine/threonine protein kinase inhibitor (IC50s of 10 to 30 nM), has been shown to block the neuronal differentiation of rat pheochromocytoma PC12 cells induced by nerve growth factor (NGF). In this report, we demonstrate that K252a is a potent inhibitor (IC50 of 3 nM) of the tyrosine protein kinase activity of the NGF receptor gp140trk, the product of the trk proto-oncogene. K252a also inhibits the kinase activity of its transforming alleles, the trk oncogenes, and of the related neurotrophin receptors gp145trkB and gp145trkC, the products of the other known members of the trk gene family, trkB and trkC. In contrast, K252a has no effect (even at micromolar concentrations) on other tyrosine protein kinases such as the receptors for EGF and PDGF and the products of the v-src and v-fms oncogenes. In addition, K252a rapidly reverts the transformed phenotype of NIH3T3 cells transformed by either autocrine stimulation of the trk family of receptors by their cognate ligands or by expression of trk oncogenes isolated from human tumors. The selectivity of K252a for the catalytic activity of the trk family of kinases should help to establish the structural basis for the rational design of highly specific tyrosine protein kinase inhibitors.			TAPLEY, P (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,POB 4000,PRINCETON,NJ 08543, USA.		Lamballe, Fabienne/P-4293-2017; Lamballe, Fabienne/GLT-0820-2022	Lamballe, Fabienne/0000-0001-7631-942X				BARBACID M, 1991, IN PRESS BBA REV CAN; BONGARZONE I, 1989, ONCOGENE, V4, P1457; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; COULIER F, 1990, MOL CELL BIOL, V10, P4202, DOI 10.1128/MCB.10.8.4202; CUADRADO A, 1990, CELL GROWTH DIFFER, V1, P9; ELLIOTT LH, 1990, BIOCHEM BIOPH RES CO, V171, P148, DOI 10.1016/0006-291X(90)91369-4; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; HARLOW E, 1988, ANTIBODIES LABORATOR; HASHIMOTO S, 1988, J CELL BIOL, V107, P1531, DOI 10.1083/jcb.107.4.1531; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HOSANG M, 1985, J BIOL CHEM, V260, P655; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; KAMPS MP, 1988, ONCOGENE, V2, P305; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KASE H, 1986, J ANTIBIOT, V39, P1059, DOI 10.7164/antibiotics.39.1059; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; KOIZUMI S, 1988, J NEUROSCI, V8, P715; KOZMA SC, 1988, EMBO J, V7, P147, DOI 10.1002/j.1460-2075.1988.tb02794.x; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LAZAROVICI P, 1989, J NEUROSCI RES, V23, P1, DOI 10.1002/jnr.490230102; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; NAKANISHI S, 1988, J BIOL CHEM, V263, P6215; NAKANISHI S, 1986, J ANTIBIOT, V39, P1066; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; OSKAM R, 1988, P NATL ACAD SCI USA, V85, P2964, DOI 10.1073/pnas.85.9.2964; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K	44	471	492	0	14	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1992	7	2					371	381						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1312698				2022-12-28	WOS:A1992HG98200024
J	GIEBEL, LB; STRUNK, KM; HOLMES, SA; SPRITZ, RA				GIEBEL, LB; STRUNK, KM; HOLMES, SA; SPRITZ, RA			ORGANIZATION AND NUCLEOTIDE-SEQUENCE OF THE HUMAN KIT (MAST STEM-CELL GROWTH-FACTOR RECEPTOR) PROTOONCOGENE	ONCOGENE			English	Article							W-MUTANT MICE; C-KIT; TYROSINE KINASE; PDGF RECEPTOR; SIGNAL-TRANSDUCTION; POINT MUTATIONS; TRANSCRIPTION FACTOR; MOUSE EMBRYOGENESIS; HEMATOPOIETIC STEM; CDNA CLONING	We have cloned and sequenced the human KIT protooncogene, which contains 21 exons and spans more than 34 kb of DNA on chromosome segment 4q12. We also establish physical linkage between the KIT gene and the related PDGFRA gene. The organization of the KIT gene is virtually identical to that of the homologous FMS gene, located on chromosome 5. Together, these data suggest that the KIT and PDGFRA genes on chromosome 4 and the FMS and PDGFRB genes on chromosome 5 arose by duplication of a common ancestral gene, followed by duplication of a chromosome.	UNIV WISCONSIN, DEPT MED GENET, 317 LAB GENET, MADISON, WI 53706 USA; UNIV WISCONSIN, DEPT PEDIAT, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NIAMS NIH HHS [AR39892] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039892] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; ANDRE C, 1989, ONCOGENE, V4, P1047; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; CLARK L, 1988, GENE DEV, V2, P991, DOI 10.1101/gad.2.8.991; COOKE JV, 1952, J PEDIATR-US, V41, P1, DOI 10.1016/S0022-3476(52)80022-8; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; DAURIOL L, 1988, HUM GENET, V78, P374, DOI 10.1007/BF00291740; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DISTECHE CM, 1989, CYTOGENET CELL GENET, V51, P990; FLEISCHMAN RA, 1991, P NATL ACAD SCI USA, V88, P10885, DOI 10.1073/pnas.88.23.10885; FROGGAT P, 1951, IRISH J MED SCI, V398, P86; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GIEBEL LB, 1991, P NATL ACAD SCI USA, V88, P8696, DOI 10.1073/pnas.88.19.8696; HAMPE A, 1989, ONCOGENE RES, V4, P9; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARDON EM, 1988, EMBO J, V7, P1711, DOI 10.1002/j.1460-2075.1988.tb03000.x; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3799, DOI 10.1093/nar/19.14.3799; Keeler CE, 1934, J AMER MED ASSOC, V103, P0179, DOI 10.1001/jama.1934.72750290001009; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRUG MS, 1987, METHOD ENZYMOL, V152, P316; LASSAM N, 1992, ONCOGENE, V7, P51; Locker J, 1990, DNA Seq, V1, P3, DOI 10.3109/10425179009041342; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MERCOLA M, 1990, DEV BIOL, V138, P114, DOI 10.1016/0012-1606(90)90181-H; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MONACI P, 1988, EMBO J, V7, P2075, DOI 10.1002/j.1460-2075.1988.tb03047.x; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; OCHOA A, 1989, NUCLEIC ACIDS RES, V17, P119, DOI 10.1093/nar/17.1.119; REGENSTREIF LJ, 1989, DEV BIOL, V133, P284, DOI 10.1016/0012-1606(89)90319-9; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; ROBERTS WM, 1988, CELL, V55, P655, DOI 10.1016/0092-8674(88)90224-3; ROBERTS WM, 1992, BLOOD, V79, P586; ROSNET O, 1991, GENOMICS, V9, P380, DOI 10.1016/0888-7543(91)90270-O; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATOH H, 1987, JPN J CANCER RES, V78, P772; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHIBAHARA S, 1991, J BIOL CHEM, V266, P15895; SHIBUYA M, 1990, ONCOGENE, V5, P519; SMITH DR, 1990, P NATL ACAD SCI USA, V87, P8242, DOI 10.1073/pnas.87.21.8242; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPRITZ RA, 1992, AM J HUM GENET, V50, P261; SPRITZ RA, 1992, IN PRESS AM J MED GE; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; TERMAN BI, 1991, ONCOGENE, V6, P1677; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VISVADER J, 1989, MOL CELL BIOL, V9, P1336, DOI 10.1128/MCB.9.3.1336; WATSON MEE, 1984, NUCLEIC ACIDS RES, V12, P5145, DOI 10.1093/nar/12.13.5145; WEIHER H, 1983, SCIENCE, V219, P626, DOI 10.1126/science.6297005; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; ZHANG H, 1988, NUCLEIC ACIDS RES, V16, P1220, DOI 10.1093/nar/16.3.1220; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	69	102	112	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1992	7	11					2207	2217						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1279499				2022-12-28	WOS:A1992JW66500013
J	HALABAN, R; RUBIN, JS; FUNASAKA, Y; COBB, M; BOULTON, T; FALETTO, D; ROSEN, E; CHAN, A; YOKO, K; WHITE, W; COOK, C; MOELLMANN, G				HALABAN, R; RUBIN, JS; FUNASAKA, Y; COBB, M; BOULTON, T; FALETTO, D; ROSEN, E; CHAN, A; YOKO, K; WHITE, W; COOK, C; MOELLMANN, G			MET AND HEPATOCYTE GROWTH-FACTOR SCATTER FACTOR SIGNAL TRANSDUCTION IN NORMAL MELANOCYTES AND MELANOMA-CELLS	ONCOGENE			English	Article							AUTOCRINE MOTILITY FACTOR; TYROSINE KINASE RECEPTOR; HUMAN GASTRIC-CARCINOMA; C-MET; MOLECULAR-CLONING; MURINE MELANOCYTES; EPITHELIAL-CELLS; REGULATED KINASES; TRANSFORMING GENE; PROTEIN-KINASES	The proto-oncogene c-MET encodes a transmembrane tyrosine kinase receptor for hepatocyte growth factor/scatter factor (HGF/SF). HGF/SF stimulates the proliferation and motility of various cell types. Because HGF/SF is also a melanocyte mitogen, we investigated the biological role of HGF/SF, including c-Met expression, activation and signal transduction, in normal and malignant human melanocytes. We show that HGF/SF is mitogenic in the presence of synergistic factors, such as basic fibroblast growth factor (bFGF) and mast cell growth factor (MGF) and that, by itself, it stimulates the motility of normal human melanocytes. The ligand also maintained high levels of tyrosinase activity and melanin content in theses cells. Signal transduction by HGF/SF included phosphorylation of tyrosyl residues on c-Met, a cascade of tyrosine phosphorylations on several other proteins and activation of microtubule-associated protein kinase/extracellular signal-regulated kinase. Met expression and activity are normal in human melanomas, and constitutive activity of HGF/SF in retrovirally infected autonomously proliferative mouse melanocytes is insufficient to confer the malignant phenotype. Our findings suggest that activation of Met in response to HGF/SF may contribute to malignant progression synergistically with the aberrant expression of bFGF in malignant melanocytes and that, in addition, the peptide may promote dispersion of factor-dependent melanocytes from early stages of primary melanomas to ectopic sites.	NCI,FREDERICK CANC RES & DEV,ABL BASIC RES PROGRAM,FREDERICK,MD 21702; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT PATHOL,WINSTON SALEM,NC 27103; YALE UNIV,SCH MED,DEPT RADIAT THERAPY,NEW HAVEN,CT 06510; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235; YALE UNIV,SCH MED,DEPT PLAST SURG,NEW HAVEN,CT 06510; NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Wake Forest University; Wake Forest Baptist Medical Center; Yale University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Yale University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	HALABAN, R (corresponding author), YALE UNIV,SCH MED,DEPT DERMATOL,333 CEDAR ST,POB 3333,NEW HAVEN,CT 06510, USA.		Chan, Andrew Man-Lok/J-9497-2013	Chan, Andrew Man-Lok/0000-0001-9923-5464; Cobb, Melanie/0000-0003-0833-5473	NATIONAL CANCER INSTITUTE [R29CA044542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039848] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034128, R37DK034128] Funding Source: NIH RePORTER; NCI NIH HHS [5-R29-CA44542] Funding Source: Medline; NIAMS NIH HHS [1RO1-AR39848] Funding Source: Medline; NIDDK NIH HHS [DK 34128] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; AHN NG, 1990, J BIOL CHEM, V265, P11495; ALBINO AP, 1991, CANCER RES, V51, P4815; ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; BAIRD A, 1991, CANCER CELL-MON REV, V3, P239; BEAN MA, 1975, CANCER RES, V35, P2902; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; BHARGAVA J, 1992, CELL GROWTH DIFFER, V3, P11; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BRADL M, 1991, P NATL ACAD SCI USA, V88, P6447, DOI 10.1073/pnas.88.15.6447; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CEPKO CL, 1984, CELL, V37, P1043; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DOTTO GP, 1989, J CELL BIOL, V109, P3115, DOI 10.1083/jcb.109.6.3115; FALETTO DL, 1992, ONCOGENE, V7, P1149; FUNASAKA Y, 1992, MOL BIOL CELL, V3, P197, DOI 10.1091/mbc.3.2.197; FURLONG RA, 1991, J CELL SCI, V100, P173; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GIORDANO S, 1988, MOL CELL BIOL, V8, P3510, DOI 10.1128/MCB.8.8.3510; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GREGORY J, 1989, J BIOL CHEM, V264, P18377; HALABAN R, 1992, J IMMUNOTHER, V12, P154, DOI 10.1097/00002371-199210000-00002; HALABAN R, 1986, J INVEST DERMATOL, V87, P95, DOI 10.1111/1523-1747.ep12523594; HALABAN R, 1987, IN VITRO CELL DEV B, V23, P47; HALABAN R, 1991, Critical Reviews in Oncogenesis, V2, P247; HALABAN R, 1988, ONCOGENE RES, V3, P177; HALABAN R, 1991, ANN NY ACAD SCI, V638, P232, DOI 10.1111/j.1749-6632.1991.tb49034.x; HALABAN R, 1983, J CELL BIOL, V97, P480, DOI 10.1083/jcb.97.2.480; HALABAN R, 1977, EXP CELL RES, V108, P119, DOI 10.1016/S0014-4827(77)80017-7; HALABAN R, 1991, CANCER METAST REV, V10, P129, DOI 10.1007/BF00049410; HERLYN M, 1985, CANCER RES, V45, P5670; IGAWA T, 1991, BIOCHEM BIOPH RES CO, V174, P831, DOI 10.1016/0006-291X(91)91493-V; IWAMOTO T, 1991, EMBO J, V10, P3167, DOI 10.1002/j.1460-2075.1991.tb04878.x; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; JAMBROSIC J, 1989, INT J CANCER, V44, P1117, DOI 10.1002/ijc.2910440630; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; LEE RM, 1992, J BIOL CHEM, V267, P1088; MATSUMOTO K, 1991, BIOCHEM BIOPH RES CO, V176, P45, DOI 10.1016/0006-291X(91)90887-D; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MONDINO A, 1991, MOL CELL BIOL, V11, P6084, DOI 10.1128/MCB.11.12.6084; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK M, 1988, P NATL ACAD SCI USA, V85, P2667, DOI 10.1073/pnas.85.8.2667; PONZETTO C, 1991, ONCOGENE, V6, P553; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RODECK U, 1991, J INVEST DERMATOL, V97, P20, DOI 10.1111/1523-1747.ep12477822; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SHIOTA G, 1992, P NATL ACAD SCI USA, V89, P373, DOI 10.1073/pnas.89.1.373; SILLETTI S, 1991, CANCER RES, V51, P3507; SOMAN NR, 1991, P NATL ACAD SCI USA, V88, P4892, DOI 10.1073/pnas.88.11.4892; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TAMURA A, 1987, IN VITRO CELL DEV B, V23, P519; WATANABE H, 1991, J BIOL CHEM, V266, P13442; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; WILSON RE, 1989, CANCER RES, V49, P711; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	73	179	183	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2195	2206						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1331934				2022-12-28	WOS:A1992JW66500012
J	PANTERNE, B; HATZFELD, J; BLANCHARD, JM; LEVESQUE, JP; BERTHIER, R; GINSBOURG, M; HATZFELD, A				PANTERNE, B; HATZFELD, J; BLANCHARD, JM; LEVESQUE, JP; BERTHIER, R; GINSBOURG, M; HATZFELD, A			C-FOS MESSENGER-RNA CONSTITUTIVE EXPRESSION BY MATURE HUMAN MEGAKARYOCYTES	ONCOGENE			English	Note							INSITU HYBRIDIZATION; GENE-EXPRESSION; HUMAN-MONOCYTES; PROTO-ONCOGENE; 3T3 CELLS; GROWTH; TRANSCRIPTION; MACROPHAGES; PROTOONCOGENE; GRANULOCYTES	By in situ hybridization with a c-fos probe, we have shown that human bone marrow megakaryocytes cultured in the presence of 20% aplastic anemia plasma constitutively express c-fos mRNA. At day 0, megakaryocytes are mostly immature and only 3% of them are labeled. The number of labeled cells reached 23% after 12 days of culture. Interleukin 3 (IL-3) and IL-6 added together at day 10 further increased this number to 31% 2 days later. Mature labeled megakaryocytes were more numerous and more strongly labeled than immature ones. These results suggest that c-fos could play a role in megakaryocytic terminal differentiation, either in the polyploidization or in the thrombopoietic function unique to these cells.	HOP PAUL BROUSSE,ICIG,BIOL CELLULAIRE & MOLEC FACTEURS CROISSANCE LAB,CNRS,F-94804 VILLEJUIF,FRANCE; CEN,DEPT HEMATOL,F-38041 GRENOBLE,FRANCE; UNIV MONTPELLIER 2,BIOCHIM LAB,CNRS,UA 1191,F-34060 MONTPELLIER,FRANCE; UNIV MONTPELLIER 2,BIOL MOLEC LAB,CNRS,UA 1191,F-34060 MONTPELLIER,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier			Levesque, Jean-Pierre/C-5426-2011; HATZFELD, Antoinette/I-2341-2013; HATZFELD, Jacques A/I-2346-2013	Levesque, Jean-Pierre/0000-0002-7299-6025; HATZFELD, Antoinette/0000-0002-9147-533X; HATZFELD, Jacques A/0000-0002-3468-6659				ANGERER LM, 1987, METHOD ENZYMOL, V152, P649; BERNAUDIN JF, 1988, J IMMUNOL, V140, P3822; BERTHIER R, 1987, EXP HEMATOL, V15, P750; CAUBET JF, 1989, BLOOD, V74, P947; COCHRAN BH, 1984, SCIENCE, V226, P1080, DOI 10.1126/science.6093261; COLLART MA, 1987, J IMMUNOL, V139, P949; COLLART MA, 1991, MOL CELL BIOL, V11, P2826, DOI 10.1128/MCB.11.5.2826; COLOTTA F, 1987, J EXP MED, V165, P1224, DOI 10.1084/jem.165.4.1224; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; Curran T, 1988, ONCOGENE HDB, P307; DEBILI N, 1991, BLOOD, V77, P2326; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HATZFELD J, 1991, J EXP MED, V174, P925, DOI 10.1084/jem.174.4.925; Hayhoe FG, 1982, COLOUR ATLAS HAEMATO; KREIPE H, 1987, J HISTOCHEM CYTOCHEM, V35, P837, DOI 10.1177/35.8.3298425; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEE J, 1987, BLOOD, V69, P1542; MCCUNE JM, 1990, SCIENCE, V217, P864; MESSNER HA, 1987, P NATL ACAD SCI USA, V84, P6765, DOI 10.1073/pnas.84.19.6765; MESSNER HA, 1984, METHODS HEMATOLOGY, V2, P73; SARIBAN E, 1988, MOL CELL BIOL, V8, P340, DOI 10.1128/MCB.8.1.340	22	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2341	2344						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437157				2022-12-28	WOS:A1992JW66500029
J	MANGUES, R; SEIDMAN, I; GORDON, JW; PELLICER, A				MANGUES, R; SEIDMAN, I; GORDON, JW; PELLICER, A			OVEREXPRESSION OF THE N-RAS PROTOONCOGENE, NOT SOMATIC MUTATIONAL ACTIVATION, ASSOCIATED WITH MALIGNANT-TUMORS IN TRANSGENIC MICE	ONCOGENE			English	Note							MURINE SARCOMA-VIRUS; HA-RAS; EXPRESSION; GENE; TRANSFORMATION; DNA; TUMORIGENESIS; INVIVO; CELLS	We have produced transgenic mice that carry a foreign gene construct consisting of the N-ras proto-oncogene driven by the mouse mammary tumor virus (MMTV) long terminal repeat. Overexpression of the normal N-ras gene is associated with development of hyperplasias and tumors in a variety of tissues. The tumors are clearly malignant, as evidenced by the presence of metastatic lesions. Extensive analysis of the foreign ras gene in these tumors by use of polymerase chain reaction and sequencing demonstrates in all cases the absence of somatically acquired mutations at those codons normally associated with activation of the ras genes. Thus, these tumors develop from overexpression of the proto-oncogene rather than the presence of the mutated oncogene. These data demonstrate that overexpression of a proto-oncogene of the ras family can predispose cells in vivo to fully malignant behavior.	NYU MED CTR, DEPT PATHOL, NEW YORK, NY 10016 USA; NYU MED CTR, KAPLAN CANC CTR, NEW YORK, NY 10016 USA; CUNY MT SINAI SCH MED, DEPT GERIATR & ADULT DEV, CTR MOLEC BIOL, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, DEPT OBSTET GYNECOL & REPROD SCI, NEW YORK, NY 10029 USA	New York University; New York University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai				Pellicer, Angel/0000-0002-5062-0692; Mangues, Ramon/0000-0003-2661-9525	NCI NIH HHS [CA 50434, CA 42103, CA 36327] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042103, R01CA036327, R01CA050434, R37CA036327] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1989, CANCER RES, V49, P4682; CARDIFF RD, 1991, AM J PATHOL, V139, P495; CHANG EH, 1982, NATURE, V297, P479, DOI 10.1038/297479a0; DEFEO D, 1981, P NATL ACAD SCI-BIOL, V78, P3328, DOI 10.1073/pnas.78.6.3328; GEORGE DL, 1986, P NATL ACAD SCI USA, V83, P1651, DOI 10.1073/pnas.83.6.1651; GEROSA MA, 1989, J NATL CANCER I, V81, P63, DOI 10.1093/jnci/81.1.63; GORDON JW, 1980, P NATL ACAD SCI-BIOL, V77, P7380, DOI 10.1073/pnas.77.12.7380; GUERRERO I, 1984, SCIENCE, V225, P1041, DOI 10.1126/science.6089339; GUERRERO I, 1988, BIOCHEM BIOPH RES CO, V150, P1185, DOI 10.1016/0006-291X(88)90754-1; HARRIS AW, 1988, CURR TOP MICROBIOL, V141, P82; HIGUCHI R, 1988, NATURE, V332, P543, DOI 10.1038/332543a0; HOFLER H, 1988, VIRCHOWS ARCH B, V55, P355; MANGUES R, 1990, ONCOGENE, V5, P1491; MCKAY IA, 1986, EMBO J, V5, P2617, DOI 10.1002/j.1460-2075.1986.tb04542.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAITOH A, 1990, ONCOGENE, V5, P1195; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; SOUYRI M, 1989, J VIROL, V63, P3944, DOI 10.1128/JVI.63.9.3944-3953.1989; SPANDIDOS DA, 1984, BRIT J CANCER, V49, P681, DOI 10.1038/bjc.1984.108; TANAKA T, 1986, CANCER RES, V46, P1465; TREMBLAY PJ, 1989, MOL CELL BIOL, V9, P854, DOI 10.1128/MCB.9.2.854; VELU TJ, 1989, J VIROL, V63, P1384, DOI 10.1128/JVI.63.3.1384-1392.1989; WESTAWAY D, 1986, EMBO J, V5, P301, DOI 10.1002/j.1460-2075.1986.tb04213.x	25	39	39	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1992	7	10					2073	2076						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1328989				2022-12-28	WOS:A1992JP42400024
J	BOISE, LH; GORSE, KM; WESTIN, EH				BOISE, LH; GORSE, KM; WESTIN, EH			MULTIPLE MECHANISMS OF REGULATION OF THE HUMAN C-MYB GENE DURING MYELOMONOCYTIC DIFFERENTIATION	ONCOGENE			English	Article							PROMYELOCYTIC LEUKEMIA-CELLS; MOUSE ERYTHROLEUKEMIA-CELLS; PROTO-ONCOGENE PRODUCT; MESSENGER-RNA; TRANS-ACTIVATION; V-MYB; EXPRESSION; PROLIFERATION; TRANSCRIPTION; SEQUENCE	Alterations in expression of c-myb can have profound effects on the growth and differentiation of hematopoietic cells. Thus, it is important to understand the mechanisms by which c-myb is regulated during hematopoietic cell differentiation. Previous studies pertaining to the regulation of c-myb have been carried out with the avian and murine forms of the gene; the current studies were designed to determine the mechanisms of regulation of the human form of c-myb. Transcriptional analysis by nuclear run-on assays revealed that an attenuation of transcription was the means of primary regulation during retinoic acid- and vitamin D3-induced differentiation of HL-60 cells, while other mechanisms in addition to attenuation were active during dimethyl sulfoxide (DMSO)- and phorbol ester-induced differentiation. Densitometric analysis of the changes in c.myb transcription caused by phorbol ester suggested that the c-myb promoter may be down-regulated during phorbol ester-induced differentiation of HL-60. Additional studies exhibited post-transcriptional regulation by phorbol ester. DMSO was also shown to regulate c-myb at the post-transcriptional level. Interestingly, the post-transcriptional regulation of c-myb by DMSO required continuous transcription. This requirement was shared for c-myc but not ornithine decarboxylase expression. The transcriptional dependency of c-myb post-transcriptional regulation did not equate to translational dependency, thus a novel post-transcriptional regulatory mechanism may control c-myb gene expression. The multiple levels of regulation of c-myb suggest the importance of proper control for hematopoietic cell differentiation.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHARMACOL & TOXICOL,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MED,RICHMOND,VA 23298	Virginia Commonwealth University; Virginia Commonwealth University			Boise, Lawrence/AAD-2314-2019	Boise, Lawrence/0000-0001-9436-8815	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007087] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 07087] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; COLLINS SJ, 1987, BLOOD, V70, P1233; Dalla-Favera R, 1983, Haematol Blood Transfus, V28, P247; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GOLAY J, 1991, BLOOD, V77, P149; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HAYWARD WS, 1989, MOL CELL BIOL, V9, P837; HICKOK NJ, 1987, DNA-J MOLEC CELL BIO, V6, P179, DOI 10.1089/dna.1987.6.179; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; KRYSTAL GW, 1990, MOL CELL BIOL, V10, P4180, DOI 10.1128/MCB.10.8.4180; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MIYAURA C, 1981, BIOCHEM BIOPH RES CO, V102, P937, DOI 10.1016/0006-291X(81)91628-4; NAKAGOSHI H, 1989, NUCLEIC ACIDS RES, V17, P7315, DOI 10.1093/nar/17.18.7315; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; WATSON RJ, 1988, ONCOGENE, V2, P267; WATSON RJ, 1988, MOL CELL BIOL, V8, P3938, DOI 10.1128/MCB.8.9.3938; WEBER BL, 1990, SCIENCE, V249, P1291, DOI 10.1126/science.2205003; WESTIN EH, 1990, ONCOGENE, V5, P1117; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	36	19	19	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1817	1825						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1323820				2022-12-28	WOS:A1992JJ37600018
J	TADOKORO, K; FUJII, H; OHSHIMA, A; KAKIZAWA, Y; SHIMIZU, K; SAKAI, A; SUMIYOSHI, K; INOUE, T; HAYASHI, Y; YAMADA, M				TADOKORO, K; FUJII, H; OHSHIMA, A; KAKIZAWA, Y; SHIMIZU, K; SAKAI, A; SUMIYOSHI, K; INOUE, T; HAYASHI, Y; YAMADA, M			INTRAGENIC HOMOZYGOUS DELETION OF THE WT1-GENE IN WILMS-TUMOR	ONCOGENE			English	Article							CHROMOSOME-11; GENE; 11P13; LOCUS; DNA; HETEROZYGOSITY; ASSOCIATION; MUTATION; ALLELES; CANCER	One example of intragenic homozygous deletion of the WT1 gene on chromosome 11p13 was found after screening 42 samples of Wilms' tumor DNA from Japanese patients. After construction of a restriction map for the genomic sequence covering the 3' half of the gene, the deletion was analysed at the nucleotide sequence level. The deletion occurred in the patient's germline on his paternal chromosome, and most of the short arm of his maternal chromosome 11 was subsequently lost in the tumor. The size of the deletion was about 8 kb, removing exons 6 and 7 and resulting in premature termination. The deletion seemed to be created by recombination between short homologous sequences found in an Alu repeat, with a 16-bp duplication left at the junction. This case conforms to a two-hit model for the genesis of a certain group of tumors, and supports the hypothesis that WT1 is one of the recessive oncogenes responsible for Wilms' tumor.	NIHON UNIV,COLL AGR & VET MED,NUCLE ACID SCI LAB,FUJISAWA,KANAGAWA 252,JAPAN; UNIV TOKYO,FAC MED,DEPT PEDIAT,TOKYO 113,JAPAN; NATL CHILDRENS HOSP,TOKYO 154,JAPAN	Nihon University; University of Tokyo; National Center for Child Health & Development - Japan	TADOKORO, K (corresponding author), NATL CHILDRENS HOSP,MED RES CTR,3-35-31 TAISHIDO,TOKYO 154,JAPAN.							ALBERTINI RJ, 1990, ANNU REV GENET, V24, P305; BONETTA L, 1990, SCIENCE, V250, P994, DOI 10.1126/science.2173146; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GRUNDY P, 1988, NATURE, V336, P374, DOI 10.1038/336374a0; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HUFF V, 1991, AM J HUM GENET, V48, P997; HUFF V, 1988, NATURE, V336, P377, DOI 10.1038/336377a0; JELINEK WR, 1982, ANNU REV BIOCHEM, V51, P813, DOI 10.1146/annurev.bi.51.070182.004121; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; PAL N, 1990, ONCOGENE, V5, P1665; Parkin D., 1988, INT INCIDENCE CHILDH, V1st; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; POLYMEROPOULOS MH, 1991, NUCLEIC ACIDS RES, V19, P3753, DOI 10.1093/nar/19.13.3753; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; RICCARDI VM, 1978, PEDIATRICS, V61, P604; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SCHROEDER WT, 1987, AM J HUM GENET, V40, P413; TADOKORO K, 1991, NUCLEIC ACIDS RES, V19, P2514, DOI 10.1093/nar/19.9.2514; TADOKORO K, 1991, NUCLEIC ACIDS RES, V24, P6967; WADEY RB, 1990, ONCOGENE, V5, P901; WAZIRI M, 1983, J PEDIATR-US, V102, P873, DOI 10.1016/S0022-3476(83)80014-6; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4036, DOI 10.1093/nar/18.13.4036; YAMADA M, 1985, P NATL ACAD SCI USA, V82, P3567, DOI 10.1073/pnas.82.11.3567; YAMADA M, 1982, GENE, V18, P309; YAMADA M, 1988, JPN J CANCER RES, V79, P670, DOI 10.1111/j.1349-7006.1988.tb02219.x	31	49	54	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1992	7	6					1215	1221						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1350671				2022-12-28	WOS:A1992HU64200020
J	PORIES, S; JAROS, K; STEELE, G; PAULEY, A; SUMMERHAYES, IC				PORIES, S; JAROS, K; STEELE, G; PAULEY, A; SUMMERHAYES, IC			ONCOGENE-MEDIATED TRANSFORMATION OF FETAL-RAT COLON INVITRO	ONCOGENE			English	Article							PP60C-SRC PROTEIN-KINASE; INTESTINAL EPITHELIAL-CELLS; C-MYC ONCOGENES; SUCRASE-ISOMALTASE; COLORECTAL CANCERS; MONOLAYER-CULTURE; GENE-MUTATIONS; HA-RAS; V-MYC; LINES	Short-term maintenance of fetal rat colonic tissue in vitro has been demonstrated using a collagen matrix organ culture system. The introduction of single (v-myc, v-ras(H), v-src) oncogenes or combinations of oncogenes (v-myc/ras(H), v-myc/src) into normal colon mucosal elements was established using retroviral vectors, resulting in enhanced proliferation and migration of epithelial cells from the lumen of tissue implants. Expression of a single oncogene in normal colon epithelium did not result in the establishment of cell lines. In contrast, expression of cooperating oncogenic elements resulted in cell lines in > 80% of experiments, revealing different morphological characteristics dependent upon the oncogene combination used. Confirmation of the expression of viral transcripts was determined using Northern blot analysis and viral oncoprotein expression using Western blot analysis (p21) and an immunoprecipitation kinase assay (src). Expression of keratin filaments was lost following passaging of cell lines but could be induced by the myc/ras transformants by growth on Rat-1 feeder layers. This induction phenomenon was not observed with myc/src lines, and although these expressed high levels of surcase isomaltase the epithelial origin of these cells is unclear. Karyotypic analysis performed on three myc/ras-transformed cell lines revealed a normal chromosome complement associated with transformation. In this report we describe a novel in vitro transformation system for normal rat colonic epithelium mediated by the introduction of oncogene elements using different retroviral vector constructs. The potential to generate cell lines representing different stages of neoplastic progression using relevant genetic components presents significant advantages for the study of cellular and molecular interactions underlying colon neoplastic progression.	HARVARD UNIV, NEW ENGLAND DEACONESS HOSP,SCH MED,CANC BIOL LAB, 50 BINNEY ST, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, CYTOGENET LAB, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School			Pories, Susan/AAB-1757-2019	Pories, Susan/0000-0001-7315-9993	NATIONAL CANCER INSTITUTE [R01CA042944, P01CA044704, R23CA042944] Funding Source: NIH RePORTER; NCI NIH HHS [CA42944, CA44704] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUTRUP H, 1978, IN VITRO CELL DEV B, V14, P868; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BLAY J, 1984, CELL BIOL INT REP, V8, P551, DOI 10.1016/0309-1651(84)90054-7; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; CATTERMOLE JA, 1989, J IMMUNOL, V142, P3746; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOPRA DP, 1981, IN VITRO CELL DEV B, V17, P441, DOI 10.1007/BF02626745; CHOPRA DP, 1987, GASTROENTEROLOGY, V92, P891, DOI 10.1016/0016-5085(87)90962-0; CONE RD, 1988, MOL CELL BIOL, V8, P1036, DOI 10.1128/MCB.8.3.1036; CZERNICHOW B, 1989, INT J CANCER, V44, P238, DOI 10.1002/ijc.2910440209; DANES BS, 1982, J NATL CANCER I, V69, P1271; DEMILIA JC, 1991, ONCOGENE, V6, P303; EMAMI S, 1989, P NATL ACAD SCI USA, V86, P3194, DOI 10.1073/pnas.86.9.3194; ERISMAN MD, 1988, ONCOGENE, V2, P367; ERISMAN MD, 1985, MOL CELL BIOL, V5, P1969, DOI 10.1128/MCB.5.8.1969; EZZELL RM, 1989, DEVELOPMENT, V106, P407; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GIBSON PR, 1989, GASTROENTEROLOGY, V96, P283, DOI 10.1016/0016-5085(89)91549-7; HAHN U, 1990, GASTROENTEROLOGY, V98, P322, DOI 10.1016/0016-5085(90)90821-H; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HUNZIKER W, 1986, CELL, V46, P227, DOI 10.1016/0092-8674(86)90739-7; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; KEDINGER M, 1987, DIFFERENTIATION, V36, P71, DOI 10.1111/j.1432-0436.1987.tb00182.x; KELEKAR A, 1987, MOL CELL BIOL, V7, P3899, DOI 10.1128/MCB.7.11.3899; KONDO Y, 1985, EXP CELL RES, V159, P158, DOI 10.1016/S0014-4827(85)80045-8; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; MESSER M, 1966, ANAL BIOCHEM, V14, P376, DOI 10.1016/0003-2697(66)90280-6; MOUGNEAU E, 1984, P NATL ACAD SCI-BIOL, V81, P5758, DOI 10.1073/pnas.81.18.5758; NEGREL R, 1983, EXP CELL RES, V143, P427, DOI 10.1016/0014-4827(83)90069-1; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OVERELL RW, 1988, MOL CELL BIOL, V8, P1803, DOI 10.1128/MCB.8.4.1803; PAETAU A, 1985, ACTA NEUROPATHOL, V65, P190, DOI 10.1007/BF00686997; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; QUARONI A, 1985, J CELL BIOL, V100, P1611, DOI 10.1083/jcb.100.5.1611; QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248; QUARONI A, 1989, GASTROENTEROLOGY, V96, P535, DOI 10.1016/0016-5085(89)91584-9; ROSEN N, 1986, J BIOL CHEM, V261, P3754; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SOLOMON E, 1987, NATURE, V328, P616, DOI 10.1038/328616a0; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; VIDRICH A, 1987, GASTROENTEROLOGY, V92, P1683; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WHITEHEAD RH, 1987, IN VITRO CELL DEV B, V23, P436; WIEHLE RD, 1990, ONCOGENE, V5, P787; WILTZ O, 1990, IN PRESS GASTROENTER; YEH KY, 1980, IN VITRO CELL DEV B, V16, P976; ZWEIBAUM A, 1983, INT J CANCER, V32, P407, DOI 10.1002/ijc.2910320403	53	8	11	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1992	7	5					885	893						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1373876				2022-12-28	WOS:A1992HP64200007
J	Garrigues, RJ; Thomas, S; Leong, JM; Garcia, BL				Garrigues, Ryan J.; Thomas, Sheila; Leong, John M.; Garcia, Brandon L.			Outer surface lipoproteins from the Lyme disease spirochete exploit the molecular switch mechanism of the complement protease C1s	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BORRELIA-BURGDORFERI; FACTOR-H; STRUCTURAL BASIS; SERINE-PROTEASE; COMPONENT C4; ERP PROTEINS; EVASION; BINDING; FAMILY; INHIBITION	Proteolytic cascades comprise several important physiolog-ical systems, including a primary arm of innate immunity called the complement cascade. To safeguard against complement -mediated attack, the etiologic agent of Lyme disease, Borre-liella burgdorferi, produces numerous outer surface-localized lipoproteins that contribute to successful complement evasion. Recently, we discovered a pair of B. burgdorferi surface lipoproteins of the OspEF-related protein family-termed ElpB and ElpQ-that inhibit antibody-mediated complement acti-vation. In this study, we investigate the molecular mechanism of ElpB and ElpQ complement inhibition using an array of biochemical and biophysical approaches. In vitro assays of complement activation show that an independently folded homologous C-terminal domain of each Elp protein maintains full complement inhibitory activity and selectively inhibits the classical pathway. Using binding assays and complement component C1s enzyme assays, we show that binding of Elp proteins to activated C1s blocks complement component C4 cleavage by competing with C1s-C4 binding without occluding the active site. C1s-mediated C4 cleavage is dependent on activation-induced binding sites, termed exosites. To test whether these exosites are involved in Elp-C1s binding, we performed site-directed mutagenesis, which showed that ElpB and ElpQ binding require C1s residues in the anion-binding exosite located on the serine protease domain of C1s. Based on these results, we propose a model whereby ElpB and ElpQ exploit activation-induced conformational changes that are normally important for C1s-mediated C4 cleavage. Our study expands the known complement evasion mechanisms of mi-crobial pathogens and reveals a novel molecular mechanism for selective C1s inhibition by Lyme disease spirochetes.	[Garrigues, Ryan J.; Thomas, Sheila; Garcia, Brandon L.] East Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Greenville, NC 27858 USA; [Leong, John M.] Tufts Univ, Tufts Sch Med, Dept Mol Biol & Microbiol, Boston, MA USA	University of North Carolina; East Carolina University; Tufts University	Garcia, BL (corresponding author), East Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Greenville, NC 27858 USA.	garciabr18@ecu.edu		Thomas, Sheila/0000-0001-6584-6240; Garrigues, Ryan/0000-0002-5923-3250; Garcia, Brandon/0000-0002-6724-8700; Leong, John/0000-0003-0240-6402	National Institute of Allergy and Infectious Diseases, National Institutes of Health [R01-AI146930]; NIAID, NIH [R01-AI121401]	National Institute of Allergy and Infectious Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Support was provided by Public Health Service grant R01-AI146930 from the National Institute of Allergy and Infectious Diseases, National Institutes of Health (to B. L. G.) and R01-AI121401 from the NIAID, NIH (to J. M. L.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Akins DR, 1999, INFECT IMMUN, V67, P1526, DOI 10.1128/IAI.67.3.1526-1532.1999; Amdahl H, 2013, J IMMUNOL, V191, P1775, DOI 10.4049/jimmunol.1300638; Bhattacharjee A, 2013, J BIOL CHEM, V288, P18685, DOI 10.1074/jbc.M113.459040; Bielefeld-Sevigny M, 2009, ASSAY DRUG DEV TECHN, V7, P90, DOI 10.1089/adt.2009.9996; Bock PE, 2007, J THROMB HAEMOST, V5, P81, DOI 10.1111/j.1538-7836.2007.02496.x; Booth C. E., 2022, FRONT IMMUNOL, V13; Brangulis K, 2015, BBA-PROTEINS PROTEOM, V1854, P349, DOI 10.1016/j.bbapap.2014.12.025; Brissette CA, 2008, INT J MED MICROBIOL, V298, P257, DOI 10.1016/j.ijmm.2007.09.004; Brissette CA, 2009, MICROBIOL-SGM, V155, P863, DOI 10.1099/mic.0.024604-0; Bykowski T, 2008, INT J MED MICROBIOL, V298, P249, DOI 10.1016/j.ijmm.2007.10.002; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Clark EA, 2011, MOL IMMUNOL, V48, P452, DOI 10.1016/j.molimm.2010.09.017; Coburn J, 2021, CURR ISSUES MOL BIOL, V42, P473, DOI 10.21775/cimb.042.473; Dowdell AS, 2017, J BACTERIOL, V199, DOI 10.1128/JB.00658-16; Duncan RC, 2012, J IMMUNOL, V189, P2365, DOI 10.4049/jimmunol.1201085; Farady CJ, 2010, CHEMBIOCHEM, V11, P2341, DOI 10.1002/cbic.201000442; FuentesPrior P, 1997, P NATL ACAD SCI USA, V94, P11845, DOI 10.1073/pnas.94.22.11845; Gaboriaud C, 2000, EMBO J, V19, P1755, DOI 10.1093/emboj/19.8.1755; Gaboriaud C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067962; Garcia BL, 2016, J IMMUNOL, V197, P2051, DOI 10.4049/jimmunol.1600863; Garcia BL, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005404; Garrigues RJ, 2021, J IMMUNOL, V207, P2856, DOI 10.4049/jimmunol.2100815; Geisbrecht BV, 2006, PROTEIN EXPRES PURIF, V46, P23, DOI 10.1016/j.pep.2005.09.003; Hallstrom T, 2013, MBIO, V4, DOI 10.1128/mBio.00481-13; Hammel M, 2007, J BIOL CHEM, V282, P30051, DOI 10.1074/jbc.M704247200; Hammel M, 2007, NAT IMMUNOL, V8, P430, DOI 10.1038/ni1450; Hart TM, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009801; Hartmann K, 2006, MOL MICROBIOL, V61, P1220, DOI 10.1111/j.1365-2958.2006.05318.x; Jumper J, 2021, NATURE, V596, P583, DOI 10.1038/s41586-021-03819-2; Kenedy MR, 2009, INFECT IMMUN, V77, P2773, DOI 10.1128/IAI.00318-09; Kidmose RT, 2012, P NATL ACAD SCI USA, V109, P15425, DOI 10.1073/pnas.1208031109; Kraiczy P, 2001, INT IMMUNOPHARMACOL, V1, P393, DOI 10.1016/S1567-5769(00)00041-2; Kraiczy P, 2013, TICKS TICK-BORNE DIS, V4, P26, DOI 10.1016/j.ttbdis.2012.10.039; Kugeler KJ, 2021, EMERG INFECT DIS, V27, P616, DOI 10.3201/eid2702.202731; Lambris JD, 2008, NAT REV MICROBIOL, V6, P132, DOI 10.1038/nrmicro1824; Lin YP, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00001; Madeira F, 2022, NUCLEIC ACIDS RES, V50, pW276, DOI 10.1093/nar/gkac240; Marconi RT, 1996, J BACTERIOL, V178, P5615, DOI 10.1128/jb.178.19.5615-5626.1996; McDowell JV, 2006, INFECT IMMUN, V74, P3030, DOI 10.1128/IAI.74.5.3030-3034.2006; McDowell JV, 2003, INFECT IMMUN, V71, P3597, DOI 10.1128/IAI.71.6.3597-3602.2003; Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00262; Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00257; Nagy ZA, 2022, J BIOL CHEM, V298, DOI 10.1016/j.jbc.2022.101985; Pereira Michael J, 2022, Proc Natl Acad Sci U S A, V119, pe2117770119, DOI 10.1073/pnas.2117770119; Perry AJ, 2013, J BIOL CHEM, V288, P15821, DOI 10.1074/jbc.M113.464545; Ricklin D, 2013, J IMMUNOL, V190, P3839, DOI 10.4049/jimmunol.1203200; Ricklin D, 2008, J IMMUNOL, V181, P7463, DOI 10.4049/jimmunol.181.11.7463; Robert X, 2014, NUCLEIC ACIDS RES, V42, pW320, DOI 10.1093/nar/gku316; Rogers EA, 2009, INFECT IMMUN, V77, P4396, DOI 10.1128/IAI.00393-09; Rooijakkers SHM, 2009, NAT IMMUNOL, V10, P721, DOI 10.1038/ni.1756; Rossi V, 1998, J BIOL CHEM, V273, P1232, DOI 10.1074/jbc.273.2.1232; Rushing BR, 2020, MOLECULES, V25, DOI 10.3390/molecules25174016; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Schmidt CQ, 2016, IMMUNOL REV, V274, P152, DOI 10.1111/imr.12475; Skare JT, 2020, TRENDS MICROBIOL, V28, P889, DOI 10.1016/j.tim.2020.05.004; SKRZYPCZAKJANKUN E, 1991, J MOL BIOL, V221, P1379; Stevenson B, 1996, J BACTERIOL, V178, P3508, DOI 10.1128/jb.178.12.3508-3516.1996; Stevenson B, 1998, INFECT IMMUN, V66, P2648, DOI 10.1128/IAI.66.6.2648-2654.1998; Stevenson B, 2022, J BACTERIOL, V204, DOI 10.1128/jb.00606-21; Takacs CN, 2021, APPL ENVIRON MICROB, V87, DOI 10.1128/AEM.02519-20; Troisi R, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221910803; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506; Xie JL, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007659; Zuckert WR, 2019, MICROBIOL SPECTR, V7, DOI 10.1128/microbiolspec.PSIB-0026-2019; Zuckert WR, 2014, BBA-MOL CELL RES, V1843, P1509, DOI 10.1016/j.bbamcr.2014.04.022	66	0	0	2	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV	2022	298	11							102557	10.1016/j.jbc.2022.102557	http://dx.doi.org/10.1016/j.jbc.2022.102557			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	6G4BI	36183830	gold, Green Submitted, Green Published			2022-12-28	WOS:000884698500002
J	Lee, PW; Marshall, AC; Knott, GJ; Kobelke, S; Martelotto, L; Cho, EL; McMillan, PJ; Lee, MH; Bond, CS; Fox, AH				Lee, Pei Wen; Marshall, Andrew C.; Knott, Gavin J.; Kobelke, Simon; Martelotto, Luciano; Cho, Ellie; McMillan, Paul J.; Lee, Mihwa; Bond, Charles S.; Fox, Archa H.			Paraspeckle subnuclear bodies depend on dynamic heterodimerisation of DBHS RNA-binding proteins via their structured domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-BODY; CELLS; SFPQ; EXPRESSION; MICROSCOPY; NONO	RNA-binding proteins of the DBHS (Drosophila Behavior Human Splicing) family, NONO, SFPQ, and PSPC1 have numerous roles in genome stability and transcriptional and posttranscriptional regulation. Critical to DBHS activity is their recruitment to distinct subnuclear locations, for example, paraspeckle condensates, where DBHS proteins bind to the long noncoding RNA NEAT1 in the first essential step in paraspeckle formation. To carry out their diverse roles, DBHS proteins form homodimers and heterodimers, but how this dimerization influences DBHS localization and function is unknown. Here, we present an inducible GFP-NONO stable cell line and use it for live-cell 3D-structured illumination microscopy, revealing paraspeckles with dynamic, twisted elongated structures. Using siRNA knockdowns, we show these labeled paraspeckles consist of GFP-NONO/endogenous SFPQ dimers and that GFP-NONO localization to paraspeckles depends on endogenous SFPQ. Using purified proteins, we confirm that partner swapping between NONO and SFPQ occurs readily in vitro. Crystallographic analysis of the NONOSFPQ heterodimer reveals conformational differences to the other DBHS dimer structures, which may contribute to partner preference, RNA specificity, and subnuclear localization. Thus overall, our study suggests heterodimer partner availability is crucial for NONO subnuclear distribution and helps explain the complexity of both DBHS protein and paraspeckle dynamics through imaging and structural approaches.	[Lee, Pei Wen; Kobelke, Simon; Martelotto, Luciano; Fox, Archa H.] QEII Med Ctr, Sch Human Sci, Nedlands, WA, Australia; [Lee, Pei Wen; Kobelke, Simon; Martelotto, Luciano; Fox, Archa H.] QEII Med Ctr, Harry Perkins Inst Med Res, Nedlands, WA, Australia; [Lee, Pei Wen; Kobelke, Simon; Martelotto, Luciano; Fox, Archa H.] Univ Western Australia, Ctr Med Res, Crawley, WA, Australia; [Marshall, Andrew C.; Knott, Gavin J.; Bond, Charles S.; Fox, Archa H.] Univ Western Australia, Sch Mol Sci, Crawley, WA, Australia; [Cho, Ellie] Univ Melbourne, Dept Biochem & Mol Biol, Melbourne, Vic, Australia; [Cho, Ellie] Univ Melbourne, Biol Opt Microscopy Platform, Melbourne, Vic, Australia; [McMillan, Paul J.] Peter MacCallum Canc Ctr, Ctr Adv Histol & Microscopy, Melbourne, Vic, Australia; [Lee, Mihwa] La Trobe Univ, Dept Biochem & Genet, Bundoora, Vic, Australia; [Martelotto, Luciano] Univ Adelaide, South Australia ImmunoGEN Canc Inst, Adelaide Ctr Epigenet, Adelaide, SA 5005, Australia; [Lee, Pei Wen] Agcy Sci Technol & Res, Inst Med Biol, Singapore 138648, Singapore; [Knott, Gavin J.] Monash Univ, Dept Biochem, Clayton, Vic, Australia	University of Western Australia; Harry Perkins Institute of Medical Research; University of Western Australia; University of Western Australia; University of Western Australia; University of Melbourne; University of Melbourne; Peter Maccallum Cancer Center; La Trobe University; University of Adelaide; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Medical Biology (IMB); Monash University	Fox, AH (corresponding author), QEII Med Ctr, Sch Human Sci, Nedlands, WA, Australia.; Fox, AH (corresponding author), QEII Med Ctr, Harry Perkins Inst Med Res, Nedlands, WA, Australia.; Fox, AH (corresponding author), Univ Western Australia, Ctr Med Res, Crawley, WA, Australia.; Fox, AH (corresponding author), Univ Western Australia, Sch Mol Sci, Crawley, WA, Australia.	Archa.fox@uwa.edu.au	Marshall, Andrew/A-3485-2019; Bond, Charles/B-4094-2011	Marshall, Andrew/0000-0002-9770-4594; Bond, Charles/0000-0002-9584-6783; McMillan, Paul/0000-0001-5629-1175	Australian Research Council [FT180100204, DP160102435]; National Health and Medical Research Council of Australia [APP1147496]	Australian Research Council(Australian Research Council); National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	This work was funded by the Australian Research Council (FT180100204 to A. H. F. and DP160102435 to C. S. B. and A H. F.) and the National Health and Medical Research Council of Australia (APP1147496 to C. S. B. and A. H. F.) . This research was made possible by the Clifford Bradley Robertson and Gwendoline Florence Anne Robertson Research Endowment Fund, established through Dr Glen Robertson's bequest to The University of Western Australia (to A. M.) .	Afonine PV, 2012, ACTA CRYSTALLOGR D, V68, P352, DOI 10.1107/S0907444912001308; Biamonti G, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000695; Bottini S, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01126-x; Chen LL, 2009, MOL CELL, V35, P467, DOI 10.1016/j.molcel.2009.06.027; Chujo T, 2017, EMBO J, V36, P1447, DOI 10.15252/embj.201695848; Clemson CM, 2009, MOL CELL, V33, P717, DOI 10.1016/j.molcel.2009.01.026; Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493; Evans PR, 2013, ACTA CRYSTALLOGR D, V69, P1204, DOI 10.1107/S0907444913000061; Fiolka R, 2012, P NATL ACAD SCI USA, V109, P5311, DOI 10.1073/pnas.1119262109; Foadi J, 2013, ACTA CRYSTALLOGR D, V69, P1617, DOI 10.1107/S0907444913012274; Fox AH, 2005, MOL BIOL CELL, V16, P5304, DOI 10.1091/mbc.e05-06-0587; Fox AH, 2002, CURR BIOL, V12, P13, DOI 10.1016/S0960-9822(01)00632-7; Guo YE, 2019, NATURE, V572, P543, DOI 10.1038/s41586-019-1464-0; Ha K, 2011, DNA REPAIR, V10, P252, DOI 10.1016/j.dnarep.2010.11.009; Hirose T, 2014, MOL BIOL CELL, V25, P169, DOI 10.1091/mbc.E13-09-0558; Huang J, 2018, J BIOL CHEM, V293, P6593, DOI 10.1074/jbc.RA117.001451; Jiang L, 2017, NAT STRUCT MOL BIOL, V24, P816, DOI 10.1038/nsmb.3455; Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337; Karczewski KJ, 2017, NUCLEIC ACIDS RES, V45, pD840, DOI 10.1093/nar/gkw971; Knott GJ, 2022, NUCLEIC ACIDS RES, V50, P522, DOI 10.1093/nar/gkab1216; Knott GJ, 2016, NUCLEIC ACIDS RES, V44, P3989, DOI 10.1093/nar/gkw271; Knott GJ, 2015, PROTEIN SCI, V24, P2033, DOI 10.1002/pro.2816; Lee MW, 2015, NUCLEIC ACIDS RES, V43, P3826, DOI 10.1093/nar/gkv156; Mao YTS, 2011, NAT CELL BIOL, V13, P95, DOI 10.1038/ncb2140; McCluggage F, 2021, BIOESSAYS, V43, DOI 10.1002/bies.202000245; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; McPhillips TM, 2002, J SYNCHROTRON RADIAT, V9, P401, DOI 10.1107/S0909049502015170; Myojin R, 2004, BIOL REPROD, V71, P926, DOI 10.1095/biolreprod.104.028159; Naganuma T, 2012, EMBO J, V31, P4020, DOI 10.1038/emboj.2012.251; Passon DM, 2011, ACTA CRYSTALLOGR F, V67, P1231, DOI [10.1107/S1744309111026212, 10.1107/S17443091110262121231]; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; Platani M, 2000, J CELL BIOL, V151, P1561, DOI 10.1083/jcb.151.7.1561; Prasanth KV, 2005, CELL, V123, P249, DOI 10.1016/j.cell.2005.08.033; Sasaki YTF, 2009, P NATL ACAD SCI USA, V106, P2525, DOI 10.1073/pnas.0807899106; Schell B, 2022, BIOCHIMIE, V198, P1, DOI 10.1016/j.biochi.2022.02.011; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Shao L, 2011, NAT METHODS, V8, P1044, DOI [10.1038/NMETH.1734, 10.1038/nmeth.1734]; Souquere S, 2010, MOL BIOL CELL, V21, P4020, DOI 10.1091/mbc.E10-08-0690; Strom AR, 2019, J CELL SCI, V132, DOI 10.1242/jcs.235093; Sunwoo H, 2009, GENOME RES, V19, P347, DOI 10.1101/gr.087775.108; Thomas-Jinu S, 2017, NEURON, V94, P322, DOI 10.1016/j.neuron.2017.03.026; Wang Y, 2018, NAT CELL BIOL, V20, P1145, DOI 10.1038/s41556-018-0204-2; West JA, 2016, J CELL BIOL, V214, P817, DOI 10.1083/jcb.201601071; Wu H, 2016, MOL CELL, V64, P534, DOI 10.1016/j.molcel.2016.10.007; Yamazaki Tomohiro, 2015, Front Biosci (Elite Ed), V7, P1	45	0	0	2	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV	2022	298	11							102563	10.1016/j.jbc.2022.102563	http://dx.doi.org/10.1016/j.jbc.2022.102563			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	6W5WW	36209820	Green Published, gold			2022-12-28	WOS:000895801300011
J	Rajebhosale, P; Talmage, DA				Rajebhosale, Prithviraj; Talmage, David A.			Seq'ing the origins of cells in the developing spinal cord	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Editorial Material							PROGENITORS	In the developing central nervous system, neurogenesis precedes gliogenesis; however, when and how progenitors are specified for a neuronal versus glial fate and the temporal regulation of this process is unclear. Progenitors within the motor neuron progenitor domain in the developing spinal cord give rise to cholinergic motor neurons and cells of the oligo-dendroglial lineage sequentially. In a recent study, Xing et al. used single cell RNA-seq to identify previously unknown het-erogeneity of these progenitors in zebrafish and to delineate the trajectories that distinct pools of these progenitors take. These data help integrate existing evidence and inform new hypotheses regarding how populations of neural progenitors in the same spatial domain commit to distinct fates.	[Rajebhosale, Prithviraj; Talmage, David A.] NINDS, Sect Genet Neuronal Signaling, NIH, Bethesda, MD 20814 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Rajebhosale, P; Talmage, DA (corresponding author), NINDS, Sect Genet Neuronal Signaling, NIH, Bethesda, MD 20814 USA.	prithviraj.rajebhosale@nih.gov; david.talmage@nih.gov		Rajebhosale, Prithviraj/0000-0001-9893-3025; Talmage, David/0000-0003-4627-3007				Guo Y, 2011, NEUROSCIENCE, V172, P329, DOI 10.1016/j.neuroscience.2010.10.026; Jessell TM, 2000, NAT REV GENET, V1, P20, DOI 10.1038/35049541; Li YN, 2020, ELIFE, V9, DOI 10.7554/eLife.59464; McCarthy M, 2001, J NEUROSCI, V21, P6772, DOI 10.1523/JNEUROSCI.21-17-06772.2001; Nielsen JA, 2004, MOL CELL NEUROSCI, V25, P111, DOI 10.1016/j.mcn.2003.10.001; Ravanelli AM, 2018, DEV BIOL, V444, P93, DOI 10.1016/j.ydbio.2018.10.004; Ravanelli AM, 2015, GENE DEV, V29, P2504, DOI 10.1101/gad.271312.115; Simon C, 2011, GLIA, V59, P869, DOI 10.1002/glia.21156; Sun T, 1998, MOL CELL NEUROSCI, V12, P228, DOI 10.1006/mcne.1998.0711; Touahri Y, 2012, J NEUROSCI, V32, P18018, DOI 10.1523/JNEUROSCI.3553-12.2012; Xing LY, 2022, J BIOL CHEM, V298, DOI 10.1016/j.jbc.2022.102452	11	0	0	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV	2022	298	11							102602	10.1016/j.jbc.2022.102602	http://dx.doi.org/10.1016/j.jbc.2022.102602			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	6W5WW	36265584	gold, Green Published			2022-12-28	WOS:000895801300002
J	MARTIN, P; CARRIERE, C; DOZIER, C; QUATANNENS, B; MIRABEL, MA; VANDENBUNDER, B; STEHELIN, D; SAULE, S				MARTIN, P; CARRIERE, C; DOZIER, C; QUATANNENS, B; MIRABEL, MA; VANDENBUNDER, B; STEHELIN, D; SAULE, S			CHARACTERIZATION OF A PAIRED BOX-CONTAINING AND HOMEOBOX-CONTAINING QUAIL GENE (PAX-QNR) EXPRESSED IN THE NEURORETINA	ONCOGENE			English	Article							DNA-BINDING DOMAIN; TRANSCRIPTION FACTOR; LEUKEMIA VIRUSES; MESSENGER-RNAS; TARGET-CELLS; NEURAL-TUBE; HOMEODOMAIN; PROTEIN; MYC; DIFFERENTIATION	The retina is an integral part of the central nervous system, and consists of two layers, the outer pigmented layer and the inner sensory layer or neuroretina (NR). The NR layer contains several strata of cells (glial and neuronal) derived from proliferating neuroectodermal precursors that differentiate after terminal mitosis. In vitro, NR cells can differentiate not only into neuronal and glial types, but also into pigment and lens cells. Quail (Coturnix coturnix japonica) NR cells (QNR) infected with MC29 transforming retrovirus become pigmented after several passages in vitro. In order to characterize the genes expressed in these pigmented MC29 QNR, a cDNA library was prepared from these cells. After differential screening we have isolated a cDNA clone which identifies an RNA expressed in NR but not in the pigmented layer of the retina. This cDNA encodes a protein related to that of Drosophila, mouse and zebrafish paired box- and homeobox-containing segmentation genes and is called Pax-QNR. The expression of Pax-QNR in the NR is confined to the ganglionic cell layer and to the lower part of the inner nuclear layer containing the amacrine or correlation neurones.	INST PASTEUR,CNRS,URA 1160,1 RUE CALMETTE,F-59019 LILLE,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille			DOZIER, Christine/P-1539-2014					ALEMA S, 1985, MOL CELL BIOL, V5, P538, DOI 10.1128/MCB.5.3.538; ALLEN JD, 1991, GENE DEV, V5, P509, DOI 10.1101/gad.5.4.509; BASTIAN H, 1990, EMBO J, V9, P1839, DOI 10.1002/j.1460-2075.1990.tb08309.x; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; FAUQUET M, 1990, P NATL ACAD SCI USA, V87, P1546, DOI 10.1073/pnas.87.4.1546; FITZGERALD M, 1981, CELL, V24, P251, DOI 10.1016/0092-8674(81)90521-3; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; GAUZZI S, 1990, EMBO J, V9, P3631; GAZZOLO L, 1979, CELL, V16, P627, DOI 10.1016/0092-8674(79)90036-9; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GRAF T, 1981, EXP CELL RES, V131, P331, DOI 10.1016/0014-4827(81)90236-6; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GUERMAH M, 1990, MOL CELL BIOL, V10, P3584, DOI 10.1128/MCB.10.7.3584; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JOSTES B, 1991, MECH DEVELOP, V33, P27; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRAUSS S, 1991, EMBO J, V10, P3609, DOI 10.1002/j.1460-2075.1991.tb04927.x; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; Maniatis T., 1982, MOL CLONING; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; Okada T.S., 1976, TESTS TERATOGENICITY, P91; QUEVA C, 1992, IN PRESS DEVELOPMENT, V114; ROMANOFF A, 1954, AVIAN EMBRYO, P382; ROSNER MH, 1991, CELL, V64, P1103, DOI 10.1016/0092-8674(91)90265-Z; SAULE S, 1981, J VIROL, V38, P409, DOI 10.1128/JVI.38.2.409-419.1981; SCOTT MP, 1987, CELL, V51, P689, DOI 10.1016/0092-8674(87)90092-4; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594; TREISMAN J, 1989, CELL, V59, P553; VANDENBUNDER B, 1989, DEVELOPMENT, V106, P265; VENNSTROM B, 1981, J VIROL, V39, P625; WALTHER C, 1991, GENOMICS, V11, P424, DOI 10.1016/0888-7543(91)90151-4	42	98	99	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1721	1728						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1354346				2022-12-28	WOS:A1992JJ37600007
J	WANG, J; ZINDY, F; CHENIVESSE, X; LAMAS, E; HENGLEIN, B; BRECHOT, C				WANG, J; ZINDY, F; CHENIVESSE, X; LAMAS, E; HENGLEIN, B; BRECHOT, C			MODIFICATION OF CYCLIN-A EXPRESSION BY HEPATITIS-B VIRUS-DNA INTEGRATION IN A HEPATOCELLULAR-CARCINOMA	ONCOGENE			English	Note							RETINOBLASTOMA GENE-PRODUCT; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; PROTEIN-KINASE; M-PHASE; SCHIZOSACCHAROMYCES-POMBE; TRANSGENIC MICE; G1 PHASE; CDC2	We have previously reported the identification of a hepatitis B virus (HBV) DNA integration in an intron of the cyclin A gene in an early hepatocellular carcinoma (HCC) and the isolation of human cyclin A cDNA. We have now constructed a cDNA library from the tumor and isolated several hybrid HBV-cyclin A cDNAs from it. The hybrid cDNAs encode an HBV-cyclin A fusion protein. In the chimeric protein, the N-terminus of cyclin A, including the signals for cyclin degradation, is deleted and replaced by viral PreS2/S sequences, transcription being initiated from the viral PreS2/S promoter. This chimeric protein is undegradable in an in vitro cyclin degradation assay. Northern blot analyses showed strong expression of the hybrid transcripts in the tumor, while cyclin A- or HBV-specific transcripts were not detected in the non-tumorous liver of the same patient. Thus, HBV DNA integration in the cyclin A gene resulted in a strong expression of hybrid HBV-cyclin A transcripts encoding a stabilized cyclin A. This chimeric protein may play an important role in the development of the tumor.	CHU NECKER ENFANTS MALAD, INSERM, U75, 156 RUE VAUGIRARD, F-75730 PARIS 15, FRANCE; INST PASTEUR, HYBRIDOTEST, F-75724 PARIS 15, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Lamas, Eugenia/L-9654-2018	Lamas, Eugenia/0000-0001-7677-9442				BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; Beasley R.P., 1984, VIRAL HEPATITIS LIVE, P209; BOOHER R, 1988, EMBO J, V7, P2321, DOI 10.1002/j.1460-2075.1988.tb03075.x; CASELMANN WH, 1990, P NATL ACAD SCI USA, V87, P2970, DOI 10.1073/pnas.87.8.2970; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; CROSS FR, 1990, MOL CELL BIOL, V10, P6482, DOI 10.1128/MCB.10.12.6482; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FORSBURG SL, 1991, NATURE, V351, P245, DOI 10.1038/351245a0; FOUREL G, 1990, NATURE, V347, P294, DOI 10.1038/347294a0; GANEM D, 1990, NATURE, V347, P230, DOI 10.1038/347230b0; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GIORDANO A, 1991, ONCOGENE, V6, P481; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; INES J, 1991, CELL, V66, P1071; KEKULE AS, 1990, NATURE, V343, P457, DOI 10.1038/343457a0; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LORCA T, 1991, MOL CELL BIOL, V11, P1171, DOI 10.1128/MCB.11.2.1171; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SIMONSEN CC, 1983, MOL CELL BIOL, V3, P2250, DOI 10.1128/MCB.3.12.2250; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	46	138	145	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1992	7	8					1653	1656						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1321406				2022-12-28	WOS:A1992JE81300024
J	ERWIN, JL; ANDERSON, SM				ERWIN, JL; ANDERSON, SM			ANALYSIS OF PHOSPHOTYROSINE-CONTAINING PROTEINS PRESENT IN V-SRC-INFECTED MYELOID PROGENITOR CELLS	ONCOGENE			English	Note							AVIAN-SARCOMA VIRUS; TYROSINE PHOSPHORYLATION; MONOCLONAL-ANTIBODIES; GRANULOCYTIC DIFFERENTIATION; INTERLEUKIN-3; LINE; KINASES; GAP; RECEPTORS; GENE	We examined the phosphotyrosine-containing proteins in v-src-infected myeloid cells. Proteins with relative molecular weights (M(r)) of 180 000, 175 000, 135 000, 125 000, 120 000, 90 000, 75 000, and 60 000 were present in v-src-infected but not in uninfected 32D c13 cells. Stimulation of 32D c13 cells with interleukin 3 (IL-3) resulted in the tyrosine phosphorylation of a protein of 150 000 (M(r)), which was not phosphorylated in v-src-infected 32D ct3 cells. A panel of monoclonal antibodies directed against phosphotyrosine-containing proteins in v-src-transformed chicken embryo fibroblasts (3C4, 2A7, 2B12 and 4F11, directed against p210, p125, p120 and p85 respectively) was used to characterize these substrates. We did not observe tyrosine phosphorylation of proteins recognized by these four monoclonal antibodies in either IL-3-stimulated or v-src-infected 32D c13 cells. However, we did detect tyrosine phosphorylation of proteins recognized by these monoclonal antibodies in v-src-transformed NIH3T3 cells. Tyrosine phosphorylation of GTPase-activating protein (GAP)-and the GAP-associated proteins p62 and p190 was observed in v-src-infected 32D c13 cells. Stimulation of 32D c13 celts with IL-3 does not induce phosphorylation of GAP or the GAP-associated proteins p62 or p190. These results suggest that substrates for v-src vary between different cell types.	SUNY STONY BROOK,DEPT PATHOL,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NCI NIH HHS [CA45241] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA045241, R01CA045241] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON SM, 1990, ONCOGENE, V5, P317; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLLETT MS, 1979, J VIROL, V29, P770, DOI 10.1128/JVI.29.2.770-781.1979; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ISFORT R, 1988, J BIOL CHEM, V263, P19203; KAMPS MP, 1988, ONCOGENE, V2, P305; KANAKURA Y, 1990, BLOOD, V76, P706; KANNER SB, 1989, J IMMUNOL METHODS, V120, P115, DOI 10.1016/0022-1759(89)90296-2; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOYASU S, 1987, EMBO J, V6, P3979, DOI 10.1002/j.1460-2075.1987.tb02740.x; KRUGER A, 1991, ONCOGENE, V6, P245; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; METCALF D, 1985, BLOOD, V65, P357; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; OPPERMANN H, 1981, VIROLOGY, V108, P47, DOI 10.1016/0042-6822(81)90526-2; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; ROVERA G, 1987, ONCOGENE, V1, P29; SORENSEN P, 1989, J BIOL CHEM, V264, P19253; SORENSEN PHB, 1989, BLOOD, V73, P406; VALTIERI M, 1987, J IMMUNOL, V138, P3829; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113	28	7	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1992	7	6					1101	1107						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1375716				2022-12-28	WOS:A1992HU64200007
J	RITTLING, SR; DENHARDT, DT				RITTLING, SR; DENHARDT, DT			P53 MUTATIONS IN SPONTANEOUSLY IMMORTALIZED 3T12 BUT NOT 3T3 MOUSE EMBRYO CELLS	ONCOGENE			English	Article							MALIGNANT TRANSFORMATION; ACTIVATING MUTATIONS; SIMIAN VIRUS-40; GENE-MUTATIONS; RAS ONCOGENE; LUNG-CANCER; FIBROBLASTS; CULTURE; PROTEIN; LINES	We have asked whether p53 mutations are involved in the process of spontaneous immortalization of mouse embryo cells. Cells from Swiss mouse embryos were used to prepare 3T3 and 3T12 lines according to the protocol of Todaro & Green [(1963). J. Cell Biol., 17, 299-313]. After the cells emerged from crisis, p53 sequences were amplified by polymerase chain reaction (PCR) from both RNA and DNA. The sequence of the aggregated cDNA from each of six 3T3 lines showed no evidence of mutation. PCR-amplified p53 cDNA from two 3T3 lines was cloned, and individual clones in M13mp19 were partially sequenced. One cell line showed a single, non-coding nucleotide change in 2/8 independent clones. Nine cDNA clones from the second 3T3 lines were sequenced, and no single nucleotide changes appeared more than once. The mutations which appeared only once were not detected in clones of genomic DNA. Since these apparent mutations are probably reverse transcriptase or Taq polymerase errors, we conclude that both the 3T3 lines contained only wild-type p53. In two out of three independent 3T12 lines however, missense mutations were readily observed in the aggregate cDNA sequence. Restriction fragment length polymorphism and Southern blot analyses of the genomic DNA indicated that these cells were homozygous for the mutations. The p53 protein molecules in four cell lines were analysed by immunoprecipitation: one 3T12 line showed the pattern of antibody reactivity characteristic of some p53 mutants, while the others displayed the wild-type pattern. We conclude that p53 mutations arise and are strongly selected for during immortalization according to the 3T12 but not the 3T3 protocol.			RITTLING, SR (corresponding author), RUTGERS STATE UNIV,DEPT BIOL SCI,POB 1059,PISCATAWAY,NJ 08855, USA.				NIA NIH HHS [AG07972] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG007972] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AARONSON SA, 1968, J CELL PHYSIOL, V72, P141, DOI 10.1002/jcp.1040720208; AARONSON SA, 1968, SCIENCE, V162, P24; AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; AUSUBEL FM, 1989, JCURRENT PROTOCOLS M; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; CHIBA I, 1990, ONCOGENE, V5, P1603; CURATOLO L, 1984, IN VITRO CELL DEV B, V20, P597; DENHARDT DT, 1991, EXP CELL RES, V192, P128, DOI 10.1016/0014-4827(91)90167-S; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; JAT PS, 1986, J VIROL, V59, P746, DOI 10.1128/JVI.59.3.746-750.1986; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KELMAN Z, 1989, BLOOD, V74, P2318; KRAEMER PM, 1986, J NATL CANCER I, V76, P703, DOI 10.1093/jnci/76.4.703; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MACIEIRACOELHO A, 1976, GERONTOLOGY, V22, P3, DOI 10.1159/000212121; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MEEK RL, 1977, EXP CELL RES, V107, P277, DOI 10.1016/0014-4827(77)90350-0; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MOUGNEAU E, 1984, P NATL ACAD SCI-BIOL, V81, P5758, DOI 10.1073/pnas.81.18.5758; NEWBOLD RF, 1982, NATURE, V299, P633, DOI 10.1038/299633a0; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PENNICA D, 1984, VIROLOGY, V134, P477, DOI 10.1016/0042-6822(84)90316-7; PETIT CA, 1983, VIROLOGY, V127, P74, DOI 10.1016/0042-6822(83)90372-0; RASSOULZADEGAN M, 1983, P NATL ACAD SCI-BIOL, V80, P4354, DOI 10.1073/pnas.80.14.4354; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; ROHME D, 1981, P NATL ACAD SCI-BIOL, V78, P5009, DOI 10.1073/pnas.78.8.5009; ROVINSKI B, 1988, ONCOGENE, V2, P445; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; TAKAHASHI T, 1990, J CLIN INVEST, V86, P363, DOI 10.1172/JCI114710; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286	52	52	54	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1992	7	5					935	942						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1349164				2022-12-28	WOS:A1992HP64200013
J	BROWN, KW; WATSON, JE; POIRIER, V; MOTT, MG; BERRY, PJ; MAITLAND, NJ				BROWN, KW; WATSON, JE; POIRIER, V; MOTT, MG; BERRY, PJ; MAITLAND, NJ			INACTIVATION OF THE REMAINING ALLELE OF THE WT1 GENE IN A WILMS-TUMOR FROM A WAGR PATIENT	ONCOGENE			English	Article							BECKWITH-WIEDEMANN SYNDROME; POLYMERASE CHAIN-REACTION; HUMAN CHROMOSOME-11; DELETION; LOCUS; DNA; 11P13; AMPLIFICATION; SEQUENCE; LINKAGE	A candidate gene (WT1) has recently been described for the 11p13 tumour-suppressor gene involved in the development of Wilms' tumour. This gene encodes a zinc finger protein which can bind to a specific DNA sequence. We have found a 226 base deletion in the mRNA from a unilateral Wilms' tumour, which would cause a frameshift that completely deletes the zinc finger domain. The tumour developed in a patient suffering from the WAGR syndrome, who had a constitutional 11p13 deletion, and so the 226 base deletion represents the inactivation of the remaining WT1 allele in the tumour. This provides further direct evidence that loss of function of WT1 is an essential step in the development of Wilms' tumour.	BRISTOL ROYAL HOSP SICK CHILDREN,BRISTOL BS2 8BJ,ENGLAND	Bristol Royal Hospital For Children	BROWN, KW (corresponding author), SCH MED SCI BRISTOL,DEPT PATHOL & MICROBIOL,CLIC RES UNIT,UNIV WALK,BRISTOL BS8 1TD,ENGLAND.		Brown, Keith/C-3355-2009	Brown, Keith/0000-0002-4258-5129				BROWN KW, 1989, BRIT J CANCER, V60, P25, DOI 10.1038/bjc.1989.213; BROWN KW, 1990, AM J HUM GENET, V46, P1000; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; COWELL JK, 1991, ONCOGENE, V6, P595; FEARON ER, 1984, NATURE, V309, P176, DOI 10.1038/309176a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GRUNDY P, 1988, NATURE, V336, P374, DOI 10.1038/336374a0; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, CELL, V64, P5, DOI 10.1016/0092-8674(91)90200-I; HENRY I, 1989, P NATL ACAD SCI USA, V86, P3247, DOI 10.1073/pnas.86.9.3247; HUANG A, 1990, SCIENCE, V250, P991, DOI 10.1126/science.2173145; HUFF V, 1991, AM J HUM GENET, V48, P997; HUFF V, 1988, NATURE, V336, P377, DOI 10.1038/336377a0; JEANPIERRE C, 1990, GENOMICS, V7, P434, DOI 10.1016/0888-7543(90)90179-X; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; KOUFOS A, 1984, NATURE, V309, P170, DOI 10.1038/309170a0; KOUFOS A, 1989, AM J HUM GENET, V44, P711; KROCZEK RA, 1990, ANAL BIOCHEM, V184, P90, DOI 10.1016/0003-2697(90)90017-4; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; MAITLAND NJ, 1987, BRIT J CANCER, V56, P245, DOI 10.1038/bjc.1987.185; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MURRAY V, 1989, NUCLEIC ACIDS RES, V17, P8889, DOI 10.1093/nar/17.21.8889; ORKIN SH, 1984, NATURE, V309, P172, DOI 10.1038/309172a0; PING AJ, 1989, AM J HUM GENET, V44, P720; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; REEVE AE, 1984, NATURE, V309, P174, DOI 10.1038/309174a0; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; REIK W, 1989, NATURE, V338, P112, DOI 10.1038/338112a0; ROYERPOKORA B, 1991, GENE CHROMOSOME CANC, V3, P89, DOI 10.1002/gcc.2870030203; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SARKAR G, 1990, NUCLEIC ACIDS RES, V18, P7465, DOI 10.1093/nar/18.24.7465; SHERMAN DR, 1989, TRENDS GENET, V5, P137; TON CCT, 1991, GENOMICS, V10, P293, DOI 10.1016/0888-7543(91)90516-H	37	69	72	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					763	768						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1314370				2022-12-28	WOS:A1992HQ68200020
J	DELMAS, V; ANDRE, CD; GARDES, M; GOUTEBROZE, L; FEUNTEUN, J				DELMAS, V; ANDRE, CD; GARDES, M; GOUTEBROZE, L; FEUNTEUN, J			EARLY GENE-EXPRESSION IN LYMPHOMA-ASSOCIATED HAMSTER POLYOMAVIRUS VIRAL GENOMES	ONCOGENE			English	Article							EMBRYONAL CARCINOMA-CELLS; MIDDLE-T-ANTIGEN; TUMOR-ANTIGEN; SV40-TRANSFORMED CELLS; PROTEIN PHOSPHATASE-2A; NONCODING SEQUENCES; MAMMALIAN-CELLS; LATE PROMOTER; REPLICATION; MICE	Hamster polyomavirus (HaPV) is the causal agent of hair follicle epithelioma in hamsters belonging to a colony bred in Berlin-Buch. These tumors shed virus particles that are assembled in the keratinized layer of the epidermis. By contrast, HaPV induces lymphomas after inoculation into newborn hamsters from a distinct colony bred in Potsdam. These lymphoid tumors accumulate massive amounts of episomal viral genomes characterized by deletions that alter specifically the regulatory and the late coding sequences. Assuming that these alterations of the regulatory region may affect the transcription of the viral oncogenes in the tumor cells, the transcriptional activity of the wild-type and deleted early promoters have been studied in vitro in transient chloramphenicol acetyltransferase (CAT) expression assays. These assays performed in various cell types demonstrate that both versions of the HaPV early promoter carry a weak constitutive activity. Simultaneous expression of the HaPV early gene products leads to a strong stimulation of CAT activity with a concomitant activation of the replication of the plasmid constructs. The results obtained with origin-defective CAT vectors indicate that the replication contributes significantly to the stimulating effect of the early gene products. Indeed, transfection of massive amounts of CAT vectors that are unable to replicate can simulate the dosage effect of replication and also leads to measurable CAT activities. Under these conditions, the wild-type promoter is more active than the deleted version, indicating that sequences within the deletion carry a distinct stimulatory effect on transcription. This conclusion is supported by the observation that the lymphoma cells contain a low level of early transcripts, indicating that the deleted episomal viral templates accumulated in these tumors carry a weak transcriptional activity.	INST GUSTAVE ROUSSY, ONCOL MOLEC LAB, F-94805 VILLEJUIF, FRANCE	UNICANCER; Gustave Roussy			Goutebroze, Laurence/H-3543-2016; Feunteun, Jean/AAZ-1267-2020	Feunteun, Jean/0000-0003-1212-9189; Delmas, veronique/0000-0001-7368-3664; Goutebroze, laurence/0000-0002-8712-000X				ANDRE CDS, 1990, VIROLOGY, V177, P532, DOI 10.1016/0042-6822(90)90518-V; BASTIEN C, 1988, ONCOGENE, V2, P129; BEREBBI M, 1988, ONCOGENE, V2, P149; BOVI PD, 1984, J VIROL, V49, P566, DOI 10.1128/JVI.49.2.566-571.1984; BRADY J, 1984, P NATL ACAD SCI-BIOL, V81, P2040, DOI 10.1073/pnas.81.7.2040; CAHILL KB, 1990, J VIROL, V64, P992, DOI 10.1128/JVI.64.3.992-1001.1990; CAMPBELL BA, 1986, MOL CELL BIOL, V6, P2068, DOI 10.1128/MCB.6.6.2068; CHENG SH, 1988, MOL CELL BIOL, V8, P1736, DOI 10.1128/MCB.8.4.1736; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; DEPAMPHILIS ML, 1986, VIRUSES PAPOVAVIRIDA, P99; DIAMANDOPOULOS GT, 1983, J NATL CANCER I, V71, P1319; DIAMANDOPOULOS GT, 1972, SCIENCE, V176, P173, DOI 10.1126/science.176.4031.173; DURST M, 1985, J GEN VIROL, V66, P1515, DOI 10.1099/0022-1317-66-7-1515; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; FREBOURG T, 1988, GENE, V65, P315, DOI 10.1016/0378-1119(88)90468-4; FREUND R, 1988, J VIROL, V62, P3896, DOI 10.1128/JVI.62.10.3896-3899.1988; FREUND R, 1987, J VIROL, V61, P2232, DOI 10.1128/JVI.61.7.2232-2239.1987; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAFFI A, 1969, P NATL ACAD SCI USA, V64, P1172, DOI 10.1073/pnas.64.4.1172; GRAFFI A, 1968, J NATL CANCER I, V40, P867; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; KELLY JJ, 1989, J VIROL, V63, P383, DOI 10.1128/JVI.63.1.383-391.1989; KERN FG, 1986, J VIROL, V60, P275, DOI 10.1128/JVI.60.1.275-285.1986; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KUSANO T, 1987, P NATL ACAD SCI USA, V84, P1789, DOI 10.1073/pnas.84.7.1789; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEWIS AM, 1979, J NATL CANCER I, V63, P695, DOI 10.1093/jnci/63.3.695; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MAIONE R, 1985, EMBO J, V4, P3215, DOI 10.1002/j.1460-2075.1985.tb04068.x; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PANUTTI A, 1987, J VIROL, V61, P1296; ROCHFORD R, 1990, J VIROL, V64, P476, DOI 10.1128/JVI.64.2.476-485.1990; SAINTANDRE CD, 1989, ICN UCI C V, P225; SALZMAN NP, 1986, VIRUSES PAPOVAVIRIDA, V1, P27; SCHERNECK S, 1987, J VIROL, V61, P3992, DOI 10.1128/JVI.61.12.3992-3998.1987; SEKIKAWA K, 1981, P NATL ACAD SCI-BIOL, V78, P1100, DOI 10.1073/pnas.78.2.1100; SPALHOLZ BA, 1985, CELL, V42, P183, DOI 10.1016/S0092-8674(85)80114-8; SVAREN J, 1990, TRENDS GENET, V6, P52, DOI 10.1016/0168-9525(90)90074-G; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0	45	6	6	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	1992	7	2					295	302						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1312694				2022-12-28	WOS:A1992HG98200014
J	BLASBAND, A; SCHRYVER, B; PAPKOFF, J				BLASBAND, A; SCHRYVER, B; PAPKOFF, J			THE BIOCHEMICAL-PROPERTIES AND TRANSFORMING POTENTIAL OF HUMAN WNT-2 ARE SIMILAR TO WNT-1	ONCOGENE			English	Article							PROTO-ONCOGENE INT-1; MOUSE MAMMARY ONCOGENE; EPITHELIAL-CELL LINE; NUCLEOTIDE-SEQUENCE; SARCOMA VIRUS; MURINE INT-1; EXPRESSION; GENE; DROSOPHILA; WINGLESS	Wnt-2 is a member of the Wnt gene family that includes the proto-oncogene Wnt-1 (formerly Int-1). Although the predicted protein product of the Wnt-2 gene has only 38% amino acid identity with Wnt-1, it exhibits significant conservation of structural properties, including a hydrophobic signal sequence and invariant spacing and conservation of 22 cysteine residues. We have sought to characterize the biological and biochemical properties of Wnt family members and here present a characterization of Wnt-2 protein and a comparison with Wnt-1. We demonstrate, using both CHO and AtT-20 cells transfected with human Wnt-2 cDNA, that Wnt-2 encodes a 33 kl)a protein that is modified by N-linked glycosylation to a 35 kDa species. Secreted Wnt-2 protein was detected in the culture medium only after cells were treated with suramin indicating that, like Wnt-1 protein, Wnt-2 is tightly associated with the cell surface. Expression of Wnt-2 cDNA in the mammary epithelial cell line C57 mg results in loss of density-inhibited growth and induces a transformed phenotype in monolayer culture similar to the effects produced by Wnt-1. These results indicate that Wnt-2 shares several biochemical and biological characteristics with Wnt-1 and suggests that other Wnt family members, by virtue of conserved structural features, may also exhibit similar properties.	SYNTEX INC,S3-1,3401 HILLVIEW AVE,PALO ALTO,CA 94304	Syntex Corporation								BETSHOLTZ C, 1986, P NATL ACAD SCI USA, V83, P6440, DOI 10.1073/pnas.83.17.6440; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; BROWN AMC, 1987, MOL CELL BIOL, V7, P3971, DOI 10.1128/MCB.7.11.3971; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTIAN JL, 1991, DEV BIOL, V143, P230, DOI 10.1016/0012-1606(91)90073-C; DAVIS CA, 1988, GENE DEV, V2, P361, DOI 10.1101/gad.2.3.361; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FUNG YKT, 1985, MOL CELL BIOL, V5, P3337, DOI 10.1128/MCB.5.12.3337; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GILMAN M, 1989, CURRENT PROTOCOLS MO; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MCMAHON JA, 1989, DEVELOPMENT, V107, P643; MORATA G, 1977, DEV BIOL, V56, P227, DOI 10.1016/0012-1606(77)90266-4; NOORDERMEER J, 1989, NUCLEIC ACIDS RES, V17, P11, DOI 10.1093/nar/17.1.11; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; NUSSE R, 1991, CELL, V64, P231, DOI 10.1016/0092-8674(91)90633-A; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PAPKOFF J, 1989, MOL CELL BIOL, V9, P3377, DOI 10.1128/MCB.9.8.3377; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PAPKOFF J, 1987, MOL CELL BIOL, V7, P3978, DOI 10.1128/MCB.7.11.3978; PETCU DJ, 1988, VIROLOGY, V167, P385, DOI 10.1016/0042-6822(88)90099-2; RIGGLEMAN B, 1990, CELL, V63, P549, DOI 10.1016/0092-8674(90)90451-J; RIJSEWIJK F, 1987, EMBO J, V6, P127, DOI 10.1002/j.1460-2075.1987.tb04729.x; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; VAIDYA AB, 1978, VIROLOGY, V90, P12, DOI 10.1016/0042-6822(78)90328-8; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WAINWRIGHT BJ, 1988, EMBO J, V7, P1743, DOI 10.1002/j.1460-2075.1988.tb03003.x; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WILLIAMS LT, 1984, J BIOL CHEM, V259, P5287	39	65	66	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1992	7	1					153	161						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1371336				2022-12-28	WOS:A1992HC22700021
J	MAIONE, R; FIMIA, GM; AMATI, P				MAIONE, R; FIMIA, GM; AMATI, P			INHIBITION OF INVITRO MYOGENIC DIFFERENTIATION BY A POLYOMAVIRUS EARLY FUNCTION	ONCOGENE			English	Article							RETINOBLASTOMA GENE-PRODUCT; FIBROBLAST GROWTH-FACTOR; MUSCLE-SPECIFIC GENES; MYOSIN HEAVY-CHAIN; LARGE T-ANTIGENS; DNA-BINDING; EMBRYO FIBROBLASTS; TRANS-ACTIVATION; EARLY PROTEINS; CELL-CYCLE	In the present work we report on the role of a polyomavirus (Py) early function in interfering with both morphological and biochemical differentiation of the myogenic C2 cell line. The analysis of cell clones stably transfected with a plasmid carrying an ORI- Py genome showed that in the presence of the whole viral early region myogenesis is blocked and a transformed phenotype is evident. By using a plasmid that only encodes large-T function, the involvement of this individual early viral gene product was determined. Inhibition of myogenic differentiation by Py large T is proportional to the level of its expression. This inhibition does not appear to require alteration of cell growth properties. The analysis of muscle-specific functions expressed at different steps in the myogenic pathway showed that Py large T blocks the expression of terminal differentiation markers without altering the expression of the regulatory gene MyoD.	UNIV ROME LA SAPIENZA,DIPARTIMENTO BIOPATOL UMANA,SEZ BIOL CELLULARE,VIALE REGINA ELENA 326,I-00161 ROME,ITALY	Sapienza University Rome			Fimia, Gian Maria/K-3232-2016	Fimia, Gian Maria/0000-0003-4438-3325				ALEMA S, 1987, ADV CANCER RES, V49, P1, DOI 10.1016/S0065-230X(08)60792-7; ASSELIN C, 1984, MOL CELL BIOL, V4, P755, DOI 10.1128/MCB.4.4.755; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; CELIS JE, 1987, FEBS LETT, V220, P1, DOI 10.1016/0014-5793(87)80865-7; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHERINGTON V, 1986, P NATL ACAD SCI USA, V83, P4307, DOI 10.1073/pnas.83.12.4307; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COPPOLA JA, 1990, ONCOGENE, V5, P1731; COWIE A, 1984, J VIROL, V52, P750, DOI 10.1128/JVI.52.3.750-760.1984; COWIE A, 1986, MOL CELL BIOL, V6, P4344, DOI 10.1128/MCB.6.12.4344; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; Endo T., 1989, CELLULAR MOL BIOL MU, P95; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; FELSANI A, 1985, COLD SPRING HARB SYM, V50, P753, DOI 10.1101/SQB.1985.050.01.093; FISZMAN MY, 1975, NATURE, V254, P429, DOI 10.1038/254429a0; FRANCKE B, 1973, VIROLOGY, V55, P127, DOI 10.1016/S0042-6822(73)81014-1; GARCEA RL, 1989, VIROLOGY, V168, P312, DOI 10.1016/0042-6822(89)90271-7; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HOLTZER H, 1975, P NATL ACAD SCI USA, V72, P4051, DOI 10.1073/pnas.72.10.4051; IUJVIDIN S, 1990, DIFFERENTIATION, V43, P192; JAINES JB, 1986, MOL CELL BIOL, V6, P2855; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KERN FG, 1986, CANCER CELL, V4, P115; KINGSTON RE, 1986, MOL CELL BIOL, V6, P3180, DOI 10.1128/MCB.6.9.3180; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LATHROP B, 1985, J CELL BIOL, V101, P2194, DOI 10.1083/jcb.101.6.2194; LINCKHART TA, 1981, DEV BIOL, V86, P19; MAIONE R, 1989, J VIROL, V63, P4890, DOI 10.1128/JVI.63.11.4890-4897.1989; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; NODA T, 1986, J VIROL, V60, P105, DOI 10.1128/JVI.60.1.105-113.1986; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; PAYNE PA, 1987, P NATL ACAD SCI USA, V84, P8956, DOI 10.1073/pnas.84.24.8956; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; RASSOULZADEGAN M, 1983, P NATL ACAD SCI-BIOL, V80, P4354, DOI 10.1073/pnas.80.14.4354; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; Sambrook J, 1989, MOL CLONING LABORATO; SPIZZ G, 1986, J BIOL CHEM, V261, P9483; STRAUSS M, 1990, ONCOGENE, V5, P1223; TATO F, 1983, DIFFERENTIATION, V24, P131, DOI 10.1111/j.1432-0436.1983.tb01312.x; TREISMAN R, 1981, NATURE, V292, P595, DOI 10.1038/292595a0; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WEYDERT A, 1985, P NATL ACAD SCI USA, V82, P7183, DOI 10.1073/pnas.82.21.7183; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YUTZEY KE, 1990, MOL CELL BIOL, V10, P3934, DOI 10.1128/MCB.10.8.3934; ZHU Z, 1984, J VIROL, V51, P170, DOI 10.1128/JVI.51.1.170-180.1984	60	29	30	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1992	7	1					85	93						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1311065				2022-12-28	WOS:A1992HC22700012
J	MITSUDOMI, T; STEINBERG, SM; NAU, MM; CARBONE, D; DAMICO, D; BODNER, S; OIE, HK; LINNOILA, RI; MULSHINE, JL; MINNA, JD; GAZDAR, AF				MITSUDOMI, T; STEINBERG, SM; NAU, MM; CARBONE, D; DAMICO, D; BODNER, S; OIE, HK; LINNOILA, RI; MULSHINE, JL; MINNA, JD; GAZDAR, AF			P53 GENE-MUTATIONS IN NON-SMALL-CELL LUNG-CANCER CELL-LINES AND THEIR CORRELATION WITH THE PRESENCE OF RAS MUTATIONS AND CLINICAL-FEATURES	ONCOGENE			English	Article								We screened 77 non-small-cell lung cancer (NSCLC) cell lines for mutations of the p53 gene using a single-strand conformation polymorphism (SSCP) assay. We found that 57 cell lines (74%) had mutations of the p53 gene. Three cell lines had a deletion of the p53 gene. Of the remaining 54 cell lines, 49 cell lines were sequenced and 52 mutations were confirmed. In contrast to previously published p53 mutations in other human tumors, the p53 gene mutations in NSCLC were diverse with regard to the location and nature of the mutations. The region corresponding to codons 144-166, which is outside the evolutionarily conserved regions, was a frequent site of p53 gene mutations in NSCLC. The presence of a p53 gene mutation was not associated with age, sex, histological types, culture site, treatment intent, presence of prior cytotoxic treatment, neuroendocrine differentiation, median culture time or patient survival. The prevalence of p53 mutations in cell lines with ras mutations did not differ from that in cell lines without ras mutations. However, p53 gene mutations in NSCLC cell lines with ras mutations tended to cluster in exon 8, suggesting the presence of a functional domain of the p53 gene relating to interaction with the ras gene. We conclude that p53 and ras mutations are frequent and apparently independent genetic alterations which play different roles in the pathogenesis, progression and prognosis of NSCLC.	USN, NCI, MED ONCOL BRANCH, BETHESDA, MD 20889 USA; NCI, BIOSTAT & DATA MANAGEMENT SECT, BETHESDA, MD 20889 USA; UNIV TEXAS, SW MED CTR, SIMMONS CANC CTR, DALLAS, TX 75235 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Defense; United States Navy; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Mitsudomi, Tetsuya/0000-0001-9860-8505; Mulshine, James/0000-0002-4648-9177				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARTEK J, 1990, ONCOGENE, V5, P893; Battey, 1986, BASIC METHODS MOL BI; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CARBONE D, 1991, IN PRESS ONCOGENE; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHIBA I, 1990, ONCOGENE, V5, P1603; COX DR, 1972, J R STAT SOC B, V34, P187; DAMICO D, 1991, UNPUB; DAVIDOFF AM, 1991, P NATL ACAD SCI USA, V88, P5006, DOI 10.1073/pnas.88.11.5006; DELACALLEMARTIN O, 1990, NUCLEIC ACIDS RES, V18, P4963, DOI 10.1093/nar/18.16.4963; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GAZDAR AF, 1986, CANCER GENET CYTOGEN, V19, P5, DOI 10.1016/0165-4608(86)90365-1; GAZDAR AF, 1988, CANCER RES, V48, P4078; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; MEUTH M, 1990, BIOCHIM BIOPHYS ACTA, V1032, P1, DOI 10.1016/0304-419X(90)90009-P; Minna JD, 1989, CANCER PRINCIPLES PR, P591; MITSUDOMI T, 1991, IN PRESS ONCOGENE; MITSUDOMI T, 1991, UNPUB; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PROSSER J, 1990, ONCOGENE, V5, P1573; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SAMESHIMA Y, 1990, BIOCHEM BIOPH RES CO, V173, P697, DOI 10.1016/S0006-291X(05)80091-9; SHIRASAWA S, 1991, CANCER RES, V51, P2874; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STEVENSON H, 1990, ANN INTERN MED, V113, P764, DOI 10.7326/0003-4819-113-10-764; SUGIMOTO K, 1991, BLOOD, V77, P1153; SUZUKI Y, 1990, ONCOGENE, V5, P1037; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKAHASHI T, 1990, J CLIN INVEST, V86, P363, DOI 10.1172/JCI114710; TAMURA G, 1991, CANCER RES, V51, P3056; VARLEY JM, 1991, ONCOGENE, V6, P413; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; WHANGPENG J, 1991, IN PRESS GENES CHROM; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252	65	505	520	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1992	7	1					171	180						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1311061				2022-12-28	WOS:A1992HC22700023
